data_5ix9_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5ix9 _Structure_validation_residue.Date_analyzed 2017-06-23 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 . . . . . 0 CA--C 1.515 -0.385 0 N-CA-C 109.805 -0.443 . . . . 2.5 109.805 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.78 114.55 15.67 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.334 0.588 . . . . 0.95 110.342 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.783 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 23.1 pt -93.98 -14.39 8.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 115.197 -0.91 . . . . 1.03 111.431 -172.205 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.47 42.79 Favored Glycine 0 CA--C 1.504 -0.64 0 C-N-CA 120.739 -0.743 . . . . 0.11 111.84 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -143.54 151.09 39.82 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.989 0.423 . . . . 0.24 110.822 -174.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.492 HG13 ' OD1' ' A' ' 30' ' ' ASP . 23.8 mm -78.75 124.43 37.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.875 -0.602 . . . . 1.03 111.528 -177.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.8 p -113.39 -26.17 8.47 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.323 0.582 . . . . 1.01 110.771 177.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.9 tptt -137.89 139.62 39.94 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.786 -0.82 . . . . 2.86 108.786 174.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.9 tt -152.74 144.91 23.87 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 120.776 0.322 . . . . 1.03 110.164 178.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -155.35 156.32 35.22 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.852 -0.613 . . . . 1.94 110.662 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.12 -155.49 50.64 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.95 -0.568 . . . . 0.32 112.809 176.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.3 t -99.43 126.0 45.25 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.186 -0.672 . . . . 1.65 109.186 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.478 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -139.76 152.96 22.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.538 0.685 . . . . 1.09 111.498 -176.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.51 158.78 44.06 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.625 -1.17 . . . . 1.0 108.982 178.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.462 HG23 ' HB3' ' A' ' 36' ' ' GLU . 0.5 OUTLIER -132.68 131.83 59.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.235 0.54 . . . . 1.03 110.034 174.857 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -97.42 99.01 10.43 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.471 -0.566 . . . . 0.72 109.471 178.385 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.555 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 39.9 m -62.2 171.59 1.76 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.928 -0.578 . . . . 1.63 109.703 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.2 pt -65.98 -1.44 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 113.757 1.021 . . . . 1.12 113.757 -170.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 49.6 m-80 -98.03 -2.16 40.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.303 0.573 . . . . 1.96 109.722 173.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.63 74.91 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 110.61 -0.996 . . . . 0.34 110.61 -176.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -84.38 118.2 24.09 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.721 -0.74 . . . . 2.76 110.519 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 4.9 tt0 -85.56 113.86 22.13 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.294 0.568 . . . . 1.0 110.483 -178.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -106.01 138.76 41.64 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.958 -1.019 . . . . 2.1 109.401 177.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -75.8 141.32 15.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.249 -0.648 . . . . 1.11 109.249 177.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.478 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 5.1 mt -106.99 145.05 32.74 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 121.493 0.663 . . . . 1.1 111.614 -178.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 35.7 mttp -137.51 169.22 18.15 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.461 -1.245 . . . . 2.19 107.735 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -61.23 140.17 57.99 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 119.761 -0.776 . . . . 1.1 109.798 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.489 ' H ' ' HB ' ' A' ' 7' ' ' ILE . . . 82.79 9.31 84.71 Favored Glycine 0 N--CA 1.437 -1.289 0 C-N-CA 120.052 -1.07 . . . . 0.25 113.08 177.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.492 ' OD1' HG13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.76 147.98 56.54 Favored Pre-proline 0 C--O 1.236 0.355 0 CA-C-N 117.419 0.609 . . . . 1.92 109.474 176.191 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -84.05 131.04 5.0 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.635 2.224 . . . . 0.31 113.219 178.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 mm -95.98 137.37 24.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.392 -0.822 . . . . 1.02 109.211 174.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -118.8 157.22 27.98 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.057 -0.52 . . . . 0.37 109.699 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.409 ' HB2' HG22 ' A' ' 4' ' ' ILE . 1.8 t80 -73.85 116.02 13.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.078 -0.51 . . . . 0.2 110.493 -174.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.19 -4.2 18.35 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.527 -0.844 . . . . 0.17 113.736 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.555 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 24.6 mt-10 -84.93 149.06 25.9 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 117.971 0.886 . . . . 0.52 110.993 -177.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.7 m -104.31 108.07 19.29 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.388 -0.823 . . . . 1.03 110.777 -178.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.8 t -81.72 133.53 29.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.145 0.498 . . . . 1.04 110.613 -176.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -122.08 107.68 12.48 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.18 -0.918 . . . . 1.1 109.964 -176.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.454 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 69.7 p -104.26 152.04 22.67 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.79 -0.448 . . . . 1.06 109.79 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.935 0 C-N-CA 120.928 -0.653 . . . . 0.9 112.205 179.395 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.404 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 6.0 m . . . . . 0 C--O 1.224 -0.285 0 N-CA-C 108.968 -0.753 . . . . 1.16 108.968 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 4.7 t -133.53 139.54 48.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.739 -0.384 . . . . 1.09 111.141 -173.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.593 ' HA ' ' O ' ' A' ' 56' ' ' VAL . 89.3 m -113.89 110.85 20.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.966 -0.561 . . . . 1.03 109.956 174.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 69.3 mt -100.37 102.0 12.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.585 -0.734 . . . . 1.05 110.24 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.6 107.79 11.53 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.431 -0.804 . . . . 1.03 109.388 177.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.48 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 61.7 m-85 -70.86 149.7 46.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.633 0.73 . . . . 0.45 111.287 -177.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -77.4 0.95 2.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 114.743 -1.117 . . . . 1.07 111.086 -172.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -90.51 -21.41 21.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.958 -0.564 . . . . 0.75 110.649 175.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.42 -18.11 5.8 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.639 -0.791 . . . . 0.32 112.8 -178.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.2 p -84.81 171.64 12.1 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.644 0.222 . . . . 1.09 111.119 178.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -130.26 -178.0 4.56 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.14 -0.689 . . . . 1.51 109.14 175.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.593 ' O ' ' HA ' ' A' ' 47' ' ' THR . 0.5 OUTLIER -160.24 151.32 5.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 2.06 109.896 178.982 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.527 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.2 p -129.12 131.53 67.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.355 0.597 . . . . 1.58 110.783 178.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.404 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.8 mt -107.28 137.18 39.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 115.668 -0.696 . . . . 1.08 109.788 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.06 -164.28 29.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.932 -0.651 . . . . 1.02 112.578 -179.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.2 142.67 17.66 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.547 -0.621 . . . . 0.64 111.547 -174.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.454 ' HA ' ' O ' ' A' ' 40' ' ' THR . 37.7 t70 56.64 30.11 16.87 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-O 122.151 0.977 . . . . 1.26 109.207 -172.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 m -112.28 163.27 14.57 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.656 -1.156 . . . . 1.64 110.727 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 83.4 mt -140.05 127.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.845 -0.616 . . . . 1.08 109.838 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.1 p -148.53 143.72 18.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 109.886 -0.413 . . . . 1.66 109.886 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -103.37 133.58 48.19 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.758 -0.377 . . . . 0.67 110.323 -178.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.412 ' HE3' HG22 ' A' ' 70' ' ' ILE . 53.2 mmm -69.19 89.2 0.45 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.645 -0.707 . . . . 1.13 110.366 -177.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.2 p -115.95 -164.9 0.99 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.756 -0.656 . . . . 1.15 111.39 -176.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -68.94 -41.15 78.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.524 -0.307 . . . . 2.13 111.252 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -61.53 -30.08 70.41 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.636 0.731 . . . . 2.51 110.306 177.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.412 HG22 ' HE3' ' A' ' 66' ' ' MET . 1.3 mm -73.45 -52.52 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 114.497 -1.229 . . . . 1.1 110.806 176.133 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.783 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.316 -0.873 0 CA-C-N 115.489 -0.778 . . . . 0.91 110.378 -176.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 . . . . . 0 N--CA 1.47 0.537 0 CA-C-O 121.372 0.606 . . . . 2.5 111.613 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.26 109.91 12.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.827 -0.624 . . . . 0.95 109.642 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.775 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.0 pt -92.77 -13.6 8.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.295 -0.866 . . . . 1.03 112.074 -170.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.64 176.64 42.3 Favored Glycine 0 CA--C 1.501 -0.799 0 C-N-CA 120.69 -0.767 . . . . 0.11 111.513 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -143.51 150.41 38.89 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.048 0.451 . . . . 0.24 110.921 -174.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.527 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -78.22 123.38 34.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.683 -0.689 . . . . 1.03 110.883 -177.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.7 p -115.44 -21.29 9.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.218 0.532 . . . . 1.01 110.801 178.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.541 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 52.3 tptt -140.82 139.65 34.55 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.317 -0.994 . . . . 2.86 108.317 172.29 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.8 tt -153.57 146.34 24.32 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 110.234 -0.284 . . . . 1.03 110.234 -179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -146.82 153.57 40.34 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.292 -0.413 . . . . 1.94 110.654 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.61 -149.48 49.67 Favored Glycine 0 N--CA 1.45 -0.402 0 O-C-N 123.689 0.618 . . . . 0.32 113.768 171.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.9 m -100.22 124.49 45.71 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.954 -0.387 . . . . 1.65 109.954 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.469 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.9 m -136.05 152.32 30.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.638 0.732 . . . . 1.09 111.692 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.23 157.55 43.21 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.751 -1.113 . . . . 1.0 108.647 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.537 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.5 OUTLIER -135.81 134.94 51.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.048 -0.661 . . . . 1.03 111.049 174.549 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.413 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.8 mt-30 -100.05 102.79 14.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.328 -0.851 . . . . 0.72 109.599 177.426 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.559 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 61.4 p -61.46 178.87 0.26 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 111.473 0.175 . . . . 1.63 111.473 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.7 pt -59.42 -24.36 27.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.091 0.472 . . . . 1.12 111.16 178.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -77.57 -16.64 58.51 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.829 -0.623 . . . . 1.96 110.402 177.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.33 7.31 62.17 Favored Glycine 0 CA--C 1.504 -0.6 0 N-CA-C 110.909 -0.877 . . . . 0.34 110.909 -176.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.0 mm100 -77.74 116.02 17.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.159 -0.521 . . . . 2.76 110.69 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.537 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 13.4 tt0 -81.89 118.44 22.93 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.069 -0.514 . . . . 1.0 110.056 176.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.49 ' HG2' HG12 ' A' ' 16' ' ' VAL . 36.0 ptt85 -120.33 169.62 10.11 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.838 -0.801 . . . . 2.1 108.838 174.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.4 p -96.62 144.33 10.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 109.496 -0.557 . . . . 1.11 109.496 -178.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.554 HD21 ' CG ' ' A' ' 30' ' ' ASP . 7.3 mt -112.68 160.73 17.62 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.124 0.487 . . . . 1.1 110.987 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.598 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 0.2 OUTLIER -159.46 177.04 11.38 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.278 -0.874 . . . . 2.19 109.027 -179.502 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 143.51 56.82 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 119.81 -0.756 . . . . 1.1 109.99 -179.38 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.57 6.71 81.81 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.219 -0.991 . . . . 0.25 112.41 178.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.598 ' HB3' ' O ' ' A' ' 27' ' ' LYS . 0.0 OUTLIER -85.37 142.27 37.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.399 0.618 . . . . 1.92 110.793 178.325 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.36 134.79 11.54 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 123.58 2.853 . . . . 0.31 113.756 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.8 mm -100.49 136.9 29.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.35 -0.841 . . . . 1.02 109.238 172.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -116.29 153.12 32.51 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 116.224 -0.444 . . . . 0.37 110.134 -178.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.466 ' HB2' HG23 ' A' ' 4' ' ' ILE . 2.0 t80 -71.37 114.5 9.5 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.058 -0.519 . . . . 0.2 110.869 -174.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.95 0.56 24.16 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.497 -0.858 . . . . 0.17 113.279 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.559 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 34.7 mt-10 -84.28 147.7 27.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.676 0.738 . . . . 0.52 110.465 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 22.2 m -106.59 106.88 17.61 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.462 -0.79 . . . . 1.03 110.488 -177.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -81.85 125.96 39.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-O 121.205 0.526 . . . . 1.04 110.916 -174.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -113.16 106.39 14.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.028 -0.987 . . . . 1.1 109.454 179.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.483 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 73.0 p -101.93 157.42 16.87 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 120.44 -0.504 . . . . 1.06 109.997 178.183 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.022 0 CA-C-N 115.631 -0.713 . . . . 0.9 111.644 178.507 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m . . . . . 0 CA--C 1.517 -0.308 0 N-CA-C 109.231 -0.655 . . . . 1.16 109.231 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.8 t -126.5 130.43 71.79 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 C-N-CA 120.677 -0.409 . . . . 1.09 111.878 -169.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.541 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 97.2 m -106.79 108.85 20.57 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.781 -0.645 . . . . 1.03 109.751 175.089 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.544 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 62.3 mt -97.73 105.35 17.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.623 -0.717 . . . . 1.05 110.117 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.81 105.42 11.08 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.413 -0.812 . . . . 1.03 109.042 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.456 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 62.5 m-85 -71.18 146.79 48.88 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.508 0.67 . . . . 0.45 110.867 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.59 2.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 114.634 -1.166 . . . . 1.07 111.582 -171.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -94.66 -20.68 19.35 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.076 -0.511 . . . . 0.75 110.384 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.0 -17.65 7.12 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.66 -0.781 . . . . 0.32 112.552 -178.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.7 p -82.99 155.7 23.83 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 122.903 -0.175 . . . . 1.09 110.866 178.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -132.33 143.26 49.74 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.897 -0.408 . . . . 1.51 109.897 178.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.544 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 10.7 m -124.44 168.56 16.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.068 0.461 . . . . 2.06 111.584 178.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.504 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.7 p -138.78 133.37 41.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.331 -0.849 . . . . 1.58 110.25 177.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -106.34 136.15 42.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.99 -0.55 . . . . 1.08 109.929 -179.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.49 178.71 53.74 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.551 -0.833 . . . . 1.02 111.606 177.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.0 151.08 19.93 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 111.584 -0.607 . . . . 0.64 111.584 -172.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.483 ' HA ' ' O ' ' A' ' 40' ' ' THR . 34.5 t70 51.15 28.48 4.08 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 121.379 0.609 . . . . 1.26 110.509 -171.22 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.5 t -104.72 161.71 13.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.882 -0.599 . . . . 1.64 110.761 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.549 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 81.3 mt -138.92 123.15 20.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.629 -0.714 . . . . 1.08 109.51 178.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.14 137.04 16.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.935 0.398 . . . . 1.66 110.855 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.7 tt0 -91.46 131.84 36.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.315 -0.402 . . . . 0.67 110.41 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.463 ' HE3' HD12 ' A' ' 48' ' ' ILE . 53.2 mmm -71.68 89.18 1.0 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 1.13 110.6 -178.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.2 p -111.05 -166.77 1.11 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.092 -0.504 . . . . 1.15 110.9 -178.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.9 -27.89 62.15 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.013 0.435 . . . . 2.13 110.044 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -65.46 -30.09 70.84 Favored 'General case' 0 CA--C 1.521 -0.144 0 CA-C-O 121.882 0.849 . . . . 2.51 109.789 174.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.437 HG22 ' HE2' ' A' ' 66' ' ' MET . 1.0 OUTLIER -80.51 -54.02 11.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 114.457 -1.247 . . . . 1.1 110.732 176.777 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.775 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.316 -0.851 0 CA-C-N 115.407 -0.815 . . . . 0.91 109.772 -177.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 . . . . . 0 N--CA 1.468 0.473 0 CA-C-O 121.242 0.544 . . . . 2.5 110.937 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.53 109.85 16.37 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.485 0.66 . . . . 0.95 109.817 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.753 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.3 pt -95.11 -12.32 8.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 114.945 -1.025 . . . . 1.03 111.777 -171.215 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.49 179.26 41.09 Favored Glycine 0 CA--C 1.5 -0.853 0 C-N-CA 120.684 -0.769 . . . . 0.11 111.698 178.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.443 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 92.3 m-85 -144.41 152.13 40.23 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.76 0.314 . . . . 0.24 110.535 -176.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.489 HG12 ' O ' ' A' ' 30' ' ' ASP . 33.0 mm -79.77 122.48 35.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.441 -0.345 . . . . 1.03 110.86 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.0 p -115.72 -21.59 9.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.207 0.527 . . . . 1.01 110.966 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.526 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.8 tttt -141.87 144.94 34.09 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.219 -1.03 . . . . 2.86 108.219 173.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.5 tt -158.95 146.54 17.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.877 0.37 . . . . 1.03 111.029 -177.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.408 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 9.0 t70 -153.36 152.14 30.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.811 -0.631 . . . . 1.94 110.854 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.15 -154.42 44.58 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.129 -0.558 . . . . 0.32 113.112 173.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.4 m -103.34 120.78 41.43 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 109.804 -0.443 . . . . 1.65 109.804 -176.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.417 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.0 m -138.35 152.1 25.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.769 0.795 . . . . 1.09 111.596 -176.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.41 159.43 44.47 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 114.64 -1.164 . . . . 1.0 108.463 178.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -132.95 136.45 55.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 119.86 -0.736 . . . . 1.03 110.94 174.377 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -101.05 102.51 13.5 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.295 -0.866 . . . . 0.72 109.843 177.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.52 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 7.6 p -63.01 172.08 1.93 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.854 -0.338 . . . . 1.63 110.507 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -54.42 -33.31 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 112.767 0.654 . . . . 1.12 112.767 -173.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -80.09 -5.03 55.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.926 0.393 . . . . 1.96 111.512 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.17 14.73 44.21 Favored Glycine 0 CA--C 1.507 -0.441 0 C-N-CA 121.276 -0.488 . . . . 0.34 112.376 174.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.3 mm100 -86.55 116.86 24.96 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.865 0.364 . . . . 2.76 110.753 -178.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.53 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.5 tt0 -84.47 117.52 23.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.371 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.492 ' HG2' HG13 ' A' ' 16' ' ' VAL . 29.4 ptt85 -119.09 168.32 10.95 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.722 -0.473 . . . . 2.1 109.722 177.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.9 p -94.59 135.03 30.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.003 -0.544 . . . . 1.11 110.372 -176.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.417 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 15.2 mt -103.08 118.39 36.7 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.605 0.717 . . . . 1.1 110.321 178.447 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -114.0 176.88 4.85 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.493 -1.23 . . . . 2.19 107.703 174.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 tp -67.69 134.53 51.24 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 119.042 -1.063 . . . . 1.1 109.424 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.15 -12.22 66.95 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 119.676 -1.25 . . . . 0.25 112.564 177.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.489 ' O ' HG12 ' A' ' 7' ' ' ILE . 10.7 m-20 -67.76 140.26 94.08 Favored Pre-proline 0 CA--C 1.514 -0.412 0 C-N-CA 120.219 -0.592 . . . . 1.92 109.857 175.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.443 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 29.7 Cg_endo -86.1 144.48 8.29 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.003 2.468 . . . . 0.31 111.834 -179.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.0 mm -100.62 138.74 23.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.639 -0.504 . . . . 1.02 109.639 176.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -114.61 149.7 36.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.174 -0.466 . . . . 0.37 109.836 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.466 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.8 t80 -68.6 109.58 3.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.096 -0.502 . . . . 0.2 110.638 -175.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 123.8 -3.98 9.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.553 -0.832 . . . . 0.17 113.673 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.52 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.0 mt-10 -82.3 150.49 27.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 117.851 0.825 . . . . 0.52 110.981 -177.435 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.9 m -108.42 107.7 18.35 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.537 -0.756 . . . . 1.03 110.767 -177.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.603 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -79.04 137.05 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.3 0.571 . . . . 1.04 110.845 -175.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -123.46 99.25 6.23 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.043 -0.981 . . . . 1.1 109.665 -177.413 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.5 p -101.01 153.46 19.52 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.119 0.485 . . . . 1.06 110.158 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.917 0 CA-C-N 115.423 -0.808 . . . . 0.9 111.65 178.412 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.488 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 36.8 m . . . . . 0 C--O 1.22 -0.465 0 N-CA-C 109.052 -0.722 . . . . 1.16 109.052 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.9 t -145.71 132.21 14.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 C-N-CA 120.548 -0.461 . . . . 1.09 110.968 -176.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.526 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -106.69 105.96 16.26 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.103 0.478 . . . . 1.03 109.949 174.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.523 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 60.7 mt -96.38 103.15 14.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.672 -0.694 . . . . 1.05 110.082 177.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 106.04 10.19 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.229 -0.896 . . . . 1.03 109.193 176.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.44 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 58.0 m-85 -71.43 146.75 48.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.591 0.71 . . . . 0.45 110.916 -177.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -71.42 -12.41 15.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.572 -1.195 . . . . 1.07 111.512 -170.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.636 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 21.0 t70 -79.39 -21.04 46.23 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.289 -0.414 . . . . 0.75 110.736 178.497 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.75 -8.91 7.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.517 -0.849 . . . . 0.32 112.717 -179.098 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.7 p -90.48 175.35 7.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.579 0.228 . . . . 1.09 110.897 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -151.79 148.45 27.87 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.72 -0.474 . . . . 1.51 109.72 176.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.523 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.2 m -129.36 165.63 28.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 120.989 0.423 . . . . 2.06 111.352 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.591 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.7 p -135.56 128.56 47.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-N 115.316 -0.856 . . . . 1.58 110.426 177.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.488 ' O ' ' HA ' ' A' ' 45' ' ' SER . 18.5 mt -101.03 139.58 21.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.373 -0.83 . . . . 1.08 109.988 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.52 -157.77 29.08 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.775 -0.726 . . . . 1.02 111.952 178.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.43 148.87 18.83 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.986 -0.625 . . . . 0.64 111.664 -173.116 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.0 t70 56.87 27.37 12.88 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.96 0.886 . . . . 1.26 109.708 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.5 t -105.3 157.64 17.17 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.372 -0.831 . . . . 1.64 110.579 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.603 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.0 mt -142.79 106.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.191 -0.67 . . . . 1.08 109.191 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.49 146.31 32.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.027 0.441 . . . . 1.66 111.339 -175.341 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -99.46 131.44 45.46 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.793 -0.64 . . . . 0.67 110.354 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.464 ' HE3' HD13 ' A' ' 48' ' ' ILE . 51.0 mmm -68.18 89.15 0.31 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.454 -0.794 . . . . 1.13 110.315 -178.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.1 p -116.55 -166.99 1.21 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.653 -0.703 . . . . 1.15 111.16 -175.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -63.89 -38.31 90.62 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 2.13 110.647 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -62.75 -28.75 70.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.587 0.708 . . . . 2.51 110.614 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.416 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.4 mm -81.97 -51.28 15.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 CA-C-N 114.904 -1.044 . . . . 1.1 110.939 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.753 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.316 -0.875 0 CA-C-N 115.553 -0.749 . . . . 0.91 109.845 -177.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 74.3 m-20 . . . . . 0 CA--C 1.513 -0.47 0 N-CA-C 110.153 -0.314 . . . . 2.5 110.153 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 109.62 6.79 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.374 0.607 . . . . 0.95 110.019 179.117 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.79 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.6 pt -91.83 -13.66 8.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.017 -0.992 . . . . 1.03 111.427 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.93 178.55 43.34 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.794 -0.717 . . . . 0.11 111.415 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -144.73 150.38 37.17 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.8 0.333 . . . . 0.24 110.425 -174.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.575 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.3 mm -77.12 124.19 35.08 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.026 -0.534 . . . . 1.03 111.596 -175.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.3 p -116.1 -22.51 8.91 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.887 0.375 . . . . 1.01 110.747 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.551 ' HB2' ' HB ' ' A' ' 47' ' ' THR . 6.4 tmtt? -134.38 144.34 48.15 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 109.364 -0.606 . . . . 2.86 109.364 170.677 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.2 tt -156.38 141.68 17.48 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.089 -0.505 . . . . 1.03 110.327 177.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -154.54 158.74 40.29 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.725 -0.671 . . . . 1.94 110.75 -177.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.48 -140.56 35.48 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.806 -0.634 . . . . 0.32 113.074 175.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.3 t -112.46 122.99 49.28 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.294 -0.632 . . . . 1.65 109.294 -178.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.443 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 4.2 m -136.06 152.16 30.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.7 0.762 . . . . 1.09 111.496 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.25 158.46 43.91 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 114.674 -1.148 . . . . 1.0 108.881 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.602 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -136.51 135.44 49.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 119.94 -0.704 . . . . 1.03 110.946 173.512 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -103.22 99.87 9.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.973 -1.012 . . . . 0.72 109.68 177.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.499 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.2 m -60.76 174.41 0.61 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.6 -0.273 . . . . 1.63 110.713 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 13.4 pt -59.42 -27.8 38.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 118.337 0.517 . . . . 1.12 112.052 -174.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -77.46 -9.33 58.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.068 -0.515 . . . . 1.96 110.982 177.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.42 3.02 60.06 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 121.351 -0.452 . . . . 0.34 112.342 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -75.06 122.02 22.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.704 0.288 . . . . 2.76 111.271 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.602 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.7 tt0 -92.8 123.18 35.89 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.919 -0.582 . . . . 1.0 110.193 177.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.47 ' HG2' HG12 ' A' ' 16' ' ' VAL . 19.4 ptt-85 -123.0 166.47 15.05 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.543 -0.54 . . . . 2.1 109.543 175.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.81 134.45 28.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 109.109 -0.7 . . . . 1.11 109.109 177.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.485 HD23 ' CG ' ' A' ' 30' ' ' ASP . 5.3 mt -97.36 153.34 18.14 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.243 0.544 . . . . 1.1 111.111 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -141.27 178.2 7.57 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.958 -1.019 . . . . 2.19 108.395 -176.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -71.94 144.23 49.01 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 119.392 -0.923 . . . . 1.1 109.203 177.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.53 -6.07 58.91 Favored Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 120.247 -0.978 . . . . 0.25 112.338 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.575 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -70.66 142.84 89.07 Favored Pre-proline 0 C--N 1.332 -0.184 0 CA-C-O 121.388 0.613 . . . . 1.92 110.157 179.414 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -87.49 128.87 2.6 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.627 2.884 . . . . 0.31 113.485 -174.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.8 mm -93.62 137.05 23.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.011 -0.54 . . . . 1.02 109.745 177.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -115.06 151.39 34.35 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.052 -0.522 . . . . 0.37 109.733 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.463 ' HB2' HG23 ' A' ' 4' ' ' ILE . 2.0 t80 -68.94 114.07 6.91 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.246 -0.433 . . . . 0.2 110.494 -176.556 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.49 0.41 18.29 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.398 -0.906 . . . . 0.17 113.54 177.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.499 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 30.2 mt-10 -88.53 146.51 25.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 118.071 0.936 . . . . 0.52 110.882 -177.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.0 m -103.49 107.88 18.9 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.422 -0.808 . . . . 1.03 110.943 -176.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.9 t -84.0 130.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 CA-C-O 121.153 0.502 . . . . 1.04 110.869 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -115.57 109.57 17.98 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.245 -0.889 . . . . 1.1 109.532 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.8 p -107.94 146.5 32.33 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.877 -0.416 . . . . 1.06 109.877 178.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.44 -1.078 0 C-N-CA 120.934 -0.65 . . . . 0.9 111.766 179.278 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 36.7 m . . . . . 0 C--O 1.222 -0.373 0 N-CA-C 109.434 -0.58 . . . . 1.16 109.434 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.559 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.9 t -141.18 128.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-O 120.621 0.248 . . . . 1.09 110.945 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.551 ' HB ' ' HB2' ' A' ' 9' ' ' LYS . 92.8 m -101.27 107.93 19.43 Favored 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 109.559 -0.534 . . . . 1.03 109.559 173.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.452 HD12 ' HE1' ' A' ' 66' ' ' MET . 84.6 mt -95.69 101.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.556 -0.747 . . . . 1.05 109.995 176.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.77 102.65 8.23 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.438 -0.801 . . . . 1.03 109.329 177.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.562 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 55.5 m-85 -65.54 152.95 42.84 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.45 111.22 -177.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -79.04 -3.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-N 114.664 -1.153 . . . . 1.07 110.917 -172.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.557 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 18.6 t70 -85.71 -21.45 28.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.605 -0.725 . . . . 0.75 110.44 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.55 -11.65 11.21 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.764 -0.731 . . . . 0.32 112.122 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.2 p -88.07 157.53 18.84 Favored 'General case' 0 C--N 1.323 -0.555 0 O-C-N 122.879 -0.189 . . . . 1.09 110.609 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -124.64 160.32 28.76 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.669 -0.493 . . . . 1.51 109.669 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.562 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.3 154.45 16.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.466 -0.334 . . . . 2.06 110.108 -179.191 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.559 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -132.96 133.11 59.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.178 0.514 . . . . 1.58 110.596 178.064 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 18.7 mt -101.57 143.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.901 -0.591 . . . . 1.08 110.192 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.7 -164.91 39.78 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.842 -0.694 . . . . 1.02 111.998 177.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -115.52 153.0 17.84 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.251 -0.74 . . . . 0.64 111.251 -174.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.3 t70 57.25 23.71 9.05 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.77 0.795 . . . . 1.26 109.665 -173.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -110.16 160.69 16.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.777 -0.647 . . . . 1.64 111.369 -176.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.426 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -139.8 125.26 21.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.422 -0.808 . . . . 1.08 109.382 177.425 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.3 p -148.64 140.73 18.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.925 0.393 . . . . 1.66 110.96 -176.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.8 tt0 -95.5 132.57 40.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.456 -0.338 . . . . 0.67 110.198 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.467 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 58.1 mmm -70.21 89.49 0.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.736 -0.666 . . . . 1.13 110.499 -178.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 36.0 p -117.06 -165.19 1.04 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.878 -0.601 . . . . 1.15 111.138 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -64.42 -36.38 83.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.934 0.397 . . . . 2.13 110.888 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -65.96 -22.35 66.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.625 0.726 . . . . 2.51 110.313 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.45 HG22 ' CE ' ' A' ' 66' ' ' MET . 1.4 mm -87.06 -56.31 5.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 114.986 -1.007 . . . . 1.1 111.023 176.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.79 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.318 -0.792 0 CA-C-N 115.574 -0.739 . . . . 0.91 110.2 -173.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 . . . . . 0 C--O 1.235 0.302 0 N-CA-C 109.762 -0.458 . . . . 2.5 109.762 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.77 112.58 8.94 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.365 0.602 . . . . 0.95 110.47 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.784 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 35.6 pt -95.94 -15.76 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 114.978 -1.01 . . . . 1.03 111.937 -171.672 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.09 175.99 40.88 Favored Glycine 0 CA--C 1.499 -0.941 0 C-N-CA 120.615 -0.803 . . . . 0.11 111.812 -177.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -145.07 147.44 32.57 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.042 0.449 . . . . 0.24 110.661 -174.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.77 123.07 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.579 -0.737 . . . . 1.03 110.964 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.2 p -112.41 -23.67 10.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.347 0.594 . . . . 1.01 110.718 178.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.468 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.6 tptt -141.6 138.73 32.81 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 108.667 -0.864 . . . . 2.86 108.667 175.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.7 tt -149.66 144.86 26.4 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.721 0.296 . . . . 1.03 110.71 -178.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -152.65 153.33 33.1 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.015 -0.539 . . . . 1.94 110.394 -177.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.16 -149.85 41.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.002 -0.618 . . . . 0.32 113.164 174.078 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.2 t -108.0 123.84 49.26 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.31 -0.626 . . . . 1.65 109.31 -177.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.456 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -136.37 152.28 29.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.855 0.836 . . . . 1.09 112.296 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.03 158.88 44.68 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 114.422 -1.263 . . . . 1.0 108.795 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.668 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.1 p -135.73 139.17 46.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 C-N-CA 120.042 -0.663 . . . . 1.03 110.895 173.097 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.492 ' HA ' ' O ' ' A' ' 22' ' ' GLN . 1.3 mt-30 -107.85 102.12 11.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.316 -0.856 . . . . 0.72 110.077 177.584 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.501 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 11.6 m -63.91 172.26 2.38 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.462 -0.57 . . . . 1.63 109.462 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.0 pt -57.78 -30.0 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 119.031 0.832 . . . . 1.12 112.521 -172.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.47 ' HB2' ' HG3' ' A' ' 22' ' ' GLN . 87.3 m-20 -63.94 -26.8 68.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.164 0.507 . . . . 1.96 110.826 175.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 106.33 13.3 23.16 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.505 -0.77 . . . . 0.34 111.691 -174.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 21.5 mt-30 -77.1 116.72 17.99 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.947 -0.126 . . . . 2.76 110.885 -179.023 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.668 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.4 tt0 -93.76 117.66 30.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.876 0.369 . . . . 1.0 110.485 176.359 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.487 ' HG2' HG12 ' A' ' 16' ' ' VAL . 23.9 ptt-85 -120.11 166.95 12.72 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.209 -0.663 . . . . 2.1 109.209 175.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.1 p -91.2 131.71 37.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 109.47 -0.567 . . . . 1.11 109.47 178.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.507 HD22 ' CG ' ' A' ' 30' ' ' ASP . 5.4 mt -94.25 156.49 16.51 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.852 -0.613 . . . . 1.1 111.014 -178.124 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -143.54 177.9 8.15 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.321 -0.992 . . . . 2.19 108.321 -172.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.61 142.18 46.55 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 118.973 -1.091 . . . . 1.1 108.77 174.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.5 5.3 85.78 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.982 -1.104 . . . . 0.25 112.173 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.57 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -80.47 139.09 51.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.671 0.748 . . . . 1.92 110.739 178.942 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -77.03 130.6 11.38 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 123.685 2.924 . . . . 0.31 113.382 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 mm -97.42 136.04 29.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.344 -0.844 . . . . 1.02 109.018 174.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 -115.16 151.4 34.46 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 116.194 -0.457 . . . . 0.37 110.101 -178.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.443 ' HB2' HG23 ' A' ' 4' ' ' ILE . 1.6 t80 -67.64 118.82 11.44 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.891 -0.595 . . . . 0.2 110.531 -175.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.74 1.1 30.59 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.583 -0.818 . . . . 0.17 113.203 177.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.52 ' O ' ' HG2' ' A' ' 66' ' ' MET . 34.4 mt-10 -88.62 146.15 25.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 117.9 0.85 . . . . 0.52 110.644 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.423 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 11.3 m -104.34 106.85 17.51 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.249 -0.887 . . . . 1.03 110.738 -174.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.7 t -82.63 122.62 37.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 121.206 0.527 . . . . 1.04 110.883 -174.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.1 mp -105.76 109.27 21.18 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.135 -0.938 . . . . 1.1 109.441 178.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.5 p -107.54 148.35 29.35 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.955 -0.387 . . . . 1.06 109.955 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.912 0 C-N-CA 120.776 -0.726 . . . . 0.9 111.984 177.391 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 3.1 m . . . . . 0 CA--C 1.511 -0.548 0 N-CA-C 109.55 -0.537 . . . . 1.16 109.55 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.9 t -130.9 119.43 45.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 CA-C-N 116.048 -0.524 . . . . 1.09 111.278 -170.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.468 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.0 m -95.13 104.27 16.14 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.455 -0.793 . . . . 1.03 109.873 176.745 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.453 HD12 ' HE3' ' A' ' 66' ' ' MET . 60.2 mt -94.83 99.66 9.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 115.274 -0.875 . . . . 1.05 109.697 177.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.21 110.11 16.38 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.413 -0.812 . . . . 1.03 109.444 178.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.529 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 59.0 m-85 -73.14 151.86 41.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.635 0.731 . . . . 0.45 111.128 -176.055 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.3 p -72.38 -5.89 6.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 114.548 -1.205 . . . . 1.07 110.671 -174.073 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -79.39 -21.37 45.76 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.079 -0.964 . . . . 0.75 110.938 176.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.11 -11.86 34.11 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.099 -0.8 . . . . 0.32 111.099 -173.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.3 p -83.3 154.67 24.0 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.267 -0.466 . . . . 1.09 109.959 175.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -126.88 156.79 40.85 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 120.777 -0.369 . . . . 1.51 110.454 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.529 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -139.44 152.0 23.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 115.905 -0.589 . . . . 2.06 109.648 178.233 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -136.62 133.21 48.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-O 121.312 0.577 . . . . 1.58 110.994 179.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.607 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -100.37 138.28 25.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.692 -0.685 . . . . 1.08 109.46 178.341 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.08 -51.24 5.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.109 -0.567 . . . . 1.02 112.34 -179.114 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.16 172.49 13.0 Favored Glycine 0 CA--C 1.505 -0.568 0 CA-C-O 119.083 -0.843 . . . . 0.64 111.521 176.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 38.3 47.07 0.97 Allowed 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 122.063 0.935 . . . . 1.26 110.559 -171.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.1 t -138.79 163.36 32.42 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 114.493 -1.231 . . . . 1.64 109.785 -176.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.47 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 84.5 mt -140.26 113.97 5.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.491 -0.559 . . . . 1.08 109.491 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 p -138.66 142.38 34.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.93 0.395 . . . . 1.66 110.885 -175.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.423 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 45.0 tt0 -96.04 131.94 41.91 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.145 -0.48 . . . . 0.67 110.406 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.528 ' CE ' HG22 ' A' ' 70' ' ' ILE . 59.9 mmm -71.07 88.97 0.8 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.643 -0.708 . . . . 1.13 110.72 -178.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 p -117.62 -162.42 0.87 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.245 -0.434 . . . . 1.15 110.369 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -71.36 -28.51 64.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.051 0.453 . . . . 2.13 110.26 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -64.49 -24.05 67.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.916 0.865 . . . . 2.51 109.859 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.528 HG22 ' CE ' ' A' ' 66' ' ' MET . 1.3 mm -91.67 -53.21 9.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 114.509 -1.223 . . . . 1.1 110.583 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.784 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 . . . . . 0 C--N 1.319 -0.749 0 CA-C-N 115.123 -0.944 . . . . 0.91 110.634 -174.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 20.3 m120 . . . . . 0 CA--C 1.515 -0.402 0 CA-C-O 120.891 0.377 . . . . 2.5 110.705 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.68 113.9 11.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.635 -0.711 . . . . 0.95 109.845 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.747 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.1 pt -96.13 -15.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 115.351 -0.841 . . . . 1.03 111.833 -171.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.21 175.88 42.24 Favored Glycine 0 CA--C 1.502 -0.774 0 N-CA-C 111.478 -0.649 . . . . 0.11 111.478 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.62 148.67 36.18 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.096 0.474 . . . . 0.24 110.949 -174.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.3 mm -75.89 123.09 31.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.689 -0.687 . . . . 1.03 111.02 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.4 p -114.63 -26.35 7.92 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.364 0.602 . . . . 1.01 110.395 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.507 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 83.6 tttt -136.21 145.82 46.12 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.584 -0.895 . . . . 2.86 108.584 172.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.437 HD12 HG22 ' A' ' 14' ' ' VAL . 5.4 tt -158.42 141.18 14.57 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.972 0.415 . . . . 1.03 110.513 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -152.12 146.45 25.51 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-N 115.705 -0.68 . . . . 1.94 111.433 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.97 -152.34 28.38 Favored Glycine 0 N--CA 1.428 -1.884 0 CA-C-N 114.928 -1.033 . . . . 0.32 113.115 168.334 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 39.8 m -95.01 118.64 32.17 Favored 'General case' 0 N--CA 1.445 -0.681 0 N-CA-C 109.747 -0.464 . . . . 1.65 109.747 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.437 HG22 HD12 ' A' ' 10' ' ' LEU . 2.8 m -136.45 151.22 28.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 1.09 111.678 -177.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -152.21 158.99 43.63 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 114.585 -1.189 . . . . 1.0 108.841 179.214 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.5 OUTLIER -136.67 133.57 48.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 C-N-CA 119.829 -0.749 . . . . 1.03 111.305 174.192 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.439 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.9 mt-30 -102.75 100.19 10.2 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.089 -0.96 . . . . 0.72 109.794 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.419 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 26.5 p -62.65 179.2 0.36 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.484 0.179 . . . . 1.63 111.484 -176.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 11.8 pt -58.66 -27.89 35.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.78 0.324 . . . . 1.12 111.661 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -75.42 -11.75 60.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.967 0.413 . . . . 1.96 110.617 178.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.46 21.26 48.95 Favored Glycine 0 CA--C 1.505 -0.563 0 N-CA-C 110.739 -0.945 . . . . 0.34 110.739 -178.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -92.57 121.12 33.69 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.93 -0.635 . . . . 2.76 110.396 -178.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.592 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.9 tt0 -93.72 116.74 29.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.985 0.422 . . . . 1.0 110.931 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.497 ' HG2' HG11 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -118.98 169.36 9.96 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.948 -0.569 . . . . 2.1 109.82 176.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.37 143.14 11.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.82 -0.627 . . . . 1.11 109.738 178.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 18.4 mt -107.85 127.23 53.54 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.154 -0.475 . . . . 1.1 110.826 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -110.05 179.59 4.06 Favored 'General case' 0 C--N 1.319 -0.761 0 N-CA-C 108.709 -0.849 . . . . 2.19 108.709 172.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.19 145.82 52.92 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.144 -0.622 . . . . 1.1 109.695 174.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.63 2.2 87.72 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.137 -1.03 . . . . 0.25 112.416 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 57.9 m-20 -78.95 142.77 60.63 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.044 0.45 . . . . 1.92 110.701 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -77.34 138.71 17.95 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.038 2.492 . . . . 0.31 113.11 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.9 mm -103.83 135.23 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.687 0 CA-C-N 115.411 -0.813 . . . . 1.02 108.847 170.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -114.51 155.5 26.31 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 116.017 -0.538 . . . . 0.37 109.947 -178.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.448 ' HB2' HG23 ' A' ' 4' ' ' ILE . 2.2 t80 -71.19 109.89 5.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.036 -0.529 . . . . 0.2 110.243 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.12 0.22 10.6 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.455 -0.878 . . . . 0.17 113.406 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.483 ' O ' ' HG2' ' A' ' 66' ' ' MET . 32.7 mt-10 -86.92 147.98 25.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 117.856 0.828 . . . . 0.52 110.645 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.445 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 17.5 m -108.06 108.63 19.81 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.662 -0.699 . . . . 1.03 110.391 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.0 t -83.69 130.3 36.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.028 0.442 . . . . 1.04 110.618 -174.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.0 mp -117.46 108.02 15.02 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.357 -0.838 . . . . 1.1 110.032 -178.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.0 p -101.02 152.97 19.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.235 -0.654 . . . . 1.06 109.235 176.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.903 0 C-N-CA 120.622 -0.799 . . . . 0.9 112.417 -177.989 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.4 m . . . . . 0 C--O 1.223 -0.303 0 CA-C-O 120.977 0.417 . . . . 1.16 110.264 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.2 t -121.2 143.77 32.44 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 120.706 0.289 . . . . 1.09 110.758 -174.429 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.507 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -120.91 110.99 16.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.179 -0.464 . . . . 1.03 109.928 175.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.535 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 55.9 mt -99.68 104.6 16.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.785 -0.643 . . . . 1.05 110.107 178.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.03 100.98 8.42 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.191 -0.913 . . . . 1.03 109.424 177.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.476 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 68.4 m-85 -68.54 146.28 53.25 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-O 121.586 0.708 . . . . 0.45 110.727 -178.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.4 p -70.99 1.62 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.567 -1.197 . . . . 1.07 110.991 -173.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -86.0 -20.84 28.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.32 -0.854 . . . . 0.75 110.432 175.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 111.97 -11.95 27.04 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 111.25 -0.74 . . . . 0.32 111.25 -175.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.68 151.98 24.08 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.352 -0.424 . . . . 1.09 110.478 176.179 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -133.0 138.94 47.0 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.08 -0.341 . . . . 1.51 110.08 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.535 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.7 m -118.32 164.47 14.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.115 0.483 . . . . 2.06 111.47 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.0 p -133.64 135.4 55.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.402 -0.817 . . . . 1.58 110.249 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 14.6 mt -109.15 133.7 53.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.977 -0.556 . . . . 1.08 110.101 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.72 -169.78 36.7 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.147 -0.549 . . . . 1.02 111.811 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.87 149.98 17.05 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.934 -0.651 . . . . 0.64 111.789 -173.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.3 t70 61.02 20.54 10.96 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 121.926 0.87 . . . . 1.26 109.523 -174.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.7 t -106.69 159.05 16.5 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.346 -0.843 . . . . 1.64 110.686 -177.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.448 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.3 mt -140.3 124.55 18.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.8 -0.636 . . . . 1.08 109.922 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 13.1 p -147.09 143.76 20.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.814 0.34 . . . . 1.66 110.822 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.445 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.4 tt0 -99.27 133.92 42.88 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.968 0.413 . . . . 0.67 110.587 -179.26 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.561 ' CE ' HG22 ' A' ' 70' ' ' ILE . 47.0 mmm -73.83 88.99 1.81 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.651 -0.704 . . . . 1.13 110.815 -177.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.3 p -119.02 -164.71 1.06 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.434 -0.348 . . . . 1.15 110.088 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -67.69 -26.86 66.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.409 0.624 . . . . 2.13 109.52 177.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -63.14 -25.7 68.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.131 -0.941 . . . . 2.51 109.888 177.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.561 HG22 ' CE ' ' A' ' 66' ' ' MET . 0.9 OUTLIER -96.87 -55.31 6.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 114.743 -1.117 . . . . 1.1 110.595 177.794 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.747 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.3 t80 . . . . . 0 C--N 1.319 -0.757 0 CA-C-N 115.326 -0.852 . . . . 0.91 110.157 -174.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.7 m120 . . . . . 0 CA--C 1.514 -0.42 0 CA-C-O 120.905 0.383 . . . . 2.5 110.443 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.66 109.28 12.74 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 115.684 -0.689 . . . . 0.95 109.328 175.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.793 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.1 pt -89.18 -12.05 10.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.32 -0.854 . . . . 1.03 111.632 -171.363 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.35 174.03 40.38 Favored Glycine 0 CA--C 1.501 -0.837 0 C-N-CA 120.858 -0.687 . . . . 0.11 111.55 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -144.91 149.7 35.75 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.013 0.435 . . . . 0.24 110.327 -176.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.567 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.66 124.54 36.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-N 115.699 -0.682 . . . . 1.03 110.871 -177.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 67.9 p -117.6 -16.83 10.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.378 0.609 . . . . 1.01 110.875 178.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.426 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 27.4 tptp -146.73 138.59 24.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.335 -0.987 . . . . 2.86 108.335 172.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.5 tt -150.37 148.03 28.3 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.807 -0.357 . . . . 1.03 110.8 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -157.48 154.49 28.78 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.923 -0.58 . . . . 1.94 110.274 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.81 -157.4 48.85 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.11 -0.567 . . . . 0.32 113.466 172.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 33.4 m -100.07 115.0 28.73 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.366 -0.417 . . . . 1.65 110.056 -178.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.46 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.6 m -133.7 152.57 35.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.525 0.678 . . . . 1.09 111.599 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.39 158.56 43.89 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 114.866 -1.061 . . . . 1.0 109.045 -178.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.602 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.7 OUTLIER -134.59 139.49 47.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 C-N-CA 120.131 -0.628 . . . . 1.03 110.857 173.007 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -104.21 99.88 9.61 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.204 -0.907 . . . . 0.72 109.251 175.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.499 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 68.6 p -63.75 -179.39 0.38 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.638 0.256 . . . . 1.63 110.935 -176.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -69.35 -3.33 2.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.944 0.402 . . . . 1.12 111.514 178.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -94.19 -7.01 43.46 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.461 -0.57 . . . . 1.96 109.461 173.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.36 19.9 65.58 Favored Glycine 0 CA--C 1.503 -0.681 0 N-CA-C 110.881 -0.888 . . . . 0.34 110.881 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -92.76 123.12 35.81 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.829 -0.686 . . . . 2.76 110.877 -177.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.602 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 19.8 tt0 -89.16 118.46 28.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.355 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.471 ' HG2' HG13 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -121.62 166.57 14.04 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.461 -0.57 . . . . 2.1 109.461 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.3 p -89.85 135.26 26.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 109.127 -0.694 . . . . 1.11 109.127 177.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.503 HD23 ' CG ' ' A' ' 30' ' ' ASP . 4.3 mt -95.79 146.95 24.13 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.227 0.537 . . . . 1.1 110.902 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 33.2 mttp -138.07 171.98 13.6 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.059 -0.973 . . . . 2.19 108.544 -176.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.82 139.02 58.28 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 119.285 -0.966 . . . . 1.1 109.254 177.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.35 89.89 Favored Glycine 0 N--CA 1.437 -1.265 0 C-N-CA 119.865 -1.16 . . . . 0.25 112.478 178.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.567 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -76.94 140.4 66.78 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 121.54 0.686 . . . . 1.92 110.48 178.581 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.14 129.3 7.73 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.601 2.868 . . . . 0.31 113.848 -176.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.2 mm -97.39 132.86 41.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 115.588 -0.733 . . . . 1.02 109.187 173.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -113.27 159.75 19.03 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.855 -0.612 . . . . 0.37 109.786 -177.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.464 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.9 t80 -74.52 116.05 14.76 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.285 -0.416 . . . . 0.2 110.16 -175.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.33 9.51 27.32 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.57 -0.824 . . . . 0.17 113.265 177.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.499 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 38.7 mt-10 -90.61 139.92 30.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 118.088 0.944 . . . . 0.52 110.343 177.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.3 m -98.28 106.25 18.51 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.207 -0.906 . . . . 1.03 110.727 -176.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.564 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.4 t -82.38 125.78 39.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.158 0.504 . . . . 1.04 110.771 -174.545 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -110.2 105.2 14.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.136 -0.938 . . . . 1.1 109.701 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 62.7 p -109.79 143.66 39.32 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.987 -0.375 . . . . 1.06 109.987 178.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.96 0 C-N-CA 120.485 -0.865 . . . . 0.9 111.633 177.86 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.683 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 49.2 m . . . . . 0 CA--C 1.512 -0.492 0 N-CA-C 109.748 -0.464 . . . . 1.16 109.748 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 6.1 t -142.92 119.99 6.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 CA-C-O 121.003 0.43 . . . . 1.09 111.286 -171.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.426 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 88.6 m -92.21 103.65 16.1 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.573 -0.739 . . . . 1.03 109.934 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.408 HD13 ' HE1' ' A' ' 66' ' ' MET . 68.2 mt -94.88 99.55 9.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 114.982 -1.008 . . . . 1.05 109.51 177.077 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.16 107.54 13.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.395 -0.82 . . . . 1.03 109.497 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.543 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 57.1 m-85 -70.7 145.67 50.39 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.47 0.652 . . . . 0.45 110.947 -177.228 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.9 p -70.98 1.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.76 -1.109 . . . . 1.07 111.754 -172.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.73 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 13.8 t70 -99.42 -16.42 18.39 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.86 0.362 . . . . 0.75 110.815 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.85 -14.76 9.06 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.466 -0.873 . . . . 0.32 112.374 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.7 p -84.38 154.61 22.74 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.372 -0.233 . . . . 1.09 110.372 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -133.67 138.2 45.75 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 120.964 0.411 . . . . 1.51 110.345 -179.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.455 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 1.1 t -123.33 150.41 27.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.983 -0.553 . . . . 2.06 110.286 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.488 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -135.54 129.91 49.61 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.419 0.628 . . . . 1.58 110.731 178.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.683 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.3 mt -94.3 139.04 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.545 -0.752 . . . . 1.08 109.599 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.85 -57.4 2.42 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 121.199 -0.524 . . . . 1.02 112.716 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 150.46 158.56 8.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.874 -0.679 . . . . 0.64 111.857 178.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.6 t70 51.83 43.23 30.25 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.703 0.763 . . . . 1.26 110.521 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.5 t -129.28 158.08 40.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.757 -0.656 . . . . 1.64 110.394 -176.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.564 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -140.28 106.88 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.536 -0.756 . . . . 1.08 109.148 177.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.33 140.41 44.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.897 0.38 . . . . 1.66 111.02 -174.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.452 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.8 tt0 -91.81 128.64 37.72 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.67 109.729 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.473 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 55.8 mmm -66.28 89.45 0.13 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.149 -0.478 . . . . 1.13 110.313 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 59.4 p -110.81 -166.47 1.08 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.871 -0.604 . . . . 1.15 111.724 -174.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.01 -33.41 74.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 2.13 110.323 178.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -70.35 -25.66 63.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.731 0.777 . . . . 2.51 109.975 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.406 HG23 ' HE3' ' A' ' 66' ' ' MET . 1.3 mm -80.06 -53.51 12.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 114.596 -1.183 . . . . 1.1 111.079 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.793 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 . . . . . 0 C--N 1.316 -0.868 0 CA-C-N 115.355 -0.839 . . . . 0.91 110.274 -175.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 19.5 m120 . . . . . 0 CA--C 1.518 -0.267 0 N-CA-C 109.994 -0.372 . . . . 2.5 109.994 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.52 116.68 17.43 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 121.438 0.637 . . . . 0.95 110.342 -178.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.782 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.1 pt -101.92 -14.62 8.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.095 -0.957 . . . . 1.03 111.811 -171.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.81 179.22 41.27 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 120.796 -0.716 . . . . 0.11 111.415 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -143.79 152.51 41.32 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.939 0.4 . . . . 0.24 110.569 -175.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.461 HG12 ' O ' ' A' ' 30' ' ' ASP . 34.2 mm -80.21 119.97 30.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.203 -0.453 . . . . 1.03 110.945 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.2 p -113.12 -18.71 12.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.281 0.563 . . . . 1.01 110.586 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.528 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.9 tttt -144.81 145.08 31.47 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.236 -1.024 . . . . 2.86 108.236 172.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.0 tt -159.91 142.34 13.42 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.792 0.33 . . . . 1.03 111.019 -177.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -150.67 153.25 35.26 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.779 -0.646 . . . . 1.94 111.274 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.22 -155.14 50.18 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.982 -0.554 . . . . 0.32 113.235 174.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 27.2 t -97.91 119.7 36.99 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.878 -0.415 . . . . 1.65 109.878 -178.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.435 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 2.7 m -132.09 152.98 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.415 0.626 . . . . 1.09 110.828 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.28 159.15 44.66 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.725 -1.125 . . . . 1.0 108.174 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.579 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.5 OUTLIER -134.97 130.44 52.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 C-N-CA 119.545 -0.862 . . . . 1.03 110.817 173.816 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.404 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.8 mt-30 -96.15 98.61 10.47 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.269 -0.878 . . . . 0.72 109.255 175.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.5 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 15.9 m -63.79 176.49 0.91 Allowed 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.031 -0.532 . . . . 1.63 110.816 -176.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.6 pt -56.81 -28.03 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 112.687 0.625 . . . . 1.12 112.687 -173.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -82.63 -1.1 50.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.788 0.328 . . . . 1.96 110.963 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 89.35 8.02 68.89 Favored Glycine 0 CA--C 1.506 -0.529 0 N-CA-C 111.047 -0.821 . . . . 0.34 111.047 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 87.7 mm-40 -79.15 115.6 18.91 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.937 -0.631 . . . . 2.76 111.115 -177.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.579 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.6 tt0 -88.15 111.25 21.39 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.94 -0.573 . . . . 1.0 110.533 178.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.522 ' HG2' HG11 ' A' ' 16' ' ' VAL . 16.8 ptt85 -112.22 170.78 7.93 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.214 -0.662 . . . . 2.1 109.214 176.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.93 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 109.772 -0.455 . . . . 1.11 109.772 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.435 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 21.2 mt -109.98 128.29 55.3 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.942 -0.572 . . . . 1.1 110.593 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -116.03 -173.9 2.44 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 108.056 -1.09 . . . . 2.19 108.056 171.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.83 143.5 52.87 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.734 -0.786 . . . . 1.1 109.389 175.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.51 -2.75 84.69 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.295 -0.955 . . . . 0.25 112.946 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.461 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.3 m-20 -73.0 143.7 84.31 Favored Pre-proline 0 CA--C 1.512 -0.488 0 N-CA-C 109.556 -0.535 . . . . 1.92 109.556 174.392 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -87.64 141.56 5.58 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.922 2.415 . . . . 0.31 112.41 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mm -100.93 139.16 22.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.662 -0.496 . . . . 1.02 109.662 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -115.33 150.0 36.98 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 116.019 -0.537 . . . . 0.37 109.676 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.462 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -68.41 113.24 5.8 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.276 -0.42 . . . . 0.2 110.322 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.68 -1.23 13.81 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.368 -0.92 . . . . 0.17 113.463 178.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.5 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.9 mt-10 -85.48 148.6 25.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 117.789 0.795 . . . . 0.52 110.951 -178.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 8.6 m -106.83 105.95 16.23 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.621 -0.718 . . . . 1.03 110.642 -176.765 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.555 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -81.86 126.39 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.351 0.596 . . . . 1.04 110.777 -174.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -114.76 100.76 8.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.83 -1.077 . . . . 1.1 109.851 -177.203 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.6 p -99.02 152.88 19.34 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.284 -0.636 . . . . 1.06 109.284 176.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.714 0 C-N-CA 120.34 -0.933 . . . . 0.9 112.526 -179.425 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 8.7 m . . . . . 0 C--O 1.225 -0.191 0 N-CA-C 108.646 -0.872 . . . . 1.16 108.646 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.5 t -148.4 134.05 11.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 O-C-N 122.012 -0.43 . . . . 1.09 110.958 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.528 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.2 m -109.84 108.16 18.38 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.76 -0.459 . . . . 1.03 109.76 173.182 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.536 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 56.7 mt -99.14 104.22 15.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.593 -0.73 . . . . 1.05 109.969 178.112 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.43 107.34 12.12 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.405 -0.816 . . . . 1.03 109.133 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.448 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 63.0 m-85 -73.72 146.63 44.27 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.491 0.662 . . . . 0.45 110.899 -177.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -77.36 0.89 2.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 114.821 -1.081 . . . . 1.07 111.398 -170.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.36 -21.75 27.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.223 0.535 . . . . 0.75 109.948 173.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.56 -12.69 7.41 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.77 -0.729 . . . . 0.32 112.802 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.0 p -87.5 162.98 16.93 Favored 'General case' 0 C--N 1.327 -0.412 0 O-C-N 122.821 -0.223 . . . . 1.09 111.074 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.2 147.46 50.73 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.762 -0.458 . . . . 1.51 109.762 176.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.536 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 11.9 m -128.2 161.2 37.05 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 CA-C-O 121.264 0.554 . . . . 2.06 111.25 175.545 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.596 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 97.9 t -135.06 123.93 41.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.814 -1.084 . . . . 1.58 110.159 178.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 45' ' ' SER . 24.0 mt -96.55 133.92 36.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.445 -0.798 . . . . 1.08 110.191 -177.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -76.58 -163.91 17.67 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.047 -0.597 . . . . 1.02 112.346 177.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.07 149.86 17.85 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 111.208 -0.757 . . . . 0.64 111.208 -174.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.5 t70 60.85 20.86 11.05 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 121.901 0.858 . . . . 1.26 109.744 -175.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.0 m -102.94 154.18 19.47 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.572 -0.74 . . . . 1.64 110.967 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.555 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.4 mt -141.68 109.69 2.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.35 -0.841 . . . . 1.08 109.727 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.3 p -139.81 142.45 32.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.803 0.335 . . . . 1.66 110.827 -177.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.419 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 34.7 tt0 -91.16 132.87 35.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.929 0.395 . . . . 0.67 110.488 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.48 ' HE3' HD13 ' A' ' 48' ' ' ILE . 63.4 mmm -67.13 89.88 0.19 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.448 -0.796 . . . . 1.13 110.808 -177.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.6 p -117.77 -162.99 0.9 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.488 -0.778 . . . . 1.15 111.305 -175.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -66.92 -40.93 87.8 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.733 0.272 . . . . 2.13 111.733 -175.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -64.57 -26.17 68.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.687 0.756 . . . . 2.51 110.605 177.158 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.418 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.6 mm -76.36 -51.33 19.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.766 -1.106 . . . . 1.1 110.557 174.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.782 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.318 -0.769 0 CA-C-N 115.33 -0.85 . . . . 0.91 110.106 -177.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 CA--C 1.514 -0.421 0 CA-C-O 121.001 0.429 . . . . 2.5 110.778 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.95 109.61 13.39 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.622 -0.717 . . . . 0.95 109.91 -178.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.763 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.4 pt -88.86 -14.9 9.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.179 -0.918 . . . . 1.03 111.616 -171.117 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -166.98 177.15 41.79 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.886 -0.673 . . . . 0.11 111.465 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -143.95 150.67 38.7 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.951 0.405 . . . . 0.24 110.529 -175.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.601 HG12 ' O ' ' A' ' 30' ' ' ASP . 20.7 mm -78.75 122.2 33.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.981 -0.554 . . . . 1.03 110.78 -178.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.7 p -114.75 -21.79 10.01 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.311 0.576 . . . . 1.01 110.67 179.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.601 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 36.1 ttpt -141.1 145.71 36.15 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.417 -0.957 . . . . 2.86 108.417 172.407 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -156.66 144.73 19.52 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 120.774 0.321 . . . . 1.03 110.684 -177.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 6.3 t70 -151.75 148.32 27.74 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.881 -0.6 . . . . 1.94 110.73 -178.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.96 -152.46 43.98 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.09 -0.576 . . . . 0.32 113.503 173.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 9.0 t -103.63 120.07 40.16 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.927 -0.397 . . . . 1.65 109.927 -177.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.446 HG22 ' HB2' ' A' ' 26' ' ' LEU . 3.9 m -135.83 153.2 32.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 1.09 111.859 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.43 159.65 44.32 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.881 -1.054 . . . . 1.0 109.457 -177.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.55 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -134.21 136.66 53.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 C-N-CA 120.152 -0.619 . . . . 1.03 110.984 173.188 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -103.28 103.52 13.55 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.155 -0.929 . . . . 0.72 109.641 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.519 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 47.6 t -62.05 176.8 0.52 Allowed 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.572 -0.451 . . . . 1.63 110.392 -178.209 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.3 pt -60.36 -31.13 47.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-O 121.107 0.48 . . . . 1.12 111.869 -173.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -74.35 -14.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.865 -0.607 . . . . 1.96 110.916 177.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.1 10.27 46.06 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.146 -0.55 . . . . 0.34 112.522 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 -80.94 119.94 24.11 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.901 0.382 . . . . 2.76 111.214 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.55 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 18.5 tt0 -88.77 119.49 29.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.623 179.192 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.514 ' HG2' HG13 ' A' ' 16' ' ' VAL . 21.3 ptt-85 -119.1 166.1 13.34 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.43 -0.581 . . . . 2.1 109.43 174.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -86.56 137.58 20.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.942 -0.572 . . . . 1.11 109.483 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.518 HD23 ' OD1' ' A' ' 30' ' ' ASP . 4.0 mt -102.08 151.88 21.64 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.196 0.522 . . . . 1.1 111.167 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.5 mttt -139.57 175.97 9.12 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.105 -0.952 . . . . 2.19 108.479 -175.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.95 140.92 49.4 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.566 -0.853 . . . . 1.1 108.957 176.487 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.77 6.04 86.81 Favored Glycine 0 N--CA 1.435 -1.389 0 C-N-CA 119.877 -1.154 . . . . 0.25 112.218 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.601 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.0 138.81 46.07 Favored Pre-proline 0 N--CA 1.454 -0.248 0 CA-C-O 121.75 0.786 . . . . 1.92 110.35 178.19 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.92 130.29 11.27 Favored 'Trans proline' 0 C--N 1.325 -0.682 0 C-N-CA 123.719 2.946 . . . . 0.31 113.509 -178.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.453 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 26.3 mm -96.02 136.54 26.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 CA-C-N 115.349 -0.841 . . . . 1.02 109.266 173.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -117.87 151.35 37.56 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 109.565 -0.531 . . . . 0.37 109.565 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.422 ' HB2' HG22 ' A' ' 4' ' ' ILE . 1.9 t80 -67.1 126.29 28.7 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.988 -0.551 . . . . 0.2 110.188 -176.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.21 -12.8 33.88 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.462 -0.875 . . . . 0.17 113.074 178.182 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.519 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.7 mt-10 -82.04 139.39 34.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.584 0.707 . . . . 0.52 111.072 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 17.8 m -98.74 109.98 22.65 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.684 -1.144 . . . . 1.03 110.718 -177.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -82.19 132.9 30.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.48 -0.488 . . . . 1.04 110.618 -175.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -119.61 113.33 20.53 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.516 -0.766 . . . . 1.1 110.298 -177.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 71.5 p -105.49 153.19 22.06 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.274 -0.639 . . . . 1.06 109.274 173.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.815 0 C-N-CA 120.587 -0.816 . . . . 0.9 111.076 177.756 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 25.4 m . . . . . 0 C--O 1.222 -0.354 0 N-CA-C 109.182 -0.673 . . . . 1.16 109.182 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.616 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.4 t -148.32 145.02 18.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 O-C-N 122.242 -0.286 . . . . 1.09 110.334 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.601 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 97.9 m -115.98 106.81 14.2 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.158 0.504 . . . . 1.03 109.87 172.268 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.0 103.0 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.291 -0.868 . . . . 1.05 109.807 178.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.74 103.67 8.85 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.463 -0.79 . . . . 1.03 109.287 177.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.568 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 50.5 m-85 -68.73 147.09 52.32 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.618 0.723 . . . . 0.45 110.907 -178.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.2 p -74.46 1.66 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.518 -1.219 . . . . 1.07 111.459 -172.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.463 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 22.0 t70 -97.26 -0.93 45.81 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.307 0.575 . . . . 0.75 109.752 177.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.61 -10.94 49.96 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.859 -0.686 . . . . 0.32 112.847 177.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.3 p -87.79 164.08 16.13 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.534 -0.173 . . . . 1.09 110.534 177.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -135.94 153.32 51.46 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.819 -0.438 . . . . 1.51 109.819 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.568 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.7 OUTLIER -135.41 147.66 28.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.968 0.413 . . . . 2.06 110.542 -179.102 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.616 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 89.5 t -125.84 130.22 72.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.638 -0.71 . . . . 1.58 110.176 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.453 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.1 mt -102.86 144.69 13.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.984 -0.553 . . . . 1.08 110.614 -176.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -88.93 -161.53 37.57 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.926 -0.579 . . . . 1.02 112.11 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -113.63 147.96 18.65 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.431 -0.668 . . . . 0.64 111.431 -174.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 29.7 t70 53.46 28.84 8.06 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.981 0.896 . . . . 1.26 109.888 -173.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.8 m -110.49 157.13 19.95 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.085 -0.961 . . . . 1.64 110.809 -179.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.41 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.8 mt -140.96 123.76 15.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.456 -0.793 . . . . 1.08 109.731 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.6 p -149.55 145.02 17.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 1.66 110.525 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.513 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 44.0 tt0 -98.17 134.69 40.88 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.28 -0.418 . . . . 0.67 111.076 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.548 ' SD ' HG23 ' A' ' 70' ' ' ILE . 21.8 mmt -64.32 89.24 0.06 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.704 -0.68 . . . . 1.13 110.725 175.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 16.5 p -121.59 -168.22 1.65 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.654 -0.703 . . . . 1.15 110.312 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -68.07 -25.25 65.25 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.272 0.558 . . . . 2.13 109.787 177.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 25.8 mm-40 -65.97 -21.73 66.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.41 -0.814 . . . . 2.51 110.098 177.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.548 HG23 ' SD ' ' A' ' 66' ' ' MET . 1.5 mm -103.02 -53.86 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 CA-C-N 114.721 -1.127 . . . . 1.1 110.883 -179.565 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.763 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 4.0 t80 . . . . . 0 C--N 1.318 -0.77 0 CA-C-N 115.261 -0.881 . . . . 0.91 110.226 -176.684 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 . . . . . 0 N--CA 1.465 0.31 0 CA-C-O 121.307 0.575 . . . . 2.5 110.434 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.39 116.29 21.15 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.4 0.619 . . . . 0.95 110.654 -174.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.78 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.0 pt -105.55 -14.4 8.97 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.855 -1.066 . . . . 1.03 111.765 -173.048 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.53 177.77 41.81 Favored Glycine 0 CA--C 1.5 -0.894 0 N-CA-C 111.046 -0.822 . . . . 0.11 111.046 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -144.12 151.18 39.23 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.979 0.419 . . . . 0.24 111.034 -175.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.426 HD12 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -78.62 120.85 30.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.715 -0.675 . . . . 1.03 110.717 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.0 p -113.25 -23.35 9.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.259 0.552 . . . . 1.01 110.205 179.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.603 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 37.8 ttpt -140.63 144.93 36.02 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.524 -0.762 . . . . 2.86 109.069 172.343 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.3 tt -155.8 144.62 20.45 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 110.292 -0.262 . . . . 1.03 110.292 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -153.17 152.36 31.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.16 -0.473 . . . . 1.94 111.136 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.25 -144.11 29.21 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.975 -0.557 . . . . 0.32 112.74 175.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t -113.61 123.31 49.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.428 -0.582 . . . . 1.65 109.428 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.457 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -138.16 152.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 1.09 111.62 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.84 159.39 44.21 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.798 -1.092 . . . . 1.0 108.175 177.454 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.475 HG21 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -132.33 133.18 60.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 C-N-CA 120.11 -0.636 . . . . 1.03 110.46 175.475 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.42 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.0 mt-30 -96.04 98.56 10.46 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.461 -0.79 . . . . 0.72 109.327 178.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.522 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 25.0 m -63.62 173.43 1.69 Allowed 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.865 -0.607 . . . . 1.63 110.035 -177.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 9.1 pt -64.55 -3.31 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 N-CA-C 114.238 1.199 . . . . 1.12 114.238 -168.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -106.03 6.98 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.344 0.592 . . . . 1.96 109.823 174.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.62 6.56 80.17 Favored Glycine 0 CA--C 1.504 -0.606 0 N-CA-C 110.75 -0.94 . . . . 0.34 110.75 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.581 ' HA ' HE22 ' A' ' 22' ' ' GLN . 0.0 OUTLIER -78.4 117.44 19.62 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.833 -0.684 . . . . 2.76 111.403 -175.619 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -80.63 126.39 31.2 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.232 0.539 . . . . 1.0 110.582 178.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.4 ' NH2' ' HD2' ' A' ' 31' ' ' PRO . 0.0 OUTLIER -130.41 144.59 51.49 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.452 -0.794 . . . . 2.1 109.239 179.974 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.3 p -78.2 142.76 13.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.963 0.411 . . . . 1.11 110.242 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.457 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 25.5 mt -108.07 128.82 55.02 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.168 -0.469 . . . . 1.1 110.615 178.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.2 mttm -111.13 -178.0 3.35 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.298 -1.001 . . . . 2.19 108.298 172.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.2 144.49 53.72 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 119.618 -0.833 . . . . 1.1 109.193 173.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.47 2.8 89.83 Favored Glycine 0 N--CA 1.439 -1.139 0 C-N-CA 120.249 -0.977 . . . . 0.25 112.551 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.412 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -70.53 145.27 92.53 Favored Pre-proline 0 CA--C 1.51 -0.571 0 CA-C-O 121.218 0.533 . . . . 1.92 109.923 174.418 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.4 ' HD2' ' NH2' ' A' ' 24' ' ' ARG . 21.7 Cg_endo -90.04 135.75 2.36 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 123.251 2.634 . . . . 0.31 111.851 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -97.99 135.29 33.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.539 -0.541 . . . . 1.02 109.539 177.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -112.19 144.37 41.69 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.63 -0.714 . . . . 0.37 109.894 -177.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.51 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.5 t80 -66.09 109.22 2.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.24 -0.437 . . . . 0.2 109.987 -177.056 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.75 -4.19 8.03 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.308 -0.949 . . . . 0.17 113.754 178.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.522 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 26.2 mt-10 -86.72 151.23 23.57 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 118.223 1.012 . . . . 0.52 110.831 -177.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.42 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 25.6 m -111.15 107.49 16.86 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.467 -0.788 . . . . 1.03 110.687 -176.547 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.665 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.9 t -78.67 129.77 37.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 120.896 0.379 . . . . 1.04 111.28 -173.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -113.23 98.41 7.1 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.527 -0.761 . . . . 1.1 109.913 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 82.5 p -96.4 152.99 18.08 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.584 -0.525 . . . . 1.06 109.584 177.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.994 0 N-CA-C 111.517 -0.633 . . . . 0.9 111.517 178.779 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.56 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 69.6 m . . . . . 0 C--O 1.222 -0.346 0 N-CA-C 109.172 -0.677 . . . . 1.16 109.172 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 19.4 t -145.85 137.49 19.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 120.602 0.239 . . . . 1.09 110.531 -177.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.603 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 87.2 m -111.36 106.74 15.77 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.042 -0.527 . . . . 1.03 109.992 174.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.556 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.3 mt -97.87 103.16 14.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.654 -0.703 . . . . 1.05 110.009 177.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.44 105.48 9.73 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.303 -0.862 . . . . 1.03 109.25 177.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.481 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.5 m-85 -72.92 145.76 46.58 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.563 0.697 . . . . 0.45 110.584 -178.623 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.0 p -74.07 -8.5 11.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 114.677 -1.147 . . . . 1.07 111.655 -169.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.437 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 15.2 t70 -81.62 -21.06 38.51 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.221 -0.445 . . . . 0.75 110.504 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.37 -13.52 6.25 Favored Glycine 0 CA--C 1.519 0.321 0 C-N-CA 120.567 -0.825 . . . . 0.32 113.045 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.8 p -87.76 162.45 17.03 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 122.727 -0.278 . . . . 1.09 111.344 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -135.41 148.0 49.18 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.96 -0.756 . . . . 1.51 108.96 177.097 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.556 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.6 m -129.7 166.54 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.574 0 CA-C-O 121.213 0.53 . . . . 2.06 111.96 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.61 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.9 p -133.12 135.89 56.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 114.908 -1.042 . . . . 1.58 110.15 176.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.3 mt -108.23 134.54 49.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.861 -0.609 . . . . 1.08 109.656 178.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.65 -159.49 21.18 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.206 -0.521 . . . . 1.02 112.336 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.7 146.66 18.32 Favored Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.901 -0.666 . . . . 0.64 111.775 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.416 ' HA ' ' O ' ' A' ' 40' ' ' THR . 29.2 t70 56.77 26.39 11.39 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 121.702 0.763 . . . . 1.26 109.909 -174.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 t -103.91 156.97 17.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.536 -0.756 . . . . 1.64 110.495 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.665 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.7 mt -142.47 104.49 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.504 -0.771 . . . . 1.08 109.16 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.1 m -131.93 150.13 33.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.006 0.431 . . . . 1.66 111.736 -175.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -102.84 128.09 49.75 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.626 -0.715 . . . . 0.67 110.609 -177.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.508 ' CE ' HG22 ' A' ' 70' ' ' ILE . 51.3 mmm -67.72 89.58 0.26 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.522 -0.763 . . . . 1.13 110.666 -177.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.5 p -121.37 -167.45 1.51 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.006 -0.543 . . . . 1.15 111.118 -177.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -65.59 -29.6 70.22 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.735 0.303 . . . . 2.13 110.846 -178.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.49 -17.3 62.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.6 0.714 . . . . 2.51 110.354 177.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.508 HG22 ' CE ' ' A' ' 66' ' ' MET . 1.1 mm -96.04 -50.43 11.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 115.127 -0.942 . . . . 1.1 110.562 177.455 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.78 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.317 -0.842 0 CA-C-N 115.363 -0.835 . . . . 0.91 109.658 -177.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 . . . . . 0 C--O 1.235 0.326 0 CA-C-O 120.848 0.356 . . . . 2.5 110.224 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.14 113.18 14.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.774 -0.648 . . . . 0.95 110.282 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.775 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.3 pt -92.01 -16.77 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.085 -0.961 . . . . 1.03 111.646 -172.192 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.42 177.25 40.82 Favored Glycine 0 CA--C 1.501 -0.816 0 C-N-CA 120.787 -0.72 . . . . 0.11 111.535 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -144.59 152.08 39.98 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 120.788 0.328 . . . . 0.24 110.291 -174.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.558 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.1 mm -80.09 123.29 36.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.272 -0.422 . . . . 1.03 111.146 -178.245 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.5 p -112.79 -23.64 10.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.117 0.484 . . . . 1.01 110.461 178.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.489 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 34.9 ttpt -141.88 145.51 34.69 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.706 -0.85 . . . . 2.86 108.706 173.459 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -158.63 144.84 17.0 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.595 0.236 . . . . 1.03 110.436 -176.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -154.2 152.44 30.36 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.017 -0.538 . . . . 1.94 110.735 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.46 -156.03 46.11 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.988 -0.551 . . . . 0.32 113.245 174.124 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 25.4 t -99.17 120.49 39.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.293 -0.632 . . . . 1.65 109.293 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.431 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 4.6 m -137.75 152.33 26.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.659 0.743 . . . . 1.09 111.729 -175.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.08 158.92 44.67 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 114.582 -1.19 . . . . 1.0 108.863 -178.399 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.687 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.6 OUTLIER -136.4 132.37 48.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 C-N-CA 119.99 -0.684 . . . . 1.03 110.982 172.221 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.4 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.7 mt-30 -96.67 99.01 10.64 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.092 -0.958 . . . . 0.72 109.284 174.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.46 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.6 m -66.32 179.6 0.95 Allowed 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.971 -0.292 . . . . 1.63 110.811 -176.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.2 pt -60.24 -26.76 37.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 O-C-N 121.886 -0.509 . . . . 1.12 112.218 -175.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 -79.69 -8.79 59.45 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.998 0.428 . . . . 1.96 110.62 178.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.8 5.81 62.58 Favored Glycine 0 CA--C 1.506 -0.478 0 N-CA-C 111.234 -0.746 . . . . 0.34 111.234 178.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -74.44 117.97 16.86 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.305 -0.447 . . . . 2.76 110.819 -179.383 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.687 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.5 tt0 -95.09 110.43 22.36 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.168 0.508 . . . . 1.0 110.224 177.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.495 ' HG2' HG11 ' A' ' 16' ' ' VAL . 17.1 ptt-85 -111.61 167.92 9.96 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.952 -0.567 . . . . 2.1 109.906 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.0 p -86.61 129.47 38.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.821 -0.627 . . . . 1.11 109.317 176.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.502 HD23 ' OD1' ' A' ' 30' ' ' ASP . 2.8 mt -91.07 143.54 26.6 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 121.526 0.679 . . . . 1.1 110.999 -178.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.467 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.8 mttp -131.21 171.59 13.13 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.658 -1.156 . . . . 2.19 109.232 -172.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.86 134.74 46.27 Favored 'General case' 0 CA--C 1.507 -0.701 0 C-N-CA 119.171 -1.011 . . . . 1.1 108.743 174.294 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.93 0.58 89.75 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 119.603 -1.284 . . . . 0.25 111.656 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.558 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.08 139.73 79.75 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-O 121.69 0.757 . . . . 1.92 110.203 177.06 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 37.2 Cg_endo -87.64 123.49 1.81 Allowed 'Trans proline' 0 C--N 1.323 -0.771 0 C-N-CA 123.923 3.082 . . . . 0.31 113.623 -174.376 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 34.4 mm -91.04 134.24 30.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.966 -0.561 . . . . 1.02 110.114 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -111.32 155.11 23.55 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.786 -0.643 . . . . 0.37 109.693 179.1 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.455 ' HB2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -69.42 116.6 10.03 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.813 0.34 . . . . 0.2 110.543 -175.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.18 7.11 23.45 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.388 -0.91 . . . . 0.17 113.478 178.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.543 ' O ' ' HG2' ' A' ' 66' ' ' MET . 48.2 mt-10 -89.21 145.11 25.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 117.699 0.75 . . . . 0.52 110.489 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.441 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.7 m -106.06 107.28 18.19 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.807 -0.633 . . . . 1.03 110.781 -176.287 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -82.18 131.06 34.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.225 0.536 . . . . 1.04 110.719 -175.215 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -118.31 108.51 15.18 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.047 -0.979 . . . . 1.1 109.703 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.4 p -106.06 155.32 19.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.048 0.451 . . . . 1.06 109.955 177.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.763 0 N-CA-C 111.369 -0.693 . . . . 0.9 111.369 177.531 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.421 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 67.0 m . . . . . 0 C--O 1.224 -0.258 0 N-CA-C 109.395 -0.595 . . . . 1.16 109.395 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -148.39 133.29 10.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 C-N-CA 120.997 -0.281 . . . . 1.09 110.764 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.489 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.1 m -106.36 106.61 17.21 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.052 -0.522 . . . . 1.03 109.62 173.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.55 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 58.8 mt -97.7 107.61 20.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.756 -0.657 . . . . 1.05 110.18 178.312 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.26 106.63 14.31 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.331 -0.85 . . . . 1.03 109.323 177.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.539 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 67.8 m-85 -73.59 144.64 45.92 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.484 0.659 . . . . 0.45 110.753 -178.48 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.7 p -73.53 -6.28 7.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 114.879 -1.055 . . . . 1.07 111.799 -169.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.547 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 11.5 t70 -84.95 -20.55 30.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.594 -0.276 . . . . 0.75 110.607 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.51 -17.32 5.57 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.479 -0.867 . . . . 0.32 112.919 -179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.6 p -86.59 156.84 19.88 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 122.795 -0.238 . . . . 1.09 111.108 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -130.38 150.73 51.48 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.442 -0.577 . . . . 1.51 109.442 177.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.55 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.9 m -130.4 169.4 21.33 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.211 0.529 . . . . 2.06 111.768 177.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.549 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.6 p -140.31 132.37 32.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.13 -0.941 . . . . 1.58 110.327 176.701 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.421 ' O ' ' HA ' ' A' ' 45' ' ' SER . 23.5 mt -102.71 143.46 15.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.99 -0.55 . . . . 1.08 110.15 -179.599 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.23 -161.54 36.63 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.858 -0.687 . . . . 1.02 112.23 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.91 146.42 17.99 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.959 -0.639 . . . . 0.64 111.57 -175.052 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.5 t70 60.39 21.65 11.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.945 0.878 . . . . 1.26 109.655 -173.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 t -102.93 155.61 18.24 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.369 -0.832 . . . . 1.64 110.847 -175.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.532 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.4 mt -140.28 122.88 16.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.248 -0.887 . . . . 1.08 109.351 179.004 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.18 141.93 17.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.702 0.287 . . . . 1.66 110.86 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.441 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.5 tt0 -94.38 130.78 40.58 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.928 0.394 . . . . 0.67 110.175 178.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.543 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 53.6 mmm -65.8 89.93 0.12 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.425 -0.807 . . . . 1.13 110.495 -178.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -116.54 -166.39 1.15 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.391 -0.822 . . . . 1.15 111.216 -175.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -63.8 -42.42 97.71 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.802 0.334 . . . . 2.13 111.471 -177.32 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 56.4 mm-40 -62.89 -23.93 67.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.295 0.569 . . . . 2.51 111.009 177.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.406 HG23 ' HE2' ' A' ' 66' ' ' MET . 1.3 mm -82.72 -50.38 15.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.212 -0.904 . . . . 1.1 111.144 177.034 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.775 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.319 -0.761 0 CA-C-N 115.671 -0.695 . . . . 0.91 109.962 -177.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.8 m120 . . . . . 0 CA--C 1.515 -0.395 0 N-CA-C 110.115 -0.328 . . . . 2.5 110.115 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 119.35 17.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.906 -0.588 . . . . 0.95 110.018 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.745 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.0 pt -101.11 -15.85 7.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-N 115.422 -0.808 . . . . 1.03 111.592 -171.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.83 176.26 42.51 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 120.999 -0.62 . . . . 0.11 111.595 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.406 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 93.9 m-85 -144.89 151.1 38.18 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.74 0.305 . . . . 0.24 110.432 -175.154 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 30' ' ' ASP . 31.4 mm -79.18 122.2 33.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.375 -0.375 . . . . 1.03 111.012 -178.363 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.6 p -114.35 -24.4 8.91 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.302 0.573 . . . . 1.01 110.661 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.526 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.5 tttm -139.76 146.85 40.03 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 108.605 -0.887 . . . . 2.86 108.605 172.037 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -160.24 140.63 11.69 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.128 -0.487 . . . . 1.03 110.525 -176.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -146.44 152.46 39.08 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.155 -0.929 . . . . 1.94 110.577 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.55 -160.7 53.82 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.883 -0.599 . . . . 0.32 113.172 174.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 19.3 m -98.46 121.9 40.99 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.953 -0.388 . . . . 1.65 109.953 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.493 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.8 m -139.18 153.57 24.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.669 0.747 . . . . 1.09 111.819 -176.29 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.84 159.15 43.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.721 -1.127 . . . . 1.0 109.082 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.3 p -131.21 133.77 62.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.097 -0.641 . . . . 1.03 110.608 172.706 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.442 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 8.5 mt-30 -97.73 97.88 9.38 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.284 -0.871 . . . . 0.72 109.552 177.557 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.456 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 51.7 m -64.52 175.93 1.25 Allowed 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.471 -0.331 . . . . 1.63 110.547 -177.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 pt -58.75 -27.21 34.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 112.814 0.672 . . . . 1.12 112.814 -175.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -80.49 -10.8 59.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 1.96 110.7 177.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.46 3.24 61.39 Favored Glycine 0 N--CA 1.452 -0.283 0 N-CA-C 111.71 -0.556 . . . . 0.34 111.71 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.2 mm-40 -65.45 120.15 12.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.784 -0.208 . . . . 2.76 110.523 176.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.547 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.8 tt0 -95.77 108.33 20.64 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.716 -0.476 . . . . 1.0 109.716 -179.444 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.432 ' HG2' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -105.34 143.3 33.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.13 -0.486 . . . . 2.1 109.784 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.4 p -74.26 131.24 35.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.846 -0.798 . . . . 1.11 108.846 171.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.493 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 26.3 mt -93.45 127.44 39.09 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.191 -0.603 . . . . 1.1 110.502 -179.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -110.62 179.25 4.12 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 107.604 -1.258 . . . . 2.19 107.604 171.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -68.12 143.39 55.45 Favored 'General case' 0 C--N 1.315 -0.915 0 C-N-CA 119.316 -0.954 . . . . 1.1 109.417 175.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.07 -10.24 69.35 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.204 -0.998 . . . . 0.25 113.057 176.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.453 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.8 m-20 -66.49 142.5 97.71 Favored Pre-proline 0 CA--C 1.515 -0.391 0 CA-C-O 121.108 0.48 . . . . 1.92 109.788 175.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.406 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 35.7 Cg_endo -89.06 142.4 4.54 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 123.115 2.543 . . . . 0.31 112.713 -178.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.492 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.8 mm -102.57 136.8 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 115.779 -0.646 . . . . 1.02 109.591 175.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . 0.425 ' HD2' ' OE2' ' A' ' 36' ' ' GLU . 80.9 m-85 -113.84 153.65 28.79 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.839 -0.619 . . . . 0.37 109.561 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.441 ' HB2' HG23 ' A' ' 4' ' ' ILE . 1.6 t80 -69.87 111.55 5.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.378 -0.374 . . . . 0.2 110.231 -176.268 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.28 -5.6 8.78 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.601 -0.809 . . . . 0.17 113.048 178.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.456 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 28.6 mt-10 -83.39 136.96 34.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.695 0.759 . . . . 0.52 111.122 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -96.32 106.97 19.26 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.614 -1.175 . . . . 1.03 110.34 -178.168 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 6.0 t -81.37 133.2 29.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.114 0.483 . . . . 1.04 111.089 -173.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.1 mp -114.92 126.12 54.42 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.956 -1.02 . . . . 1.1 109.636 178.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.3 p -119.8 152.39 37.34 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.613 -0.514 . . . . 1.06 109.613 172.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.818 0 C-N-CA 120.992 -0.623 . . . . 0.9 112.211 179.33 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.534 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 23.2 m . . . . . 0 C--O 1.22 -0.469 0 N-CA-C 108.625 -0.88 . . . . 1.16 108.625 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -141.81 138.36 31.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 C-N-CA 120.385 -0.526 . . . . 1.09 111.158 -175.057 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.526 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.1 m -108.89 105.9 15.65 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.781 -0.645 . . . . 1.03 109.648 173.625 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.524 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.2 mt -94.5 109.45 22.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.896 -0.593 . . . . 1.05 110.045 177.09 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.73 99.26 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.236 -0.893 . . . . 1.03 109.335 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.513 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 66.9 m-85 -67.21 144.67 55.85 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.411 0.624 . . . . 0.45 110.336 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -70.18 2.01 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 114.558 -1.201 . . . . 1.07 110.846 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.407 ' H ' ' C ' ' A' ' 50' ' ' PHE . 2.2 t70 -84.89 -21.97 29.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.925 -1.034 . . . . 0.75 110.725 177.105 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 115.99 -17.37 15.17 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 111.162 -0.775 . . . . 0.32 111.162 -175.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 p -87.07 150.75 23.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.516 -0.342 . . . . 1.09 111.042 178.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -126.13 150.2 48.42 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.277 -0.638 . . . . 1.51 109.277 178.363 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.524 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -125.14 171.39 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.012 0.434 . . . . 2.06 111.366 178.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.1 p -137.81 130.08 40.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.461 -0.791 . . . . 1.58 110.318 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.534 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -105.08 136.87 37.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.881 -0.6 . . . . 1.08 109.926 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.94 -163.59 27.89 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.979 -0.629 . . . . 1.02 112.328 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.5 150.5 18.29 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.946 -0.645 . . . . 0.64 111.736 -173.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 34.7 t70 56.89 22.68 7.35 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.723 0.773 . . . . 1.26 110.264 -173.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.3 m -105.64 164.02 12.23 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.122 0.487 . . . . 1.64 111.338 -177.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.483 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.1 mt -140.86 128.2 22.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.506 -0.77 . . . . 1.08 109.374 176.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.61 138.68 15.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.852 0.358 . . . . 1.66 110.973 -177.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.494 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.9 tt0 -97.13 131.28 44.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.843 0.354 . . . . 0.67 111.138 -176.038 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.627 ' SD ' HG21 ' A' ' 70' ' ' ILE . 17.8 mmt -62.94 90.48 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.651 -0.704 . . . . 1.13 111.177 177.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.6 p -126.13 -169.1 1.95 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.502 -0.772 . . . . 1.15 110.241 -178.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -69.46 -26.61 64.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 117.814 0.279 . . . . 2.13 111.157 -176.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.06 -22.93 63.02 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.972 0.891 . . . . 2.51 109.688 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.627 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.9 mm -90.32 -51.76 11.48 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 114.72 -1.127 . . . . 1.1 110.762 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.745 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 . . . . . 0 C--N 1.314 -0.937 0 CA-C-N 115.491 -0.777 . . . . 0.91 110.729 -176.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 . . . . . 0 CA--C 1.517 -0.299 0 CA-C-O 120.914 0.388 . . . . 2.5 110.385 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.31 109.67 12.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.768 -0.651 . . . . 0.95 109.623 178.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.832 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.5 pt -92.34 -11.39 9.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.088 -0.96 . . . . 1.03 112.046 -169.564 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.45 42.79 Favored Glycine 0 CA--C 1.5 -0.85 0 C-N-CA 120.593 -0.813 . . . . 0.11 111.48 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -144.98 151.05 37.98 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.954 0.407 . . . . 0.24 110.883 -174.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.503 HG12 ' O ' ' A' ' 30' ' ' ASP . 21.2 mm -78.44 121.71 31.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 115.783 -0.644 . . . . 1.03 110.903 -178.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 72.7 p -113.63 -21.16 10.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.343 0.592 . . . . 1.01 110.406 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.448 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 84.4 tttt -142.63 145.2 33.25 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.775 -0.824 . . . . 2.86 108.775 173.455 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.0 tt -159.47 142.62 14.29 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 120.765 0.317 . . . . 1.03 110.945 -177.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -148.82 165.24 32.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.67 -0.695 . . . . 1.94 110.795 176.441 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 67.57 -149.67 50.87 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.991 -0.55 . . . . 0.32 113.183 175.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 29.8 t -108.9 133.64 52.64 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.042 -0.725 . . . . 1.65 109.042 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.431 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 5.2 m -142.8 153.3 17.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.786 0.803 . . . . 1.09 111.582 -176.467 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.26 157.99 43.3 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.683 -1.144 . . . . 1.0 108.67 177.567 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.1 p -131.94 134.95 59.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.354 -0.538 . . . . 1.03 110.316 174.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.433 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -104.65 99.9 9.56 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.376 -0.829 . . . . 0.72 109.56 178.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.485 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 22.5 p -62.96 178.46 0.47 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.552 -0.295 . . . . 1.63 111.279 -175.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 2.9 pt -57.03 -33.61 42.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 112.597 0.591 . . . . 1.12 112.597 -174.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.49 ' OD1' ' HG3' ' A' ' 22' ' ' GLN . 9.5 p30 -81.93 -12.07 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.894 -0.322 . . . . 1.96 110.762 179.298 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.42 7.58 36.98 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.768 -0.73 . . . . 0.34 113.755 176.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.49 ' HG3' ' OD1' ' A' ' 20' ' ' ASN . 54.7 mt-30 -70.88 120.87 17.1 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.107 0.453 . . . . 2.76 111.127 179.203 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.52 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.6 tt0 -91.59 113.11 25.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.976 0.417 . . . . 1.0 109.969 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.92 138.22 51.39 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.793 -0.639 . . . . 2.1 109.796 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.61 134.96 29.11 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 109.113 -0.699 . . . . 1.11 109.113 175.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.547 HD21 ' OD1' ' A' ' 30' ' ' ASP . 5.4 mt -99.45 150.41 22.21 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.62 0.724 . . . . 1.1 111.442 -177.508 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.523 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 41.1 mttp -135.52 173.12 12.07 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.424 -1.262 . . . . 2.19 109.152 -171.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.52 141.78 46.74 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 119.133 -1.027 . . . . 1.1 109.347 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.61 0.96 85.92 Favored Glycine 0 N--CA 1.435 -1.395 0 C-N-CA 120.13 -1.034 . . . . 0.25 111.824 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.547 ' OD1' HD21 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -78.36 142.45 62.88 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-O 121.553 0.692 . . . . 1.92 111.1 -179.187 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.04 133.74 11.26 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.771 2.981 . . . . 0.31 113.836 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mm -99.98 136.8 29.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.005 -0.998 . . . . 1.02 109.092 172.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -116.57 154.62 30.14 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 120.976 0.417 . . . . 0.37 109.945 -178.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.457 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.7 t80 -71.51 115.7 11.0 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.003 -0.544 . . . . 0.2 110.581 -175.462 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.13 7.61 22.89 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.461 -0.876 . . . . 0.17 113.345 177.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.489 ' HB3' HG22 ' A' ' 16' ' ' VAL . 28.4 mt-10 -94.77 147.75 23.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.763 0.781 . . . . 0.52 110.673 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.433 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 10.1 m -104.09 108.39 19.73 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.094 -0.957 . . . . 1.03 110.661 -176.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.2 t -83.56 121.88 36.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.315 0.579 . . . . 1.04 110.934 -175.094 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -107.46 104.77 14.42 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.796 -1.093 . . . . 1.1 109.679 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.3 p -99.93 156.47 17.12 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.651 -0.5 . . . . 1.06 109.651 177.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.994 0 C-N-CA 120.767 -0.73 . . . . 0.9 111.982 179.688 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m . . . . . 0 CA--C 1.512 -0.482 0 N-CA-C 109.334 -0.617 . . . . 1.16 109.334 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.1 t -126.63 132.46 70.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.93 -0.577 . . . . 1.09 111.206 -169.248 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.448 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.0 m -109.02 108.24 18.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.031 -0.531 . . . . 1.03 110.288 178.359 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 79.1 mt -97.75 102.69 13.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-N 115.216 -0.902 . . . . 1.05 109.966 178.184 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.05 99.68 8.59 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.644 -0.707 . . . . 1.03 109.371 178.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.563 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 48.8 m-85 -61.77 144.9 54.02 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.518 0.675 . . . . 0.45 111.197 -178.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.13 -12.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.707 -1.133 . . . . 1.07 111.493 -170.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.415 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 28.6 t70 -74.55 -17.38 60.75 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.215 0.531 . . . . 0.75 110.529 176.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.78 -7.3 17.51 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.916 -0.659 . . . . 0.32 111.896 -177.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.0 p -88.63 177.47 6.75 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.396 -0.224 . . . . 1.09 110.396 176.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -151.58 157.38 42.13 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.259 -0.274 . . . . 1.51 110.259 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.508 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.53 150.78 17.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.35 -0.387 . . . . 2.06 110.427 -177.689 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 9.1 p -126.57 133.16 69.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.318 0.58 . . . . 1.58 110.668 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -102.53 147.6 8.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.739 -0.664 . . . . 1.08 110.196 -177.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.9 -178.44 43.48 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.733 -0.746 . . . . 1.02 111.413 175.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -101.57 148.57 17.95 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 121.043 -0.598 . . . . 0.64 111.656 -172.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t70 58.3 24.53 11.68 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 121.843 0.83 . . . . 1.26 110.179 -173.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.7 t -106.1 161.13 14.77 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.439 -0.8 . . . . 1.64 110.445 -179.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.504 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 79.1 mt -139.88 118.47 11.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.859 -0.61 . . . . 1.08 109.629 179.063 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.5 p -140.45 141.4 32.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.508 -0.315 . . . . 1.66 110.829 -175.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -97.99 126.84 43.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.905 0.383 . . . . 0.67 110.332 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 50.5 mmm -67.06 89.54 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.66 -0.7 . . . . 1.13 110.658 -178.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 10.8 p -115.02 -165.98 1.07 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.819 -0.628 . . . . 1.15 111.547 -175.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.83 -36.77 75.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.814 0.34 . . . . 2.13 110.718 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -61.97 -32.83 73.31 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.626 0.726 . . . . 2.51 110.095 175.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 1.1 mm -75.41 -53.09 16.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-N 114.476 -1.238 . . . . 1.1 111.029 178.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.832 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 . . . . . 0 C--N 1.317 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.91 109.993 -176.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 . . . . . 0 CA--C 1.514 -0.442 0 CA-C-O 120.908 0.385 . . . . 2.5 110.517 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.06 113.17 18.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.547 0.689 . . . . 0.95 110.351 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.826 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.9 pt -97.54 -14.09 7.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-N 115.106 -0.952 . . . . 1.03 111.709 -172.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.9 176.39 42.52 Favored Glycine 0 CA--C 1.502 -0.767 0 N-CA-C 111.01 -0.836 . . . . 0.11 111.01 179.163 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -143.35 151.57 40.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.041 0.448 . . . . 0.24 111.041 -175.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 35.2 mm -78.19 121.87 31.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.94 -0.573 . . . . 1.03 110.689 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.8 p -115.45 -20.28 10.31 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 1.01 110.546 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.539 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.1 tttt -143.83 143.3 31.26 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.47 -0.937 . . . . 2.86 108.47 173.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.3 tt -160.27 140.28 11.39 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-O 121.074 0.464 . . . . 1.03 111.107 -178.026 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -149.08 149.75 31.6 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.164 -0.925 . . . . 1.94 110.479 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.46 -160.2 41.54 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.972 -0.632 . . . . 0.32 113.035 175.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.0 m -101.32 119.25 38.47 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 120.667 0.27 . . . . 1.65 110.312 -177.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.466 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -136.91 152.0 28.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.817 0.817 . . . . 1.09 111.753 -176.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 159.34 42.7 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 114.706 -1.134 . . . . 1.0 108.703 178.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.456 HG23 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -131.57 132.62 62.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 121.29 0.567 . . . . 1.03 110.424 174.938 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.467 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.9 mt-30 -98.91 99.23 10.27 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.445 -0.798 . . . . 0.72 109.734 178.592 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.547 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 13.9 m -60.94 172.85 0.88 Allowed 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 110.039 -0.356 . . . . 1.63 110.039 -179.223 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -60.99 -14.7 10.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 112.248 0.462 . . . . 1.12 112.248 -177.499 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -85.53 -9.32 57.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.178 0.514 . . . . 1.96 110.372 177.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 88.54 5.66 74.78 Favored Glycine 0 CA--C 1.508 -0.372 0 N-CA-C 110.877 -0.889 . . . . 0.34 110.877 -175.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -70.21 118.52 13.13 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.792 -0.704 . . . . 2.76 110.664 178.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -90.41 111.28 22.47 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.228 0.537 . . . . 1.0 109.629 177.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.41 ' NH2' ' HD2' ' A' ' 31' ' ' PRO . 0.0 OUTLIER -115.35 142.14 47.09 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.232 -0.894 . . . . 2.1 109.706 -177.311 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -75.65 143.19 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.835 0.35 . . . . 1.11 110.144 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.466 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 24.9 mt -110.12 128.97 55.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.994 0.426 . . . . 1.1 110.933 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 77.5 mttt -117.77 -179.72 3.82 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 108.246 -1.02 . . . . 2.19 108.246 170.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.4 tp -65.39 148.58 51.47 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.573 -0.851 . . . . 1.1 110.3 178.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.55 -7.24 58.59 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.531 -0.842 . . . . 0.25 112.677 177.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.9 143.68 97.16 Favored Pre-proline 0 CA--C 1.512 -0.515 0 CA-C-O 121.187 0.518 . . . . 1.92 110.105 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.41 ' HD2' ' NH2' ' A' ' 24' ' ' ARG . 24.6 Cg_endo -90.15 131.4 1.79 Allowed 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 123.262 2.641 . . . . 0.31 111.827 178.641 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.525 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.3 mm -94.08 134.48 31.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 109.747 -0.464 . . . . 1.02 109.747 176.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.98 150.25 30.84 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.558 -0.746 . . . . 0.37 109.396 -179.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.474 ' HB2' HG21 ' A' ' 4' ' ' ILE . 3.0 t80 -67.3 116.8 8.48 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.2 110.364 -174.524 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.17 -10.42 20.28 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.789 -0.72 . . . . 0.17 113.234 176.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.547 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 28.7 mt-10 -76.02 140.4 41.94 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 117.877 0.839 . . . . 0.52 110.685 179.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.565 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -101.43 109.04 20.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.809 -1.087 . . . . 1.03 110.84 -175.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.6 t -82.11 132.04 32.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.189 0.518 . . . . 1.04 110.934 -174.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -117.84 109.49 16.62 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 114.975 -1.011 . . . . 1.1 110.017 -177.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -105.26 157.01 17.6 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.428 -0.509 . . . . 1.06 109.789 175.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.886 0 C-N-CA 120.81 -0.71 . . . . 0.9 111.872 178.973 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.524 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 7.3 m . . . . . 0 C--O 1.225 -0.231 0 N-CA-C 109.349 -0.611 . . . . 1.16 109.349 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 7.5 t -134.72 147.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.901 -0.32 . . . . 1.09 111.107 -173.444 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.539 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -117.98 110.63 17.93 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.157 -0.474 . . . . 1.03 110.01 173.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.551 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 64.4 mt -98.66 109.35 23.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.805 -0.634 . . . . 1.05 110.014 176.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.44 102.22 11.92 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.418 -0.81 . . . . 1.03 109.171 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.467 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.7 m-85 -70.1 144.43 52.11 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.372 0.606 . . . . 0.45 110.78 -178.738 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.75 1.9 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 114.651 -1.159 . . . . 1.07 111.725 -171.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -92.51 -11.97 33.18 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.98 -0.554 . . . . 0.75 109.962 175.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.79 -5.41 25.93 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.516 -0.849 . . . . 0.32 112.726 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.6 p -93.95 159.79 15.01 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.819 -0.224 . . . . 1.09 110.717 177.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.63 143.6 47.39 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.417 -0.586 . . . . 1.51 109.417 179.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.551 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.9 m -121.75 164.16 18.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.103 0.478 . . . . 2.06 111.441 177.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.512 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -131.86 129.44 60.9 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 115.241 -0.89 . . . . 1.58 109.875 177.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.524 ' O ' ' HA ' ' A' ' 45' ' ' SER . 17.1 mt -103.43 131.58 51.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 116.257 -0.428 . . . . 1.08 109.993 -178.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.23 -163.92 23.56 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 121.151 -0.547 . . . . 1.02 112.259 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.93 145.25 16.5 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.772 -0.728 . . . . 0.64 111.728 -173.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.5 t70 58.24 25.22 12.38 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 121.547 0.689 . . . . 1.26 110.217 -174.313 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.4 m -103.04 156.47 17.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.957 -0.565 . . . . 1.64 110.935 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.495 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 89.7 mt -140.6 117.31 8.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.618 -0.719 . . . . 1.08 109.588 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.8 p -147.66 143.96 19.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 110.108 -0.33 . . . . 1.66 110.108 -177.16 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.565 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -103.99 139.21 39.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.545 0.688 . . . . 0.67 111.079 -176.113 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.552 ' SD ' HG23 ' A' ' 70' ' ' ILE . 22.7 mmt -64.19 89.62 0.06 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.627 -1.17 . . . . 1.13 111.667 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.403 HG21 ' CG ' ' A' ' 65' ' ' GLU . 2.3 p -114.25 -172.15 2.05 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.622 -0.717 . . . . 1.15 110.125 177.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -71.98 -24.45 61.58 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.748 0.309 . . . . 2.13 110.657 -178.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -70.08 -23.54 63.08 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.472 0.653 . . . . 2.51 110.229 175.384 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.552 HG23 ' SD ' ' A' ' 66' ' ' MET . 1.4 mm -88.17 -56.52 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.119 -0.946 . . . . 1.1 109.728 175.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.826 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 . . . . . 0 C--N 1.319 -0.757 0 CA-C-N 114.543 -1.208 . . . . 0.91 109.786 -178.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 . . . . . 0 CA--C 1.511 -0.539 0 N-CA-C 110.165 -0.309 . . . . 2.5 110.165 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.11 108.09 8.78 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.798 -0.816 . . . . 0.95 108.798 174.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.739 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.3 pt -92.96 -10.42 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.22 -0.9 . . . . 1.03 111.419 -170.485 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.78 176.3 42.47 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.623 -0.799 . . . . 0.11 111.469 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -144.49 150.07 36.98 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.04 0.448 . . . . 0.24 110.446 -175.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.565 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.2 mm -78.04 123.68 35.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.775 -0.648 . . . . 1.03 110.972 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 p -116.19 -23.41 8.45 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.127 0.489 . . . . 1.01 110.856 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 25.8 tptp -139.99 136.18 33.49 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.959 -1.126 . . . . 2.86 107.959 173.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -152.85 138.11 17.47 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.016 0.436 . . . . 1.03 111.043 -179.09 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.4 m-20 -147.95 157.24 43.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.158 -0.928 . . . . 1.94 110.861 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.03 -158.79 46.7 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.842 -0.617 . . . . 0.32 112.752 176.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.9 t -103.68 118.69 37.31 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.251 -0.648 . . . . 1.65 109.251 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.439 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.7 m -135.65 153.17 32.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.687 0.756 . . . . 1.09 111.681 -175.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.11 158.86 44.52 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.796 -1.093 . . . . 1.0 108.687 -178.129 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.671 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -136.61 134.5 49.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 119.917 -0.713 . . . . 1.03 111.375 173.636 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -97.56 100.32 11.73 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 114.924 -1.034 . . . . 0.72 108.98 174.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.508 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 58.1 p -63.01 179.06 0.41 Allowed 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.962 -0.295 . . . . 1.63 111.145 -175.139 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.8 pt -60.98 -21.17 23.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 1.12 110.937 176.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -80.1 -9.91 59.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 1.96 110.14 176.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.93 12.45 71.35 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 110.973 -0.851 . . . . 0.34 110.973 179.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -89.06 121.74 31.71 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.9 -0.65 . . . . 2.76 110.81 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.671 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 22.2 tt0 -89.65 118.13 29.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.903 -0.59 . . . . 1.0 110.46 178.75 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.471 ' HG2' HG13 ' A' ' 16' ' ' VAL . 22.1 ptt-85 -119.16 165.96 13.55 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.502 -0.555 . . . . 2.1 109.502 175.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.7 p -91.24 127.49 43.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.372 0.606 . . . . 1.11 109.432 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.477 HD22 ' OD1' ' A' ' 30' ' ' ASP . 4.1 mt -90.49 151.17 21.49 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.5 0.667 . . . . 1.1 111.351 -175.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -141.87 176.15 9.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.748 -1.114 . . . . 2.19 108.324 -171.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -74.29 141.63 45.27 Favored 'General case' 0 C--N 1.313 -1.014 0 C-N-CA 119.303 -0.959 . . . . 1.1 108.988 176.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.77 7.31 88.31 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 119.918 -1.134 . . . . 0.25 111.917 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.565 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -85.03 140.37 37.09 Favored Pre-proline 0 CA--C 1.52 -0.184 0 CA-C-O 121.612 0.72 . . . . 1.92 110.472 178.6 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -78.21 132.01 11.16 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.677 2.918 . . . . 0.31 113.426 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.41 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.4 mm -99.45 133.61 41.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 1.02 109.175 173.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -113.88 152.61 30.51 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.145 -0.479 . . . . 0.37 110.238 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.477 ' HB2' HG23 ' A' ' 4' ' ' ILE . 1.7 t80 -68.48 111.77 4.9 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.963 -0.562 . . . . 0.2 110.019 -177.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.67 6.25 19.62 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.34 -0.933 . . . . 0.17 113.348 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.539 ' O ' ' HG2' ' A' ' 66' ' ' MET . 39.9 mt-10 -91.05 135.12 33.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 117.869 0.834 . . . . 0.52 110.739 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.514 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 9.0 m -94.47 106.12 18.09 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.99 -1.005 . . . . 1.03 110.94 -176.532 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.542 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 4.3 t -82.47 129.58 37.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.137 0.494 . . . . 1.04 110.916 -175.209 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.6 mp -117.31 108.09 15.19 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.223 -0.899 . . . . 1.1 109.694 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.7 p -105.13 153.5 21.43 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.9 -0.408 . . . . 1.06 109.9 178.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.826 0 C-N-CA 121.115 -0.564 . . . . 0.9 111.886 178.872 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 50.7 m . . . . . 0 CA--C 1.518 -0.273 0 N-CA-C 109.596 -0.52 . . . . 1.16 109.596 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.517 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.0 t -143.36 129.77 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.677 0.275 . . . . 1.09 111.034 -175.124 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.544 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -99.26 105.77 17.82 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.533 -0.543 . . . . 1.03 109.533 172.267 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.536 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 69.3 mt -95.89 107.43 19.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 CA-C-N 115.821 -0.627 . . . . 1.05 109.997 176.667 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.74 104.96 13.38 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.322 -0.853 . . . . 1.03 109.08 176.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.494 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 60.9 m-85 -69.96 152.7 44.15 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.601 0.715 . . . . 0.45 110.746 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.5 p -72.61 -11.6 15.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.654 -1.157 . . . . 1.07 111.496 -170.198 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.623 ' H ' ' HH ' ' A' ' 71' ' ' TYR . 33.9 t70 -81.17 -21.77 39.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.102 0.477 . . . . 0.75 110.598 176.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.43 -7.12 14.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.615 -0.802 . . . . 0.32 112.182 -177.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.5 p -85.19 150.11 25.04 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 110.366 -0.235 . . . . 1.09 110.366 176.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -127.53 147.4 50.32 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.664 -0.414 . . . . 1.51 109.932 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.536 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.8 m -129.75 171.32 17.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.117 0.484 . . . . 2.06 111.596 178.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.8 p -137.61 134.88 46.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.169 -0.923 . . . . 1.58 110.168 177.517 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.594 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.7 mt -107.43 136.09 43.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.4 -0.364 . . . . 1.08 110.309 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.51 -169.88 43.05 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.083 -0.579 . . . . 1.02 112.37 178.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -110.34 152.8 17.28 Favored Glycine 0 CA--C 1.504 -0.642 0 N-CA-C 111.595 -0.602 . . . . 0.64 111.595 -173.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.3 t70 56.65 21.73 6.1 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.963 0.887 . . . . 1.26 109.775 -172.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.0 m -106.18 158.97 16.45 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.721 -0.672 . . . . 1.64 111.297 -176.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.542 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.6 mt -139.99 119.63 12.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.417 -0.811 . . . . 1.08 109.459 178.329 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.4 p -145.71 138.3 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 120.904 0.383 . . . . 1.66 110.654 -178.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.514 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.0 tt0 -92.01 130.55 37.73 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.222 -0.444 . . . . 0.67 109.963 179.332 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.539 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 60.8 mmm -66.67 89.56 0.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.948 -0.569 . . . . 1.13 110.591 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 17.0 p -115.46 -165.34 1.02 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.819 -0.628 . . . . 1.15 111.47 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -64.89 -39.31 93.33 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.182 -0.463 . . . . 2.13 111.061 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -64.35 -28.86 69.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.843 0.83 . . . . 2.51 110.075 178.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.427 HG21 ' HE2' ' A' ' 66' ' ' MET . 1.0 OUTLIER -77.48 -46.45 27.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.734 -1.121 . . . . 1.1 111.212 176.928 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.739 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 . . . . . 0 C--N 1.315 -0.892 0 CA-C-N 115.638 -0.71 . . . . 0.91 110.662 -174.323 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 . . . . . 0 C--O 1.236 0.371 0 CA-C-O 121.031 0.444 . . . . 2.5 110.597 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.67 109.36 13.99 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.648 -0.705 . . . . 0.95 109.584 178.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.766 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 32.9 pt -92.97 -12.99 8.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 114.896 -1.047 . . . . 1.03 111.841 -170.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.38 176.34 44.02 Favored Glycine 0 CA--C 1.501 -0.814 0 C-N-CA 120.61 -0.805 . . . . 0.11 111.688 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.94 149.39 36.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.972 0.415 . . . . 0.24 110.961 -174.332 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.429 HD12 ' CG1' ' A' ' 46' ' ' VAL . 37.6 mm -76.43 124.08 33.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.829 -0.623 . . . . 1.03 111.782 -176.147 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.2 p -116.75 -20.68 9.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.034 0.445 . . . . 1.01 111.403 179.099 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.584 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 23.3 tptm -140.21 136.24 33.2 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.104 -1.073 . . . . 2.86 108.104 174.359 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.402 HD11 HG21 ' A' ' 14' ' ' VAL . 5.6 tt -155.71 139.66 16.32 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.395 -0.522 . . . . 1.03 111.552 -179.42 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -144.76 155.77 43.71 Favored 'General case' 0 CA--C 1.496 -1.119 0 CA-C-N 115.655 -0.702 . . . . 1.94 110.914 173.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.16 -162.56 38.72 Favored Glycine 0 N--CA 1.419 -2.462 0 CA-C-N 115.005 -0.998 . . . . 0.32 112.866 164.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.4 m -92.15 116.24 28.77 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 109.841 -0.429 . . . . 1.65 109.841 177.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.431 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.7 m -135.5 152.67 32.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.711 0.767 . . . . 1.09 111.397 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.98 158.3 44.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.701 -1.136 . . . . 1.0 108.79 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.647 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.0 OUTLIER -131.62 133.11 61.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 C-N-CA 119.971 -0.692 . . . . 1.03 111.244 173.933 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.446 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -97.7 99.1 10.44 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.004 -0.998 . . . . 0.72 109.503 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.477 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 20.0 m -64.52 176.54 1.08 Allowed 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 116.344 -0.389 . . . . 1.63 110.584 -178.352 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -59.66 -26.91 36.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 O-C-N 122.005 -0.434 . . . . 1.12 111.569 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.6 m-20 -71.82 -16.51 62.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.04 0.448 . . . . 1.96 110.678 176.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.52 4.87 65.55 Favored Glycine 0 N--CA 1.451 -0.318 0 N-CA-C 110.839 -0.905 . . . . 0.34 110.839 -175.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 92.5 mt-30 -73.53 129.19 37.45 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.827 -0.686 . . . . 2.76 110.619 179.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.647 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 6.8 tt0 -106.37 109.18 21.03 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.411 -0.359 . . . . 1.0 110.601 -176.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.521 ' HG2' HG13 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -109.57 165.74 11.43 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.669 -0.493 . . . . 2.1 109.669 176.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -89.92 139.45 17.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 115.862 -0.608 . . . . 1.11 109.425 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.431 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 22.6 mt -103.91 131.1 51.47 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.129 0.49 . . . . 1.1 110.799 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.3 mttp -118.46 -177.12 3.22 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 107.939 -1.134 . . . . 2.19 107.939 171.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 146.7 54.26 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 119.859 -0.736 . . . . 1.1 109.519 175.054 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.92 1.58 87.55 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 120.13 -1.033 . . . . 0.25 112.918 176.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -78.78 144.75 65.04 Favored Pre-proline 0 CA--C 1.517 -0.317 0 CA-C-O 121.103 0.478 . . . . 1.92 110.608 176.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -79.5 142.95 16.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.967 2.445 . . . . 0.31 112.743 178.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.448 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.3 mm -108.44 135.97 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-N 115.614 -0.721 . . . . 1.02 109.092 171.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -115.96 152.45 33.46 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 116.218 -0.446 . . . . 0.37 110.066 -177.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.443 ' HB2' HG23 ' A' ' 4' ' ' ILE . 1.4 t80 -69.41 110.89 4.94 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.872 -0.604 . . . . 0.2 110.469 -176.397 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.58 4.06 15.76 Favored Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.478 -0.868 . . . . 0.17 113.351 178.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.488 ' O ' ' HG2' ' A' ' 66' ' ' MET . 35.7 mt-10 -93.22 144.97 24.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 117.819 0.809 . . . . 0.52 110.832 -179.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.506 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.5 m -105.01 109.16 21.05 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.383 -0.826 . . . . 1.03 110.921 -174.652 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -83.46 128.36 38.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.349 0.595 . . . . 1.04 111.028 -175.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.5 mp -114.29 106.5 14.4 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.759 -1.109 . . . . 1.1 109.716 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 58.4 p -105.07 154.08 20.63 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.881 0.372 . . . . 1.06 110.086 178.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.94 0 N-CA-C 111.517 -0.633 . . . . 0.9 111.517 178.202 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.4 t . . . . . 0 CA--C 1.501 -0.913 0 N-CA-C 109.08 -0.711 . . . . 1.16 109.08 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.533 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.4 t -145.35 136.75 20.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.841 -0.618 . . . . 1.09 111.001 -168.408 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.584 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 91.4 m -111.09 112.62 24.55 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.222 0.534 . . . . 1.03 109.876 175.427 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.411 HD11 ' HE3' ' A' ' 66' ' ' MET . 77.1 mt -99.78 103.52 14.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.205 -0.907 . . . . 1.05 110.098 178.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.59 101.53 7.47 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.259 -0.882 . . . . 1.03 109.44 177.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.529 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 51.9 m-85 -65.8 143.66 57.34 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.689 0.757 . . . . 0.45 110.988 -178.748 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -69.03 -12.36 15.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 114.285 -1.325 . . . . 1.07 111.427 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.47 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 23.3 t70 -74.48 -21.67 59.46 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.169 -0.469 . . . . 0.75 110.624 177.323 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.39 -17.22 8.46 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.815 -0.707 . . . . 0.32 112.137 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 6.1 p -85.86 164.78 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 122.084 0.154 . . . . 1.09 110.729 178.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -133.54 163.44 29.39 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.158 -0.312 . . . . 1.51 110.158 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.529 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -146.05 157.1 12.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.423 -0.353 . . . . 2.06 110.568 -177.409 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.533 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.9 p -133.14 133.91 58.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.166 0.508 . . . . 1.58 110.916 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 20.6 mt -104.04 137.7 31.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.871 -0.604 . . . . 1.08 109.952 -179.533 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.07 174.53 52.67 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.387 -0.911 . . . . 1.02 111.475 176.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.67 151.29 19.83 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 111.283 -0.727 . . . . 0.64 111.283 -173.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.37 26.14 12.13 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-O 121.858 0.837 . . . . 1.26 109.448 -173.425 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -111.55 162.58 14.98 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.425 -0.807 . . . . 1.64 110.944 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.461 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.2 mt -140.37 124.87 18.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.778 -0.646 . . . . 1.08 109.533 178.197 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.0 p -150.11 142.32 17.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.841 0.353 . . . . 1.66 110.843 -178.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.506 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.3 tt0 -94.79 136.08 35.52 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.892 0.377 . . . . 0.67 110.528 178.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.488 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 50.5 mmm -71.46 88.57 0.91 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.697 -0.683 . . . . 1.13 110.393 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -111.08 -163.67 0.86 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.057 -0.519 . . . . 1.15 111.249 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -77.1 -28.24 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.876 -0.147 . . . . 2.13 111.003 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -66.68 -29.47 69.48 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.95 0.881 . . . . 2.51 109.684 173.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.433 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.5 mm -77.35 -55.35 10.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.268 -1.333 . . . . 1.1 110.345 176.352 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.766 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 . . . . . 0 C--N 1.318 -0.792 0 CA-C-N 115.271 -0.877 . . . . 0.91 109.742 -178.007 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 12.8 m120 . . . . . 0 CA--C 1.512 -0.496 0 N-CA-C 109.223 -0.658 . . . . 2.5 109.223 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.52 109.42 12.68 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.503 0.668 . . . . 0.95 109.906 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.778 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.5 pt -96.92 -13.2 8.17 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.83 -1.077 . . . . 1.03 111.577 -171.593 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.8 174.07 43.4 Favored Glycine 0 CA--C 1.501 -0.818 0 N-CA-C 111.171 -0.772 . . . . 0.11 111.171 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -142.98 148.69 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.96 0.41 . . . . 0.24 111.247 -174.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.427 HD13 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -77.01 121.67 29.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.704 -0.68 . . . . 1.03 111.157 -177.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 71.1 p -116.53 -21.51 9.15 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.067 0.461 . . . . 1.01 111.017 179.284 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.559 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.8 tptt -141.74 136.95 31.28 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.536 -0.913 . . . . 2.86 108.536 173.275 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.1 tt -152.97 142.83 22.12 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.883 0.373 . . . . 1.03 111.156 -178.007 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -143.97 141.85 30.4 Favored 'General case' 0 CA--C 1.499 -0.998 0 CA-C-N 115.777 -0.647 . . . . 1.94 111.767 177.315 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.21 -148.88 19.56 Favored Glycine 0 N--CA 1.422 -2.28 0 CA-C-N 114.695 -1.139 . . . . 0.32 113.159 164.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.2 t -104.49 113.04 26.35 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.527 -0.546 . . . . 1.65 109.527 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.408 HG21 ' HB2' ' A' ' 26' ' ' LEU . 3.3 m -133.18 152.89 36.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.562 0.696 . . . . 1.09 111.411 -177.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.18 159.43 43.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.959 -1.019 . . . . 1.0 108.477 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.448 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.1 p -131.92 129.35 60.65 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 C-N-CA 119.957 -0.697 . . . . 1.03 110.691 175.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.427 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 1.9 mt-30 -93.36 98.71 11.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.44 -0.8 . . . . 0.72 108.972 177.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.502 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.1 m -65.23 179.13 0.77 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.962 -0.563 . . . . 1.63 110.495 -176.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 15.1 pt -69.21 -4.88 4.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.913 0.709 . . . . 1.12 112.913 -172.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 57.0 m-80 -95.78 -5.35 42.13 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.176 0.513 . . . . 1.96 109.944 173.004 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.32 8.56 74.47 Favored Glycine 0 CA--C 1.507 -0.456 0 N-CA-C 110.709 -0.956 . . . . 0.34 110.709 -177.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -78.65 120.89 23.97 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.958 -0.621 . . . . 2.76 110.589 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.444 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.5 tt0 -89.25 109.9 20.73 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.323 0.582 . . . . 1.0 110.224 -179.016 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.409 ' HG2' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -110.83 144.74 39.37 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.206 -0.907 . . . . 2.1 109.711 -176.778 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -73.28 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.783 0.325 . . . . 1.11 110.268 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.408 ' HB2' HG21 ' A' ' 14' ' ' VAL . 16.4 mt -110.83 124.07 51.32 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.047 0.451 . . . . 1.1 110.552 177.161 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -115.67 178.73 4.2 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.511 -0.922 . . . . 2.19 108.511 173.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -65.61 147.74 52.9 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 119.766 -0.774 . . . . 1.1 109.909 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.52 -8.73 63.99 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.237 -0.982 . . . . 0.25 112.57 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.401 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 0.4 OUTLIER -65.08 144.59 99.09 Favored Pre-proline 0 CA--C 1.515 -0.377 0 CA-C-O 121.425 0.631 . . . . 1.92 111.021 179.559 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 38.1 Cg_endo -83.17 133.55 6.53 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 123.467 2.778 . . . . 0.31 112.393 175.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.408 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 29.0 mm -98.54 132.66 43.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 109.136 -0.69 . . . . 1.02 109.136 174.276 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -114.41 149.01 36.85 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 116.007 -0.542 . . . . 0.37 110.163 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.463 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -67.71 109.01 3.14 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.801 -0.636 . . . . 0.2 110.375 -174.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 121.49 -1.29 11.31 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.271 -0.966 . . . . 0.17 113.589 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.531 ' O ' ' HG2' ' A' ' 66' ' ' MET . 34.7 mt-10 -88.67 146.93 24.79 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 117.929 0.865 . . . . 0.52 110.367 -179.188 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.515 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.1 m -105.76 107.98 19.25 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.72 -0.673 . . . . 1.03 111.171 -175.544 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.1 t -81.4 133.62 28.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.154 0.502 . . . . 1.04 110.913 -175.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.9 mp -119.06 109.63 16.14 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.044 -0.98 . . . . 1.1 109.789 -178.691 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.9 p -105.01 155.7 18.72 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.541 -0.54 . . . . 1.06 109.541 176.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.899 0 C-N-CA 120.724 -0.75 . . . . 0.9 111.97 178.443 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.47 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 31.1 m . . . . . 0 CA--C 1.516 -0.362 0 N-CA-C 109.838 -0.43 . . . . 1.16 109.838 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.6 t -139.61 131.28 33.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 CA-C-N 116.559 -0.291 . . . . 1.09 111.433 -170.861 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.559 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 80.2 m -102.64 107.95 19.05 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.079 -0.51 . . . . 1.03 109.842 175.018 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.544 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 68.5 mt -96.52 109.64 23.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 CA-C-N 115.717 -0.674 . . . . 1.05 110.22 176.371 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.21 100.81 12.01 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.289 -0.869 . . . . 1.03 109.788 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.466 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 67.3 m-85 -68.09 148.36 51.06 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.71 0.767 . . . . 0.45 111.082 -177.798 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.8 p -73.45 -8.71 12.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-N 114.276 -1.329 . . . . 1.07 111.128 -171.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.436 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 32.1 t70 -80.15 -20.63 44.47 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.014 -0.539 . . . . 0.75 110.395 176.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.92 -10.58 11.1 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.749 -0.738 . . . . 0.32 112.173 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.7 p -85.23 157.29 20.65 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.65 -0.13 . . . . 1.09 110.65 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -133.81 140.99 47.26 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.507 -0.553 . . . . 1.51 109.507 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.544 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.6 m -121.47 172.65 8.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.192 0.52 . . . . 2.06 111.584 178.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -140.01 133.15 35.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.254 -0.884 . . . . 1.58 110.124 177.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.47 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.7 mt -103.54 133.25 47.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.003 -0.544 . . . . 1.08 109.951 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.51 178.97 53.71 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.661 -0.78 . . . . 1.02 111.367 175.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.52 155.08 20.84 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.718 -0.553 . . . . 0.64 111.718 -171.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 37.9 t70 59.1 17.13 5.29 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.929 0.871 . . . . 1.26 109.702 -176.568 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -102.58 156.42 17.63 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.524 -0.762 . . . . 1.64 111.343 -176.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.491 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 90.9 mt -140.69 120.73 12.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.292 -0.867 . . . . 1.08 109.57 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.4 p -150.2 143.74 17.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.644 0.259 . . . . 1.66 110.872 -177.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.515 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 36.2 tt0 -90.72 136.11 33.28 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.982 0.42 . . . . 0.67 110.42 177.782 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.531 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 61.3 mmm -69.13 89.05 0.43 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.332 -0.849 . . . . 1.13 110.283 179.054 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.1 p -112.73 -164.21 0.9 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.86 -0.609 . . . . 1.15 110.669 -177.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -75.4 -25.17 57.38 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.787 0.327 . . . . 2.13 110.874 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -66.2 -29.81 70.15 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 122.07 0.938 . . . . 2.51 109.612 172.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.47 HG23 ' CE ' ' A' ' 66' ' ' MET . 1.2 mm -82.46 -51.94 14.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 114.254 -1.339 . . . . 1.1 110.489 177.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.778 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.317 -0.833 0 CA-C-N 115.459 -0.791 . . . . 0.91 110.147 -176.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 . . . . . 0 C--O 1.238 0.486 0 CA-C-O 121.293 0.568 . . . . 2.5 110.767 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.23 110.05 17.74 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.061 -0.972 . . . . 0.95 109.931 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.771 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.9 pt -87.55 -14.87 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.125 -0.943 . . . . 1.03 111.688 -171.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.82 175.84 40.71 Favored Glycine 0 CA--C 1.502 -0.728 0 C-N-CA 120.671 -0.776 . . . . 0.11 111.817 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -144.15 149.55 36.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.038 0.446 . . . . 0.24 110.61 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.507 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.6 mm -76.61 126.11 36.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 115.731 -0.668 . . . . 1.03 110.787 -178.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.6 p -117.13 -16.92 10.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.307 0.575 . . . . 1.01 110.773 177.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.463 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.4 tttt -145.3 143.83 30.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.607 -0.886 . . . . 2.86 108.607 174.478 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.8 tt -160.47 139.1 10.26 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.778 0.323 . . . . 1.03 110.987 -175.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -144.07 145.32 32.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.956 -0.566 . . . . 1.94 111.49 177.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.18 -146.25 27.64 Favored Glycine 0 N--CA 1.436 -1.348 0 CA-C-N 115.026 -0.988 . . . . 0.32 114.063 167.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.9 m -102.03 115.66 31.03 Favored 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 122.832 0.453 . . . . 1.65 110.445 -175.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.447 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.8 m -135.14 153.59 34.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.594 0.711 . . . . 1.09 111.598 -175.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.12 158.32 44.03 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.781 -1.099 . . . . 1.0 108.954 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.605 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.9 OUTLIER -134.31 139.06 48.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 C-N-CA 120.015 -0.674 . . . . 1.03 110.727 171.901 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -107.11 100.03 9.53 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.149 -0.932 . . . . 0.72 109.71 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.448 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 43.0 t -62.73 179.93 0.31 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.594 -0.275 . . . . 1.63 110.753 -178.253 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.4 pt -61.16 -30.64 48.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.143 0.497 . . . . 1.12 111.567 -176.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 16.4 p30 -80.64 -6.71 58.74 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.907 -0.588 . . . . 1.96 111.0 177.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 94.37 1.28 64.52 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.121 -0.561 . . . . 0.34 112.413 176.033 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -67.08 121.24 15.16 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.817 0.341 . . . . 2.76 111.424 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.605 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 14.6 tt0 -93.77 118.18 31.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.641 177.069 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.504 ' HG2' HG12 ' A' ' 16' ' ' VAL . 21.8 ptt-85 -120.24 168.01 11.69 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.167 -0.679 . . . . 2.1 109.167 174.518 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.7 p -93.98 136.81 24.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.996 -0.742 . . . . 1.11 108.996 177.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.539 HD21 ' OD1' ' A' ' 30' ' ' ASP . 5.2 mt -97.13 153.58 17.88 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.014 -0.539 . . . . 1.1 111.316 -176.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.3 mttm -138.44 -178.12 5.15 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.149 -0.932 . . . . 2.19 108.585 -173.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.78 140.85 39.48 Favored 'General case' 0 C--N 1.314 -0.954 0 C-N-CA 119.494 -0.882 . . . . 1.1 108.971 174.26 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.81 1.09 77.07 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 120.041 -1.076 . . . . 0.25 111.887 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.539 ' OD1' HD21 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -73.83 137.14 76.65 Favored Pre-proline 0 CA--C 1.517 -0.312 0 CA-C-O 121.79 0.805 . . . . 1.92 110.614 179.095 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -77.23 130.23 10.94 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.62 2.88 . . . . 0.31 113.405 -177.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.4 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.5 mm -99.53 135.93 32.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.075 -0.966 . . . . 1.02 109.313 174.217 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -116.15 154.71 29.54 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 116.004 -0.544 . . . . 0.37 109.731 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.471 ' HB2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -71.21 109.57 5.33 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.361 -0.382 . . . . 0.2 110.657 -174.555 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.14 10.28 9.04 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.443 -0.884 . . . . 0.17 113.422 178.072 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.479 ' O ' ' HG2' ' A' ' 66' ' ' MET . 40.6 mt-10 -96.01 145.08 25.74 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 117.868 0.834 . . . . 0.52 110.687 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.407 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 31.7 m -105.27 108.2 19.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.412 -0.813 . . . . 1.03 110.806 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -82.71 133.72 28.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.128 0.489 . . . . 1.04 110.756 -175.567 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -122.2 110.15 15.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.175 -0.921 . . . . 1.1 110.051 -177.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.9 p -107.48 158.06 17.5 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.425 -0.583 . . . . 1.06 109.425 176.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 C-N-CA 120.378 -0.915 . . . . 0.9 113.346 -177.497 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.515 -0.368 0 CA-C-O 121.059 0.457 . . . . 1.16 109.937 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.0 t -126.09 142.35 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 CA-C-O 120.793 0.33 . . . . 1.09 111.093 -170.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.463 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.1 m -119.34 110.59 17.15 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.297 0.57 . . . . 1.03 110.341 177.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 70.2 mt -98.88 102.5 13.49 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-N 115.163 -0.926 . . . . 1.05 109.925 178.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.76 102.62 11.68 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.476 -0.784 . . . . 1.03 109.259 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.539 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 58.6 m-85 -64.85 149.28 49.76 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.437 0.637 . . . . 0.45 110.881 -177.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.28 -9.03 12.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 114.784 -1.098 . . . . 1.07 111.134 -172.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.495 ' N ' ' HH ' ' A' ' 71' ' ' TYR . 19.5 t70 -78.39 -22.27 48.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.71 -0.677 . . . . 0.75 111.0 177.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.21 -11.85 16.94 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.32 111.65 -174.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -85.1 161.08 19.82 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.127 -0.323 . . . . 1.09 110.127 175.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -131.78 155.53 47.58 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.24 -0.281 . . . . 1.51 110.24 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.497 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.8 OUTLIER -137.5 151.27 26.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.433 -0.349 . . . . 2.06 110.151 178.401 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.422 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.1 p -129.39 141.53 46.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.333 -0.394 . . . . 1.58 110.139 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 mt -116.2 131.38 68.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.224 -0.444 . . . . 1.08 110.209 -177.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.46 179.7 52.83 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.925 -0.655 . . . . 1.02 111.635 176.201 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.78 148.73 19.09 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 111.285 -0.726 . . . . 0.64 111.285 -173.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.8 t70 59.22 23.42 11.76 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 121.914 0.864 . . . . 1.26 109.605 -173.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -104.47 159.99 15.29 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.728 -0.669 . . . . 1.64 110.712 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.481 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 92.2 mt -140.07 125.83 21.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.123 -0.944 . . . . 1.08 108.809 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 13.8 p -147.67 141.74 19.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-O 120.886 0.374 . . . . 1.66 110.866 -177.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.407 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.3 tt0 -100.86 124.93 47.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.151 -0.477 . . . . 0.67 110.25 -179.089 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.479 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 44.3 mmm -65.46 90.29 0.11 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.72 -0.673 . . . . 1.13 110.725 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.406 ' HB ' ' H ' ' A' ' 68' ' ' ASP . 1.3 p -118.48 -165.48 1.12 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 1.15 111.7 -176.532 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.406 ' H ' ' HB ' ' A' ' 67' ' ' THR . 29.1 t70 -65.9 -44.22 85.88 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.857 0.317 . . . . 2.13 111.857 -174.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -62.94 -29.99 71.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.456 0.646 . . . . 2.51 110.49 178.111 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.41 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.1 mm -71.99 -53.11 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.903 -1.044 . . . . 1.1 110.769 176.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.771 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 . . . . . 0 C--N 1.318 -0.778 0 CA-C-N 115.61 -0.723 . . . . 0.91 110.318 -176.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 7.8 p30 . . . . . 0 N--CA 1.447 -0.604 0 CA-C-O 121.017 0.437 . . . . 2.5 110.35 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.08 117.94 20.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.488 -0.778 . . . . 0.95 110.228 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.817 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 26.6 pt -96.96 -13.47 8.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.454 -0.794 . . . . 1.03 111.487 -172.638 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.6 179.21 42.21 Favored Glycine 0 CA--C 1.502 -0.752 0 C-N-CA 120.947 -0.644 . . . . 0.11 111.635 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -145.18 152.24 39.69 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.819 0.342 . . . . 0.24 110.604 -175.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 30' ' ' ASP . 29.6 mm -81.55 120.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.032 -0.531 . . . . 1.03 111.11 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 43.8 p -111.94 -27.25 8.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.276 0.56 . . . . 1.01 110.307 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.477 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 85.8 tttt -136.43 147.37 47.21 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.464 -0.939 . . . . 2.86 108.464 172.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.9 tt -158.74 141.06 14.07 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.852 0.358 . . . . 1.03 110.8 -176.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.51 144.36 30.51 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 115.643 -0.708 . . . . 1.94 112.128 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.81 -148.4 27.35 Favored Glycine 0 N--CA 1.425 -2.038 0 CA-C-N 114.561 -1.2 . . . . 0.32 113.479 165.562 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 5.7 t -103.05 109.91 21.65 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.715 -0.476 . . . . 1.65 109.715 -179.142 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.452 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 2.6 m -132.21 153.02 37.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.379 0.609 . . . . 1.09 111.569 -175.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.13 159.71 44.22 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.219 -0.901 . . . . 1.0 109.413 -179.56 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.485 HG21 ' HB3' ' A' ' 36' ' ' GLU . 0.5 OUTLIER -132.6 131.09 59.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.239 0.543 . . . . 1.03 110.213 176.017 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 mt-30 -103.35 99.6 9.45 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.708 -0.678 . . . . 0.72 109.835 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.531 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.6 m -61.64 174.07 0.86 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.535 -0.302 . . . . 1.63 111.072 -176.28 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.7 pt -54.92 -32.51 26.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.301 0.482 . . . . 1.12 112.301 -176.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -75.71 -12.11 60.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.384 -0.371 . . . . 1.96 111.421 178.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.12 6.08 59.17 Favored Glycine 0 CA--C 1.51 -0.261 0 N-CA-C 111.864 -0.494 . . . . 0.34 111.864 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.0 mm-40 -74.35 124.96 27.47 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.639 0.257 . . . . 2.76 110.491 178.589 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.407 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 23.7 tt0 -91.69 110.13 21.46 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.425 0.631 . . . . 1.0 110.801 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.429 HH11 ' HD2' ' A' ' 24' ' ' ARG . 0.1 OUTLIER -105.08 139.05 40.33 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.295 -0.866 . . . . 2.1 109.872 177.466 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.22 138.03 21.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.444 -0.576 . . . . 1.11 109.444 176.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.452 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 28.8 mt -102.96 127.54 50.15 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.304 0.574 . . . . 1.1 111.102 -178.117 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 74.0 mttt -116.55 179.43 4.01 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.514 -1.291 . . . . 2.19 107.514 170.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -67.58 146.74 53.59 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 119.306 -0.958 . . . . 1.1 109.95 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.52 0.04 86.35 Favored Glycine 0 N--CA 1.438 -1.178 0 C-N-CA 120.313 -0.946 . . . . 0.25 112.721 177.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.474 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.8 OUTLIER -71.84 143.13 86.44 Favored Pre-proline 0 CA--C 1.513 -0.461 0 C-N-CA 120.36 -0.536 . . . . 1.92 109.775 173.946 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -89.78 137.47 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.143 2.562 . . . . 0.31 112.1 178.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.474 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.5 mm -98.52 139.65 20.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 116.132 -0.485 . . . . 1.02 109.914 176.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -117.13 155.38 29.43 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.893 -0.594 . . . . 0.37 109.498 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.428 ' HB2' HG21 ' A' ' 4' ' ' ILE . 2.5 t80 -71.64 118.6 14.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.39 -0.368 . . . . 0.2 110.541 -175.424 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.68 -0.36 24.63 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.502 -0.856 . . . . 0.17 113.324 177.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.531 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 23.4 mt-10 -85.42 147.94 26.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 117.8 0.8 . . . . 0.52 110.909 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.8 m -107.71 108.27 19.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.812 -1.086 . . . . 1.03 110.388 -176.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.618 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.2 t -82.08 136.97 21.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 C-N-CA 120.703 -0.399 . . . . 1.04 110.759 -174.328 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -125.66 107.03 10.17 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.437 -0.801 . . . . 1.1 110.562 -175.742 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.5 p -105.74 163.3 12.81 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 108.981 -0.748 . . . . 1.06 108.981 173.27 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.316 -0.562 0 C-N-CA 120.384 -0.912 . . . . 0.9 112.538 -179.664 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.538 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 46.6 t . . . . . 0 CA--C 1.508 -0.666 0 N-CA-C 109.09 -0.707 . . . . 1.16 109.09 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 17.8 t -152.21 136.2 8.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 110.121 -0.325 . . . . 1.09 110.121 -176.256 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.9 m -109.79 105.36 14.55 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.145 0.497 . . . . 1.03 109.768 173.194 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 78.4 mt -96.34 99.88 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 115.43 -0.805 . . . . 1.05 109.739 177.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.91 102.38 8.22 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.215 -0.902 . . . . 1.03 109.079 176.639 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.611 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 53.1 m-85 -66.28 151.35 47.23 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.617 0.722 . . . . 0.45 111.081 -176.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -75.24 1.63 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 114.588 -1.187 . . . . 1.07 111.273 -172.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -94.16 -20.79 19.55 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.106 0.479 . . . . 0.75 110.5 178.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 123.36 -19.77 7.57 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.637 -0.792 . . . . 0.32 111.892 -176.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -78.27 160.2 28.03 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 122.15 0.18 . . . . 1.09 110.766 177.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -133.3 146.03 50.99 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.427 -0.582 . . . . 1.51 109.427 178.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.611 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -130.85 147.27 33.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.008 0.432 . . . . 2.06 110.834 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.522 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.3 p -120.7 138.94 49.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.841 -0.618 . . . . 1.58 110.123 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 45' ' ' SER . 34.6 mt -110.64 134.45 52.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.078 -0.51 . . . . 1.08 110.096 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.76 -168.96 43.56 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.803 -0.713 . . . . 1.02 112.262 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -100.56 143.39 16.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.95 -0.643 . . . . 0.64 111.562 -176.149 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.2 t70 60.44 21.53 11.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 121.612 0.72 . . . . 1.26 110.052 -174.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.2 t -97.54 154.27 17.63 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.725 -0.67 . . . . 1.64 110.176 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.618 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.6 mt -141.78 106.21 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.486 -0.779 . . . . 1.08 108.937 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -133.56 149.18 30.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.122 0.487 . . . . 1.66 111.414 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -105.94 128.96 54.14 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.611 -0.722 . . . . 0.67 110.543 -175.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.544 ' SD ' HG23 ' A' ' 70' ' ' ILE . 22.2 mmt -64.3 89.88 0.06 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.607 -0.724 . . . . 1.13 111.333 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 72.7 p -124.89 -165.14 1.35 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.85 -0.613 . . . . 1.15 110.988 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -68.33 -26.04 65.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.31 0.576 . . . . 2.13 110.226 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -74.19 -20.28 60.25 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.362 -0.836 . . . . 2.51 110.361 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.544 HG23 ' SD ' ' A' ' 66' ' ' MET . 2.2 mm -98.49 -55.1 6.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-N 114.785 -1.098 . . . . 1.1 110.948 -179.59 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.817 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.044 -0.98 . . . . 0.91 109.921 -175.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.3 p-10 . . . . . 0 CA--C 1.516 -0.36 0 CA-C-O 120.861 0.363 . . . . 2.5 110.201 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.04 109.2 14.27 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.854 -0.612 . . . . 0.95 109.78 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.686 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.4 pt -95.35 -11.85 8.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 115.058 -0.974 . . . . 1.03 111.565 -171.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.91 175.58 43.32 Favored Glycine 0 CA--C 1.498 -1.027 0 N-CA-C 111.241 -0.743 . . . . 0.11 111.241 178.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -144.1 151.18 39.26 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.952 0.406 . . . . 0.24 110.581 -174.363 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.55 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.7 mm -78.3 124.43 36.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.96 -0.563 . . . . 1.03 111.389 -177.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.0 p -115.1 -21.3 10.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.182 0.515 . . . . 1.01 110.627 177.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.527 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 81.8 tttt -140.9 143.58 34.72 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.54 -0.911 . . . . 2.86 108.54 172.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.424 HD11 HG23 ' A' ' 14' ' ' VAL . 7.6 tt -161.21 140.84 10.53 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.682 0.277 . . . . 1.03 110.82 -177.264 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -156.0 158.5 37.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.49 -0.777 . . . . 1.94 111.159 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.81 -163.66 52.64 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.811 -0.631 . . . . 0.32 112.974 175.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.0 m -92.83 116.62 29.2 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 109.762 -0.459 . . . . 1.65 109.762 -177.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.453 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.9 m -134.48 152.5 33.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.672 0.748 . . . . 1.09 111.988 -175.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.04 159.05 44.78 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 114.567 -1.197 . . . . 1.0 108.853 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.63 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.9 OUTLIER -133.95 135.76 54.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.109 -0.637 . . . . 1.03 110.922 172.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.402 ' HA ' ' O ' ' A' ' 22' ' ' GLN . 2.3 mt-30 -102.46 100.75 10.9 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.364 -0.835 . . . . 0.72 109.911 177.412 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.525 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 37.7 m -62.86 176.64 0.66 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.5 -0.318 . . . . 1.63 110.861 -178.367 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -66.68 -5.55 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 N-CA-C 112.142 0.423 . . . . 1.12 112.142 -178.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -92.25 -8.48 45.21 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.294 0.569 . . . . 1.96 109.682 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.5 6.46 80.63 Favored Glycine 0 CA--C 1.507 -0.465 0 CA-C-N 115.278 -0.874 . . . . 0.34 111.093 -177.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.402 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 46.6 mm-40 -79.65 127.85 32.68 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.225 -0.488 . . . . 2.76 110.953 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLU . . . . . 0.63 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 25.4 tt0 -101.64 117.87 35.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.702 -0.681 . . . . 1.0 110.762 -178.149 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.502 ' HG2' HG12 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -116.62 168.78 9.88 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.619 -0.512 . . . . 2.1 109.619 176.156 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -87.77 140.84 15.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.329 -0.619 . . . . 1.11 109.329 176.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.525 HD23 ' CG ' ' A' ' 30' ' ' ASP . 4.8 mt -101.44 152.3 20.91 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.478 -0.489 . . . . 1.1 111.129 179.15 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.44 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 53.4 mttt -141.61 178.53 7.4 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.139 -0.937 . . . . 2.19 108.638 -174.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.14 139.3 44.43 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.353 -0.939 . . . . 1.1 109.108 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 2.42 86.82 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 120.051 -1.071 . . . . 0.25 111.968 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.55 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -74.89 141.59 75.39 Favored Pre-proline 0 N--CA 1.454 -0.237 0 CA-C-O 121.55 0.69 . . . . 1.92 109.981 177.574 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -86.88 127.28 2.6 Favored 'Trans proline' 0 C--N 1.325 -0.709 0 C-N-CA 123.628 2.885 . . . . 0.31 113.353 -174.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 32.2 mm -93.11 134.28 31.48 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-N 116.183 -0.462 . . . . 1.02 109.815 176.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -111.89 151.29 29.32 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.697 -0.683 . . . . 0.37 109.747 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.484 ' HB2' HG23 ' A' ' 4' ' ' ILE . 2.2 t80 -69.42 113.9 7.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.318 -0.401 . . . . 0.2 110.796 -175.527 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.13 0.55 22.44 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.527 -0.844 . . . . 0.17 113.408 177.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLU . . . . . 0.546 ' O ' ' HG2' ' A' ' 66' ' ' MET . 30.8 mt-10 -86.87 144.7 26.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 117.976 0.888 . . . . 0.52 110.81 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.6 m -101.33 107.64 19.05 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.211 -0.904 . . . . 1.03 110.887 -177.11 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.6 t -82.24 130.51 35.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.137 0.494 . . . . 1.04 110.412 -176.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.1 mp -119.11 103.4 9.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.075 -0.966 . . . . 1.1 109.958 -177.357 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 20.3 p -100.67 159.33 15.26 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.253 -0.647 . . . . 1.06 109.253 175.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.991 0 C-N-CA 120.66 -0.781 . . . . 0.9 112.133 178.223 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' SER . . . . . 0.567 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 18.9 m . . . . . 0 C--O 1.224 -0.268 0 N-CA-C 109.002 -0.74 . . . . 1.16 109.002 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.533 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 11.0 t -140.18 146.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 O-C-N 122.171 -0.33 . . . . 1.09 110.761 -176.085 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.527 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.5 m -119.43 111.21 17.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.115 -0.493 . . . . 1.03 109.731 174.106 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.54 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 62.4 mt -101.0 104.16 15.85 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 CA-C-N 115.705 -0.679 . . . . 1.05 110.271 179.798 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 104.4 9.09 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.406 -0.816 . . . . 1.03 108.995 176.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.478 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 53.4 m-85 -69.55 148.72 49.06 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.269 0.557 . . . . 0.45 110.681 -177.592 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -70.69 -5.55 5.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 114.878 -1.055 . . . . 1.07 111.04 -171.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.437 ' N ' ' HH ' ' A' ' 71' ' ' TYR . 30.4 t70 -81.57 -21.37 38.49 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.37 0.605 . . . . 0.75 110.42 174.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 117.13 -7.01 16.9 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.781 -0.723 . . . . 0.32 112.275 -177.444 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 23.3 p -86.55 175.18 8.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.436 -0.209 . . . . 1.09 110.436 177.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -149.53 150.49 32.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.706 0.289 . . . . 1.51 110.338 177.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.54 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.8 m -130.88 166.86 27.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.972 -0.558 . . . . 2.06 111.006 179.136 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' VAL . . . . . 0.533 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.0 p -135.19 132.21 52.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 115.763 -0.653 . . . . 1.58 110.819 179.241 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.567 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.3 mt -106.24 132.97 52.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.607 -0.724 . . . . 1.08 109.838 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.14 -160.38 26.9 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.977 -0.63 . . . . 1.02 112.598 -178.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -104.07 141.7 15.32 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.595 -0.602 . . . . 0.64 111.595 -176.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.422 ' HA ' ' O ' ' A' ' 40' ' ' THR . 32.9 t70 58.16 26.15 13.4 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 122.174 0.988 . . . . 1.26 109.313 -171.084 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -91.05 131.67 36.49 Favored 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.465 -1.243 . . . . 1.64 110.967 -178.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ILE . . . . . 0.572 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.0 mt -129.08 106.12 13.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.092 -0.707 . . . . 1.08 109.092 178.003 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.28 144.47 31.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.096 -0.502 . . . . 1.66 110.555 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.6 tt0 -97.46 131.04 44.47 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.426 -0.352 . . . . 0.67 110.303 -179.571 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.546 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 53.5 mmm -68.45 89.46 0.35 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.748 -0.66 . . . . 1.13 110.717 -178.307 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.9 p -112.13 -164.62 0.93 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.098 -0.501 . . . . 1.15 111.456 -176.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -72.35 -25.52 61.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.941 0.4 . . . . 2.13 110.852 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -71.05 -31.24 67.64 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 122.102 0.954 . . . . 2.51 109.236 176.124 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.452 HG23 ' HE1' ' A' ' 66' ' ' MET . 1.2 mm -78.77 -47.03 23.86 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 CA-C-N 113.844 -1.525 . . . . 1.1 110.832 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.686 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.318 -0.797 0 CA-C-N 115.281 -0.872 . . . . 0.91 110.061 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.693 0 N-CA-C 111.738 -0.545 . . . . 1.83 111.738 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 -100.93 144.98 29.22 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.805 -0.443 . . . . 2.5 109.805 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.78 114.55 15.67 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.334 0.588 . . . . 0.95 110.342 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.783 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 23.1 pt -93.98 -14.39 8.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 115.197 -0.91 . . . . 1.03 111.431 -172.205 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.47 42.79 Favored Glycine 0 CA--C 1.504 -0.64 0 C-N-CA 120.739 -0.743 . . . . 0.11 111.84 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -143.54 151.09 39.82 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.989 0.423 . . . . 0.24 110.822 -174.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.492 HG13 ' OD1' ' A' ' 30' ' ' ASP . 23.8 mm -78.75 124.43 37.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.875 -0.602 . . . . 1.03 111.528 -177.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.8 p -113.39 -26.17 8.47 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.323 0.582 . . . . 1.01 110.771 177.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.9 tptt -137.89 139.62 39.94 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.786 -0.82 . . . . 2.86 108.786 174.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.9 tt -152.74 144.91 23.87 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 120.776 0.322 . . . . 1.03 110.164 178.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.464 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 0.2 OUTLIER -155.35 156.32 35.22 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.852 -0.613 . . . . 1.94 110.662 179.124 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.12 -155.49 50.64 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.95 -0.568 . . . . 0.32 112.809 176.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.3 t -99.43 126.0 45.25 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.186 -0.672 . . . . 1.65 109.186 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.478 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -139.76 152.96 22.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.538 0.685 . . . . 1.09 111.498 -176.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.51 158.78 44.06 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.625 -1.17 . . . . 1.0 108.982 178.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.462 HG23 ' HB3' ' A' ' 36' ' ' GLU . 0.5 OUTLIER -132.68 131.83 59.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.235 0.54 . . . . 1.03 110.034 174.857 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -97.42 99.01 10.43 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.471 -0.566 . . . . 0.72 109.471 178.385 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.555 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 39.9 m -62.2 171.59 1.76 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.928 -0.578 . . . . 1.63 109.703 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.2 pt -65.98 -1.44 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 113.757 1.021 . . . . 1.12 113.757 -170.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 49.6 m-80 -98.03 -2.16 40.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.303 0.573 . . . . 1.96 109.722 173.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.63 74.91 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 110.61 -0.996 . . . . 0.34 110.61 -176.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -84.38 118.2 24.09 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.721 -0.74 . . . . 2.76 110.519 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 4.9 tt0 -85.56 113.86 22.13 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.294 0.568 . . . . 1.0 110.483 -178.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -106.01 138.76 41.64 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.958 -1.019 . . . . 2.1 109.401 177.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -75.8 141.32 15.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.249 -0.648 . . . . 1.11 109.249 177.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.478 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 5.1 mt -106.99 145.05 32.74 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 121.493 0.663 . . . . 1.1 111.614 -178.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 35.7 mttp -137.51 169.22 18.15 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.461 -1.245 . . . . 2.19 107.735 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -61.23 140.17 57.99 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 119.761 -0.776 . . . . 1.1 109.798 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.489 ' H ' ' HB ' ' A' ' 7' ' ' ILE . . . 82.79 9.31 84.71 Favored Glycine 0 N--CA 1.437 -1.289 0 C-N-CA 120.052 -1.07 . . . . 0.25 113.08 177.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.492 ' OD1' HG13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.76 147.98 56.54 Favored Pre-proline 0 C--O 1.236 0.355 0 CA-C-N 117.419 0.609 . . . . 1.92 109.474 176.191 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -84.05 131.04 5.0 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.635 2.224 . . . . 0.31 113.219 178.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 mm -95.98 137.37 24.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.392 -0.822 . . . . 1.02 109.211 174.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -118.8 157.22 27.98 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.057 -0.52 . . . . 0.37 109.699 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.409 ' HB2' HG22 ' A' ' 4' ' ' ILE . 1.8 t80 -73.85 116.02 13.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.078 -0.51 . . . . 0.2 110.493 -174.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.19 -4.2 18.35 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.527 -0.844 . . . . 0.17 113.736 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.555 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 24.6 mt-10 -84.93 149.06 25.9 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 117.971 0.886 . . . . 0.52 110.993 -177.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 11.7 m -104.31 108.07 19.29 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.388 -0.823 . . . . 1.03 110.777 -178.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.8 t -81.72 133.53 29.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.145 0.498 . . . . 1.04 110.613 -176.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -122.08 107.68 12.48 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.18 -0.918 . . . . 1.1 109.964 -176.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.454 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 69.7 p -104.26 152.04 22.67 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.79 -0.448 . . . . 1.06 109.79 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -130.29 135.14 8.16 Favored Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 120.928 -0.653 . . . . 0.9 112.205 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 56.61 -108.35 1.18 Allowed Glycine 0 N--CA 1.451 -0.318 0 O-C-N 123.946 0.439 . . . . 1.79 113.491 177.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.5 m -90.48 28.95 1.36 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.934 0.397 . . . . 1.94 111.198 -174.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -65.49 134.13 35.75 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 121.062 -0.59 . . . . 0.89 112.365 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.404 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 6.0 m -152.62 121.81 6.68 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.968 -0.753 . . . . 1.16 108.968 173.212 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.527 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 4.7 t -133.53 139.54 48.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.739 -0.384 . . . . 1.09 111.141 -173.671 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.593 ' HA ' ' O ' ' A' ' 56' ' ' VAL . 89.3 m -113.89 110.85 20.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.966 -0.561 . . . . 1.03 109.956 174.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 69.3 mt -100.37 102.0 12.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.585 -0.734 . . . . 1.05 110.24 178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.6 107.79 11.53 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.431 -0.804 . . . . 1.03 109.388 177.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.48 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 61.7 m-85 -70.86 149.7 46.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.633 0.73 . . . . 0.45 111.287 -177.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -77.4 0.95 2.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 114.743 -1.117 . . . . 1.07 111.086 -172.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -90.51 -21.41 21.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.958 -0.564 . . . . 0.75 110.649 175.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.42 -18.11 5.8 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.639 -0.791 . . . . 0.32 112.8 -178.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.2 p -84.81 171.64 12.1 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.644 0.222 . . . . 1.09 111.119 178.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -130.26 -178.0 4.56 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.14 -0.689 . . . . 1.51 109.14 175.308 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.593 ' O ' ' HA ' ' A' ' 47' ' ' THR . 0.5 OUTLIER -160.24 151.32 5.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 2.06 109.896 178.982 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.527 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.2 p -129.12 131.53 67.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.355 0.597 . . . . 1.58 110.783 178.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.404 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.8 mt -107.28 137.18 39.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 115.668 -0.696 . . . . 1.08 109.788 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.06 -164.28 29.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.932 -0.651 . . . . 1.02 112.578 -179.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.2 142.67 17.66 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.547 -0.621 . . . . 0.64 111.547 -174.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.454 ' HA ' ' O ' ' A' ' 40' ' ' THR . 37.7 t70 56.64 30.11 16.87 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-O 122.151 0.977 . . . . 1.26 109.207 -172.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 m -112.28 163.27 14.57 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.656 -1.156 . . . . 1.64 110.727 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 83.4 mt -140.05 127.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.845 -0.616 . . . . 1.08 109.838 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.1 p -148.53 143.72 18.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 109.886 -0.413 . . . . 1.66 109.886 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -103.37 133.58 48.19 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.758 -0.377 . . . . 0.67 110.323 -178.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.412 ' HE3' HG22 ' A' ' 70' ' ' ILE . 53.2 mmm -69.19 89.2 0.45 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.645 -0.707 . . . . 1.13 110.366 -177.797 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 19.2 p -115.95 -164.9 0.99 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.756 -0.656 . . . . 1.15 111.39 -176.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -68.94 -41.15 78.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.524 -0.307 . . . . 2.13 111.252 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -61.53 -30.08 70.41 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.636 0.731 . . . . 2.51 110.306 177.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.412 HG22 ' HE3' ' A' ' 66' ' ' MET . 1.3 mm -73.45 -52.52 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 114.497 -1.229 . . . . 1.1 110.806 176.133 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.783 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -104.88 79.72 1.55 Allowed 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.489 -0.778 . . . . 0.91 110.378 -176.321 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -77.89 106.48 9.76 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.427 -0.806 . . . . 1.95 109.791 176.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.9 p -81.29 131.92 35.31 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.136 -0.484 . . . . 1.12 111.061 -178.092 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.72 -40.63 7.6 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.965 -0.636 . . . . 1.91 112.336 -178.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 47.8 m-20 -81.63 -79.56 0.17 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.773 0.321 . . . . 5.57 110.176 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.981 0 CA-C-O 118.909 -0.567 . . . . 7.51 110.141 178.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.724 0 N-CA-C 111.926 -0.47 . . . . 1.83 111.926 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 69.16 147.83 0.06 Allowed 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.413 0.685 . . . . 2.5 111.613 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.26 109.91 12.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.827 -0.624 . . . . 0.95 109.642 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.775 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.0 pt -92.77 -13.6 8.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.295 -0.866 . . . . 1.03 112.074 -170.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.64 176.64 42.3 Favored Glycine 0 CA--C 1.501 -0.799 0 C-N-CA 120.69 -0.767 . . . . 0.11 111.513 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -143.51 150.41 38.89 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.048 0.451 . . . . 0.24 110.921 -174.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.527 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -78.22 123.38 34.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.683 -0.689 . . . . 1.03 110.883 -177.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.7 p -115.44 -21.29 9.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.218 0.532 . . . . 1.01 110.801 178.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.541 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 52.3 tptt -140.82 139.65 34.55 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.317 -0.994 . . . . 2.86 108.317 172.29 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.8 tt -153.57 146.34 24.32 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 110.234 -0.284 . . . . 1.03 110.234 -179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.668 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 3.9 t70 -146.82 153.57 40.34 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.292 -0.413 . . . . 1.94 110.654 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.61 -149.48 49.67 Favored Glycine 0 N--CA 1.45 -0.402 0 O-C-N 123.689 0.618 . . . . 0.32 113.768 171.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.9 m -100.22 124.49 45.71 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.954 -0.387 . . . . 1.65 109.954 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.469 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.9 m -136.05 152.32 30.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.638 0.732 . . . . 1.09 111.692 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.23 157.55 43.21 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.751 -1.113 . . . . 1.0 108.647 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.537 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.5 OUTLIER -135.81 134.94 51.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.048 -0.661 . . . . 1.03 111.049 174.549 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.413 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.8 mt-30 -100.05 102.79 14.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.328 -0.851 . . . . 0.72 109.599 177.426 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.559 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 61.4 p -61.46 178.87 0.26 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 111.473 0.175 . . . . 1.63 111.473 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.7 pt -59.42 -24.36 27.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.091 0.472 . . . . 1.12 111.16 178.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -77.57 -16.64 58.51 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.829 -0.623 . . . . 1.96 110.402 177.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.33 7.31 62.17 Favored Glycine 0 CA--C 1.504 -0.6 0 N-CA-C 110.909 -0.877 . . . . 0.34 110.909 -176.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.0 mm100 -77.74 116.02 17.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.159 -0.521 . . . . 2.76 110.69 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.537 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 13.4 tt0 -81.89 118.44 22.93 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.069 -0.514 . . . . 1.0 110.056 176.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.49 ' HG2' HG12 ' A' ' 16' ' ' VAL . 36.0 ptt85 -120.33 169.62 10.11 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.838 -0.801 . . . . 2.1 108.838 174.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.4 p -96.62 144.33 10.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 109.496 -0.557 . . . . 1.11 109.496 -178.33 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.554 HD21 ' CG ' ' A' ' 30' ' ' ASP . 7.3 mt -112.68 160.73 17.62 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.124 0.487 . . . . 1.1 110.987 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.598 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 0.2 OUTLIER -159.46 177.04 11.38 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.278 -0.874 . . . . 2.19 109.027 -179.502 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 143.51 56.82 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 119.81 -0.756 . . . . 1.1 109.99 -179.38 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.57 6.71 81.81 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.219 -0.991 . . . . 0.25 112.41 178.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.598 ' HB3' ' O ' ' A' ' 27' ' ' LYS . 0.0 OUTLIER -85.37 142.27 37.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.399 0.618 . . . . 1.92 110.793 178.325 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.36 134.79 11.54 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 123.58 2.853 . . . . 0.31 113.756 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.8 mm -100.49 136.9 29.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.35 -0.841 . . . . 1.02 109.238 172.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -116.29 153.12 32.51 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 116.224 -0.444 . . . . 0.37 110.134 -178.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.466 ' HB2' HG23 ' A' ' 4' ' ' ILE . 2.0 t80 -71.37 114.5 9.5 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.058 -0.519 . . . . 0.2 110.869 -174.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.95 0.56 24.16 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.497 -0.858 . . . . 0.17 113.279 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.559 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 34.7 mt-10 -84.28 147.7 27.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.676 0.738 . . . . 0.52 110.465 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 22.2 m -106.59 106.88 17.61 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.462 -0.79 . . . . 1.03 110.488 -177.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -81.85 125.96 39.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-O 121.205 0.526 . . . . 1.04 110.916 -174.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -113.16 106.39 14.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.028 -0.987 . . . . 1.1 109.454 179.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.483 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 73.0 p -101.93 157.42 16.87 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 120.44 -0.504 . . . . 1.06 109.997 178.183 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -139.74 140.09 10.47 Favored Glycine 0 N--CA 1.441 -1.022 0 CA-C-N 115.631 -0.713 . . . . 0.9 111.644 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 62.07 -121.37 25.39 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.307 -0.473 . . . . 1.79 112.562 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 97.5 p -86.84 25.33 1.31 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.862 0.331 . . . . 1.94 110.9 -178.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.668 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -58.74 94.63 0.05 OUTLIER Glycine 0 C--O 1.222 -0.656 0 CA-C-N 116.096 -0.502 . . . . 0.89 112.772 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -120.26 112.35 18.94 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.231 -0.655 . . . . 1.16 109.231 -175.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.8 t -126.5 130.43 71.79 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 C-N-CA 120.677 -0.409 . . . . 1.09 111.878 -169.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.541 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 97.2 m -106.79 108.85 20.57 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.781 -0.645 . . . . 1.03 109.751 175.089 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.544 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 62.3 mt -97.73 105.35 17.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.623 -0.717 . . . . 1.05 110.117 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.81 105.42 11.08 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.413 -0.812 . . . . 1.03 109.042 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.456 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 62.5 m-85 -71.18 146.79 48.88 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.508 0.67 . . . . 0.45 110.867 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.59 2.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 114.634 -1.166 . . . . 1.07 111.582 -171.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -94.66 -20.68 19.35 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.076 -0.511 . . . . 0.75 110.384 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.0 -17.65 7.12 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.66 -0.781 . . . . 0.32 112.552 -178.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.7 p -82.99 155.7 23.83 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 122.903 -0.175 . . . . 1.09 110.866 178.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -132.33 143.26 49.74 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.897 -0.408 . . . . 1.51 109.897 178.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.544 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 10.7 m -124.44 168.56 16.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.068 0.461 . . . . 2.06 111.584 178.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.504 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.7 p -138.78 133.37 41.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.331 -0.849 . . . . 1.58 110.25 177.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -106.34 136.15 42.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.99 -0.55 . . . . 1.08 109.929 -179.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.49 178.71 53.74 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.551 -0.833 . . . . 1.02 111.606 177.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.0 151.08 19.93 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 111.584 -0.607 . . . . 0.64 111.584 -172.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.483 ' HA ' ' O ' ' A' ' 40' ' ' THR . 34.5 t70 51.15 28.48 4.08 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 121.379 0.609 . . . . 1.26 110.509 -171.22 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.5 t -104.72 161.71 13.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.882 -0.599 . . . . 1.64 110.761 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.549 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 81.3 mt -138.92 123.15 20.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.629 -0.714 . . . . 1.08 109.51 178.11 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.14 137.04 16.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.935 0.398 . . . . 1.66 110.855 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.7 tt0 -91.46 131.84 36.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.315 -0.402 . . . . 0.67 110.41 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.463 ' HE3' HD12 ' A' ' 48' ' ' ILE . 53.2 mmm -71.68 89.18 1.0 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 1.13 110.6 -178.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.2 p -111.05 -166.77 1.11 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.092 -0.504 . . . . 1.15 110.9 -178.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.9 -27.89 62.15 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.013 0.435 . . . . 2.13 110.044 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -65.46 -30.09 70.84 Favored 'General case' 0 CA--C 1.521 -0.144 0 CA-C-O 121.882 0.849 . . . . 2.51 109.789 174.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.437 HG22 ' HE2' ' A' ' 66' ' ' MET . 1.0 OUTLIER -80.51 -54.02 11.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 114.457 -1.247 . . . . 1.1 110.732 176.777 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.775 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -98.0 79.76 2.65 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.407 -0.815 . . . . 0.91 109.772 -177.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -80.55 98.68 7.72 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.634 -0.712 . . . . 1.95 109.892 178.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 10.3 p -71.17 135.25 47.48 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.081 -0.509 . . . . 1.12 111.261 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.35 42.17 0.2 Allowed Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.525 -0.845 . . . . 1.91 112.711 178.152 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -65.99 -37.44 85.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.222 0.534 . . . . 5.57 110.036 175.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 14.8 m120 . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.569 -0.729 . . . . 7.51 109.715 175.392 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.705 0 N-CA-C 111.811 -0.516 . . . . 1.83 111.811 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 69.35 152.68 0.1 Allowed 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.091 0.557 . . . . 2.5 110.937 179.198 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.53 109.85 16.37 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.485 0.66 . . . . 0.95 109.817 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.753 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.3 pt -95.11 -12.32 8.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 114.945 -1.025 . . . . 1.03 111.777 -171.215 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.49 179.26 41.09 Favored Glycine 0 CA--C 1.5 -0.853 0 C-N-CA 120.684 -0.769 . . . . 0.11 111.698 178.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.443 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 92.3 m-85 -144.41 152.13 40.23 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.76 0.314 . . . . 0.24 110.535 -176.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.489 HG12 ' O ' ' A' ' 30' ' ' ASP . 33.0 mm -79.77 122.48 35.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.441 -0.345 . . . . 1.03 110.86 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.0 p -115.72 -21.59 9.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.207 0.527 . . . . 1.01 110.966 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.526 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.8 tttt -141.87 144.94 34.09 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.219 -1.03 . . . . 2.86 108.219 173.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.5 tt -158.95 146.54 17.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.877 0.37 . . . . 1.03 111.029 -177.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.408 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 9.0 t70 -153.36 152.14 30.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.811 -0.631 . . . . 1.94 110.854 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.15 -154.42 44.58 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.129 -0.558 . . . . 0.32 113.112 173.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.4 m -103.34 120.78 41.43 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 109.804 -0.443 . . . . 1.65 109.804 -176.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.417 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.0 m -138.35 152.1 25.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.769 0.795 . . . . 1.09 111.596 -176.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.41 159.43 44.47 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 114.64 -1.164 . . . . 1.0 108.463 178.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.53 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -132.95 136.45 55.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 119.86 -0.736 . . . . 1.03 110.94 174.377 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -101.05 102.51 13.5 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.295 -0.866 . . . . 0.72 109.843 177.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.52 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 7.6 p -63.01 172.08 1.93 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.854 -0.338 . . . . 1.63 110.507 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -54.42 -33.31 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 112.767 0.654 . . . . 1.12 112.767 -173.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -80.09 -5.03 55.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.926 0.393 . . . . 1.96 111.512 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.17 14.73 44.21 Favored Glycine 0 CA--C 1.507 -0.441 0 C-N-CA 121.276 -0.488 . . . . 0.34 112.376 174.445 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.3 mm100 -86.55 116.86 24.96 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.865 0.364 . . . . 2.76 110.753 -178.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.53 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.5 tt0 -84.47 117.52 23.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.371 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.492 ' HG2' HG13 ' A' ' 16' ' ' VAL . 29.4 ptt85 -119.09 168.32 10.95 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.722 -0.473 . . . . 2.1 109.722 177.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.9 p -94.59 135.03 30.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.003 -0.544 . . . . 1.11 110.372 -176.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.417 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 15.2 mt -103.08 118.39 36.7 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.605 0.717 . . . . 1.1 110.321 178.447 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -114.0 176.88 4.85 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.493 -1.23 . . . . 2.19 107.703 174.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 tp -67.69 134.53 51.24 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 119.042 -1.063 . . . . 1.1 109.424 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.15 -12.22 66.95 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 119.676 -1.25 . . . . 0.25 112.564 177.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.489 ' O ' HG12 ' A' ' 7' ' ' ILE . 10.7 m-20 -67.76 140.26 94.08 Favored Pre-proline 0 CA--C 1.514 -0.412 0 C-N-CA 120.219 -0.592 . . . . 1.92 109.857 175.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.443 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 29.7 Cg_endo -86.1 144.48 8.29 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.003 2.468 . . . . 0.31 111.834 -179.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.0 mm -100.62 138.74 23.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.639 -0.504 . . . . 1.02 109.639 176.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -114.61 149.7 36.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.174 -0.466 . . . . 0.37 109.836 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.466 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.8 t80 -68.6 109.58 3.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.096 -0.502 . . . . 0.2 110.638 -175.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 123.8 -3.98 9.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.553 -0.832 . . . . 0.17 113.673 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.52 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.0 mt-10 -82.3 150.49 27.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 117.851 0.825 . . . . 0.52 110.981 -177.435 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.9 m -108.42 107.7 18.35 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.537 -0.756 . . . . 1.03 110.767 -177.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.603 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -79.04 137.05 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.3 0.571 . . . . 1.04 110.845 -175.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -123.46 99.25 6.23 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.043 -0.981 . . . . 1.1 109.665 -177.413 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.5 p -101.01 153.46 19.52 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.119 0.485 . . . . 1.06 110.158 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -116.99 -153.0 9.72 Favored Glycine 0 N--CA 1.442 -0.917 0 CA-C-N 115.423 -0.808 . . . . 0.9 111.65 178.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.38 131.23 47.37 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.962 -0.637 . . . . 1.79 112.26 -178.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 18.8 m 63.66 19.83 11.92 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 122.94 0.496 . . . . 1.94 111.049 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.51 132.83 23.04 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.78 -0.724 . . . . 0.89 111.647 177.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.488 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 36.8 m -152.66 134.69 14.85 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.052 -0.722 . . . . 1.16 109.052 175.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.9 t -145.71 132.21 14.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 C-N-CA 120.548 -0.461 . . . . 1.09 110.968 -176.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.526 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -106.69 105.96 16.26 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.103 0.478 . . . . 1.03 109.949 174.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.523 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 60.7 mt -96.38 103.15 14.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.672 -0.694 . . . . 1.05 110.082 177.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 106.04 10.19 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.229 -0.896 . . . . 1.03 109.193 176.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.44 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 58.0 m-85 -71.43 146.75 48.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.591 0.71 . . . . 0.45 110.916 -177.588 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -71.42 -12.41 15.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.572 -1.195 . . . . 1.07 111.512 -170.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.636 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 21.0 t70 -79.39 -21.04 46.23 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.289 -0.414 . . . . 0.75 110.736 178.497 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.75 -8.91 7.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.517 -0.849 . . . . 0.32 112.717 -179.098 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.7 p -90.48 175.35 7.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.579 0.228 . . . . 1.09 110.897 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -151.79 148.45 27.87 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.72 -0.474 . . . . 1.51 109.72 176.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.523 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.2 m -129.36 165.63 28.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 120.989 0.423 . . . . 2.06 111.352 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.591 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.7 p -135.56 128.56 47.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-N 115.316 -0.856 . . . . 1.58 110.426 177.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.488 ' O ' ' HA ' ' A' ' 45' ' ' SER . 18.5 mt -101.03 139.58 21.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.373 -0.83 . . . . 1.08 109.988 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.52 -157.77 29.08 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.775 -0.726 . . . . 1.02 111.952 178.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.43 148.87 18.83 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.986 -0.625 . . . . 0.64 111.664 -173.116 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.0 t70 56.87 27.37 12.88 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.96 0.886 . . . . 1.26 109.708 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.5 t -105.3 157.64 17.17 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.372 -0.831 . . . . 1.64 110.579 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.603 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.0 mt -142.79 106.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.191 -0.67 . . . . 1.08 109.191 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.49 146.31 32.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.027 0.441 . . . . 1.66 111.339 -175.341 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -99.46 131.44 45.46 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.793 -0.64 . . . . 0.67 110.354 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.464 ' HE3' HD13 ' A' ' 48' ' ' ILE . 51.0 mmm -68.18 89.15 0.31 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.454 -0.794 . . . . 1.13 110.315 -178.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 20.1 p -116.55 -166.99 1.21 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.653 -0.703 . . . . 1.15 111.16 -175.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -63.89 -38.31 90.62 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 2.13 110.647 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -62.75 -28.75 70.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.587 0.708 . . . . 2.51 110.614 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.416 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.4 mm -81.97 -51.28 15.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 CA-C-N 114.904 -1.044 . . . . 1.1 110.939 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.753 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -102.7 83.63 2.29 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.553 -0.749 . . . . 0.91 109.845 -177.176 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -71.96 97.94 1.96 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.477 -0.783 . . . . 1.95 109.89 175.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 11.1 p -80.61 127.94 33.04 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.987 -0.551 . . . . 1.12 110.903 -178.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -143.18 72.4 0.37 Allowed Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.732 -0.747 . . . . 1.91 111.956 -179.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -84.64 94.9 8.73 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.936 0.398 . . . . 5.57 110.361 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.315 -0.85 . . . . 7.51 110.438 179.506 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.609 0 N-CA-C 112.069 -0.412 . . . . 1.83 112.069 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 74.3 m-20 -95.1 174.96 6.81 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 110.153 -0.314 . . . . 2.5 110.153 177.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 109.62 6.79 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.374 0.607 . . . . 0.95 110.019 179.117 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.79 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.6 pt -91.83 -13.66 8.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.017 -0.992 . . . . 1.03 111.427 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.93 178.55 43.34 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.794 -0.717 . . . . 0.11 111.415 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -144.73 150.38 37.17 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.8 0.333 . . . . 0.24 110.425 -174.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.575 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.3 mm -77.12 124.19 35.08 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.026 -0.534 . . . . 1.03 111.596 -175.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.3 p -116.1 -22.51 8.91 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.887 0.375 . . . . 1.01 110.747 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.551 ' HB2' ' HB ' ' A' ' 47' ' ' THR . 6.4 tmtt? -134.38 144.34 48.15 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 109.364 -0.606 . . . . 2.86 109.364 170.677 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.2 tt -156.38 141.68 17.48 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.089 -0.505 . . . . 1.03 110.327 177.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -154.54 158.74 40.29 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.725 -0.671 . . . . 1.94 110.75 -177.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.48 -140.56 35.48 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.806 -0.634 . . . . 0.32 113.074 175.487 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.3 t -112.46 122.99 49.28 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.294 -0.632 . . . . 1.65 109.294 -178.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.443 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 4.2 m -136.06 152.16 30.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.7 0.762 . . . . 1.09 111.496 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.25 158.46 43.91 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 114.674 -1.148 . . . . 1.0 108.881 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.602 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -136.51 135.44 49.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 119.94 -0.704 . . . . 1.03 110.946 173.512 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -103.22 99.87 9.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.973 -1.012 . . . . 0.72 109.68 177.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.499 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.2 m -60.76 174.41 0.61 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.6 -0.273 . . . . 1.63 110.713 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 13.4 pt -59.42 -27.8 38.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 118.337 0.517 . . . . 1.12 112.052 -174.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -77.46 -9.33 58.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.068 -0.515 . . . . 1.96 110.982 177.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.42 3.02 60.06 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 121.351 -0.452 . . . . 0.34 112.342 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -75.06 122.02 22.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.704 0.288 . . . . 2.76 111.271 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.602 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.7 tt0 -92.8 123.18 35.89 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.919 -0.582 . . . . 1.0 110.193 177.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.47 ' HG2' HG12 ' A' ' 16' ' ' VAL . 19.4 ptt-85 -123.0 166.47 15.05 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.543 -0.54 . . . . 2.1 109.543 175.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.81 134.45 28.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 109.109 -0.7 . . . . 1.11 109.109 177.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.485 HD23 ' CG ' ' A' ' 30' ' ' ASP . 5.3 mt -97.36 153.34 18.14 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.243 0.544 . . . . 1.1 111.111 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 46.1 mttt -141.27 178.2 7.57 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.958 -1.019 . . . . 2.19 108.395 -176.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -71.94 144.23 49.01 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 119.392 -0.923 . . . . 1.1 109.203 177.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.53 -6.07 58.91 Favored Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 120.247 -0.978 . . . . 0.25 112.338 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.575 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -70.66 142.84 89.07 Favored Pre-proline 0 C--N 1.332 -0.184 0 CA-C-O 121.388 0.613 . . . . 1.92 110.157 179.414 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -87.49 128.87 2.6 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.627 2.884 . . . . 0.31 113.485 -174.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.8 mm -93.62 137.05 23.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.011 -0.54 . . . . 1.02 109.745 177.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -115.06 151.39 34.35 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.052 -0.522 . . . . 0.37 109.733 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.463 ' HB2' HG23 ' A' ' 4' ' ' ILE . 2.0 t80 -68.94 114.07 6.91 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.246 -0.433 . . . . 0.2 110.494 -176.556 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.49 0.41 18.29 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.398 -0.906 . . . . 0.17 113.54 177.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.499 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 30.2 mt-10 -88.53 146.51 25.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 118.071 0.936 . . . . 0.52 110.882 -177.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.0 m -103.49 107.88 18.9 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.422 -0.808 . . . . 1.03 110.943 -176.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.9 t -84.0 130.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 CA-C-O 121.153 0.502 . . . . 1.04 110.869 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -115.57 109.57 17.98 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.245 -0.889 . . . . 1.1 109.532 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.8 p -107.94 146.5 32.33 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.877 -0.416 . . . . 1.06 109.877 178.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -125.69 147.57 16.66 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.934 -0.65 . . . . 0.9 111.766 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.4 -112.55 3.07 Favored Glycine 0 N--CA 1.449 -0.462 0 O-C-N 123.922 0.424 . . . . 1.79 113.668 177.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.3 m -97.61 34.31 1.87 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.057 0.456 . . . . 1.94 110.847 -175.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.24 133.9 52.56 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.672 -0.694 . . . . 0.89 112.276 177.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 36.7 m -152.8 124.61 7.87 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.434 -0.58 . . . . 1.16 109.434 174.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.559 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.9 t -141.18 128.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-O 120.621 0.248 . . . . 1.09 110.945 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.551 ' HB ' ' HB2' ' A' ' 9' ' ' LYS . 92.8 m -101.27 107.93 19.43 Favored 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 109.559 -0.534 . . . . 1.03 109.559 173.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.452 HD12 ' HE1' ' A' ' 66' ' ' MET . 84.6 mt -95.69 101.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.556 -0.747 . . . . 1.05 109.995 176.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.77 102.65 8.23 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.438 -0.801 . . . . 1.03 109.329 177.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.562 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 55.5 m-85 -65.54 152.95 42.84 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.45 111.22 -177.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -79.04 -3.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-N 114.664 -1.153 . . . . 1.07 110.917 -172.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.557 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 18.6 t70 -85.71 -21.45 28.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.605 -0.725 . . . . 0.75 110.44 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.55 -11.65 11.21 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.764 -0.731 . . . . 0.32 112.122 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.2 p -88.07 157.53 18.84 Favored 'General case' 0 C--N 1.323 -0.555 0 O-C-N 122.879 -0.189 . . . . 1.09 110.609 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -124.64 160.32 28.76 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.669 -0.493 . . . . 1.51 109.669 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.562 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.3 154.45 16.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.466 -0.334 . . . . 2.06 110.108 -179.191 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.559 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -132.96 133.11 59.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.178 0.514 . . . . 1.58 110.596 178.064 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 18.7 mt -101.57 143.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.901 -0.591 . . . . 1.08 110.192 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.7 -164.91 39.78 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.842 -0.694 . . . . 1.02 111.998 177.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -115.52 153.0 17.84 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.251 -0.74 . . . . 0.64 111.251 -174.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.3 t70 57.25 23.71 9.05 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.77 0.795 . . . . 1.26 109.665 -173.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -110.16 160.69 16.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.777 -0.647 . . . . 1.64 111.369 -176.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.426 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -139.8 125.26 21.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.422 -0.808 . . . . 1.08 109.382 177.425 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.3 p -148.64 140.73 18.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.925 0.393 . . . . 1.66 110.96 -176.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.455 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.8 tt0 -95.5 132.57 40.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.456 -0.338 . . . . 0.67 110.198 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.467 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 58.1 mmm -70.21 89.49 0.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.736 -0.666 . . . . 1.13 110.499 -178.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 36.0 p -117.06 -165.19 1.04 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.878 -0.601 . . . . 1.15 111.138 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -64.42 -36.38 83.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.934 0.397 . . . . 2.13 110.888 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -65.96 -22.35 66.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.625 0.726 . . . . 2.51 110.313 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.45 HG22 ' CE ' ' A' ' 66' ' ' MET . 1.4 mm -87.06 -56.31 5.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 114.986 -1.007 . . . . 1.1 111.023 176.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.79 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -95.4 86.0 4.38 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.574 -0.739 . . . . 0.91 110.2 -173.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -64.99 102.6 0.63 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.95 -1.023 . . . . 1.95 109.737 171.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.436 ' HB ' ' OD1' ' A' ' 75' ' ' ASP . 26.7 p -95.36 140.92 29.56 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.099 -0.5 . . . . 1.12 111.291 -176.556 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.04 -12.99 35.05 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.898 -0.668 . . . . 1.91 111.481 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.436 ' OD1' ' HB ' ' A' ' 73' ' ' THR . 5.5 p-10 -76.82 -20.67 56.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.47 0.176 . . . . 5.57 110.534 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 18.6 m120 . . . . . 0 C--O 1.247 0.936 0 CA-C-O 118.135 -0.936 . . . . 7.51 110.867 -179.627 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.708 0 N-CA-C 112.037 -0.425 . . . . 1.83 112.037 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.58 158.53 15.39 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.762 -0.458 . . . . 2.5 109.762 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.77 112.58 8.94 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.365 0.602 . . . . 0.95 110.47 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.784 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 35.6 pt -95.94 -15.76 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 114.978 -1.01 . . . . 1.03 111.937 -171.672 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.09 175.99 40.88 Favored Glycine 0 CA--C 1.499 -0.941 0 C-N-CA 120.615 -0.803 . . . . 0.11 111.812 -177.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -145.07 147.44 32.57 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.042 0.449 . . . . 0.24 110.661 -174.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.77 123.07 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.579 -0.737 . . . . 1.03 110.964 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.2 p -112.41 -23.67 10.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.347 0.594 . . . . 1.01 110.718 178.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.468 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.6 tptt -141.6 138.73 32.81 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 108.667 -0.864 . . . . 2.86 108.667 175.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.7 tt -149.66 144.86 26.4 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.721 0.296 . . . . 1.03 110.71 -178.386 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.456 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 14.1 t70 -152.65 153.33 33.1 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.015 -0.539 . . . . 1.94 110.394 -177.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.16 -149.85 41.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.002 -0.618 . . . . 0.32 113.164 174.078 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.2 t -108.0 123.84 49.26 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.31 -0.626 . . . . 1.65 109.31 -177.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.456 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -136.37 152.28 29.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.855 0.836 . . . . 1.09 112.296 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.03 158.88 44.68 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 114.422 -1.263 . . . . 1.0 108.795 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.668 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.1 p -135.73 139.17 46.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 C-N-CA 120.042 -0.663 . . . . 1.03 110.895 173.097 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.492 ' HA ' ' O ' ' A' ' 22' ' ' GLN . 1.3 mt-30 -107.85 102.12 11.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.316 -0.856 . . . . 0.72 110.077 177.584 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.501 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 11.6 m -63.91 172.26 2.38 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.462 -0.57 . . . . 1.63 109.462 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.0 pt -57.78 -30.0 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 119.031 0.832 . . . . 1.12 112.521 -172.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.47 ' HB2' ' HG3' ' A' ' 22' ' ' GLN . 87.3 m-20 -63.94 -26.8 68.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.164 0.507 . . . . 1.96 110.826 175.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 106.33 13.3 23.16 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.505 -0.77 . . . . 0.34 111.691 -174.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.492 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 21.5 mt-30 -77.1 116.72 17.99 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.947 -0.126 . . . . 2.76 110.885 -179.023 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.668 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.4 tt0 -93.76 117.66 30.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.876 0.369 . . . . 1.0 110.485 176.359 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.487 ' HG2' HG12 ' A' ' 16' ' ' VAL . 23.9 ptt-85 -120.11 166.95 12.72 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.209 -0.663 . . . . 2.1 109.209 175.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.1 p -91.2 131.71 37.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 109.47 -0.567 . . . . 1.11 109.47 178.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.507 HD22 ' CG ' ' A' ' 30' ' ' ASP . 5.4 mt -94.25 156.49 16.51 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.852 -0.613 . . . . 1.1 111.014 -178.124 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -143.54 177.9 8.15 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.321 -0.992 . . . . 2.19 108.321 -172.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.61 142.18 46.55 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 118.973 -1.091 . . . . 1.1 108.77 174.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.5 5.3 85.78 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.982 -1.104 . . . . 0.25 112.173 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.57 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -80.47 139.09 51.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.671 0.748 . . . . 1.92 110.739 178.942 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -77.03 130.6 11.38 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 123.685 2.924 . . . . 0.31 113.382 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 mm -97.42 136.04 29.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.344 -0.844 . . . . 1.02 109.018 174.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 -115.16 151.4 34.46 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 116.194 -0.457 . . . . 0.37 110.101 -178.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.443 ' HB2' HG23 ' A' ' 4' ' ' ILE . 1.6 t80 -67.64 118.82 11.44 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.891 -0.595 . . . . 0.2 110.531 -175.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.74 1.1 30.59 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.583 -0.818 . . . . 0.17 113.203 177.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.52 ' O ' ' HG2' ' A' ' 66' ' ' MET . 34.4 mt-10 -88.62 146.15 25.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 117.9 0.85 . . . . 0.52 110.644 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.423 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 11.3 m -104.34 106.85 17.51 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.249 -0.887 . . . . 1.03 110.738 -174.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.7 t -82.63 122.62 37.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 121.206 0.527 . . . . 1.04 110.883 -174.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.1 mp -105.76 109.27 21.18 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.135 -0.938 . . . . 1.1 109.441 178.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.5 p -107.54 148.35 29.35 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.955 -0.387 . . . . 1.06 109.955 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.32 138.47 9.54 Favored Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 120.776 -0.726 . . . . 0.9 111.984 177.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.95 71.18 0.77 Allowed Glycine 0 N--CA 1.447 -0.571 0 O-C-N 123.959 0.447 . . . . 1.79 113.092 178.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 65.0 m 53.89 39.33 30.31 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.817 0.342 . . . . 1.94 111.734 179.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.501 ' N ' ' HA3' ' A' ' 60' ' ' GLY . . . -60.09 96.83 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.411 0 N-CA-C 111.395 -0.682 . . . . 0.89 111.395 172.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 3.1 m -101.77 109.6 21.4 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.55 -0.537 . . . . 1.16 109.55 -171.13 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.9 t -130.9 119.43 45.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 CA-C-N 116.048 -0.524 . . . . 1.09 111.278 -170.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.468 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.0 m -95.13 104.27 16.14 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.455 -0.793 . . . . 1.03 109.873 176.745 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.453 HD12 ' HE3' ' A' ' 66' ' ' MET . 60.2 mt -94.83 99.66 9.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 115.274 -0.875 . . . . 1.05 109.697 177.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.21 110.11 16.38 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.413 -0.812 . . . . 1.03 109.444 178.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.529 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 59.0 m-85 -73.14 151.86 41.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.635 0.731 . . . . 0.45 111.128 -176.055 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.3 p -72.38 -5.89 6.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 114.548 -1.205 . . . . 1.07 110.671 -174.073 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -79.39 -21.37 45.76 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.079 -0.964 . . . . 0.75 110.938 176.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.11 -11.86 34.11 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.099 -0.8 . . . . 0.32 111.099 -173.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.3 p -83.3 154.67 24.0 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.267 -0.466 . . . . 1.09 109.959 175.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -126.88 156.79 40.85 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 120.777 -0.369 . . . . 1.51 110.454 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.529 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -139.44 152.0 23.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 115.905 -0.589 . . . . 2.06 109.648 178.233 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -136.62 133.21 48.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-O 121.312 0.577 . . . . 1.58 110.994 179.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.607 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -100.37 138.28 25.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.692 -0.685 . . . . 1.08 109.46 178.341 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.08 -51.24 5.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.109 -0.567 . . . . 1.02 112.34 -179.114 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.501 ' HA3' ' N ' ' A' ' 44' ' ' GLY . . . 133.16 172.49 13.0 Favored Glycine 0 CA--C 1.505 -0.568 0 CA-C-O 119.083 -0.843 . . . . 0.64 111.521 176.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 38.3 47.07 0.97 Allowed 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 122.063 0.935 . . . . 1.26 110.559 -171.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.1 t -138.79 163.36 32.42 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 114.493 -1.231 . . . . 1.64 109.785 -176.287 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.47 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 84.5 mt -140.26 113.97 5.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.491 -0.559 . . . . 1.08 109.491 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 p -138.66 142.38 34.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.93 0.395 . . . . 1.66 110.885 -175.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.423 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 45.0 tt0 -96.04 131.94 41.91 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.145 -0.48 . . . . 0.67 110.406 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.528 ' CE ' HG22 ' A' ' 70' ' ' ILE . 59.9 mmm -71.07 88.97 0.8 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.643 -0.708 . . . . 1.13 110.72 -178.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 p -117.62 -162.42 0.87 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.245 -0.434 . . . . 1.15 110.369 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -71.36 -28.51 64.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.051 0.453 . . . . 2.13 110.26 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -64.49 -24.05 67.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.916 0.865 . . . . 2.51 109.859 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.528 HG22 ' CE ' ' A' ' 66' ' ' MET . 1.3 mm -91.67 -53.21 9.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 114.509 -1.223 . . . . 1.1 110.583 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.784 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 -111.41 72.77 0.79 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.123 -0.944 . . . . 0.91 110.634 -174.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -87.96 103.25 15.51 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.852 -0.795 . . . . 1.95 108.852 171.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.0 p -60.79 138.11 58.14 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.753 -0.658 . . . . 1.12 112.265 -173.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.83 -19.43 15.29 Favored Glycine 0 N--CA 1.445 -0.733 0 CA-C-N 115.698 -0.683 . . . . 1.91 111.944 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -110.94 80.05 1.26 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.087 0.47 . . . . 5.57 110.46 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.41 ' N ' HD22 ' A' ' 76' ' ' ASN . 0.9 OUTLIER . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.849 -0.595 . . . . 7.51 109.724 176.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.601 0 N-CA-C 111.76 -0.536 . . . . 1.83 111.76 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -94.91 155.51 16.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.891 0.377 . . . . 2.5 110.705 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.68 113.9 11.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.635 -0.711 . . . . 0.95 109.845 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.747 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.1 pt -96.13 -15.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 115.351 -0.841 . . . . 1.03 111.833 -171.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.21 175.88 42.24 Favored Glycine 0 CA--C 1.502 -0.774 0 N-CA-C 111.478 -0.649 . . . . 0.11 111.478 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.62 148.67 36.18 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.096 0.474 . . . . 0.24 110.949 -174.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.3 mm -75.89 123.09 31.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.689 -0.687 . . . . 1.03 111.02 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.4 p -114.63 -26.35 7.92 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.364 0.602 . . . . 1.01 110.395 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.507 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 83.6 tttt -136.21 145.82 46.12 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.584 -0.895 . . . . 2.86 108.584 172.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.437 HD12 HG22 ' A' ' 14' ' ' VAL . 5.4 tt -158.42 141.18 14.57 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.972 0.415 . . . . 1.03 110.513 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -152.12 146.45 25.51 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-N 115.705 -0.68 . . . . 1.94 111.433 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.585 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 83.97 -152.34 28.38 Favored Glycine 0 N--CA 1.428 -1.884 0 CA-C-N 114.928 -1.033 . . . . 0.32 113.115 168.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 39.8 m -95.01 118.64 32.17 Favored 'General case' 0 N--CA 1.445 -0.681 0 N-CA-C 109.747 -0.464 . . . . 1.65 109.747 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.437 HG22 HD12 ' A' ' 10' ' ' LEU . 2.8 m -136.45 151.22 28.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 1.09 111.678 -177.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -152.21 158.99 43.63 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 114.585 -1.189 . . . . 1.0 108.841 179.214 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.5 OUTLIER -136.67 133.57 48.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 C-N-CA 119.829 -0.749 . . . . 1.03 111.305 174.192 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.439 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.9 mt-30 -102.75 100.19 10.2 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.089 -0.96 . . . . 0.72 109.794 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.419 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 26.5 p -62.65 179.2 0.36 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.484 0.179 . . . . 1.63 111.484 -176.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 11.8 pt -58.66 -27.89 35.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.78 0.324 . . . . 1.12 111.661 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -75.42 -11.75 60.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.967 0.413 . . . . 1.96 110.617 178.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.46 21.26 48.95 Favored Glycine 0 CA--C 1.505 -0.563 0 N-CA-C 110.739 -0.945 . . . . 0.34 110.739 -178.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -92.57 121.12 33.69 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.93 -0.635 . . . . 2.76 110.396 -178.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.592 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.9 tt0 -93.72 116.74 29.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.985 0.422 . . . . 1.0 110.931 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.497 ' HG2' HG11 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -118.98 169.36 9.96 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.948 -0.569 . . . . 2.1 109.82 176.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.37 143.14 11.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.82 -0.627 . . . . 1.11 109.738 178.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 18.4 mt -107.85 127.23 53.54 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.154 -0.475 . . . . 1.1 110.826 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -110.05 179.59 4.06 Favored 'General case' 0 C--N 1.319 -0.761 0 N-CA-C 108.709 -0.849 . . . . 2.19 108.709 172.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.19 145.82 52.92 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.144 -0.622 . . . . 1.1 109.695 174.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.63 2.2 87.72 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.137 -1.03 . . . . 0.25 112.416 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 57.9 m-20 -78.95 142.77 60.63 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.044 0.45 . . . . 1.92 110.701 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -77.34 138.71 17.95 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.038 2.492 . . . . 0.31 113.11 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.9 mm -103.83 135.23 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.687 0 CA-C-N 115.411 -0.813 . . . . 1.02 108.847 170.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -114.51 155.5 26.31 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 116.017 -0.538 . . . . 0.37 109.947 -178.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.448 ' HB2' HG23 ' A' ' 4' ' ' ILE . 2.2 t80 -71.19 109.89 5.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.036 -0.529 . . . . 0.2 110.243 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.12 0.22 10.6 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.455 -0.878 . . . . 0.17 113.406 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.483 ' O ' ' HG2' ' A' ' 66' ' ' MET . 32.7 mt-10 -86.92 147.98 25.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 117.856 0.828 . . . . 0.52 110.645 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.445 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 17.5 m -108.06 108.63 19.81 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.662 -0.699 . . . . 1.03 110.391 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.0 t -83.69 130.3 36.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.028 0.442 . . . . 1.04 110.618 -174.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.0 mp -117.46 108.02 15.02 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.357 -0.838 . . . . 1.1 110.032 -178.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.0 p -101.02 152.97 19.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.235 -0.654 . . . . 1.06 109.235 176.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -130.64 128.72 5.61 Favored Glycine 0 N--CA 1.442 -0.903 0 C-N-CA 120.622 -0.799 . . . . 0.9 112.417 -177.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 54.8 -108.84 1.03 Allowed Glycine 0 N--CA 1.449 -0.444 0 O-C-N 124.172 0.572 . . . . 1.79 112.431 -179.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.585 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 18.2 m -92.46 66.96 4.69 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.88 0.372 . . . . 1.94 110.852 -178.462 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -101.4 132.37 10.93 Favored Glycine 0 CA--C 1.523 0.55 0 CA-C-N 115.804 -0.635 . . . . 0.89 111.726 176.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.4 m -142.57 110.04 5.72 Favored 'General case' 0 C--O 1.223 -0.303 0 CA-C-N 118.04 0.92 . . . . 1.16 110.264 175.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.2 t -121.2 143.77 32.44 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 120.706 0.289 . . . . 1.09 110.758 -174.429 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.507 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -120.91 110.99 16.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.179 -0.464 . . . . 1.03 109.928 175.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.535 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 55.9 mt -99.68 104.6 16.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.785 -0.643 . . . . 1.05 110.107 178.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.03 100.98 8.42 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.191 -0.913 . . . . 1.03 109.424 177.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.476 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 68.4 m-85 -68.54 146.28 53.25 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-O 121.586 0.708 . . . . 0.45 110.727 -178.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.4 p -70.99 1.62 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.567 -1.197 . . . . 1.07 110.991 -173.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -86.0 -20.84 28.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.32 -0.854 . . . . 0.75 110.432 175.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 111.97 -11.95 27.04 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 111.25 -0.74 . . . . 0.32 111.25 -175.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.68 151.98 24.08 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.352 -0.424 . . . . 1.09 110.478 176.179 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -133.0 138.94 47.0 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.08 -0.341 . . . . 1.51 110.08 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.535 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.7 m -118.32 164.47 14.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.115 0.483 . . . . 2.06 111.47 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.0 p -133.64 135.4 55.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.402 -0.817 . . . . 1.58 110.249 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 14.6 mt -109.15 133.7 53.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.977 -0.556 . . . . 1.08 110.101 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.72 -169.78 36.7 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.147 -0.549 . . . . 1.02 111.811 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.87 149.98 17.05 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.934 -0.651 . . . . 0.64 111.789 -173.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.3 t70 61.02 20.54 10.96 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 121.926 0.87 . . . . 1.26 109.523 -174.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.7 t -106.69 159.05 16.5 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.346 -0.843 . . . . 1.64 110.686 -177.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.448 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.3 mt -140.3 124.55 18.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.8 -0.636 . . . . 1.08 109.922 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 13.1 p -147.09 143.76 20.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.814 0.34 . . . . 1.66 110.822 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.445 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.4 tt0 -99.27 133.92 42.88 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.968 0.413 . . . . 0.67 110.587 -179.26 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.561 ' CE ' HG22 ' A' ' 70' ' ' ILE . 47.0 mmm -73.83 88.99 1.81 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.651 -0.704 . . . . 1.13 110.815 -177.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.3 p -119.02 -164.71 1.06 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.434 -0.348 . . . . 1.15 110.088 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -67.69 -26.86 66.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.409 0.624 . . . . 2.13 109.52 177.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -63.14 -25.7 68.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.131 -0.941 . . . . 2.51 109.888 177.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.561 HG22 ' CE ' ' A' ' 66' ' ' MET . 0.9 OUTLIER -96.87 -55.31 6.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 114.743 -1.117 . . . . 1.1 110.595 177.794 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.747 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.3 t80 -96.76 82.66 3.32 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.326 -0.852 . . . . 0.91 110.157 -174.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -85.92 98.68 10.93 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.162 -0.926 . . . . 1.95 110.102 175.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 24.7 p -68.75 124.37 23.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 1.12 110.758 -179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.23 -42.08 2.11 Favored Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.585 -0.816 . . . . 1.91 112.064 -177.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -134.99 -1.06 2.71 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.749 0.309 . . . . 5.57 111.033 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.508 -0.758 . . . . 7.51 110.752 177.188 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.71 0 N-CA-C 112.165 -0.374 . . . . 1.83 112.165 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -97.72 144.74 27.04 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-O 120.905 0.383 . . . . 2.5 110.443 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.66 109.28 12.74 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 115.684 -0.689 . . . . 0.95 109.328 175.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.793 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.1 pt -89.18 -12.05 10.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.32 -0.854 . . . . 1.03 111.632 -171.363 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.35 174.03 40.38 Favored Glycine 0 CA--C 1.501 -0.837 0 C-N-CA 120.858 -0.687 . . . . 0.11 111.55 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -144.91 149.7 35.75 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.013 0.435 . . . . 0.24 110.327 -176.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.567 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.66 124.54 36.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-N 115.699 -0.682 . . . . 1.03 110.871 -177.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 67.9 p -117.6 -16.83 10.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.378 0.609 . . . . 1.01 110.875 178.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.426 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 27.4 tptp -146.73 138.59 24.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.335 -0.987 . . . . 2.86 108.335 172.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.5 tt -150.37 148.03 28.3 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.807 -0.357 . . . . 1.03 110.8 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -157.48 154.49 28.78 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.923 -0.58 . . . . 1.94 110.274 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.81 -157.4 48.85 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.11 -0.567 . . . . 0.32 113.466 172.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 33.4 m -100.07 115.0 28.73 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.366 -0.417 . . . . 1.65 110.056 -178.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.46 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.6 m -133.7 152.57 35.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.525 0.678 . . . . 1.09 111.599 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.39 158.56 43.89 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 114.866 -1.061 . . . . 1.0 109.045 -178.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.602 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.7 OUTLIER -134.59 139.49 47.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 C-N-CA 120.131 -0.628 . . . . 1.03 110.857 173.007 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -104.21 99.88 9.61 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.204 -0.907 . . . . 0.72 109.251 175.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.499 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 68.6 p -63.75 -179.39 0.38 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.638 0.256 . . . . 1.63 110.935 -176.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -69.35 -3.33 2.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.944 0.402 . . . . 1.12 111.514 178.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -94.19 -7.01 43.46 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.461 -0.57 . . . . 1.96 109.461 173.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.36 19.9 65.58 Favored Glycine 0 CA--C 1.503 -0.681 0 N-CA-C 110.881 -0.888 . . . . 0.34 110.881 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -92.76 123.12 35.81 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.829 -0.686 . . . . 2.76 110.877 -177.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.602 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 19.8 tt0 -89.16 118.46 28.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.355 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.471 ' HG2' HG13 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -121.62 166.57 14.04 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.461 -0.57 . . . . 2.1 109.461 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.3 p -89.85 135.26 26.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 109.127 -0.694 . . . . 1.11 109.127 177.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.503 HD23 ' CG ' ' A' ' 30' ' ' ASP . 4.3 mt -95.79 146.95 24.13 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.227 0.537 . . . . 1.1 110.902 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 33.2 mttp -138.07 171.98 13.6 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.059 -0.973 . . . . 2.19 108.544 -176.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.82 139.02 58.28 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 119.285 -0.966 . . . . 1.1 109.254 177.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.35 89.89 Favored Glycine 0 N--CA 1.437 -1.265 0 C-N-CA 119.865 -1.16 . . . . 0.25 112.478 178.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.567 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -76.94 140.4 66.78 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 121.54 0.686 . . . . 1.92 110.48 178.581 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.14 129.3 7.73 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.601 2.868 . . . . 0.31 113.848 -176.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.2 mm -97.39 132.86 41.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 115.588 -0.733 . . . . 1.02 109.187 173.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -113.27 159.75 19.03 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.855 -0.612 . . . . 0.37 109.786 -177.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.464 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.9 t80 -74.52 116.05 14.76 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.285 -0.416 . . . . 0.2 110.16 -175.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.33 9.51 27.32 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.57 -0.824 . . . . 0.17 113.265 177.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.499 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 38.7 mt-10 -90.61 139.92 30.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 118.088 0.944 . . . . 0.52 110.343 177.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.3 m -98.28 106.25 18.51 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.207 -0.906 . . . . 1.03 110.727 -176.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.564 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.4 t -82.38 125.78 39.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.158 0.504 . . . . 1.04 110.771 -174.545 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -110.2 105.2 14.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.136 -0.938 . . . . 1.1 109.701 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 62.7 p -109.79 143.66 39.32 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.987 -0.375 . . . . 1.06 109.987 178.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -121.37 151.89 16.91 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 120.485 -0.865 . . . . 0.9 111.633 177.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.66 -113.25 2.96 Favored Glycine 0 N--CA 1.453 -0.227 0 C-N-CA 121.467 -0.396 . . . . 1.79 113.006 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.6 m -103.5 35.61 2.54 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.771 0.32 . . . . 1.94 110.621 -178.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.16 93.99 0.09 OUTLIER Glycine 0 CA--C 1.52 0.374 0 CA-C-N 115.91 -0.586 . . . . 0.89 112.543 177.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.683 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 49.2 m -109.54 124.68 51.52 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.748 -0.464 . . . . 1.16 109.748 -174.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 6.1 t -142.92 119.99 6.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 CA-C-O 121.003 0.43 . . . . 1.09 111.286 -171.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.426 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 88.6 m -92.21 103.65 16.1 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.573 -0.739 . . . . 1.03 109.934 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.408 HD13 ' HE1' ' A' ' 66' ' ' MET . 68.2 mt -94.88 99.55 9.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 114.982 -1.008 . . . . 1.05 109.51 177.077 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.16 107.54 13.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.395 -0.82 . . . . 1.03 109.497 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.543 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 57.1 m-85 -70.7 145.67 50.39 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.47 0.652 . . . . 0.45 110.947 -177.228 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.9 p -70.98 1.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.76 -1.109 . . . . 1.07 111.754 -172.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.73 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 13.8 t70 -99.42 -16.42 18.39 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.86 0.362 . . . . 0.75 110.815 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.85 -14.76 9.06 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.466 -0.873 . . . . 0.32 112.374 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.7 p -84.38 154.61 22.74 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.372 -0.233 . . . . 1.09 110.372 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -133.67 138.2 45.75 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 120.964 0.411 . . . . 1.51 110.345 -179.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.455 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 1.1 t -123.33 150.41 27.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.983 -0.553 . . . . 2.06 110.286 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.488 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -135.54 129.91 49.61 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.419 0.628 . . . . 1.58 110.731 178.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.683 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.3 mt -94.3 139.04 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.545 -0.752 . . . . 1.08 109.599 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.85 -57.4 2.42 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 121.199 -0.524 . . . . 1.02 112.716 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 150.46 158.56 8.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.874 -0.679 . . . . 0.64 111.857 178.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.6 t70 51.83 43.23 30.25 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.703 0.763 . . . . 1.26 110.521 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.5 t -129.28 158.08 40.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.757 -0.656 . . . . 1.64 110.394 -176.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.564 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -140.28 106.88 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.536 -0.756 . . . . 1.08 109.148 177.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.33 140.41 44.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.897 0.38 . . . . 1.66 111.02 -174.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.452 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.8 tt0 -91.81 128.64 37.72 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.67 109.729 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.473 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 55.8 mmm -66.28 89.45 0.13 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.149 -0.478 . . . . 1.13 110.313 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 59.4 p -110.81 -166.47 1.08 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.871 -0.604 . . . . 1.15 111.724 -174.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.01 -33.41 74.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 2.13 110.323 178.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -70.35 -25.66 63.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.731 0.777 . . . . 2.51 109.975 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.406 HG23 ' HE3' ' A' ' 66' ' ' MET . 1.3 mm -80.06 -53.51 12.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 114.596 -1.183 . . . . 1.1 111.079 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.793 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 -102.99 82.52 2.1 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.355 -0.839 . . . . 0.91 110.274 -175.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -73.54 113.1 10.26 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.602 -0.726 . . . . 1.95 109.842 174.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.9 p -93.7 140.52 29.54 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.097 -0.501 . . . . 1.12 110.966 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 78.39 32.2 43.55 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.853 -0.689 . . . . 1.91 112.514 178.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -79.07 -44.77 21.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.491 0.186 . . . . 5.57 111.046 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.447 HD22 ' N ' ' A' ' 76' ' ' ASN . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.918 0 CA-C-O 117.99 -1.005 . . . . 7.51 110.627 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.593 0 N-CA-C 112.062 -0.415 . . . . 1.83 112.062 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -102.55 160.51 14.5 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.994 -0.372 . . . . 2.5 109.994 179.312 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.52 116.68 17.43 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 121.438 0.637 . . . . 0.95 110.342 -178.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.782 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.1 pt -101.92 -14.62 8.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.095 -0.957 . . . . 1.03 111.811 -171.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.81 179.22 41.27 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 120.796 -0.716 . . . . 0.11 111.415 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -143.79 152.51 41.32 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.939 0.4 . . . . 0.24 110.569 -175.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.461 HG12 ' O ' ' A' ' 30' ' ' ASP . 34.2 mm -80.21 119.97 30.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.203 -0.453 . . . . 1.03 110.945 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.2 p -113.12 -18.71 12.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.281 0.563 . . . . 1.01 110.586 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.528 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.9 tttt -144.81 145.08 31.47 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.236 -1.024 . . . . 2.86 108.236 172.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.0 tt -159.91 142.34 13.42 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.792 0.33 . . . . 1.03 111.019 -177.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -150.67 153.25 35.26 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.779 -0.646 . . . . 1.94 111.274 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.22 -155.14 50.18 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.982 -0.554 . . . . 0.32 113.235 174.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 27.2 t -97.91 119.7 36.99 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.878 -0.415 . . . . 1.65 109.878 -178.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.435 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 2.7 m -132.09 152.98 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.415 0.626 . . . . 1.09 110.828 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.28 159.15 44.66 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.725 -1.125 . . . . 1.0 108.174 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.579 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.5 OUTLIER -134.97 130.44 52.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 C-N-CA 119.545 -0.862 . . . . 1.03 110.817 173.816 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.404 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.8 mt-30 -96.15 98.61 10.47 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.269 -0.878 . . . . 0.72 109.255 175.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.5 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 15.9 m -63.79 176.49 0.91 Allowed 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.031 -0.532 . . . . 1.63 110.816 -176.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.6 pt -56.81 -28.03 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 112.687 0.625 . . . . 1.12 112.687 -173.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -82.63 -1.1 50.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.788 0.328 . . . . 1.96 110.963 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 89.35 8.02 68.89 Favored Glycine 0 CA--C 1.506 -0.529 0 N-CA-C 111.047 -0.821 . . . . 0.34 111.047 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 87.7 mm-40 -79.15 115.6 18.91 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.937 -0.631 . . . . 2.76 111.115 -177.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.579 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.6 tt0 -88.15 111.25 21.39 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.94 -0.573 . . . . 1.0 110.533 178.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.522 ' HG2' HG11 ' A' ' 16' ' ' VAL . 16.8 ptt85 -112.22 170.78 7.93 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.214 -0.662 . . . . 2.1 109.214 176.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.93 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 109.772 -0.455 . . . . 1.11 109.772 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.435 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 21.2 mt -109.98 128.29 55.3 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.942 -0.572 . . . . 1.1 110.593 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -116.03 -173.9 2.44 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 108.056 -1.09 . . . . 2.19 108.056 171.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.83 143.5 52.87 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.734 -0.786 . . . . 1.1 109.389 175.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.51 -2.75 84.69 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.295 -0.955 . . . . 0.25 112.946 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.461 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.3 m-20 -73.0 143.7 84.31 Favored Pre-proline 0 CA--C 1.512 -0.488 0 N-CA-C 109.556 -0.535 . . . . 1.92 109.556 174.392 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -87.64 141.56 5.58 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.922 2.415 . . . . 0.31 112.41 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mm -100.93 139.16 22.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.662 -0.496 . . . . 1.02 109.662 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -115.33 150.0 36.98 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 116.019 -0.537 . . . . 0.37 109.676 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.462 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -68.41 113.24 5.8 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.276 -0.42 . . . . 0.2 110.322 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.68 -1.23 13.81 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.368 -0.92 . . . . 0.17 113.463 178.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.5 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.9 mt-10 -85.48 148.6 25.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 117.789 0.795 . . . . 0.52 110.951 -178.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.419 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 8.6 m -106.83 105.95 16.23 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.621 -0.718 . . . . 1.03 110.642 -176.765 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.555 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -81.86 126.39 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.351 0.596 . . . . 1.04 110.777 -174.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -114.76 100.76 8.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.83 -1.077 . . . . 1.1 109.851 -177.203 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.6 p -99.02 152.88 19.34 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.284 -0.636 . . . . 1.06 109.284 176.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -126.22 136.88 9.8 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.34 -0.933 . . . . 0.9 112.526 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 52.6 -103.24 0.11 Allowed Glycine 0 C--N 1.33 0.248 0 O-C-N 123.844 0.379 . . . . 1.79 113.69 177.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 18.3 m -96.15 26.38 4.27 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.719 0.295 . . . . 1.94 111.644 -175.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.21 144.68 47.0 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 121.123 -0.56 . . . . 0.89 112.74 177.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 8.7 m -151.12 139.61 20.52 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.646 -0.872 . . . . 1.16 108.646 175.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.5 t -148.4 134.05 11.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 O-C-N 122.012 -0.43 . . . . 1.09 110.958 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.528 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.2 m -109.84 108.16 18.38 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.76 -0.459 . . . . 1.03 109.76 173.182 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.536 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 56.7 mt -99.14 104.22 15.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.593 -0.73 . . . . 1.05 109.969 178.112 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.43 107.34 12.12 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.405 -0.816 . . . . 1.03 109.133 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.448 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 63.0 m-85 -73.72 146.63 44.27 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.491 0.662 . . . . 0.45 110.899 -177.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -77.36 0.89 2.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 114.821 -1.081 . . . . 1.07 111.398 -170.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.36 -21.75 27.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.223 0.535 . . . . 0.75 109.948 173.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.56 -12.69 7.41 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.77 -0.729 . . . . 0.32 112.802 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.0 p -87.5 162.98 16.93 Favored 'General case' 0 C--N 1.327 -0.412 0 O-C-N 122.821 -0.223 . . . . 1.09 111.074 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.2 147.46 50.73 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.762 -0.458 . . . . 1.51 109.762 176.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.536 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 11.9 m -128.2 161.2 37.05 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 CA-C-O 121.264 0.554 . . . . 2.06 111.25 175.545 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.596 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 97.9 t -135.06 123.93 41.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.814 -1.084 . . . . 1.58 110.159 178.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 45' ' ' SER . 24.0 mt -96.55 133.92 36.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.445 -0.798 . . . . 1.08 110.191 -177.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -76.58 -163.91 17.67 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.047 -0.597 . . . . 1.02 112.346 177.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.07 149.86 17.85 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 111.208 -0.757 . . . . 0.64 111.208 -174.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.5 t70 60.85 20.86 11.05 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 121.901 0.858 . . . . 1.26 109.744 -175.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.0 m -102.94 154.18 19.47 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.572 -0.74 . . . . 1.64 110.967 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.555 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.4 mt -141.68 109.69 2.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.35 -0.841 . . . . 1.08 109.727 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.3 p -139.81 142.45 32.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.803 0.335 . . . . 1.66 110.827 -177.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.419 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 34.7 tt0 -91.16 132.87 35.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.929 0.395 . . . . 0.67 110.488 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.48 ' HE3' HD13 ' A' ' 48' ' ' ILE . 63.4 mmm -67.13 89.88 0.19 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.448 -0.796 . . . . 1.13 110.808 -177.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.6 p -117.77 -162.99 0.9 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.488 -0.778 . . . . 1.15 111.305 -175.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -66.92 -40.93 87.8 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.733 0.272 . . . . 2.13 111.733 -175.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -64.57 -26.17 68.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.687 0.756 . . . . 2.51 110.605 177.158 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.418 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.6 mm -76.36 -51.33 19.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.766 -1.106 . . . . 1.1 110.557 174.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.782 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -108.42 76.78 1.05 Allowed 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.33 -0.85 . . . . 0.91 110.106 -177.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -73.65 107.23 5.79 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.605 -0.725 . . . . 1.95 109.167 175.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 5.6 p -80.16 127.08 31.91 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.002 -0.545 . . . . 1.12 110.919 -176.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -92.45 -60.9 1.2 Allowed Glycine 0 N--CA 1.445 -0.754 0 CA-C-N 115.894 -0.593 . . . . 1.91 113.36 -173.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -139.43 -37.2 0.5 Allowed 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.498 0.555 . . . . 5.57 112.498 -175.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 . . . . . 0 C--O 1.25 1.117 0 CA-C-O 118.337 -0.84 . . . . 7.51 110.946 -176.066 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.58 0 N-CA-C 112.106 -0.398 . . . . 1.83 112.106 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -102.31 141.08 35.71 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.001 0.429 . . . . 2.5 110.778 178.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.95 109.61 13.39 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.622 -0.717 . . . . 0.95 109.91 -178.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.763 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.4 pt -88.86 -14.9 9.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.179 -0.918 . . . . 1.03 111.616 -171.117 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -166.98 177.15 41.79 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.886 -0.673 . . . . 0.11 111.465 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -143.95 150.67 38.7 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.951 0.405 . . . . 0.24 110.529 -175.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.601 HG12 ' O ' ' A' ' 30' ' ' ASP . 20.7 mm -78.75 122.2 33.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.981 -0.554 . . . . 1.03 110.78 -178.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.7 p -114.75 -21.79 10.01 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.311 0.576 . . . . 1.01 110.67 179.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.601 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 36.1 ttpt -141.1 145.71 36.15 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.417 -0.957 . . . . 2.86 108.417 172.407 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -156.66 144.73 19.52 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 120.774 0.321 . . . . 1.03 110.684 -177.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 6.3 t70 -151.75 148.32 27.74 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.881 -0.6 . . . . 1.94 110.73 -178.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 74.96 -152.46 43.98 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.09 -0.576 . . . . 0.32 113.503 173.388 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 9.0 t -103.63 120.07 40.16 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.927 -0.397 . . . . 1.65 109.927 -177.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.446 HG22 ' HB2' ' A' ' 26' ' ' LEU . 3.9 m -135.83 153.2 32.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 1.09 111.859 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.43 159.65 44.32 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.881 -1.054 . . . . 1.0 109.457 -177.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.55 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -134.21 136.66 53.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 C-N-CA 120.152 -0.619 . . . . 1.03 110.984 173.188 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -103.28 103.52 13.55 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.155 -0.929 . . . . 0.72 109.641 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.519 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 47.6 t -62.05 176.8 0.52 Allowed 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.572 -0.451 . . . . 1.63 110.392 -178.209 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.3 pt -60.36 -31.13 47.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-O 121.107 0.48 . . . . 1.12 111.869 -173.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -74.35 -14.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.865 -0.607 . . . . 1.96 110.916 177.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.1 10.27 46.06 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.146 -0.55 . . . . 0.34 112.522 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 -80.94 119.94 24.11 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.901 0.382 . . . . 2.76 111.214 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.55 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 18.5 tt0 -88.77 119.49 29.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.623 179.192 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.514 ' HG2' HG13 ' A' ' 16' ' ' VAL . 21.3 ptt-85 -119.1 166.1 13.34 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.43 -0.581 . . . . 2.1 109.43 174.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -86.56 137.58 20.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.942 -0.572 . . . . 1.11 109.483 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.518 HD23 ' OD1' ' A' ' 30' ' ' ASP . 4.0 mt -102.08 151.88 21.64 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.196 0.522 . . . . 1.1 111.167 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.5 mttt -139.57 175.97 9.12 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.105 -0.952 . . . . 2.19 108.479 -175.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.95 140.92 49.4 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.566 -0.853 . . . . 1.1 108.957 176.487 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.77 6.04 86.81 Favored Glycine 0 N--CA 1.435 -1.389 0 C-N-CA 119.877 -1.154 . . . . 0.25 112.218 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.601 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.0 138.81 46.07 Favored Pre-proline 0 N--CA 1.454 -0.248 0 CA-C-O 121.75 0.786 . . . . 1.92 110.35 178.19 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.92 130.29 11.27 Favored 'Trans proline' 0 C--N 1.325 -0.682 0 C-N-CA 123.719 2.946 . . . . 0.31 113.509 -178.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.453 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 26.3 mm -96.02 136.54 26.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 CA-C-N 115.349 -0.841 . . . . 1.02 109.266 173.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -117.87 151.35 37.56 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 109.565 -0.531 . . . . 0.37 109.565 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.422 ' HB2' HG22 ' A' ' 4' ' ' ILE . 1.9 t80 -67.1 126.29 28.7 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.988 -0.551 . . . . 0.2 110.188 -176.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.21 -12.8 33.88 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.462 -0.875 . . . . 0.17 113.074 178.182 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.519 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.7 mt-10 -82.04 139.39 34.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.584 0.707 . . . . 0.52 111.072 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 17.8 m -98.74 109.98 22.65 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.684 -1.144 . . . . 1.03 110.718 -177.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -82.19 132.9 30.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.48 -0.488 . . . . 1.04 110.618 -175.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -119.61 113.33 20.53 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.516 -0.766 . . . . 1.1 110.298 -177.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 71.5 p -105.49 153.19 22.06 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.274 -0.639 . . . . 1.06 109.274 173.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -113.61 -171.13 17.58 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 120.587 -0.816 . . . . 0.9 111.076 177.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -51.71 117.15 5.55 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 110.694 -0.962 . . . . 1.79 110.694 175.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.508 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 32.6 t 69.96 80.74 0.17 Allowed 'General case' 0 C--N 1.327 -0.379 0 O-C-N 124.229 0.606 . . . . 1.94 109.768 -169.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -142.39 139.38 9.12 Favored Glycine 0 N--CA 1.448 -0.55 0 N-CA-C 110.879 -0.888 . . . . 0.89 110.879 174.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 25.4 m -156.01 142.61 18.65 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.182 -0.673 . . . . 1.16 109.182 174.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.616 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.4 t -148.32 145.02 18.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 O-C-N 122.242 -0.286 . . . . 1.09 110.334 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.601 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 97.9 m -115.98 106.81 14.2 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.158 0.504 . . . . 1.03 109.87 172.268 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.0 103.0 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.291 -0.868 . . . . 1.05 109.807 178.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.74 103.67 8.85 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.463 -0.79 . . . . 1.03 109.287 177.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.568 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 50.5 m-85 -68.73 147.09 52.32 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.618 0.723 . . . . 0.45 110.907 -178.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.2 p -74.46 1.66 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.518 -1.219 . . . . 1.07 111.459 -172.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.463 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 22.0 t70 -97.26 -0.93 45.81 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.307 0.575 . . . . 0.75 109.752 177.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.61 -10.94 49.96 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.859 -0.686 . . . . 0.32 112.847 177.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.3 p -87.79 164.08 16.13 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.534 -0.173 . . . . 1.09 110.534 177.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -135.94 153.32 51.46 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.819 -0.438 . . . . 1.51 109.819 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.568 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.7 OUTLIER -135.41 147.66 28.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.968 0.413 . . . . 2.06 110.542 -179.102 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.616 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 89.5 t -125.84 130.22 72.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.638 -0.71 . . . . 1.58 110.176 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.453 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.1 mt -102.86 144.69 13.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.984 -0.553 . . . . 1.08 110.614 -176.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -88.93 -161.53 37.57 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.926 -0.579 . . . . 1.02 112.11 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -113.63 147.96 18.65 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.431 -0.668 . . . . 0.64 111.431 -174.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 29.7 t70 53.46 28.84 8.06 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.981 0.896 . . . . 1.26 109.888 -173.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.8 m -110.49 157.13 19.95 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.085 -0.961 . . . . 1.64 110.809 -179.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.41 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.8 mt -140.96 123.76 15.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.456 -0.793 . . . . 1.08 109.731 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.6 p -149.55 145.02 17.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 1.66 110.525 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.513 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 44.0 tt0 -98.17 134.69 40.88 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.28 -0.418 . . . . 0.67 111.076 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.548 ' SD ' HG23 ' A' ' 70' ' ' ILE . 21.8 mmt -64.32 89.24 0.06 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.704 -0.68 . . . . 1.13 110.725 175.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 16.5 p -121.59 -168.22 1.65 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.654 -0.703 . . . . 1.15 110.312 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -68.07 -25.25 65.25 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.272 0.558 . . . . 2.13 109.787 177.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 25.8 mm-40 -65.97 -21.73 66.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.41 -0.814 . . . . 2.51 110.098 177.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.548 HG23 ' SD ' ' A' ' 66' ' ' MET . 1.5 mm -103.02 -53.86 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 CA-C-N 114.721 -1.127 . . . . 1.1 110.883 -179.565 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.763 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 4.0 t80 -113.27 73.86 0.84 Allowed 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.261 -0.881 . . . . 0.91 110.226 -176.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -79.64 98.24 6.85 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.755 -0.657 . . . . 1.95 109.814 175.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 32.5 p -68.62 142.36 55.14 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.902 -0.59 . . . . 1.12 111.383 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 143.55 15.83 0.26 Allowed Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.339 -0.934 . . . . 1.91 113.246 178.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -95.09 -52.51 4.18 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.891 -0.411 . . . . 5.57 109.891 177.097 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 . . . . . 0 C--O 1.249 1.027 0 O-C-N 123.848 0.717 . . . . 7.51 111.048 179.162 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.922 0 N-CA-C 111.96 -0.456 . . . . 1.83 111.96 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 67.22 162.73 0.18 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.59 0.756 . . . . 2.5 110.434 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.39 116.29 21.15 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.4 0.619 . . . . 0.95 110.654 -174.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.78 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.0 pt -105.55 -14.4 8.97 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.855 -1.066 . . . . 1.03 111.765 -173.048 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.53 177.77 41.81 Favored Glycine 0 CA--C 1.5 -0.894 0 N-CA-C 111.046 -0.822 . . . . 0.11 111.046 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -144.12 151.18 39.23 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.979 0.419 . . . . 0.24 111.034 -175.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.426 HD12 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -78.62 120.85 30.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.715 -0.675 . . . . 1.03 110.717 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.0 p -113.25 -23.35 9.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.259 0.552 . . . . 1.01 110.205 179.046 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.603 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 37.8 ttpt -140.63 144.93 36.02 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.524 -0.762 . . . . 2.86 109.069 172.343 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.3 tt -155.8 144.62 20.45 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 110.292 -0.262 . . . . 1.03 110.292 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -153.17 152.36 31.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.16 -0.473 . . . . 1.94 111.136 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.25 -144.11 29.21 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.975 -0.557 . . . . 0.32 112.74 175.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t -113.61 123.31 49.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.428 -0.582 . . . . 1.65 109.428 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.457 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -138.16 152.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 1.09 111.62 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.84 159.39 44.21 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.798 -1.092 . . . . 1.0 108.175 177.454 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.475 HG21 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -132.33 133.18 60.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 C-N-CA 120.11 -0.636 . . . . 1.03 110.46 175.475 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.42 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.0 mt-30 -96.04 98.56 10.46 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.461 -0.79 . . . . 0.72 109.327 178.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.522 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 25.0 m -63.62 173.43 1.69 Allowed 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.865 -0.607 . . . . 1.63 110.035 -177.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 9.1 pt -64.55 -3.31 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 N-CA-C 114.238 1.199 . . . . 1.12 114.238 -168.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -106.03 6.98 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.344 0.592 . . . . 1.96 109.823 174.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.62 6.56 80.17 Favored Glycine 0 CA--C 1.504 -0.606 0 N-CA-C 110.75 -0.94 . . . . 0.34 110.75 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.581 ' HA ' HE22 ' A' ' 22' ' ' GLN . 0.0 OUTLIER -78.4 117.44 19.62 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.833 -0.684 . . . . 2.76 111.403 -175.619 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -80.63 126.39 31.2 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.232 0.539 . . . . 1.0 110.582 178.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.4 ' NH2' ' HD2' ' A' ' 31' ' ' PRO . 0.0 OUTLIER -130.41 144.59 51.49 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.452 -0.794 . . . . 2.1 109.239 179.974 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.3 p -78.2 142.76 13.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.963 0.411 . . . . 1.11 110.242 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.457 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 25.5 mt -108.07 128.82 55.02 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.168 -0.469 . . . . 1.1 110.615 178.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.2 mttm -111.13 -178.0 3.35 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.298 -1.001 . . . . 2.19 108.298 172.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.2 144.49 53.72 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 119.618 -0.833 . . . . 1.1 109.193 173.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.47 2.8 89.83 Favored Glycine 0 N--CA 1.439 -1.139 0 C-N-CA 120.249 -0.977 . . . . 0.25 112.551 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.412 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -70.53 145.27 92.53 Favored Pre-proline 0 CA--C 1.51 -0.571 0 CA-C-O 121.218 0.533 . . . . 1.92 109.923 174.418 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.4 ' HD2' ' NH2' ' A' ' 24' ' ' ARG . 21.7 Cg_endo -90.04 135.75 2.36 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 123.251 2.634 . . . . 0.31 111.851 178.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -97.99 135.29 33.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.539 -0.541 . . . . 1.02 109.539 177.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -112.19 144.37 41.69 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.63 -0.714 . . . . 0.37 109.894 -177.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.51 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.5 t80 -66.09 109.22 2.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.24 -0.437 . . . . 0.2 109.987 -177.056 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.75 -4.19 8.03 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.308 -0.949 . . . . 0.17 113.754 178.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.522 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 26.2 mt-10 -86.72 151.23 23.57 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 118.223 1.012 . . . . 0.52 110.831 -177.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.42 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 25.6 m -111.15 107.49 16.86 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.467 -0.788 . . . . 1.03 110.687 -176.547 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.665 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.9 t -78.67 129.77 37.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 120.896 0.379 . . . . 1.04 111.28 -173.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -113.23 98.41 7.1 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.527 -0.761 . . . . 1.1 109.913 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 82.5 p -96.4 152.99 18.08 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.584 -0.525 . . . . 1.06 109.584 177.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -116.79 -155.82 10.43 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 111.517 -0.633 . . . . 0.9 111.517 178.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -56.76 128.7 47.58 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.898 -0.668 . . . . 1.79 112.333 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 15.4 m 68.69 19.83 8.4 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 123.119 0.568 . . . . 1.94 111.621 178.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.35 134.33 22.71 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.885 -0.674 . . . . 0.89 112.596 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.56 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 69.6 m -152.82 136.73 16.27 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.172 -0.677 . . . . 1.16 109.172 172.579 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 19.4 t -145.85 137.49 19.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 120.602 0.239 . . . . 1.09 110.531 -177.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.603 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 87.2 m -111.36 106.74 15.77 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.042 -0.527 . . . . 1.03 109.992 174.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.556 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.3 mt -97.87 103.16 14.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.654 -0.703 . . . . 1.05 110.009 177.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.44 105.48 9.73 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.303 -0.862 . . . . 1.03 109.25 177.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.481 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.5 m-85 -72.92 145.76 46.58 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.563 0.697 . . . . 0.45 110.584 -178.623 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.0 p -74.07 -8.5 11.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 114.677 -1.147 . . . . 1.07 111.655 -169.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.437 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 15.2 t70 -81.62 -21.06 38.51 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.221 -0.445 . . . . 0.75 110.504 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.37 -13.52 6.25 Favored Glycine 0 CA--C 1.519 0.321 0 C-N-CA 120.567 -0.825 . . . . 0.32 113.045 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.8 p -87.76 162.45 17.03 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 122.727 -0.278 . . . . 1.09 111.344 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -135.41 148.0 49.18 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.96 -0.756 . . . . 1.51 108.96 177.097 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.556 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.6 m -129.7 166.54 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.574 0 CA-C-O 121.213 0.53 . . . . 2.06 111.96 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.61 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.9 p -133.12 135.89 56.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 114.908 -1.042 . . . . 1.58 110.15 176.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.56 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.3 mt -108.23 134.54 49.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.861 -0.609 . . . . 1.08 109.656 178.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.65 -159.49 21.18 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.206 -0.521 . . . . 1.02 112.336 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.7 146.66 18.32 Favored Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.901 -0.666 . . . . 0.64 111.775 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.416 ' HA ' ' O ' ' A' ' 40' ' ' THR . 29.2 t70 56.77 26.39 11.39 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 121.702 0.763 . . . . 1.26 109.909 -174.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 t -103.91 156.97 17.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.536 -0.756 . . . . 1.64 110.495 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.665 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.7 mt -142.47 104.49 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.504 -0.771 . . . . 1.08 109.16 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.1 m -131.93 150.13 33.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.006 0.431 . . . . 1.66 111.736 -175.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -102.84 128.09 49.75 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.626 -0.715 . . . . 0.67 110.609 -177.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.508 ' CE ' HG22 ' A' ' 70' ' ' ILE . 51.3 mmm -67.72 89.58 0.26 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.522 -0.763 . . . . 1.13 110.666 -177.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.5 p -121.37 -167.45 1.51 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.006 -0.543 . . . . 1.15 111.118 -177.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -65.59 -29.6 70.22 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.735 0.303 . . . . 2.13 110.846 -178.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.49 -17.3 62.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.6 0.714 . . . . 2.51 110.354 177.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.508 HG22 ' CE ' ' A' ' 66' ' ' MET . 1.1 mm -96.04 -50.43 11.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 115.127 -0.942 . . . . 1.1 110.562 177.455 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.78 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -98.55 87.25 3.77 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.363 -0.835 . . . . 0.91 109.658 -177.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -69.52 88.26 0.49 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.732 -1.122 . . . . 1.95 110.659 176.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 16.5 p -83.96 118.04 23.76 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.077 -0.511 . . . . 1.12 110.226 176.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.469 ' C ' ' H ' ' A' ' 76' ' ' ASN . . . -164.1 36.79 0.3 Allowed Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.037 -1.077 . . . . 1.91 112.838 -178.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.6 t70 73.72 -32.81 0.24 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 123.464 0.706 . . . . 5.57 111.74 177.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.469 ' H ' ' C ' ' A' ' 74' ' ' GLY . 10.3 t-20 . . . . . 0 C--O 1.248 0.987 0 O-C-N 123.819 0.699 . . . . 7.51 110.414 177.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.657 0 N-CA-C 112.054 -0.419 . . . . 1.83 112.054 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 -122.5 154.37 37.94 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.848 0.356 . . . . 2.5 110.224 -179.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.14 113.18 14.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.774 -0.648 . . . . 0.95 110.282 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.775 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.3 pt -92.01 -16.77 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.085 -0.961 . . . . 1.03 111.646 -172.192 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.42 177.25 40.82 Favored Glycine 0 CA--C 1.501 -0.816 0 C-N-CA 120.787 -0.72 . . . . 0.11 111.535 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -144.59 152.08 39.98 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 120.788 0.328 . . . . 0.24 110.291 -174.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.558 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.1 mm -80.09 123.29 36.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.272 -0.422 . . . . 1.03 111.146 -178.245 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.5 p -112.79 -23.64 10.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.117 0.484 . . . . 1.01 110.461 178.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.489 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 34.9 ttpt -141.88 145.51 34.69 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.706 -0.85 . . . . 2.86 108.706 173.459 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -158.63 144.84 17.0 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.595 0.236 . . . . 1.03 110.436 -176.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -154.2 152.44 30.36 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.017 -0.538 . . . . 1.94 110.735 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.46 -156.03 46.11 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.988 -0.551 . . . . 0.32 113.245 174.124 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 25.4 t -99.17 120.49 39.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.293 -0.632 . . . . 1.65 109.293 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.431 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 4.6 m -137.75 152.33 26.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.659 0.743 . . . . 1.09 111.729 -175.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.08 158.92 44.67 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 114.582 -1.19 . . . . 1.0 108.863 -178.399 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.687 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.6 OUTLIER -136.4 132.37 48.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 C-N-CA 119.99 -0.684 . . . . 1.03 110.982 172.221 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.4 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.7 mt-30 -96.67 99.01 10.64 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.092 -0.958 . . . . 0.72 109.284 174.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.46 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.6 m -66.32 179.6 0.95 Allowed 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.971 -0.292 . . . . 1.63 110.811 -176.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.2 pt -60.24 -26.76 37.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 O-C-N 121.886 -0.509 . . . . 1.12 112.218 -175.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 -79.69 -8.79 59.45 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.998 0.428 . . . . 1.96 110.62 178.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.8 5.81 62.58 Favored Glycine 0 CA--C 1.506 -0.478 0 N-CA-C 111.234 -0.746 . . . . 0.34 111.234 178.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -74.44 117.97 16.86 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.305 -0.447 . . . . 2.76 110.819 -179.383 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.687 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.5 tt0 -95.09 110.43 22.36 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.168 0.508 . . . . 1.0 110.224 177.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.495 ' HG2' HG11 ' A' ' 16' ' ' VAL . 17.1 ptt-85 -111.61 167.92 9.96 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.952 -0.567 . . . . 2.1 109.906 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.0 p -86.61 129.47 38.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.821 -0.627 . . . . 1.11 109.317 176.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.502 HD23 ' OD1' ' A' ' 30' ' ' ASP . 2.8 mt -91.07 143.54 26.6 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 121.526 0.679 . . . . 1.1 110.999 -178.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.467 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.8 mttp -131.21 171.59 13.13 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.658 -1.156 . . . . 2.19 109.232 -172.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.86 134.74 46.27 Favored 'General case' 0 CA--C 1.507 -0.701 0 C-N-CA 119.171 -1.011 . . . . 1.1 108.743 174.294 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.93 0.58 89.75 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 119.603 -1.284 . . . . 0.25 111.656 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.558 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.08 139.73 79.75 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-O 121.69 0.757 . . . . 1.92 110.203 177.06 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 37.2 Cg_endo -87.64 123.49 1.81 Allowed 'Trans proline' 0 C--N 1.323 -0.771 0 C-N-CA 123.923 3.082 . . . . 0.31 113.623 -174.376 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 34.4 mm -91.04 134.24 30.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.966 -0.561 . . . . 1.02 110.114 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -111.32 155.11 23.55 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.786 -0.643 . . . . 0.37 109.693 179.1 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.455 ' HB2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -69.42 116.6 10.03 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.813 0.34 . . . . 0.2 110.543 -175.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.18 7.11 23.45 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.388 -0.91 . . . . 0.17 113.478 178.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.543 ' O ' ' HG2' ' A' ' 66' ' ' MET . 48.2 mt-10 -89.21 145.11 25.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 117.699 0.75 . . . . 0.52 110.489 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.441 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.7 m -106.06 107.28 18.19 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.807 -0.633 . . . . 1.03 110.781 -176.287 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -82.18 131.06 34.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.225 0.536 . . . . 1.04 110.719 -175.215 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -118.31 108.51 15.18 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.047 -0.979 . . . . 1.1 109.703 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.4 p -106.06 155.32 19.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.048 0.451 . . . . 1.06 109.955 177.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -117.46 -156.07 10.33 Favored Glycine 0 N--CA 1.445 -0.763 0 N-CA-C 111.369 -0.693 . . . . 0.9 111.369 177.531 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.1 132.02 52.34 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.8 -0.714 . . . . 1.79 112.034 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 14.8 m 67.43 19.39 10.05 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 121.096 0.474 . . . . 1.94 111.266 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -78.83 136.15 17.06 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.951 -0.642 . . . . 0.89 112.362 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.421 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 67.0 m -156.9 141.13 16.48 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.395 -0.595 . . . . 1.16 109.395 174.507 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -148.39 133.29 10.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 C-N-CA 120.997 -0.281 . . . . 1.09 110.764 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.489 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.1 m -106.36 106.61 17.21 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.052 -0.522 . . . . 1.03 109.62 173.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.55 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 58.8 mt -97.7 107.61 20.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.756 -0.657 . . . . 1.05 110.18 178.312 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.26 106.63 14.31 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.331 -0.85 . . . . 1.03 109.323 177.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.539 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 67.8 m-85 -73.59 144.64 45.92 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.484 0.659 . . . . 0.45 110.753 -178.48 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.7 p -73.53 -6.28 7.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 114.879 -1.055 . . . . 1.07 111.799 -169.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.547 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 11.5 t70 -84.95 -20.55 30.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.594 -0.276 . . . . 0.75 110.607 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.51 -17.32 5.57 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.479 -0.867 . . . . 0.32 112.919 -179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.6 p -86.59 156.84 19.88 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 122.795 -0.238 . . . . 1.09 111.108 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -130.38 150.73 51.48 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.442 -0.577 . . . . 1.51 109.442 177.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.55 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.9 m -130.4 169.4 21.33 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.211 0.529 . . . . 2.06 111.768 177.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.549 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.6 p -140.31 132.37 32.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.13 -0.941 . . . . 1.58 110.327 176.701 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.421 ' O ' ' HA ' ' A' ' 45' ' ' SER . 23.5 mt -102.71 143.46 15.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.99 -0.55 . . . . 1.08 110.15 -179.599 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.23 -161.54 36.63 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.858 -0.687 . . . . 1.02 112.23 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.91 146.42 17.99 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.959 -0.639 . . . . 0.64 111.57 -175.052 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.5 t70 60.39 21.65 11.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.945 0.878 . . . . 1.26 109.655 -173.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 t -102.93 155.61 18.24 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.369 -0.832 . . . . 1.64 110.847 -175.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.532 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.4 mt -140.28 122.88 16.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.248 -0.887 . . . . 1.08 109.351 179.004 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.18 141.93 17.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.702 0.287 . . . . 1.66 110.86 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.441 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.5 tt0 -94.38 130.78 40.58 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.928 0.394 . . . . 0.67 110.175 178.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.543 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 53.6 mmm -65.8 89.93 0.12 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.425 -0.807 . . . . 1.13 110.495 -178.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -116.54 -166.39 1.15 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.391 -0.822 . . . . 1.15 111.216 -175.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -63.8 -42.42 97.71 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.802 0.334 . . . . 2.13 111.471 -177.32 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 56.4 mm-40 -62.89 -23.93 67.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.295 0.569 . . . . 2.51 111.009 177.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.406 HG23 ' HE2' ' A' ' 66' ' ' MET . 1.3 mm -82.72 -50.38 15.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.212 -0.904 . . . . 1.1 111.144 177.034 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.775 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -103.51 81.31 1.9 Allowed 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.671 -0.695 . . . . 0.91 109.962 -177.36 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -79.26 110.18 14.3 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.698 -0.683 . . . . 1.95 109.889 177.09 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 21.8 p -90.49 154.79 19.37 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.944 -0.571 . . . . 1.12 110.944 -178.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 142.01 18.15 0.31 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.595 -0.812 . . . . 1.91 113.161 177.524 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -111.02 133.54 53.33 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 117.033 0.416 . . . . 5.57 110.187 176.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.44 -0.79 . . . . 7.51 110.614 -178.508 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 112.29 -0.324 . . . . 1.83 112.29 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -119.69 147.78 44.16 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.115 -0.328 . . . . 2.5 110.115 178.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 119.35 17.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.906 -0.588 . . . . 0.95 110.018 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.745 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.0 pt -101.11 -15.85 7.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-N 115.422 -0.808 . . . . 1.03 111.592 -171.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.83 176.26 42.51 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 120.999 -0.62 . . . . 0.11 111.595 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.406 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 93.9 m-85 -144.89 151.1 38.18 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.74 0.305 . . . . 0.24 110.432 -175.154 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.453 HG12 ' O ' ' A' ' 30' ' ' ASP . 31.4 mm -79.18 122.2 33.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.375 -0.375 . . . . 1.03 111.012 -178.363 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.6 p -114.35 -24.4 8.91 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.302 0.573 . . . . 1.01 110.661 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.526 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.5 tttm -139.76 146.85 40.03 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 108.605 -0.887 . . . . 2.86 108.605 172.037 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -160.24 140.63 11.69 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.128 -0.487 . . . . 1.03 110.525 -176.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -146.44 152.46 39.08 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.155 -0.929 . . . . 1.94 110.577 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.55 -160.7 53.82 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.883 -0.599 . . . . 0.32 113.172 174.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 19.3 m -98.46 121.9 40.99 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.953 -0.388 . . . . 1.65 109.953 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.493 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.8 m -139.18 153.57 24.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.669 0.747 . . . . 1.09 111.819 -176.29 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.84 159.15 43.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.721 -1.127 . . . . 1.0 109.082 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.3 p -131.21 133.77 62.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.097 -0.641 . . . . 1.03 110.608 172.706 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.442 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 8.5 mt-30 -97.73 97.88 9.38 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.284 -0.871 . . . . 0.72 109.552 177.557 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.456 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 51.7 m -64.52 175.93 1.25 Allowed 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.471 -0.331 . . . . 1.63 110.547 -177.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 pt -58.75 -27.21 34.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 112.814 0.672 . . . . 1.12 112.814 -175.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -80.49 -10.8 59.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 1.96 110.7 177.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.46 3.24 61.39 Favored Glycine 0 N--CA 1.452 -0.283 0 N-CA-C 111.71 -0.556 . . . . 0.34 111.71 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.2 mm-40 -65.45 120.15 12.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.784 -0.208 . . . . 2.76 110.523 176.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.547 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.8 tt0 -95.77 108.33 20.64 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.716 -0.476 . . . . 1.0 109.716 -179.444 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.432 ' HG2' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -105.34 143.3 33.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.13 -0.486 . . . . 2.1 109.784 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.4 p -74.26 131.24 35.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.846 -0.798 . . . . 1.11 108.846 171.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.493 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 26.3 mt -93.45 127.44 39.09 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.191 -0.603 . . . . 1.1 110.502 -179.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -110.62 179.25 4.12 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 107.604 -1.258 . . . . 2.19 107.604 171.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -68.12 143.39 55.45 Favored 'General case' 0 C--N 1.315 -0.915 0 C-N-CA 119.316 -0.954 . . . . 1.1 109.417 175.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.07 -10.24 69.35 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.204 -0.998 . . . . 0.25 113.057 176.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.453 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.8 m-20 -66.49 142.5 97.71 Favored Pre-proline 0 CA--C 1.515 -0.391 0 CA-C-O 121.108 0.48 . . . . 1.92 109.788 175.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.406 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 35.7 Cg_endo -89.06 142.4 4.54 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 123.115 2.543 . . . . 0.31 112.713 -178.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.492 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.8 mm -102.57 136.8 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 115.779 -0.646 . . . . 1.02 109.591 175.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . 0.425 ' HD2' ' OE2' ' A' ' 36' ' ' GLU . 80.9 m-85 -113.84 153.65 28.79 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.839 -0.619 . . . . 0.37 109.561 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.441 ' HB2' HG23 ' A' ' 4' ' ' ILE . 1.6 t80 -69.87 111.55 5.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.378 -0.374 . . . . 0.2 110.231 -176.268 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.28 -5.6 8.78 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.601 -0.809 . . . . 0.17 113.048 178.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.456 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 28.6 mt-10 -83.39 136.96 34.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.695 0.759 . . . . 0.52 111.122 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -96.32 106.97 19.26 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.614 -1.175 . . . . 1.03 110.34 -178.168 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 6.0 t -81.37 133.2 29.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.114 0.483 . . . . 1.04 111.089 -173.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.1 mp -114.92 126.12 54.42 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.956 -1.02 . . . . 1.1 109.636 178.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.3 p -119.8 152.39 37.34 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.613 -0.514 . . . . 1.06 109.613 172.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -131.38 138.99 10.57 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.992 -0.623 . . . . 0.9 112.211 179.33 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 56.47 -113.86 4.6 Favored Glycine 0 N--CA 1.451 -0.345 0 O-C-N 123.822 0.366 . . . . 1.79 113.204 178.256 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.9 p -89.16 24.15 2.23 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.985 0.421 . . . . 1.94 111.34 -177.522 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.14 136.03 51.29 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.992 -0.549 . . . . 0.89 112.418 177.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.534 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 23.2 m -154.12 136.24 14.76 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.625 -0.88 . . . . 1.16 108.625 174.053 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -141.81 138.36 31.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 C-N-CA 120.385 -0.526 . . . . 1.09 111.158 -175.057 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.526 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.1 m -108.89 105.9 15.65 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.781 -0.645 . . . . 1.03 109.648 173.625 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.524 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.2 mt -94.5 109.45 22.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.896 -0.593 . . . . 1.05 110.045 177.09 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.73 99.26 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.236 -0.893 . . . . 1.03 109.335 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.513 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 66.9 m-85 -67.21 144.67 55.85 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.411 0.624 . . . . 0.45 110.336 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -70.18 2.01 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 114.558 -1.201 . . . . 1.07 110.846 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.407 ' H ' ' C ' ' A' ' 50' ' ' PHE . 2.2 t70 -84.89 -21.97 29.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.925 -1.034 . . . . 0.75 110.725 177.105 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 115.99 -17.37 15.17 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 111.162 -0.775 . . . . 0.32 111.162 -175.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 p -87.07 150.75 23.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.516 -0.342 . . . . 1.09 111.042 178.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -126.13 150.2 48.42 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.277 -0.638 . . . . 1.51 109.277 178.363 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.524 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -125.14 171.39 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.012 0.434 . . . . 2.06 111.366 178.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.1 p -137.81 130.08 40.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.461 -0.791 . . . . 1.58 110.318 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.534 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -105.08 136.87 37.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.881 -0.6 . . . . 1.08 109.926 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.94 -163.59 27.89 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.979 -0.629 . . . . 1.02 112.328 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.5 150.5 18.29 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.946 -0.645 . . . . 0.64 111.736 -173.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 34.7 t70 56.89 22.68 7.35 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.723 0.773 . . . . 1.26 110.264 -173.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.3 m -105.64 164.02 12.23 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.122 0.487 . . . . 1.64 111.338 -177.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.483 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.1 mt -140.86 128.2 22.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.506 -0.77 . . . . 1.08 109.374 176.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.61 138.68 15.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.852 0.358 . . . . 1.66 110.973 -177.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.494 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.9 tt0 -97.13 131.28 44.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.843 0.354 . . . . 0.67 111.138 -176.038 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.627 ' SD ' HG21 ' A' ' 70' ' ' ILE . 17.8 mmt -62.94 90.48 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.651 -0.704 . . . . 1.13 111.177 177.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.6 p -126.13 -169.1 1.95 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.502 -0.772 . . . . 1.15 110.241 -178.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -69.46 -26.61 64.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 117.814 0.279 . . . . 2.13 111.157 -176.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.06 -22.93 63.02 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.972 0.891 . . . . 2.51 109.688 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.627 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.9 mm -90.32 -51.76 11.48 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 114.72 -1.127 . . . . 1.1 110.762 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.745 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 -113.18 77.14 1.02 Allowed 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.491 -0.777 . . . . 0.91 110.729 -176.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 47.2 t-20 -80.52 107.82 13.64 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.852 -0.613 . . . . 1.95 109.413 171.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 26.1 p -76.21 133.81 40.05 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.463 -0.335 . . . . 1.12 110.987 -178.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -141.35 14.19 2.75 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.923 -0.656 . . . . 1.91 112.228 -177.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -67.48 -21.31 65.52 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 122.261 0.225 . . . . 5.57 110.78 178.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.111 -0.947 . . . . 7.51 110.86 178.165 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.858 0 N-CA-C 112.252 -0.339 . . . . 1.83 112.252 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 -95.84 160.47 14.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.914 0.388 . . . . 2.5 110.385 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.31 109.67 12.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.768 -0.651 . . . . 0.95 109.623 178.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.832 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.5 pt -92.34 -11.39 9.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.088 -0.96 . . . . 1.03 112.046 -169.564 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.45 42.79 Favored Glycine 0 CA--C 1.5 -0.85 0 C-N-CA 120.593 -0.813 . . . . 0.11 111.48 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -144.98 151.05 37.98 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.954 0.407 . . . . 0.24 110.883 -174.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.503 HG12 ' O ' ' A' ' 30' ' ' ASP . 21.2 mm -78.44 121.71 31.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 115.783 -0.644 . . . . 1.03 110.903 -178.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 72.7 p -113.63 -21.16 10.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.343 0.592 . . . . 1.01 110.406 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.448 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 84.4 tttt -142.63 145.2 33.25 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.775 -0.824 . . . . 2.86 108.775 173.455 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.0 tt -159.47 142.62 14.29 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 120.765 0.317 . . . . 1.03 110.945 -177.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.532 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 2.3 m-20 -148.82 165.24 32.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.67 -0.695 . . . . 1.94 110.795 176.441 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 67.57 -149.67 50.87 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.991 -0.55 . . . . 0.32 113.183 175.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 29.8 t -108.9 133.64 52.64 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.042 -0.725 . . . . 1.65 109.042 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.431 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 5.2 m -142.8 153.3 17.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.786 0.803 . . . . 1.09 111.582 -176.467 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.26 157.99 43.3 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.683 -1.144 . . . . 1.0 108.67 177.567 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.1 p -131.94 134.95 59.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.354 -0.538 . . . . 1.03 110.316 174.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.433 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -104.65 99.9 9.56 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.376 -0.829 . . . . 0.72 109.56 178.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.485 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 22.5 p -62.96 178.46 0.47 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.552 -0.295 . . . . 1.63 111.279 -175.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 2.9 pt -57.03 -33.61 42.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 112.597 0.591 . . . . 1.12 112.597 -174.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.49 ' OD1' ' HG3' ' A' ' 22' ' ' GLN . 9.5 p30 -81.93 -12.07 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.894 -0.322 . . . . 1.96 110.762 179.298 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.42 7.58 36.98 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.768 -0.73 . . . . 0.34 113.755 176.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.49 ' HG3' ' OD1' ' A' ' 20' ' ' ASN . 54.7 mt-30 -70.88 120.87 17.1 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.107 0.453 . . . . 2.76 111.127 179.203 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.52 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.6 tt0 -91.59 113.11 25.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.976 0.417 . . . . 1.0 109.969 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.92 138.22 51.39 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.793 -0.639 . . . . 2.1 109.796 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.61 134.96 29.11 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 109.113 -0.699 . . . . 1.11 109.113 175.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.547 HD21 ' OD1' ' A' ' 30' ' ' ASP . 5.4 mt -99.45 150.41 22.21 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.62 0.724 . . . . 1.1 111.442 -177.508 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.523 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 41.1 mttp -135.52 173.12 12.07 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.424 -1.262 . . . . 2.19 109.152 -171.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.52 141.78 46.74 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 119.133 -1.027 . . . . 1.1 109.347 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.61 0.96 85.92 Favored Glycine 0 N--CA 1.435 -1.395 0 C-N-CA 120.13 -1.034 . . . . 0.25 111.824 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.547 ' OD1' HD21 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -78.36 142.45 62.88 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-O 121.553 0.692 . . . . 1.92 111.1 -179.187 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.04 133.74 11.26 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.771 2.981 . . . . 0.31 113.836 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mm -99.98 136.8 29.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.005 -0.998 . . . . 1.02 109.092 172.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -116.57 154.62 30.14 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 120.976 0.417 . . . . 0.37 109.945 -178.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.457 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.7 t80 -71.51 115.7 11.0 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.003 -0.544 . . . . 0.2 110.581 -175.462 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.13 7.61 22.89 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.461 -0.876 . . . . 0.17 113.345 177.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.489 ' HB3' HG22 ' A' ' 16' ' ' VAL . 28.4 mt-10 -94.77 147.75 23.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.763 0.781 . . . . 0.52 110.673 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.433 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 10.1 m -104.09 108.39 19.73 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.094 -0.957 . . . . 1.03 110.661 -176.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.2 t -83.56 121.88 36.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.315 0.579 . . . . 1.04 110.934 -175.094 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -107.46 104.77 14.42 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.796 -1.093 . . . . 1.1 109.679 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.446 ' HB ' ' HA3' ' A' ' 44' ' ' GLY . 69.3 p -99.93 156.47 17.12 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.651 -0.5 . . . . 1.06 109.651 177.24 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -149.42 121.37 1.28 Allowed Glycine 0 N--CA 1.441 -0.994 0 C-N-CA 120.767 -0.73 . . . . 0.9 111.982 179.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.51 89.73 0.02 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 O-C-N 123.799 0.353 . . . . 1.79 113.576 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 22.7 t 62.08 32.78 17.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.077 0.465 . . . . 1.94 111.004 175.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.532 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -77.17 83.81 1.07 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.857 -0.687 . . . . 0.89 111.797 177.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m -102.33 109.92 21.72 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.334 -0.617 . . . . 1.16 109.334 -174.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.1 t -126.63 132.46 70.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.93 -0.577 . . . . 1.09 111.206 -169.248 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.448 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.0 m -109.02 108.24 18.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.031 -0.531 . . . . 1.03 110.288 178.359 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 79.1 mt -97.75 102.69 13.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-N 115.216 -0.902 . . . . 1.05 109.966 178.184 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.05 99.68 8.59 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.644 -0.707 . . . . 1.03 109.371 178.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.563 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 48.8 m-85 -61.77 144.9 54.02 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.518 0.675 . . . . 0.45 111.197 -178.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.13 -12.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.707 -1.133 . . . . 1.07 111.493 -170.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.415 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 28.6 t70 -74.55 -17.38 60.75 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.215 0.531 . . . . 0.75 110.529 176.755 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.78 -7.3 17.51 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.916 -0.659 . . . . 0.32 111.896 -177.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.0 p -88.63 177.47 6.75 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.396 -0.224 . . . . 1.09 110.396 176.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -151.58 157.38 42.13 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.259 -0.274 . . . . 1.51 110.259 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.508 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.53 150.78 17.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.35 -0.387 . . . . 2.06 110.427 -177.689 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 9.1 p -126.57 133.16 69.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.318 0.58 . . . . 1.58 110.668 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -102.53 147.6 8.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.739 -0.664 . . . . 1.08 110.196 -177.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.9 -178.44 43.48 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.733 -0.746 . . . . 1.02 111.413 175.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -101.57 148.57 17.95 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 121.043 -0.598 . . . . 0.64 111.656 -172.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t70 58.3 24.53 11.68 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 121.843 0.83 . . . . 1.26 110.179 -173.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.7 t -106.1 161.13 14.77 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.439 -0.8 . . . . 1.64 110.445 -179.46 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.504 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 79.1 mt -139.88 118.47 11.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.859 -0.61 . . . . 1.08 109.629 179.063 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.5 p -140.45 141.4 32.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.508 -0.315 . . . . 1.66 110.829 -175.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -97.99 126.84 43.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.905 0.383 . . . . 0.67 110.332 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 50.5 mmm -67.06 89.54 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.66 -0.7 . . . . 1.13 110.658 -178.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 10.8 p -115.02 -165.98 1.07 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.819 -0.628 . . . . 1.15 111.547 -175.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.83 -36.77 75.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.814 0.34 . . . . 2.13 110.718 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -61.97 -32.83 73.31 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.626 0.726 . . . . 2.51 110.095 175.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 1.1 mm -75.41 -53.09 16.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-N 114.476 -1.238 . . . . 1.1 111.029 178.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.832 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 -103.34 81.3 1.92 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.91 109.993 -176.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -77.42 106.39 9.15 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.543 -0.753 . . . . 1.95 109.512 175.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 39.2 p -92.6 144.55 25.22 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.082 -0.508 . . . . 1.12 111.561 -174.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.6 -17.17 62.48 Favored Glycine 0 N--CA 1.448 -0.52 0 N-CA-C 111.144 -0.782 . . . . 1.91 111.144 172.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -83.79 -29.7 27.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.991 0.424 . . . . 5.57 110.04 175.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 t30 . . . . . 0 C--O 1.248 1.022 0 CA-C-O 117.957 -1.02 . . . . 7.51 110.689 179.316 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.657 0 N-CA-C 112.027 -0.429 . . . . 1.83 112.027 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 -99.18 146.76 25.82 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.908 0.385 . . . . 2.5 110.517 -178.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.06 113.17 18.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.547 0.689 . . . . 0.95 110.351 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.826 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.9 pt -97.54 -14.09 7.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-N 115.106 -0.952 . . . . 1.03 111.709 -172.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.9 176.39 42.52 Favored Glycine 0 CA--C 1.502 -0.767 0 N-CA-C 111.01 -0.836 . . . . 0.11 111.01 179.163 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -143.35 151.57 40.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.041 0.448 . . . . 0.24 111.041 -175.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 35.2 mm -78.19 121.87 31.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.94 -0.573 . . . . 1.03 110.689 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.8 p -115.45 -20.28 10.31 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 1.01 110.546 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.539 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.1 tttt -143.83 143.3 31.26 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.47 -0.937 . . . . 2.86 108.47 173.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.3 tt -160.27 140.28 11.39 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-O 121.074 0.464 . . . . 1.03 111.107 -178.026 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -149.08 149.75 31.6 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.164 -0.925 . . . . 1.94 110.479 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.46 -160.2 41.54 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.972 -0.632 . . . . 0.32 113.035 175.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.0 m -101.32 119.25 38.47 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 120.667 0.27 . . . . 1.65 110.312 -177.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.466 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -136.91 152.0 28.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.817 0.817 . . . . 1.09 111.753 -176.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 159.34 42.7 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 114.706 -1.134 . . . . 1.0 108.703 178.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.456 HG23 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -131.57 132.62 62.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 121.29 0.567 . . . . 1.03 110.424 174.938 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.467 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.9 mt-30 -98.91 99.23 10.27 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.445 -0.798 . . . . 0.72 109.734 178.592 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.547 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 13.9 m -60.94 172.85 0.88 Allowed 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 110.039 -0.356 . . . . 1.63 110.039 -179.223 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -60.99 -14.7 10.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 112.248 0.462 . . . . 1.12 112.248 -177.499 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -85.53 -9.32 57.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.178 0.514 . . . . 1.96 110.372 177.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 88.54 5.66 74.78 Favored Glycine 0 CA--C 1.508 -0.372 0 N-CA-C 110.877 -0.889 . . . . 0.34 110.877 -175.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 92.7 mt-30 -70.21 118.52 13.13 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.792 -0.704 . . . . 2.76 110.664 178.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -90.41 111.28 22.47 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.228 0.537 . . . . 1.0 109.629 177.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.41 ' NH2' ' HD2' ' A' ' 31' ' ' PRO . 0.0 OUTLIER -115.35 142.14 47.09 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.232 -0.894 . . . . 2.1 109.706 -177.311 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -75.65 143.19 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.835 0.35 . . . . 1.11 110.144 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.466 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 24.9 mt -110.12 128.97 55.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.994 0.426 . . . . 1.1 110.933 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 77.5 mttt -117.77 -179.72 3.82 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 108.246 -1.02 . . . . 2.19 108.246 170.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.4 tp -65.39 148.58 51.47 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.573 -0.851 . . . . 1.1 110.3 178.586 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.55 -7.24 58.59 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.531 -0.842 . . . . 0.25 112.677 177.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.9 143.68 97.16 Favored Pre-proline 0 CA--C 1.512 -0.515 0 CA-C-O 121.187 0.518 . . . . 1.92 110.105 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.41 ' HD2' ' NH2' ' A' ' 24' ' ' ARG . 24.6 Cg_endo -90.15 131.4 1.79 Allowed 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 123.262 2.641 . . . . 0.31 111.827 178.641 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.525 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.3 mm -94.08 134.48 31.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 109.747 -0.464 . . . . 1.02 109.747 176.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.98 150.25 30.84 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.558 -0.746 . . . . 0.37 109.396 -179.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.474 ' HB2' HG21 ' A' ' 4' ' ' ILE . 3.0 t80 -67.3 116.8 8.48 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.2 110.364 -174.524 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.17 -10.42 20.28 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.789 -0.72 . . . . 0.17 113.234 176.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.547 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 28.7 mt-10 -76.02 140.4 41.94 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 117.877 0.839 . . . . 0.52 110.685 179.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.565 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -101.43 109.04 20.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.809 -1.087 . . . . 1.03 110.84 -175.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.6 t -82.11 132.04 32.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.189 0.518 . . . . 1.04 110.934 -174.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -117.84 109.49 16.62 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 114.975 -1.011 . . . . 1.1 110.017 -177.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -105.26 157.01 17.6 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.428 -0.509 . . . . 1.06 109.789 175.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -136.0 137.16 8.92 Favored Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 120.81 -0.71 . . . . 0.9 111.872 178.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.73 -112.22 2.34 Favored Glycine 0 N--CA 1.449 -0.494 0 O-C-N 123.931 0.43 . . . . 1.79 113.207 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 33.4 m -87.6 28.11 1.03 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.91 0.386 . . . . 1.94 111.491 -176.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.27 130.38 35.07 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.949 -0.644 . . . . 0.89 111.874 176.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.524 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 7.3 m -150.68 126.24 10.2 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.349 -0.611 . . . . 1.16 109.349 174.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 7.5 t -134.72 147.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.901 -0.32 . . . . 1.09 111.107 -173.444 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.539 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -117.98 110.63 17.93 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.157 -0.474 . . . . 1.03 110.01 173.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.551 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 64.4 mt -98.66 109.35 23.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.805 -0.634 . . . . 1.05 110.014 176.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.44 102.22 11.92 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.418 -0.81 . . . . 1.03 109.171 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.467 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.7 m-85 -70.1 144.43 52.11 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.372 0.606 . . . . 0.45 110.78 -178.738 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.75 1.9 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 114.651 -1.159 . . . . 1.07 111.725 -171.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -92.51 -11.97 33.18 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.98 -0.554 . . . . 0.75 109.962 175.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.79 -5.41 25.93 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.516 -0.849 . . . . 0.32 112.726 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.6 p -93.95 159.79 15.01 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.819 -0.224 . . . . 1.09 110.717 177.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.63 143.6 47.39 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.417 -0.586 . . . . 1.51 109.417 179.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.551 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.9 m -121.75 164.16 18.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.103 0.478 . . . . 2.06 111.441 177.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.512 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -131.86 129.44 60.9 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 115.241 -0.89 . . . . 1.58 109.875 177.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.524 ' O ' ' HA ' ' A' ' 45' ' ' SER . 17.1 mt -103.43 131.58 51.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 116.257 -0.428 . . . . 1.08 109.993 -178.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.23 -163.92 23.56 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 121.151 -0.547 . . . . 1.02 112.259 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.93 145.25 16.5 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.772 -0.728 . . . . 0.64 111.728 -173.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.5 t70 58.24 25.22 12.38 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 121.547 0.689 . . . . 1.26 110.217 -174.313 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.4 m -103.04 156.47 17.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.957 -0.565 . . . . 1.64 110.935 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.495 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 89.7 mt -140.6 117.31 8.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.618 -0.719 . . . . 1.08 109.588 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.8 p -147.66 143.96 19.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 110.108 -0.33 . . . . 1.66 110.108 -177.16 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.565 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -103.99 139.21 39.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.545 0.688 . . . . 0.67 111.079 -176.113 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.552 ' SD ' HG23 ' A' ' 70' ' ' ILE . 22.7 mmt -64.19 89.62 0.06 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.627 -1.17 . . . . 1.13 111.667 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.403 HG21 ' CG ' ' A' ' 65' ' ' GLU . 2.3 p -114.25 -172.15 2.05 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.622 -0.717 . . . . 1.15 110.125 177.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -71.98 -24.45 61.58 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.748 0.309 . . . . 2.13 110.657 -178.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -70.08 -23.54 63.08 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.472 0.653 . . . . 2.51 110.229 175.384 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.552 HG23 ' SD ' ' A' ' 66' ' ' MET . 1.4 mm -88.17 -56.52 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.119 -0.946 . . . . 1.1 109.728 175.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.826 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 -100.46 80.02 2.18 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.543 -1.208 . . . . 0.91 109.786 -178.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 10.7 t30 -80.05 105.92 11.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.641 -0.709 . . . . 1.95 109.694 176.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 24.3 p -80.04 126.3 30.88 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.997 -0.547 . . . . 1.12 111.512 -176.16 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.68 -37.65 22.59 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 110.688 -0.965 . . . . 1.91 110.688 174.042 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -95.37 104.82 16.73 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.273 -0.64 . . . . 5.57 109.273 173.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.7 m-80 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.568 -0.729 . . . . 7.51 110.699 -176.774 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.643 0 N-CA-C 112.037 -0.425 . . . . 1.83 112.037 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -112.25 149.03 32.9 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 110.165 -0.309 . . . . 2.5 110.165 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.11 108.09 8.78 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.798 -0.816 . . . . 0.95 108.798 174.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.739 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.3 pt -92.96 -10.42 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.22 -0.9 . . . . 1.03 111.419 -170.485 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.78 176.3 42.47 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.623 -0.799 . . . . 0.11 111.469 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -144.49 150.07 36.98 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.04 0.448 . . . . 0.24 110.446 -175.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.565 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.2 mm -78.04 123.68 35.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.775 -0.648 . . . . 1.03 110.972 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 p -116.19 -23.41 8.45 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.127 0.489 . . . . 1.01 110.856 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.544 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 25.8 tptp -139.99 136.18 33.49 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.959 -1.126 . . . . 2.86 107.959 173.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -152.85 138.11 17.47 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.016 0.436 . . . . 1.03 111.043 -179.09 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.4 m-20 -147.95 157.24 43.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.158 -0.928 . . . . 1.94 110.861 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.03 -158.79 46.7 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.842 -0.617 . . . . 0.32 112.752 176.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.9 t -103.68 118.69 37.31 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.251 -0.648 . . . . 1.65 109.251 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.439 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.7 m -135.65 153.17 32.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.687 0.756 . . . . 1.09 111.681 -175.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.11 158.86 44.52 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.796 -1.093 . . . . 1.0 108.687 -178.129 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.671 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -136.61 134.5 49.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 119.917 -0.713 . . . . 1.03 111.375 173.636 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -97.56 100.32 11.73 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 114.924 -1.034 . . . . 0.72 108.98 174.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.508 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 58.1 p -63.01 179.06 0.41 Allowed 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.962 -0.295 . . . . 1.63 111.145 -175.139 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.8 pt -60.98 -21.17 23.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 1.12 110.937 176.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -80.1 -9.91 59.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 1.96 110.14 176.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.93 12.45 71.35 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 110.973 -0.851 . . . . 0.34 110.973 179.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -89.06 121.74 31.71 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.9 -0.65 . . . . 2.76 110.81 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.671 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 22.2 tt0 -89.65 118.13 29.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.903 -0.59 . . . . 1.0 110.46 178.75 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.471 ' HG2' HG13 ' A' ' 16' ' ' VAL . 22.1 ptt-85 -119.16 165.96 13.55 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.502 -0.555 . . . . 2.1 109.502 175.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.7 p -91.24 127.49 43.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.372 0.606 . . . . 1.11 109.432 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.477 HD22 ' OD1' ' A' ' 30' ' ' ASP . 4.1 mt -90.49 151.17 21.49 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.5 0.667 . . . . 1.1 111.351 -175.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 18.6 mttp -141.87 176.15 9.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.748 -1.114 . . . . 2.19 108.324 -171.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -74.29 141.63 45.27 Favored 'General case' 0 C--N 1.313 -1.014 0 C-N-CA 119.303 -0.959 . . . . 1.1 108.988 176.856 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.77 7.31 88.31 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 119.918 -1.134 . . . . 0.25 111.917 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.565 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -85.03 140.37 37.09 Favored Pre-proline 0 CA--C 1.52 -0.184 0 CA-C-O 121.612 0.72 . . . . 1.92 110.472 178.6 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -78.21 132.01 11.16 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.677 2.918 . . . . 0.31 113.426 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.41 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.4 mm -99.45 133.61 41.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 1.02 109.175 173.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -113.88 152.61 30.51 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.145 -0.479 . . . . 0.37 110.238 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.477 ' HB2' HG23 ' A' ' 4' ' ' ILE . 1.7 t80 -68.48 111.77 4.9 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.963 -0.562 . . . . 0.2 110.019 -177.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.67 6.25 19.62 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.34 -0.933 . . . . 0.17 113.348 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.539 ' O ' ' HG2' ' A' ' 66' ' ' MET . 39.9 mt-10 -91.05 135.12 33.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 117.869 0.834 . . . . 0.52 110.739 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.514 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 9.0 m -94.47 106.12 18.09 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.99 -1.005 . . . . 1.03 110.94 -176.532 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.542 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 4.3 t -82.47 129.58 37.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.137 0.494 . . . . 1.04 110.916 -175.209 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.6 mp -117.31 108.09 15.19 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.223 -0.899 . . . . 1.1 109.694 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.7 p -105.13 153.5 21.43 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.9 -0.408 . . . . 1.06 109.9 178.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -128.66 142.3 13.4 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 121.115 -0.564 . . . . 0.9 111.886 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.27 -115.49 5.79 Favored Glycine 0 N--CA 1.451 -0.337 0 O-C-N 123.756 0.327 . . . . 1.79 113.129 178.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 17.1 t -95.04 45.31 1.1 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.332 0.587 . . . . 1.94 110.388 -178.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.46 135.92 27.62 Favored Glycine 0 N--CA 1.448 -0.558 0 CA-C-N 115.702 -0.681 . . . . 0.89 111.487 175.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 50.7 m -152.79 134.98 14.93 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 117.286 0.543 . . . . 1.16 109.596 173.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.517 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.0 t -143.36 129.77 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.677 0.275 . . . . 1.09 111.034 -175.124 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.544 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -99.26 105.77 17.82 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.533 -0.543 . . . . 1.03 109.533 172.267 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.536 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 69.3 mt -95.89 107.43 19.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 CA-C-N 115.821 -0.627 . . . . 1.05 109.997 176.667 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.74 104.96 13.38 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.322 -0.853 . . . . 1.03 109.08 176.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.494 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 60.9 m-85 -69.96 152.7 44.15 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.601 0.715 . . . . 0.45 110.746 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.5 p -72.61 -11.6 15.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.654 -1.157 . . . . 1.07 111.496 -170.198 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.623 ' H ' ' HH ' ' A' ' 71' ' ' TYR . 33.9 t70 -81.17 -21.77 39.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.102 0.477 . . . . 0.75 110.598 176.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.43 -7.12 14.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.615 -0.802 . . . . 0.32 112.182 -177.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.5 p -85.19 150.11 25.04 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 110.366 -0.235 . . . . 1.09 110.366 176.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -127.53 147.4 50.32 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.664 -0.414 . . . . 1.51 109.932 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.536 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.8 m -129.75 171.32 17.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.117 0.484 . . . . 2.06 111.596 178.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.8 p -137.61 134.88 46.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.169 -0.923 . . . . 1.58 110.168 177.517 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.594 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.7 mt -107.43 136.09 43.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.4 -0.364 . . . . 1.08 110.309 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.51 -169.88 43.05 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.083 -0.579 . . . . 1.02 112.37 178.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -110.34 152.8 17.28 Favored Glycine 0 CA--C 1.504 -0.642 0 N-CA-C 111.595 -0.602 . . . . 0.64 111.595 -173.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.3 t70 56.65 21.73 6.1 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.963 0.887 . . . . 1.26 109.775 -172.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.0 m -106.18 158.97 16.45 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.721 -0.672 . . . . 1.64 111.297 -176.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.542 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.6 mt -139.99 119.63 12.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.417 -0.811 . . . . 1.08 109.459 178.329 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.4 p -145.71 138.3 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 120.904 0.383 . . . . 1.66 110.654 -178.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.514 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.0 tt0 -92.01 130.55 37.73 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.222 -0.444 . . . . 0.67 109.963 179.332 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.539 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 60.8 mmm -66.67 89.56 0.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.948 -0.569 . . . . 1.13 110.591 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 17.0 p -115.46 -165.34 1.02 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.819 -0.628 . . . . 1.15 111.47 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -64.89 -39.31 93.33 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.182 -0.463 . . . . 2.13 111.061 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -64.35 -28.86 69.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.843 0.83 . . . . 2.51 110.075 178.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.427 HG21 ' HE2' ' A' ' 66' ' ' MET . 1.0 OUTLIER -77.48 -46.45 27.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.734 -1.121 . . . . 1.1 111.212 176.928 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.739 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 -110.48 79.48 1.21 Allowed 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.638 -0.71 . . . . 0.91 110.662 -174.323 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -81.61 106.94 13.96 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.789 -0.641 . . . . 1.95 109.748 174.394 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.1 p -82.2 137.86 34.81 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.424 -0.353 . . . . 1.12 111.471 -177.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 109.07 97.67 2.5 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.785 -0.721 . . . . 1.91 113.232 176.039 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -83.3 168.03 17.06 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.968 0.413 . . . . 5.57 110.365 173.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.3 t30 . . . . . 0 C--O 1.251 1.145 0 CA-C-O 118.662 -0.685 . . . . 7.51 109.997 178.216 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.796 0 N-CA-C 112.028 -0.429 . . . . 1.83 112.028 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -88.31 162.27 16.68 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.031 0.444 . . . . 2.5 110.597 -179.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.67 109.36 13.99 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.648 -0.705 . . . . 0.95 109.584 178.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.766 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 32.9 pt -92.97 -12.99 8.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 114.896 -1.047 . . . . 1.03 111.841 -170.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.38 176.34 44.02 Favored Glycine 0 CA--C 1.501 -0.814 0 C-N-CA 120.61 -0.805 . . . . 0.11 111.688 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.94 149.39 36.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.972 0.415 . . . . 0.24 110.961 -174.332 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.429 HD12 ' CG1' ' A' ' 46' ' ' VAL . 37.6 mm -76.43 124.08 33.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.829 -0.623 . . . . 1.03 111.782 -176.147 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.2 p -116.75 -20.68 9.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.034 0.445 . . . . 1.01 111.403 179.099 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.584 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 23.3 tptm -140.21 136.24 33.2 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.104 -1.073 . . . . 2.86 108.104 174.359 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.402 HD11 HG21 ' A' ' 14' ' ' VAL . 5.6 tt -155.71 139.66 16.32 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.395 -0.522 . . . . 1.03 111.552 -179.42 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.564 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 25.9 t70 -144.76 155.77 43.71 Favored 'General case' 0 CA--C 1.496 -1.119 0 CA-C-N 115.655 -0.702 . . . . 1.94 110.914 173.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.16 -162.56 38.72 Favored Glycine 0 N--CA 1.419 -2.462 0 CA-C-N 115.005 -0.998 . . . . 0.32 112.866 164.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.4 m -92.15 116.24 28.77 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 109.841 -0.429 . . . . 1.65 109.841 177.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.431 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.7 m -135.5 152.67 32.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.711 0.767 . . . . 1.09 111.397 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.98 158.3 44.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.701 -1.136 . . . . 1.0 108.79 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.647 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.0 OUTLIER -131.62 133.11 61.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 C-N-CA 119.971 -0.692 . . . . 1.03 111.244 173.933 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.446 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -97.7 99.1 10.44 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.004 -0.998 . . . . 0.72 109.503 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.477 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 20.0 m -64.52 176.54 1.08 Allowed 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 116.344 -0.389 . . . . 1.63 110.584 -178.352 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -59.66 -26.91 36.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 O-C-N 122.005 -0.434 . . . . 1.12 111.569 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.6 m-20 -71.82 -16.51 62.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.04 0.448 . . . . 1.96 110.678 176.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.52 4.87 65.55 Favored Glycine 0 N--CA 1.451 -0.318 0 N-CA-C 110.839 -0.905 . . . . 0.34 110.839 -175.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 92.5 mt-30 -73.53 129.19 37.45 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.827 -0.686 . . . . 2.76 110.619 179.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.647 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 6.8 tt0 -106.37 109.18 21.03 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.411 -0.359 . . . . 1.0 110.601 -176.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.521 ' HG2' HG13 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -109.57 165.74 11.43 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.669 -0.493 . . . . 2.1 109.669 176.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -89.92 139.45 17.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 115.862 -0.608 . . . . 1.11 109.425 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.431 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 22.6 mt -103.91 131.1 51.47 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.129 0.49 . . . . 1.1 110.799 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.3 mttp -118.46 -177.12 3.22 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 107.939 -1.134 . . . . 2.19 107.939 171.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 146.7 54.26 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 119.859 -0.736 . . . . 1.1 109.519 175.054 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.92 1.58 87.55 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 120.13 -1.033 . . . . 0.25 112.918 176.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -78.78 144.75 65.04 Favored Pre-proline 0 CA--C 1.517 -0.317 0 CA-C-O 121.103 0.478 . . . . 1.92 110.608 176.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -79.5 142.95 16.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.967 2.445 . . . . 0.31 112.743 178.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.448 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.3 mm -108.44 135.97 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-N 115.614 -0.721 . . . . 1.02 109.092 171.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -115.96 152.45 33.46 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 116.218 -0.446 . . . . 0.37 110.066 -177.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.443 ' HB2' HG23 ' A' ' 4' ' ' ILE . 1.4 t80 -69.41 110.89 4.94 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.872 -0.604 . . . . 0.2 110.469 -176.397 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.58 4.06 15.76 Favored Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.478 -0.868 . . . . 0.17 113.351 178.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.488 ' O ' ' HG2' ' A' ' 66' ' ' MET . 35.7 mt-10 -93.22 144.97 24.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 117.819 0.809 . . . . 0.52 110.832 -179.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.506 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.5 m -105.01 109.16 21.05 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.383 -0.826 . . . . 1.03 110.921 -174.652 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -83.46 128.36 38.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.349 0.595 . . . . 1.04 111.028 -175.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.5 mp -114.29 106.5 14.4 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.759 -1.109 . . . . 1.1 109.716 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 58.4 p -105.07 154.08 20.63 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.881 0.372 . . . . 1.06 110.086 178.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -129.97 139.51 11.01 Favored Glycine 0 N--CA 1.442 -0.94 0 N-CA-C 111.517 -0.633 . . . . 0.9 111.517 178.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 58.32 -104.25 0.45 Allowed Glycine 0 N--CA 1.45 -0.418 0 O-C-N 123.782 0.342 . . . . 1.79 113.402 179.272 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 19.5 m -103.9 20.03 18.9 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.696 0.284 . . . . 1.94 110.932 -177.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.564 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -59.76 96.34 0.08 OUTLIER Glycine 0 C--O 1.224 -0.471 0 CA-C-N 115.955 -0.566 . . . . 0.89 112.97 178.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.4 t -119.45 138.45 53.12 Favored 'General case' 0 CA--C 1.501 -0.913 0 N-CA-C 109.08 -0.711 . . . . 1.16 109.08 -178.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.533 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.4 t -145.35 136.75 20.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.841 -0.618 . . . . 1.09 111.001 -168.408 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.584 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 91.4 m -111.09 112.62 24.55 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.222 0.534 . . . . 1.03 109.876 175.427 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.411 HD11 ' HE3' ' A' ' 66' ' ' MET . 77.1 mt -99.78 103.52 14.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.205 -0.907 . . . . 1.05 110.098 178.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.59 101.53 7.47 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.259 -0.882 . . . . 1.03 109.44 177.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.529 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 51.9 m-85 -65.8 143.66 57.34 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.689 0.757 . . . . 0.45 110.988 -178.748 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -69.03 -12.36 15.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 114.285 -1.325 . . . . 1.07 111.427 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.47 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 23.3 t70 -74.48 -21.67 59.46 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.169 -0.469 . . . . 0.75 110.624 177.323 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.39 -17.22 8.46 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.815 -0.707 . . . . 0.32 112.137 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 6.1 p -85.86 164.78 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 122.084 0.154 . . . . 1.09 110.729 178.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -133.54 163.44 29.39 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.158 -0.312 . . . . 1.51 110.158 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.529 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -146.05 157.1 12.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.423 -0.353 . . . . 2.06 110.568 -177.409 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.533 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.9 p -133.14 133.91 58.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.166 0.508 . . . . 1.58 110.916 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 20.6 mt -104.04 137.7 31.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.871 -0.604 . . . . 1.08 109.952 -179.533 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.07 174.53 52.67 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.387 -0.911 . . . . 1.02 111.475 176.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.67 151.29 19.83 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 111.283 -0.727 . . . . 0.64 111.283 -173.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.37 26.14 12.13 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-O 121.858 0.837 . . . . 1.26 109.448 -173.425 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -111.55 162.58 14.98 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.425 -0.807 . . . . 1.64 110.944 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.461 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.2 mt -140.37 124.87 18.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.778 -0.646 . . . . 1.08 109.533 178.197 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.0 p -150.11 142.32 17.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.841 0.353 . . . . 1.66 110.843 -178.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.506 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.3 tt0 -94.79 136.08 35.52 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.892 0.377 . . . . 0.67 110.528 178.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.488 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 50.5 mmm -71.46 88.57 0.91 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.697 -0.683 . . . . 1.13 110.393 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -111.08 -163.67 0.86 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.057 -0.519 . . . . 1.15 111.249 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -77.1 -28.24 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.876 -0.147 . . . . 2.13 111.003 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -66.68 -29.47 69.48 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.95 0.881 . . . . 2.51 109.684 173.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.433 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.5 mm -77.35 -55.35 10.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.268 -1.333 . . . . 1.1 110.345 176.352 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.766 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 -109.4 76.41 1.0 Allowed 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.271 -0.877 . . . . 0.91 109.742 -178.007 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -81.34 96.35 7.29 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.747 -0.66 . . . . 1.95 109.835 177.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.4 p -72.05 131.81 43.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.339 -0.392 . . . . 1.12 110.806 -179.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 88.52 27.8 23.8 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.634 -0.793 . . . . 1.91 111.883 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -82.8 79.61 9.13 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.346 0.593 . . . . 5.57 109.976 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.339 -0.839 . . . . 7.51 110.195 179.869 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.743 0 N-CA-C 112.344 -0.302 . . . . 1.83 112.344 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -120.22 141.83 49.57 Favored 'General case' 0 CA--C 1.512 -0.496 0 N-CA-C 109.223 -0.658 . . . . 2.5 109.223 177.127 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.52 109.42 12.68 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.503 0.668 . . . . 0.95 109.906 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.778 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.5 pt -96.92 -13.2 8.17 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.83 -1.077 . . . . 1.03 111.577 -171.593 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.8 174.07 43.4 Favored Glycine 0 CA--C 1.501 -0.818 0 N-CA-C 111.171 -0.772 . . . . 0.11 111.171 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -142.98 148.69 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.96 0.41 . . . . 0.24 111.247 -174.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.427 HD13 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -77.01 121.67 29.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.704 -0.68 . . . . 1.03 111.157 -177.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 71.1 p -116.53 -21.51 9.15 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.067 0.461 . . . . 1.01 111.017 179.284 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.559 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.8 tptt -141.74 136.95 31.28 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.536 -0.913 . . . . 2.86 108.536 173.275 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.1 tt -152.97 142.83 22.12 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.883 0.373 . . . . 1.03 111.156 -178.007 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -143.97 141.85 30.4 Favored 'General case' 0 CA--C 1.499 -0.998 0 CA-C-N 115.777 -0.647 . . . . 1.94 111.767 177.315 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.21 -148.88 19.56 Favored Glycine 0 N--CA 1.422 -2.28 0 CA-C-N 114.695 -1.139 . . . . 0.32 113.159 164.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.2 t -104.49 113.04 26.35 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.527 -0.546 . . . . 1.65 109.527 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.408 HG21 ' HB2' ' A' ' 26' ' ' LEU . 3.3 m -133.18 152.89 36.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.562 0.696 . . . . 1.09 111.411 -177.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.18 159.43 43.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.959 -1.019 . . . . 1.0 108.477 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.448 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.1 p -131.92 129.35 60.65 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 C-N-CA 119.957 -0.697 . . . . 1.03 110.691 175.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.427 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 1.9 mt-30 -93.36 98.71 11.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.44 -0.8 . . . . 0.72 108.972 177.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.502 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.1 m -65.23 179.13 0.77 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.962 -0.563 . . . . 1.63 110.495 -176.814 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 15.1 pt -69.21 -4.88 4.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.913 0.709 . . . . 1.12 112.913 -172.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 57.0 m-80 -95.78 -5.35 42.13 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.176 0.513 . . . . 1.96 109.944 173.004 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.32 8.56 74.47 Favored Glycine 0 CA--C 1.507 -0.456 0 N-CA-C 110.709 -0.956 . . . . 0.34 110.709 -177.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -78.65 120.89 23.97 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.958 -0.621 . . . . 2.76 110.589 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.444 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.5 tt0 -89.25 109.9 20.73 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.323 0.582 . . . . 1.0 110.224 -179.016 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.409 ' HG2' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -110.83 144.74 39.37 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.206 -0.907 . . . . 2.1 109.711 -176.778 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -73.28 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.783 0.325 . . . . 1.11 110.268 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.408 ' HB2' HG21 ' A' ' 14' ' ' VAL . 16.4 mt -110.83 124.07 51.32 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.047 0.451 . . . . 1.1 110.552 177.161 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -115.67 178.73 4.2 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.511 -0.922 . . . . 2.19 108.511 173.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -65.61 147.74 52.9 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 119.766 -0.774 . . . . 1.1 109.909 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.52 -8.73 63.99 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.237 -0.982 . . . . 0.25 112.57 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.401 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 0.4 OUTLIER -65.08 144.59 99.09 Favored Pre-proline 0 CA--C 1.515 -0.377 0 CA-C-O 121.425 0.631 . . . . 1.92 111.021 179.559 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 38.1 Cg_endo -83.17 133.55 6.53 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 123.467 2.778 . . . . 0.31 112.393 175.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.408 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 29.0 mm -98.54 132.66 43.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 109.136 -0.69 . . . . 1.02 109.136 174.276 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -114.41 149.01 36.85 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 116.007 -0.542 . . . . 0.37 110.163 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.463 ' HB2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -67.71 109.01 3.14 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.801 -0.636 . . . . 0.2 110.375 -174.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 121.49 -1.29 11.31 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.271 -0.966 . . . . 0.17 113.589 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.531 ' O ' ' HG2' ' A' ' 66' ' ' MET . 34.7 mt-10 -88.67 146.93 24.79 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 117.929 0.865 . . . . 0.52 110.367 -179.188 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.515 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.1 m -105.76 107.98 19.25 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.72 -0.673 . . . . 1.03 111.171 -175.544 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.1 t -81.4 133.62 28.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.154 0.502 . . . . 1.04 110.913 -175.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.9 mp -119.06 109.63 16.14 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.044 -0.98 . . . . 1.1 109.789 -178.691 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.9 p -105.01 155.7 18.72 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.541 -0.54 . . . . 1.06 109.541 176.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -124.14 137.92 11.01 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.724 -0.75 . . . . 0.9 111.97 178.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.09 -100.43 0.21 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 121.677 -0.297 . . . . 1.79 113.266 178.661 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 20.2 m -111.17 17.26 20.49 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 122.792 -0.24 . . . . 1.94 111.053 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.83 110.74 0.68 Allowed Glycine 0 C--O 1.221 -0.68 0 O-C-N 123.505 0.503 . . . . 0.89 112.856 178.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.47 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 31.1 m -125.17 130.61 52.49 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.838 -0.43 . . . . 1.16 109.838 -174.493 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.6 t -139.61 131.28 33.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 CA-C-N 116.559 -0.291 . . . . 1.09 111.433 -170.861 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.559 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 80.2 m -102.64 107.95 19.05 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.079 -0.51 . . . . 1.03 109.842 175.018 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.544 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 68.5 mt -96.52 109.64 23.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 CA-C-N 115.717 -0.674 . . . . 1.05 110.22 176.371 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.21 100.81 12.01 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.289 -0.869 . . . . 1.03 109.788 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.466 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 67.3 m-85 -68.09 148.36 51.06 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.71 0.767 . . . . 0.45 111.082 -177.798 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.8 p -73.45 -8.71 12.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-N 114.276 -1.329 . . . . 1.07 111.128 -171.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.436 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 32.1 t70 -80.15 -20.63 44.47 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.014 -0.539 . . . . 0.75 110.395 176.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.92 -10.58 11.1 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.749 -0.738 . . . . 0.32 112.173 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.7 p -85.23 157.29 20.65 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.65 -0.13 . . . . 1.09 110.65 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -133.81 140.99 47.26 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.507 -0.553 . . . . 1.51 109.507 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.544 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.6 m -121.47 172.65 8.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.192 0.52 . . . . 2.06 111.584 178.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -140.01 133.15 35.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.254 -0.884 . . . . 1.58 110.124 177.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.47 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.7 mt -103.54 133.25 47.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.003 -0.544 . . . . 1.08 109.951 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.51 178.97 53.71 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.661 -0.78 . . . . 1.02 111.367 175.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.52 155.08 20.84 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.718 -0.553 . . . . 0.64 111.718 -171.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 37.9 t70 59.1 17.13 5.29 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.929 0.871 . . . . 1.26 109.702 -176.568 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -102.58 156.42 17.63 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.524 -0.762 . . . . 1.64 111.343 -176.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.491 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 90.9 mt -140.69 120.73 12.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.292 -0.867 . . . . 1.08 109.57 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.4 p -150.2 143.74 17.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.644 0.259 . . . . 1.66 110.872 -177.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.515 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 36.2 tt0 -90.72 136.11 33.28 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.982 0.42 . . . . 0.67 110.42 177.782 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.531 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 61.3 mmm -69.13 89.05 0.43 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.332 -0.849 . . . . 1.13 110.283 179.054 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.1 p -112.73 -164.21 0.9 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.86 -0.609 . . . . 1.15 110.669 -177.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -75.4 -25.17 57.38 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.787 0.327 . . . . 2.13 110.874 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -66.2 -29.81 70.15 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 122.07 0.938 . . . . 2.51 109.612 172.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.47 HG23 ' CE ' ' A' ' 66' ' ' MET . 1.2 mm -82.46 -51.94 14.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 114.254 -1.339 . . . . 1.1 110.489 177.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.778 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -103.42 82.86 2.09 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.459 -0.791 . . . . 0.91 110.147 -176.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -75.27 100.18 4.28 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.484 -0.78 . . . . 1.95 109.669 175.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 5.8 p -82.62 121.59 27.02 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.832 -0.622 . . . . 1.12 111.632 -176.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -172.96 -68.44 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 111.241 -0.743 . . . . 1.91 111.241 178.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -176.77 -37.61 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.531 -0.544 . . . . 5.57 109.531 175.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.0 t30 . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.548 -0.739 . . . . 7.51 109.562 177.953 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.773 0 N-CA-C 112.258 -0.337 . . . . 1.83 112.258 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 -93.43 155.01 17.61 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.293 0.568 . . . . 2.5 110.767 178.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.23 110.05 17.74 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.061 -0.972 . . . . 0.95 109.931 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.771 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.9 pt -87.55 -14.87 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.125 -0.943 . . . . 1.03 111.688 -171.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.82 175.84 40.71 Favored Glycine 0 CA--C 1.502 -0.728 0 C-N-CA 120.671 -0.776 . . . . 0.11 111.817 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -144.15 149.55 36.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.038 0.446 . . . . 0.24 110.61 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.507 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.6 mm -76.61 126.11 36.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 115.731 -0.668 . . . . 1.03 110.787 -178.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.6 p -117.13 -16.92 10.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.307 0.575 . . . . 1.01 110.773 177.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.463 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.4 tttt -145.3 143.83 30.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.607 -0.886 . . . . 2.86 108.607 174.478 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.8 tt -160.47 139.1 10.26 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.778 0.323 . . . . 1.03 110.987 -175.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.527 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 0.0 OUTLIER -144.07 145.32 32.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.956 -0.566 . . . . 1.94 111.49 177.487 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.723 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 80.18 -146.25 27.64 Favored Glycine 0 N--CA 1.436 -1.348 0 CA-C-N 115.026 -0.988 . . . . 0.32 114.063 167.037 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.9 m -102.03 115.66 31.03 Favored 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 122.832 0.453 . . . . 1.65 110.445 -175.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.447 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.8 m -135.14 153.59 34.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.594 0.711 . . . . 1.09 111.598 -175.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.12 158.32 44.03 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.781 -1.099 . . . . 1.0 108.954 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.605 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.9 OUTLIER -134.31 139.06 48.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 C-N-CA 120.015 -0.674 . . . . 1.03 110.727 171.901 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -107.11 100.03 9.53 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.149 -0.932 . . . . 0.72 109.71 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.448 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 43.0 t -62.73 179.93 0.31 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.594 -0.275 . . . . 1.63 110.753 -178.253 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.4 pt -61.16 -30.64 48.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.143 0.497 . . . . 1.12 111.567 -176.683 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 16.4 p30 -80.64 -6.71 58.74 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.907 -0.588 . . . . 1.96 111.0 177.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 94.37 1.28 64.52 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.121 -0.561 . . . . 0.34 112.413 176.033 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -67.08 121.24 15.16 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.817 0.341 . . . . 2.76 111.424 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.605 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 14.6 tt0 -93.77 118.18 31.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.641 177.069 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.504 ' HG2' HG12 ' A' ' 16' ' ' VAL . 21.8 ptt-85 -120.24 168.01 11.69 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.167 -0.679 . . . . 2.1 109.167 174.518 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.7 p -93.98 136.81 24.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.996 -0.742 . . . . 1.11 108.996 177.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.539 HD21 ' OD1' ' A' ' 30' ' ' ASP . 5.2 mt -97.13 153.58 17.88 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.014 -0.539 . . . . 1.1 111.316 -176.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.3 mttm -138.44 -178.12 5.15 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.149 -0.932 . . . . 2.19 108.585 -173.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.78 140.85 39.48 Favored 'General case' 0 C--N 1.314 -0.954 0 C-N-CA 119.494 -0.882 . . . . 1.1 108.971 174.26 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.81 1.09 77.07 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 120.041 -1.076 . . . . 0.25 111.887 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.539 ' OD1' HD21 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -73.83 137.14 76.65 Favored Pre-proline 0 CA--C 1.517 -0.312 0 CA-C-O 121.79 0.805 . . . . 1.92 110.614 179.095 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -77.23 130.23 10.94 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.62 2.88 . . . . 0.31 113.405 -177.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.4 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.5 mm -99.53 135.93 32.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.075 -0.966 . . . . 1.02 109.313 174.217 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -116.15 154.71 29.54 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 116.004 -0.544 . . . . 0.37 109.731 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.471 ' HB2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -71.21 109.57 5.33 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.361 -0.382 . . . . 0.2 110.657 -174.555 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.14 10.28 9.04 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.443 -0.884 . . . . 0.17 113.422 178.072 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.479 ' O ' ' HG2' ' A' ' 66' ' ' MET . 40.6 mt-10 -96.01 145.08 25.74 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 117.868 0.834 . . . . 0.52 110.687 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.407 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 31.7 m -105.27 108.2 19.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.412 -0.813 . . . . 1.03 110.806 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -82.71 133.72 28.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.128 0.489 . . . . 1.04 110.756 -175.567 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -122.2 110.15 15.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.175 -0.921 . . . . 1.1 110.051 -177.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.406 ' HB ' ' HA3' ' A' ' 44' ' ' GLY . 68.9 p -107.48 158.06 17.5 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.425 -0.583 . . . . 1.06 109.425 176.272 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -135.56 108.12 0.67 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.378 -0.915 . . . . 0.9 113.346 -177.497 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.52 ' H ' ' HB2' ' A' ' 61' ' ' ASP . . . 62.92 -87.55 0.05 OUTLIER Glycine 0 C--N 1.332 0.339 0 CA-C-O 121.196 0.331 . . . . 1.79 112.367 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.723 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 15.7 m -93.41 93.14 7.98 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 107.826 -1.175 . . . . 1.94 107.826 174.251 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -153.2 91.7 0.13 Allowed Glycine 0 C--N 1.309 -0.97 0 CA-C-N 115.328 -0.851 . . . . 0.89 112.189 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.99 114.13 22.71 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.281 0.541 . . . . 1.16 109.937 -175.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.0 t -126.09 142.35 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 CA-C-O 120.793 0.33 . . . . 1.09 111.093 -170.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.463 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.1 m -119.34 110.59 17.15 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.297 0.57 . . . . 1.03 110.341 177.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 70.2 mt -98.88 102.5 13.49 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-N 115.163 -0.926 . . . . 1.05 109.925 178.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.76 102.62 11.68 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.476 -0.784 . . . . 1.03 109.259 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.539 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 58.6 m-85 -64.85 149.28 49.76 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.437 0.637 . . . . 0.45 110.881 -177.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.28 -9.03 12.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 114.784 -1.098 . . . . 1.07 111.134 -172.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.495 ' N ' ' HH ' ' A' ' 71' ' ' TYR . 19.5 t70 -78.39 -22.27 48.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.71 -0.677 . . . . 0.75 111.0 177.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.21 -11.85 16.94 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.32 111.65 -174.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -85.1 161.08 19.82 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.127 -0.323 . . . . 1.09 110.127 175.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -131.78 155.53 47.58 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.24 -0.281 . . . . 1.51 110.24 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.497 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.8 OUTLIER -137.5 151.27 26.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.433 -0.349 . . . . 2.06 110.151 178.401 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.422 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.1 p -129.39 141.53 46.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.333 -0.394 . . . . 1.58 110.139 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 mt -116.2 131.38 68.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.224 -0.444 . . . . 1.08 110.209 -177.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.46 179.7 52.83 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.925 -0.655 . . . . 1.02 111.635 176.201 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.78 148.73 19.09 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 111.285 -0.726 . . . . 0.64 111.285 -173.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.52 ' HB2' ' H ' ' A' ' 42' ' ' GLY . 31.8 t70 59.22 23.42 11.76 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 121.914 0.864 . . . . 1.26 109.605 -173.024 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -104.47 159.99 15.29 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.728 -0.669 . . . . 1.64 110.712 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.481 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 92.2 mt -140.07 125.83 21.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.123 -0.944 . . . . 1.08 108.809 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 13.8 p -147.67 141.74 19.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-O 120.886 0.374 . . . . 1.66 110.866 -177.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.407 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.3 tt0 -100.86 124.93 47.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.151 -0.477 . . . . 0.67 110.25 -179.089 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.479 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 44.3 mmm -65.46 90.29 0.11 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.72 -0.673 . . . . 1.13 110.725 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.406 ' HB ' ' H ' ' A' ' 68' ' ' ASP . 1.3 p -118.48 -165.48 1.12 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 1.15 111.7 -176.532 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.406 ' H ' ' HB ' ' A' ' 67' ' ' THR . 29.1 t70 -65.9 -44.22 85.88 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.857 0.317 . . . . 2.13 111.857 -174.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -62.94 -29.99 71.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.456 0.646 . . . . 2.51 110.49 178.111 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.41 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.1 mm -71.99 -53.11 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.903 -1.044 . . . . 1.1 110.769 176.484 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.771 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 -103.76 80.27 1.75 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.61 -0.723 . . . . 0.91 110.318 -176.495 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -79.87 105.0 10.83 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.549 -0.751 . . . . 1.95 109.482 175.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.3 p -79.09 125.5 29.49 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.079 -0.51 . . . . 1.12 111.428 -177.078 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -97.84 -1.18 58.7 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.999 -0.62 . . . . 1.91 111.73 176.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -70.22 121.27 17.27 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.735 0.303 . . . . 5.57 110.433 176.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.216 -0.897 . . . . 7.51 109.942 178.812 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.701 0 N-CA-C 111.777 -0.529 . . . . 1.83 111.777 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -135.09 159.88 40.11 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.017 0.437 . . . . 2.5 110.35 179.426 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.08 117.94 20.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.488 -0.778 . . . . 0.95 110.228 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.817 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 26.6 pt -96.96 -13.47 8.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.454 -0.794 . . . . 1.03 111.487 -172.638 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.6 179.21 42.21 Favored Glycine 0 CA--C 1.502 -0.752 0 C-N-CA 120.947 -0.644 . . . . 0.11 111.635 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -145.18 152.24 39.69 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.819 0.342 . . . . 0.24 110.604 -175.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 30' ' ' ASP . 29.6 mm -81.55 120.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.032 -0.531 . . . . 1.03 111.11 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 43.8 p -111.94 -27.25 8.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.276 0.56 . . . . 1.01 110.307 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.477 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 85.8 tttt -136.43 147.37 47.21 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.464 -0.939 . . . . 2.86 108.464 172.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.9 tt -158.74 141.06 14.07 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.852 0.358 . . . . 1.03 110.8 -176.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.51 144.36 30.51 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 115.643 -0.708 . . . . 1.94 112.128 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.659 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 81.81 -148.4 27.35 Favored Glycine 0 N--CA 1.425 -2.038 0 CA-C-N 114.561 -1.2 . . . . 0.32 113.479 165.562 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 5.7 t -103.05 109.91 21.65 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.715 -0.476 . . . . 1.65 109.715 -179.142 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.452 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 2.6 m -132.21 153.02 37.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.379 0.609 . . . . 1.09 111.569 -175.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.13 159.71 44.22 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.219 -0.901 . . . . 1.0 109.413 -179.56 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.485 HG21 ' HB3' ' A' ' 36' ' ' GLU . 0.5 OUTLIER -132.6 131.09 59.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.239 0.543 . . . . 1.03 110.213 176.017 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 mt-30 -103.35 99.6 9.45 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.708 -0.678 . . . . 0.72 109.835 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.531 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.6 m -61.64 174.07 0.86 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.535 -0.302 . . . . 1.63 111.072 -176.28 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.7 pt -54.92 -32.51 26.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.301 0.482 . . . . 1.12 112.301 -176.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -75.71 -12.11 60.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.384 -0.371 . . . . 1.96 111.421 178.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.12 6.08 59.17 Favored Glycine 0 CA--C 1.51 -0.261 0 N-CA-C 111.864 -0.494 . . . . 0.34 111.864 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.0 mm-40 -74.35 124.96 27.47 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.639 0.257 . . . . 2.76 110.491 178.589 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.407 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 23.7 tt0 -91.69 110.13 21.46 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.425 0.631 . . . . 1.0 110.801 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.429 HH11 ' HD2' ' A' ' 24' ' ' ARG . 0.1 OUTLIER -105.08 139.05 40.33 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.295 -0.866 . . . . 2.1 109.872 177.466 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.22 138.03 21.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.444 -0.576 . . . . 1.11 109.444 176.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.452 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 28.8 mt -102.96 127.54 50.15 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.304 0.574 . . . . 1.1 111.102 -178.117 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 74.0 mttt -116.55 179.43 4.01 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.514 -1.291 . . . . 2.19 107.514 170.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -67.58 146.74 53.59 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 119.306 -0.958 . . . . 1.1 109.95 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.52 0.04 86.35 Favored Glycine 0 N--CA 1.438 -1.178 0 C-N-CA 120.313 -0.946 . . . . 0.25 112.721 177.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.474 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.8 OUTLIER -71.84 143.13 86.44 Favored Pre-proline 0 CA--C 1.513 -0.461 0 C-N-CA 120.36 -0.536 . . . . 1.92 109.775 173.946 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -89.78 137.47 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.143 2.562 . . . . 0.31 112.1 178.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.474 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.5 mm -98.52 139.65 20.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 116.132 -0.485 . . . . 1.02 109.914 176.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -117.13 155.38 29.43 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.893 -0.594 . . . . 0.37 109.498 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.428 ' HB2' HG21 ' A' ' 4' ' ' ILE . 2.5 t80 -71.64 118.6 14.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.39 -0.368 . . . . 0.2 110.541 -175.424 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.68 -0.36 24.63 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.502 -0.856 . . . . 0.17 113.324 177.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.531 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 23.4 mt-10 -85.42 147.94 26.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 117.8 0.8 . . . . 0.52 110.909 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.8 m -107.71 108.27 19.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.812 -1.086 . . . . 1.03 110.388 -176.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.618 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.2 t -82.08 136.97 21.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 C-N-CA 120.703 -0.399 . . . . 1.04 110.759 -174.328 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -125.66 107.03 10.17 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.437 -0.801 . . . . 1.1 110.562 -175.742 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.5 p -105.74 163.3 12.81 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 108.981 -0.748 . . . . 1.06 108.981 173.27 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -141.69 120.7 1.7 Allowed Glycine 0 C--N 1.316 -0.562 0 C-N-CA 120.384 -0.912 . . . . 0.9 112.538 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.451 ' H ' ' HB2' ' A' ' 61' ' ' ASP . . . 54.24 -94.36 0.02 OUTLIER Glycine 0 C--N 1.334 0.436 0 O-C-N 124.021 0.483 . . . . 1.79 112.551 -178.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.659 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 8.5 m -89.23 87.76 7.27 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.677 -0.86 . . . . 1.94 108.677 177.161 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -141.26 137.66 8.27 Favored Glycine 0 N--CA 1.443 -0.867 0 CA-C-N 115.023 -0.99 . . . . 0.89 111.54 176.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.538 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 46.6 t -153.54 151.36 29.7 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 109.09 -0.707 . . . . 1.16 109.09 169.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 17.8 t -152.21 136.2 8.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 110.121 -0.325 . . . . 1.09 110.121 -176.256 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.9 m -109.79 105.36 14.55 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.145 0.497 . . . . 1.03 109.768 173.194 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 78.4 mt -96.34 99.88 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 115.43 -0.805 . . . . 1.05 109.739 177.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.91 102.38 8.22 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.215 -0.902 . . . . 1.03 109.079 176.639 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.611 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 53.1 m-85 -66.28 151.35 47.23 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.617 0.722 . . . . 0.45 111.081 -176.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -75.24 1.63 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 114.588 -1.187 . . . . 1.07 111.273 -172.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -94.16 -20.79 19.55 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.106 0.479 . . . . 0.75 110.5 178.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 123.36 -19.77 7.57 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.637 -0.792 . . . . 0.32 111.892 -176.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -78.27 160.2 28.03 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 122.15 0.18 . . . . 1.09 110.766 177.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -133.3 146.03 50.99 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.427 -0.582 . . . . 1.51 109.427 178.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.611 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -130.85 147.27 33.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.008 0.432 . . . . 2.06 110.834 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.522 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.3 p -120.7 138.94 49.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.841 -0.618 . . . . 1.58 110.123 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 45' ' ' SER . 34.6 mt -110.64 134.45 52.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.078 -0.51 . . . . 1.08 110.096 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.76 -168.96 43.56 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.803 -0.713 . . . . 1.02 112.262 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -100.56 143.39 16.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.95 -0.643 . . . . 0.64 111.562 -176.149 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.451 ' HB2' ' H ' ' A' ' 42' ' ' GLY . 28.2 t70 60.44 21.53 11.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 121.612 0.72 . . . . 1.26 110.052 -174.051 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.2 t -97.54 154.27 17.63 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.725 -0.67 . . . . 1.64 110.176 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.618 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.6 mt -141.78 106.21 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.486 -0.779 . . . . 1.08 108.937 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -133.56 149.18 30.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.122 0.487 . . . . 1.66 111.414 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -105.94 128.96 54.14 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.611 -0.722 . . . . 0.67 110.543 -175.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.544 ' SD ' HG23 ' A' ' 70' ' ' ILE . 22.2 mmt -64.3 89.88 0.06 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.607 -0.724 . . . . 1.13 111.333 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 72.7 p -124.89 -165.14 1.35 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.85 -0.613 . . . . 1.15 110.988 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -68.33 -26.04 65.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.31 0.576 . . . . 2.13 110.226 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -74.19 -20.28 60.25 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.362 -0.836 . . . . 2.51 110.361 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.544 HG23 ' SD ' ' A' ' 66' ' ' MET . 2.2 mm -98.49 -55.1 6.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-N 114.785 -1.098 . . . . 1.1 110.948 -179.59 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.817 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -95.47 85.81 4.31 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.044 -0.98 . . . . 0.91 109.921 -175.676 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 35.7 t30 -73.74 115.23 12.91 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.241 -0.89 . . . . 1.95 109.944 173.039 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 2.1 p -95.01 115.16 27.07 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.186 -0.461 . . . . 1.12 110.299 176.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 146.51 43.93 0.04 OUTLIER Glycine 0 N--CA 1.441 -0.999 0 C-N-CA 120.654 -0.784 . . . . 1.91 112.322 -178.209 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -82.08 55.91 2.97 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.609 0.719 . . . . 5.57 109.86 177.094 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 . . . . . 0 C--O 1.247 0.948 0 CA-C-N 115.327 -0.851 . . . . 7.51 109.74 -178.115 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.762 0 N-CA-C 112.316 -0.313 . . . . 1.83 112.316 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.3 p-10 -90.58 164.61 14.14 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.861 0.363 . . . . 2.5 110.201 178.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.04 109.2 14.27 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.854 -0.612 . . . . 0.95 109.78 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.686 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.4 pt -95.35 -11.85 8.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 115.058 -0.974 . . . . 1.03 111.565 -171.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.91 175.58 43.32 Favored Glycine 0 CA--C 1.498 -1.027 0 N-CA-C 111.241 -0.743 . . . . 0.11 111.241 178.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -144.1 151.18 39.26 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.952 0.406 . . . . 0.24 110.581 -174.363 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.55 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.7 mm -78.3 124.43 36.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.96 -0.563 . . . . 1.03 111.389 -177.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.0 p -115.1 -21.3 10.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.182 0.515 . . . . 1.01 110.627 177.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.527 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 81.8 tttt -140.9 143.58 34.72 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.54 -0.911 . . . . 2.86 108.54 172.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.424 HD11 HG23 ' A' ' 14' ' ' VAL . 7.6 tt -161.21 140.84 10.53 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.682 0.277 . . . . 1.03 110.82 -177.264 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -156.0 158.5 37.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.49 -0.777 . . . . 1.94 111.159 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.401 ' HA3' ' HA2' ' A' ' 44' ' ' GLY . . . 76.81 -163.66 52.64 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.811 -0.631 . . . . 0.32 112.974 175.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.0 m -92.83 116.62 29.2 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 109.762 -0.459 . . . . 1.65 109.762 -177.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.453 ' CG2' ' HB2' ' A' ' 26' ' ' LEU . 3.9 m -134.48 152.5 33.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.672 0.748 . . . . 1.09 111.988 -175.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.04 159.05 44.78 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 114.567 -1.197 . . . . 1.0 108.853 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.63 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.9 OUTLIER -133.95 135.76 54.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.109 -0.637 . . . . 1.03 110.922 172.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.402 ' HA ' ' O ' ' A' ' 22' ' ' GLN . 2.3 mt-30 -102.46 100.75 10.9 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.364 -0.835 . . . . 0.72 109.911 177.412 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.525 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 37.7 m -62.86 176.64 0.66 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.5 -0.318 . . . . 1.63 110.861 -178.367 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -66.68 -5.55 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 N-CA-C 112.142 0.423 . . . . 1.12 112.142 -178.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -92.25 -8.48 45.21 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.294 0.569 . . . . 1.96 109.682 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.5 6.46 80.63 Favored Glycine 0 CA--C 1.507 -0.465 0 CA-C-N 115.278 -0.874 . . . . 0.34 111.093 -177.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.402 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 46.6 mm-40 -79.65 127.85 32.68 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.225 -0.488 . . . . 2.76 110.953 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLU . . . . . 0.63 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 25.4 tt0 -101.64 117.87 35.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.702 -0.681 . . . . 1.0 110.762 -178.149 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.502 ' HG2' HG12 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -116.62 168.78 9.88 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.619 -0.512 . . . . 2.1 109.619 176.156 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -87.77 140.84 15.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.329 -0.619 . . . . 1.11 109.329 176.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.525 HD23 ' CG ' ' A' ' 30' ' ' ASP . 4.8 mt -101.44 152.3 20.91 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.478 -0.489 . . . . 1.1 111.129 179.15 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.44 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 53.4 mttt -141.61 178.53 7.4 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.139 -0.937 . . . . 2.19 108.638 -174.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.14 139.3 44.43 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.353 -0.939 . . . . 1.1 109.108 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 2.42 86.82 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 120.051 -1.071 . . . . 0.25 111.968 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.55 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -74.89 141.59 75.39 Favored Pre-proline 0 N--CA 1.454 -0.237 0 CA-C-O 121.55 0.69 . . . . 1.92 109.981 177.574 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -86.88 127.28 2.6 Favored 'Trans proline' 0 C--N 1.325 -0.709 0 C-N-CA 123.628 2.885 . . . . 0.31 113.353 -174.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 32.2 mm -93.11 134.28 31.48 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-N 116.183 -0.462 . . . . 1.02 109.815 176.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -111.89 151.29 29.32 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.697 -0.683 . . . . 0.37 109.747 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.484 ' HB2' HG23 ' A' ' 4' ' ' ILE . 2.2 t80 -69.42 113.9 7.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.318 -0.401 . . . . 0.2 110.796 -175.527 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.13 0.55 22.44 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.527 -0.844 . . . . 0.17 113.408 177.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . 0.546 ' O ' ' HG2' ' A' ' 66' ' ' MET . 30.8 mt-10 -86.87 144.7 26.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 117.976 0.888 . . . . 0.52 110.81 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.6 m -101.33 107.64 19.05 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.211 -0.904 . . . . 1.03 110.887 -177.11 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.6 t -82.24 130.51 35.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.137 0.494 . . . . 1.04 110.412 -176.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.1 mp -119.11 103.4 9.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.075 -0.966 . . . . 1.1 109.958 -177.357 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 20.3 p -100.67 159.33 15.26 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.253 -0.647 . . . . 1.06 109.253 175.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.78 138.07 9.15 Favored Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.66 -0.781 . . . . 0.9 112.133 178.223 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 54.33 -104.77 0.26 Allowed Glycine 0 N--CA 1.451 -0.339 0 O-C-N 124.097 0.528 . . . . 1.79 113.777 177.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.1 t -87.18 27.61 1.03 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.187 0.518 . . . . 1.94 110.82 -174.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.401 ' HA2' ' HA3' ' A' ' 12' ' ' GLY . . . -71.96 135.46 22.98 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 121.128 -0.558 . . . . 0.89 112.723 -179.295 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' SER . . . . . 0.567 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 18.9 m -156.27 133.07 10.35 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.002 -0.74 . . . . 1.16 109.002 172.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.533 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 11.0 t -140.18 146.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 O-C-N 122.171 -0.33 . . . . 1.09 110.761 -176.085 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.527 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.5 m -119.43 111.21 17.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.115 -0.493 . . . . 1.03 109.731 174.106 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.54 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 62.4 mt -101.0 104.16 15.85 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 CA-C-N 115.705 -0.679 . . . . 1.05 110.271 179.798 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 104.4 9.09 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.406 -0.816 . . . . 1.03 108.995 176.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.478 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 53.4 m-85 -69.55 148.72 49.06 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.269 0.557 . . . . 0.45 110.681 -177.592 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -70.69 -5.55 5.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 114.878 -1.055 . . . . 1.07 111.04 -171.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.437 ' N ' ' HH ' ' A' ' 71' ' ' TYR . 30.4 t70 -81.57 -21.37 38.49 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.37 0.605 . . . . 0.75 110.42 174.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 117.13 -7.01 16.9 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.781 -0.723 . . . . 0.32 112.275 -177.444 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 23.3 p -86.55 175.18 8.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.436 -0.209 . . . . 1.09 110.436 177.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -149.53 150.49 32.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.706 0.289 . . . . 1.51 110.338 177.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.54 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.8 m -130.88 166.86 27.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.972 -0.558 . . . . 2.06 111.006 179.136 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' VAL . . . . . 0.533 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.0 p -135.19 132.21 52.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 115.763 -0.653 . . . . 1.58 110.819 179.241 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.567 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.3 mt -106.24 132.97 52.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.607 -0.724 . . . . 1.08 109.838 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.14 -160.38 26.9 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.977 -0.63 . . . . 1.02 112.598 -178.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -104.07 141.7 15.32 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.595 -0.602 . . . . 0.64 111.595 -176.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.422 ' HA ' ' O ' ' A' ' 40' ' ' THR . 32.9 t70 58.16 26.15 13.4 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 122.174 0.988 . . . . 1.26 109.313 -171.084 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -91.05 131.67 36.49 Favored 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.465 -1.243 . . . . 1.64 110.967 -178.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.572 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.0 mt -129.08 106.12 13.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.092 -0.707 . . . . 1.08 109.092 178.003 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.28 144.47 31.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.096 -0.502 . . . . 1.66 110.555 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.6 tt0 -97.46 131.04 44.47 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.426 -0.352 . . . . 0.67 110.303 -179.571 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.546 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 53.5 mmm -68.45 89.46 0.35 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.748 -0.66 . . . . 1.13 110.717 -178.307 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.9 p -112.13 -164.62 0.93 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.098 -0.501 . . . . 1.15 111.456 -176.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -72.35 -25.52 61.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.941 0.4 . . . . 2.13 110.852 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -71.05 -31.24 67.64 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 122.102 0.954 . . . . 2.51 109.236 176.124 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.452 HG23 ' HE1' ' A' ' 66' ' ' MET . 1.2 mm -78.77 -47.03 23.86 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 CA-C-N 113.844 -1.525 . . . . 1.1 110.832 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.686 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -110.45 78.38 1.12 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.281 -0.872 . . . . 0.91 110.061 -178.135 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -88.18 101.81 14.19 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.817 -0.629 . . . . 1.95 109.465 174.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 32.3 p -65.6 134.7 53.86 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.992 -0.549 . . . . 1.12 111.542 -176.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.63 -38.81 1.04 Allowed Glycine 0 N--CA 1.443 -0.854 0 N-CA-C 111.476 -0.649 . . . . 1.91 111.476 178.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -79.67 -42.82 23.95 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.584 0.23 . . . . 5.57 110.682 -178.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 9.2 m120 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.563 -0.732 . . . . 7.51 110.443 175.301 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 . . . . . 0 CA--C 1.515 -0.385 0 N-CA-C 109.805 -0.443 . . . . 2.0 109.805 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.78 114.55 15.67 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.334 0.588 . . . . 0.24 110.342 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.79 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 23.1 pt -93.98 -14.39 8.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 115.197 -0.91 . . . . 0.15 111.431 -172.205 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.47 42.79 Favored Glycine 0 CA--C 1.504 -0.64 0 C-N-CA 120.739 -0.743 . . . . 0.1 111.84 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -143.54 151.09 39.82 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.989 0.423 . . . . 0.2 110.822 -174.747 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.519 ' HB ' ' H ' ' A' ' 29' ' ' GLY . 23.8 mm -78.75 124.43 37.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.875 -0.602 . . . . 0.14 111.528 -177.337 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.8 p -113.39 -26.17 8.47 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.323 0.582 . . . . 0.2 110.771 177.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.565 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.9 tptt -137.89 139.62 39.94 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.786 -0.82 . . . . 2.36 108.786 174.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.567 HD11 HG21 ' A' ' 14' ' ' VAL . 6.9 tt -152.74 144.91 23.87 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 120.776 0.322 . . . . 0.2 110.164 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -155.35 156.32 35.22 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.852 -0.613 . . . . 1.94 110.662 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.12 -155.49 50.64 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.95 -0.568 . . . . 0.27 112.809 176.23 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.3 t -99.43 126.0 45.25 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.186 -0.672 . . . . 1.16 109.186 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.589 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -139.76 152.96 22.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.538 0.685 . . . . 0.2 111.498 -176.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.51 158.78 44.06 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.625 -1.17 . . . . 0.17 108.982 178.814 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.535 HG23 HG22 ' A' ' 38' ' ' VAL . 0.5 OUTLIER -132.68 131.83 59.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.235 0.54 . . . . 0.16 110.034 174.857 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -97.42 99.01 10.43 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.471 -0.566 . . . . 0.51 109.471 178.385 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.567 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 39.9 m -62.2 171.59 1.76 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.928 -0.578 . . . . 1.25 109.703 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.2 pt -65.98 -1.44 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 113.757 1.021 . . . . 0.59 113.757 -170.205 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 49.6 m-80 -98.03 -2.16 40.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.303 0.573 . . . . 1.96 109.722 173.244 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.63 74.91 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 110.61 -0.996 . . . . 0.32 110.61 -176.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -84.38 118.2 24.09 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.721 -0.74 . . . . 2.21 110.519 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.417 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 4.9 tt0 -85.56 113.86 22.13 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.294 0.568 . . . . 1.0 110.483 -178.135 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -106.01 138.76 41.64 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.958 -1.019 . . . . 1.55 109.401 177.668 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -75.8 141.32 15.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.249 -0.648 . . . . 0.35 109.249 177.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.589 ' HB2' HG23 ' A' ' 14' ' ' VAL . 5.1 mt -106.99 145.05 32.74 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 121.493 0.663 . . . . 0.32 111.614 -178.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 35.7 mttp -137.51 169.22 18.15 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.461 -1.245 . . . . 1.65 107.735 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -61.23 140.17 57.99 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 119.761 -0.776 . . . . 0.23 109.798 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.519 ' H ' ' HB ' ' A' ' 7' ' ' ILE . . . 82.79 9.31 84.71 Favored Glycine 0 N--CA 1.437 -1.289 0 C-N-CA 120.052 -1.07 . . . . 0.24 113.08 177.469 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.509 ' OD1' HG13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.76 147.98 56.54 Favored Pre-proline 0 C--O 1.236 0.355 0 CA-C-N 117.419 0.609 . . . . 1.92 109.474 176.191 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -84.05 131.04 5.0 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.635 2.224 . . . . 0.22 113.219 178.153 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 mm -95.98 137.37 24.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.392 -0.822 . . . . 0.13 109.211 174.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -118.8 157.22 27.98 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.057 -0.52 . . . . 0.29 109.699 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.526 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.8 t80 -73.85 116.02 13.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.078 -0.51 . . . . 0.18 110.493 -174.562 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.19 -4.2 18.35 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.527 -0.844 . . . . 0.17 113.736 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.567 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 24.6 mt-10 -84.93 149.06 25.9 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 117.971 0.886 . . . . 0.52 110.993 -177.097 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.425 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 11.7 m -104.31 108.07 19.29 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.388 -0.823 . . . . 0.16 110.777 -178.066 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 16' ' ' VAL . 2.8 t -81.72 133.53 29.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.145 0.498 . . . . 0.16 110.613 -176.206 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -122.08 107.68 12.48 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.18 -0.918 . . . . 0.27 109.964 -176.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.423 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 69.7 p -104.26 152.04 22.67 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.79 -0.448 . . . . 0.23 109.79 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.935 0 C-N-CA 120.928 -0.653 . . . . 0.9 112.205 179.395 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 6.0 m . . . . . 0 C--O 1.224 -0.285 0 N-CA-C 108.968 -0.753 . . . . 0.85 108.968 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 4.7 t -133.53 139.54 48.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.739 -0.384 . . . . 0.25 111.141 -173.671 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.588 ' HA ' ' O ' ' A' ' 56' ' ' VAL . 89.3 m -113.89 110.85 20.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.966 -0.561 . . . . 0.19 109.956 174.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.496 HD13 ' HE2' ' A' ' 66' ' ' MET . 69.3 mt -100.37 102.0 12.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.585 -0.734 . . . . 0.15 110.24 178.337 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.6 107.79 11.53 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.431 -0.804 . . . . 0.14 109.388 177.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.49 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 61.7 m-85 -70.86 149.7 46.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.633 0.73 . . . . 0.32 111.287 -177.145 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -77.4 0.95 2.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 114.743 -1.117 . . . . 0.25 111.086 -172.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -90.51 -21.41 21.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.958 -0.564 . . . . 0.75 110.649 175.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.42 -18.11 5.8 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.639 -0.791 . . . . 0.27 112.8 -178.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.2 p -84.81 171.64 12.1 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.644 0.222 . . . . 0.36 111.119 178.619 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -130.26 -178.0 4.56 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.14 -0.689 . . . . 1.51 109.14 175.308 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.588 ' O ' ' HA ' ' A' ' 47' ' ' THR . 0.5 OUTLIER -160.24 151.32 5.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 1.39 109.896 178.982 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.532 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.2 p -129.12 131.53 67.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.355 0.597 . . . . 0.81 110.783 178.795 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.8 mt -107.28 137.18 39.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 115.668 -0.696 . . . . 0.32 109.788 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.06 -164.28 29.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.932 -0.651 . . . . 1.02 112.578 -179.121 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.2 142.67 17.66 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.547 -0.621 . . . . 0.4 111.547 -174.262 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.423 ' HA ' ' O ' ' A' ' 40' ' ' THR . 37.7 t70 56.64 30.11 16.87 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-O 122.151 0.977 . . . . 1.26 109.207 -172.608 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 m -112.28 163.27 14.57 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.656 -1.156 . . . . 1.19 110.727 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 83.4 mt -140.05 127.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.845 -0.616 . . . . 0.38 109.838 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.1 p -148.53 143.72 18.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 109.886 -0.413 . . . . 1.0 109.886 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.425 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 29.8 tt0 -103.37 133.58 48.19 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.758 -0.377 . . . . 0.67 110.323 -178.292 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.496 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.2 mmm -69.19 89.2 0.45 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.645 -0.707 . . . . 0.88 110.366 -177.797 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.412 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 19.2 p -115.95 -164.9 0.99 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.756 -0.656 . . . . 0.29 111.39 -176.161 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -68.94 -41.15 78.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.524 -0.307 . . . . 2.13 111.252 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -61.53 -30.08 70.41 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.636 0.731 . . . . 2.51 110.306 177.145 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.412 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.3 mm -73.45 -52.52 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 114.497 -1.229 . . . . 0.25 110.806 176.133 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.79 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.316 -0.873 0 CA-C-N 115.489 -0.778 . . . . 0.31 110.378 -176.321 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 . . . . . 0 N--CA 1.47 0.537 0 CA-C-O 121.372 0.606 . . . . 2.0 111.613 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.26 109.91 12.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.827 -0.624 . . . . 0.24 109.642 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.779 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.0 pt -92.77 -13.6 8.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.295 -0.866 . . . . 0.15 112.074 -170.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.64 176.64 42.3 Favored Glycine 0 CA--C 1.501 -0.799 0 C-N-CA 120.69 -0.767 . . . . 0.1 111.513 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -143.51 150.41 38.89 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.048 0.451 . . . . 0.2 110.921 -174.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.542 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -78.22 123.38 34.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.683 -0.689 . . . . 0.14 110.883 -177.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.7 p -115.44 -21.29 9.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.218 0.532 . . . . 0.2 110.801 178.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.562 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 52.3 tptt -140.82 139.65 34.55 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.317 -0.994 . . . . 2.36 108.317 172.29 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.602 HD11 HG21 ' A' ' 14' ' ' VAL . 5.8 tt -153.57 146.34 24.32 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 110.234 -0.284 . . . . 0.2 110.234 -179.23 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -146.82 153.57 40.34 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.292 -0.413 . . . . 1.94 110.654 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.61 -149.48 49.67 Favored Glycine 0 N--CA 1.45 -0.402 0 O-C-N 123.689 0.618 . . . . 0.27 113.768 171.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.9 m -100.22 124.49 45.71 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.954 -0.387 . . . . 1.16 109.954 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.602 HG21 HD11 ' A' ' 10' ' ' LEU . 3.9 m -136.05 152.32 30.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.638 0.732 . . . . 0.2 111.692 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.23 157.55 43.21 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.751 -1.113 . . . . 0.17 108.647 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.682 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -135.81 134.94 51.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.048 -0.661 . . . . 0.16 111.049 174.549 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.46 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.8 mt-30 -100.05 102.79 14.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.328 -0.851 . . . . 0.51 109.599 177.426 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.568 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 61.4 p -61.46 178.87 0.26 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 111.473 0.175 . . . . 1.25 111.473 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.7 pt -59.42 -24.36 27.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.091 0.472 . . . . 0.59 111.16 178.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -77.57 -16.64 58.51 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.829 -0.623 . . . . 1.96 110.402 177.435 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.33 7.31 62.17 Favored Glycine 0 CA--C 1.504 -0.6 0 N-CA-C 110.909 -0.877 . . . . 0.32 110.909 -176.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.5 mm-40 -77.74 116.02 17.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.159 -0.521 . . . . 2.21 110.69 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.542 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 13.4 tt0 -81.89 118.44 22.93 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.069 -0.514 . . . . 1.0 110.056 176.7 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HG2' HG12 ' A' ' 16' ' ' VAL . 36.0 ptt85 -120.33 169.62 10.11 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.838 -0.801 . . . . 1.55 108.838 174.737 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.411 ' O ' HD23 ' A' ' 26' ' ' LEU . 7.4 p -96.62 144.33 10.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 109.496 -0.557 . . . . 0.35 109.496 -178.33 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.553 HD22 ' CG ' ' A' ' 30' ' ' ASP . 7.3 mt -112.68 160.73 17.62 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.124 0.487 . . . . 0.32 110.987 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.621 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 0.2 OUTLIER -159.46 177.04 11.38 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.278 -0.874 . . . . 1.65 109.027 -179.502 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 143.51 56.82 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 119.81 -0.756 . . . . 0.23 109.99 -179.38 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.57 6.71 81.81 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.219 -0.991 . . . . 0.24 112.41 178.02 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.621 ' HB3' ' O ' ' A' ' 27' ' ' LYS . 0.0 OUTLIER -85.37 142.27 37.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.399 0.618 . . . . 1.92 110.793 178.325 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.36 134.79 11.54 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 123.58 2.853 . . . . 0.22 113.756 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.8 mm -100.49 136.9 29.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.35 -0.841 . . . . 0.13 109.238 172.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -116.29 153.12 32.51 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 116.224 -0.444 . . . . 0.29 110.134 -178.694 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.559 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -71.37 114.5 9.5 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.058 -0.519 . . . . 0.18 110.869 -174.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.95 0.56 24.16 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.497 -0.858 . . . . 0.17 113.279 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.568 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 34.7 mt-10 -84.28 147.7 27.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.676 0.738 . . . . 0.52 110.465 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 22.2 m -106.59 106.88 17.61 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.462 -0.79 . . . . 0.16 110.488 -177.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.555 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -81.85 125.96 39.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-O 121.205 0.526 . . . . 0.16 110.916 -174.146 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -113.16 106.39 14.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.028 -0.987 . . . . 0.27 109.454 179.124 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.485 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 73.0 p -101.93 157.42 16.87 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 120.44 -0.504 . . . . 0.23 109.997 178.183 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.022 0 CA-C-N 115.631 -0.713 . . . . 0.9 111.644 178.507 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m . . . . . 0 CA--C 1.517 -0.308 0 N-CA-C 109.231 -0.655 . . . . 0.85 109.231 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.8 t -126.5 130.43 71.79 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 C-N-CA 120.677 -0.409 . . . . 0.25 111.878 -169.33 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.562 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 97.2 m -106.79 108.85 20.57 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.781 -0.645 . . . . 0.19 109.751 175.089 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.549 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 62.3 mt -97.73 105.35 17.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.623 -0.717 . . . . 0.15 110.117 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.81 105.42 11.08 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.413 -0.812 . . . . 0.14 109.042 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.448 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 62.5 m-85 -71.18 146.79 48.88 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.508 0.67 . . . . 0.32 110.867 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.59 2.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 114.634 -1.166 . . . . 0.25 111.582 -171.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -94.66 -20.68 19.35 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.076 -0.511 . . . . 0.75 110.384 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.0 -17.65 7.12 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.66 -0.781 . . . . 0.27 112.552 -178.144 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.7 p -82.99 155.7 23.83 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 122.903 -0.175 . . . . 0.36 110.866 178.623 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -132.33 143.26 49.74 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.897 -0.408 . . . . 1.51 109.897 178.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.549 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 10.7 m -124.44 168.56 16.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.068 0.461 . . . . 1.39 111.584 178.344 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.506 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.7 p -138.78 133.37 41.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.331 -0.849 . . . . 0.81 110.25 177.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -106.34 136.15 42.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.99 -0.55 . . . . 0.32 109.929 -179.383 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.49 178.71 53.74 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.551 -0.833 . . . . 1.02 111.606 177.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.0 151.08 19.93 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 111.584 -0.607 . . . . 0.4 111.584 -172.597 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.485 ' HA ' ' O ' ' A' ' 40' ' ' THR . 34.5 t70 51.15 28.48 4.08 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 121.379 0.609 . . . . 1.26 110.509 -171.22 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.5 t -104.72 161.71 13.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.882 -0.599 . . . . 1.19 110.761 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.555 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 81.3 mt -138.92 123.15 20.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.629 -0.714 . . . . 0.38 109.51 178.11 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.14 137.04 16.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.935 0.398 . . . . 1.0 110.855 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.496 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.7 tt0 -91.46 131.84 36.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.315 -0.402 . . . . 0.67 110.41 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.539 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.2 mmm -71.68 89.18 1.0 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 0.88 110.6 -178.64 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.2 p -111.05 -166.77 1.11 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.092 -0.504 . . . . 0.29 110.9 -178.484 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.9 -27.89 62.15 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.013 0.435 . . . . 2.13 110.044 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -65.46 -30.09 70.84 Favored 'General case' 0 CA--C 1.521 -0.144 0 CA-C-O 121.882 0.849 . . . . 2.51 109.789 174.303 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.438 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.0 OUTLIER -80.51 -54.02 11.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 114.457 -1.247 . . . . 0.25 110.732 176.777 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.779 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.316 -0.851 0 CA-C-N 115.407 -0.815 . . . . 0.31 109.772 -177.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ASN . . . . . 0.528 ' N ' HD21 ' A' ' 2' ' ' ASN . 0.7 OUTLIER . . . . . 0 N--CA 1.468 0.473 0 CA-C-O 121.242 0.544 . . . . 2.0 110.937 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.53 109.85 16.37 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.485 0.66 . . . . 0.24 109.817 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.759 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.3 pt -95.11 -12.32 8.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 114.945 -1.025 . . . . 0.15 111.777 -171.215 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.49 179.26 41.09 Favored Glycine 0 CA--C 1.5 -0.853 0 C-N-CA 120.684 -0.769 . . . . 0.1 111.698 178.212 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.455 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 92.3 m-85 -144.41 152.13 40.23 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.76 0.314 . . . . 0.2 110.535 -176.501 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.507 HG12 ' O ' ' A' ' 30' ' ' ASP . 33.0 mm -79.77 122.48 35.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.441 -0.345 . . . . 0.14 110.86 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.0 p -115.72 -21.59 9.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.207 0.527 . . . . 0.2 110.966 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.552 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.8 tttt -141.87 144.94 34.09 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.219 -1.03 . . . . 2.36 108.219 173.224 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.425 HD11 HG21 ' A' ' 14' ' ' VAL . 6.5 tt -158.95 146.54 17.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.877 0.37 . . . . 0.2 111.029 -177.135 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.449 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 9.0 t70 -153.36 152.14 30.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.811 -0.631 . . . . 1.94 110.854 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.15 -154.42 44.58 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.129 -0.558 . . . . 0.27 113.112 173.188 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.4 m -103.34 120.78 41.43 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 109.804 -0.443 . . . . 1.16 109.804 -176.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.514 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.0 m -138.35 152.1 25.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.769 0.795 . . . . 0.2 111.596 -176.49 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.41 159.43 44.47 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 114.64 -1.164 . . . . 0.17 108.463 178.039 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.682 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -132.95 136.45 55.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 119.86 -0.736 . . . . 0.16 110.94 174.377 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -101.05 102.51 13.5 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.295 -0.866 . . . . 0.51 109.843 177.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.533 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 7.6 p -63.01 172.08 1.93 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.854 -0.338 . . . . 1.25 110.507 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -54.42 -33.31 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 112.767 0.654 . . . . 0.59 112.767 -173.609 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -80.09 -5.03 55.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.926 0.393 . . . . 1.96 111.512 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.17 14.73 44.21 Favored Glycine 0 CA--C 1.507 -0.441 0 C-N-CA 121.276 -0.488 . . . . 0.32 112.376 174.445 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.404 ' HB2' ' OG ' ' A' ' 18' ' ' SER . 90.0 mm-40 -86.55 116.86 24.96 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.865 0.364 . . . . 2.21 110.753 -178.252 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.544 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.5 tt0 -84.47 117.52 23.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.371 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HG2' HG12 ' A' ' 16' ' ' VAL . 29.4 ptt85 -119.09 168.32 10.95 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.722 -0.473 . . . . 1.55 109.722 177.166 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.9 p -94.59 135.03 30.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.003 -0.544 . . . . 0.35 110.372 -176.297 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.514 ' HB2' HG23 ' A' ' 14' ' ' VAL . 15.2 mt -103.08 118.39 36.7 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.605 0.717 . . . . 0.32 110.321 178.447 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -114.0 176.88 4.85 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.493 -1.23 . . . . 1.65 107.703 174.447 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 tp -67.69 134.53 51.24 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 119.042 -1.063 . . . . 0.23 109.424 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.15 -12.22 66.95 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 119.676 -1.25 . . . . 0.24 112.564 177.485 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.507 ' O ' HG12 ' A' ' 7' ' ' ILE . 10.7 m-20 -67.76 140.26 94.08 Favored Pre-proline 0 CA--C 1.514 -0.412 0 C-N-CA 120.219 -0.592 . . . . 1.92 109.857 175.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.455 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 29.7 Cg_endo -86.1 144.48 8.29 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.003 2.468 . . . . 0.22 111.834 -179.166 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.0 mm -100.62 138.74 23.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.639 -0.504 . . . . 0.13 109.639 176.335 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -114.61 149.7 36.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.174 -0.466 . . . . 0.29 109.836 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.522 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.8 t80 -68.6 109.58 3.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.096 -0.502 . . . . 0.18 110.638 -175.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 123.8 -3.98 9.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.553 -0.832 . . . . 0.17 113.673 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.533 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.0 mt-10 -82.3 150.49 27.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 117.851 0.825 . . . . 0.52 110.981 -177.435 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.9 m -108.42 107.7 18.35 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.537 -0.756 . . . . 0.16 110.767 -177.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.603 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -79.04 137.05 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.3 0.571 . . . . 0.16 110.845 -175.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -123.46 99.25 6.23 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.043 -0.981 . . . . 0.27 109.665 -177.413 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.5 p -101.01 153.46 19.52 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.119 0.485 . . . . 0.23 110.158 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.917 0 CA-C-N 115.423 -0.808 . . . . 0.9 111.65 178.412 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.494 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 36.8 m . . . . . 0 C--O 1.22 -0.465 0 N-CA-C 109.052 -0.722 . . . . 0.85 109.052 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.9 t -145.71 132.21 14.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 C-N-CA 120.548 -0.461 . . . . 0.25 110.968 -176.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.552 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -106.69 105.96 16.26 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.103 0.478 . . . . 0.19 109.949 174.183 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.535 HD13 ' HE2' ' A' ' 66' ' ' MET . 60.7 mt -96.38 103.15 14.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.672 -0.694 . . . . 0.15 110.082 177.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 106.04 10.19 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.229 -0.896 . . . . 0.14 109.193 176.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.434 ' CE1' HG22 ' A' ' 56' ' ' VAL . 58.0 m-85 -71.43 146.75 48.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.591 0.71 . . . . 0.32 110.916 -177.588 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -71.42 -12.41 15.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.572 -1.195 . . . . 0.25 111.512 -170.343 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.649 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 21.0 t70 -79.39 -21.04 46.23 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.289 -0.414 . . . . 0.75 110.736 178.497 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.75 -8.91 7.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.517 -0.849 . . . . 0.27 112.717 -179.098 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.7 p -90.48 175.35 7.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.579 0.228 . . . . 0.36 110.897 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -151.79 148.45 27.87 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.72 -0.474 . . . . 1.51 109.72 176.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.529 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.2 m -129.36 165.63 28.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 120.989 0.423 . . . . 1.39 111.352 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.595 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.7 p -135.56 128.56 47.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-N 115.316 -0.856 . . . . 0.81 110.426 177.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.494 ' O ' ' HA ' ' A' ' 45' ' ' SER . 18.5 mt -101.03 139.58 21.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.373 -0.83 . . . . 0.32 109.988 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.52 -157.77 29.08 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.775 -0.726 . . . . 1.02 111.952 178.269 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.43 148.87 18.83 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.986 -0.625 . . . . 0.4 111.664 -173.116 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.0 t70 56.87 27.37 12.88 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.96 0.886 . . . . 1.26 109.708 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.5 t -105.3 157.64 17.17 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.372 -0.831 . . . . 1.19 110.579 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.603 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.0 mt -142.79 106.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.191 -0.67 . . . . 0.38 109.191 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.49 146.31 32.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.027 0.441 . . . . 1.0 111.339 -175.341 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -99.46 131.44 45.46 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.793 -0.64 . . . . 0.67 110.354 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.535 ' HE2' HD13 ' A' ' 48' ' ' ILE . 51.0 mmm -68.18 89.15 0.31 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.454 -0.794 . . . . 0.88 110.315 -178.632 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.428 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 20.1 p -116.55 -166.99 1.21 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.653 -0.703 . . . . 0.29 111.16 -175.35 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -63.89 -38.31 90.62 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 2.13 110.647 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -62.75 -28.75 70.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.587 0.708 . . . . 2.51 110.614 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.428 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.4 mm -81.97 -51.28 15.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 CA-C-N 114.904 -1.044 . . . . 0.25 110.939 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.759 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.316 -0.875 0 CA-C-N 115.553 -0.749 . . . . 0.31 109.845 -177.176 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 74.3 m-20 . . . . . 0 CA--C 1.513 -0.47 0 N-CA-C 110.153 -0.314 . . . . 2.0 110.153 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 109.62 6.79 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.374 0.607 . . . . 0.24 110.019 179.117 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.798 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.6 pt -91.83 -13.66 8.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.017 -0.992 . . . . 0.15 111.427 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.93 178.55 43.34 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.794 -0.717 . . . . 0.1 111.415 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -144.73 150.38 37.17 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.8 0.333 . . . . 0.2 110.425 -174.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.59 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.3 mm -77.12 124.19 35.08 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.026 -0.534 . . . . 0.14 111.596 -175.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.3 p -116.1 -22.51 8.91 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.887 0.375 . . . . 0.2 110.747 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.578 ' HB2' ' HB ' ' A' ' 47' ' ' THR . 6.4 tmtt? -134.38 144.34 48.15 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 109.364 -0.606 . . . . 2.36 109.364 170.677 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.442 HD11 HG21 ' A' ' 14' ' ' VAL . 6.2 tt -156.38 141.68 17.48 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.089 -0.505 . . . . 0.2 110.327 177.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -154.54 158.74 40.29 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.725 -0.671 . . . . 1.94 110.75 -177.489 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.48 -140.56 35.48 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.806 -0.634 . . . . 0.27 113.074 175.487 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.3 t -112.46 122.99 49.28 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.294 -0.632 . . . . 1.16 109.294 -178.6 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.2 m -136.06 152.16 30.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.7 0.762 . . . . 0.2 111.496 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.25 158.46 43.91 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 114.674 -1.148 . . . . 0.17 108.881 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.676 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -136.51 135.44 49.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 119.94 -0.704 . . . . 0.16 110.946 173.512 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.434 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.0 mt-30 -103.22 99.87 9.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.973 -1.012 . . . . 0.51 109.68 177.519 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.504 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.2 m -60.76 174.41 0.61 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.6 -0.273 . . . . 1.25 110.713 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 13.4 pt -59.42 -27.8 38.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 118.337 0.517 . . . . 0.59 112.052 -174.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -77.46 -9.33 58.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.068 -0.515 . . . . 1.96 110.982 177.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.42 3.02 60.06 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 121.351 -0.452 . . . . 0.32 112.342 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 82.7 mt-30 -75.06 122.02 22.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.704 0.288 . . . . 2.21 111.271 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.614 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.7 tt0 -92.8 123.18 35.89 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.919 -0.582 . . . . 1.0 110.193 177.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.676 ' HG2' HG12 ' A' ' 16' ' ' VAL . 19.4 ptt-85 -123.0 166.47 15.05 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.543 -0.54 . . . . 1.55 109.543 175.558 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.81 134.45 28.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 109.109 -0.7 . . . . 0.35 109.109 177.207 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.516 HD22 ' CG ' ' A' ' 30' ' ' ASP . 5.3 mt -97.36 153.34 18.14 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.243 0.544 . . . . 0.32 111.111 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.4 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 46.1 mttt -141.27 178.2 7.57 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.958 -1.019 . . . . 1.65 108.395 -176.393 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -71.94 144.23 49.01 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 119.392 -0.923 . . . . 0.23 109.203 177.769 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.53 -6.07 58.91 Favored Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 120.247 -0.978 . . . . 0.24 112.338 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.59 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -70.66 142.84 89.07 Favored Pre-proline 0 C--N 1.332 -0.184 0 CA-C-O 121.388 0.613 . . . . 1.92 110.157 179.414 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 24.3 Cg_endo -87.49 128.87 2.6 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.627 2.884 . . . . 0.22 113.485 -174.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.8 mm -93.62 137.05 23.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.011 -0.54 . . . . 0.13 109.745 177.033 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -115.06 151.39 34.35 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.052 -0.522 . . . . 0.29 109.733 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.552 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -68.94 114.07 6.91 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.246 -0.433 . . . . 0.18 110.494 -176.556 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.49 0.41 18.29 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.398 -0.906 . . . . 0.17 113.54 177.532 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.504 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 30.2 mt-10 -88.53 146.51 25.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 118.071 0.936 . . . . 0.52 110.882 -177.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.0 m -103.49 107.88 18.9 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.422 -0.808 . . . . 0.16 110.943 -176.616 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.474 HG22 HG23 ' A' ' 16' ' ' VAL . 3.9 t -84.0 130.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 CA-C-O 121.153 0.502 . . . . 0.16 110.869 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -115.57 109.57 17.98 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.245 -0.889 . . . . 0.27 109.532 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.8 p -107.94 146.5 32.33 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.877 -0.416 . . . . 0.23 109.877 178.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.44 -1.078 0 C-N-CA 120.934 -0.65 . . . . 0.9 111.766 179.278 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 36.7 m . . . . . 0 C--O 1.222 -0.373 0 N-CA-C 109.434 -0.58 . . . . 0.85 109.434 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.9 t -141.18 128.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-O 120.621 0.248 . . . . 0.25 110.945 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.578 ' HB ' ' HB2' ' A' ' 9' ' ' LYS . 92.8 m -101.27 107.93 19.43 Favored 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 109.559 -0.534 . . . . 0.19 109.559 173.777 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.475 HD13 ' HE2' ' A' ' 66' ' ' MET . 84.6 mt -95.69 101.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.556 -0.747 . . . . 0.15 109.995 176.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.77 102.65 8.23 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.438 -0.801 . . . . 0.14 109.329 177.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.563 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 55.5 m-85 -65.54 152.95 42.84 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.32 111.22 -177.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -79.04 -3.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-N 114.664 -1.153 . . . . 0.25 110.917 -172.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.573 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 18.6 t70 -85.71 -21.45 28.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.605 -0.725 . . . . 0.75 110.44 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.55 -11.65 11.21 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.764 -0.731 . . . . 0.27 112.122 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.2 p -88.07 157.53 18.84 Favored 'General case' 0 C--N 1.323 -0.555 0 O-C-N 122.879 -0.189 . . . . 0.36 110.609 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -124.64 160.32 28.76 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.669 -0.493 . . . . 1.51 109.669 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.558 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.3 154.45 16.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.466 -0.334 . . . . 1.39 110.108 -179.191 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.563 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -132.96 133.11 59.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.178 0.514 . . . . 0.81 110.596 178.064 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 18.7 mt -101.57 143.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.901 -0.591 . . . . 0.32 110.192 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.7 -164.91 39.78 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.842 -0.694 . . . . 1.02 111.998 177.049 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -115.52 153.0 17.84 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.251 -0.74 . . . . 0.4 111.251 -174.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.3 t70 57.25 23.71 9.05 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.77 0.795 . . . . 1.26 109.665 -173.315 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -110.16 160.69 16.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.777 -0.647 . . . . 1.19 111.369 -176.177 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.429 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -139.8 125.26 21.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.422 -0.808 . . . . 0.38 109.382 177.425 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.3 p -148.64 140.73 18.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.925 0.393 . . . . 1.0 110.96 -176.287 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.472 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.8 tt0 -95.5 132.57 40.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.456 -0.338 . . . . 0.67 110.198 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.477 ' HE3' HG21 ' A' ' 70' ' ' ILE . 58.1 mmm -70.21 89.49 0.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.736 -0.666 . . . . 0.88 110.499 -178.702 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 36.0 p -117.06 -165.19 1.04 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.878 -0.601 . . . . 0.29 111.138 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -64.42 -36.38 83.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.934 0.397 . . . . 2.13 110.888 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -65.96 -22.35 66.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.625 0.726 . . . . 2.51 110.313 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.477 HG21 ' HE3' ' A' ' 66' ' ' MET . 1.4 mm -87.06 -56.31 5.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 114.986 -1.007 . . . . 0.25 111.023 176.672 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.798 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.318 -0.792 0 CA-C-N 115.574 -0.739 . . . . 0.31 110.2 -173.545 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ASN . . . . . 0.498 ' N ' HD21 ' A' ' 2' ' ' ASN . 0.7 OUTLIER . . . . . 0 C--O 1.235 0.302 0 N-CA-C 109.762 -0.458 . . . . 2.0 109.762 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.77 112.58 8.94 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.365 0.602 . . . . 0.24 110.47 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.796 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 35.6 pt -95.94 -15.76 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 114.978 -1.01 . . . . 0.15 111.937 -171.672 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.09 175.99 40.88 Favored Glycine 0 CA--C 1.499 -0.941 0 C-N-CA 120.615 -0.803 . . . . 0.1 111.812 -177.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -145.07 147.44 32.57 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.042 0.449 . . . . 0.2 110.661 -174.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.583 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.77 123.07 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.579 -0.737 . . . . 0.14 110.964 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.2 p -112.41 -23.67 10.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.347 0.594 . . . . 0.2 110.718 178.387 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.478 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.6 tptt -141.6 138.73 32.81 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 108.667 -0.864 . . . . 2.36 108.667 175.414 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.46 HD11 HG21 ' A' ' 14' ' ' VAL . 5.7 tt -149.66 144.86 26.4 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.721 0.296 . . . . 0.2 110.71 -178.386 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -152.65 153.33 33.1 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.015 -0.539 . . . . 1.94 110.394 -177.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.16 -149.85 41.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.002 -0.618 . . . . 0.27 113.164 174.078 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.2 t -108.0 123.84 49.26 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.31 -0.626 . . . . 1.16 109.31 -177.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -136.37 152.28 29.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.855 0.836 . . . . 0.2 112.296 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.03 158.88 44.68 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 114.422 -1.263 . . . . 0.17 108.795 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.679 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.1 p -135.73 139.17 46.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 C-N-CA 120.042 -0.663 . . . . 0.16 110.895 173.097 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' GLN . 1.3 mt-30 -107.85 102.12 11.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.316 -0.856 . . . . 0.51 110.077 177.584 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.518 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 11.6 m -63.91 172.26 2.38 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.462 -0.57 . . . . 1.25 109.462 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.0 pt -57.78 -30.0 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 119.031 0.832 . . . . 0.59 112.521 -172.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.504 ' HB2' ' HG3' ' A' ' 22' ' ' GLN . 87.3 m-20 -63.94 -26.8 68.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.164 0.507 . . . . 1.96 110.826 175.526 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 106.33 13.3 23.16 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.505 -0.77 . . . . 0.32 111.691 -174.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.504 ' HG3' ' HB2' ' A' ' 20' ' ' ASN . 85.2 mt-30 -77.1 116.72 17.99 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.947 -0.126 . . . . 2.21 110.885 -179.023 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.679 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.4 tt0 -93.76 117.66 30.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.876 0.369 . . . . 1.0 110.485 176.359 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.655 ' HG2' HG12 ' A' ' 16' ' ' VAL . 23.9 ptt-85 -120.11 166.95 12.72 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.209 -0.663 . . . . 1.55 109.209 175.224 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.1 p -91.2 131.71 37.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 109.47 -0.567 . . . . 0.35 109.47 178.049 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' HG23 ' A' ' 14' ' ' VAL . 5.4 mt -94.25 156.49 16.51 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.852 -0.613 . . . . 0.32 111.014 -178.124 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -143.54 177.9 8.15 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.321 -0.992 . . . . 1.65 108.321 -172.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.61 142.18 46.55 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 118.973 -1.091 . . . . 0.23 108.77 174.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.5 5.3 85.78 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.982 -1.104 . . . . 0.24 112.173 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.583 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -80.47 139.09 51.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.671 0.748 . . . . 1.92 110.739 178.942 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -77.03 130.6 11.38 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 123.685 2.924 . . . . 0.22 113.382 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 mm -97.42 136.04 29.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.344 -0.844 . . . . 0.13 109.018 174.027 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 -115.16 151.4 34.46 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 116.194 -0.457 . . . . 0.29 110.101 -178.487 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.542 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -67.64 118.82 11.44 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.891 -0.595 . . . . 0.18 110.531 -175.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.74 1.1 30.59 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.583 -0.818 . . . . 0.17 113.203 177.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.524 ' O ' ' HG2' ' A' ' 66' ' ' MET . 34.4 mt-10 -88.62 146.15 25.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 117.9 0.85 . . . . 0.52 110.644 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 11.3 m -104.34 106.85 17.51 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.249 -0.887 . . . . 0.16 110.738 -174.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.7 t -82.63 122.62 37.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 121.206 0.527 . . . . 0.16 110.883 -174.662 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.1 mp -105.76 109.27 21.18 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.135 -0.938 . . . . 0.27 109.441 178.475 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.5 p -107.54 148.35 29.35 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.955 -0.387 . . . . 0.23 109.955 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.912 0 C-N-CA 120.776 -0.726 . . . . 0.9 111.984 177.391 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.617 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 3.1 m . . . . . 0 CA--C 1.511 -0.548 0 N-CA-C 109.55 -0.537 . . . . 0.85 109.55 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.9 t -130.9 119.43 45.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 CA-C-N 116.048 -0.524 . . . . 0.25 111.278 -170.108 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.478 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.0 m -95.13 104.27 16.14 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.455 -0.793 . . . . 0.19 109.873 176.745 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.467 HD13 ' HE2' ' A' ' 66' ' ' MET . 60.2 mt -94.83 99.66 9.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 115.274 -0.875 . . . . 0.15 109.697 177.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.21 110.11 16.38 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.413 -0.812 . . . . 0.14 109.444 178.452 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.524 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 59.0 m-85 -73.14 151.86 41.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.635 0.731 . . . . 0.32 111.128 -176.055 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.3 p -72.38 -5.89 6.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 114.548 -1.205 . . . . 0.25 110.671 -174.073 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -79.39 -21.37 45.76 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.079 -0.964 . . . . 0.75 110.938 176.277 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.11 -11.86 34.11 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.099 -0.8 . . . . 0.27 111.099 -173.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.3 p -83.3 154.67 24.0 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.267 -0.466 . . . . 0.36 109.959 175.442 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -126.88 156.79 40.85 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 120.777 -0.369 . . . . 1.51 110.454 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.524 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -139.44 152.0 23.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 115.905 -0.589 . . . . 1.39 109.648 178.233 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -136.62 133.21 48.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-O 121.312 0.577 . . . . 0.81 110.994 179.411 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.617 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -100.37 138.28 25.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.692 -0.685 . . . . 0.32 109.46 178.341 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.08 -51.24 5.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.109 -0.567 . . . . 1.02 112.34 -179.114 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.16 172.49 13.0 Favored Glycine 0 CA--C 1.505 -0.568 0 CA-C-O 119.083 -0.843 . . . . 0.4 111.521 176.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 38.3 47.07 0.97 Allowed 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 122.063 0.935 . . . . 1.26 110.559 -171.507 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.1 t -138.79 163.36 32.42 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 114.493 -1.231 . . . . 1.19 109.785 -176.287 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 84.5 mt -140.26 113.97 5.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.491 -0.559 . . . . 0.38 109.491 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 p -138.66 142.38 34.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.93 0.395 . . . . 1.0 110.885 -175.098 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 45.0 tt0 -96.04 131.94 41.91 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.145 -0.48 . . . . 0.67 110.406 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.546 ' CE ' HG21 ' A' ' 70' ' ' ILE . 59.9 mmm -71.07 88.97 0.8 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.643 -0.708 . . . . 0.88 110.72 -178.583 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 p -117.62 -162.42 0.87 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.245 -0.434 . . . . 0.29 110.369 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -71.36 -28.51 64.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.051 0.453 . . . . 2.13 110.26 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -64.49 -24.05 67.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.916 0.865 . . . . 2.51 109.859 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.546 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.3 mm -91.67 -53.21 9.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 114.509 -1.223 . . . . 0.25 110.583 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.796 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 . . . . . 0 C--N 1.319 -0.749 0 CA-C-N 115.123 -0.944 . . . . 0.31 110.634 -174.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 20.3 m120 . . . . . 0 CA--C 1.515 -0.402 0 CA-C-O 120.891 0.377 . . . . 2.0 110.705 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.68 113.9 11.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.635 -0.711 . . . . 0.24 109.845 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.752 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.1 pt -96.13 -15.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 115.351 -0.841 . . . . 0.15 111.833 -171.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.21 175.88 42.24 Favored Glycine 0 CA--C 1.502 -0.774 0 N-CA-C 111.478 -0.649 . . . . 0.1 111.478 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.62 148.67 36.18 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.096 0.474 . . . . 0.2 110.949 -174.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.3 mm -75.89 123.09 31.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.689 -0.687 . . . . 0.14 111.02 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.4 p -114.63 -26.35 7.92 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.364 0.602 . . . . 0.2 110.395 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.528 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 83.6 tttt -136.21 145.82 46.12 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.584 -0.895 . . . . 2.36 108.584 172.482 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.643 HD11 HG21 ' A' ' 14' ' ' VAL . 5.4 tt -158.42 141.18 14.57 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.972 0.415 . . . . 0.2 110.513 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -152.12 146.45 25.51 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-N 115.705 -0.68 . . . . 1.94 111.433 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.97 -152.34 28.38 Favored Glycine 0 N--CA 1.428 -1.884 0 CA-C-N 114.928 -1.033 . . . . 0.27 113.115 168.334 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 39.8 m -95.01 118.64 32.17 Favored 'General case' 0 N--CA 1.445 -0.681 0 N-CA-C 109.747 -0.464 . . . . 1.16 109.747 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.643 HG21 HD11 ' A' ' 10' ' ' LEU . 2.8 m -136.45 151.22 28.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 0.2 111.678 -177.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -152.21 158.99 43.63 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 114.585 -1.189 . . . . 0.17 108.841 179.214 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.677 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -136.67 133.57 48.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 C-N-CA 119.829 -0.749 . . . . 0.16 111.305 174.192 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.482 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.9 mt-30 -102.75 100.19 10.2 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.089 -0.96 . . . . 0.51 109.794 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.414 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 26.5 p -62.65 179.2 0.36 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.484 0.179 . . . . 1.25 111.484 -176.587 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 11.8 pt -58.66 -27.89 35.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.78 0.324 . . . . 0.59 111.661 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -75.42 -11.75 60.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.967 0.413 . . . . 1.96 110.617 178.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.46 21.26 48.95 Favored Glycine 0 CA--C 1.505 -0.563 0 N-CA-C 110.739 -0.945 . . . . 0.32 110.739 -178.352 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -92.57 121.12 33.69 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.93 -0.635 . . . . 2.21 110.396 -178.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.607 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.9 tt0 -93.72 116.74 29.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.985 0.422 . . . . 1.0 110.931 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.677 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -118.98 169.36 9.96 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.948 -0.569 . . . . 1.55 109.82 176.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.37 143.14 11.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.82 -0.627 . . . . 0.35 109.738 178.111 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.417 ' HB2' HG23 ' A' ' 14' ' ' VAL . 18.4 mt -107.85 127.23 53.54 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.154 -0.475 . . . . 0.32 110.826 178.362 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -110.05 179.59 4.06 Favored 'General case' 0 C--N 1.319 -0.761 0 N-CA-C 108.709 -0.849 . . . . 1.65 108.709 172.039 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.19 145.82 52.92 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.144 -0.622 . . . . 0.23 109.695 174.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.63 2.2 87.72 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.137 -1.03 . . . . 0.24 112.416 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 57.9 m-20 -78.95 142.77 60.63 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.044 0.45 . . . . 1.92 110.701 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -77.34 138.71 17.95 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.038 2.492 . . . . 0.22 113.11 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.9 mm -103.83 135.23 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.687 0 CA-C-N 115.411 -0.813 . . . . 0.13 108.847 170.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.461 ' H ' ' CD ' ' A' ' 36' ' ' GLU . 62.2 m-85 -114.51 155.5 26.31 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 116.017 -0.538 . . . . 0.29 109.947 -178.409 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -71.19 109.89 5.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.036 -0.529 . . . . 0.18 110.243 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.12 0.22 10.6 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.455 -0.878 . . . . 0.17 113.406 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.482 ' O ' ' HG2' ' A' ' 66' ' ' MET . 32.7 mt-10 -86.92 147.98 25.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 117.856 0.828 . . . . 0.52 110.645 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.482 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 17.5 m -108.06 108.63 19.81 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.662 -0.699 . . . . 0.16 110.391 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.0 t -83.69 130.3 36.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.028 0.442 . . . . 0.16 110.618 -174.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.0 mp -117.46 108.02 15.02 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.357 -0.838 . . . . 0.27 110.032 -178.599 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.0 p -101.02 152.97 19.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.235 -0.654 . . . . 0.23 109.235 176.097 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.903 0 C-N-CA 120.622 -0.799 . . . . 0.9 112.417 -177.989 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.4 m . . . . . 0 C--O 1.223 -0.303 0 CA-C-O 120.977 0.417 . . . . 0.85 110.264 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.446 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.2 t -121.2 143.77 32.44 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 120.706 0.289 . . . . 0.25 110.758 -174.429 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.528 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -120.91 110.99 16.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.179 -0.464 . . . . 0.19 109.928 175.643 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.535 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 55.9 mt -99.68 104.6 16.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.785 -0.643 . . . . 0.15 110.107 178.763 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.03 100.98 8.42 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.191 -0.913 . . . . 0.14 109.424 177.721 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.485 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 68.4 m-85 -68.54 146.28 53.25 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-O 121.586 0.708 . . . . 0.32 110.727 -178.403 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.4 p -70.99 1.62 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.567 -1.197 . . . . 0.25 110.991 -173.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.418 ' HB3' ' HE1' ' A' ' 71' ' ' TYR . 4.1 t70 -86.0 -20.84 28.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.32 -0.854 . . . . 0.75 110.432 175.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 111.97 -11.95 27.04 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 111.25 -0.74 . . . . 0.27 111.25 -175.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.68 151.98 24.08 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.352 -0.424 . . . . 0.36 110.478 176.179 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -133.0 138.94 47.0 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.08 -0.341 . . . . 1.51 110.08 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.535 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.7 m -118.32 164.47 14.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.115 0.483 . . . . 1.39 111.47 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.446 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.0 p -133.64 135.4 55.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.402 -0.817 . . . . 0.81 110.249 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 14.6 mt -109.15 133.7 53.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.977 -0.556 . . . . 0.32 110.101 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.72 -169.78 36.7 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.147 -0.549 . . . . 1.02 111.811 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.87 149.98 17.05 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.934 -0.651 . . . . 0.4 111.789 -173.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.3 t70 61.02 20.54 10.96 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 121.926 0.87 . . . . 1.26 109.523 -174.115 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.7 t -106.69 159.05 16.5 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.346 -0.843 . . . . 1.19 110.686 -177.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.453 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.3 mt -140.3 124.55 18.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.8 -0.636 . . . . 0.38 109.922 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 13.1 p -147.09 143.76 20.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.814 0.34 . . . . 1.0 110.822 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.4 tt0 -99.27 133.92 42.88 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.968 0.413 . . . . 0.67 110.587 -179.26 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.571 ' CE ' HG21 ' A' ' 70' ' ' ILE . 47.0 mmm -73.83 88.99 1.81 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.651 -0.704 . . . . 0.88 110.815 -177.363 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.3 p -119.02 -164.71 1.06 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.434 -0.348 . . . . 0.29 110.088 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -67.69 -26.86 66.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.409 0.624 . . . . 2.13 109.52 177.456 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -63.14 -25.7 68.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.131 -0.941 . . . . 2.51 109.888 177.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.571 HG21 ' CE ' ' A' ' 66' ' ' MET . 0.9 OUTLIER -96.87 -55.31 6.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 114.743 -1.117 . . . . 0.25 110.595 177.794 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.752 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.3 t80 . . . . . 0 C--N 1.319 -0.757 0 CA-C-N 115.326 -0.852 . . . . 0.31 110.157 -174.735 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 . . . . . 0 CA--C 1.514 -0.42 0 CA-C-O 120.905 0.383 . . . . 2.0 110.443 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.66 109.28 12.74 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 115.684 -0.689 . . . . 0.24 109.328 175.12 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.8 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.1 pt -89.18 -12.05 10.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.32 -0.854 . . . . 0.15 111.632 -171.363 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.35 174.03 40.38 Favored Glycine 0 CA--C 1.501 -0.837 0 C-N-CA 120.858 -0.687 . . . . 0.1 111.55 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -144.91 149.7 35.75 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.013 0.435 . . . . 0.2 110.327 -176.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.578 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.66 124.54 36.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-N 115.699 -0.682 . . . . 0.14 110.871 -177.759 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 67.9 p -117.6 -16.83 10.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.378 0.609 . . . . 0.2 110.875 178.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.442 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 27.4 tptp -146.73 138.59 24.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.335 -0.987 . . . . 2.36 108.335 172.388 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.418 HD11 HG21 ' A' ' 14' ' ' VAL . 6.5 tt -150.37 148.03 28.3 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.807 -0.357 . . . . 0.2 110.8 -178.213 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -157.48 154.49 28.78 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.923 -0.58 . . . . 1.94 110.274 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.81 -157.4 48.85 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.11 -0.567 . . . . 0.27 113.466 172.595 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 33.4 m -100.07 115.0 28.73 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.366 -0.417 . . . . 1.16 110.056 -178.65 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.564 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.6 m -133.7 152.57 35.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.525 0.678 . . . . 0.2 111.599 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.39 158.56 43.89 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 114.866 -1.061 . . . . 0.17 109.045 -178.789 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.625 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.7 OUTLIER -134.59 139.49 47.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 C-N-CA 120.131 -0.628 . . . . 0.16 110.857 173.007 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.434 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.3 mt-30 -104.21 99.88 9.61 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.204 -0.907 . . . . 0.51 109.251 175.767 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.495 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 68.6 p -63.75 -179.39 0.38 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.638 0.256 . . . . 1.25 110.935 -176.07 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -69.35 -3.33 2.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.944 0.402 . . . . 0.59 111.514 178.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -94.19 -7.01 43.46 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.461 -0.57 . . . . 1.96 109.461 173.115 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.36 19.9 65.58 Favored Glycine 0 CA--C 1.503 -0.681 0 N-CA-C 110.881 -0.888 . . . . 0.32 110.881 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 77.4 mt-30 -92.76 123.12 35.81 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.829 -0.686 . . . . 2.21 110.877 -177.153 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.608 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 19.8 tt0 -89.16 118.46 28.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.355 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.625 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -121.62 166.57 14.04 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.461 -0.57 . . . . 1.55 109.461 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.3 p -89.85 135.26 26.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 109.127 -0.694 . . . . 0.35 109.127 177.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.564 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.3 mt -95.79 146.95 24.13 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.227 0.537 . . . . 0.32 110.902 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.508 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 33.2 mttp -138.07 171.98 13.6 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.059 -0.973 . . . . 1.65 108.544 -176.573 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.82 139.02 58.28 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 119.285 -0.966 . . . . 0.23 109.254 177.269 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.35 89.89 Favored Glycine 0 N--CA 1.437 -1.265 0 C-N-CA 119.865 -1.16 . . . . 0.24 112.478 178.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -76.94 140.4 66.78 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 121.54 0.686 . . . . 1.92 110.48 178.581 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.14 129.3 7.73 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.601 2.868 . . . . 0.22 113.848 -176.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.2 mm -97.39 132.86 41.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 115.588 -0.733 . . . . 0.13 109.187 173.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -113.27 159.75 19.03 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.855 -0.612 . . . . 0.29 109.786 -177.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.497 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.9 t80 -74.52 116.05 14.76 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.285 -0.416 . . . . 0.18 110.16 -175.825 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.33 9.51 27.32 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.57 -0.824 . . . . 0.17 113.265 177.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.495 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 38.7 mt-10 -90.61 139.92 30.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 118.088 0.944 . . . . 0.52 110.343 177.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.3 m -98.28 106.25 18.51 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.207 -0.906 . . . . 0.16 110.727 -176.533 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.4 t -82.38 125.78 39.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.158 0.504 . . . . 0.16 110.771 -174.545 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -110.2 105.2 14.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.136 -0.938 . . . . 0.27 109.701 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.468 HG21 HG21 ' A' ' 58' ' ' ILE . 62.7 p -109.79 143.66 39.32 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.987 -0.375 . . . . 0.23 109.987 178.52 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.96 0 C-N-CA 120.485 -0.865 . . . . 0.9 111.633 177.86 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.695 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 49.2 m . . . . . 0 CA--C 1.512 -0.492 0 N-CA-C 109.748 -0.464 . . . . 0.85 109.748 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 6.1 t -142.92 119.99 6.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 CA-C-O 121.003 0.43 . . . . 0.25 111.286 -171.458 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 88.6 m -92.21 103.65 16.1 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.573 -0.739 . . . . 0.19 109.934 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.464 HD13 ' HE2' ' A' ' 66' ' ' MET . 68.2 mt -94.88 99.55 9.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 114.982 -1.008 . . . . 0.15 109.51 177.077 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.16 107.54 13.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.395 -0.82 . . . . 0.14 109.497 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.554 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 57.1 m-85 -70.7 145.67 50.39 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.47 0.652 . . . . 0.32 110.947 -177.228 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.9 p -70.98 1.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.76 -1.109 . . . . 0.25 111.754 -172.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.744 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 13.8 t70 -99.42 -16.42 18.39 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.86 0.362 . . . . 0.75 110.815 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.85 -14.76 9.06 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.466 -0.873 . . . . 0.27 112.374 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.7 p -84.38 154.61 22.74 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.372 -0.233 . . . . 0.36 110.372 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -133.67 138.2 45.75 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 120.964 0.411 . . . . 1.51 110.345 -179.464 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.448 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 1.1 t -123.33 150.41 27.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.983 -0.553 . . . . 1.39 110.286 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -135.54 129.91 49.61 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.419 0.628 . . . . 0.81 110.731 178.688 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.695 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.3 mt -94.3 139.04 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.545 -0.752 . . . . 0.32 109.599 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.85 -57.4 2.42 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 121.199 -0.524 . . . . 1.02 112.716 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 150.46 158.56 8.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.874 -0.679 . . . . 0.4 111.857 178.181 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.6 t70 51.83 43.23 30.25 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.703 0.763 . . . . 1.26 110.521 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.5 t -129.28 158.08 40.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.757 -0.656 . . . . 1.19 110.394 -176.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.56 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -140.28 106.88 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.536 -0.756 . . . . 0.38 109.148 177.223 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.33 140.41 44.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.897 0.38 . . . . 1.0 111.02 -174.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.464 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.8 tt0 -91.81 128.64 37.72 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.67 109.729 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.477 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 55.8 mmm -66.28 89.45 0.13 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.149 -0.478 . . . . 0.88 110.313 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.425 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 59.4 p -110.81 -166.47 1.08 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.871 -0.604 . . . . 0.29 111.724 -174.383 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.01 -33.41 74.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 2.13 110.323 178.84 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -70.35 -25.66 63.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.731 0.777 . . . . 2.51 109.975 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.425 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.3 mm -80.06 -53.51 12.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 114.596 -1.183 . . . . 0.25 111.079 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.8 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 . . . . . 0 C--N 1.316 -0.868 0 CA-C-N 115.355 -0.839 . . . . 0.31 110.274 -175.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 19.5 m120 . . . . . 0 CA--C 1.518 -0.267 0 N-CA-C 109.994 -0.372 . . . . 2.0 109.994 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.52 116.68 17.43 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 121.438 0.637 . . . . 0.24 110.342 -178.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.787 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.1 pt -101.92 -14.62 8.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.095 -0.957 . . . . 0.15 111.811 -171.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.81 179.22 41.27 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 120.796 -0.716 . . . . 0.1 111.415 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.405 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 95.0 m-85 -143.79 152.51 41.32 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.939 0.4 . . . . 0.2 110.569 -175.655 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.477 HG12 ' O ' ' A' ' 30' ' ' ASP . 34.2 mm -80.21 119.97 30.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.203 -0.453 . . . . 0.14 110.945 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.2 p -113.12 -18.71 12.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.281 0.563 . . . . 0.2 110.586 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.556 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.9 tttt -144.81 145.08 31.47 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.236 -1.024 . . . . 2.36 108.236 172.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.608 HD11 HG21 ' A' ' 14' ' ' VAL . 7.0 tt -159.91 142.34 13.42 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.792 0.33 . . . . 0.2 111.019 -177.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -150.67 153.25 35.26 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.779 -0.646 . . . . 1.94 111.274 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.22 -155.14 50.18 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.982 -0.554 . . . . 0.27 113.235 174.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 27.2 t -97.91 119.7 36.99 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.878 -0.415 . . . . 1.16 109.878 -178.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.608 HG21 HD11 ' A' ' 10' ' ' LEU . 2.7 m -132.09 152.98 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.415 0.626 . . . . 0.2 110.828 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.28 159.15 44.66 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.725 -1.125 . . . . 0.17 108.174 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.708 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -134.97 130.44 52.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 C-N-CA 119.545 -0.862 . . . . 0.16 110.817 173.816 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.44 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.8 mt-30 -96.15 98.61 10.47 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.269 -0.878 . . . . 0.51 109.255 175.407 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.506 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 15.9 m -63.79 176.49 0.91 Allowed 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.031 -0.532 . . . . 1.25 110.816 -176.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.6 pt -56.81 -28.03 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 112.687 0.625 . . . . 0.59 112.687 -173.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -82.63 -1.1 50.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.788 0.328 . . . . 1.96 110.963 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 89.35 8.02 68.89 Favored Glycine 0 CA--C 1.506 -0.529 0 N-CA-C 111.047 -0.821 . . . . 0.32 111.047 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 87.7 mm-40 -79.15 115.6 18.91 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.937 -0.631 . . . . 2.21 111.115 -177.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.592 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.6 tt0 -88.15 111.25 21.39 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.94 -0.573 . . . . 1.0 110.533 178.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.708 ' HG2' HG12 ' A' ' 16' ' ' VAL . 16.8 ptt85 -112.22 170.78 7.93 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.214 -0.662 . . . . 1.55 109.214 176.416 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.93 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 109.772 -0.455 . . . . 0.35 109.772 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.445 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 21.2 mt -109.98 128.29 55.3 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.942 -0.572 . . . . 0.32 110.593 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -116.03 -173.9 2.44 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 108.056 -1.09 . . . . 1.65 108.056 171.492 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.83 143.5 52.87 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.734 -0.786 . . . . 0.23 109.389 175.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.51 -2.75 84.69 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.295 -0.955 . . . . 0.24 112.946 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.477 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.3 m-20 -73.0 143.7 84.31 Favored Pre-proline 0 CA--C 1.512 -0.488 0 N-CA-C 109.556 -0.535 . . . . 1.92 109.556 174.392 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.405 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 25.4 Cg_endo -87.64 141.56 5.58 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.922 2.415 . . . . 0.22 112.41 -179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mm -100.93 139.16 22.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.662 -0.496 . . . . 0.13 109.662 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -115.33 150.0 36.98 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 116.019 -0.537 . . . . 0.29 109.676 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.586 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -68.41 113.24 5.8 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.276 -0.42 . . . . 0.18 110.322 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.68 -1.23 13.81 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.368 -0.92 . . . . 0.17 113.463 178.088 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.518 ' HB3' HG22 ' A' ' 16' ' ' VAL . 36.9 mt-10 -85.48 148.6 25.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 117.789 0.795 . . . . 0.52 110.951 -178.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 8.6 m -106.83 105.95 16.23 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.621 -0.718 . . . . 0.16 110.642 -176.765 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -81.86 126.39 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.351 0.596 . . . . 0.16 110.777 -174.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -114.76 100.76 8.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.83 -1.077 . . . . 0.27 109.851 -177.203 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.6 p -99.02 152.88 19.34 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.284 -0.636 . . . . 0.23 109.284 176.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.714 0 C-N-CA 120.34 -0.933 . . . . 0.9 112.526 -179.425 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 8.7 m . . . . . 0 C--O 1.225 -0.191 0 N-CA-C 108.646 -0.872 . . . . 0.85 108.646 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.5 t -148.4 134.05 11.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 O-C-N 122.012 -0.43 . . . . 0.25 110.958 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.556 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.2 m -109.84 108.16 18.38 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.76 -0.459 . . . . 0.19 109.76 173.182 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.619 HD13 ' HE2' ' A' ' 66' ' ' MET . 56.7 mt -99.14 104.22 15.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.593 -0.73 . . . . 0.15 109.969 178.112 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.43 107.34 12.12 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.405 -0.816 . . . . 0.14 109.133 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.44 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 63.0 m-85 -73.72 146.63 44.27 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.491 0.662 . . . . 0.32 110.899 -177.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -77.36 0.89 2.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 114.821 -1.081 . . . . 0.25 111.398 -170.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.36 -21.75 27.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.223 0.535 . . . . 0.75 109.948 173.427 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.56 -12.69 7.41 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.77 -0.729 . . . . 0.27 112.802 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.0 p -87.5 162.98 16.93 Favored 'General case' 0 C--N 1.327 -0.412 0 O-C-N 122.821 -0.223 . . . . 0.36 111.074 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.2 147.46 50.73 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.762 -0.458 . . . . 1.51 109.762 176.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.539 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 11.9 m -128.2 161.2 37.05 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 CA-C-O 121.264 0.554 . . . . 1.39 111.25 175.545 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.596 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 97.9 t -135.06 123.93 41.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.814 -1.084 . . . . 0.81 110.159 178.22 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 45' ' ' SER . 24.0 mt -96.55 133.92 36.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.445 -0.798 . . . . 0.32 110.191 -177.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -76.58 -163.91 17.67 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.047 -0.597 . . . . 1.02 112.346 177.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.07 149.86 17.85 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 111.208 -0.757 . . . . 0.4 111.208 -174.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.5 t70 60.85 20.86 11.05 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 121.901 0.858 . . . . 1.26 109.744 -175.071 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.0 m -102.94 154.18 19.47 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.572 -0.74 . . . . 1.19 110.967 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.56 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.4 mt -141.68 109.69 2.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.35 -0.841 . . . . 0.38 109.727 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.3 p -139.81 142.45 32.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.803 0.335 . . . . 1.0 110.827 -177.009 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.442 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 34.7 tt0 -91.16 132.87 35.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.929 0.395 . . . . 0.67 110.488 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.619 ' HE2' HD13 ' A' ' 48' ' ' ILE . 63.4 mmm -67.13 89.88 0.19 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.448 -0.796 . . . . 0.88 110.808 -177.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.414 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.6 p -117.77 -162.99 0.9 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.488 -0.778 . . . . 0.29 111.305 -175.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -66.92 -40.93 87.8 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.733 0.272 . . . . 2.13 111.733 -175.538 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -64.57 -26.17 68.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.687 0.756 . . . . 2.51 110.605 177.158 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.439 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.6 mm -76.36 -51.33 19.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.766 -1.106 . . . . 0.25 110.557 174.413 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.787 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.318 -0.769 0 CA-C-N 115.33 -0.85 . . . . 0.31 110.106 -177.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 CA--C 1.514 -0.421 0 CA-C-O 121.001 0.429 . . . . 2.0 110.778 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.95 109.61 13.39 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.622 -0.717 . . . . 0.24 109.91 -178.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.774 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.4 pt -88.86 -14.9 9.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.179 -0.918 . . . . 0.15 111.616 -171.117 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -166.98 177.15 41.79 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.886 -0.673 . . . . 0.1 111.465 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -143.95 150.67 38.7 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.951 0.405 . . . . 0.2 110.529 -175.464 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.613 HG12 ' O ' ' A' ' 30' ' ' ASP . 20.7 mm -78.75 122.2 33.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.981 -0.554 . . . . 0.14 110.78 -178.488 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.7 p -114.75 -21.79 10.01 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.311 0.576 . . . . 0.2 110.67 179.131 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.625 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 36.1 ttpt -141.1 145.71 36.15 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.417 -0.957 . . . . 2.36 108.417 172.407 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.418 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -156.66 144.73 19.52 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 120.774 0.321 . . . . 0.2 110.684 -177.601 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.484 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 6.3 t70 -151.75 148.32 27.74 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.881 -0.6 . . . . 1.94 110.73 -178.159 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.96 -152.46 43.98 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.09 -0.576 . . . . 0.27 113.503 173.388 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 9.0 t -103.63 120.07 40.16 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.927 -0.397 . . . . 1.16 109.927 -177.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.599 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.9 m -135.83 153.2 32.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.2 111.859 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.43 159.65 44.32 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.881 -1.054 . . . . 0.17 109.457 -177.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.715 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -134.21 136.66 53.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 C-N-CA 120.152 -0.619 . . . . 0.16 110.984 173.188 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -103.28 103.52 13.55 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.155 -0.929 . . . . 0.51 109.641 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.532 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 47.6 t -62.05 176.8 0.52 Allowed 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.572 -0.451 . . . . 1.25 110.392 -178.209 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.3 pt -60.36 -31.13 47.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-O 121.107 0.48 . . . . 0.59 111.869 -173.609 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -74.35 -14.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.865 -0.607 . . . . 1.96 110.916 177.581 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.1 10.27 46.06 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.146 -0.55 . . . . 0.32 112.522 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.8 mm-40 -80.94 119.94 24.11 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.901 0.382 . . . . 2.21 111.214 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.567 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 18.5 tt0 -88.77 119.49 29.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.623 179.192 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.715 ' HG2' HG12 ' A' ' 16' ' ' VAL . 21.3 ptt-85 -119.1 166.1 13.34 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.43 -0.581 . . . . 1.55 109.43 174.754 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -86.56 137.58 20.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.942 -0.572 . . . . 0.35 109.483 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.599 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.0 mt -102.08 151.88 21.64 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.196 0.522 . . . . 0.32 111.167 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.432 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.5 mttt -139.57 175.97 9.12 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.105 -0.952 . . . . 1.65 108.479 -175.34 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.95 140.92 49.4 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.566 -0.853 . . . . 0.23 108.957 176.487 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.77 6.04 86.81 Favored Glycine 0 N--CA 1.435 -1.389 0 C-N-CA 119.877 -1.154 . . . . 0.24 112.218 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.613 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.0 138.81 46.07 Favored Pre-proline 0 N--CA 1.454 -0.248 0 CA-C-O 121.75 0.786 . . . . 1.92 110.35 178.19 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.92 130.29 11.27 Favored 'Trans proline' 0 C--N 1.325 -0.682 0 C-N-CA 123.719 2.946 . . . . 0.22 113.509 -178.089 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.446 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 26.3 mm -96.02 136.54 26.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 CA-C-N 115.349 -0.841 . . . . 0.13 109.266 173.787 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -117.87 151.35 37.56 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 109.565 -0.531 . . . . 0.29 109.565 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.569 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.9 t80 -67.1 126.29 28.7 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.988 -0.551 . . . . 0.18 110.188 -176.458 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.21 -12.8 33.88 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.462 -0.875 . . . . 0.17 113.074 178.182 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.532 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.7 mt-10 -82.04 139.39 34.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.584 0.707 . . . . 0.52 111.072 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.527 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 17.8 m -98.74 109.98 22.65 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.684 -1.144 . . . . 0.16 110.718 -177.122 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -82.19 132.9 30.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.48 -0.488 . . . . 0.16 110.618 -175.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -119.61 113.33 20.53 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.516 -0.766 . . . . 0.27 110.298 -177.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 71.5 p -105.49 153.19 22.06 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.274 -0.639 . . . . 0.23 109.274 173.061 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.815 0 C-N-CA 120.587 -0.816 . . . . 0.9 111.076 177.756 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.484 ' HB2' ' HB3' ' A' ' 11' ' ' ASP . 25.4 m . . . . . 0 C--O 1.222 -0.354 0 N-CA-C 109.182 -0.673 . . . . 0.85 109.182 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.619 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.4 t -148.32 145.02 18.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 O-C-N 122.242 -0.286 . . . . 0.25 110.334 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.625 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 97.9 m -115.98 106.81 14.2 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.158 0.504 . . . . 0.19 109.87 172.268 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.0 103.0 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.291 -0.868 . . . . 0.15 109.807 178.56 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.74 103.67 8.85 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.463 -0.79 . . . . 0.14 109.287 177.41 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.565 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 50.5 m-85 -68.73 147.09 52.32 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.618 0.723 . . . . 0.32 110.907 -178.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.2 p -74.46 1.66 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.518 -1.219 . . . . 0.25 111.459 -172.387 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.474 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 22.0 t70 -97.26 -0.93 45.81 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.307 0.575 . . . . 0.75 109.752 177.271 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.61 -10.94 49.96 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.859 -0.686 . . . . 0.27 112.847 177.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.3 p -87.79 164.08 16.13 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.534 -0.173 . . . . 0.36 110.534 177.402 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -135.94 153.32 51.46 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.819 -0.438 . . . . 1.51 109.819 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.565 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.7 OUTLIER -135.41 147.66 28.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.968 0.413 . . . . 1.39 110.542 -179.102 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.619 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 89.5 t -125.84 130.22 72.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.638 -0.71 . . . . 0.81 110.176 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.1 mt -102.86 144.69 13.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.984 -0.553 . . . . 0.32 110.614 -176.705 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -88.93 -161.53 37.57 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.926 -0.579 . . . . 1.02 112.11 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -113.63 147.96 18.65 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.431 -0.668 . . . . 0.4 111.431 -174.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 29.7 t70 53.46 28.84 8.06 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.981 0.896 . . . . 1.26 109.888 -173.488 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.8 m -110.49 157.13 19.95 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.085 -0.961 . . . . 1.19 110.809 -179.193 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.414 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.8 mt -140.96 123.76 15.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.456 -0.793 . . . . 0.38 109.731 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.6 p -149.55 145.02 17.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 1.0 110.525 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.527 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 44.0 tt0 -98.17 134.69 40.88 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.28 -0.418 . . . . 0.67 111.076 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.554 ' SD ' HG21 ' A' ' 70' ' ' ILE . 21.8 mmt -64.32 89.24 0.06 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.704 -0.68 . . . . 0.88 110.725 175.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 16.5 p -121.59 -168.22 1.65 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.654 -0.703 . . . . 0.29 110.312 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -68.07 -25.25 65.25 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.272 0.558 . . . . 2.13 109.787 177.309 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 25.8 mm-40 -65.97 -21.73 66.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.41 -0.814 . . . . 2.51 110.098 177.205 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.554 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.5 mm -103.02 -53.86 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 CA-C-N 114.721 -1.127 . . . . 0.25 110.883 -179.565 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.774 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 4.0 t80 . . . . . 0 C--N 1.318 -0.77 0 CA-C-N 115.261 -0.881 . . . . 0.31 110.226 -176.684 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ASN . . . . . 0.414 ' O ' ' HA ' ' A' ' 33' ' ' PHE . 19.8 t-20 . . . . . 0 N--CA 1.465 0.31 0 CA-C-O 121.307 0.575 . . . . 2.0 110.434 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.39 116.29 21.15 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.4 0.619 . . . . 0.24 110.654 -174.302 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.79 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.0 pt -105.55 -14.4 8.97 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.855 -1.066 . . . . 0.15 111.765 -173.048 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.53 177.77 41.81 Favored Glycine 0 CA--C 1.5 -0.894 0 N-CA-C 111.046 -0.822 . . . . 0.1 111.046 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -144.12 151.18 39.23 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.979 0.419 . . . . 0.2 111.034 -175.068 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.468 HD13 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -78.62 120.85 30.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.715 -0.675 . . . . 0.14 110.717 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.0 p -113.25 -23.35 9.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.259 0.552 . . . . 0.2 110.205 179.046 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.62 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 37.8 ttpt -140.63 144.93 36.02 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.524 -0.762 . . . . 2.36 109.069 172.343 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.443 HD11 HG21 ' A' ' 14' ' ' VAL . 6.3 tt -155.8 144.62 20.45 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 110.292 -0.262 . . . . 0.2 110.292 -178.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -153.17 152.36 31.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.16 -0.473 . . . . 1.94 111.136 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.25 -144.11 29.21 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.975 -0.557 . . . . 0.27 112.74 175.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t -113.61 123.31 49.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.428 -0.582 . . . . 1.16 109.428 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.491 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -138.16 152.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.2 111.62 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.84 159.39 44.21 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.798 -1.092 . . . . 0.17 108.175 177.454 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.541 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -132.33 133.18 60.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 C-N-CA 120.11 -0.636 . . . . 0.16 110.46 175.475 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.462 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.0 mt-30 -96.04 98.56 10.46 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.461 -0.79 . . . . 0.51 109.327 178.01 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.53 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 25.0 m -63.62 173.43 1.69 Allowed 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.865 -0.607 . . . . 1.25 110.035 -177.417 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 9.1 pt -64.55 -3.31 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 N-CA-C 114.238 1.199 . . . . 0.59 114.238 -168.371 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -106.03 6.98 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.344 0.592 . . . . 1.96 109.823 174.706 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.62 6.56 80.17 Favored Glycine 0 CA--C 1.504 -0.606 0 N-CA-C 110.75 -0.94 . . . . 0.32 110.75 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.5 mm-40 -78.4 117.44 19.62 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.833 -0.684 . . . . 2.21 111.403 -175.619 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -80.63 126.39 31.2 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.232 0.539 . . . . 1.0 110.582 178.76 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.41 144.59 51.49 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.452 -0.794 . . . . 1.55 109.239 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.3 p -78.2 142.76 13.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.963 0.411 . . . . 0.35 110.242 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.491 ' HB2' HG23 ' A' ' 14' ' ' VAL . 25.5 mt -108.07 128.82 55.02 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.168 -0.469 . . . . 0.32 110.615 178.428 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.2 mttm -111.13 -178.0 3.35 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.298 -1.001 . . . . 1.65 108.298 172.398 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.2 144.49 53.72 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 119.618 -0.833 . . . . 0.23 109.193 173.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.47 2.8 89.83 Favored Glycine 0 N--CA 1.439 -1.139 0 C-N-CA 120.249 -0.977 . . . . 0.24 112.551 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.428 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -70.53 145.27 92.53 Favored Pre-proline 0 CA--C 1.51 -0.571 0 CA-C-O 121.218 0.533 . . . . 1.92 109.923 174.418 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -90.04 135.75 2.36 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 123.251 2.634 . . . . 0.22 111.851 178.822 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -97.99 135.29 33.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.539 -0.541 . . . . 0.13 109.539 177.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.414 ' HA ' ' O ' ' A' ' 2' ' ' ASN . 80.2 m-85 -112.19 144.37 41.69 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.63 -0.714 . . . . 0.29 109.894 -177.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.631 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.5 t80 -66.09 109.22 2.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.24 -0.437 . . . . 0.18 109.987 -177.056 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.75 -4.19 8.03 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.308 -0.949 . . . . 0.17 113.754 178.275 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.541 ' HB3' HG22 ' A' ' 16' ' ' VAL . 26.2 mt-10 -86.72 151.23 23.57 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 118.223 1.012 . . . . 0.52 110.831 -177.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.462 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 25.6 m -111.15 107.49 16.86 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.467 -0.788 . . . . 0.16 110.687 -176.547 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.662 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.9 t -78.67 129.77 37.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 120.896 0.379 . . . . 0.16 111.28 -173.709 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -113.23 98.41 7.1 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.527 -0.761 . . . . 0.27 109.913 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.404 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 82.5 p -96.4 152.99 18.08 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.584 -0.525 . . . . 0.23 109.584 177.617 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.994 0 N-CA-C 111.517 -0.633 . . . . 0.9 111.517 178.779 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.562 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 69.6 m . . . . . 0 C--O 1.222 -0.346 0 N-CA-C 109.172 -0.677 . . . . 0.85 109.172 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.612 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 19.4 t -145.85 137.49 19.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 120.602 0.239 . . . . 0.25 110.531 -177.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.62 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 87.2 m -111.36 106.74 15.77 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.042 -0.527 . . . . 0.19 109.992 174.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.557 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.3 mt -97.87 103.16 14.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.654 -0.703 . . . . 0.15 110.009 177.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.44 105.48 9.73 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.303 -0.862 . . . . 0.14 109.25 177.208 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.489 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.5 m-85 -72.92 145.76 46.58 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.563 0.697 . . . . 0.32 110.584 -178.623 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.0 p -74.07 -8.5 11.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 114.677 -1.147 . . . . 0.25 111.655 -169.483 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.45 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 15.2 t70 -81.62 -21.06 38.51 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.221 -0.445 . . . . 0.75 110.504 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.37 -13.52 6.25 Favored Glycine 0 CA--C 1.519 0.321 0 C-N-CA 120.567 -0.825 . . . . 0.27 113.045 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.8 p -87.76 162.45 17.03 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 122.727 -0.278 . . . . 0.36 111.344 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -135.41 148.0 49.18 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.96 -0.756 . . . . 1.51 108.96 177.097 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.557 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.6 m -129.7 166.54 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.574 0 CA-C-O 121.213 0.53 . . . . 1.39 111.96 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.612 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.9 p -133.12 135.89 56.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 114.908 -1.042 . . . . 0.81 110.15 176.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.562 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.3 mt -108.23 134.54 49.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.861 -0.609 . . . . 0.32 109.656 178.733 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.65 -159.49 21.18 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.206 -0.521 . . . . 1.02 112.336 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.7 146.66 18.32 Favored Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.901 -0.666 . . . . 0.4 111.775 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.404 ' HA ' ' O ' ' A' ' 40' ' ' THR . 29.2 t70 56.77 26.39 11.39 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 121.702 0.763 . . . . 1.26 109.909 -174.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 t -103.91 156.97 17.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.536 -0.756 . . . . 1.19 110.495 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.662 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.7 mt -142.47 104.49 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.504 -0.771 . . . . 0.38 109.16 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.1 m -131.93 150.13 33.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.006 0.431 . . . . 1.0 111.736 -175.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -102.84 128.09 49.75 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.626 -0.715 . . . . 0.67 110.609 -177.112 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.525 ' HE2' HD13 ' A' ' 48' ' ' ILE . 51.3 mmm -67.72 89.58 0.26 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.522 -0.763 . . . . 0.88 110.666 -177.317 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.5 p -121.37 -167.45 1.51 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.006 -0.543 . . . . 0.29 111.118 -177.289 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -65.59 -29.6 70.22 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.735 0.303 . . . . 2.13 110.846 -178.147 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.49 -17.3 62.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.6 0.714 . . . . 2.51 110.354 177.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.512 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.1 mm -96.04 -50.43 11.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 115.127 -0.942 . . . . 0.25 110.562 177.455 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.79 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.317 -0.842 0 CA-C-N 115.363 -0.835 . . . . 0.31 109.658 -177.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 . . . . . 0 C--O 1.235 0.326 0 CA-C-O 120.848 0.356 . . . . 2.0 110.224 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.14 113.18 14.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.774 -0.648 . . . . 0.24 110.282 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.783 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.3 pt -92.01 -16.77 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.085 -0.961 . . . . 0.15 111.646 -172.192 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.42 177.25 40.82 Favored Glycine 0 CA--C 1.501 -0.816 0 C-N-CA 120.787 -0.72 . . . . 0.1 111.535 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -144.59 152.08 39.98 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 120.788 0.328 . . . . 0.2 110.291 -174.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.572 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.1 mm -80.09 123.29 36.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.272 -0.422 . . . . 0.14 111.146 -178.245 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.5 p -112.79 -23.64 10.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.117 0.484 . . . . 0.2 110.461 178.312 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.512 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 34.9 ttpt -141.88 145.51 34.69 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.706 -0.85 . . . . 2.36 108.706 173.459 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.581 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -158.63 144.84 17.0 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.595 0.236 . . . . 0.2 110.436 -176.076 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -154.2 152.44 30.36 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.017 -0.538 . . . . 1.94 110.735 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.46 -156.03 46.11 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.988 -0.551 . . . . 0.27 113.245 174.124 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 25.4 t -99.17 120.49 39.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.293 -0.632 . . . . 1.16 109.293 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.581 HG21 HD11 ' A' ' 10' ' ' LEU . 4.6 m -137.75 152.33 26.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.659 0.743 . . . . 0.2 111.729 -175.074 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.08 158.92 44.67 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 114.582 -1.19 . . . . 0.17 108.863 -178.399 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.696 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.6 OUTLIER -136.4 132.37 48.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 C-N-CA 119.99 -0.684 . . . . 0.16 110.982 172.221 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.441 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.7 mt-30 -96.67 99.01 10.64 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.092 -0.958 . . . . 0.51 109.284 174.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.474 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.6 m -66.32 179.6 0.95 Allowed 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.971 -0.292 . . . . 1.25 110.811 -176.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.2 pt -60.24 -26.76 37.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 O-C-N 121.886 -0.509 . . . . 0.59 112.218 -175.792 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 -79.69 -8.79 59.45 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.998 0.428 . . . . 1.96 110.62 178.056 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.8 5.81 62.58 Favored Glycine 0 CA--C 1.506 -0.478 0 N-CA-C 111.234 -0.746 . . . . 0.32 111.234 178.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -74.44 117.97 16.86 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.305 -0.447 . . . . 2.21 110.819 -179.383 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.696 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.5 tt0 -95.09 110.43 22.36 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.168 0.508 . . . . 1.0 110.224 177.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.63 ' HG2' HG12 ' A' ' 16' ' ' VAL . 17.1 ptt-85 -111.61 167.92 9.96 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.952 -0.567 . . . . 1.55 109.906 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.0 p -86.61 129.47 38.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.821 -0.627 . . . . 0.35 109.317 176.563 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.555 HD22 ' OD1' ' A' ' 30' ' ' ASP . 2.8 mt -91.07 143.54 26.6 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 121.526 0.679 . . . . 0.32 110.999 -178.829 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.488 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.8 mttp -131.21 171.59 13.13 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.658 -1.156 . . . . 1.65 109.232 -172.835 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.86 134.74 46.27 Favored 'General case' 0 CA--C 1.507 -0.701 0 C-N-CA 119.171 -1.011 . . . . 0.23 108.743 174.294 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.93 0.58 89.75 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 119.603 -1.284 . . . . 0.24 111.656 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.572 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.08 139.73 79.75 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-O 121.69 0.757 . . . . 1.92 110.203 177.06 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 37.2 Cg_endo -87.64 123.49 1.81 Allowed 'Trans proline' 0 C--N 1.323 -0.771 0 C-N-CA 123.923 3.082 . . . . 0.22 113.623 -174.376 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 34.4 mm -91.04 134.24 30.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.966 -0.561 . . . . 0.13 110.114 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -111.32 155.11 23.55 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.786 -0.643 . . . . 0.29 109.693 179.1 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.54 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -69.42 116.6 10.03 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.813 0.34 . . . . 0.18 110.543 -175.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.18 7.11 23.45 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.388 -0.91 . . . . 0.17 113.478 178.232 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.544 ' O ' ' HG2' ' A' ' 66' ' ' MET . 48.2 mt-10 -89.21 145.11 25.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 117.699 0.75 . . . . 0.52 110.489 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.7 m -106.06 107.28 18.19 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.807 -0.633 . . . . 0.16 110.781 -176.287 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -82.18 131.06 34.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.225 0.536 . . . . 0.16 110.719 -175.215 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -118.31 108.51 15.18 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.047 -0.979 . . . . 0.27 109.703 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.4 p -106.06 155.32 19.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.048 0.451 . . . . 0.23 109.955 177.499 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.763 0 N-CA-C 111.369 -0.693 . . . . 0.9 111.369 177.531 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.433 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 67.0 m . . . . . 0 C--O 1.224 -0.258 0 N-CA-C 109.395 -0.595 . . . . 0.85 109.395 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -148.39 133.29 10.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 C-N-CA 120.997 -0.281 . . . . 0.25 110.764 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.512 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.1 m -106.36 106.61 17.21 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.052 -0.522 . . . . 0.19 109.62 173.78 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.553 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 58.8 mt -97.7 107.61 20.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.756 -0.657 . . . . 0.15 110.18 178.312 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.26 106.63 14.31 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.331 -0.85 . . . . 0.14 109.323 177.655 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.547 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 67.8 m-85 -73.59 144.64 45.92 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.484 0.659 . . . . 0.32 110.753 -178.48 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.7 p -73.53 -6.28 7.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 114.879 -1.055 . . . . 0.25 111.799 -169.762 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.56 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 11.5 t70 -84.95 -20.55 30.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.594 -0.276 . . . . 0.75 110.607 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.51 -17.32 5.57 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.479 -0.867 . . . . 0.27 112.919 -179.674 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.6 p -86.59 156.84 19.88 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 122.795 -0.238 . . . . 0.36 111.108 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -130.38 150.73 51.48 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.442 -0.577 . . . . 1.51 109.442 177.359 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.553 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.9 m -130.4 169.4 21.33 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.211 0.529 . . . . 1.39 111.768 177.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.554 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.6 p -140.31 132.37 32.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.13 -0.941 . . . . 0.81 110.327 176.701 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 45' ' ' SER . 23.5 mt -102.71 143.46 15.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.99 -0.55 . . . . 0.32 110.15 -179.599 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.23 -161.54 36.63 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.858 -0.687 . . . . 1.02 112.23 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.91 146.42 17.99 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.959 -0.639 . . . . 0.4 111.57 -175.052 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.5 t70 60.39 21.65 11.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.945 0.878 . . . . 1.26 109.655 -173.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 t -102.93 155.61 18.24 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.369 -0.832 . . . . 1.19 110.847 -175.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.539 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.4 mt -140.28 122.88 16.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.248 -0.887 . . . . 0.38 109.351 179.004 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.18 141.93 17.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.702 0.287 . . . . 1.0 110.86 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.5 tt0 -94.38 130.78 40.58 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.928 0.394 . . . . 0.67 110.175 178.603 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.544 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 53.6 mmm -65.8 89.93 0.12 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.425 -0.807 . . . . 0.88 110.495 -178.78 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.401 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.5 p -116.54 -166.39 1.15 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.391 -0.822 . . . . 0.29 111.216 -175.595 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -63.8 -42.42 97.71 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.802 0.334 . . . . 2.13 111.471 -177.32 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 56.4 mm-40 -62.89 -23.93 67.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.295 0.569 . . . . 2.51 111.009 177.661 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.414 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.3 mm -82.72 -50.38 15.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.212 -0.904 . . . . 0.25 111.144 177.034 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.783 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.319 -0.761 0 CA-C-N 115.671 -0.695 . . . . 0.31 109.962 -177.36 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.8 m120 . . . . . 0 CA--C 1.515 -0.395 0 N-CA-C 110.115 -0.328 . . . . 2.0 110.115 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 119.35 17.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.906 -0.588 . . . . 0.24 110.018 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.753 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.0 pt -101.11 -15.85 7.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-N 115.422 -0.808 . . . . 0.15 111.592 -171.809 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.83 176.26 42.51 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 120.999 -0.62 . . . . 0.1 111.595 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.417 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 93.9 m-85 -144.89 151.1 38.18 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.74 0.305 . . . . 0.2 110.432 -175.154 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.471 HG12 ' O ' ' A' ' 30' ' ' ASP . 31.4 mm -79.18 122.2 33.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.375 -0.375 . . . . 0.14 111.012 -178.363 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.6 p -114.35 -24.4 8.91 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.302 0.573 . . . . 0.2 110.661 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.554 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.5 tttm -139.76 146.85 40.03 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 108.605 -0.887 . . . . 2.36 108.605 172.037 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -160.24 140.63 11.69 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.128 -0.487 . . . . 0.2 110.525 -176.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -146.44 152.46 39.08 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.155 -0.929 . . . . 1.94 110.577 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.55 -160.7 53.82 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.883 -0.599 . . . . 0.27 113.172 174.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 19.3 m -98.46 121.9 40.99 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.953 -0.388 . . . . 1.16 109.953 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.56 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.8 m -139.18 153.57 24.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.669 0.747 . . . . 0.2 111.819 -176.29 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.84 159.15 43.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.721 -1.127 . . . . 0.17 109.082 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.561 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.3 p -131.21 133.77 62.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.097 -0.641 . . . . 0.16 110.608 172.706 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.486 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 8.5 mt-30 -97.73 97.88 9.38 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.284 -0.871 . . . . 0.51 109.552 177.557 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.468 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 51.7 m -64.52 175.93 1.25 Allowed 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.471 -0.331 . . . . 1.25 110.547 -177.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 pt -58.75 -27.21 34.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 112.814 0.672 . . . . 0.59 112.814 -175.171 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -80.49 -10.8 59.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 1.96 110.7 177.711 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.46 3.24 61.39 Favored Glycine 0 N--CA 1.452 -0.283 0 N-CA-C 111.71 -0.556 . . . . 0.32 111.71 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.2 mm-40 -65.45 120.15 12.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.784 -0.208 . . . . 2.21 110.523 176.41 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.561 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.8 tt0 -95.77 108.33 20.64 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.716 -0.476 . . . . 1.0 109.716 -179.444 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.41 ' HG2' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -105.34 143.3 33.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.13 -0.486 . . . . 1.55 109.784 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.4 p -74.26 131.24 35.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.846 -0.798 . . . . 0.35 108.846 171.451 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' HG23 ' A' ' 14' ' ' VAL . 26.3 mt -93.45 127.44 39.09 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.191 -0.603 . . . . 0.32 110.502 -179.746 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -110.62 179.25 4.12 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 107.604 -1.258 . . . . 1.65 107.604 171.875 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -68.12 143.39 55.45 Favored 'General case' 0 C--N 1.315 -0.915 0 C-N-CA 119.316 -0.954 . . . . 0.23 109.417 175.115 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.07 -10.24 69.35 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.204 -0.998 . . . . 0.24 113.057 176.242 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.471 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.8 m-20 -66.49 142.5 97.71 Favored Pre-proline 0 CA--C 1.515 -0.391 0 CA-C-O 121.108 0.48 . . . . 1.92 109.788 175.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.417 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 35.7 Cg_endo -89.06 142.4 4.54 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 123.115 2.543 . . . . 0.22 112.713 -178.499 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.487 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.8 mm -102.57 136.8 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 115.779 -0.646 . . . . 0.13 109.591 175.828 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.442 ' H ' ' CD ' ' A' ' 36' ' ' GLU . 80.9 m-85 -113.84 153.65 28.79 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.839 -0.619 . . . . 0.29 109.561 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.553 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -69.87 111.55 5.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.378 -0.374 . . . . 0.18 110.231 -176.268 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.28 -5.6 8.78 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.601 -0.809 . . . . 0.17 113.048 178.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.468 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 28.6 mt-10 -83.39 136.96 34.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.695 0.759 . . . . 0.52 111.122 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -96.32 106.97 19.26 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.614 -1.175 . . . . 0.16 110.34 -178.168 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 6.0 t -81.37 133.2 29.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.114 0.483 . . . . 0.16 111.089 -173.667 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.1 mp -114.92 126.12 54.42 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.956 -1.02 . . . . 0.27 109.636 178.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.3 p -119.8 152.39 37.34 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.613 -0.514 . . . . 0.23 109.613 172.104 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.818 0 C-N-CA 120.992 -0.623 . . . . 0.9 112.211 179.33 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.545 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 23.2 m . . . . . 0 C--O 1.22 -0.469 0 N-CA-C 108.625 -0.88 . . . . 0.85 108.625 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -141.81 138.36 31.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 C-N-CA 120.385 -0.526 . . . . 0.25 111.158 -175.057 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.554 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.1 m -108.89 105.9 15.65 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.781 -0.645 . . . . 0.19 109.648 173.625 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.529 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.2 mt -94.5 109.45 22.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.896 -0.593 . . . . 0.15 110.045 177.09 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.73 99.26 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.236 -0.893 . . . . 0.14 109.335 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.504 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 66.9 m-85 -67.21 144.67 55.85 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.411 0.624 . . . . 0.32 110.336 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -70.18 2.01 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 114.558 -1.201 . . . . 0.25 110.846 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -84.89 -21.97 29.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.925 -1.034 . . . . 0.75 110.725 177.105 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 115.99 -17.37 15.17 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 111.162 -0.775 . . . . 0.27 111.162 -175.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 p -87.07 150.75 23.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.516 -0.342 . . . . 0.36 111.042 178.32 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -126.13 150.2 48.42 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.277 -0.638 . . . . 1.51 109.277 178.363 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.529 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -125.14 171.39 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.012 0.434 . . . . 1.39 111.366 178.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.534 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.1 p -137.81 130.08 40.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.461 -0.791 . . . . 0.81 110.318 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -105.08 136.87 37.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.881 -0.6 . . . . 0.32 109.926 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.94 -163.59 27.89 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.979 -0.629 . . . . 1.02 112.328 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.5 150.5 18.29 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.946 -0.645 . . . . 0.4 111.736 -173.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 34.7 t70 56.89 22.68 7.35 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.723 0.773 . . . . 1.26 110.264 -173.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.3 m -105.64 164.02 12.23 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.122 0.487 . . . . 1.19 111.338 -177.066 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.488 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.1 mt -140.86 128.2 22.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.506 -0.77 . . . . 0.38 109.374 176.596 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.429 HG21 HD11 ' A' ' 70' ' ' ILE . 11.0 p -149.61 138.68 15.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.852 0.358 . . . . 1.0 110.973 -177.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.507 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.9 tt0 -97.13 131.28 44.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.843 0.354 . . . . 0.67 111.138 -176.038 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.628 ' SD ' HG21 ' A' ' 70' ' ' ILE . 17.8 mmt -62.94 90.48 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.651 -0.704 . . . . 0.88 111.177 177.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.6 p -126.13 -169.1 1.95 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.502 -0.772 . . . . 0.29 110.241 -178.702 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -69.46 -26.61 64.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 117.814 0.279 . . . . 2.13 111.157 -176.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.06 -22.93 63.02 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.972 0.891 . . . . 2.51 109.688 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.628 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.9 mm -90.32 -51.76 11.48 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 114.72 -1.127 . . . . 0.25 110.762 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.753 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 . . . . . 0 C--N 1.314 -0.937 0 CA-C-N 115.491 -0.777 . . . . 0.31 110.729 -176.013 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ASN . . . . . 0.597 ' N ' HD21 ' A' ' 2' ' ' ASN . 0.0 OUTLIER . . . . . 0 CA--C 1.517 -0.299 0 CA-C-O 120.914 0.388 . . . . 2.0 110.385 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.31 109.67 12.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.768 -0.651 . . . . 0.24 109.623 178.643 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.842 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.5 pt -92.34 -11.39 9.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.088 -0.96 . . . . 0.15 112.046 -169.564 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.45 42.79 Favored Glycine 0 CA--C 1.5 -0.85 0 C-N-CA 120.593 -0.813 . . . . 0.1 111.48 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -144.98 151.05 37.98 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.954 0.407 . . . . 0.2 110.883 -174.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.517 HG12 ' O ' ' A' ' 30' ' ' ASP . 21.2 mm -78.44 121.71 31.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 115.783 -0.644 . . . . 0.14 110.903 -178.66 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 72.7 p -113.63 -21.16 10.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.343 0.592 . . . . 0.2 110.406 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.464 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 84.4 tttt -142.63 145.2 33.25 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.775 -0.824 . . . . 2.36 108.775 173.455 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.446 HD11 HG21 ' A' ' 14' ' ' VAL . 6.0 tt -159.47 142.62 14.29 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 120.765 0.317 . . . . 0.2 110.945 -177.077 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -148.82 165.24 32.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.67 -0.695 . . . . 1.94 110.795 176.441 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 67.57 -149.67 50.87 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.991 -0.55 . . . . 0.27 113.183 175.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 29.8 t -108.9 133.64 52.64 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.042 -0.725 . . . . 1.16 109.042 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.474 HG23 ' HB2' ' A' ' 26' ' ' LEU . 5.2 m -142.8 153.3 17.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.786 0.803 . . . . 0.2 111.582 -176.467 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.26 157.99 43.3 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.683 -1.144 . . . . 0.17 108.67 177.567 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.572 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.1 p -131.94 134.95 59.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.354 -0.538 . . . . 0.16 110.316 174.265 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.479 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -104.65 99.9 9.56 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.376 -0.829 . . . . 0.51 109.56 178.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.489 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 22.5 p -62.96 178.46 0.47 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.552 -0.295 . . . . 1.25 111.279 -175.864 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 2.9 pt -57.03 -33.61 42.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 112.597 0.591 . . . . 0.59 112.597 -174.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.485 ' OD1' ' HG3' ' A' ' 22' ' ' GLN . 9.5 p30 -81.93 -12.07 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.894 -0.322 . . . . 1.96 110.762 179.298 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.42 7.58 36.98 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.768 -0.73 . . . . 0.32 113.755 176.424 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.485 ' HG3' ' OD1' ' A' ' 20' ' ' ASN . 54.7 mt-30 -70.88 120.87 17.1 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.107 0.453 . . . . 2.21 111.127 179.203 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.527 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.6 tt0 -91.59 113.11 25.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.976 0.417 . . . . 1.0 109.969 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.92 138.22 51.39 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.793 -0.639 . . . . 1.55 109.796 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.61 134.96 29.11 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 109.113 -0.699 . . . . 0.35 109.113 175.799 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.6 HD22 ' OD1' ' A' ' 30' ' ' ASP . 5.4 mt -99.45 150.41 22.21 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.62 0.724 . . . . 0.32 111.442 -177.508 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.544 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 41.1 mttp -135.52 173.12 12.07 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.424 -1.262 . . . . 1.65 109.152 -171.34 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.52 141.78 46.74 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 119.133 -1.027 . . . . 0.23 109.347 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.61 0.96 85.92 Favored Glycine 0 N--CA 1.435 -1.395 0 C-N-CA 120.13 -1.034 . . . . 0.24 111.824 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.6 ' OD1' HD22 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -78.36 142.45 62.88 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-O 121.553 0.692 . . . . 1.92 111.1 -179.187 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.04 133.74 11.26 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.771 2.981 . . . . 0.22 113.836 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mm -99.98 136.8 29.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.005 -0.998 . . . . 0.13 109.092 172.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -116.57 154.62 30.14 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 120.976 0.417 . . . . 0.29 109.945 -178.67 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.509 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.7 t80 -71.51 115.7 11.0 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.003 -0.544 . . . . 0.18 110.581 -175.462 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.13 7.61 22.89 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.461 -0.876 . . . . 0.17 113.345 177.204 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.572 ' HB3' HG22 ' A' ' 16' ' ' VAL . 28.4 mt-10 -94.77 147.75 23.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.763 0.781 . . . . 0.52 110.673 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.479 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 10.1 m -104.09 108.39 19.73 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.094 -0.957 . . . . 0.16 110.661 -176.126 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.2 t -83.56 121.88 36.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.315 0.579 . . . . 0.16 110.934 -175.094 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -107.46 104.77 14.42 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.796 -1.093 . . . . 0.27 109.679 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.3 p -99.93 156.47 17.12 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.651 -0.5 . . . . 0.23 109.651 177.24 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.994 0 C-N-CA 120.767 -0.73 . . . . 0.9 111.982 179.688 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m . . . . . 0 CA--C 1.512 -0.482 0 N-CA-C 109.334 -0.617 . . . . 0.85 109.334 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.1 t -126.63 132.46 70.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.93 -0.577 . . . . 0.25 111.206 -169.248 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.464 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.0 m -109.02 108.24 18.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.031 -0.531 . . . . 0.19 110.288 178.359 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.457 HD13 ' HE2' ' A' ' 66' ' ' MET . 79.1 mt -97.75 102.69 13.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-N 115.216 -0.902 . . . . 0.15 109.966 178.184 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.05 99.68 8.59 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.644 -0.707 . . . . 0.14 109.371 178.115 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.572 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 48.8 m-85 -61.77 144.9 54.02 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.518 0.675 . . . . 0.32 111.197 -178.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.13 -12.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.707 -1.133 . . . . 0.25 111.493 -170.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.428 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 28.6 t70 -74.55 -17.38 60.75 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.215 0.531 . . . . 0.75 110.529 176.755 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.78 -7.3 17.51 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.916 -0.659 . . . . 0.27 111.896 -177.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.0 p -88.63 177.47 6.75 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.396 -0.224 . . . . 0.36 110.396 176.597 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -151.58 157.38 42.13 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.259 -0.274 . . . . 1.51 110.259 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.513 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.53 150.78 17.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.35 -0.387 . . . . 1.39 110.427 -177.689 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 9.1 p -126.57 133.16 69.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.318 0.58 . . . . 0.81 110.668 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -102.53 147.6 8.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.739 -0.664 . . . . 0.32 110.196 -177.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.9 -178.44 43.48 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.733 -0.746 . . . . 1.02 111.413 175.086 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -101.57 148.57 17.95 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 121.043 -0.598 . . . . 0.4 111.656 -172.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t70 58.3 24.53 11.68 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 121.843 0.83 . . . . 1.26 110.179 -173.008 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.7 t -106.1 161.13 14.77 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.439 -0.8 . . . . 1.19 110.445 -179.46 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.507 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 79.1 mt -139.88 118.47 11.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.859 -0.61 . . . . 0.38 109.629 179.063 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.5 p -140.45 141.4 32.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.508 -0.315 . . . . 1.0 110.829 -175.558 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.416 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 41.8 tt0 -97.99 126.84 43.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.905 0.383 . . . . 0.67 110.332 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.457 ' HE2' HD13 ' A' ' 48' ' ' ILE . 50.5 mmm -67.06 89.54 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.66 -0.7 . . . . 0.88 110.658 -178.796 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.407 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 10.8 p -115.02 -165.98 1.07 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.819 -0.628 . . . . 0.29 111.547 -175.587 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.83 -36.77 75.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.814 0.34 . . . . 2.13 110.718 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -61.97 -32.83 73.31 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.626 0.726 . . . . 2.51 110.095 175.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.407 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.1 mm -75.41 -53.09 16.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-N 114.476 -1.238 . . . . 0.25 111.029 178.736 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.842 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 . . . . . 0 C--N 1.317 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.31 109.993 -176.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 . . . . . 0 CA--C 1.514 -0.442 0 CA-C-O 120.908 0.385 . . . . 2.0 110.517 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.06 113.17 18.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.547 0.689 . . . . 0.24 110.351 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.828 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.9 pt -97.54 -14.09 7.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-N 115.106 -0.952 . . . . 0.15 111.709 -172.75 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.9 176.39 42.52 Favored Glycine 0 CA--C 1.502 -0.767 0 N-CA-C 111.01 -0.836 . . . . 0.1 111.01 179.163 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -143.35 151.57 40.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.041 0.448 . . . . 0.2 111.041 -175.678 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 35.2 mm -78.19 121.87 31.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.94 -0.573 . . . . 0.14 110.689 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.8 p -115.45 -20.28 10.31 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 0.2 110.546 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.1 tttt -143.83 143.3 31.26 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.47 -0.937 . . . . 2.36 108.47 173.811 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.3 tt -160.27 140.28 11.39 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-O 121.074 0.464 . . . . 0.2 111.107 -178.026 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -149.08 149.75 31.6 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.164 -0.925 . . . . 1.94 110.479 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.46 -160.2 41.54 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.972 -0.632 . . . . 0.27 113.035 175.113 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.0 m -101.32 119.25 38.47 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 120.667 0.27 . . . . 1.16 110.312 -177.558 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -136.91 152.0 28.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.817 0.817 . . . . 0.2 111.753 -176.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 159.34 42.7 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 114.706 -1.134 . . . . 0.17 108.703 178.438 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.573 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -131.57 132.62 62.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 121.29 0.567 . . . . 0.16 110.424 174.938 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.519 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.9 mt-30 -98.91 99.23 10.27 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.445 -0.798 . . . . 0.51 109.734 178.592 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.561 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 13.9 m -60.94 172.85 0.88 Allowed 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 110.039 -0.356 . . . . 1.25 110.039 -179.223 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -60.99 -14.7 10.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 112.248 0.462 . . . . 0.59 112.248 -177.499 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -85.53 -9.32 57.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.178 0.514 . . . . 1.96 110.372 177.331 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 88.54 5.66 74.78 Favored Glycine 0 CA--C 1.508 -0.372 0 N-CA-C 110.877 -0.889 . . . . 0.32 110.877 -175.57 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.401 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 92.7 mt-30 -70.21 118.52 13.13 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.792 -0.704 . . . . 2.21 110.664 178.272 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 6.5 tt0 -90.41 111.28 22.47 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.228 0.537 . . . . 1.0 109.629 177.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.4 ' NH2' ' HD2' ' A' ' 31' ' ' PRO . 0.0 OUTLIER -115.35 142.14 47.09 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.232 -0.894 . . . . 1.55 109.706 -177.311 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -75.65 143.19 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.835 0.35 . . . . 0.35 110.144 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' HG23 ' A' ' 14' ' ' VAL . 24.9 mt -110.12 128.97 55.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.994 0.426 . . . . 0.32 110.933 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 77.5 mttt -117.77 -179.72 3.82 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 108.246 -1.02 . . . . 1.65 108.246 170.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.4 tp -65.39 148.58 51.47 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.573 -0.851 . . . . 0.23 110.3 178.586 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.55 -7.24 58.59 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.531 -0.842 . . . . 0.24 112.677 177.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.9 143.68 97.16 Favored Pre-proline 0 CA--C 1.512 -0.515 0 CA-C-O 121.187 0.518 . . . . 1.92 110.105 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.4 ' HD2' ' NH2' ' A' ' 24' ' ' ARG . 24.6 Cg_endo -90.15 131.4 1.79 Allowed 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 123.262 2.641 . . . . 0.22 111.827 178.641 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.523 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.3 mm -94.08 134.48 31.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 109.747 -0.464 . . . . 0.13 109.747 176.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.98 150.25 30.84 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.558 -0.746 . . . . 0.29 109.396 -179.75 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.556 ' HD2' HG21 ' A' ' 4' ' ' ILE . 3.0 t80 -67.3 116.8 8.48 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.18 110.364 -174.524 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.17 -10.42 20.28 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.789 -0.72 . . . . 0.17 113.234 176.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.573 ' HB3' HG22 ' A' ' 16' ' ' VAL . 28.7 mt-10 -76.02 140.4 41.94 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 117.877 0.839 . . . . 0.52 110.685 179.803 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -101.43 109.04 20.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.809 -1.087 . . . . 0.16 110.84 -175.433 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.6 t -82.11 132.04 32.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.189 0.518 . . . . 0.16 110.934 -174.203 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -117.84 109.49 16.62 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 114.975 -1.011 . . . . 0.27 110.017 -177.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -105.26 157.01 17.6 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.428 -0.509 . . . . 0.23 109.789 175.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.886 0 C-N-CA 120.81 -0.71 . . . . 0.9 111.872 178.973 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.53 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 7.3 m . . . . . 0 C--O 1.225 -0.231 0 N-CA-C 109.349 -0.611 . . . . 0.85 109.349 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.517 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 7.5 t -134.72 147.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.901 -0.32 . . . . 0.25 111.107 -173.444 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.569 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -117.98 110.63 17.93 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.157 -0.474 . . . . 0.19 110.01 173.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.554 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 64.4 mt -98.66 109.35 23.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.805 -0.634 . . . . 0.15 110.014 176.6 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.44 102.22 11.92 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.418 -0.81 . . . . 0.14 109.171 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.46 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.7 m-85 -70.1 144.43 52.11 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.372 0.606 . . . . 0.32 110.78 -178.738 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.75 1.9 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 114.651 -1.159 . . . . 0.25 111.725 -171.108 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -92.51 -11.97 33.18 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.98 -0.554 . . . . 0.75 109.962 175.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.79 -5.41 25.93 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.516 -0.849 . . . . 0.27 112.726 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.6 p -93.95 159.79 15.01 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.819 -0.224 . . . . 0.36 110.717 177.808 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.63 143.6 47.39 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.417 -0.586 . . . . 1.51 109.417 179.178 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.554 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.9 m -121.75 164.16 18.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.103 0.478 . . . . 1.39 111.441 177.335 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -131.86 129.44 60.9 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 115.241 -0.89 . . . . 0.81 109.875 177.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.53 ' O ' ' HA ' ' A' ' 45' ' ' SER . 17.1 mt -103.43 131.58 51.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 116.257 -0.428 . . . . 0.32 109.993 -178.438 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.23 -163.92 23.56 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 121.151 -0.547 . . . . 1.02 112.259 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.93 145.25 16.5 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.772 -0.728 . . . . 0.4 111.728 -173.066 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.5 t70 58.24 25.22 12.38 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 121.547 0.689 . . . . 1.26 110.217 -174.313 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.4 m -103.04 156.47 17.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.957 -0.565 . . . . 1.19 110.935 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.499 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 89.7 mt -140.6 117.31 8.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.618 -0.719 . . . . 0.38 109.588 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.8 p -147.66 143.96 19.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 110.108 -0.33 . . . . 1.0 110.108 -177.16 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.594 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -103.99 139.21 39.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.545 0.688 . . . . 0.67 111.079 -176.113 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.553 ' SD ' HG21 ' A' ' 70' ' ' ILE . 22.7 mmt -64.19 89.62 0.06 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.627 -1.17 . . . . 0.88 111.667 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.428 HG23 ' CG ' ' A' ' 65' ' ' GLU . 2.3 p -114.25 -172.15 2.05 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.622 -0.717 . . . . 0.29 110.125 177.959 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -71.98 -24.45 61.58 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.748 0.309 . . . . 2.13 110.657 -178.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -70.08 -23.54 63.08 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.472 0.653 . . . . 2.51 110.229 175.384 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.553 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.4 mm -88.17 -56.52 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.119 -0.946 . . . . 0.25 109.728 175.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.828 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 . . . . . 0 C--N 1.319 -0.757 0 CA-C-N 114.543 -1.208 . . . . 0.31 109.786 -178.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ASN . . . . . 0.435 ' N ' HD21 ' A' ' 2' ' ' ASN . 0.8 OUTLIER . . . . . 0 CA--C 1.511 -0.539 0 N-CA-C 110.165 -0.309 . . . . 2.0 110.165 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.11 108.09 8.78 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.798 -0.816 . . . . 0.24 108.798 174.372 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.749 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.3 pt -92.96 -10.42 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.22 -0.9 . . . . 0.15 111.419 -170.485 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.78 176.3 42.47 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.623 -0.799 . . . . 0.1 111.469 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -144.49 150.07 36.98 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.04 0.448 . . . . 0.2 110.446 -175.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.578 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.2 mm -78.04 123.68 35.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.775 -0.648 . . . . 0.14 110.972 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 p -116.19 -23.41 8.45 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.127 0.489 . . . . 0.2 110.856 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.575 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 25.8 tptp -139.99 136.18 33.49 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.959 -1.126 . . . . 2.36 107.959 173.562 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.492 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -152.85 138.11 17.47 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.016 0.436 . . . . 0.2 111.043 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.4 m-20 -147.95 157.24 43.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.158 -0.928 . . . . 1.94 110.861 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.03 -158.79 46.7 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.842 -0.617 . . . . 0.27 112.752 176.036 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.9 t -103.68 118.69 37.31 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.251 -0.648 . . . . 1.16 109.251 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.601 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.7 m -135.65 153.17 32.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.687 0.756 . . . . 0.2 111.681 -175.754 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.11 158.86 44.52 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.796 -1.093 . . . . 0.17 108.687 -178.129 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.681 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -136.61 134.5 49.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 119.917 -0.713 . . . . 0.16 111.375 173.636 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.419 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.1 mt-30 -97.56 100.32 11.73 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 114.924 -1.034 . . . . 0.51 108.98 174.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.505 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 58.1 p -63.01 179.06 0.41 Allowed 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.962 -0.295 . . . . 1.25 111.145 -175.139 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.8 pt -60.98 -21.17 23.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 0.59 110.937 176.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -80.1 -9.91 59.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 1.96 110.14 176.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.93 12.45 71.35 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 110.973 -0.851 . . . . 0.32 110.973 179.284 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -89.06 121.74 31.71 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.9 -0.65 . . . . 2.21 110.81 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.681 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 22.2 tt0 -89.65 118.13 29.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.903 -0.59 . . . . 1.0 110.46 178.75 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.61 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.1 ptt-85 -119.16 165.96 13.55 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.502 -0.555 . . . . 1.55 109.502 175.83 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.7 p -91.24 127.49 43.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.372 0.606 . . . . 0.35 109.432 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.601 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.1 mt -90.49 151.17 21.49 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.5 0.667 . . . . 0.32 111.351 -175.468 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.41 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 18.6 mttp -141.87 176.15 9.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.748 -1.114 . . . . 1.65 108.324 -171.257 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -74.29 141.63 45.27 Favored 'General case' 0 C--N 1.313 -1.014 0 C-N-CA 119.303 -0.959 . . . . 0.23 108.988 176.856 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.77 7.31 88.31 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 119.918 -1.134 . . . . 0.24 111.917 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -85.03 140.37 37.09 Favored Pre-proline 0 CA--C 1.52 -0.184 0 CA-C-O 121.612 0.72 . . . . 1.92 110.472 178.6 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -78.21 132.01 11.16 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.677 2.918 . . . . 0.22 113.426 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.413 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.4 mm -99.45 133.61 41.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 0.13 109.175 173.561 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -113.88 152.61 30.51 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.145 -0.479 . . . . 0.29 110.238 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.7 t80 -68.48 111.77 4.9 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.963 -0.562 . . . . 0.18 110.019 -177.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.67 6.25 19.62 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.34 -0.933 . . . . 0.17 113.348 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.545 ' O ' ' HG2' ' A' ' 66' ' ' MET . 39.9 mt-10 -91.05 135.12 33.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 117.869 0.834 . . . . 0.52 110.739 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.541 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 9.0 m -94.47 106.12 18.09 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.99 -1.005 . . . . 0.16 110.94 -176.532 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.544 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 4.3 t -82.47 129.58 37.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.137 0.494 . . . . 0.16 110.916 -175.209 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.6 mp -117.31 108.09 15.19 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.223 -0.899 . . . . 0.27 109.694 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.7 p -105.13 153.5 21.43 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.9 -0.408 . . . . 0.23 109.9 178.328 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.826 0 C-N-CA 121.115 -0.564 . . . . 0.9 111.886 178.872 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 50.7 m . . . . . 0 CA--C 1.518 -0.273 0 N-CA-C 109.596 -0.52 . . . . 0.85 109.596 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.0 t -143.36 129.77 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.677 0.275 . . . . 0.25 111.034 -175.124 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.575 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -99.26 105.77 17.82 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.533 -0.543 . . . . 0.19 109.533 172.267 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.556 HD13 ' HE2' ' A' ' 66' ' ' MET . 69.3 mt -95.89 107.43 19.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 CA-C-N 115.821 -0.627 . . . . 0.15 109.997 176.667 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.74 104.96 13.38 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.322 -0.853 . . . . 0.14 109.08 176.032 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.497 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 60.9 m-85 -69.96 152.7 44.15 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.601 0.715 . . . . 0.32 110.746 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.5 p -72.61 -11.6 15.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.654 -1.157 . . . . 0.25 111.496 -170.198 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -81.17 -21.77 39.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.102 0.477 . . . . 0.75 110.598 176.137 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.43 -7.12 14.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.615 -0.802 . . . . 0.27 112.182 -177.361 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.5 p -85.19 150.11 25.04 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 110.366 -0.235 . . . . 0.36 110.366 176.679 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -127.53 147.4 50.32 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.664 -0.414 . . . . 1.51 109.932 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.541 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.8 m -129.75 171.32 17.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.117 0.484 . . . . 1.39 111.596 178.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.523 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.8 p -137.61 134.88 46.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.169 -0.923 . . . . 0.81 110.168 177.517 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.604 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.7 mt -107.43 136.09 43.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.4 -0.364 . . . . 0.32 110.309 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.51 -169.88 43.05 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.083 -0.579 . . . . 1.02 112.37 178.831 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -110.34 152.8 17.28 Favored Glycine 0 CA--C 1.504 -0.642 0 N-CA-C 111.595 -0.602 . . . . 0.4 111.595 -173.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.3 t70 56.65 21.73 6.1 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.963 0.887 . . . . 1.26 109.775 -172.495 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.0 m -106.18 158.97 16.45 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.721 -0.672 . . . . 1.19 111.297 -176.594 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.544 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.6 mt -139.99 119.63 12.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.417 -0.811 . . . . 0.38 109.459 178.329 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.4 p -145.71 138.3 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 120.904 0.383 . . . . 1.0 110.654 -178.298 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.0 tt0 -92.01 130.55 37.73 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.222 -0.444 . . . . 0.67 109.963 179.332 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.556 ' HE2' HD13 ' A' ' 48' ' ' ILE . 60.8 mmm -66.67 89.56 0.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.948 -0.569 . . . . 0.88 110.591 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 17.0 p -115.46 -165.34 1.02 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.819 -0.628 . . . . 0.29 111.47 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -64.89 -39.31 93.33 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.182 -0.463 . . . . 2.13 111.061 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -64.35 -28.86 69.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.843 0.83 . . . . 2.51 110.075 178.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -77.48 -46.45 27.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.734 -1.121 . . . . 0.25 111.212 176.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.749 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 . . . . . 0 C--N 1.315 -0.892 0 CA-C-N 115.638 -0.71 . . . . 0.31 110.662 -174.323 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' ASN . . . . . 0.552 ' N ' HD21 ' A' ' 2' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--O 1.236 0.371 0 CA-C-O 121.031 0.444 . . . . 2.0 110.597 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.67 109.36 13.99 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.648 -0.705 . . . . 0.24 109.584 178.347 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.773 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 32.9 pt -92.97 -12.99 8.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 114.896 -1.047 . . . . 0.15 111.841 -170.59 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.38 176.34 44.02 Favored Glycine 0 CA--C 1.501 -0.814 0 C-N-CA 120.61 -0.805 . . . . 0.1 111.688 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.94 149.39 36.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.972 0.415 . . . . 0.2 110.961 -174.332 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.44 HD12 ' CG1' ' A' ' 46' ' ' VAL . 37.6 mm -76.43 124.08 33.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.829 -0.623 . . . . 0.14 111.782 -176.147 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.2 p -116.75 -20.68 9.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.034 0.445 . . . . 0.2 111.403 179.099 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.606 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 23.3 tptm -140.21 136.24 33.2 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.104 -1.073 . . . . 2.36 108.104 174.359 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.595 HD11 HG21 ' A' ' 14' ' ' VAL . 5.6 tt -155.71 139.66 16.32 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.395 -0.522 . . . . 0.2 111.552 -179.42 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -144.76 155.77 43.71 Favored 'General case' 0 CA--C 1.496 -1.119 0 CA-C-N 115.655 -0.702 . . . . 1.94 110.914 173.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.16 -162.56 38.72 Favored Glycine 0 N--CA 1.419 -2.462 0 CA-C-N 115.005 -0.998 . . . . 0.27 112.866 164.771 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.4 m -92.15 116.24 28.77 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 109.841 -0.429 . . . . 1.16 109.841 177.721 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.595 HG21 HD11 ' A' ' 10' ' ' LEU . 3.7 m -135.5 152.67 32.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.711 0.767 . . . . 0.2 111.397 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.98 158.3 44.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.701 -1.136 . . . . 0.17 108.79 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.691 HG12 ' HG2' ' A' ' 24' ' ' ARG . 1.0 OUTLIER -131.62 133.11 61.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 C-N-CA 119.971 -0.692 . . . . 0.16 111.244 173.933 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.493 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -97.7 99.1 10.44 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.004 -0.998 . . . . 0.51 109.503 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.477 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 20.0 m -64.52 176.54 1.08 Allowed 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 116.344 -0.389 . . . . 1.25 110.584 -178.352 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -59.66 -26.91 36.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 O-C-N 122.005 -0.434 . . . . 0.59 111.569 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.6 m-20 -71.82 -16.51 62.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.04 0.448 . . . . 1.96 110.678 176.523 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.52 4.87 65.55 Favored Glycine 0 N--CA 1.451 -0.318 0 N-CA-C 110.839 -0.905 . . . . 0.32 110.839 -175.81 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 92.5 mt-30 -73.53 129.19 37.45 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.827 -0.686 . . . . 2.21 110.619 179.171 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.666 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 6.8 tt0 -106.37 109.18 21.03 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.411 -0.359 . . . . 1.0 110.601 -176.739 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.691 ' HG2' HG12 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -109.57 165.74 11.43 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.669 -0.493 . . . . 1.55 109.669 176.769 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -89.92 139.45 17.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 115.862 -0.608 . . . . 0.35 109.425 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.505 ' HB2' HG23 ' A' ' 14' ' ' VAL . 22.6 mt -103.91 131.1 51.47 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.129 0.49 . . . . 0.32 110.799 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.3 mttp -118.46 -177.12 3.22 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 107.939 -1.134 . . . . 1.65 107.939 171.846 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 146.7 54.26 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 119.859 -0.736 . . . . 0.23 109.519 175.054 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.92 1.58 87.55 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 120.13 -1.033 . . . . 0.24 112.918 176.554 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.401 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.4 m-20 -78.78 144.75 65.04 Favored Pre-proline 0 CA--C 1.517 -0.317 0 CA-C-O 121.103 0.478 . . . . 1.92 110.608 176.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -79.5 142.95 16.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.967 2.445 . . . . 0.22 112.743 178.669 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.454 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.3 mm -108.44 135.97 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-N 115.614 -0.721 . . . . 0.13 109.092 171.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -115.96 152.45 33.46 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 116.218 -0.446 . . . . 0.29 110.066 -177.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.529 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.4 t80 -69.41 110.89 4.94 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.872 -0.604 . . . . 0.18 110.469 -176.397 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.58 4.06 15.76 Favored Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.478 -0.868 . . . . 0.17 113.351 178.463 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.49 ' O ' ' HG2' ' A' ' 66' ' ' MET . 35.7 mt-10 -93.22 144.97 24.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 117.819 0.809 . . . . 0.52 110.832 -179.158 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.5 m -105.01 109.16 21.05 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.383 -0.826 . . . . 0.16 110.921 -174.652 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -83.46 128.36 38.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.349 0.595 . . . . 0.16 111.028 -175.224 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.5 mp -114.29 106.5 14.4 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.759 -1.109 . . . . 0.27 109.716 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 58.4 p -105.07 154.08 20.63 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.881 0.372 . . . . 0.23 110.086 178.401 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.94 0 N-CA-C 111.517 -0.633 . . . . 0.9 111.517 178.202 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.4 t . . . . . 0 CA--C 1.501 -0.913 0 N-CA-C 109.08 -0.711 . . . . 0.85 109.08 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.4 t -145.35 136.75 20.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.841 -0.618 . . . . 0.25 111.001 -168.408 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.606 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 91.4 m -111.09 112.62 24.55 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.222 0.534 . . . . 0.19 109.876 175.427 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.466 HD13 ' HE2' ' A' ' 66' ' ' MET . 77.1 mt -99.78 103.52 14.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.205 -0.907 . . . . 0.15 110.098 178.658 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.59 101.53 7.47 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.259 -0.882 . . . . 0.14 109.44 177.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.529 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 51.9 m-85 -65.8 143.66 57.34 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.689 0.757 . . . . 0.32 110.988 -178.748 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -69.03 -12.36 15.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 114.285 -1.325 . . . . 0.25 111.427 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.485 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 23.3 t70 -74.48 -21.67 59.46 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.169 -0.469 . . . . 0.75 110.624 177.323 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.39 -17.22 8.46 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.815 -0.707 . . . . 0.27 112.137 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 6.1 p -85.86 164.78 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 122.084 0.154 . . . . 0.36 110.729 178.074 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -133.54 163.44 29.39 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.158 -0.312 . . . . 1.51 110.158 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.529 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -146.05 157.1 12.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.423 -0.353 . . . . 1.39 110.568 -177.409 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.539 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.9 p -133.14 133.91 58.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.166 0.508 . . . . 0.81 110.916 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 20.6 mt -104.04 137.7 31.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.871 -0.604 . . . . 0.32 109.952 -179.533 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.07 174.53 52.67 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.387 -0.911 . . . . 1.02 111.475 176.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.67 151.29 19.83 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 111.283 -0.727 . . . . 0.4 111.283 -173.438 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.37 26.14 12.13 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-O 121.858 0.837 . . . . 1.26 109.448 -173.425 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -111.55 162.58 14.98 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.425 -0.807 . . . . 1.19 110.944 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.2 mt -140.37 124.87 18.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.778 -0.646 . . . . 0.38 109.533 178.197 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.0 p -150.11 142.32 17.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.841 0.353 . . . . 1.0 110.843 -178.707 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.534 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.3 tt0 -94.79 136.08 35.52 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.892 0.377 . . . . 0.67 110.528 178.768 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.49 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 50.5 mmm -71.46 88.57 0.91 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.697 -0.683 . . . . 0.88 110.393 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -111.08 -163.67 0.86 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.057 -0.519 . . . . 0.29 111.249 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -77.1 -28.24 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.876 -0.147 . . . . 2.13 111.003 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -66.68 -29.47 69.48 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.95 0.881 . . . . 2.51 109.684 173.478 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.479 HG21 ' HE3' ' A' ' 66' ' ' MET . 1.5 mm -77.35 -55.35 10.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.268 -1.333 . . . . 0.25 110.345 176.352 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.773 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 . . . . . 0 C--N 1.318 -0.792 0 CA-C-N 115.271 -0.877 . . . . 0.31 109.742 -178.007 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 12.8 m120 . . . . . 0 CA--C 1.512 -0.496 0 N-CA-C 109.223 -0.658 . . . . 2.0 109.223 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.52 109.42 12.68 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.503 0.668 . . . . 0.24 109.906 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.786 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.5 pt -96.92 -13.2 8.17 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.83 -1.077 . . . . 0.15 111.577 -171.593 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.8 174.07 43.4 Favored Glycine 0 CA--C 1.501 -0.818 0 N-CA-C 111.171 -0.772 . . . . 0.1 111.171 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -142.98 148.69 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.96 0.41 . . . . 0.2 111.247 -174.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.479 HD13 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -77.01 121.67 29.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.704 -0.68 . . . . 0.14 111.157 -177.787 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 71.1 p -116.53 -21.51 9.15 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.067 0.461 . . . . 0.2 111.017 179.284 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.589 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.8 tptt -141.74 136.95 31.28 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.536 -0.913 . . . . 2.36 108.536 173.275 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.532 HD11 HG21 ' A' ' 14' ' ' VAL . 6.1 tt -152.97 142.83 22.12 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.883 0.373 . . . . 0.2 111.156 -178.007 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -143.97 141.85 30.4 Favored 'General case' 0 CA--C 1.499 -0.998 0 CA-C-N 115.777 -0.647 . . . . 1.94 111.767 177.315 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.21 -148.88 19.56 Favored Glycine 0 N--CA 1.422 -2.28 0 CA-C-N 114.695 -1.139 . . . . 0.27 113.159 164.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.2 t -104.49 113.04 26.35 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.527 -0.546 . . . . 1.16 109.527 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.537 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.3 m -133.18 152.89 36.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.562 0.696 . . . . 0.2 111.411 -177.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.18 159.43 43.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.959 -1.019 . . . . 0.17 108.477 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.544 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.1 p -131.92 129.35 60.65 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 C-N-CA 119.957 -0.697 . . . . 0.16 110.691 175.225 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.461 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 1.9 mt-30 -93.36 98.71 11.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.44 -0.8 . . . . 0.51 108.972 177.14 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.51 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.1 m -65.23 179.13 0.77 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.962 -0.563 . . . . 1.25 110.495 -176.814 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 15.1 pt -69.21 -4.88 4.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.913 0.709 . . . . 0.59 112.913 -172.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 57.0 m-80 -95.78 -5.35 42.13 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.176 0.513 . . . . 1.96 109.944 173.004 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.32 8.56 74.47 Favored Glycine 0 CA--C 1.507 -0.456 0 N-CA-C 110.709 -0.956 . . . . 0.32 110.709 -177.191 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -78.65 120.89 23.97 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.958 -0.621 . . . . 2.21 110.589 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.455 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.5 tt0 -89.25 109.9 20.73 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.323 0.582 . . . . 1.0 110.224 -179.016 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.83 144.74 39.37 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.206 -0.907 . . . . 1.55 109.711 -176.778 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -73.28 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.783 0.325 . . . . 0.35 110.268 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HB2' HG23 ' A' ' 14' ' ' VAL . 16.4 mt -110.83 124.07 51.32 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.047 0.451 . . . . 0.32 110.552 177.161 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -115.67 178.73 4.2 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.511 -0.922 . . . . 1.65 108.511 173.126 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -65.61 147.74 52.9 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 119.766 -0.774 . . . . 0.23 109.909 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.52 -8.73 63.99 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.237 -0.982 . . . . 0.24 112.57 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.403 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 0.4 OUTLIER -65.08 144.59 99.09 Favored Pre-proline 0 CA--C 1.515 -0.377 0 CA-C-O 121.425 0.631 . . . . 1.92 111.021 179.559 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 38.1 Cg_endo -83.17 133.55 6.53 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 123.467 2.778 . . . . 0.22 112.393 175.699 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.41 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 29.0 mm -98.54 132.66 43.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 109.136 -0.69 . . . . 0.13 109.136 174.276 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -114.41 149.01 36.85 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 116.007 -0.542 . . . . 0.29 110.163 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.598 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -67.71 109.01 3.14 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.801 -0.636 . . . . 0.18 110.375 -174.764 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 121.49 -1.29 11.31 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.271 -0.966 . . . . 0.17 113.589 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.544 ' HB3' HG22 ' A' ' 16' ' ' VAL . 34.7 mt-10 -88.67 146.93 24.79 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 117.929 0.865 . . . . 0.52 110.367 -179.188 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.1 m -105.76 107.98 19.25 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.72 -0.673 . . . . 0.16 111.171 -175.544 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.1 t -81.4 133.62 28.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.154 0.502 . . . . 0.16 110.913 -175.713 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.9 mp -119.06 109.63 16.14 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.044 -0.98 . . . . 0.27 109.789 -178.691 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.9 p -105.01 155.7 18.72 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.541 -0.54 . . . . 0.23 109.541 176.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.899 0 C-N-CA 120.724 -0.75 . . . . 0.9 111.97 178.443 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 31.1 m . . . . . 0 CA--C 1.516 -0.362 0 N-CA-C 109.838 -0.43 . . . . 0.85 109.838 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.6 t -139.61 131.28 33.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 CA-C-N 116.559 -0.291 . . . . 0.25 111.433 -170.861 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.589 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 80.2 m -102.64 107.95 19.05 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.079 -0.51 . . . . 0.19 109.842 175.018 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.577 HD13 ' HE2' ' A' ' 66' ' ' MET . 68.5 mt -96.52 109.64 23.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 CA-C-N 115.717 -0.674 . . . . 0.15 110.22 176.371 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.21 100.81 12.01 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.289 -0.869 . . . . 0.14 109.788 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.459 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 67.3 m-85 -68.09 148.36 51.06 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.71 0.767 . . . . 0.32 111.082 -177.798 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.8 p -73.45 -8.71 12.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-N 114.276 -1.329 . . . . 0.25 111.128 -171.053 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.449 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 32.1 t70 -80.15 -20.63 44.47 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.014 -0.539 . . . . 0.75 110.395 176.448 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.92 -10.58 11.1 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.749 -0.738 . . . . 0.27 112.173 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.7 p -85.23 157.29 20.65 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.65 -0.13 . . . . 0.36 110.65 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -133.81 140.99 47.26 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.507 -0.553 . . . . 1.51 109.507 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.548 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.6 m -121.47 172.65 8.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.192 0.52 . . . . 1.39 111.584 178.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.483 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -140.01 133.15 35.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.254 -0.884 . . . . 0.81 110.124 177.725 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.482 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.7 mt -103.54 133.25 47.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.003 -0.544 . . . . 0.32 109.951 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.51 178.97 53.71 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.661 -0.78 . . . . 1.02 111.367 175.535 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.52 155.08 20.84 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.718 -0.553 . . . . 0.4 111.718 -171.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 37.9 t70 59.1 17.13 5.29 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.929 0.871 . . . . 1.26 109.702 -176.568 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -102.58 156.42 17.63 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.524 -0.762 . . . . 1.19 111.343 -176.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.497 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 90.9 mt -140.69 120.73 12.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.292 -0.867 . . . . 0.38 109.57 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.4 p -150.2 143.74 17.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.644 0.259 . . . . 1.0 110.872 -177.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.55 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 36.2 tt0 -90.72 136.11 33.28 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.982 0.42 . . . . 0.67 110.42 177.782 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.577 ' HE2' HD13 ' A' ' 48' ' ' ILE . 61.3 mmm -69.13 89.05 0.43 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.332 -0.849 . . . . 0.88 110.283 179.054 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.1 p -112.73 -164.21 0.9 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.86 -0.609 . . . . 0.29 110.669 -177.664 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -75.4 -25.17 57.38 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.787 0.327 . . . . 2.13 110.874 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -66.2 -29.81 70.15 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 122.07 0.938 . . . . 2.51 109.612 172.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.478 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.2 mm -82.46 -51.94 14.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 114.254 -1.339 . . . . 0.25 110.489 177.696 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.786 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.317 -0.833 0 CA-C-N 115.459 -0.791 . . . . 0.31 110.147 -176.773 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' ASN . . . . . 0.508 ' N ' HD21 ' A' ' 2' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--O 1.238 0.486 0 CA-C-O 121.293 0.568 . . . . 2.0 110.767 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.23 110.05 17.74 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.061 -0.972 . . . . 0.24 109.931 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.779 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.9 pt -87.55 -14.87 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.125 -0.943 . . . . 0.15 111.688 -171.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.82 175.84 40.71 Favored Glycine 0 CA--C 1.502 -0.728 0 C-N-CA 120.671 -0.776 . . . . 0.1 111.817 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -144.15 149.55 36.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.038 0.446 . . . . 0.2 110.61 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.522 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.6 mm -76.61 126.11 36.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 115.731 -0.668 . . . . 0.14 110.787 -178.537 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.6 p -117.13 -16.92 10.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.307 0.575 . . . . 0.2 110.773 177.342 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.477 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.4 tttt -145.3 143.83 30.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.607 -0.886 . . . . 2.36 108.607 174.478 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.529 HD11 HG21 ' A' ' 14' ' ' VAL . 4.8 tt -160.47 139.1 10.26 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.778 0.323 . . . . 0.2 110.987 -175.558 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -144.07 145.32 32.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.956 -0.566 . . . . 1.94 111.49 177.487 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.18 -146.25 27.64 Favored Glycine 0 N--CA 1.436 -1.348 0 CA-C-N 115.026 -0.988 . . . . 0.27 114.063 167.037 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.9 m -102.03 115.66 31.03 Favored 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 122.832 0.453 . . . . 1.16 110.445 -175.808 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.529 HG21 HD11 ' A' ' 10' ' ' LEU . 3.8 m -135.14 153.59 34.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.594 0.711 . . . . 0.2 111.598 -175.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.12 158.32 44.03 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.781 -1.099 . . . . 0.17 108.954 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.67 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -134.31 139.06 48.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 C-N-CA 120.015 -0.674 . . . . 0.16 110.727 171.901 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -107.11 100.03 9.53 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.149 -0.932 . . . . 0.51 109.71 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.453 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 43.0 t -62.73 179.93 0.31 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.594 -0.275 . . . . 1.25 110.753 -178.253 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.4 pt -61.16 -30.64 48.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.143 0.497 . . . . 0.59 111.567 -176.683 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 16.4 p30 -80.64 -6.71 58.74 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.907 -0.588 . . . . 1.96 111.0 177.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 94.37 1.28 64.52 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.121 -0.561 . . . . 0.32 112.413 176.033 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -67.08 121.24 15.16 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.817 0.341 . . . . 2.21 111.424 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.618 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 14.6 tt0 -93.77 118.18 31.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.641 177.069 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.67 ' HG2' HG12 ' A' ' 16' ' ' VAL . 21.8 ptt-85 -120.24 168.01 11.69 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.167 -0.679 . . . . 1.55 109.167 174.518 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.7 p -93.98 136.81 24.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.996 -0.742 . . . . 0.35 108.996 177.435 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.599 HD22 ' OD1' ' A' ' 30' ' ' ASP . 5.2 mt -97.13 153.58 17.88 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.014 -0.539 . . . . 0.32 111.316 -176.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.3 mttm -138.44 -178.12 5.15 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.149 -0.932 . . . . 1.65 108.585 -173.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.78 140.85 39.48 Favored 'General case' 0 C--N 1.314 -0.954 0 C-N-CA 119.494 -0.882 . . . . 0.23 108.971 174.26 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.81 1.09 77.07 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 120.041 -1.076 . . . . 0.24 111.887 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.599 ' OD1' HD22 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -73.83 137.14 76.65 Favored Pre-proline 0 CA--C 1.517 -0.312 0 CA-C-O 121.79 0.805 . . . . 1.92 110.614 179.095 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -77.23 130.23 10.94 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.62 2.88 . . . . 0.22 113.405 -177.578 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.403 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.5 mm -99.53 135.93 32.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.075 -0.966 . . . . 0.13 109.313 174.217 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -116.15 154.71 29.54 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 116.004 -0.544 . . . . 0.29 109.731 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.56 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -71.21 109.57 5.33 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.361 -0.382 . . . . 0.18 110.657 -174.555 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.14 10.28 9.04 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.443 -0.884 . . . . 0.17 113.422 178.072 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.481 ' O ' ' HG2' ' A' ' 66' ' ' MET . 40.6 mt-10 -96.01 145.08 25.74 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 117.868 0.834 . . . . 0.52 110.687 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 31.7 m -105.27 108.2 19.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.412 -0.813 . . . . 0.16 110.806 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -82.71 133.72 28.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.128 0.489 . . . . 0.16 110.756 -175.567 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -122.2 110.15 15.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.175 -0.921 . . . . 0.27 110.051 -177.162 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.9 p -107.48 158.06 17.5 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.425 -0.583 . . . . 0.23 109.425 176.272 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 C-N-CA 120.378 -0.915 . . . . 0.9 113.346 -177.497 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.515 -0.368 0 CA-C-O 121.059 0.457 . . . . 0.85 109.937 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.0 t -126.09 142.35 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 CA-C-O 120.793 0.33 . . . . 0.25 111.093 -170.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.1 m -119.34 110.59 17.15 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.297 0.57 . . . . 0.19 110.341 177.408 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.442 HD13 ' HE2' ' A' ' 66' ' ' MET . 70.2 mt -98.88 102.5 13.49 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-N 115.163 -0.926 . . . . 0.15 109.925 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.76 102.62 11.68 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.476 -0.784 . . . . 0.14 109.259 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.549 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 58.6 m-85 -64.85 149.28 49.76 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.437 0.637 . . . . 0.32 110.881 -177.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.28 -9.03 12.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 114.784 -1.098 . . . . 0.25 111.134 -172.878 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.423 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 19.5 t70 -78.39 -22.27 48.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.71 -0.677 . . . . 0.75 111.0 177.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.21 -11.85 16.94 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.27 111.65 -174.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -85.1 161.08 19.82 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.127 -0.323 . . . . 0.36 110.127 175.571 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -131.78 155.53 47.58 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.24 -0.281 . . . . 1.51 110.24 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.49 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.8 OUTLIER -137.5 151.27 26.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.433 -0.349 . . . . 1.39 110.151 178.401 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.43 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.1 p -129.39 141.53 46.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.333 -0.394 . . . . 0.81 110.139 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 mt -116.2 131.38 68.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.224 -0.444 . . . . 0.32 110.209 -177.788 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.46 179.7 52.83 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.925 -0.655 . . . . 1.02 111.635 176.201 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.78 148.73 19.09 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 111.285 -0.726 . . . . 0.4 111.285 -173.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.8 t70 59.22 23.42 11.76 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 121.914 0.864 . . . . 1.26 109.605 -173.024 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -104.47 159.99 15.29 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.728 -0.669 . . . . 1.19 110.712 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.483 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 92.2 mt -140.07 125.83 21.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.123 -0.944 . . . . 0.38 108.809 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.407 HG21 HD11 ' A' ' 70' ' ' ILE . 13.8 p -147.67 141.74 19.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-O 120.886 0.374 . . . . 1.0 110.866 -177.226 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.414 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.3 tt0 -100.86 124.93 47.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.151 -0.477 . . . . 0.67 110.25 -179.089 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 44.3 mmm -65.46 90.29 0.11 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.72 -0.673 . . . . 0.88 110.725 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.408 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.3 p -118.48 -165.48 1.12 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 0.29 111.7 -176.532 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -65.9 -44.22 85.88 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.857 0.317 . . . . 2.13 111.857 -174.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -62.94 -29.99 71.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.456 0.646 . . . . 2.51 110.49 178.111 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.432 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.1 mm -71.99 -53.11 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.903 -1.044 . . . . 0.25 110.769 176.484 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.779 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 . . . . . 0 C--N 1.318 -0.778 0 CA-C-N 115.61 -0.723 . . . . 0.31 110.318 -176.495 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 7.8 p30 . . . . . 0 N--CA 1.447 -0.604 0 CA-C-O 121.017 0.437 . . . . 2.0 110.35 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.08 117.94 20.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.488 -0.778 . . . . 0.24 110.228 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.823 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 26.6 pt -96.96 -13.47 8.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.454 -0.794 . . . . 0.15 111.487 -172.638 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.6 179.21 42.21 Favored Glycine 0 CA--C 1.502 -0.752 0 C-N-CA 120.947 -0.644 . . . . 0.1 111.635 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.402 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 98.0 m-85 -145.18 152.24 39.69 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.819 0.342 . . . . 0.2 110.604 -175.59 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 30' ' ' ASP . 29.6 mm -81.55 120.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.032 -0.531 . . . . 0.14 111.11 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 43.8 p -111.94 -27.25 8.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.276 0.56 . . . . 0.2 110.307 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.491 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 85.8 tttt -136.43 147.37 47.21 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.464 -0.939 . . . . 2.36 108.464 172.488 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.484 HD11 HG21 ' A' ' 14' ' ' VAL . 4.9 tt -158.74 141.06 14.07 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.852 0.358 . . . . 0.2 110.8 -176.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.51 144.36 30.51 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 115.643 -0.708 . . . . 1.94 112.128 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.81 -148.4 27.35 Favored Glycine 0 N--CA 1.425 -2.038 0 CA-C-N 114.561 -1.2 . . . . 0.27 113.479 165.562 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 5.7 t -103.05 109.91 21.65 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.715 -0.476 . . . . 1.16 109.715 -179.142 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.579 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.6 m -132.21 153.02 37.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.379 0.609 . . . . 0.2 111.569 -175.751 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.13 159.71 44.22 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.219 -0.901 . . . . 0.17 109.413 -179.56 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.532 HG22 ' HB3' ' A' ' 36' ' ' GLU . 0.5 OUTLIER -132.6 131.09 59.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.239 0.543 . . . . 0.16 110.213 176.017 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 mt-30 -103.35 99.6 9.45 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.708 -0.678 . . . . 0.51 109.835 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.54 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.6 m -61.64 174.07 0.86 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.535 -0.302 . . . . 1.25 111.072 -176.28 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.7 pt -54.92 -32.51 26.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.301 0.482 . . . . 0.59 112.301 -176.777 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -75.71 -12.11 60.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.384 -0.371 . . . . 1.96 111.421 178.787 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.12 6.08 59.17 Favored Glycine 0 CA--C 1.51 -0.261 0 N-CA-C 111.864 -0.494 . . . . 0.32 111.864 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.0 mm-40 -74.35 124.96 27.47 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.639 0.257 . . . . 2.21 110.491 178.589 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 23.7 tt0 -91.69 110.13 21.46 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.425 0.631 . . . . 1.0 110.801 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.08 139.05 40.33 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.295 -0.866 . . . . 1.55 109.872 177.466 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.22 138.03 21.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.444 -0.576 . . . . 0.35 109.444 176.381 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.579 ' HB2' HG23 ' A' ' 14' ' ' VAL . 28.8 mt -102.96 127.54 50.15 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.304 0.574 . . . . 0.32 111.102 -178.117 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 74.0 mttt -116.55 179.43 4.01 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.514 -1.291 . . . . 1.65 107.514 170.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -67.58 146.74 53.59 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 119.306 -0.958 . . . . 0.23 109.95 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.52 0.04 86.35 Favored Glycine 0 N--CA 1.438 -1.178 0 C-N-CA 120.313 -0.946 . . . . 0.24 112.721 177.667 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.49 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.8 OUTLIER -71.84 143.13 86.44 Favored Pre-proline 0 CA--C 1.513 -0.461 0 C-N-CA 120.36 -0.536 . . . . 1.92 109.775 173.946 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.402 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 21.4 Cg_endo -89.78 137.47 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.143 2.562 . . . . 0.22 112.1 178.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.467 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.5 mm -98.52 139.65 20.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 116.132 -0.485 . . . . 0.13 109.914 176.629 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -117.13 155.38 29.43 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.893 -0.594 . . . . 0.29 109.498 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.51 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.5 t80 -71.64 118.6 14.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.39 -0.368 . . . . 0.18 110.541 -175.424 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.68 -0.36 24.63 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.502 -0.856 . . . . 0.17 113.324 177.274 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.54 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 23.4 mt-10 -85.42 147.94 26.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 117.8 0.8 . . . . 0.52 110.909 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.8 m -107.71 108.27 19.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.812 -1.086 . . . . 0.16 110.388 -176.478 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.619 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.2 t -82.08 136.97 21.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 C-N-CA 120.703 -0.399 . . . . 0.16 110.759 -174.328 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -125.66 107.03 10.17 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.437 -0.801 . . . . 0.27 110.562 -175.742 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.467 HG22 HG12 ' A' ' 14' ' ' VAL . 81.5 p -105.74 163.3 12.81 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 108.981 -0.748 . . . . 0.23 108.981 173.27 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.316 -0.562 0 C-N-CA 120.384 -0.912 . . . . 0.9 112.538 -179.664 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.554 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 46.6 t . . . . . 0 CA--C 1.508 -0.666 0 N-CA-C 109.09 -0.707 . . . . 0.85 109.09 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 17.8 t -152.21 136.2 8.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 110.121 -0.325 . . . . 0.25 110.121 -176.256 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.491 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.9 m -109.79 105.36 14.55 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.145 0.497 . . . . 0.19 109.768 173.194 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 78.4 mt -96.34 99.88 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 115.43 -0.805 . . . . 0.15 109.739 177.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.91 102.38 8.22 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.215 -0.902 . . . . 0.14 109.079 176.639 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.613 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 53.1 m-85 -66.28 151.35 47.23 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.617 0.722 . . . . 0.32 111.081 -176.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -75.24 1.63 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 114.588 -1.187 . . . . 0.25 111.273 -172.74 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -94.16 -20.79 19.55 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.106 0.479 . . . . 0.75 110.5 178.15 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 123.36 -19.77 7.57 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.637 -0.792 . . . . 0.27 111.892 -176.158 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -78.27 160.2 28.03 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 122.15 0.18 . . . . 0.36 110.766 177.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -133.3 146.03 50.99 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.427 -0.582 . . . . 1.51 109.427 178.528 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.613 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -130.85 147.27 33.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.008 0.432 . . . . 1.39 110.834 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.3 p -120.7 138.94 49.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.841 -0.618 . . . . 0.81 110.123 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.554 ' O ' ' HA ' ' A' ' 45' ' ' SER . 34.6 mt -110.64 134.45 52.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.078 -0.51 . . . . 0.32 110.096 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.76 -168.96 43.56 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.803 -0.713 . . . . 1.02 112.262 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -100.56 143.39 16.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.95 -0.643 . . . . 0.4 111.562 -176.149 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.2 t70 60.44 21.53 11.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 121.612 0.72 . . . . 1.26 110.052 -174.051 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.2 t -97.54 154.27 17.63 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.725 -0.67 . . . . 1.19 110.176 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.619 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.6 mt -141.78 106.21 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.486 -0.779 . . . . 0.38 108.937 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -133.56 149.18 30.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.122 0.487 . . . . 1.0 111.414 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.406 ' O ' HG13 ' A' ' 70' ' ' ILE . 43.3 tt0 -105.94 128.96 54.14 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.611 -0.722 . . . . 0.67 110.543 -175.637 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.546 ' SD ' HG21 ' A' ' 70' ' ' ILE . 22.2 mmt -64.3 89.88 0.06 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.607 -0.724 . . . . 0.88 111.333 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 72.7 p -124.89 -165.14 1.35 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.85 -0.613 . . . . 0.29 110.988 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -68.33 -26.04 65.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.31 0.576 . . . . 2.13 110.226 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -74.19 -20.28 60.25 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.362 -0.836 . . . . 2.51 110.361 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.546 HG21 ' SD ' ' A' ' 66' ' ' MET . 2.2 mm -98.49 -55.1 6.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-N 114.785 -1.098 . . . . 0.25 110.948 -179.59 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.823 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.044 -0.98 . . . . 0.31 109.921 -175.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' ASN . . . . . 0.549 ' N ' HD21 ' A' ' 2' ' ' ASN . 0.0 OUTLIER . . . . . 0 CA--C 1.516 -0.36 0 CA-C-O 120.861 0.363 . . . . 2.0 110.201 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.04 109.2 14.27 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.854 -0.612 . . . . 0.24 109.78 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.694 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.4 pt -95.35 -11.85 8.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 115.058 -0.974 . . . . 0.15 111.565 -171.481 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.91 175.58 43.32 Favored Glycine 0 CA--C 1.498 -1.027 0 N-CA-C 111.241 -0.743 . . . . 0.1 111.241 178.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -144.1 151.18 39.26 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.952 0.406 . . . . 0.2 110.581 -174.363 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.564 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.7 mm -78.3 124.43 36.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.96 -0.563 . . . . 0.14 111.389 -177.218 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.0 p -115.1 -21.3 10.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.182 0.515 . . . . 0.2 110.627 177.573 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.549 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 81.8 tttt -140.9 143.58 34.72 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.54 -0.911 . . . . 2.36 108.54 172.375 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.632 HD11 HG21 ' A' ' 14' ' ' VAL . 7.6 tt -161.21 140.84 10.53 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.682 0.277 . . . . 0.2 110.82 -177.264 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -156.0 158.5 37.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.49 -0.777 . . . . 1.94 111.159 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.81 -163.66 52.64 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.811 -0.631 . . . . 0.27 112.974 175.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.0 m -92.83 116.62 29.2 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 109.762 -0.459 . . . . 1.16 109.762 -177.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.632 HG21 HD11 ' A' ' 10' ' ' LEU . 3.9 m -134.48 152.5 33.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.672 0.748 . . . . 0.2 111.988 -175.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.04 159.05 44.78 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 114.567 -1.197 . . . . 0.17 108.853 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.664 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -133.95 135.76 54.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.109 -0.637 . . . . 0.16 110.922 172.957 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.413 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.3 mt-30 -102.46 100.75 10.9 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.364 -0.835 . . . . 0.51 109.911 177.412 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.527 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 37.7 m -62.86 176.64 0.66 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.5 -0.318 . . . . 1.25 110.861 -178.367 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -66.68 -5.55 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 N-CA-C 112.142 0.423 . . . . 0.59 112.142 -178.115 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -92.25 -8.48 45.21 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.294 0.569 . . . . 1.96 109.682 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.5 6.46 80.63 Favored Glycine 0 CA--C 1.507 -0.465 0 CA-C-N 115.278 -0.874 . . . . 0.32 111.093 -177.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.411 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 46.6 mm-40 -79.65 127.85 32.68 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.225 -0.488 . . . . 2.21 110.953 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLU . . . . . 0.655 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 25.4 tt0 -101.64 117.87 35.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.702 -0.681 . . . . 1.0 110.762 -178.149 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.664 ' HG2' HG12 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -116.62 168.78 9.88 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.619 -0.512 . . . . 1.55 109.619 176.156 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -87.77 140.84 15.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.329 -0.619 . . . . 0.35 109.329 176.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.545 HD22 ' CG ' ' A' ' 30' ' ' ASP . 4.8 mt -101.44 152.3 20.91 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.478 -0.489 . . . . 0.32 111.129 179.15 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.46 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 53.4 mttt -141.61 178.53 7.4 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.139 -0.937 . . . . 1.65 108.638 -174.401 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.14 139.3 44.43 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.353 -0.939 . . . . 0.23 109.108 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 2.42 86.82 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 120.051 -1.071 . . . . 0.24 111.968 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.564 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -74.89 141.59 75.39 Favored Pre-proline 0 N--CA 1.454 -0.237 0 CA-C-O 121.55 0.69 . . . . 1.92 109.981 177.574 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 28.2 Cg_endo -86.88 127.28 2.6 Favored 'Trans proline' 0 C--N 1.325 -0.709 0 C-N-CA 123.628 2.885 . . . . 0.22 113.353 -174.461 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 32.2 mm -93.11 134.28 31.48 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-N 116.183 -0.462 . . . . 0.13 109.815 176.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -111.89 151.29 29.32 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.697 -0.683 . . . . 0.29 109.747 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -69.42 113.9 7.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.318 -0.401 . . . . 0.18 110.796 -175.527 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.13 0.55 22.44 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.527 -0.844 . . . . 0.17 113.408 177.2 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLU . . . . . 0.546 ' O ' ' HG2' ' A' ' 66' ' ' MET . 30.8 mt-10 -86.87 144.7 26.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 117.976 0.888 . . . . 0.52 110.81 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.6 m -101.33 107.64 19.05 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.211 -0.904 . . . . 0.16 110.887 -177.11 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.575 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.6 t -82.24 130.51 35.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.137 0.494 . . . . 0.16 110.412 -176.253 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.1 mp -119.11 103.4 9.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.075 -0.966 . . . . 0.27 109.958 -177.357 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 20.3 p -100.67 159.33 15.26 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.253 -0.647 . . . . 0.23 109.253 175.734 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.991 0 C-N-CA 120.66 -0.781 . . . . 0.9 112.133 178.223 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.57 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 18.9 m . . . . . 0 C--O 1.224 -0.268 0 N-CA-C 109.002 -0.74 . . . . 0.85 109.002 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 11.0 t -140.18 146.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 O-C-N 122.171 -0.33 . . . . 0.25 110.761 -176.085 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.5 m -119.43 111.21 17.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.115 -0.493 . . . . 0.19 109.731 174.106 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.585 HD13 ' HE2' ' A' ' 66' ' ' MET . 62.4 mt -101.0 104.16 15.85 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 CA-C-N 115.705 -0.679 . . . . 0.15 110.271 179.798 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 104.4 9.09 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.406 -0.816 . . . . 0.14 108.995 176.42 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.469 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 53.4 m-85 -69.55 148.72 49.06 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.269 0.557 . . . . 0.32 110.681 -177.592 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -70.69 -5.55 5.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 114.878 -1.055 . . . . 0.25 111.04 -171.778 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.423 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 30.4 t70 -81.57 -21.37 38.49 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.37 0.605 . . . . 0.75 110.42 174.738 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 117.13 -7.01 16.9 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.781 -0.723 . . . . 0.27 112.275 -177.444 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 23.3 p -86.55 175.18 8.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.436 -0.209 . . . . 0.36 110.436 177.618 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -149.53 150.49 32.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.706 0.289 . . . . 1.51 110.338 177.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.546 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.8 m -130.88 166.86 27.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.972 -0.558 . . . . 1.39 111.006 179.136 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' VAL . . . . . 0.541 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.0 p -135.19 132.21 52.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 115.763 -0.653 . . . . 0.81 110.819 179.241 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.57 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.3 mt -106.24 132.97 52.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.607 -0.724 . . . . 0.32 109.838 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.14 -160.38 26.9 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.977 -0.63 . . . . 1.02 112.598 -178.407 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -104.07 141.7 15.32 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.595 -0.602 . . . . 0.4 111.595 -176.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.408 ' HA ' ' O ' ' A' ' 40' ' ' THR . 32.9 t70 58.16 26.15 13.4 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 122.174 0.988 . . . . 1.26 109.313 -171.084 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -91.05 131.67 36.49 Favored 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.465 -1.243 . . . . 1.19 110.967 -178.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ILE . . . . . 0.575 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.0 mt -129.08 106.12 13.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.092 -0.707 . . . . 0.38 109.092 178.003 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.28 144.47 31.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.096 -0.502 . . . . 1.0 110.555 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.6 tt0 -97.46 131.04 44.47 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.426 -0.352 . . . . 0.67 110.303 -179.571 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.585 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.5 mmm -68.45 89.46 0.35 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.748 -0.66 . . . . 0.88 110.717 -178.307 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.416 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 44.9 p -112.13 -164.62 0.93 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.098 -0.501 . . . . 0.29 111.456 -176.689 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -72.35 -25.52 61.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.941 0.4 . . . . 2.13 110.852 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -71.05 -31.24 67.64 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 122.102 0.954 . . . . 2.51 109.236 176.124 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.416 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.2 mm -78.77 -47.03 23.86 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 CA-C-N 113.844 -1.525 . . . . 0.25 110.832 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.694 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.318 -0.797 0 CA-C-N 115.281 -0.872 . . . . 0.31 110.061 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.693 0 N-CA-C 111.738 -0.545 . . . . 1.71 111.738 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 -100.93 144.98 29.22 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.805 -0.443 . . . . 2.0 109.805 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.78 114.55 15.67 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.334 0.588 . . . . 0.24 110.342 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.79 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 23.1 pt -93.98 -14.39 8.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 115.197 -0.91 . . . . 0.15 111.431 -172.205 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.47 42.79 Favored Glycine 0 CA--C 1.504 -0.64 0 C-N-CA 120.739 -0.743 . . . . 0.1 111.84 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -143.54 151.09 39.82 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.989 0.423 . . . . 0.2 110.822 -174.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.519 ' HB ' ' H ' ' A' ' 29' ' ' GLY . 23.8 mm -78.75 124.43 37.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.875 -0.602 . . . . 0.14 111.528 -177.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.8 p -113.39 -26.17 8.47 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.323 0.582 . . . . 0.2 110.771 177.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.565 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.9 tptt -137.89 139.62 39.94 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.786 -0.82 . . . . 2.36 108.786 174.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.567 HD11 HG21 ' A' ' 14' ' ' VAL . 6.9 tt -152.74 144.91 23.87 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 120.776 0.322 . . . . 0.2 110.164 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.474 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 0.2 OUTLIER -155.35 156.32 35.22 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.852 -0.613 . . . . 1.94 110.662 179.124 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.12 -155.49 50.64 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.95 -0.568 . . . . 0.27 112.809 176.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.3 t -99.43 126.0 45.25 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.186 -0.672 . . . . 1.16 109.186 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.589 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -139.76 152.96 22.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.538 0.685 . . . . 0.2 111.498 -176.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.51 158.78 44.06 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.625 -1.17 . . . . 0.17 108.982 178.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.535 HG23 HG22 ' A' ' 38' ' ' VAL . 0.5 OUTLIER -132.68 131.83 59.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.235 0.54 . . . . 0.16 110.034 174.857 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -97.42 99.01 10.43 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.471 -0.566 . . . . 0.51 109.471 178.385 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.567 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 39.9 m -62.2 171.59 1.76 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.928 -0.578 . . . . 1.25 109.703 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.2 pt -65.98 -1.44 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 113.757 1.021 . . . . 0.59 113.757 -170.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 49.6 m-80 -98.03 -2.16 40.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.303 0.573 . . . . 1.96 109.722 173.244 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.63 74.91 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 110.61 -0.996 . . . . 0.32 110.61 -176.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -84.38 118.2 24.09 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.721 -0.74 . . . . 2.21 110.519 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.417 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 4.9 tt0 -85.56 113.86 22.13 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.294 0.568 . . . . 1.0 110.483 -178.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -106.01 138.76 41.64 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.958 -1.019 . . . . 1.55 109.401 177.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -75.8 141.32 15.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.249 -0.648 . . . . 0.35 109.249 177.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.589 ' HB2' HG23 ' A' ' 14' ' ' VAL . 5.1 mt -106.99 145.05 32.74 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 121.493 0.663 . . . . 0.32 111.614 -178.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 35.7 mttp -137.51 169.22 18.15 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.461 -1.245 . . . . 1.65 107.735 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -61.23 140.17 57.99 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 119.761 -0.776 . . . . 0.23 109.798 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.519 ' H ' ' HB ' ' A' ' 7' ' ' ILE . . . 82.79 9.31 84.71 Favored Glycine 0 N--CA 1.437 -1.289 0 C-N-CA 120.052 -1.07 . . . . 0.24 113.08 177.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.509 ' OD1' HG13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.76 147.98 56.54 Favored Pre-proline 0 C--O 1.236 0.355 0 CA-C-N 117.419 0.609 . . . . 1.92 109.474 176.191 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -84.05 131.04 5.0 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.635 2.224 . . . . 0.22 113.219 178.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 mm -95.98 137.37 24.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.392 -0.822 . . . . 0.13 109.211 174.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -118.8 157.22 27.98 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.057 -0.52 . . . . 0.29 109.699 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.526 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.8 t80 -73.85 116.02 13.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.078 -0.51 . . . . 0.18 110.493 -174.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.19 -4.2 18.35 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.527 -0.844 . . . . 0.17 113.736 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.567 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 24.6 mt-10 -84.93 149.06 25.9 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 117.971 0.886 . . . . 0.52 110.993 -177.097 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.425 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 11.7 m -104.31 108.07 19.29 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.388 -0.823 . . . . 0.16 110.777 -178.066 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 16' ' ' VAL . 2.8 t -81.72 133.53 29.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.145 0.498 . . . . 0.16 110.613 -176.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -122.08 107.68 12.48 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.18 -0.918 . . . . 0.27 109.964 -176.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.423 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 69.7 p -104.26 152.04 22.67 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.79 -0.448 . . . . 0.23 109.79 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -130.29 135.14 8.16 Favored Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 120.928 -0.653 . . . . 0.9 112.205 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 56.61 -108.35 1.18 Allowed Glycine 0 N--CA 1.451 -0.318 0 O-C-N 123.946 0.439 . . . . 1.79 113.491 177.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.5 m -90.48 28.95 1.36 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.934 0.397 . . . . 1.64 111.198 -174.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.474 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -65.49 134.13 35.75 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 121.062 -0.59 . . . . 0.89 112.365 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 6.0 m -152.62 121.81 6.68 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.968 -0.753 . . . . 0.85 108.968 173.212 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 4.7 t -133.53 139.54 48.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.739 -0.384 . . . . 0.25 111.141 -173.671 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.588 ' HA ' ' O ' ' A' ' 56' ' ' VAL . 89.3 m -113.89 110.85 20.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.966 -0.561 . . . . 0.19 109.956 174.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.496 HD13 ' HE2' ' A' ' 66' ' ' MET . 69.3 mt -100.37 102.0 12.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.585 -0.734 . . . . 0.15 110.24 178.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.6 107.79 11.53 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.431 -0.804 . . . . 0.14 109.388 177.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.49 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 61.7 m-85 -70.86 149.7 46.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.633 0.73 . . . . 0.32 111.287 -177.145 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -77.4 0.95 2.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 114.743 -1.117 . . . . 0.25 111.086 -172.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -90.51 -21.41 21.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.958 -0.564 . . . . 0.75 110.649 175.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.42 -18.11 5.8 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.639 -0.791 . . . . 0.27 112.8 -178.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.2 p -84.81 171.64 12.1 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.644 0.222 . . . . 0.36 111.119 178.619 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -130.26 -178.0 4.56 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.14 -0.689 . . . . 1.51 109.14 175.308 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.588 ' O ' ' HA ' ' A' ' 47' ' ' THR . 0.5 OUTLIER -160.24 151.32 5.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 1.39 109.896 178.982 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.532 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.2 p -129.12 131.53 67.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.355 0.597 . . . . 0.81 110.783 178.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.8 mt -107.28 137.18 39.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 115.668 -0.696 . . . . 0.32 109.788 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.06 -164.28 29.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.932 -0.651 . . . . 1.02 112.578 -179.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.2 142.67 17.66 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.547 -0.621 . . . . 0.4 111.547 -174.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.423 ' HA ' ' O ' ' A' ' 40' ' ' THR . 37.7 t70 56.64 30.11 16.87 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-O 122.151 0.977 . . . . 1.26 109.207 -172.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 m -112.28 163.27 14.57 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.656 -1.156 . . . . 1.19 110.727 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 83.4 mt -140.05 127.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.845 -0.616 . . . . 0.38 109.838 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.1 p -148.53 143.72 18.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 109.886 -0.413 . . . . 1.0 109.886 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.425 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 29.8 tt0 -103.37 133.58 48.19 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.758 -0.377 . . . . 0.67 110.323 -178.292 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.496 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.2 mmm -69.19 89.2 0.45 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.645 -0.707 . . . . 0.88 110.366 -177.797 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.412 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 19.2 p -115.95 -164.9 0.99 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.756 -0.656 . . . . 0.29 111.39 -176.161 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -68.94 -41.15 78.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.524 -0.307 . . . . 2.13 111.252 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -61.53 -30.08 70.41 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.636 0.731 . . . . 2.51 110.306 177.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.412 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.3 mm -73.45 -52.52 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 114.497 -1.229 . . . . 0.25 110.806 176.133 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.79 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -104.88 79.72 1.55 Allowed 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.489 -0.778 . . . . 0.31 110.378 -176.321 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -77.89 106.48 9.76 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.427 -0.806 . . . . 1.46 109.791 176.307 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.9 p -81.29 131.92 35.31 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.136 -0.484 . . . . 0.69 111.061 -178.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.72 -40.63 7.6 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.965 -0.636 . . . . 1.91 112.336 -178.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 47.8 m-20 -81.63 -79.56 0.17 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.773 0.321 . . . . 5.57 110.176 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 . . . . . 0 C--O 1.248 0.981 0 CA-C-O 118.909 -0.567 . . . . 6.87 110.141 178.331 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.724 0 N-CA-C 111.926 -0.47 . . . . 1.71 111.926 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 69.16 147.83 0.06 Allowed 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.413 0.685 . . . . 2.0 111.613 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.26 109.91 12.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.827 -0.624 . . . . 0.24 109.642 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.779 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.0 pt -92.77 -13.6 8.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.295 -0.866 . . . . 0.15 112.074 -170.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.64 176.64 42.3 Favored Glycine 0 CA--C 1.501 -0.799 0 C-N-CA 120.69 -0.767 . . . . 0.1 111.513 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -143.51 150.41 38.89 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.048 0.451 . . . . 0.2 110.921 -174.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.542 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -78.22 123.38 34.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.683 -0.689 . . . . 0.14 110.883 -177.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.7 p -115.44 -21.29 9.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.218 0.532 . . . . 0.2 110.801 178.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.562 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 52.3 tptt -140.82 139.65 34.55 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.317 -0.994 . . . . 2.36 108.317 172.29 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.602 HD11 HG21 ' A' ' 14' ' ' VAL . 5.8 tt -153.57 146.34 24.32 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 110.234 -0.284 . . . . 0.2 110.234 -179.23 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.678 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 3.9 t70 -146.82 153.57 40.34 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.292 -0.413 . . . . 1.94 110.654 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.61 -149.48 49.67 Favored Glycine 0 N--CA 1.45 -0.402 0 O-C-N 123.689 0.618 . . . . 0.27 113.768 171.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.9 m -100.22 124.49 45.71 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.954 -0.387 . . . . 1.16 109.954 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.602 HG21 HD11 ' A' ' 10' ' ' LEU . 3.9 m -136.05 152.32 30.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.638 0.732 . . . . 0.2 111.692 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.23 157.55 43.21 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.751 -1.113 . . . . 0.17 108.647 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.682 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -135.81 134.94 51.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.048 -0.661 . . . . 0.16 111.049 174.549 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.46 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.8 mt-30 -100.05 102.79 14.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.328 -0.851 . . . . 0.51 109.599 177.426 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.568 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 61.4 p -61.46 178.87 0.26 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 111.473 0.175 . . . . 1.25 111.473 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.7 pt -59.42 -24.36 27.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.091 0.472 . . . . 0.59 111.16 178.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -77.57 -16.64 58.51 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.829 -0.623 . . . . 1.96 110.402 177.435 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.33 7.31 62.17 Favored Glycine 0 CA--C 1.504 -0.6 0 N-CA-C 110.909 -0.877 . . . . 0.32 110.909 -176.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.5 mm-40 -77.74 116.02 17.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.159 -0.521 . . . . 2.21 110.69 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.542 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 13.4 tt0 -81.89 118.44 22.93 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.069 -0.514 . . . . 1.0 110.056 176.7 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HG2' HG12 ' A' ' 16' ' ' VAL . 36.0 ptt85 -120.33 169.62 10.11 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.838 -0.801 . . . . 1.55 108.838 174.737 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.411 ' O ' HD23 ' A' ' 26' ' ' LEU . 7.4 p -96.62 144.33 10.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 109.496 -0.557 . . . . 0.35 109.496 -178.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.553 HD22 ' CG ' ' A' ' 30' ' ' ASP . 7.3 mt -112.68 160.73 17.62 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.124 0.487 . . . . 0.32 110.987 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.621 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 0.2 OUTLIER -159.46 177.04 11.38 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.278 -0.874 . . . . 1.65 109.027 -179.502 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 143.51 56.82 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 119.81 -0.756 . . . . 0.23 109.99 -179.38 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.57 6.71 81.81 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.219 -0.991 . . . . 0.24 112.41 178.02 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.621 ' HB3' ' O ' ' A' ' 27' ' ' LYS . 0.0 OUTLIER -85.37 142.27 37.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.399 0.618 . . . . 1.92 110.793 178.325 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.36 134.79 11.54 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 123.58 2.853 . . . . 0.22 113.756 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.8 mm -100.49 136.9 29.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.35 -0.841 . . . . 0.13 109.238 172.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -116.29 153.12 32.51 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 116.224 -0.444 . . . . 0.29 110.134 -178.694 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.559 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -71.37 114.5 9.5 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.058 -0.519 . . . . 0.18 110.869 -174.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.95 0.56 24.16 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.497 -0.858 . . . . 0.17 113.279 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.568 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 34.7 mt-10 -84.28 147.7 27.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.676 0.738 . . . . 0.52 110.465 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 22.2 m -106.59 106.88 17.61 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.462 -0.79 . . . . 0.16 110.488 -177.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.555 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -81.85 125.96 39.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-O 121.205 0.526 . . . . 0.16 110.916 -174.146 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -113.16 106.39 14.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.028 -0.987 . . . . 0.27 109.454 179.124 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.485 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 73.0 p -101.93 157.42 16.87 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 120.44 -0.504 . . . . 0.23 109.997 178.183 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -139.74 140.09 10.47 Favored Glycine 0 N--CA 1.441 -1.022 0 CA-C-N 115.631 -0.713 . . . . 0.9 111.644 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 62.07 -121.37 25.39 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.307 -0.473 . . . . 1.79 112.562 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 97.5 p -86.84 25.33 1.31 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.862 0.331 . . . . 1.64 110.9 -178.064 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.678 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -58.74 94.63 0.05 OUTLIER Glycine 0 C--O 1.222 -0.656 0 CA-C-N 116.096 -0.502 . . . . 0.89 112.772 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -120.26 112.35 18.94 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.231 -0.655 . . . . 0.85 109.231 -175.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.8 t -126.5 130.43 71.79 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 C-N-CA 120.677 -0.409 . . . . 0.25 111.878 -169.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.562 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 97.2 m -106.79 108.85 20.57 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.781 -0.645 . . . . 0.19 109.751 175.089 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.549 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 62.3 mt -97.73 105.35 17.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.623 -0.717 . . . . 0.15 110.117 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.81 105.42 11.08 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.413 -0.812 . . . . 0.14 109.042 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.448 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 62.5 m-85 -71.18 146.79 48.88 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.508 0.67 . . . . 0.32 110.867 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.59 2.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 114.634 -1.166 . . . . 0.25 111.582 -171.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -94.66 -20.68 19.35 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.076 -0.511 . . . . 0.75 110.384 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.0 -17.65 7.12 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.66 -0.781 . . . . 0.27 112.552 -178.144 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.7 p -82.99 155.7 23.83 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 122.903 -0.175 . . . . 0.36 110.866 178.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -132.33 143.26 49.74 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.897 -0.408 . . . . 1.51 109.897 178.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.549 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 10.7 m -124.44 168.56 16.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.068 0.461 . . . . 1.39 111.584 178.344 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.506 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.7 p -138.78 133.37 41.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.331 -0.849 . . . . 0.81 110.25 177.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -106.34 136.15 42.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.99 -0.55 . . . . 0.32 109.929 -179.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.49 178.71 53.74 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.551 -0.833 . . . . 1.02 111.606 177.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.0 151.08 19.93 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 111.584 -0.607 . . . . 0.4 111.584 -172.597 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.485 ' HA ' ' O ' ' A' ' 40' ' ' THR . 34.5 t70 51.15 28.48 4.08 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 121.379 0.609 . . . . 1.26 110.509 -171.22 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.5 t -104.72 161.71 13.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.882 -0.599 . . . . 1.19 110.761 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.555 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 81.3 mt -138.92 123.15 20.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.629 -0.714 . . . . 0.38 109.51 178.11 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.14 137.04 16.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.935 0.398 . . . . 1.0 110.855 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.496 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.7 tt0 -91.46 131.84 36.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.315 -0.402 . . . . 0.67 110.41 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.539 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.2 mmm -71.68 89.18 1.0 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 0.88 110.6 -178.64 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.2 p -111.05 -166.77 1.11 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.092 -0.504 . . . . 0.29 110.9 -178.484 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.9 -27.89 62.15 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.013 0.435 . . . . 2.13 110.044 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -65.46 -30.09 70.84 Favored 'General case' 0 CA--C 1.521 -0.144 0 CA-C-O 121.882 0.849 . . . . 2.51 109.789 174.303 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.438 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.0 OUTLIER -80.51 -54.02 11.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 114.457 -1.247 . . . . 0.25 110.732 176.777 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.779 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -98.0 79.76 2.65 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.407 -0.815 . . . . 0.31 109.772 -177.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 52.2 t30 -80.55 98.68 7.72 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.634 -0.712 . . . . 1.46 109.892 178.111 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 10.3 p -71.17 135.25 47.48 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.081 -0.509 . . . . 0.69 111.261 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.35 42.17 0.2 Allowed Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.525 -0.845 . . . . 1.91 112.711 178.152 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -65.99 -37.44 85.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.222 0.534 . . . . 5.57 110.036 175.471 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 91.9 m-20 . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.569 -0.729 . . . . 6.87 109.715 175.392 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.705 0 N-CA-C 111.811 -0.516 . . . . 1.71 111.811 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 69.35 152.68 0.1 Allowed 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.091 0.557 . . . . 2.0 110.937 179.198 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.53 109.85 16.37 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.485 0.66 . . . . 0.24 109.817 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.759 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.3 pt -95.11 -12.32 8.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 114.945 -1.025 . . . . 0.15 111.777 -171.215 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.49 179.26 41.09 Favored Glycine 0 CA--C 1.5 -0.853 0 C-N-CA 120.684 -0.769 . . . . 0.1 111.698 178.212 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.455 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 92.3 m-85 -144.41 152.13 40.23 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.76 0.314 . . . . 0.2 110.535 -176.501 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.507 HG12 ' O ' ' A' ' 30' ' ' ASP . 33.0 mm -79.77 122.48 35.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.441 -0.345 . . . . 0.14 110.86 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.0 p -115.72 -21.59 9.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.207 0.527 . . . . 0.2 110.966 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.552 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.8 tttt -141.87 144.94 34.09 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.219 -1.03 . . . . 2.36 108.219 173.224 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.425 HD11 HG21 ' A' ' 14' ' ' VAL . 6.5 tt -158.95 146.54 17.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.877 0.37 . . . . 0.2 111.029 -177.135 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.449 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 9.0 t70 -153.36 152.14 30.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.811 -0.631 . . . . 1.94 110.854 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.15 -154.42 44.58 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.129 -0.558 . . . . 0.27 113.112 173.188 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.4 m -103.34 120.78 41.43 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 109.804 -0.443 . . . . 1.16 109.804 -176.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.514 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.0 m -138.35 152.1 25.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.769 0.795 . . . . 0.2 111.596 -176.49 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.41 159.43 44.47 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 114.64 -1.164 . . . . 0.17 108.463 178.039 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.682 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -132.95 136.45 55.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 119.86 -0.736 . . . . 0.16 110.94 174.377 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -101.05 102.51 13.5 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.295 -0.866 . . . . 0.51 109.843 177.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.533 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 7.6 p -63.01 172.08 1.93 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.854 -0.338 . . . . 1.25 110.507 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -54.42 -33.31 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 112.767 0.654 . . . . 0.59 112.767 -173.609 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -80.09 -5.03 55.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.926 0.393 . . . . 1.96 111.512 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.17 14.73 44.21 Favored Glycine 0 CA--C 1.507 -0.441 0 C-N-CA 121.276 -0.488 . . . . 0.32 112.376 174.445 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.404 ' HB2' ' OG ' ' A' ' 18' ' ' SER . 90.0 mm-40 -86.55 116.86 24.96 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.865 0.364 . . . . 2.21 110.753 -178.252 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.544 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.5 tt0 -84.47 117.52 23.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.371 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HG2' HG12 ' A' ' 16' ' ' VAL . 29.4 ptt85 -119.09 168.32 10.95 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.722 -0.473 . . . . 1.55 109.722 177.166 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.9 p -94.59 135.03 30.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.003 -0.544 . . . . 0.35 110.372 -176.297 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.514 ' HB2' HG23 ' A' ' 14' ' ' VAL . 15.2 mt -103.08 118.39 36.7 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.605 0.717 . . . . 0.32 110.321 178.447 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -114.0 176.88 4.85 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.493 -1.23 . . . . 1.65 107.703 174.447 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 tp -67.69 134.53 51.24 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 119.042 -1.063 . . . . 0.23 109.424 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.15 -12.22 66.95 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 119.676 -1.25 . . . . 0.24 112.564 177.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.507 ' O ' HG12 ' A' ' 7' ' ' ILE . 10.7 m-20 -67.76 140.26 94.08 Favored Pre-proline 0 CA--C 1.514 -0.412 0 C-N-CA 120.219 -0.592 . . . . 1.92 109.857 175.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.455 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 29.7 Cg_endo -86.1 144.48 8.29 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.003 2.468 . . . . 0.22 111.834 -179.166 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.0 mm -100.62 138.74 23.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.639 -0.504 . . . . 0.13 109.639 176.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -114.61 149.7 36.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.174 -0.466 . . . . 0.29 109.836 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.522 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.8 t80 -68.6 109.58 3.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.096 -0.502 . . . . 0.18 110.638 -175.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 123.8 -3.98 9.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.553 -0.832 . . . . 0.17 113.673 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.533 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.0 mt-10 -82.3 150.49 27.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 117.851 0.825 . . . . 0.52 110.981 -177.435 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.9 m -108.42 107.7 18.35 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.537 -0.756 . . . . 0.16 110.767 -177.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.603 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -79.04 137.05 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.3 0.571 . . . . 0.16 110.845 -175.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -123.46 99.25 6.23 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.043 -0.981 . . . . 0.27 109.665 -177.413 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.5 p -101.01 153.46 19.52 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.119 0.485 . . . . 0.23 110.158 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -116.99 -153.0 9.72 Favored Glycine 0 N--CA 1.442 -0.917 0 CA-C-N 115.423 -0.808 . . . . 0.9 111.65 178.412 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.38 131.23 47.37 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.962 -0.637 . . . . 1.79 112.26 -178.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 18.8 m 63.66 19.83 11.92 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 122.94 0.496 . . . . 1.64 111.049 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.51 132.83 23.04 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.78 -0.724 . . . . 0.89 111.647 177.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.494 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 36.8 m -152.66 134.69 14.85 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.052 -0.722 . . . . 0.85 109.052 175.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.9 t -145.71 132.21 14.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 C-N-CA 120.548 -0.461 . . . . 0.25 110.968 -176.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.552 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -106.69 105.96 16.26 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.103 0.478 . . . . 0.19 109.949 174.183 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.535 HD13 ' HE2' ' A' ' 66' ' ' MET . 60.7 mt -96.38 103.15 14.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.672 -0.694 . . . . 0.15 110.082 177.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 106.04 10.19 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.229 -0.896 . . . . 0.14 109.193 176.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.434 ' CE1' HG22 ' A' ' 56' ' ' VAL . 58.0 m-85 -71.43 146.75 48.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.591 0.71 . . . . 0.32 110.916 -177.588 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -71.42 -12.41 15.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.572 -1.195 . . . . 0.25 111.512 -170.343 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.649 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 21.0 t70 -79.39 -21.04 46.23 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.289 -0.414 . . . . 0.75 110.736 178.497 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.75 -8.91 7.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.517 -0.849 . . . . 0.27 112.717 -179.098 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.7 p -90.48 175.35 7.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.579 0.228 . . . . 0.36 110.897 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -151.79 148.45 27.87 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.72 -0.474 . . . . 1.51 109.72 176.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.529 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.2 m -129.36 165.63 28.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 120.989 0.423 . . . . 1.39 111.352 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.595 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.7 p -135.56 128.56 47.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-N 115.316 -0.856 . . . . 0.81 110.426 177.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.494 ' O ' ' HA ' ' A' ' 45' ' ' SER . 18.5 mt -101.03 139.58 21.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.373 -0.83 . . . . 0.32 109.988 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.52 -157.77 29.08 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.775 -0.726 . . . . 1.02 111.952 178.269 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.43 148.87 18.83 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.986 -0.625 . . . . 0.4 111.664 -173.116 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.0 t70 56.87 27.37 12.88 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.96 0.886 . . . . 1.26 109.708 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.5 t -105.3 157.64 17.17 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.372 -0.831 . . . . 1.19 110.579 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.603 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.0 mt -142.79 106.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.191 -0.67 . . . . 0.38 109.191 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.49 146.31 32.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.027 0.441 . . . . 1.0 111.339 -175.341 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -99.46 131.44 45.46 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.793 -0.64 . . . . 0.67 110.354 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.535 ' HE2' HD13 ' A' ' 48' ' ' ILE . 51.0 mmm -68.18 89.15 0.31 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.454 -0.794 . . . . 0.88 110.315 -178.632 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.428 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 20.1 p -116.55 -166.99 1.21 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.653 -0.703 . . . . 0.29 111.16 -175.35 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -63.89 -38.31 90.62 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 2.13 110.647 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -62.75 -28.75 70.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.587 0.708 . . . . 2.51 110.614 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.428 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.4 mm -81.97 -51.28 15.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 CA-C-N 114.904 -1.044 . . . . 0.25 110.939 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.759 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -102.7 83.63 2.29 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.553 -0.749 . . . . 0.31 109.845 -177.176 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -71.96 97.94 1.96 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.477 -0.783 . . . . 1.46 109.89 175.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 11.1 p -80.61 127.94 33.04 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.987 -0.551 . . . . 0.69 110.903 -178.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -143.18 72.4 0.37 Allowed Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.732 -0.747 . . . . 1.91 111.956 -179.108 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -84.64 94.9 8.73 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.936 0.398 . . . . 5.57 110.361 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.315 -0.85 . . . . 6.87 110.438 179.506 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.609 0 N-CA-C 112.069 -0.412 . . . . 1.71 112.069 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 74.3 m-20 -95.1 174.96 6.81 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 110.153 -0.314 . . . . 2.0 110.153 177.074 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 109.62 6.79 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.374 0.607 . . . . 0.24 110.019 179.117 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.798 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.6 pt -91.83 -13.66 8.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.017 -0.992 . . . . 0.15 111.427 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.93 178.55 43.34 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.794 -0.717 . . . . 0.1 111.415 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -144.73 150.38 37.17 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.8 0.333 . . . . 0.2 110.425 -174.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.59 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.3 mm -77.12 124.19 35.08 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.026 -0.534 . . . . 0.14 111.596 -175.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.3 p -116.1 -22.51 8.91 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.887 0.375 . . . . 0.2 110.747 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.578 ' HB2' ' HB ' ' A' ' 47' ' ' THR . 6.4 tmtt? -134.38 144.34 48.15 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 109.364 -0.606 . . . . 2.36 109.364 170.677 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.442 HD11 HG21 ' A' ' 14' ' ' VAL . 6.2 tt -156.38 141.68 17.48 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.089 -0.505 . . . . 0.2 110.327 177.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -154.54 158.74 40.29 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.725 -0.671 . . . . 1.94 110.75 -177.489 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.48 -140.56 35.48 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.806 -0.634 . . . . 0.27 113.074 175.487 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.3 t -112.46 122.99 49.28 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.294 -0.632 . . . . 1.16 109.294 -178.6 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.2 m -136.06 152.16 30.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.7 0.762 . . . . 0.2 111.496 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.25 158.46 43.91 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 114.674 -1.148 . . . . 0.17 108.881 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.676 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -136.51 135.44 49.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 119.94 -0.704 . . . . 0.16 110.946 173.512 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.434 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.0 mt-30 -103.22 99.87 9.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.973 -1.012 . . . . 0.51 109.68 177.519 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.504 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.2 m -60.76 174.41 0.61 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.6 -0.273 . . . . 1.25 110.713 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 13.4 pt -59.42 -27.8 38.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 118.337 0.517 . . . . 0.59 112.052 -174.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -77.46 -9.33 58.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.068 -0.515 . . . . 1.96 110.982 177.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.42 3.02 60.06 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 121.351 -0.452 . . . . 0.32 112.342 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 82.7 mt-30 -75.06 122.02 22.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.704 0.288 . . . . 2.21 111.271 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.614 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.7 tt0 -92.8 123.18 35.89 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.919 -0.582 . . . . 1.0 110.193 177.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.676 ' HG2' HG12 ' A' ' 16' ' ' VAL . 19.4 ptt-85 -123.0 166.47 15.05 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.543 -0.54 . . . . 1.55 109.543 175.558 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.81 134.45 28.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 109.109 -0.7 . . . . 0.35 109.109 177.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.516 HD22 ' CG ' ' A' ' 30' ' ' ASP . 5.3 mt -97.36 153.34 18.14 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.243 0.544 . . . . 0.32 111.111 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.4 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 46.1 mttt -141.27 178.2 7.57 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.958 -1.019 . . . . 1.65 108.395 -176.393 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -71.94 144.23 49.01 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 119.392 -0.923 . . . . 0.23 109.203 177.769 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.53 -6.07 58.91 Favored Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 120.247 -0.978 . . . . 0.24 112.338 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.59 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -70.66 142.84 89.07 Favored Pre-proline 0 C--N 1.332 -0.184 0 CA-C-O 121.388 0.613 . . . . 1.92 110.157 179.414 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 24.3 Cg_endo -87.49 128.87 2.6 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.627 2.884 . . . . 0.22 113.485 -174.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.8 mm -93.62 137.05 23.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.011 -0.54 . . . . 0.13 109.745 177.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -115.06 151.39 34.35 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.052 -0.522 . . . . 0.29 109.733 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.552 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -68.94 114.07 6.91 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.246 -0.433 . . . . 0.18 110.494 -176.556 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.49 0.41 18.29 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.398 -0.906 . . . . 0.17 113.54 177.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.504 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 30.2 mt-10 -88.53 146.51 25.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 118.071 0.936 . . . . 0.52 110.882 -177.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.0 m -103.49 107.88 18.9 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.422 -0.808 . . . . 0.16 110.943 -176.616 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.474 HG22 HG23 ' A' ' 16' ' ' VAL . 3.9 t -84.0 130.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 CA-C-O 121.153 0.502 . . . . 0.16 110.869 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -115.57 109.57 17.98 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.245 -0.889 . . . . 0.27 109.532 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.8 p -107.94 146.5 32.33 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.877 -0.416 . . . . 0.23 109.877 178.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -125.69 147.57 16.66 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.934 -0.65 . . . . 0.9 111.766 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.4 -112.55 3.07 Favored Glycine 0 N--CA 1.449 -0.462 0 O-C-N 123.922 0.424 . . . . 1.79 113.668 177.392 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.3 m -97.61 34.31 1.87 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.057 0.456 . . . . 1.64 110.847 -175.542 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.24 133.9 52.56 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.672 -0.694 . . . . 0.89 112.276 177.133 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 36.7 m -152.8 124.61 7.87 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.434 -0.58 . . . . 0.85 109.434 174.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.9 t -141.18 128.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-O 120.621 0.248 . . . . 0.25 110.945 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.578 ' HB ' ' HB2' ' A' ' 9' ' ' LYS . 92.8 m -101.27 107.93 19.43 Favored 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 109.559 -0.534 . . . . 0.19 109.559 173.777 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.475 HD13 ' HE2' ' A' ' 66' ' ' MET . 84.6 mt -95.69 101.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.556 -0.747 . . . . 0.15 109.995 176.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.77 102.65 8.23 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.438 -0.801 . . . . 0.14 109.329 177.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.563 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 55.5 m-85 -65.54 152.95 42.84 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.32 111.22 -177.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -79.04 -3.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-N 114.664 -1.153 . . . . 0.25 110.917 -172.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.573 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 18.6 t70 -85.71 -21.45 28.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.605 -0.725 . . . . 0.75 110.44 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.55 -11.65 11.21 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.764 -0.731 . . . . 0.27 112.122 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.2 p -88.07 157.53 18.84 Favored 'General case' 0 C--N 1.323 -0.555 0 O-C-N 122.879 -0.189 . . . . 0.36 110.609 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -124.64 160.32 28.76 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.669 -0.493 . . . . 1.51 109.669 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.558 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.3 154.45 16.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.466 -0.334 . . . . 1.39 110.108 -179.191 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.563 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -132.96 133.11 59.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.178 0.514 . . . . 0.81 110.596 178.064 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 18.7 mt -101.57 143.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.901 -0.591 . . . . 0.32 110.192 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.7 -164.91 39.78 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.842 -0.694 . . . . 1.02 111.998 177.049 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -115.52 153.0 17.84 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.251 -0.74 . . . . 0.4 111.251 -174.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.3 t70 57.25 23.71 9.05 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.77 0.795 . . . . 1.26 109.665 -173.315 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -110.16 160.69 16.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.777 -0.647 . . . . 1.19 111.369 -176.177 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.429 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -139.8 125.26 21.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.422 -0.808 . . . . 0.38 109.382 177.425 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.3 p -148.64 140.73 18.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.925 0.393 . . . . 1.0 110.96 -176.287 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.472 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.8 tt0 -95.5 132.57 40.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.456 -0.338 . . . . 0.67 110.198 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.477 ' HE3' HG21 ' A' ' 70' ' ' ILE . 58.1 mmm -70.21 89.49 0.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.736 -0.666 . . . . 0.88 110.499 -178.702 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 36.0 p -117.06 -165.19 1.04 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.878 -0.601 . . . . 0.29 111.138 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -64.42 -36.38 83.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.934 0.397 . . . . 2.13 110.888 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -65.96 -22.35 66.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.625 0.726 . . . . 2.51 110.313 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.477 HG21 ' HE3' ' A' ' 66' ' ' MET . 1.4 mm -87.06 -56.31 5.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 114.986 -1.007 . . . . 0.25 111.023 176.672 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.798 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -95.4 86.0 4.38 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.574 -0.739 . . . . 0.31 110.2 -173.545 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -64.99 102.6 0.63 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.95 -1.023 . . . . 1.46 109.737 171.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.441 ' HB ' ' OD1' ' A' ' 75' ' ' ASP . 26.7 p -95.36 140.92 29.56 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.099 -0.5 . . . . 0.69 111.291 -176.556 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.414 ' H ' ' CG ' ' A' ' 52' ' ' ASP . . . -101.04 -12.99 35.05 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.898 -0.668 . . . . 1.91 111.481 178.171 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.441 ' OD1' ' HB ' ' A' ' 73' ' ' THR . 5.5 p-10 -76.82 -20.67 56.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.47 0.176 . . . . 5.57 110.534 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 18.6 m120 . . . . . 0 C--O 1.247 0.936 0 CA-C-O 118.135 -0.936 . . . . 6.87 110.867 -179.627 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.708 0 N-CA-C 112.037 -0.425 . . . . 1.71 112.037 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.58 158.53 15.39 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.762 -0.458 . . . . 2.0 109.762 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.77 112.58 8.94 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.365 0.602 . . . . 0.24 110.47 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.796 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 35.6 pt -95.94 -15.76 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 114.978 -1.01 . . . . 0.15 111.937 -171.672 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.09 175.99 40.88 Favored Glycine 0 CA--C 1.499 -0.941 0 C-N-CA 120.615 -0.803 . . . . 0.1 111.812 -177.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -145.07 147.44 32.57 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.042 0.449 . . . . 0.2 110.661 -174.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.583 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.77 123.07 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.579 -0.737 . . . . 0.14 110.964 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.2 p -112.41 -23.67 10.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.347 0.594 . . . . 0.2 110.718 178.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.478 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.6 tptt -141.6 138.73 32.81 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 108.667 -0.864 . . . . 2.36 108.667 175.414 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.46 HD11 HG21 ' A' ' 14' ' ' VAL . 5.7 tt -149.66 144.86 26.4 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.721 0.296 . . . . 0.2 110.71 -178.386 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.467 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 14.1 t70 -152.65 153.33 33.1 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.015 -0.539 . . . . 1.94 110.394 -177.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.16 -149.85 41.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.002 -0.618 . . . . 0.27 113.164 174.078 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.2 t -108.0 123.84 49.26 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.31 -0.626 . . . . 1.16 109.31 -177.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -136.37 152.28 29.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.855 0.836 . . . . 0.2 112.296 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.03 158.88 44.68 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 114.422 -1.263 . . . . 0.17 108.795 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.679 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.1 p -135.73 139.17 46.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 C-N-CA 120.042 -0.663 . . . . 0.16 110.895 173.097 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' GLN . 1.3 mt-30 -107.85 102.12 11.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.316 -0.856 . . . . 0.51 110.077 177.584 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.518 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 11.6 m -63.91 172.26 2.38 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.462 -0.57 . . . . 1.25 109.462 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.0 pt -57.78 -30.0 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 119.031 0.832 . . . . 0.59 112.521 -172.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.504 ' HB2' ' HG3' ' A' ' 22' ' ' GLN . 87.3 m-20 -63.94 -26.8 68.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.164 0.507 . . . . 1.96 110.826 175.526 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 106.33 13.3 23.16 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.505 -0.77 . . . . 0.32 111.691 -174.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.504 ' HG3' ' HB2' ' A' ' 20' ' ' ASN . 85.2 mt-30 -77.1 116.72 17.99 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.947 -0.126 . . . . 2.21 110.885 -179.023 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.679 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.4 tt0 -93.76 117.66 30.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.876 0.369 . . . . 1.0 110.485 176.359 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.655 ' HG2' HG12 ' A' ' 16' ' ' VAL . 23.9 ptt-85 -120.11 166.95 12.72 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.209 -0.663 . . . . 1.55 109.209 175.224 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.1 p -91.2 131.71 37.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 109.47 -0.567 . . . . 0.35 109.47 178.049 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' HG23 ' A' ' 14' ' ' VAL . 5.4 mt -94.25 156.49 16.51 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.852 -0.613 . . . . 0.32 111.014 -178.124 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -143.54 177.9 8.15 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.321 -0.992 . . . . 1.65 108.321 -172.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.61 142.18 46.55 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 118.973 -1.091 . . . . 0.23 108.77 174.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.5 5.3 85.78 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.982 -1.104 . . . . 0.24 112.173 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.583 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -80.47 139.09 51.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.671 0.748 . . . . 1.92 110.739 178.942 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -77.03 130.6 11.38 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 123.685 2.924 . . . . 0.22 113.382 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 mm -97.42 136.04 29.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.344 -0.844 . . . . 0.13 109.018 174.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 -115.16 151.4 34.46 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 116.194 -0.457 . . . . 0.29 110.101 -178.487 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.542 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -67.64 118.82 11.44 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.891 -0.595 . . . . 0.18 110.531 -175.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.74 1.1 30.59 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.583 -0.818 . . . . 0.17 113.203 177.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.524 ' O ' ' HG2' ' A' ' 66' ' ' MET . 34.4 mt-10 -88.62 146.15 25.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 117.9 0.85 . . . . 0.52 110.644 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 11.3 m -104.34 106.85 17.51 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.249 -0.887 . . . . 0.16 110.738 -174.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.7 t -82.63 122.62 37.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 121.206 0.527 . . . . 0.16 110.883 -174.662 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.1 mp -105.76 109.27 21.18 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.135 -0.938 . . . . 0.27 109.441 178.475 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.5 p -107.54 148.35 29.35 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.955 -0.387 . . . . 0.23 109.955 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.32 138.47 9.54 Favored Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 120.776 -0.726 . . . . 0.9 111.984 177.391 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.95 71.18 0.77 Allowed Glycine 0 N--CA 1.447 -0.571 0 O-C-N 123.959 0.447 . . . . 1.79 113.092 178.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 65.0 m 53.89 39.33 30.31 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.817 0.342 . . . . 1.64 111.734 179.005 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.513 ' N ' ' HA3' ' A' ' 60' ' ' GLY . . . -60.09 96.83 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.411 0 N-CA-C 111.395 -0.682 . . . . 0.89 111.395 172.268 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.617 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 3.1 m -101.77 109.6 21.4 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.55 -0.537 . . . . 0.85 109.55 -171.13 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.9 t -130.9 119.43 45.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 CA-C-N 116.048 -0.524 . . . . 0.25 111.278 -170.108 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.478 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.0 m -95.13 104.27 16.14 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.455 -0.793 . . . . 0.19 109.873 176.745 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.467 HD13 ' HE2' ' A' ' 66' ' ' MET . 60.2 mt -94.83 99.66 9.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 115.274 -0.875 . . . . 0.15 109.697 177.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.21 110.11 16.38 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.413 -0.812 . . . . 0.14 109.444 178.452 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.524 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 59.0 m-85 -73.14 151.86 41.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.635 0.731 . . . . 0.32 111.128 -176.055 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.3 p -72.38 -5.89 6.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 114.548 -1.205 . . . . 0.25 110.671 -174.073 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -79.39 -21.37 45.76 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.079 -0.964 . . . . 0.75 110.938 176.277 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.11 -11.86 34.11 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.099 -0.8 . . . . 0.27 111.099 -173.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.3 p -83.3 154.67 24.0 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.267 -0.466 . . . . 0.36 109.959 175.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -126.88 156.79 40.85 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 120.777 -0.369 . . . . 1.51 110.454 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.524 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -139.44 152.0 23.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 115.905 -0.589 . . . . 1.39 109.648 178.233 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -136.62 133.21 48.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-O 121.312 0.577 . . . . 0.81 110.994 179.411 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.617 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -100.37 138.28 25.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.692 -0.685 . . . . 0.32 109.46 178.341 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.08 -51.24 5.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.109 -0.567 . . . . 1.02 112.34 -179.114 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.513 ' HA3' ' N ' ' A' ' 44' ' ' GLY . . . 133.16 172.49 13.0 Favored Glycine 0 CA--C 1.505 -0.568 0 CA-C-O 119.083 -0.843 . . . . 0.4 111.521 176.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 38.3 47.07 0.97 Allowed 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 122.063 0.935 . . . . 1.26 110.559 -171.507 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.1 t -138.79 163.36 32.42 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 114.493 -1.231 . . . . 1.19 109.785 -176.287 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 84.5 mt -140.26 113.97 5.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.491 -0.559 . . . . 0.38 109.491 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 p -138.66 142.38 34.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.93 0.395 . . . . 1.0 110.885 -175.098 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 45.0 tt0 -96.04 131.94 41.91 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.145 -0.48 . . . . 0.67 110.406 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.546 ' CE ' HG21 ' A' ' 70' ' ' ILE . 59.9 mmm -71.07 88.97 0.8 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.643 -0.708 . . . . 0.88 110.72 -178.583 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 p -117.62 -162.42 0.87 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.245 -0.434 . . . . 0.29 110.369 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -71.36 -28.51 64.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.051 0.453 . . . . 2.13 110.26 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -64.49 -24.05 67.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.916 0.865 . . . . 2.51 109.859 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.546 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.3 mm -91.67 -53.21 9.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 114.509 -1.223 . . . . 0.25 110.583 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.796 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 -111.41 72.77 0.79 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.123 -0.944 . . . . 0.31 110.634 -174.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -87.96 103.25 15.51 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.852 -0.795 . . . . 1.46 108.852 171.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.0 p -60.79 138.11 58.14 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.753 -0.658 . . . . 0.69 112.265 -173.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.83 -19.43 15.29 Favored Glycine 0 N--CA 1.445 -0.733 0 CA-C-N 115.698 -0.683 . . . . 1.91 111.944 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -110.94 80.05 1.26 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.087 0.47 . . . . 5.57 110.46 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.849 -0.595 . . . . 6.87 109.724 176.764 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.601 0 N-CA-C 111.76 -0.536 . . . . 1.71 111.76 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -94.91 155.51 16.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.891 0.377 . . . . 2.0 110.705 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.68 113.9 11.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.635 -0.711 . . . . 0.24 109.845 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.752 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.1 pt -96.13 -15.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 115.351 -0.841 . . . . 0.15 111.833 -171.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.21 175.88 42.24 Favored Glycine 0 CA--C 1.502 -0.774 0 N-CA-C 111.478 -0.649 . . . . 0.1 111.478 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.62 148.67 36.18 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.096 0.474 . . . . 0.2 110.949 -174.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.3 mm -75.89 123.09 31.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.689 -0.687 . . . . 0.14 111.02 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.4 p -114.63 -26.35 7.92 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.364 0.602 . . . . 0.2 110.395 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.528 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 83.6 tttt -136.21 145.82 46.12 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.584 -0.895 . . . . 2.36 108.584 172.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.643 HD11 HG21 ' A' ' 14' ' ' VAL . 5.4 tt -158.42 141.18 14.57 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.972 0.415 . . . . 0.2 110.513 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -152.12 146.45 25.51 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-N 115.705 -0.68 . . . . 1.94 111.433 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.598 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 83.97 -152.34 28.38 Favored Glycine 0 N--CA 1.428 -1.884 0 CA-C-N 114.928 -1.033 . . . . 0.27 113.115 168.334 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 39.8 m -95.01 118.64 32.17 Favored 'General case' 0 N--CA 1.445 -0.681 0 N-CA-C 109.747 -0.464 . . . . 1.16 109.747 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.643 HG21 HD11 ' A' ' 10' ' ' LEU . 2.8 m -136.45 151.22 28.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 0.2 111.678 -177.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -152.21 158.99 43.63 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 114.585 -1.189 . . . . 0.17 108.841 179.214 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.677 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -136.67 133.57 48.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 C-N-CA 119.829 -0.749 . . . . 0.16 111.305 174.192 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.482 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.9 mt-30 -102.75 100.19 10.2 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.089 -0.96 . . . . 0.51 109.794 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.414 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 26.5 p -62.65 179.2 0.36 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.484 0.179 . . . . 1.25 111.484 -176.587 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 11.8 pt -58.66 -27.89 35.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.78 0.324 . . . . 0.59 111.661 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -75.42 -11.75 60.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.967 0.413 . . . . 1.96 110.617 178.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.46 21.26 48.95 Favored Glycine 0 CA--C 1.505 -0.563 0 N-CA-C 110.739 -0.945 . . . . 0.32 110.739 -178.352 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 -92.57 121.12 33.69 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.93 -0.635 . . . . 2.21 110.396 -178.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.607 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.9 tt0 -93.72 116.74 29.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.985 0.422 . . . . 1.0 110.931 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.677 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -118.98 169.36 9.96 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.948 -0.569 . . . . 1.55 109.82 176.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.37 143.14 11.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.82 -0.627 . . . . 0.35 109.738 178.111 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.417 ' HB2' HG23 ' A' ' 14' ' ' VAL . 18.4 mt -107.85 127.23 53.54 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.154 -0.475 . . . . 0.32 110.826 178.362 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -110.05 179.59 4.06 Favored 'General case' 0 C--N 1.319 -0.761 0 N-CA-C 108.709 -0.849 . . . . 1.65 108.709 172.039 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.19 145.82 52.92 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.144 -0.622 . . . . 0.23 109.695 174.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.63 2.2 87.72 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.137 -1.03 . . . . 0.24 112.416 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 57.9 m-20 -78.95 142.77 60.63 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.044 0.45 . . . . 1.92 110.701 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -77.34 138.71 17.95 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.038 2.492 . . . . 0.22 113.11 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.9 mm -103.83 135.23 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.687 0 CA-C-N 115.411 -0.813 . . . . 0.13 108.847 170.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.461 ' H ' ' CD ' ' A' ' 36' ' ' GLU . 62.2 m-85 -114.51 155.5 26.31 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 116.017 -0.538 . . . . 0.29 109.947 -178.409 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -71.19 109.89 5.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.036 -0.529 . . . . 0.18 110.243 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.12 0.22 10.6 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.455 -0.878 . . . . 0.17 113.406 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.482 ' O ' ' HG2' ' A' ' 66' ' ' MET . 32.7 mt-10 -86.92 147.98 25.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 117.856 0.828 . . . . 0.52 110.645 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.482 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 17.5 m -108.06 108.63 19.81 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.662 -0.699 . . . . 0.16 110.391 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.0 t -83.69 130.3 36.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.028 0.442 . . . . 0.16 110.618 -174.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.0 mp -117.46 108.02 15.02 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.357 -0.838 . . . . 0.27 110.032 -178.599 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.0 p -101.02 152.97 19.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.235 -0.654 . . . . 0.23 109.235 176.097 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -130.64 128.72 5.61 Favored Glycine 0 N--CA 1.442 -0.903 0 C-N-CA 120.622 -0.799 . . . . 0.9 112.417 -177.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 54.8 -108.84 1.03 Allowed Glycine 0 N--CA 1.449 -0.444 0 O-C-N 124.172 0.572 . . . . 1.79 112.431 -179.134 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.598 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 18.2 m -92.46 66.96 4.69 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.88 0.372 . . . . 1.64 110.852 -178.462 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -101.4 132.37 10.93 Favored Glycine 0 CA--C 1.523 0.55 0 CA-C-N 115.804 -0.635 . . . . 0.89 111.726 176.404 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.4 m -142.57 110.04 5.72 Favored 'General case' 0 C--O 1.223 -0.303 0 CA-C-N 118.04 0.92 . . . . 0.85 110.264 175.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.446 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.2 t -121.2 143.77 32.44 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 120.706 0.289 . . . . 0.25 110.758 -174.429 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.528 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -120.91 110.99 16.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.179 -0.464 . . . . 0.19 109.928 175.643 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.535 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 55.9 mt -99.68 104.6 16.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.785 -0.643 . . . . 0.15 110.107 178.763 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.03 100.98 8.42 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.191 -0.913 . . . . 0.14 109.424 177.721 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.485 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 68.4 m-85 -68.54 146.28 53.25 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-O 121.586 0.708 . . . . 0.32 110.727 -178.403 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.4 p -70.99 1.62 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.567 -1.197 . . . . 0.25 110.991 -173.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.418 ' HB3' ' HE1' ' A' ' 71' ' ' TYR . 4.1 t70 -86.0 -20.84 28.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.32 -0.854 . . . . 0.75 110.432 175.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 111.97 -11.95 27.04 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 111.25 -0.74 . . . . 0.27 111.25 -175.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.68 151.98 24.08 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.352 -0.424 . . . . 0.36 110.478 176.179 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -133.0 138.94 47.0 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.08 -0.341 . . . . 1.51 110.08 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.535 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.7 m -118.32 164.47 14.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.115 0.483 . . . . 1.39 111.47 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.446 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.0 p -133.64 135.4 55.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.402 -0.817 . . . . 0.81 110.249 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 14.6 mt -109.15 133.7 53.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.977 -0.556 . . . . 0.32 110.101 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.72 -169.78 36.7 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.147 -0.549 . . . . 1.02 111.811 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.87 149.98 17.05 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.934 -0.651 . . . . 0.4 111.789 -173.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.3 t70 61.02 20.54 10.96 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 121.926 0.87 . . . . 1.26 109.523 -174.115 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.7 t -106.69 159.05 16.5 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.346 -0.843 . . . . 1.19 110.686 -177.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.453 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.3 mt -140.3 124.55 18.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.8 -0.636 . . . . 0.38 109.922 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 13.1 p -147.09 143.76 20.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.814 0.34 . . . . 1.0 110.822 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.4 tt0 -99.27 133.92 42.88 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.968 0.413 . . . . 0.67 110.587 -179.26 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.571 ' CE ' HG21 ' A' ' 70' ' ' ILE . 47.0 mmm -73.83 88.99 1.81 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.651 -0.704 . . . . 0.88 110.815 -177.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.3 p -119.02 -164.71 1.06 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.434 -0.348 . . . . 0.29 110.088 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -67.69 -26.86 66.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.409 0.624 . . . . 2.13 109.52 177.456 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -63.14 -25.7 68.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.131 -0.941 . . . . 2.51 109.888 177.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.571 HG21 ' CE ' ' A' ' 66' ' ' MET . 0.9 OUTLIER -96.87 -55.31 6.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 114.743 -1.117 . . . . 0.25 110.595 177.794 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.752 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.3 t80 -96.76 82.66 3.32 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.326 -0.852 . . . . 0.31 110.157 -174.735 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -85.92 98.68 10.93 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.162 -0.926 . . . . 1.46 110.102 175.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 24.7 p -68.75 124.37 23.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.69 110.758 -179.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.23 -42.08 2.11 Favored Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.585 -0.816 . . . . 1.91 112.064 -177.541 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -134.99 -1.06 2.71 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.749 0.309 . . . . 5.57 111.033 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.508 -0.758 . . . . 6.87 110.752 177.188 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.71 0 N-CA-C 112.165 -0.374 . . . . 1.71 112.165 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 -97.72 144.74 27.04 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-O 120.905 0.383 . . . . 2.0 110.443 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.66 109.28 12.74 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 115.684 -0.689 . . . . 0.24 109.328 175.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.8 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.1 pt -89.18 -12.05 10.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.32 -0.854 . . . . 0.15 111.632 -171.363 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.35 174.03 40.38 Favored Glycine 0 CA--C 1.501 -0.837 0 C-N-CA 120.858 -0.687 . . . . 0.1 111.55 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -144.91 149.7 35.75 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.013 0.435 . . . . 0.2 110.327 -176.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.578 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.66 124.54 36.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-N 115.699 -0.682 . . . . 0.14 110.871 -177.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 67.9 p -117.6 -16.83 10.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.378 0.609 . . . . 0.2 110.875 178.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.442 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 27.4 tptp -146.73 138.59 24.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.335 -0.987 . . . . 2.36 108.335 172.388 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.418 HD11 HG21 ' A' ' 14' ' ' VAL . 6.5 tt -150.37 148.03 28.3 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.807 -0.357 . . . . 0.2 110.8 -178.213 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -157.48 154.49 28.78 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.923 -0.58 . . . . 1.94 110.274 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.81 -157.4 48.85 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.11 -0.567 . . . . 0.27 113.466 172.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 33.4 m -100.07 115.0 28.73 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.366 -0.417 . . . . 1.16 110.056 -178.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.564 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.6 m -133.7 152.57 35.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.525 0.678 . . . . 0.2 111.599 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.39 158.56 43.89 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 114.866 -1.061 . . . . 0.17 109.045 -178.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.625 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.7 OUTLIER -134.59 139.49 47.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 C-N-CA 120.131 -0.628 . . . . 0.16 110.857 173.007 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.434 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.3 mt-30 -104.21 99.88 9.61 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.204 -0.907 . . . . 0.51 109.251 175.767 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.495 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 68.6 p -63.75 -179.39 0.38 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.638 0.256 . . . . 1.25 110.935 -176.07 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -69.35 -3.33 2.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.944 0.402 . . . . 0.59 111.514 178.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -94.19 -7.01 43.46 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.461 -0.57 . . . . 1.96 109.461 173.115 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.36 19.9 65.58 Favored Glycine 0 CA--C 1.503 -0.681 0 N-CA-C 110.881 -0.888 . . . . 0.32 110.881 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 77.4 mt-30 -92.76 123.12 35.81 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.829 -0.686 . . . . 2.21 110.877 -177.153 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.608 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 19.8 tt0 -89.16 118.46 28.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.355 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.625 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -121.62 166.57 14.04 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.461 -0.57 . . . . 1.55 109.461 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.3 p -89.85 135.26 26.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 109.127 -0.694 . . . . 0.35 109.127 177.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.564 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.3 mt -95.79 146.95 24.13 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.227 0.537 . . . . 0.32 110.902 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.508 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 33.2 mttp -138.07 171.98 13.6 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.059 -0.973 . . . . 1.65 108.544 -176.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.82 139.02 58.28 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 119.285 -0.966 . . . . 0.23 109.254 177.269 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.35 89.89 Favored Glycine 0 N--CA 1.437 -1.265 0 C-N-CA 119.865 -1.16 . . . . 0.24 112.478 178.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -76.94 140.4 66.78 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 121.54 0.686 . . . . 1.92 110.48 178.581 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.14 129.3 7.73 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.601 2.868 . . . . 0.22 113.848 -176.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.2 mm -97.39 132.86 41.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 115.588 -0.733 . . . . 0.13 109.187 173.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -113.27 159.75 19.03 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.855 -0.612 . . . . 0.29 109.786 -177.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.497 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.9 t80 -74.52 116.05 14.76 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.285 -0.416 . . . . 0.18 110.16 -175.825 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.33 9.51 27.32 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.57 -0.824 . . . . 0.17 113.265 177.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.495 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 38.7 mt-10 -90.61 139.92 30.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 118.088 0.944 . . . . 0.52 110.343 177.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.3 m -98.28 106.25 18.51 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.207 -0.906 . . . . 0.16 110.727 -176.533 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.4 t -82.38 125.78 39.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.158 0.504 . . . . 0.16 110.771 -174.545 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -110.2 105.2 14.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.136 -0.938 . . . . 0.27 109.701 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.468 HG21 HG21 ' A' ' 58' ' ' ILE . 62.7 p -109.79 143.66 39.32 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.987 -0.375 . . . . 0.23 109.987 178.52 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -121.37 151.89 16.91 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 120.485 -0.865 . . . . 0.9 111.633 177.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.66 -113.25 2.96 Favored Glycine 0 N--CA 1.453 -0.227 0 C-N-CA 121.467 -0.396 . . . . 1.79 113.006 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.6 m -103.5 35.61 2.54 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.771 0.32 . . . . 1.64 110.621 -178.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.16 93.99 0.09 OUTLIER Glycine 0 CA--C 1.52 0.374 0 CA-C-N 115.91 -0.586 . . . . 0.89 112.543 177.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.695 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 49.2 m -109.54 124.68 51.52 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.748 -0.464 . . . . 0.85 109.748 -174.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 6.1 t -142.92 119.99 6.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 CA-C-O 121.003 0.43 . . . . 0.25 111.286 -171.458 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 88.6 m -92.21 103.65 16.1 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.573 -0.739 . . . . 0.19 109.934 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.464 HD13 ' HE2' ' A' ' 66' ' ' MET . 68.2 mt -94.88 99.55 9.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 114.982 -1.008 . . . . 0.15 109.51 177.077 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.16 107.54 13.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.395 -0.82 . . . . 0.14 109.497 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.554 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 57.1 m-85 -70.7 145.67 50.39 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.47 0.652 . . . . 0.32 110.947 -177.228 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.9 p -70.98 1.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.76 -1.109 . . . . 0.25 111.754 -172.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.744 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 13.8 t70 -99.42 -16.42 18.39 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.86 0.362 . . . . 0.75 110.815 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.85 -14.76 9.06 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.466 -0.873 . . . . 0.27 112.374 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.7 p -84.38 154.61 22.74 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.372 -0.233 . . . . 0.36 110.372 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -133.67 138.2 45.75 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 120.964 0.411 . . . . 1.51 110.345 -179.464 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.448 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 1.1 t -123.33 150.41 27.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.983 -0.553 . . . . 1.39 110.286 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -135.54 129.91 49.61 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.419 0.628 . . . . 0.81 110.731 178.688 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.695 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.3 mt -94.3 139.04 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.545 -0.752 . . . . 0.32 109.599 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.85 -57.4 2.42 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 121.199 -0.524 . . . . 1.02 112.716 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 150.46 158.56 8.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.874 -0.679 . . . . 0.4 111.857 178.181 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.6 t70 51.83 43.23 30.25 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.703 0.763 . . . . 1.26 110.521 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.5 t -129.28 158.08 40.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.757 -0.656 . . . . 1.19 110.394 -176.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.56 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -140.28 106.88 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.536 -0.756 . . . . 0.38 109.148 177.223 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.33 140.41 44.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.897 0.38 . . . . 1.0 111.02 -174.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.464 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.8 tt0 -91.81 128.64 37.72 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.67 109.729 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.477 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 55.8 mmm -66.28 89.45 0.13 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.149 -0.478 . . . . 0.88 110.313 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.425 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 59.4 p -110.81 -166.47 1.08 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.871 -0.604 . . . . 0.29 111.724 -174.383 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.01 -33.41 74.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 2.13 110.323 178.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -70.35 -25.66 63.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.731 0.777 . . . . 2.51 109.975 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.425 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.3 mm -80.06 -53.51 12.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 114.596 -1.183 . . . . 0.25 111.079 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.8 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 -102.99 82.52 2.1 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.355 -0.839 . . . . 0.31 110.274 -175.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -73.54 113.1 10.26 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.602 -0.726 . . . . 1.46 109.842 174.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.9 p -93.7 140.52 29.54 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.097 -0.501 . . . . 0.69 110.966 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 78.39 32.2 43.55 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.853 -0.689 . . . . 1.91 112.514 178.282 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -79.07 -44.77 21.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.491 0.186 . . . . 5.57 111.046 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.6 m-20 . . . . . 0 C--O 1.246 0.918 0 CA-C-O 117.99 -1.005 . . . . 6.87 110.627 -179.246 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.593 0 N-CA-C 112.062 -0.415 . . . . 1.71 112.062 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -102.55 160.51 14.5 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.994 -0.372 . . . . 2.0 109.994 179.312 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.52 116.68 17.43 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 121.438 0.637 . . . . 0.24 110.342 -178.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.787 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.1 pt -101.92 -14.62 8.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.095 -0.957 . . . . 0.15 111.811 -171.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.81 179.22 41.27 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 120.796 -0.716 . . . . 0.1 111.415 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.405 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 95.0 m-85 -143.79 152.51 41.32 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.939 0.4 . . . . 0.2 110.569 -175.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.477 HG12 ' O ' ' A' ' 30' ' ' ASP . 34.2 mm -80.21 119.97 30.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.203 -0.453 . . . . 0.14 110.945 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.2 p -113.12 -18.71 12.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.281 0.563 . . . . 0.2 110.586 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.556 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.9 tttt -144.81 145.08 31.47 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.236 -1.024 . . . . 2.36 108.236 172.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.608 HD11 HG21 ' A' ' 14' ' ' VAL . 7.0 tt -159.91 142.34 13.42 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.792 0.33 . . . . 0.2 111.019 -177.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -150.67 153.25 35.26 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.779 -0.646 . . . . 1.94 111.274 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.22 -155.14 50.18 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.982 -0.554 . . . . 0.27 113.235 174.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 27.2 t -97.91 119.7 36.99 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.878 -0.415 . . . . 1.16 109.878 -178.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.608 HG21 HD11 ' A' ' 10' ' ' LEU . 2.7 m -132.09 152.98 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.415 0.626 . . . . 0.2 110.828 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.28 159.15 44.66 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.725 -1.125 . . . . 0.17 108.174 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.708 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -134.97 130.44 52.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 C-N-CA 119.545 -0.862 . . . . 0.16 110.817 173.816 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.44 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.8 mt-30 -96.15 98.61 10.47 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.269 -0.878 . . . . 0.51 109.255 175.407 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.506 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 15.9 m -63.79 176.49 0.91 Allowed 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.031 -0.532 . . . . 1.25 110.816 -176.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.6 pt -56.81 -28.03 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 112.687 0.625 . . . . 0.59 112.687 -173.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -82.63 -1.1 50.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.788 0.328 . . . . 1.96 110.963 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 89.35 8.02 68.89 Favored Glycine 0 CA--C 1.506 -0.529 0 N-CA-C 111.047 -0.821 . . . . 0.32 111.047 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 87.7 mm-40 -79.15 115.6 18.91 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.937 -0.631 . . . . 2.21 111.115 -177.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.592 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.6 tt0 -88.15 111.25 21.39 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.94 -0.573 . . . . 1.0 110.533 178.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.708 ' HG2' HG12 ' A' ' 16' ' ' VAL . 16.8 ptt85 -112.22 170.78 7.93 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.214 -0.662 . . . . 1.55 109.214 176.416 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.93 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 109.772 -0.455 . . . . 0.35 109.772 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.445 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 21.2 mt -109.98 128.29 55.3 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.942 -0.572 . . . . 0.32 110.593 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -116.03 -173.9 2.44 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 108.056 -1.09 . . . . 1.65 108.056 171.492 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.83 143.5 52.87 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.734 -0.786 . . . . 0.23 109.389 175.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.51 -2.75 84.69 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.295 -0.955 . . . . 0.24 112.946 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.477 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.3 m-20 -73.0 143.7 84.31 Favored Pre-proline 0 CA--C 1.512 -0.488 0 N-CA-C 109.556 -0.535 . . . . 1.92 109.556 174.392 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.405 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 25.4 Cg_endo -87.64 141.56 5.58 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.922 2.415 . . . . 0.22 112.41 -179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mm -100.93 139.16 22.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.662 -0.496 . . . . 0.13 109.662 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -115.33 150.0 36.98 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 116.019 -0.537 . . . . 0.29 109.676 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.586 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -68.41 113.24 5.8 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.276 -0.42 . . . . 0.18 110.322 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.68 -1.23 13.81 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.368 -0.92 . . . . 0.17 113.463 178.088 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.518 ' HB3' HG22 ' A' ' 16' ' ' VAL . 36.9 mt-10 -85.48 148.6 25.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 117.789 0.795 . . . . 0.52 110.951 -178.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 8.6 m -106.83 105.95 16.23 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.621 -0.718 . . . . 0.16 110.642 -176.765 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -81.86 126.39 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.351 0.596 . . . . 0.16 110.777 -174.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -114.76 100.76 8.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.83 -1.077 . . . . 0.27 109.851 -177.203 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.6 p -99.02 152.88 19.34 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.284 -0.636 . . . . 0.23 109.284 176.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -126.22 136.88 9.8 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.34 -0.933 . . . . 0.9 112.526 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 52.6 -103.24 0.11 Allowed Glycine 0 C--N 1.33 0.248 0 O-C-N 123.844 0.379 . . . . 1.79 113.69 177.45 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 18.3 m -96.15 26.38 4.27 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.719 0.295 . . . . 1.64 111.644 -175.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.21 144.68 47.0 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 121.123 -0.56 . . . . 0.89 112.74 177.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 8.7 m -151.12 139.61 20.52 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.646 -0.872 . . . . 0.85 108.646 175.45 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.5 t -148.4 134.05 11.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 O-C-N 122.012 -0.43 . . . . 0.25 110.958 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.556 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.2 m -109.84 108.16 18.38 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.76 -0.459 . . . . 0.19 109.76 173.182 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.619 HD13 ' HE2' ' A' ' 66' ' ' MET . 56.7 mt -99.14 104.22 15.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.593 -0.73 . . . . 0.15 109.969 178.112 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.43 107.34 12.12 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.405 -0.816 . . . . 0.14 109.133 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.44 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 63.0 m-85 -73.72 146.63 44.27 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.491 0.662 . . . . 0.32 110.899 -177.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -77.36 0.89 2.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 114.821 -1.081 . . . . 0.25 111.398 -170.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.36 -21.75 27.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.223 0.535 . . . . 0.75 109.948 173.427 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.56 -12.69 7.41 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.77 -0.729 . . . . 0.27 112.802 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.0 p -87.5 162.98 16.93 Favored 'General case' 0 C--N 1.327 -0.412 0 O-C-N 122.821 -0.223 . . . . 0.36 111.074 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.2 147.46 50.73 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.762 -0.458 . . . . 1.51 109.762 176.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.539 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 11.9 m -128.2 161.2 37.05 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 CA-C-O 121.264 0.554 . . . . 1.39 111.25 175.545 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.596 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 97.9 t -135.06 123.93 41.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.814 -1.084 . . . . 0.81 110.159 178.22 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 45' ' ' SER . 24.0 mt -96.55 133.92 36.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.445 -0.798 . . . . 0.32 110.191 -177.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -76.58 -163.91 17.67 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.047 -0.597 . . . . 1.02 112.346 177.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.07 149.86 17.85 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 111.208 -0.757 . . . . 0.4 111.208 -174.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.5 t70 60.85 20.86 11.05 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 121.901 0.858 . . . . 1.26 109.744 -175.071 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.0 m -102.94 154.18 19.47 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.572 -0.74 . . . . 1.19 110.967 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.56 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.4 mt -141.68 109.69 2.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.35 -0.841 . . . . 0.38 109.727 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.3 p -139.81 142.45 32.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.803 0.335 . . . . 1.0 110.827 -177.009 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.442 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 34.7 tt0 -91.16 132.87 35.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.929 0.395 . . . . 0.67 110.488 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.619 ' HE2' HD13 ' A' ' 48' ' ' ILE . 63.4 mmm -67.13 89.88 0.19 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.448 -0.796 . . . . 0.88 110.808 -177.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.414 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.6 p -117.77 -162.99 0.9 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.488 -0.778 . . . . 0.29 111.305 -175.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -66.92 -40.93 87.8 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.733 0.272 . . . . 2.13 111.733 -175.538 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -64.57 -26.17 68.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.687 0.756 . . . . 2.51 110.605 177.158 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.439 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.6 mm -76.36 -51.33 19.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.766 -1.106 . . . . 0.25 110.557 174.413 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.787 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -108.42 76.78 1.05 Allowed 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.33 -0.85 . . . . 0.31 110.106 -177.371 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -73.65 107.23 5.79 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.605 -0.725 . . . . 1.46 109.167 175.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 5.6 p -80.16 127.08 31.91 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.002 -0.545 . . . . 0.69 110.919 -176.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -92.45 -60.9 1.2 Allowed Glycine 0 N--CA 1.445 -0.754 0 CA-C-N 115.894 -0.593 . . . . 1.91 113.36 -173.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -139.43 -37.2 0.5 Allowed 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.498 0.555 . . . . 5.57 112.498 -175.06 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 . . . . . 0 C--O 1.25 1.117 0 CA-C-O 118.337 -0.84 . . . . 6.87 110.946 -176.066 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.58 0 N-CA-C 112.106 -0.398 . . . . 1.71 112.106 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -102.31 141.08 35.71 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.001 0.429 . . . . 2.0 110.778 178.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.95 109.61 13.39 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.622 -0.717 . . . . 0.24 109.91 -178.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.774 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.4 pt -88.86 -14.9 9.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.179 -0.918 . . . . 0.15 111.616 -171.117 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -166.98 177.15 41.79 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.886 -0.673 . . . . 0.1 111.465 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -143.95 150.67 38.7 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.951 0.405 . . . . 0.2 110.529 -175.464 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.613 HG12 ' O ' ' A' ' 30' ' ' ASP . 20.7 mm -78.75 122.2 33.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.981 -0.554 . . . . 0.14 110.78 -178.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.7 p -114.75 -21.79 10.01 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.311 0.576 . . . . 0.2 110.67 179.131 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.625 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 36.1 ttpt -141.1 145.71 36.15 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.417 -0.957 . . . . 2.36 108.417 172.407 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.418 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -156.66 144.73 19.52 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 120.774 0.321 . . . . 0.2 110.684 -177.601 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.484 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 6.3 t70 -151.75 148.32 27.74 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.881 -0.6 . . . . 1.94 110.73 -178.159 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.517 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 74.96 -152.46 43.98 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.09 -0.576 . . . . 0.27 113.503 173.388 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 9.0 t -103.63 120.07 40.16 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.927 -0.397 . . . . 1.16 109.927 -177.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.599 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.9 m -135.83 153.2 32.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.2 111.859 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.43 159.65 44.32 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.881 -1.054 . . . . 0.17 109.457 -177.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.715 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -134.21 136.66 53.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 C-N-CA 120.152 -0.619 . . . . 0.16 110.984 173.188 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -103.28 103.52 13.55 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.155 -0.929 . . . . 0.51 109.641 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.532 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 47.6 t -62.05 176.8 0.52 Allowed 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.572 -0.451 . . . . 1.25 110.392 -178.209 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.3 pt -60.36 -31.13 47.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-O 121.107 0.48 . . . . 0.59 111.869 -173.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -74.35 -14.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.865 -0.607 . . . . 1.96 110.916 177.581 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.1 10.27 46.06 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.146 -0.55 . . . . 0.32 112.522 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.8 mm-40 -80.94 119.94 24.11 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.901 0.382 . . . . 2.21 111.214 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.567 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 18.5 tt0 -88.77 119.49 29.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.623 179.192 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.715 ' HG2' HG12 ' A' ' 16' ' ' VAL . 21.3 ptt-85 -119.1 166.1 13.34 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.43 -0.581 . . . . 1.55 109.43 174.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -86.56 137.58 20.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.942 -0.572 . . . . 0.35 109.483 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.599 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.0 mt -102.08 151.88 21.64 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.196 0.522 . . . . 0.32 111.167 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.432 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.5 mttt -139.57 175.97 9.12 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.105 -0.952 . . . . 1.65 108.479 -175.34 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.95 140.92 49.4 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.566 -0.853 . . . . 0.23 108.957 176.487 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.77 6.04 86.81 Favored Glycine 0 N--CA 1.435 -1.389 0 C-N-CA 119.877 -1.154 . . . . 0.24 112.218 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.613 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.0 138.81 46.07 Favored Pre-proline 0 N--CA 1.454 -0.248 0 CA-C-O 121.75 0.786 . . . . 1.92 110.35 178.19 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.92 130.29 11.27 Favored 'Trans proline' 0 C--N 1.325 -0.682 0 C-N-CA 123.719 2.946 . . . . 0.22 113.509 -178.089 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.446 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 26.3 mm -96.02 136.54 26.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 CA-C-N 115.349 -0.841 . . . . 0.13 109.266 173.787 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -117.87 151.35 37.56 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 109.565 -0.531 . . . . 0.29 109.565 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.569 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.9 t80 -67.1 126.29 28.7 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.988 -0.551 . . . . 0.18 110.188 -176.458 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.21 -12.8 33.88 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.462 -0.875 . . . . 0.17 113.074 178.182 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.532 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.7 mt-10 -82.04 139.39 34.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.584 0.707 . . . . 0.52 111.072 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.527 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 17.8 m -98.74 109.98 22.65 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.684 -1.144 . . . . 0.16 110.718 -177.122 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -82.19 132.9 30.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.48 -0.488 . . . . 0.16 110.618 -175.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -119.61 113.33 20.53 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.516 -0.766 . . . . 0.27 110.298 -177.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 71.5 p -105.49 153.19 22.06 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.274 -0.639 . . . . 0.23 109.274 173.061 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -113.61 -171.13 17.58 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 120.587 -0.816 . . . . 0.9 111.076 177.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 43' ' ' SER . . . -51.71 117.15 5.55 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 110.694 -0.962 . . . . 1.79 110.694 175.557 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.517 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 32.6 t 69.96 80.74 0.17 Allowed 'General case' 0 C--N 1.327 -0.379 0 O-C-N 124.229 0.606 . . . . 1.64 109.768 -169.787 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -142.39 139.38 9.12 Favored Glycine 0 N--CA 1.448 -0.55 0 N-CA-C 110.879 -0.888 . . . . 0.89 110.879 174.09 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.484 ' HB2' ' HB3' ' A' ' 11' ' ' ASP . 25.4 m -156.01 142.61 18.65 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.182 -0.673 . . . . 0.85 109.182 174.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.619 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.4 t -148.32 145.02 18.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 O-C-N 122.242 -0.286 . . . . 0.25 110.334 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.625 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 97.9 m -115.98 106.81 14.2 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.158 0.504 . . . . 0.19 109.87 172.268 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.0 103.0 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.291 -0.868 . . . . 0.15 109.807 178.56 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.74 103.67 8.85 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.463 -0.79 . . . . 0.14 109.287 177.41 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.565 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 50.5 m-85 -68.73 147.09 52.32 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.618 0.723 . . . . 0.32 110.907 -178.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.2 p -74.46 1.66 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.518 -1.219 . . . . 0.25 111.459 -172.387 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.474 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 22.0 t70 -97.26 -0.93 45.81 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.307 0.575 . . . . 0.75 109.752 177.271 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.61 -10.94 49.96 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.859 -0.686 . . . . 0.27 112.847 177.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.3 p -87.79 164.08 16.13 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.534 -0.173 . . . . 0.36 110.534 177.402 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -135.94 153.32 51.46 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.819 -0.438 . . . . 1.51 109.819 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.565 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.7 OUTLIER -135.41 147.66 28.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.968 0.413 . . . . 1.39 110.542 -179.102 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.619 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 89.5 t -125.84 130.22 72.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.638 -0.71 . . . . 0.81 110.176 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.1 mt -102.86 144.69 13.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.984 -0.553 . . . . 0.32 110.614 -176.705 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -88.93 -161.53 37.57 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.926 -0.579 . . . . 1.02 112.11 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -113.63 147.96 18.65 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.431 -0.668 . . . . 0.4 111.431 -174.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 29.7 t70 53.46 28.84 8.06 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.981 0.896 . . . . 1.26 109.888 -173.488 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.8 m -110.49 157.13 19.95 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.085 -0.961 . . . . 1.19 110.809 -179.193 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.414 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.8 mt -140.96 123.76 15.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.456 -0.793 . . . . 0.38 109.731 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.6 p -149.55 145.02 17.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 1.0 110.525 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.527 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 44.0 tt0 -98.17 134.69 40.88 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.28 -0.418 . . . . 0.67 111.076 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.554 ' SD ' HG21 ' A' ' 70' ' ' ILE . 21.8 mmt -64.32 89.24 0.06 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.704 -0.68 . . . . 0.88 110.725 175.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 16.5 p -121.59 -168.22 1.65 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.654 -0.703 . . . . 0.29 110.312 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -68.07 -25.25 65.25 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.272 0.558 . . . . 2.13 109.787 177.309 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 25.8 mm-40 -65.97 -21.73 66.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.41 -0.814 . . . . 2.51 110.098 177.205 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.554 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.5 mm -103.02 -53.86 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 CA-C-N 114.721 -1.127 . . . . 0.25 110.883 -179.565 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.774 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 4.0 t80 -113.27 73.86 0.84 Allowed 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.261 -0.881 . . . . 0.31 110.226 -176.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -79.64 98.24 6.85 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.755 -0.657 . . . . 1.46 109.814 175.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 32.5 p -68.62 142.36 55.14 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.902 -0.59 . . . . 0.69 111.383 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 143.55 15.83 0.26 Allowed Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.339 -0.934 . . . . 1.91 113.246 178.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -95.09 -52.51 4.18 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.891 -0.411 . . . . 5.57 109.891 177.097 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 . . . . . 0 C--O 1.249 1.027 0 O-C-N 123.848 0.717 . . . . 6.87 111.048 179.162 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.922 0 N-CA-C 111.96 -0.456 . . . . 1.71 111.96 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.414 ' O ' ' HA ' ' A' ' 33' ' ' PHE . 19.8 t-20 67.22 162.73 0.18 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.59 0.756 . . . . 2.0 110.434 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.39 116.29 21.15 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.4 0.619 . . . . 0.24 110.654 -174.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.79 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.0 pt -105.55 -14.4 8.97 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.855 -1.066 . . . . 0.15 111.765 -173.048 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.53 177.77 41.81 Favored Glycine 0 CA--C 1.5 -0.894 0 N-CA-C 111.046 -0.822 . . . . 0.1 111.046 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -144.12 151.18 39.23 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.979 0.419 . . . . 0.2 111.034 -175.068 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.468 HD13 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -78.62 120.85 30.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.715 -0.675 . . . . 0.14 110.717 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.0 p -113.25 -23.35 9.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.259 0.552 . . . . 0.2 110.205 179.046 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.62 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 37.8 ttpt -140.63 144.93 36.02 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.524 -0.762 . . . . 2.36 109.069 172.343 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.443 HD11 HG21 ' A' ' 14' ' ' VAL . 6.3 tt -155.8 144.62 20.45 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 110.292 -0.262 . . . . 0.2 110.292 -178.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -153.17 152.36 31.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.16 -0.473 . . . . 1.94 111.136 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.25 -144.11 29.21 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.975 -0.557 . . . . 0.27 112.74 175.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t -113.61 123.31 49.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.428 -0.582 . . . . 1.16 109.428 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.491 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -138.16 152.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.2 111.62 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.84 159.39 44.21 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.798 -1.092 . . . . 0.17 108.175 177.454 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.541 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -132.33 133.18 60.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 C-N-CA 120.11 -0.636 . . . . 0.16 110.46 175.475 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.462 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.0 mt-30 -96.04 98.56 10.46 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.461 -0.79 . . . . 0.51 109.327 178.01 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.53 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 25.0 m -63.62 173.43 1.69 Allowed 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.865 -0.607 . . . . 1.25 110.035 -177.417 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 9.1 pt -64.55 -3.31 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 N-CA-C 114.238 1.199 . . . . 0.59 114.238 -168.371 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -106.03 6.98 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.344 0.592 . . . . 1.96 109.823 174.706 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.62 6.56 80.17 Favored Glycine 0 CA--C 1.504 -0.606 0 N-CA-C 110.75 -0.94 . . . . 0.32 110.75 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.5 mm-40 -78.4 117.44 19.62 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.833 -0.684 . . . . 2.21 111.403 -175.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -80.63 126.39 31.2 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.232 0.539 . . . . 1.0 110.582 178.76 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.41 144.59 51.49 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.452 -0.794 . . . . 1.55 109.239 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.3 p -78.2 142.76 13.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.963 0.411 . . . . 0.35 110.242 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.491 ' HB2' HG23 ' A' ' 14' ' ' VAL . 25.5 mt -108.07 128.82 55.02 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.168 -0.469 . . . . 0.32 110.615 178.428 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.2 mttm -111.13 -178.0 3.35 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.298 -1.001 . . . . 1.65 108.298 172.398 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.2 144.49 53.72 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 119.618 -0.833 . . . . 0.23 109.193 173.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.47 2.8 89.83 Favored Glycine 0 N--CA 1.439 -1.139 0 C-N-CA 120.249 -0.977 . . . . 0.24 112.551 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.428 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -70.53 145.27 92.53 Favored Pre-proline 0 CA--C 1.51 -0.571 0 CA-C-O 121.218 0.533 . . . . 1.92 109.923 174.418 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -90.04 135.75 2.36 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 123.251 2.634 . . . . 0.22 111.851 178.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -97.99 135.29 33.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.539 -0.541 . . . . 0.13 109.539 177.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.414 ' HA ' ' O ' ' A' ' 2' ' ' ASN . 80.2 m-85 -112.19 144.37 41.69 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.63 -0.714 . . . . 0.29 109.894 -177.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.631 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.5 t80 -66.09 109.22 2.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.24 -0.437 . . . . 0.18 109.987 -177.056 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.75 -4.19 8.03 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.308 -0.949 . . . . 0.17 113.754 178.275 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.541 ' HB3' HG22 ' A' ' 16' ' ' VAL . 26.2 mt-10 -86.72 151.23 23.57 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 118.223 1.012 . . . . 0.52 110.831 -177.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.462 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 25.6 m -111.15 107.49 16.86 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.467 -0.788 . . . . 0.16 110.687 -176.547 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.662 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.9 t -78.67 129.77 37.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 120.896 0.379 . . . . 0.16 111.28 -173.709 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -113.23 98.41 7.1 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.527 -0.761 . . . . 0.27 109.913 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.404 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 82.5 p -96.4 152.99 18.08 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.584 -0.525 . . . . 0.23 109.584 177.617 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -116.79 -155.82 10.43 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 111.517 -0.633 . . . . 0.9 111.517 178.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -56.76 128.7 47.58 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.898 -0.668 . . . . 1.79 112.333 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 15.4 m 68.69 19.83 8.4 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 123.119 0.568 . . . . 1.64 111.621 178.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.35 134.33 22.71 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.885 -0.674 . . . . 0.89 112.596 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.562 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 69.6 m -152.82 136.73 16.27 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.172 -0.677 . . . . 0.85 109.172 172.579 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.612 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 19.4 t -145.85 137.49 19.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 120.602 0.239 . . . . 0.25 110.531 -177.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.62 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 87.2 m -111.36 106.74 15.77 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.042 -0.527 . . . . 0.19 109.992 174.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.557 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.3 mt -97.87 103.16 14.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.654 -0.703 . . . . 0.15 110.009 177.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.44 105.48 9.73 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.303 -0.862 . . . . 0.14 109.25 177.208 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.489 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.5 m-85 -72.92 145.76 46.58 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.563 0.697 . . . . 0.32 110.584 -178.623 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.0 p -74.07 -8.5 11.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 114.677 -1.147 . . . . 0.25 111.655 -169.483 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.45 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 15.2 t70 -81.62 -21.06 38.51 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.221 -0.445 . . . . 0.75 110.504 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.37 -13.52 6.25 Favored Glycine 0 CA--C 1.519 0.321 0 C-N-CA 120.567 -0.825 . . . . 0.27 113.045 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.8 p -87.76 162.45 17.03 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 122.727 -0.278 . . . . 0.36 111.344 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -135.41 148.0 49.18 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.96 -0.756 . . . . 1.51 108.96 177.097 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.557 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.6 m -129.7 166.54 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.574 0 CA-C-O 121.213 0.53 . . . . 1.39 111.96 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.612 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.9 p -133.12 135.89 56.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 114.908 -1.042 . . . . 0.81 110.15 176.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.562 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.3 mt -108.23 134.54 49.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.861 -0.609 . . . . 0.32 109.656 178.733 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.65 -159.49 21.18 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.206 -0.521 . . . . 1.02 112.336 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.7 146.66 18.32 Favored Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.901 -0.666 . . . . 0.4 111.775 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.404 ' HA ' ' O ' ' A' ' 40' ' ' THR . 29.2 t70 56.77 26.39 11.39 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 121.702 0.763 . . . . 1.26 109.909 -174.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 t -103.91 156.97 17.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.536 -0.756 . . . . 1.19 110.495 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.662 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.7 mt -142.47 104.49 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.504 -0.771 . . . . 0.38 109.16 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.1 m -131.93 150.13 33.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.006 0.431 . . . . 1.0 111.736 -175.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -102.84 128.09 49.75 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.626 -0.715 . . . . 0.67 110.609 -177.112 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.525 ' HE2' HD13 ' A' ' 48' ' ' ILE . 51.3 mmm -67.72 89.58 0.26 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.522 -0.763 . . . . 0.88 110.666 -177.317 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.5 p -121.37 -167.45 1.51 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.006 -0.543 . . . . 0.29 111.118 -177.289 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -65.59 -29.6 70.22 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.735 0.303 . . . . 2.13 110.846 -178.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.49 -17.3 62.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.6 0.714 . . . . 2.51 110.354 177.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.512 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.1 mm -96.04 -50.43 11.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 115.127 -0.942 . . . . 0.25 110.562 177.455 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.79 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -98.55 87.25 3.77 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.363 -0.835 . . . . 0.31 109.658 -177.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -69.52 88.26 0.49 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.732 -1.122 . . . . 1.46 110.659 176.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 16.5 p -83.96 118.04 23.76 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.077 -0.511 . . . . 0.69 110.226 176.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.433 ' C ' ' H ' ' A' ' 76' ' ' ASN . . . -164.1 36.79 0.3 Allowed Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.037 -1.077 . . . . 1.91 112.838 -178.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.6 t70 73.72 -32.81 0.24 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 123.464 0.706 . . . . 5.57 111.74 177.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.433 ' H ' ' C ' ' A' ' 74' ' ' GLY . 5.5 t30 . . . . . 0 C--O 1.248 0.987 0 O-C-N 123.819 0.699 . . . . 6.87 110.414 177.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.657 0 N-CA-C 112.054 -0.419 . . . . 1.71 112.054 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 -122.5 154.37 37.94 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.848 0.356 . . . . 2.0 110.224 -179.117 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.14 113.18 14.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.774 -0.648 . . . . 0.24 110.282 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.783 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.3 pt -92.01 -16.77 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.085 -0.961 . . . . 0.15 111.646 -172.192 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.42 177.25 40.82 Favored Glycine 0 CA--C 1.501 -0.816 0 C-N-CA 120.787 -0.72 . . . . 0.1 111.535 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -144.59 152.08 39.98 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 120.788 0.328 . . . . 0.2 110.291 -174.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.572 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.1 mm -80.09 123.29 36.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.272 -0.422 . . . . 0.14 111.146 -178.245 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.5 p -112.79 -23.64 10.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.117 0.484 . . . . 0.2 110.461 178.312 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.512 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 34.9 ttpt -141.88 145.51 34.69 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.706 -0.85 . . . . 2.36 108.706 173.459 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.581 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -158.63 144.84 17.0 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.595 0.236 . . . . 0.2 110.436 -176.076 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -154.2 152.44 30.36 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.017 -0.538 . . . . 1.94 110.735 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.46 -156.03 46.11 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.988 -0.551 . . . . 0.27 113.245 174.124 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 25.4 t -99.17 120.49 39.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.293 -0.632 . . . . 1.16 109.293 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.581 HG21 HD11 ' A' ' 10' ' ' LEU . 4.6 m -137.75 152.33 26.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.659 0.743 . . . . 0.2 111.729 -175.074 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.08 158.92 44.67 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 114.582 -1.19 . . . . 0.17 108.863 -178.399 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.696 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.6 OUTLIER -136.4 132.37 48.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 C-N-CA 119.99 -0.684 . . . . 0.16 110.982 172.221 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.441 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.7 mt-30 -96.67 99.01 10.64 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.092 -0.958 . . . . 0.51 109.284 174.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.474 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.6 m -66.32 179.6 0.95 Allowed 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.971 -0.292 . . . . 1.25 110.811 -176.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.2 pt -60.24 -26.76 37.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 O-C-N 121.886 -0.509 . . . . 0.59 112.218 -175.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 -79.69 -8.79 59.45 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.998 0.428 . . . . 1.96 110.62 178.056 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.8 5.81 62.58 Favored Glycine 0 CA--C 1.506 -0.478 0 N-CA-C 111.234 -0.746 . . . . 0.32 111.234 178.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -74.44 117.97 16.86 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.305 -0.447 . . . . 2.21 110.819 -179.383 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.696 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.5 tt0 -95.09 110.43 22.36 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.168 0.508 . . . . 1.0 110.224 177.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.63 ' HG2' HG12 ' A' ' 16' ' ' VAL . 17.1 ptt-85 -111.61 167.92 9.96 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.952 -0.567 . . . . 1.55 109.906 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.0 p -86.61 129.47 38.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.821 -0.627 . . . . 0.35 109.317 176.563 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.555 HD22 ' OD1' ' A' ' 30' ' ' ASP . 2.8 mt -91.07 143.54 26.6 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 121.526 0.679 . . . . 0.32 110.999 -178.829 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.488 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.8 mttp -131.21 171.59 13.13 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.658 -1.156 . . . . 1.65 109.232 -172.835 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.86 134.74 46.27 Favored 'General case' 0 CA--C 1.507 -0.701 0 C-N-CA 119.171 -1.011 . . . . 0.23 108.743 174.294 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.93 0.58 89.75 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 119.603 -1.284 . . . . 0.24 111.656 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.572 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.08 139.73 79.75 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-O 121.69 0.757 . . . . 1.92 110.203 177.06 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 37.2 Cg_endo -87.64 123.49 1.81 Allowed 'Trans proline' 0 C--N 1.323 -0.771 0 C-N-CA 123.923 3.082 . . . . 0.22 113.623 -174.376 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 34.4 mm -91.04 134.24 30.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.966 -0.561 . . . . 0.13 110.114 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -111.32 155.11 23.55 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.786 -0.643 . . . . 0.29 109.693 179.1 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.54 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -69.42 116.6 10.03 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.813 0.34 . . . . 0.18 110.543 -175.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.18 7.11 23.45 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.388 -0.91 . . . . 0.17 113.478 178.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.544 ' O ' ' HG2' ' A' ' 66' ' ' MET . 48.2 mt-10 -89.21 145.11 25.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 117.699 0.75 . . . . 0.52 110.489 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.7 m -106.06 107.28 18.19 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.807 -0.633 . . . . 0.16 110.781 -176.287 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -82.18 131.06 34.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.225 0.536 . . . . 0.16 110.719 -175.215 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -118.31 108.51 15.18 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.047 -0.979 . . . . 0.27 109.703 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.4 p -106.06 155.32 19.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.048 0.451 . . . . 0.23 109.955 177.499 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -117.46 -156.07 10.33 Favored Glycine 0 N--CA 1.445 -0.763 0 N-CA-C 111.369 -0.693 . . . . 0.9 111.369 177.531 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.1 132.02 52.34 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.8 -0.714 . . . . 1.79 112.034 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 14.8 m 67.43 19.39 10.05 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 121.096 0.474 . . . . 1.64 111.266 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -78.83 136.15 17.06 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.951 -0.642 . . . . 0.89 112.362 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.433 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 67.0 m -156.9 141.13 16.48 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.395 -0.595 . . . . 0.85 109.395 174.507 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -148.39 133.29 10.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 C-N-CA 120.997 -0.281 . . . . 0.25 110.764 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.512 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.1 m -106.36 106.61 17.21 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.052 -0.522 . . . . 0.19 109.62 173.78 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.553 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 58.8 mt -97.7 107.61 20.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.756 -0.657 . . . . 0.15 110.18 178.312 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.26 106.63 14.31 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.331 -0.85 . . . . 0.14 109.323 177.655 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.547 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 67.8 m-85 -73.59 144.64 45.92 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.484 0.659 . . . . 0.32 110.753 -178.48 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.7 p -73.53 -6.28 7.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 114.879 -1.055 . . . . 0.25 111.799 -169.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.56 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 11.5 t70 -84.95 -20.55 30.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.594 -0.276 . . . . 0.75 110.607 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.51 -17.32 5.57 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.479 -0.867 . . . . 0.27 112.919 -179.674 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.6 p -86.59 156.84 19.88 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 122.795 -0.238 . . . . 0.36 111.108 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -130.38 150.73 51.48 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.442 -0.577 . . . . 1.51 109.442 177.359 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.553 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.9 m -130.4 169.4 21.33 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.211 0.529 . . . . 1.39 111.768 177.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.554 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.6 p -140.31 132.37 32.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.13 -0.941 . . . . 0.81 110.327 176.701 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 45' ' ' SER . 23.5 mt -102.71 143.46 15.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.99 -0.55 . . . . 0.32 110.15 -179.599 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.23 -161.54 36.63 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.858 -0.687 . . . . 1.02 112.23 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.91 146.42 17.99 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.959 -0.639 . . . . 0.4 111.57 -175.052 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.5 t70 60.39 21.65 11.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.945 0.878 . . . . 1.26 109.655 -173.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 t -102.93 155.61 18.24 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.369 -0.832 . . . . 1.19 110.847 -175.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.539 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.4 mt -140.28 122.88 16.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.248 -0.887 . . . . 0.38 109.351 179.004 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.18 141.93 17.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.702 0.287 . . . . 1.0 110.86 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.5 tt0 -94.38 130.78 40.58 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.928 0.394 . . . . 0.67 110.175 178.603 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.544 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 53.6 mmm -65.8 89.93 0.12 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.425 -0.807 . . . . 0.88 110.495 -178.78 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.401 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.5 p -116.54 -166.39 1.15 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.391 -0.822 . . . . 0.29 111.216 -175.595 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -63.8 -42.42 97.71 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.802 0.334 . . . . 2.13 111.471 -177.32 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 56.4 mm-40 -62.89 -23.93 67.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.295 0.569 . . . . 2.51 111.009 177.661 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.414 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.3 mm -82.72 -50.38 15.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.212 -0.904 . . . . 0.25 111.144 177.034 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.783 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -103.51 81.31 1.9 Allowed 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.671 -0.695 . . . . 0.31 109.962 -177.36 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -79.26 110.18 14.3 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.698 -0.683 . . . . 1.46 109.889 177.09 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 21.8 p -90.49 154.79 19.37 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.944 -0.571 . . . . 0.69 110.944 -178.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 142.01 18.15 0.31 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.595 -0.812 . . . . 1.91 113.161 177.524 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -111.02 133.54 53.33 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 117.033 0.416 . . . . 5.57 110.187 176.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.44 -0.79 . . . . 6.87 110.614 -178.508 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 112.29 -0.324 . . . . 1.71 112.29 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -119.69 147.78 44.16 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.115 -0.328 . . . . 2.0 110.115 178.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 119.35 17.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.906 -0.588 . . . . 0.24 110.018 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.753 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.0 pt -101.11 -15.85 7.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-N 115.422 -0.808 . . . . 0.15 111.592 -171.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.83 176.26 42.51 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 120.999 -0.62 . . . . 0.1 111.595 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.417 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 93.9 m-85 -144.89 151.1 38.18 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.74 0.305 . . . . 0.2 110.432 -175.154 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.471 HG12 ' O ' ' A' ' 30' ' ' ASP . 31.4 mm -79.18 122.2 33.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.375 -0.375 . . . . 0.14 111.012 -178.363 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.6 p -114.35 -24.4 8.91 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.302 0.573 . . . . 0.2 110.661 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.554 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.5 tttm -139.76 146.85 40.03 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 108.605 -0.887 . . . . 2.36 108.605 172.037 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -160.24 140.63 11.69 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.128 -0.487 . . . . 0.2 110.525 -176.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -146.44 152.46 39.08 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.155 -0.929 . . . . 1.94 110.577 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.55 -160.7 53.82 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.883 -0.599 . . . . 0.27 113.172 174.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 19.3 m -98.46 121.9 40.99 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.953 -0.388 . . . . 1.16 109.953 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.56 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.8 m -139.18 153.57 24.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.669 0.747 . . . . 0.2 111.819 -176.29 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.84 159.15 43.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.721 -1.127 . . . . 0.17 109.082 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.561 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.3 p -131.21 133.77 62.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.097 -0.641 . . . . 0.16 110.608 172.706 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.486 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 8.5 mt-30 -97.73 97.88 9.38 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.284 -0.871 . . . . 0.51 109.552 177.557 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.468 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 51.7 m -64.52 175.93 1.25 Allowed 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.471 -0.331 . . . . 1.25 110.547 -177.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 pt -58.75 -27.21 34.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 112.814 0.672 . . . . 0.59 112.814 -175.171 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -80.49 -10.8 59.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 1.96 110.7 177.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.46 3.24 61.39 Favored Glycine 0 N--CA 1.452 -0.283 0 N-CA-C 111.71 -0.556 . . . . 0.32 111.71 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.2 mm-40 -65.45 120.15 12.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.784 -0.208 . . . . 2.21 110.523 176.41 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.561 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.8 tt0 -95.77 108.33 20.64 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.716 -0.476 . . . . 1.0 109.716 -179.444 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.41 ' HG2' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -105.34 143.3 33.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.13 -0.486 . . . . 1.55 109.784 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.4 p -74.26 131.24 35.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.846 -0.798 . . . . 0.35 108.846 171.451 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' HG23 ' A' ' 14' ' ' VAL . 26.3 mt -93.45 127.44 39.09 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.191 -0.603 . . . . 0.32 110.502 -179.746 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -110.62 179.25 4.12 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 107.604 -1.258 . . . . 1.65 107.604 171.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -68.12 143.39 55.45 Favored 'General case' 0 C--N 1.315 -0.915 0 C-N-CA 119.316 -0.954 . . . . 0.23 109.417 175.115 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.07 -10.24 69.35 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.204 -0.998 . . . . 0.24 113.057 176.242 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.471 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.8 m-20 -66.49 142.5 97.71 Favored Pre-proline 0 CA--C 1.515 -0.391 0 CA-C-O 121.108 0.48 . . . . 1.92 109.788 175.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.417 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 35.7 Cg_endo -89.06 142.4 4.54 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 123.115 2.543 . . . . 0.22 112.713 -178.499 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.487 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.8 mm -102.57 136.8 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 115.779 -0.646 . . . . 0.13 109.591 175.828 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.442 ' H ' ' CD ' ' A' ' 36' ' ' GLU . 80.9 m-85 -113.84 153.65 28.79 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.839 -0.619 . . . . 0.29 109.561 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.553 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -69.87 111.55 5.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.378 -0.374 . . . . 0.18 110.231 -176.268 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.28 -5.6 8.78 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.601 -0.809 . . . . 0.17 113.048 178.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.468 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 28.6 mt-10 -83.39 136.96 34.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.695 0.759 . . . . 0.52 111.122 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -96.32 106.97 19.26 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.614 -1.175 . . . . 0.16 110.34 -178.168 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 6.0 t -81.37 133.2 29.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.114 0.483 . . . . 0.16 111.089 -173.667 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.1 mp -114.92 126.12 54.42 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.956 -1.02 . . . . 0.27 109.636 178.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.3 p -119.8 152.39 37.34 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.613 -0.514 . . . . 0.23 109.613 172.104 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -131.38 138.99 10.57 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.992 -0.623 . . . . 0.9 112.211 179.33 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 56.47 -113.86 4.6 Favored Glycine 0 N--CA 1.451 -0.345 0 O-C-N 123.822 0.366 . . . . 1.79 113.204 178.256 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.9 p -89.16 24.15 2.23 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.985 0.421 . . . . 1.64 111.34 -177.522 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.14 136.03 51.29 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.992 -0.549 . . . . 0.89 112.418 177.332 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.545 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 23.2 m -154.12 136.24 14.76 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.625 -0.88 . . . . 0.85 108.625 174.053 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -141.81 138.36 31.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 C-N-CA 120.385 -0.526 . . . . 0.25 111.158 -175.057 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.554 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.1 m -108.89 105.9 15.65 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.781 -0.645 . . . . 0.19 109.648 173.625 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.529 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.2 mt -94.5 109.45 22.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.896 -0.593 . . . . 0.15 110.045 177.09 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.73 99.26 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.236 -0.893 . . . . 0.14 109.335 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.504 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 66.9 m-85 -67.21 144.67 55.85 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.411 0.624 . . . . 0.32 110.336 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -70.18 2.01 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 114.558 -1.201 . . . . 0.25 110.846 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -84.89 -21.97 29.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.925 -1.034 . . . . 0.75 110.725 177.105 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 115.99 -17.37 15.17 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 111.162 -0.775 . . . . 0.27 111.162 -175.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 p -87.07 150.75 23.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.516 -0.342 . . . . 0.36 111.042 178.32 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -126.13 150.2 48.42 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.277 -0.638 . . . . 1.51 109.277 178.363 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.529 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -125.14 171.39 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.012 0.434 . . . . 1.39 111.366 178.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.534 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.1 p -137.81 130.08 40.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.461 -0.791 . . . . 0.81 110.318 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -105.08 136.87 37.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.881 -0.6 . . . . 0.32 109.926 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.94 -163.59 27.89 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.979 -0.629 . . . . 1.02 112.328 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.5 150.5 18.29 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.946 -0.645 . . . . 0.4 111.736 -173.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 34.7 t70 56.89 22.68 7.35 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.723 0.773 . . . . 1.26 110.264 -173.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.3 m -105.64 164.02 12.23 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.122 0.487 . . . . 1.19 111.338 -177.066 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.488 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.1 mt -140.86 128.2 22.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.506 -0.77 . . . . 0.38 109.374 176.596 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.429 HG21 HD11 ' A' ' 70' ' ' ILE . 11.0 p -149.61 138.68 15.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.852 0.358 . . . . 1.0 110.973 -177.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.507 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.9 tt0 -97.13 131.28 44.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.843 0.354 . . . . 0.67 111.138 -176.038 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.628 ' SD ' HG21 ' A' ' 70' ' ' ILE . 17.8 mmt -62.94 90.48 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.651 -0.704 . . . . 0.88 111.177 177.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.6 p -126.13 -169.1 1.95 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.502 -0.772 . . . . 0.29 110.241 -178.702 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -69.46 -26.61 64.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 117.814 0.279 . . . . 2.13 111.157 -176.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.06 -22.93 63.02 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.972 0.891 . . . . 2.51 109.688 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.628 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.9 mm -90.32 -51.76 11.48 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 114.72 -1.127 . . . . 0.25 110.762 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.753 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 -113.18 77.14 1.02 Allowed 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.491 -0.777 . . . . 0.31 110.729 -176.013 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 47.2 t-20 -80.52 107.82 13.64 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.852 -0.613 . . . . 1.46 109.413 171.513 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 26.1 p -76.21 133.81 40.05 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.463 -0.335 . . . . 0.69 110.987 -178.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -141.35 14.19 2.75 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.923 -0.656 . . . . 1.91 112.228 -177.291 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -67.48 -21.31 65.52 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 122.261 0.225 . . . . 5.57 110.78 178.736 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.111 -0.947 . . . . 6.87 110.86 178.165 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.858 0 N-CA-C 112.252 -0.339 . . . . 1.71 112.252 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 -95.84 160.47 14.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.914 0.388 . . . . 2.0 110.385 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.31 109.67 12.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.768 -0.651 . . . . 0.24 109.623 178.643 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.842 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.5 pt -92.34 -11.39 9.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.088 -0.96 . . . . 0.15 112.046 -169.564 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.45 42.79 Favored Glycine 0 CA--C 1.5 -0.85 0 C-N-CA 120.593 -0.813 . . . . 0.1 111.48 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -144.98 151.05 37.98 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.954 0.407 . . . . 0.2 110.883 -174.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.517 HG12 ' O ' ' A' ' 30' ' ' ASP . 21.2 mm -78.44 121.71 31.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 115.783 -0.644 . . . . 0.14 110.903 -178.66 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 72.7 p -113.63 -21.16 10.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.343 0.592 . . . . 0.2 110.406 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.464 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 84.4 tttt -142.63 145.2 33.25 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.775 -0.824 . . . . 2.36 108.775 173.455 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.446 HD11 HG21 ' A' ' 14' ' ' VAL . 6.0 tt -159.47 142.62 14.29 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 120.765 0.317 . . . . 0.2 110.945 -177.077 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.541 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 2.3 m-20 -148.82 165.24 32.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.67 -0.695 . . . . 1.94 110.795 176.441 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 67.57 -149.67 50.87 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.991 -0.55 . . . . 0.27 113.183 175.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 29.8 t -108.9 133.64 52.64 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.042 -0.725 . . . . 1.16 109.042 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.474 HG23 ' HB2' ' A' ' 26' ' ' LEU . 5.2 m -142.8 153.3 17.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.786 0.803 . . . . 0.2 111.582 -176.467 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.26 157.99 43.3 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.683 -1.144 . . . . 0.17 108.67 177.567 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.572 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.1 p -131.94 134.95 59.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.354 -0.538 . . . . 0.16 110.316 174.265 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.479 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -104.65 99.9 9.56 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.376 -0.829 . . . . 0.51 109.56 178.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.489 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 22.5 p -62.96 178.46 0.47 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.552 -0.295 . . . . 1.25 111.279 -175.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 2.9 pt -57.03 -33.61 42.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 112.597 0.591 . . . . 0.59 112.597 -174.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.485 ' OD1' ' HG3' ' A' ' 22' ' ' GLN . 9.5 p30 -81.93 -12.07 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.894 -0.322 . . . . 1.96 110.762 179.298 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.42 7.58 36.98 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.768 -0.73 . . . . 0.32 113.755 176.424 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.485 ' HG3' ' OD1' ' A' ' 20' ' ' ASN . 54.7 mt-30 -70.88 120.87 17.1 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.107 0.453 . . . . 2.21 111.127 179.203 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.527 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.6 tt0 -91.59 113.11 25.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.976 0.417 . . . . 1.0 109.969 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.92 138.22 51.39 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.793 -0.639 . . . . 1.55 109.796 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.61 134.96 29.11 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 109.113 -0.699 . . . . 0.35 109.113 175.799 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.6 HD22 ' OD1' ' A' ' 30' ' ' ASP . 5.4 mt -99.45 150.41 22.21 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.62 0.724 . . . . 0.32 111.442 -177.508 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.544 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 41.1 mttp -135.52 173.12 12.07 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.424 -1.262 . . . . 1.65 109.152 -171.34 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.52 141.78 46.74 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 119.133 -1.027 . . . . 0.23 109.347 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.61 0.96 85.92 Favored Glycine 0 N--CA 1.435 -1.395 0 C-N-CA 120.13 -1.034 . . . . 0.24 111.824 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.6 ' OD1' HD22 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -78.36 142.45 62.88 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-O 121.553 0.692 . . . . 1.92 111.1 -179.187 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.04 133.74 11.26 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.771 2.981 . . . . 0.22 113.836 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mm -99.98 136.8 29.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.005 -0.998 . . . . 0.13 109.092 172.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -116.57 154.62 30.14 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 120.976 0.417 . . . . 0.29 109.945 -178.67 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.509 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.7 t80 -71.51 115.7 11.0 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.003 -0.544 . . . . 0.18 110.581 -175.462 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.13 7.61 22.89 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.461 -0.876 . . . . 0.17 113.345 177.204 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.572 ' HB3' HG22 ' A' ' 16' ' ' VAL . 28.4 mt-10 -94.77 147.75 23.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.763 0.781 . . . . 0.52 110.673 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.479 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 10.1 m -104.09 108.39 19.73 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.094 -0.957 . . . . 0.16 110.661 -176.126 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.2 t -83.56 121.88 36.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.315 0.579 . . . . 0.16 110.934 -175.094 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -107.46 104.77 14.42 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.796 -1.093 . . . . 0.27 109.679 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.461 ' HB ' ' HA3' ' A' ' 44' ' ' GLY . 69.3 p -99.93 156.47 17.12 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.651 -0.5 . . . . 0.23 109.651 177.24 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -149.42 121.37 1.28 Allowed Glycine 0 N--CA 1.441 -0.994 0 C-N-CA 120.767 -0.73 . . . . 0.9 111.982 179.688 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.51 89.73 0.02 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 O-C-N 123.799 0.353 . . . . 1.79 113.576 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 22.7 t 62.08 32.78 17.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.077 0.465 . . . . 1.64 111.004 175.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.541 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -77.17 83.81 1.07 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.857 -0.687 . . . . 0.89 111.797 177.688 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m -102.33 109.92 21.72 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.334 -0.617 . . . . 0.85 109.334 -174.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.1 t -126.63 132.46 70.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.93 -0.577 . . . . 0.25 111.206 -169.248 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.464 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.0 m -109.02 108.24 18.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.031 -0.531 . . . . 0.19 110.288 178.359 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.457 HD13 ' HE2' ' A' ' 66' ' ' MET . 79.1 mt -97.75 102.69 13.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-N 115.216 -0.902 . . . . 0.15 109.966 178.184 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.05 99.68 8.59 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.644 -0.707 . . . . 0.14 109.371 178.115 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.572 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 48.8 m-85 -61.77 144.9 54.02 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.518 0.675 . . . . 0.32 111.197 -178.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.13 -12.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.707 -1.133 . . . . 0.25 111.493 -170.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.428 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 28.6 t70 -74.55 -17.38 60.75 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.215 0.531 . . . . 0.75 110.529 176.755 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.78 -7.3 17.51 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.916 -0.659 . . . . 0.27 111.896 -177.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.0 p -88.63 177.47 6.75 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.396 -0.224 . . . . 0.36 110.396 176.597 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -151.58 157.38 42.13 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.259 -0.274 . . . . 1.51 110.259 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.513 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.53 150.78 17.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.35 -0.387 . . . . 1.39 110.427 -177.689 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 9.1 p -126.57 133.16 69.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.318 0.58 . . . . 0.81 110.668 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -102.53 147.6 8.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.739 -0.664 . . . . 0.32 110.196 -177.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.9 -178.44 43.48 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.733 -0.746 . . . . 1.02 111.413 175.086 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -101.57 148.57 17.95 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 121.043 -0.598 . . . . 0.4 111.656 -172.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t70 58.3 24.53 11.68 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 121.843 0.83 . . . . 1.26 110.179 -173.008 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.7 t -106.1 161.13 14.77 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.439 -0.8 . . . . 1.19 110.445 -179.46 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.507 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 79.1 mt -139.88 118.47 11.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.859 -0.61 . . . . 0.38 109.629 179.063 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.5 p -140.45 141.4 32.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.508 -0.315 . . . . 1.0 110.829 -175.558 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.416 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 41.8 tt0 -97.99 126.84 43.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.905 0.383 . . . . 0.67 110.332 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.457 ' HE2' HD13 ' A' ' 48' ' ' ILE . 50.5 mmm -67.06 89.54 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.66 -0.7 . . . . 0.88 110.658 -178.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.407 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 10.8 p -115.02 -165.98 1.07 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.819 -0.628 . . . . 0.29 111.547 -175.587 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.83 -36.77 75.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.814 0.34 . . . . 2.13 110.718 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -61.97 -32.83 73.31 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.626 0.726 . . . . 2.51 110.095 175.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.407 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.1 mm -75.41 -53.09 16.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-N 114.476 -1.238 . . . . 0.25 111.029 178.736 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.842 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 -103.34 81.3 1.92 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.31 109.993 -176.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -77.42 106.39 9.15 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.543 -0.753 . . . . 1.46 109.512 175.784 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 39.2 p -92.6 144.55 25.22 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.082 -0.508 . . . . 0.69 111.561 -174.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.6 -17.17 62.48 Favored Glycine 0 N--CA 1.448 -0.52 0 N-CA-C 111.144 -0.782 . . . . 1.91 111.144 172.484 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -83.79 -29.7 27.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.991 0.424 . . . . 5.57 110.04 175.484 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 t30 . . . . . 0 C--O 1.248 1.022 0 CA-C-O 117.957 -1.02 . . . . 6.87 110.689 179.316 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.657 0 N-CA-C 112.027 -0.429 . . . . 1.71 112.027 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 -99.18 146.76 25.82 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.908 0.385 . . . . 2.0 110.517 -178.728 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.06 113.17 18.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.547 0.689 . . . . 0.24 110.351 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.828 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.9 pt -97.54 -14.09 7.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-N 115.106 -0.952 . . . . 0.15 111.709 -172.75 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.9 176.39 42.52 Favored Glycine 0 CA--C 1.502 -0.767 0 N-CA-C 111.01 -0.836 . . . . 0.1 111.01 179.163 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -143.35 151.57 40.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.041 0.448 . . . . 0.2 111.041 -175.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 35.2 mm -78.19 121.87 31.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.94 -0.573 . . . . 0.14 110.689 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.8 p -115.45 -20.28 10.31 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 0.2 110.546 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.1 tttt -143.83 143.3 31.26 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.47 -0.937 . . . . 2.36 108.47 173.811 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.3 tt -160.27 140.28 11.39 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-O 121.074 0.464 . . . . 0.2 111.107 -178.026 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -149.08 149.75 31.6 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.164 -0.925 . . . . 1.94 110.479 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.46 -160.2 41.54 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.972 -0.632 . . . . 0.27 113.035 175.113 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.0 m -101.32 119.25 38.47 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 120.667 0.27 . . . . 1.16 110.312 -177.558 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -136.91 152.0 28.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.817 0.817 . . . . 0.2 111.753 -176.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 159.34 42.7 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 114.706 -1.134 . . . . 0.17 108.703 178.438 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.573 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -131.57 132.62 62.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 121.29 0.567 . . . . 0.16 110.424 174.938 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.519 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.9 mt-30 -98.91 99.23 10.27 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.445 -0.798 . . . . 0.51 109.734 178.592 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.561 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 13.9 m -60.94 172.85 0.88 Allowed 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 110.039 -0.356 . . . . 1.25 110.039 -179.223 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -60.99 -14.7 10.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 112.248 0.462 . . . . 0.59 112.248 -177.499 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -85.53 -9.32 57.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.178 0.514 . . . . 1.96 110.372 177.331 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 88.54 5.66 74.78 Favored Glycine 0 CA--C 1.508 -0.372 0 N-CA-C 110.877 -0.889 . . . . 0.32 110.877 -175.57 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.401 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 92.7 mt-30 -70.21 118.52 13.13 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.792 -0.704 . . . . 2.21 110.664 178.272 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 6.5 tt0 -90.41 111.28 22.47 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.228 0.537 . . . . 1.0 109.629 177.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.4 ' NH2' ' HD2' ' A' ' 31' ' ' PRO . 0.0 OUTLIER -115.35 142.14 47.09 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.232 -0.894 . . . . 1.55 109.706 -177.311 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -75.65 143.19 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.835 0.35 . . . . 0.35 110.144 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' HG23 ' A' ' 14' ' ' VAL . 24.9 mt -110.12 128.97 55.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.994 0.426 . . . . 0.32 110.933 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 77.5 mttt -117.77 -179.72 3.82 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 108.246 -1.02 . . . . 1.65 108.246 170.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.4 tp -65.39 148.58 51.47 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.573 -0.851 . . . . 0.23 110.3 178.586 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.55 -7.24 58.59 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.531 -0.842 . . . . 0.24 112.677 177.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.9 143.68 97.16 Favored Pre-proline 0 CA--C 1.512 -0.515 0 CA-C-O 121.187 0.518 . . . . 1.92 110.105 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.4 ' HD2' ' NH2' ' A' ' 24' ' ' ARG . 24.6 Cg_endo -90.15 131.4 1.79 Allowed 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 123.262 2.641 . . . . 0.22 111.827 178.641 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.523 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.3 mm -94.08 134.48 31.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 109.747 -0.464 . . . . 0.13 109.747 176.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.98 150.25 30.84 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.558 -0.746 . . . . 0.29 109.396 -179.75 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.556 ' HD2' HG21 ' A' ' 4' ' ' ILE . 3.0 t80 -67.3 116.8 8.48 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.18 110.364 -174.524 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.17 -10.42 20.28 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.789 -0.72 . . . . 0.17 113.234 176.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.573 ' HB3' HG22 ' A' ' 16' ' ' VAL . 28.7 mt-10 -76.02 140.4 41.94 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 117.877 0.839 . . . . 0.52 110.685 179.803 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -101.43 109.04 20.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.809 -1.087 . . . . 0.16 110.84 -175.433 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.6 t -82.11 132.04 32.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.189 0.518 . . . . 0.16 110.934 -174.203 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -117.84 109.49 16.62 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 114.975 -1.011 . . . . 0.27 110.017 -177.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -105.26 157.01 17.6 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.428 -0.509 . . . . 0.23 109.789 175.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -136.0 137.16 8.92 Favored Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 120.81 -0.71 . . . . 0.9 111.872 178.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.73 -112.22 2.34 Favored Glycine 0 N--CA 1.449 -0.494 0 O-C-N 123.931 0.43 . . . . 1.79 113.207 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 33.4 m -87.6 28.11 1.03 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.91 0.386 . . . . 1.64 111.491 -176.287 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.27 130.38 35.07 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.949 -0.644 . . . . 0.89 111.874 176.407 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.53 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 7.3 m -150.68 126.24 10.2 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.349 -0.611 . . . . 0.85 109.349 174.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.517 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 7.5 t -134.72 147.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.901 -0.32 . . . . 0.25 111.107 -173.444 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.569 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -117.98 110.63 17.93 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.157 -0.474 . . . . 0.19 110.01 173.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.554 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 64.4 mt -98.66 109.35 23.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.805 -0.634 . . . . 0.15 110.014 176.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.44 102.22 11.92 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.418 -0.81 . . . . 0.14 109.171 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.46 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.7 m-85 -70.1 144.43 52.11 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.372 0.606 . . . . 0.32 110.78 -178.738 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.75 1.9 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 114.651 -1.159 . . . . 0.25 111.725 -171.108 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -92.51 -11.97 33.18 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.98 -0.554 . . . . 0.75 109.962 175.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.79 -5.41 25.93 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.516 -0.849 . . . . 0.27 112.726 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.6 p -93.95 159.79 15.01 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.819 -0.224 . . . . 0.36 110.717 177.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.63 143.6 47.39 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.417 -0.586 . . . . 1.51 109.417 179.178 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.554 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.9 m -121.75 164.16 18.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.103 0.478 . . . . 1.39 111.441 177.335 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -131.86 129.44 60.9 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 115.241 -0.89 . . . . 0.81 109.875 177.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.53 ' O ' ' HA ' ' A' ' 45' ' ' SER . 17.1 mt -103.43 131.58 51.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 116.257 -0.428 . . . . 0.32 109.993 -178.438 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.23 -163.92 23.56 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 121.151 -0.547 . . . . 1.02 112.259 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.93 145.25 16.5 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.772 -0.728 . . . . 0.4 111.728 -173.066 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.5 t70 58.24 25.22 12.38 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 121.547 0.689 . . . . 1.26 110.217 -174.313 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.4 m -103.04 156.47 17.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.957 -0.565 . . . . 1.19 110.935 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.499 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 89.7 mt -140.6 117.31 8.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.618 -0.719 . . . . 0.38 109.588 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.8 p -147.66 143.96 19.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 110.108 -0.33 . . . . 1.0 110.108 -177.16 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.594 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -103.99 139.21 39.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.545 0.688 . . . . 0.67 111.079 -176.113 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.553 ' SD ' HG21 ' A' ' 70' ' ' ILE . 22.7 mmt -64.19 89.62 0.06 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.627 -1.17 . . . . 0.88 111.667 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.428 HG23 ' CG ' ' A' ' 65' ' ' GLU . 2.3 p -114.25 -172.15 2.05 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.622 -0.717 . . . . 0.29 110.125 177.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -71.98 -24.45 61.58 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.748 0.309 . . . . 2.13 110.657 -178.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -70.08 -23.54 63.08 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.472 0.653 . . . . 2.51 110.229 175.384 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.553 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.4 mm -88.17 -56.52 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.119 -0.946 . . . . 0.25 109.728 175.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.828 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 -100.46 80.02 2.18 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.543 -1.208 . . . . 0.31 109.786 -178.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 10.7 t30 -80.05 105.92 11.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.641 -0.709 . . . . 1.46 109.694 176.399 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 24.3 p -80.04 126.3 30.88 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.997 -0.547 . . . . 0.69 111.512 -176.16 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.68 -37.65 22.59 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 110.688 -0.965 . . . . 1.91 110.688 174.042 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -95.37 104.82 16.73 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.273 -0.64 . . . . 5.57 109.273 173.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.7 m-80 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.568 -0.729 . . . . 6.87 110.699 -176.774 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.643 0 N-CA-C 112.037 -0.425 . . . . 1.71 112.037 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -112.25 149.03 32.9 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 110.165 -0.309 . . . . 2.0 110.165 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.11 108.09 8.78 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.798 -0.816 . . . . 0.24 108.798 174.372 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.749 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.3 pt -92.96 -10.42 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.22 -0.9 . . . . 0.15 111.419 -170.485 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.78 176.3 42.47 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.623 -0.799 . . . . 0.1 111.469 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -144.49 150.07 36.98 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.04 0.448 . . . . 0.2 110.446 -175.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.578 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.2 mm -78.04 123.68 35.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.775 -0.648 . . . . 0.14 110.972 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 p -116.19 -23.41 8.45 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.127 0.489 . . . . 0.2 110.856 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.575 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 25.8 tptp -139.99 136.18 33.49 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.959 -1.126 . . . . 2.36 107.959 173.562 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.492 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -152.85 138.11 17.47 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.016 0.436 . . . . 0.2 111.043 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.4 m-20 -147.95 157.24 43.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.158 -0.928 . . . . 1.94 110.861 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.03 -158.79 46.7 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.842 -0.617 . . . . 0.27 112.752 176.036 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.9 t -103.68 118.69 37.31 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.251 -0.648 . . . . 1.16 109.251 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.601 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.7 m -135.65 153.17 32.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.687 0.756 . . . . 0.2 111.681 -175.754 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.11 158.86 44.52 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.796 -1.093 . . . . 0.17 108.687 -178.129 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.681 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -136.61 134.5 49.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 119.917 -0.713 . . . . 0.16 111.375 173.636 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.419 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.1 mt-30 -97.56 100.32 11.73 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 114.924 -1.034 . . . . 0.51 108.98 174.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.505 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 58.1 p -63.01 179.06 0.41 Allowed 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.962 -0.295 . . . . 1.25 111.145 -175.139 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.8 pt -60.98 -21.17 23.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 0.59 110.937 176.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -80.1 -9.91 59.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 1.96 110.14 176.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.93 12.45 71.35 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 110.973 -0.851 . . . . 0.32 110.973 179.284 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -89.06 121.74 31.71 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.9 -0.65 . . . . 2.21 110.81 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.681 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 22.2 tt0 -89.65 118.13 29.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.903 -0.59 . . . . 1.0 110.46 178.75 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.61 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.1 ptt-85 -119.16 165.96 13.55 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.502 -0.555 . . . . 1.55 109.502 175.83 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.7 p -91.24 127.49 43.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.372 0.606 . . . . 0.35 109.432 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.601 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.1 mt -90.49 151.17 21.49 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.5 0.667 . . . . 0.32 111.351 -175.468 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.41 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 18.6 mttp -141.87 176.15 9.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.748 -1.114 . . . . 1.65 108.324 -171.257 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -74.29 141.63 45.27 Favored 'General case' 0 C--N 1.313 -1.014 0 C-N-CA 119.303 -0.959 . . . . 0.23 108.988 176.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.77 7.31 88.31 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 119.918 -1.134 . . . . 0.24 111.917 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -85.03 140.37 37.09 Favored Pre-proline 0 CA--C 1.52 -0.184 0 CA-C-O 121.612 0.72 . . . . 1.92 110.472 178.6 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -78.21 132.01 11.16 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.677 2.918 . . . . 0.22 113.426 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.413 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.4 mm -99.45 133.61 41.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 0.13 109.175 173.561 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -113.88 152.61 30.51 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.145 -0.479 . . . . 0.29 110.238 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.7 t80 -68.48 111.77 4.9 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.963 -0.562 . . . . 0.18 110.019 -177.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.67 6.25 19.62 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.34 -0.933 . . . . 0.17 113.348 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.545 ' O ' ' HG2' ' A' ' 66' ' ' MET . 39.9 mt-10 -91.05 135.12 33.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 117.869 0.834 . . . . 0.52 110.739 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.541 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 9.0 m -94.47 106.12 18.09 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.99 -1.005 . . . . 0.16 110.94 -176.532 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.544 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 4.3 t -82.47 129.58 37.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.137 0.494 . . . . 0.16 110.916 -175.209 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.6 mp -117.31 108.09 15.19 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.223 -0.899 . . . . 0.27 109.694 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.7 p -105.13 153.5 21.43 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.9 -0.408 . . . . 0.23 109.9 178.328 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -128.66 142.3 13.4 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 121.115 -0.564 . . . . 0.9 111.886 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.27 -115.49 5.79 Favored Glycine 0 N--CA 1.451 -0.337 0 O-C-N 123.756 0.327 . . . . 1.79 113.129 178.296 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 17.1 t -95.04 45.31 1.1 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.332 0.587 . . . . 1.64 110.388 -178.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.46 135.92 27.62 Favored Glycine 0 N--CA 1.448 -0.558 0 CA-C-N 115.702 -0.681 . . . . 0.89 111.487 175.222 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 50.7 m -152.79 134.98 14.93 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 117.286 0.543 . . . . 0.85 109.596 173.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.0 t -143.36 129.77 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.677 0.275 . . . . 0.25 111.034 -175.124 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.575 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -99.26 105.77 17.82 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.533 -0.543 . . . . 0.19 109.533 172.267 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.556 HD13 ' HE2' ' A' ' 66' ' ' MET . 69.3 mt -95.89 107.43 19.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 CA-C-N 115.821 -0.627 . . . . 0.15 109.997 176.667 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.74 104.96 13.38 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.322 -0.853 . . . . 0.14 109.08 176.032 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.497 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 60.9 m-85 -69.96 152.7 44.15 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.601 0.715 . . . . 0.32 110.746 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.5 p -72.61 -11.6 15.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.654 -1.157 . . . . 0.25 111.496 -170.198 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -81.17 -21.77 39.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.102 0.477 . . . . 0.75 110.598 176.137 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.43 -7.12 14.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.615 -0.802 . . . . 0.27 112.182 -177.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.5 p -85.19 150.11 25.04 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 110.366 -0.235 . . . . 0.36 110.366 176.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -127.53 147.4 50.32 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.664 -0.414 . . . . 1.51 109.932 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.541 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.8 m -129.75 171.32 17.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.117 0.484 . . . . 1.39 111.596 178.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.523 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.8 p -137.61 134.88 46.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.169 -0.923 . . . . 0.81 110.168 177.517 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.604 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.7 mt -107.43 136.09 43.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.4 -0.364 . . . . 0.32 110.309 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.51 -169.88 43.05 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.083 -0.579 . . . . 1.02 112.37 178.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -110.34 152.8 17.28 Favored Glycine 0 CA--C 1.504 -0.642 0 N-CA-C 111.595 -0.602 . . . . 0.4 111.595 -173.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.3 t70 56.65 21.73 6.1 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.963 0.887 . . . . 1.26 109.775 -172.495 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.0 m -106.18 158.97 16.45 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.721 -0.672 . . . . 1.19 111.297 -176.594 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.544 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.6 mt -139.99 119.63 12.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.417 -0.811 . . . . 0.38 109.459 178.329 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.4 p -145.71 138.3 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 120.904 0.383 . . . . 1.0 110.654 -178.298 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.0 tt0 -92.01 130.55 37.73 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.222 -0.444 . . . . 0.67 109.963 179.332 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.556 ' HE2' HD13 ' A' ' 48' ' ' ILE . 60.8 mmm -66.67 89.56 0.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.948 -0.569 . . . . 0.88 110.591 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 17.0 p -115.46 -165.34 1.02 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.819 -0.628 . . . . 0.29 111.47 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -64.89 -39.31 93.33 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.182 -0.463 . . . . 2.13 111.061 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -64.35 -28.86 69.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.843 0.83 . . . . 2.51 110.075 178.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -77.48 -46.45 27.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.734 -1.121 . . . . 0.25 111.212 176.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.749 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 -110.48 79.48 1.21 Allowed 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.638 -0.71 . . . . 0.31 110.662 -174.323 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -81.61 106.94 13.96 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.789 -0.641 . . . . 1.46 109.748 174.394 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.1 p -82.2 137.86 34.81 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.424 -0.353 . . . . 0.69 111.471 -177.213 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 109.07 97.67 2.5 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.785 -0.721 . . . . 1.91 113.232 176.039 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -83.3 168.03 17.06 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.968 0.413 . . . . 5.57 110.365 173.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.3 t30 . . . . . 0 C--O 1.251 1.145 0 CA-C-O 118.662 -0.685 . . . . 6.87 109.997 178.216 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.796 0 N-CA-C 112.028 -0.429 . . . . 1.71 112.028 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -88.31 162.27 16.68 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.031 0.444 . . . . 2.0 110.597 -179.438 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.67 109.36 13.99 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.648 -0.705 . . . . 0.24 109.584 178.347 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.773 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 32.9 pt -92.97 -12.99 8.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 114.896 -1.047 . . . . 0.15 111.841 -170.59 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.38 176.34 44.02 Favored Glycine 0 CA--C 1.501 -0.814 0 C-N-CA 120.61 -0.805 . . . . 0.1 111.688 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.94 149.39 36.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.972 0.415 . . . . 0.2 110.961 -174.332 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.44 HD12 ' CG1' ' A' ' 46' ' ' VAL . 37.6 mm -76.43 124.08 33.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.829 -0.623 . . . . 0.14 111.782 -176.147 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.2 p -116.75 -20.68 9.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.034 0.445 . . . . 0.2 111.403 179.099 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.606 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 23.3 tptm -140.21 136.24 33.2 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.104 -1.073 . . . . 2.36 108.104 174.359 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.595 HD11 HG21 ' A' ' 14' ' ' VAL . 5.6 tt -155.71 139.66 16.32 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.395 -0.522 . . . . 0.2 111.552 -179.42 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.574 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 25.9 t70 -144.76 155.77 43.71 Favored 'General case' 0 CA--C 1.496 -1.119 0 CA-C-N 115.655 -0.702 . . . . 1.94 110.914 173.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.16 -162.56 38.72 Favored Glycine 0 N--CA 1.419 -2.462 0 CA-C-N 115.005 -0.998 . . . . 0.27 112.866 164.771 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.4 m -92.15 116.24 28.77 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 109.841 -0.429 . . . . 1.16 109.841 177.721 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.595 HG21 HD11 ' A' ' 10' ' ' LEU . 3.7 m -135.5 152.67 32.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.711 0.767 . . . . 0.2 111.397 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.98 158.3 44.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.701 -1.136 . . . . 0.17 108.79 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.691 HG12 ' HG2' ' A' ' 24' ' ' ARG . 1.0 OUTLIER -131.62 133.11 61.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 C-N-CA 119.971 -0.692 . . . . 0.16 111.244 173.933 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.493 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -97.7 99.1 10.44 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.004 -0.998 . . . . 0.51 109.503 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.477 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 20.0 m -64.52 176.54 1.08 Allowed 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 116.344 -0.389 . . . . 1.25 110.584 -178.352 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -59.66 -26.91 36.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 O-C-N 122.005 -0.434 . . . . 0.59 111.569 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.6 m-20 -71.82 -16.51 62.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.04 0.448 . . . . 1.96 110.678 176.523 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.52 4.87 65.55 Favored Glycine 0 N--CA 1.451 -0.318 0 N-CA-C 110.839 -0.905 . . . . 0.32 110.839 -175.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 92.5 mt-30 -73.53 129.19 37.45 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.827 -0.686 . . . . 2.21 110.619 179.171 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.666 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 6.8 tt0 -106.37 109.18 21.03 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.411 -0.359 . . . . 1.0 110.601 -176.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.691 ' HG2' HG12 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -109.57 165.74 11.43 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.669 -0.493 . . . . 1.55 109.669 176.769 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -89.92 139.45 17.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 115.862 -0.608 . . . . 0.35 109.425 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.505 ' HB2' HG23 ' A' ' 14' ' ' VAL . 22.6 mt -103.91 131.1 51.47 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.129 0.49 . . . . 0.32 110.799 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.3 mttp -118.46 -177.12 3.22 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 107.939 -1.134 . . . . 1.65 107.939 171.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 146.7 54.26 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 119.859 -0.736 . . . . 0.23 109.519 175.054 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.92 1.58 87.55 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 120.13 -1.033 . . . . 0.24 112.918 176.554 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.401 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.4 m-20 -78.78 144.75 65.04 Favored Pre-proline 0 CA--C 1.517 -0.317 0 CA-C-O 121.103 0.478 . . . . 1.92 110.608 176.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -79.5 142.95 16.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.967 2.445 . . . . 0.22 112.743 178.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.454 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.3 mm -108.44 135.97 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-N 115.614 -0.721 . . . . 0.13 109.092 171.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -115.96 152.45 33.46 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 116.218 -0.446 . . . . 0.29 110.066 -177.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.529 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.4 t80 -69.41 110.89 4.94 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.872 -0.604 . . . . 0.18 110.469 -176.397 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.58 4.06 15.76 Favored Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.478 -0.868 . . . . 0.17 113.351 178.463 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.49 ' O ' ' HG2' ' A' ' 66' ' ' MET . 35.7 mt-10 -93.22 144.97 24.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 117.819 0.809 . . . . 0.52 110.832 -179.158 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.5 m -105.01 109.16 21.05 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.383 -0.826 . . . . 0.16 110.921 -174.652 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -83.46 128.36 38.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.349 0.595 . . . . 0.16 111.028 -175.224 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.5 mp -114.29 106.5 14.4 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.759 -1.109 . . . . 0.27 109.716 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 58.4 p -105.07 154.08 20.63 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.881 0.372 . . . . 0.23 110.086 178.401 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -129.97 139.51 11.01 Favored Glycine 0 N--CA 1.442 -0.94 0 N-CA-C 111.517 -0.633 . . . . 0.9 111.517 178.202 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 58.32 -104.25 0.45 Allowed Glycine 0 N--CA 1.45 -0.418 0 O-C-N 123.782 0.342 . . . . 1.79 113.402 179.272 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 19.5 m -103.9 20.03 18.9 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.696 0.284 . . . . 1.64 110.932 -177.038 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.574 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -59.76 96.34 0.08 OUTLIER Glycine 0 C--O 1.224 -0.471 0 CA-C-N 115.955 -0.566 . . . . 0.89 112.97 178.543 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.4 t -119.45 138.45 53.12 Favored 'General case' 0 CA--C 1.501 -0.913 0 N-CA-C 109.08 -0.711 . . . . 0.85 109.08 -178.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.4 t -145.35 136.75 20.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.841 -0.618 . . . . 0.25 111.001 -168.408 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.606 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 91.4 m -111.09 112.62 24.55 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.222 0.534 . . . . 0.19 109.876 175.427 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.466 HD13 ' HE2' ' A' ' 66' ' ' MET . 77.1 mt -99.78 103.52 14.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.205 -0.907 . . . . 0.15 110.098 178.658 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.59 101.53 7.47 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.259 -0.882 . . . . 0.14 109.44 177.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.529 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 51.9 m-85 -65.8 143.66 57.34 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.689 0.757 . . . . 0.32 110.988 -178.748 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -69.03 -12.36 15.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 114.285 -1.325 . . . . 0.25 111.427 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.485 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 23.3 t70 -74.48 -21.67 59.46 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.169 -0.469 . . . . 0.75 110.624 177.323 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.39 -17.22 8.46 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.815 -0.707 . . . . 0.27 112.137 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 6.1 p -85.86 164.78 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 122.084 0.154 . . . . 0.36 110.729 178.074 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -133.54 163.44 29.39 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.158 -0.312 . . . . 1.51 110.158 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.529 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -146.05 157.1 12.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.423 -0.353 . . . . 1.39 110.568 -177.409 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.539 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.9 p -133.14 133.91 58.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.166 0.508 . . . . 0.81 110.916 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 20.6 mt -104.04 137.7 31.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.871 -0.604 . . . . 0.32 109.952 -179.533 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.07 174.53 52.67 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.387 -0.911 . . . . 1.02 111.475 176.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.67 151.29 19.83 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 111.283 -0.727 . . . . 0.4 111.283 -173.438 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.37 26.14 12.13 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-O 121.858 0.837 . . . . 1.26 109.448 -173.425 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -111.55 162.58 14.98 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.425 -0.807 . . . . 1.19 110.944 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.2 mt -140.37 124.87 18.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.778 -0.646 . . . . 0.38 109.533 178.197 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.0 p -150.11 142.32 17.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.841 0.353 . . . . 1.0 110.843 -178.707 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.534 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.3 tt0 -94.79 136.08 35.52 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.892 0.377 . . . . 0.67 110.528 178.768 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.49 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 50.5 mmm -71.46 88.57 0.91 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.697 -0.683 . . . . 0.88 110.393 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -111.08 -163.67 0.86 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.057 -0.519 . . . . 0.29 111.249 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -77.1 -28.24 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.876 -0.147 . . . . 2.13 111.003 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -66.68 -29.47 69.48 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.95 0.881 . . . . 2.51 109.684 173.478 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.479 HG21 ' HE3' ' A' ' 66' ' ' MET . 1.5 mm -77.35 -55.35 10.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.268 -1.333 . . . . 0.25 110.345 176.352 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.773 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 -109.4 76.41 1.0 Allowed 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.271 -0.877 . . . . 0.31 109.742 -178.007 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -81.34 96.35 7.29 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.747 -0.66 . . . . 1.46 109.835 177.675 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.4 p -72.05 131.81 43.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.339 -0.392 . . . . 0.69 110.806 -179.094 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 88.52 27.8 23.8 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.634 -0.793 . . . . 1.91 111.883 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -82.8 79.61 9.13 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.346 0.593 . . . . 5.57 109.976 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 55.5 t30 . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.339 -0.839 . . . . 6.87 110.195 179.869 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.743 0 N-CA-C 112.344 -0.302 . . . . 1.71 112.344 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -120.22 141.83 49.57 Favored 'General case' 0 CA--C 1.512 -0.496 0 N-CA-C 109.223 -0.658 . . . . 2.0 109.223 177.127 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.52 109.42 12.68 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.503 0.668 . . . . 0.24 109.906 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.786 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.5 pt -96.92 -13.2 8.17 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.83 -1.077 . . . . 0.15 111.577 -171.593 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.8 174.07 43.4 Favored Glycine 0 CA--C 1.501 -0.818 0 N-CA-C 111.171 -0.772 . . . . 0.1 111.171 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -142.98 148.69 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.96 0.41 . . . . 0.2 111.247 -174.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.479 HD13 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -77.01 121.67 29.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.704 -0.68 . . . . 0.14 111.157 -177.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 71.1 p -116.53 -21.51 9.15 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.067 0.461 . . . . 0.2 111.017 179.284 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.589 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.8 tptt -141.74 136.95 31.28 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.536 -0.913 . . . . 2.36 108.536 173.275 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.532 HD11 HG21 ' A' ' 14' ' ' VAL . 6.1 tt -152.97 142.83 22.12 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.883 0.373 . . . . 0.2 111.156 -178.007 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -143.97 141.85 30.4 Favored 'General case' 0 CA--C 1.499 -0.998 0 CA-C-N 115.777 -0.647 . . . . 1.94 111.767 177.315 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.21 -148.88 19.56 Favored Glycine 0 N--CA 1.422 -2.28 0 CA-C-N 114.695 -1.139 . . . . 0.27 113.159 164.39 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.2 t -104.49 113.04 26.35 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.527 -0.546 . . . . 1.16 109.527 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.537 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.3 m -133.18 152.89 36.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.562 0.696 . . . . 0.2 111.411 -177.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.18 159.43 43.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.959 -1.019 . . . . 0.17 108.477 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.544 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.1 p -131.92 129.35 60.65 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 C-N-CA 119.957 -0.697 . . . . 0.16 110.691 175.225 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.461 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 1.9 mt-30 -93.36 98.71 11.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.44 -0.8 . . . . 0.51 108.972 177.14 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.51 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.1 m -65.23 179.13 0.77 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.962 -0.563 . . . . 1.25 110.495 -176.814 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 15.1 pt -69.21 -4.88 4.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.913 0.709 . . . . 0.59 112.913 -172.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 57.0 m-80 -95.78 -5.35 42.13 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.176 0.513 . . . . 1.96 109.944 173.004 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.32 8.56 74.47 Favored Glycine 0 CA--C 1.507 -0.456 0 N-CA-C 110.709 -0.956 . . . . 0.32 110.709 -177.191 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -78.65 120.89 23.97 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.958 -0.621 . . . . 2.21 110.589 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.455 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.5 tt0 -89.25 109.9 20.73 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.323 0.582 . . . . 1.0 110.224 -179.016 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.83 144.74 39.37 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.206 -0.907 . . . . 1.55 109.711 -176.778 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -73.28 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.783 0.325 . . . . 0.35 110.268 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HB2' HG23 ' A' ' 14' ' ' VAL . 16.4 mt -110.83 124.07 51.32 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.047 0.451 . . . . 0.32 110.552 177.161 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -115.67 178.73 4.2 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.511 -0.922 . . . . 1.65 108.511 173.126 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -65.61 147.74 52.9 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 119.766 -0.774 . . . . 0.23 109.909 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.52 -8.73 63.99 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.237 -0.982 . . . . 0.24 112.57 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.403 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 0.4 OUTLIER -65.08 144.59 99.09 Favored Pre-proline 0 CA--C 1.515 -0.377 0 CA-C-O 121.425 0.631 . . . . 1.92 111.021 179.559 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 38.1 Cg_endo -83.17 133.55 6.53 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 123.467 2.778 . . . . 0.22 112.393 175.699 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.41 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 29.0 mm -98.54 132.66 43.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 109.136 -0.69 . . . . 0.13 109.136 174.276 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -114.41 149.01 36.85 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 116.007 -0.542 . . . . 0.29 110.163 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.598 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -67.71 109.01 3.14 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.801 -0.636 . . . . 0.18 110.375 -174.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 121.49 -1.29 11.31 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.271 -0.966 . . . . 0.17 113.589 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.544 ' HB3' HG22 ' A' ' 16' ' ' VAL . 34.7 mt-10 -88.67 146.93 24.79 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 117.929 0.865 . . . . 0.52 110.367 -179.188 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.1 m -105.76 107.98 19.25 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.72 -0.673 . . . . 0.16 111.171 -175.544 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.1 t -81.4 133.62 28.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.154 0.502 . . . . 0.16 110.913 -175.713 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.9 mp -119.06 109.63 16.14 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.044 -0.98 . . . . 0.27 109.789 -178.691 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.9 p -105.01 155.7 18.72 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.541 -0.54 . . . . 0.23 109.541 176.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -124.14 137.92 11.01 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.724 -0.75 . . . . 0.9 111.97 178.443 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.09 -100.43 0.21 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 121.677 -0.297 . . . . 1.79 113.266 178.661 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 20.2 m -111.17 17.26 20.49 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 122.792 -0.24 . . . . 1.64 111.053 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.83 110.74 0.68 Allowed Glycine 0 C--O 1.221 -0.68 0 O-C-N 123.505 0.503 . . . . 0.89 112.856 178.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 31.1 m -125.17 130.61 52.49 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.838 -0.43 . . . . 0.85 109.838 -174.493 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.6 t -139.61 131.28 33.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 CA-C-N 116.559 -0.291 . . . . 0.25 111.433 -170.861 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.589 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 80.2 m -102.64 107.95 19.05 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.079 -0.51 . . . . 0.19 109.842 175.018 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.577 HD13 ' HE2' ' A' ' 66' ' ' MET . 68.5 mt -96.52 109.64 23.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 CA-C-N 115.717 -0.674 . . . . 0.15 110.22 176.371 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.21 100.81 12.01 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.289 -0.869 . . . . 0.14 109.788 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.459 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 67.3 m-85 -68.09 148.36 51.06 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.71 0.767 . . . . 0.32 111.082 -177.798 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.8 p -73.45 -8.71 12.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-N 114.276 -1.329 . . . . 0.25 111.128 -171.053 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.449 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 32.1 t70 -80.15 -20.63 44.47 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.014 -0.539 . . . . 0.75 110.395 176.448 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.92 -10.58 11.1 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.749 -0.738 . . . . 0.27 112.173 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.7 p -85.23 157.29 20.65 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.65 -0.13 . . . . 0.36 110.65 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -133.81 140.99 47.26 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.507 -0.553 . . . . 1.51 109.507 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.548 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.6 m -121.47 172.65 8.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.192 0.52 . . . . 1.39 111.584 178.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.483 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -140.01 133.15 35.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.254 -0.884 . . . . 0.81 110.124 177.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.482 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.7 mt -103.54 133.25 47.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.003 -0.544 . . . . 0.32 109.951 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.51 178.97 53.71 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.661 -0.78 . . . . 1.02 111.367 175.535 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.52 155.08 20.84 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.718 -0.553 . . . . 0.4 111.718 -171.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 37.9 t70 59.1 17.13 5.29 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.929 0.871 . . . . 1.26 109.702 -176.568 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -102.58 156.42 17.63 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.524 -0.762 . . . . 1.19 111.343 -176.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.497 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 90.9 mt -140.69 120.73 12.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.292 -0.867 . . . . 0.38 109.57 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.4 p -150.2 143.74 17.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.644 0.259 . . . . 1.0 110.872 -177.682 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.55 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 36.2 tt0 -90.72 136.11 33.28 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.982 0.42 . . . . 0.67 110.42 177.782 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.577 ' HE2' HD13 ' A' ' 48' ' ' ILE . 61.3 mmm -69.13 89.05 0.43 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.332 -0.849 . . . . 0.88 110.283 179.054 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.1 p -112.73 -164.21 0.9 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.86 -0.609 . . . . 0.29 110.669 -177.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -75.4 -25.17 57.38 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.787 0.327 . . . . 2.13 110.874 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -66.2 -29.81 70.15 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 122.07 0.938 . . . . 2.51 109.612 172.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.478 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.2 mm -82.46 -51.94 14.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 114.254 -1.339 . . . . 0.25 110.489 177.696 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.786 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -103.42 82.86 2.09 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.459 -0.791 . . . . 0.31 110.147 -176.773 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -75.27 100.18 4.28 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.484 -0.78 . . . . 1.46 109.669 175.056 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 5.8 p -82.62 121.59 27.02 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.832 -0.622 . . . . 0.69 111.632 -176.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -172.96 -68.44 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 111.241 -0.743 . . . . 1.91 111.241 178.347 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -176.77 -37.61 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.531 -0.544 . . . . 5.57 109.531 175.317 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.0 t30 . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.548 -0.739 . . . . 6.87 109.562 177.953 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.773 0 N-CA-C 112.258 -0.337 . . . . 1.71 112.258 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 -93.43 155.01 17.61 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.293 0.568 . . . . 2.0 110.767 178.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.23 110.05 17.74 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.061 -0.972 . . . . 0.24 109.931 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.779 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.9 pt -87.55 -14.87 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.125 -0.943 . . . . 0.15 111.688 -171.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.82 175.84 40.71 Favored Glycine 0 CA--C 1.502 -0.728 0 C-N-CA 120.671 -0.776 . . . . 0.1 111.817 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -144.15 149.55 36.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.038 0.446 . . . . 0.2 110.61 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.522 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.6 mm -76.61 126.11 36.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 115.731 -0.668 . . . . 0.14 110.787 -178.537 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.6 p -117.13 -16.92 10.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.307 0.575 . . . . 0.2 110.773 177.342 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.477 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.4 tttt -145.3 143.83 30.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.607 -0.886 . . . . 2.36 108.607 174.478 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.529 HD11 HG21 ' A' ' 14' ' ' VAL . 4.8 tt -160.47 139.1 10.26 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.778 0.323 . . . . 0.2 110.987 -175.558 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.539 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 0.0 OUTLIER -144.07 145.32 32.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.956 -0.566 . . . . 1.94 111.49 177.487 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.733 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 80.18 -146.25 27.64 Favored Glycine 0 N--CA 1.436 -1.348 0 CA-C-N 115.026 -0.988 . . . . 0.27 114.063 167.037 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.9 m -102.03 115.66 31.03 Favored 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 122.832 0.453 . . . . 1.16 110.445 -175.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.529 HG21 HD11 ' A' ' 10' ' ' LEU . 3.8 m -135.14 153.59 34.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.594 0.711 . . . . 0.2 111.598 -175.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.12 158.32 44.03 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.781 -1.099 . . . . 0.17 108.954 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.67 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -134.31 139.06 48.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 C-N-CA 120.015 -0.674 . . . . 0.16 110.727 171.901 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -107.11 100.03 9.53 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.149 -0.932 . . . . 0.51 109.71 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.453 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 43.0 t -62.73 179.93 0.31 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.594 -0.275 . . . . 1.25 110.753 -178.253 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.4 pt -61.16 -30.64 48.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.143 0.497 . . . . 0.59 111.567 -176.683 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 16.4 p30 -80.64 -6.71 58.74 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.907 -0.588 . . . . 1.96 111.0 177.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 94.37 1.28 64.52 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.121 -0.561 . . . . 0.32 112.413 176.033 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -67.08 121.24 15.16 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.817 0.341 . . . . 2.21 111.424 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.618 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 14.6 tt0 -93.77 118.18 31.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.641 177.069 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.67 ' HG2' HG12 ' A' ' 16' ' ' VAL . 21.8 ptt-85 -120.24 168.01 11.69 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.167 -0.679 . . . . 1.55 109.167 174.518 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.7 p -93.98 136.81 24.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.996 -0.742 . . . . 0.35 108.996 177.435 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.599 HD22 ' OD1' ' A' ' 30' ' ' ASP . 5.2 mt -97.13 153.58 17.88 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.014 -0.539 . . . . 0.32 111.316 -176.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.3 mttm -138.44 -178.12 5.15 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.149 -0.932 . . . . 1.65 108.585 -173.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.78 140.85 39.48 Favored 'General case' 0 C--N 1.314 -0.954 0 C-N-CA 119.494 -0.882 . . . . 0.23 108.971 174.26 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.81 1.09 77.07 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 120.041 -1.076 . . . . 0.24 111.887 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.599 ' OD1' HD22 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -73.83 137.14 76.65 Favored Pre-proline 0 CA--C 1.517 -0.312 0 CA-C-O 121.79 0.805 . . . . 1.92 110.614 179.095 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -77.23 130.23 10.94 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.62 2.88 . . . . 0.22 113.405 -177.578 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.403 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.5 mm -99.53 135.93 32.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.075 -0.966 . . . . 0.13 109.313 174.217 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -116.15 154.71 29.54 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 116.004 -0.544 . . . . 0.29 109.731 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.56 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -71.21 109.57 5.33 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.361 -0.382 . . . . 0.18 110.657 -174.555 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.14 10.28 9.04 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.443 -0.884 . . . . 0.17 113.422 178.072 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.481 ' O ' ' HG2' ' A' ' 66' ' ' MET . 40.6 mt-10 -96.01 145.08 25.74 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 117.868 0.834 . . . . 0.52 110.687 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 31.7 m -105.27 108.2 19.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.412 -0.813 . . . . 0.16 110.806 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -82.71 133.72 28.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.128 0.489 . . . . 0.16 110.756 -175.567 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -122.2 110.15 15.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.175 -0.921 . . . . 0.27 110.051 -177.162 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.424 ' HB ' ' HA3' ' A' ' 44' ' ' GLY . 68.9 p -107.48 158.06 17.5 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.425 -0.583 . . . . 0.23 109.425 176.272 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -135.56 108.12 0.67 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.378 -0.915 . . . . 0.9 113.346 -177.497 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.606 ' H ' ' HB2' ' A' ' 61' ' ' ASP . . . 62.92 -87.55 0.05 OUTLIER Glycine 0 C--N 1.332 0.339 0 CA-C-O 121.196 0.331 . . . . 1.79 112.367 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.733 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 15.7 m -93.41 93.14 7.98 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 107.826 -1.175 . . . . 1.64 107.826 174.251 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.539 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -153.2 91.7 0.13 Allowed Glycine 0 C--N 1.309 -0.97 0 CA-C-N 115.328 -0.851 . . . . 0.89 112.189 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.99 114.13 22.71 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.281 0.541 . . . . 0.85 109.937 -175.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.0 t -126.09 142.35 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 CA-C-O 120.793 0.33 . . . . 0.25 111.093 -170.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.1 m -119.34 110.59 17.15 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.297 0.57 . . . . 0.19 110.341 177.408 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.442 HD13 ' HE2' ' A' ' 66' ' ' MET . 70.2 mt -98.88 102.5 13.49 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-N 115.163 -0.926 . . . . 0.15 109.925 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.76 102.62 11.68 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.476 -0.784 . . . . 0.14 109.259 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.549 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 58.6 m-85 -64.85 149.28 49.76 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.437 0.637 . . . . 0.32 110.881 -177.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.28 -9.03 12.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 114.784 -1.098 . . . . 0.25 111.134 -172.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.423 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 19.5 t70 -78.39 -22.27 48.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.71 -0.677 . . . . 0.75 111.0 177.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.21 -11.85 16.94 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.27 111.65 -174.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -85.1 161.08 19.82 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.127 -0.323 . . . . 0.36 110.127 175.571 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -131.78 155.53 47.58 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.24 -0.281 . . . . 1.51 110.24 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.49 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.8 OUTLIER -137.5 151.27 26.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.433 -0.349 . . . . 1.39 110.151 178.401 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.43 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.1 p -129.39 141.53 46.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.333 -0.394 . . . . 0.81 110.139 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 mt -116.2 131.38 68.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.224 -0.444 . . . . 0.32 110.209 -177.788 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.46 179.7 52.83 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.925 -0.655 . . . . 1.02 111.635 176.201 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.78 148.73 19.09 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 111.285 -0.726 . . . . 0.4 111.285 -173.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.606 ' HB2' ' H ' ' A' ' 42' ' ' GLY . 31.8 t70 59.22 23.42 11.76 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 121.914 0.864 . . . . 1.26 109.605 -173.024 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -104.47 159.99 15.29 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.728 -0.669 . . . . 1.19 110.712 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.483 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 92.2 mt -140.07 125.83 21.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.123 -0.944 . . . . 0.38 108.809 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.407 HG21 HD11 ' A' ' 70' ' ' ILE . 13.8 p -147.67 141.74 19.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-O 120.886 0.374 . . . . 1.0 110.866 -177.226 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.414 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.3 tt0 -100.86 124.93 47.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.151 -0.477 . . . . 0.67 110.25 -179.089 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 44.3 mmm -65.46 90.29 0.11 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.72 -0.673 . . . . 0.88 110.725 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.408 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.3 p -118.48 -165.48 1.12 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 0.29 111.7 -176.532 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -65.9 -44.22 85.88 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.857 0.317 . . . . 2.13 111.857 -174.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -62.94 -29.99 71.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.456 0.646 . . . . 2.51 110.49 178.111 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.432 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.1 mm -71.99 -53.11 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.903 -1.044 . . . . 0.25 110.769 176.484 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.779 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 -103.76 80.27 1.75 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.61 -0.723 . . . . 0.31 110.318 -176.495 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -79.87 105.0 10.83 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.549 -0.751 . . . . 1.46 109.482 175.543 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.3 p -79.09 125.5 29.49 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.079 -0.51 . . . . 0.69 111.428 -177.078 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -97.84 -1.18 58.7 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.999 -0.62 . . . . 1.91 111.73 176.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -70.22 121.27 17.27 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.735 0.303 . . . . 5.57 110.433 176.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 52.1 t30 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.216 -0.897 . . . . 6.87 109.942 178.812 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.701 0 N-CA-C 111.777 -0.529 . . . . 1.71 111.777 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -135.09 159.88 40.11 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.017 0.437 . . . . 2.0 110.35 179.426 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.08 117.94 20.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.488 -0.778 . . . . 0.24 110.228 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.823 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 26.6 pt -96.96 -13.47 8.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.454 -0.794 . . . . 0.15 111.487 -172.638 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.6 179.21 42.21 Favored Glycine 0 CA--C 1.502 -0.752 0 C-N-CA 120.947 -0.644 . . . . 0.1 111.635 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.402 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 98.0 m-85 -145.18 152.24 39.69 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.819 0.342 . . . . 0.2 110.604 -175.59 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 30' ' ' ASP . 29.6 mm -81.55 120.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.032 -0.531 . . . . 0.14 111.11 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 43.8 p -111.94 -27.25 8.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.276 0.56 . . . . 0.2 110.307 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.491 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 85.8 tttt -136.43 147.37 47.21 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.464 -0.939 . . . . 2.36 108.464 172.488 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.484 HD11 HG21 ' A' ' 14' ' ' VAL . 4.9 tt -158.74 141.06 14.07 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.852 0.358 . . . . 0.2 110.8 -176.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.51 144.36 30.51 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 115.643 -0.708 . . . . 1.94 112.128 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.678 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 81.81 -148.4 27.35 Favored Glycine 0 N--CA 1.425 -2.038 0 CA-C-N 114.561 -1.2 . . . . 0.27 113.479 165.562 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 5.7 t -103.05 109.91 21.65 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.715 -0.476 . . . . 1.16 109.715 -179.142 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.579 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.6 m -132.21 153.02 37.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.379 0.609 . . . . 0.2 111.569 -175.751 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.13 159.71 44.22 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.219 -0.901 . . . . 0.17 109.413 -179.56 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.532 HG22 ' HB3' ' A' ' 36' ' ' GLU . 0.5 OUTLIER -132.6 131.09 59.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.239 0.543 . . . . 0.16 110.213 176.017 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 mt-30 -103.35 99.6 9.45 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.708 -0.678 . . . . 0.51 109.835 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.54 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.6 m -61.64 174.07 0.86 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.535 -0.302 . . . . 1.25 111.072 -176.28 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.7 pt -54.92 -32.51 26.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.301 0.482 . . . . 0.59 112.301 -176.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -75.71 -12.11 60.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.384 -0.371 . . . . 1.96 111.421 178.787 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.12 6.08 59.17 Favored Glycine 0 CA--C 1.51 -0.261 0 N-CA-C 111.864 -0.494 . . . . 0.32 111.864 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.0 mm-40 -74.35 124.96 27.47 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.639 0.257 . . . . 2.21 110.491 178.589 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 23.7 tt0 -91.69 110.13 21.46 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.425 0.631 . . . . 1.0 110.801 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.08 139.05 40.33 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.295 -0.866 . . . . 1.55 109.872 177.466 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.22 138.03 21.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.444 -0.576 . . . . 0.35 109.444 176.381 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.579 ' HB2' HG23 ' A' ' 14' ' ' VAL . 28.8 mt -102.96 127.54 50.15 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.304 0.574 . . . . 0.32 111.102 -178.117 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 74.0 mttt -116.55 179.43 4.01 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.514 -1.291 . . . . 1.65 107.514 170.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -67.58 146.74 53.59 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 119.306 -0.958 . . . . 0.23 109.95 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.52 0.04 86.35 Favored Glycine 0 N--CA 1.438 -1.178 0 C-N-CA 120.313 -0.946 . . . . 0.24 112.721 177.667 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.49 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.8 OUTLIER -71.84 143.13 86.44 Favored Pre-proline 0 CA--C 1.513 -0.461 0 C-N-CA 120.36 -0.536 . . . . 1.92 109.775 173.946 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.402 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 21.4 Cg_endo -89.78 137.47 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.143 2.562 . . . . 0.22 112.1 178.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.467 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.5 mm -98.52 139.65 20.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 116.132 -0.485 . . . . 0.13 109.914 176.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -117.13 155.38 29.43 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.893 -0.594 . . . . 0.29 109.498 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.51 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.5 t80 -71.64 118.6 14.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.39 -0.368 . . . . 0.18 110.541 -175.424 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.68 -0.36 24.63 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.502 -0.856 . . . . 0.17 113.324 177.274 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.54 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 23.4 mt-10 -85.42 147.94 26.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 117.8 0.8 . . . . 0.52 110.909 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.8 m -107.71 108.27 19.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.812 -1.086 . . . . 0.16 110.388 -176.478 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.619 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.2 t -82.08 136.97 21.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 C-N-CA 120.703 -0.399 . . . . 0.16 110.759 -174.328 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -125.66 107.03 10.17 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.437 -0.801 . . . . 0.27 110.562 -175.742 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.467 HG22 HG12 ' A' ' 14' ' ' VAL . 81.5 p -105.74 163.3 12.81 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 108.981 -0.748 . . . . 0.23 108.981 173.27 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -141.69 120.7 1.7 Allowed Glycine 0 C--N 1.316 -0.562 0 C-N-CA 120.384 -0.912 . . . . 0.9 112.538 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.526 ' H ' ' HB2' ' A' ' 61' ' ' ASP . . . 54.24 -94.36 0.02 OUTLIER Glycine 0 C--N 1.334 0.436 0 O-C-N 124.021 0.483 . . . . 1.79 112.551 -178.683 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.678 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 8.5 m -89.23 87.76 7.27 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.677 -0.86 . . . . 1.64 108.677 177.161 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -141.26 137.66 8.27 Favored Glycine 0 N--CA 1.443 -0.867 0 CA-C-N 115.023 -0.99 . . . . 0.89 111.54 176.424 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.554 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 46.6 t -153.54 151.36 29.7 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 109.09 -0.707 . . . . 0.85 109.09 169.758 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 17.8 t -152.21 136.2 8.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 110.121 -0.325 . . . . 0.25 110.121 -176.256 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.491 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.9 m -109.79 105.36 14.55 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.145 0.497 . . . . 0.19 109.768 173.194 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 78.4 mt -96.34 99.88 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 115.43 -0.805 . . . . 0.15 109.739 177.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.91 102.38 8.22 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.215 -0.902 . . . . 0.14 109.079 176.639 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.613 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 53.1 m-85 -66.28 151.35 47.23 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.617 0.722 . . . . 0.32 111.081 -176.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -75.24 1.63 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 114.588 -1.187 . . . . 0.25 111.273 -172.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -94.16 -20.79 19.55 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.106 0.479 . . . . 0.75 110.5 178.15 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 123.36 -19.77 7.57 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.637 -0.792 . . . . 0.27 111.892 -176.158 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -78.27 160.2 28.03 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 122.15 0.18 . . . . 0.36 110.766 177.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -133.3 146.03 50.99 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.427 -0.582 . . . . 1.51 109.427 178.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.613 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -130.85 147.27 33.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.008 0.432 . . . . 1.39 110.834 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.3 p -120.7 138.94 49.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.841 -0.618 . . . . 0.81 110.123 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.554 ' O ' ' HA ' ' A' ' 45' ' ' SER . 34.6 mt -110.64 134.45 52.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.078 -0.51 . . . . 0.32 110.096 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.76 -168.96 43.56 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.803 -0.713 . . . . 1.02 112.262 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -100.56 143.39 16.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.95 -0.643 . . . . 0.4 111.562 -176.149 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.526 ' HB2' ' H ' ' A' ' 42' ' ' GLY . 28.2 t70 60.44 21.53 11.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 121.612 0.72 . . . . 1.26 110.052 -174.051 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.2 t -97.54 154.27 17.63 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.725 -0.67 . . . . 1.19 110.176 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.619 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.6 mt -141.78 106.21 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.486 -0.779 . . . . 0.38 108.937 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -133.56 149.18 30.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.122 0.487 . . . . 1.0 111.414 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.406 ' O ' HG13 ' A' ' 70' ' ' ILE . 43.3 tt0 -105.94 128.96 54.14 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.611 -0.722 . . . . 0.67 110.543 -175.637 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.546 ' SD ' HG21 ' A' ' 70' ' ' ILE . 22.2 mmt -64.3 89.88 0.06 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.607 -0.724 . . . . 0.88 111.333 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 72.7 p -124.89 -165.14 1.35 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.85 -0.613 . . . . 0.29 110.988 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -68.33 -26.04 65.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.31 0.576 . . . . 2.13 110.226 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -74.19 -20.28 60.25 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.362 -0.836 . . . . 2.51 110.361 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.546 HG21 ' SD ' ' A' ' 66' ' ' MET . 2.2 mm -98.49 -55.1 6.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-N 114.785 -1.098 . . . . 0.25 110.948 -179.59 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.823 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -95.47 85.81 4.31 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.044 -0.98 . . . . 0.31 109.921 -175.676 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 35.7 t30 -73.74 115.23 12.91 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.241 -0.89 . . . . 1.46 109.944 173.039 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 2.1 p -95.01 115.16 27.07 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.186 -0.461 . . . . 0.69 110.299 176.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 146.51 43.93 0.04 OUTLIER Glycine 0 N--CA 1.441 -0.999 0 C-N-CA 120.654 -0.784 . . . . 1.91 112.322 -178.209 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -82.08 55.91 2.97 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.609 0.719 . . . . 5.57 109.86 177.094 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 52.9 t30 . . . . . 0 C--O 1.247 0.948 0 CA-C-N 115.327 -0.851 . . . . 6.87 109.74 -178.115 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.762 0 N-CA-C 112.316 -0.313 . . . . 1.71 112.316 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.3 p-10 -90.58 164.61 14.14 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.861 0.363 . . . . 2.0 110.201 178.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.04 109.2 14.27 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.854 -0.612 . . . . 0.24 109.78 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.694 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.4 pt -95.35 -11.85 8.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 115.058 -0.974 . . . . 0.15 111.565 -171.481 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.91 175.58 43.32 Favored Glycine 0 CA--C 1.498 -1.027 0 N-CA-C 111.241 -0.743 . . . . 0.1 111.241 178.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -144.1 151.18 39.26 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.952 0.406 . . . . 0.2 110.581 -174.363 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.564 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.7 mm -78.3 124.43 36.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.96 -0.563 . . . . 0.14 111.389 -177.218 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.0 p -115.1 -21.3 10.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.182 0.515 . . . . 0.2 110.627 177.573 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.549 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 81.8 tttt -140.9 143.58 34.72 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.54 -0.911 . . . . 2.36 108.54 172.375 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.632 HD11 HG21 ' A' ' 14' ' ' VAL . 7.6 tt -161.21 140.84 10.53 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.682 0.277 . . . . 0.2 110.82 -177.264 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -156.0 158.5 37.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.49 -0.777 . . . . 1.94 111.159 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.403 ' HA3' ' HA2' ' A' ' 44' ' ' GLY . . . 76.81 -163.66 52.64 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.811 -0.631 . . . . 0.27 112.974 175.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.0 m -92.83 116.62 29.2 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 109.762 -0.459 . . . . 1.16 109.762 -177.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.632 HG21 HD11 ' A' ' 10' ' ' LEU . 3.9 m -134.48 152.5 33.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.672 0.748 . . . . 0.2 111.988 -175.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.04 159.05 44.78 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 114.567 -1.197 . . . . 0.17 108.853 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.664 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -133.95 135.76 54.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.109 -0.637 . . . . 0.16 110.922 172.957 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.413 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.3 mt-30 -102.46 100.75 10.9 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.364 -0.835 . . . . 0.51 109.911 177.412 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.527 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 37.7 m -62.86 176.64 0.66 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.5 -0.318 . . . . 1.25 110.861 -178.367 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -66.68 -5.55 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 N-CA-C 112.142 0.423 . . . . 0.59 112.142 -178.115 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -92.25 -8.48 45.21 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.294 0.569 . . . . 1.96 109.682 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.5 6.46 80.63 Favored Glycine 0 CA--C 1.507 -0.465 0 CA-C-N 115.278 -0.874 . . . . 0.32 111.093 -177.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.411 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 46.6 mm-40 -79.65 127.85 32.68 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.225 -0.488 . . . . 2.21 110.953 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLU . . . . . 0.655 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 25.4 tt0 -101.64 117.87 35.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.702 -0.681 . . . . 1.0 110.762 -178.149 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.664 ' HG2' HG12 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -116.62 168.78 9.88 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.619 -0.512 . . . . 1.55 109.619 176.156 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -87.77 140.84 15.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.329 -0.619 . . . . 0.35 109.329 176.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.545 HD22 ' CG ' ' A' ' 30' ' ' ASP . 4.8 mt -101.44 152.3 20.91 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.478 -0.489 . . . . 0.32 111.129 179.15 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.46 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 53.4 mttt -141.61 178.53 7.4 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.139 -0.937 . . . . 1.65 108.638 -174.401 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.14 139.3 44.43 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.353 -0.939 . . . . 0.23 109.108 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 2.42 86.82 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 120.051 -1.071 . . . . 0.24 111.968 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.564 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -74.89 141.59 75.39 Favored Pre-proline 0 N--CA 1.454 -0.237 0 CA-C-O 121.55 0.69 . . . . 1.92 109.981 177.574 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 28.2 Cg_endo -86.88 127.28 2.6 Favored 'Trans proline' 0 C--N 1.325 -0.709 0 C-N-CA 123.628 2.885 . . . . 0.22 113.353 -174.461 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 32.2 mm -93.11 134.28 31.48 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-N 116.183 -0.462 . . . . 0.13 109.815 176.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -111.89 151.29 29.32 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.697 -0.683 . . . . 0.29 109.747 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -69.42 113.9 7.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.318 -0.401 . . . . 0.18 110.796 -175.527 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.13 0.55 22.44 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.527 -0.844 . . . . 0.17 113.408 177.2 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLU . . . . . 0.546 ' O ' ' HG2' ' A' ' 66' ' ' MET . 30.8 mt-10 -86.87 144.7 26.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 117.976 0.888 . . . . 0.52 110.81 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.6 m -101.33 107.64 19.05 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.211 -0.904 . . . . 0.16 110.887 -177.11 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.575 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.6 t -82.24 130.51 35.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.137 0.494 . . . . 0.16 110.412 -176.253 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.1 mp -119.11 103.4 9.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.075 -0.966 . . . . 0.27 109.958 -177.357 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 20.3 p -100.67 159.33 15.26 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.253 -0.647 . . . . 0.23 109.253 175.734 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.78 138.07 9.15 Favored Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.66 -0.781 . . . . 0.9 112.133 178.223 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 54.33 -104.77 0.26 Allowed Glycine 0 N--CA 1.451 -0.339 0 O-C-N 124.097 0.528 . . . . 1.79 113.777 177.648 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.1 t -87.18 27.61 1.03 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.187 0.518 . . . . 1.64 110.82 -174.762 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.406 ' HA3' ' HB ' ' A' ' 40' ' ' THR . . . -71.96 135.46 22.98 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 121.128 -0.558 . . . . 0.89 112.723 -179.295 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.57 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 18.9 m -156.27 133.07 10.35 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.002 -0.74 . . . . 0.85 109.002 172.52 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 11.0 t -140.18 146.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 O-C-N 122.171 -0.33 . . . . 0.25 110.761 -176.085 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.5 m -119.43 111.21 17.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.115 -0.493 . . . . 0.19 109.731 174.106 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.585 HD13 ' HE2' ' A' ' 66' ' ' MET . 62.4 mt -101.0 104.16 15.85 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 CA-C-N 115.705 -0.679 . . . . 0.15 110.271 179.798 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 104.4 9.09 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.406 -0.816 . . . . 0.14 108.995 176.42 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.469 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 53.4 m-85 -69.55 148.72 49.06 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.269 0.557 . . . . 0.32 110.681 -177.592 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -70.69 -5.55 5.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 114.878 -1.055 . . . . 0.25 111.04 -171.778 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.423 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 30.4 t70 -81.57 -21.37 38.49 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.37 0.605 . . . . 0.75 110.42 174.738 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 117.13 -7.01 16.9 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.781 -0.723 . . . . 0.27 112.275 -177.444 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 23.3 p -86.55 175.18 8.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.436 -0.209 . . . . 0.36 110.436 177.618 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -149.53 150.49 32.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.706 0.289 . . . . 1.51 110.338 177.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.546 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.8 m -130.88 166.86 27.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.972 -0.558 . . . . 1.39 111.006 179.136 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' VAL . . . . . 0.541 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.0 p -135.19 132.21 52.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 115.763 -0.653 . . . . 0.81 110.819 179.241 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.57 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.3 mt -106.24 132.97 52.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.607 -0.724 . . . . 0.32 109.838 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.14 -160.38 26.9 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.977 -0.63 . . . . 1.02 112.598 -178.407 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -104.07 141.7 15.32 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.595 -0.602 . . . . 0.4 111.595 -176.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.408 ' HA ' ' O ' ' A' ' 40' ' ' THR . 32.9 t70 58.16 26.15 13.4 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 122.174 0.988 . . . . 1.26 109.313 -171.084 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -91.05 131.67 36.49 Favored 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.465 -1.243 . . . . 1.19 110.967 -178.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.575 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.0 mt -129.08 106.12 13.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.092 -0.707 . . . . 0.38 109.092 178.003 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.28 144.47 31.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.096 -0.502 . . . . 1.0 110.555 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.6 tt0 -97.46 131.04 44.47 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.426 -0.352 . . . . 0.67 110.303 -179.571 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.585 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.5 mmm -68.45 89.46 0.35 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.748 -0.66 . . . . 0.88 110.717 -178.307 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.416 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 44.9 p -112.13 -164.62 0.93 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.098 -0.501 . . . . 0.29 111.456 -176.689 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -72.35 -25.52 61.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.941 0.4 . . . . 2.13 110.852 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -71.05 -31.24 67.64 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 122.102 0.954 . . . . 2.51 109.236 176.124 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.416 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.2 mm -78.77 -47.03 23.86 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 CA-C-N 113.844 -1.525 . . . . 0.25 110.832 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.694 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -110.45 78.38 1.12 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.281 -0.872 . . . . 0.31 110.061 -178.135 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -88.18 101.81 14.19 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.817 -0.629 . . . . 1.46 109.465 174.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 32.3 p -65.6 134.7 53.86 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.992 -0.549 . . . . 0.69 111.542 -176.473 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.63 -38.81 1.04 Allowed Glycine 0 N--CA 1.443 -0.854 0 N-CA-C 111.476 -0.649 . . . . 1.91 111.476 178.083 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -79.67 -42.82 23.95 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.584 0.23 . . . . 5.57 110.682 -178.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.563 -0.732 . . . . 6.87 110.443 175.301 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 . . . . . 0 CA--C 1.515 -0.385 0 N-CA-C 109.805 -0.443 . . . . 2.0 109.805 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.78 114.55 15.67 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.334 0.588 . . . . 0.23999999999999999 110.342 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.79 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 23.1 pt -93.98 -14.39 8.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 115.197 -0.91 . . . . 0.14999999999999999 111.431 -172.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.47 42.79 Favored Glycine 0 CA--C 1.504 -0.64 0 C-N-CA 120.739 -0.743 . . . . 0.10000000000000001 111.84 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -143.54 151.09 39.82 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.989 0.423 . . . . 0.20000000000000001 110.822 -174.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.519 ' HB ' ' H ' ' A' ' 29' ' ' GLY . 23.8 mm -78.75 124.43 37.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.875 -0.602 . . . . 0.14000000000000001 111.528 -177.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.8 p -113.39 -26.17 8.47 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.323 0.582 . . . . 0.20000000000000001 110.771 177.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.565 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.9 tptt -137.89 139.62 39.94 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.786 -0.82 . . . . 2.3599999999999999 108.786 174.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.567 HD11 HG21 ' A' ' 14' ' ' VAL . 6.9 tt -152.74 144.91 23.87 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 120.776 0.322 . . . . 0.20000000000000001 110.164 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -155.35 156.32 35.22 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.852 -0.613 . . . . 1.9399999999999999 110.662 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.12 -155.49 50.64 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.95 -0.568 . . . . 0.27000000000000002 112.809 176.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.3 t -99.43 126.0 45.25 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.186 -0.672 . . . . 1.1599999999999999 109.186 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.589 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -139.76 152.96 22.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.538 0.685 . . . . 0.20000000000000001 111.498 -176.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.51 158.78 44.06 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.625 -1.17 . . . . 0.17000000000000001 108.982 178.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.535 HG23 HG22 ' A' ' 38' ' ' VAL . 0.5 OUTLIER -132.68 131.83 59.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.235 0.54 . . . . 0.16 110.034 174.857 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -97.42 99.01 10.43 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.471 -0.566 . . . . 0.51000000000000001 109.471 178.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.567 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 39.9 m -62.2 171.59 1.76 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.928 -0.578 . . . . 1.25 109.703 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.2 pt -65.98 -1.44 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 113.757 1.021 . . . . 0.58999999999999997 113.757 -170.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 49.6 m-80 -98.03 -2.16 40.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.303 0.573 . . . . 1.96 109.722 173.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.63 74.91 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 110.61 -0.996 . . . . 0.32000000000000001 110.61 -176.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -84.38 118.2 24.09 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.721 -0.74 . . . . 2.21 110.519 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.417 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 4.9 tt0 -85.56 113.86 22.13 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.294 0.568 . . . . 1.0 110.483 -178.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -106.01 138.76 41.64 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.958 -1.019 . . . . 1.55 109.401 177.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -75.8 141.32 15.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.249 -0.648 . . . . 0.34999999999999998 109.249 177.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.589 ' HB2' HG23 ' A' ' 14' ' ' VAL . 5.1 mt -106.99 145.05 32.74 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 121.493 0.663 . . . . 0.32000000000000001 111.614 -178.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 35.7 mttp -137.51 169.22 18.15 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.461 -1.245 . . . . 1.6499999999999999 107.735 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -61.23 140.17 57.99 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 119.761 -0.776 . . . . 0.23000000000000001 109.798 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.519 ' H ' ' HB ' ' A' ' 7' ' ' ILE . . . 82.79 9.31 84.71 Favored Glycine 0 N--CA 1.437 -1.289 0 C-N-CA 120.052 -1.07 . . . . 0.23999999999999999 113.08 177.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.509 ' OD1' HG13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.76 147.98 56.54 Favored Pre-proline 0 C--O 1.236 0.355 0 CA-C-N 117.419 0.609 . . . . 1.9199999999999999 109.474 176.191 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -84.05 131.04 5.0 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.635 2.224 . . . . 0.22 113.219 178.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 mm -95.98 137.37 24.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.392 -0.822 . . . . 0.13 109.211 174.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -118.8 157.22 27.98 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.057 -0.52 . . . . 0.28999999999999998 109.699 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.526 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.8 t80 -73.85 116.02 13.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.078 -0.51 . . . . 0.17999999999999999 110.493 -174.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.19 -4.2 18.35 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.527 -0.844 . . . . 0.17000000000000001 113.736 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.567 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 24.6 mt-10 -84.93 149.06 25.9 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 117.971 0.886 . . . . 0.52000000000000002 110.993 -177.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.425 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 11.7 m -104.31 108.07 19.29 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.388 -0.823 . . . . 0.16 110.777 -178.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 16' ' ' VAL . 2.8 t -81.72 133.53 29.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.145 0.498 . . . . 0.16 110.613 -176.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -122.08 107.68 12.48 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.18 -0.918 . . . . 0.27000000000000002 109.964 -176.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.423 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 69.7 p -104.26 152.04 22.67 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.79 -0.448 . . . . 0.23000000000000001 109.79 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.935 0 C-N-CA 120.928 -0.653 . . . . 0.90000000000000002 112.205 179.395 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 6.0 m . . . . . 0 C--O 1.224 -0.285 0 N-CA-C 108.968 -0.753 . . . . 0.84999999999999998 108.968 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 4.7 t -133.53 139.54 48.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.739 -0.384 . . . . 0.25 111.141 -173.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.588 ' HA ' ' O ' ' A' ' 56' ' ' VAL . 89.3 m -113.89 110.85 20.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.966 -0.561 . . . . 0.19 109.956 174.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.496 HD13 ' HE2' ' A' ' 66' ' ' MET . 69.3 mt -100.37 102.0 12.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.585 -0.734 . . . . 0.14999999999999999 110.24 178.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.6 107.79 11.53 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.431 -0.804 . . . . 0.14000000000000001 109.388 177.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.49 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 61.7 m-85 -70.86 149.7 46.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.633 0.73 . . . . 0.32000000000000001 111.287 -177.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -77.4 0.95 2.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 114.743 -1.117 . . . . 0.25 111.086 -172.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -90.51 -21.41 21.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.958 -0.564 . . . . 0.75 110.649 175.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.42 -18.11 5.8 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.639 -0.791 . . . . 0.27000000000000002 112.8 -178.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.2 p -84.81 171.64 12.1 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.644 0.222 . . . . 0.35999999999999999 111.119 178.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -130.26 -178.0 4.56 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.14 -0.689 . . . . 1.51 109.14 175.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.588 ' O ' ' HA ' ' A' ' 47' ' ' THR . 0.5 OUTLIER -160.24 151.32 5.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 1.3899999999999999 109.896 178.982 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.532 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.2 p -129.12 131.53 67.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.355 0.597 . . . . 0.81000000000000005 110.783 178.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.8 mt -107.28 137.18 39.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 115.668 -0.696 . . . . 0.32000000000000001 109.788 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.06 -164.28 29.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.932 -0.651 . . . . 1.02 112.578 -179.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.2 142.67 17.66 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.547 -0.621 . . . . 0.40000000000000002 111.547 -174.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.423 ' HA ' ' O ' ' A' ' 40' ' ' THR . 37.7 t70 56.64 30.11 16.87 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-O 122.151 0.977 . . . . 1.26 109.207 -172.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 m -112.28 163.27 14.57 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.656 -1.156 . . . . 1.1899999999999999 110.727 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 83.4 mt -140.05 127.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.845 -0.616 . . . . 0.38 109.838 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.1 p -148.53 143.72 18.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 109.886 -0.413 . . . . 1.0 109.886 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.425 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 29.8 tt0 -103.37 133.58 48.19 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.758 -0.377 . . . . 0.67000000000000004 110.323 -178.292 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.496 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.2 mmm -69.19 89.2 0.45 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.645 -0.707 . . . . 0.88 110.366 -177.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.412 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 19.2 p -115.95 -164.9 0.99 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.756 -0.656 . . . . 0.28999999999999998 111.39 -176.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -68.94 -41.15 78.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.524 -0.307 . . . . 2.1299999999999999 111.252 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -61.53 -30.08 70.41 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.636 0.731 . . . . 2.5099999999999998 110.306 177.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.412 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.3 mm -73.45 -52.52 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 114.497 -1.229 . . . . 0.25 110.806 176.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.79 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.316 -0.873 0 CA-C-N 115.489 -0.778 . . . . 0.31 110.378 -176.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 . . . . . 0 N--CA 1.47 0.537 0 CA-C-O 121.372 0.606 . . . . 2.0 111.613 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.26 109.91 12.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.827 -0.624 . . . . 0.23999999999999999 109.642 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.779 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.0 pt -92.77 -13.6 8.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.295 -0.866 . . . . 0.14999999999999999 112.074 -170.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.64 176.64 42.3 Favored Glycine 0 CA--C 1.501 -0.799 0 C-N-CA 120.69 -0.767 . . . . 0.10000000000000001 111.513 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -143.51 150.41 38.89 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.048 0.451 . . . . 0.20000000000000001 110.921 -174.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.542 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -78.22 123.38 34.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.683 -0.689 . . . . 0.14000000000000001 110.883 -177.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.7 p -115.44 -21.29 9.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.218 0.532 . . . . 0.20000000000000001 110.801 178.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.562 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 52.3 tptt -140.82 139.65 34.55 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.317 -0.994 . . . . 2.3599999999999999 108.317 172.29 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.602 HD11 HG21 ' A' ' 14' ' ' VAL . 5.8 tt -153.57 146.34 24.32 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 110.234 -0.284 . . . . 0.20000000000000001 110.234 -179.23 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -146.82 153.57 40.34 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.292 -0.413 . . . . 1.9399999999999999 110.654 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.61 -149.48 49.67 Favored Glycine 0 N--CA 1.45 -0.402 0 O-C-N 123.689 0.618 . . . . 0.27000000000000002 113.768 171.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.9 m -100.22 124.49 45.71 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.954 -0.387 . . . . 1.1599999999999999 109.954 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.602 HG21 HD11 ' A' ' 10' ' ' LEU . 3.9 m -136.05 152.32 30.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.638 0.732 . . . . 0.20000000000000001 111.692 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.23 157.55 43.21 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.751 -1.113 . . . . 0.17000000000000001 108.647 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.682 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -135.81 134.94 51.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.048 -0.661 . . . . 0.16 111.049 174.549 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.46 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.8 mt-30 -100.05 102.79 14.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.328 -0.851 . . . . 0.51000000000000001 109.599 177.426 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.568 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 61.4 p -61.46 178.87 0.26 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 111.473 0.175 . . . . 1.25 111.473 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.7 pt -59.42 -24.36 27.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.091 0.472 . . . . 0.58999999999999997 111.16 178.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -77.57 -16.64 58.51 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.829 -0.623 . . . . 1.96 110.402 177.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.33 7.31 62.17 Favored Glycine 0 CA--C 1.504 -0.6 0 N-CA-C 110.909 -0.877 . . . . 0.32000000000000001 110.909 -176.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.0 mm100 -77.74 116.02 17.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.159 -0.521 . . . . 2.21 110.69 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.542 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 13.4 tt0 -81.89 118.44 22.93 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.069 -0.514 . . . . 1.0 110.056 176.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HG2' HG12 ' A' ' 16' ' ' VAL . 36.0 ptt85 -120.33 169.62 10.11 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.838 -0.801 . . . . 1.55 108.838 174.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.411 ' O ' HD23 ' A' ' 26' ' ' LEU . 7.4 p -96.62 144.33 10.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 109.496 -0.557 . . . . 0.34999999999999998 109.496 -178.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.553 HD22 ' CG ' ' A' ' 30' ' ' ASP . 7.3 mt -112.68 160.73 17.62 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.124 0.487 . . . . 0.32000000000000001 110.987 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.621 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 0.2 OUTLIER -159.46 177.04 11.38 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.278 -0.874 . . . . 1.6499999999999999 109.027 -179.502 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 143.51 56.82 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 119.81 -0.756 . . . . 0.23000000000000001 109.99 -179.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.57 6.71 81.81 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.219 -0.991 . . . . 0.23999999999999999 112.41 178.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.621 ' HB3' ' O ' ' A' ' 27' ' ' LYS . 0.0 OUTLIER -85.37 142.27 37.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.399 0.618 . . . . 1.9199999999999999 110.793 178.325 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.36 134.79 11.54 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 123.58 2.853 . . . . 0.22 113.756 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.8 mm -100.49 136.9 29.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.35 -0.841 . . . . 0.13 109.238 172.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -116.29 153.12 32.51 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 116.224 -0.444 . . . . 0.28999999999999998 110.134 -178.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.559 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -71.37 114.5 9.5 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.058 -0.519 . . . . 0.17999999999999999 110.869 -174.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.95 0.56 24.16 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.497 -0.858 . . . . 0.17000000000000001 113.279 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.568 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 34.7 mt-10 -84.28 147.7 27.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.676 0.738 . . . . 0.52000000000000002 110.465 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 22.2 m -106.59 106.88 17.61 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.462 -0.79 . . . . 0.16 110.488 -177.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.555 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -81.85 125.96 39.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-O 121.205 0.526 . . . . 0.16 110.916 -174.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -113.16 106.39 14.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.028 -0.987 . . . . 0.27000000000000002 109.454 179.124 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.485 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 73.0 p -101.93 157.42 16.87 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 120.44 -0.504 . . . . 0.23000000000000001 109.997 178.183 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.022 0 CA-C-N 115.631 -0.713 . . . . 0.90000000000000002 111.644 178.507 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m . . . . . 0 CA--C 1.517 -0.308 0 N-CA-C 109.231 -0.655 . . . . 0.84999999999999998 109.231 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.8 t -126.5 130.43 71.79 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 C-N-CA 120.677 -0.409 . . . . 0.25 111.878 -169.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.562 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 97.2 m -106.79 108.85 20.57 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.781 -0.645 . . . . 0.19 109.751 175.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.549 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 62.3 mt -97.73 105.35 17.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.623 -0.717 . . . . 0.14999999999999999 110.117 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.81 105.42 11.08 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.413 -0.812 . . . . 0.14000000000000001 109.042 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.448 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 62.5 m-85 -71.18 146.79 48.88 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.508 0.67 . . . . 0.32000000000000001 110.867 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.59 2.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 114.634 -1.166 . . . . 0.25 111.582 -171.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -94.66 -20.68 19.35 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.076 -0.511 . . . . 0.75 110.384 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.0 -17.65 7.12 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.66 -0.781 . . . . 0.27000000000000002 112.552 -178.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.7 p -82.99 155.7 23.83 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 122.903 -0.175 . . . . 0.35999999999999999 110.866 178.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -132.33 143.26 49.74 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.897 -0.408 . . . . 1.51 109.897 178.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.549 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 10.7 m -124.44 168.56 16.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.068 0.461 . . . . 1.3899999999999999 111.584 178.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.506 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.7 p -138.78 133.37 41.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.331 -0.849 . . . . 0.81000000000000005 110.25 177.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -106.34 136.15 42.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.99 -0.55 . . . . 0.32000000000000001 109.929 -179.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.49 178.71 53.74 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.551 -0.833 . . . . 1.02 111.606 177.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.0 151.08 19.93 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 111.584 -0.607 . . . . 0.40000000000000002 111.584 -172.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.485 ' HA ' ' O ' ' A' ' 40' ' ' THR . 34.5 t70 51.15 28.48 4.08 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 121.379 0.609 . . . . 1.26 110.509 -171.22 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.5 t -104.72 161.71 13.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.882 -0.599 . . . . 1.1899999999999999 110.761 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.555 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 81.3 mt -138.92 123.15 20.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.629 -0.714 . . . . 0.38 109.51 178.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.14 137.04 16.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.935 0.398 . . . . 1.0 110.855 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.496 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.7 tt0 -91.46 131.84 36.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.315 -0.402 . . . . 0.67000000000000004 110.41 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.539 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.2 mmm -71.68 89.18 1.0 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 0.88 110.6 -178.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.2 p -111.05 -166.77 1.11 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.092 -0.504 . . . . 0.28999999999999998 110.9 -178.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.9 -27.89 62.15 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.013 0.435 . . . . 2.1299999999999999 110.044 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -65.46 -30.09 70.84 Favored 'General case' 0 CA--C 1.521 -0.144 0 CA-C-O 121.882 0.849 . . . . 2.5099999999999998 109.789 174.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.438 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.0 OUTLIER -80.51 -54.02 11.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 114.457 -1.247 . . . . 0.25 110.732 176.777 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.779 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.316 -0.851 0 CA-C-N 115.407 -0.815 . . . . 0.31 109.772 -177.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 . . . . . 0 N--CA 1.468 0.473 0 CA-C-O 121.242 0.544 . . . . 2.0 110.937 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.53 109.85 16.37 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.485 0.66 . . . . 0.23999999999999999 109.817 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.759 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.3 pt -95.11 -12.32 8.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 114.945 -1.025 . . . . 0.14999999999999999 111.777 -171.215 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.49 179.26 41.09 Favored Glycine 0 CA--C 1.5 -0.853 0 C-N-CA 120.684 -0.769 . . . . 0.10000000000000001 111.698 178.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.455 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 92.3 m-85 -144.41 152.13 40.23 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.76 0.314 . . . . 0.20000000000000001 110.535 -176.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.507 HG12 ' O ' ' A' ' 30' ' ' ASP . 33.0 mm -79.77 122.48 35.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.441 -0.345 . . . . 0.14000000000000001 110.86 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.0 p -115.72 -21.59 9.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.207 0.527 . . . . 0.20000000000000001 110.966 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.552 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.8 tttt -141.87 144.94 34.09 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.219 -1.03 . . . . 2.3599999999999999 108.219 173.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.425 HD11 HG21 ' A' ' 14' ' ' VAL . 6.5 tt -158.95 146.54 17.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.877 0.37 . . . . 0.20000000000000001 111.029 -177.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.449 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 9.0 t70 -153.36 152.14 30.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.811 -0.631 . . . . 1.9399999999999999 110.854 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.15 -154.42 44.58 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.129 -0.558 . . . . 0.27000000000000002 113.112 173.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.4 m -103.34 120.78 41.43 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 109.804 -0.443 . . . . 1.1599999999999999 109.804 -176.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.514 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.0 m -138.35 152.1 25.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.769 0.795 . . . . 0.20000000000000001 111.596 -176.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.41 159.43 44.47 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 114.64 -1.164 . . . . 0.17000000000000001 108.463 178.039 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.682 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -132.95 136.45 55.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 119.86 -0.736 . . . . 0.16 110.94 174.377 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -101.05 102.51 13.5 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.295 -0.866 . . . . 0.51000000000000001 109.843 177.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.533 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 7.6 p -63.01 172.08 1.93 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.854 -0.338 . . . . 1.25 110.507 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -54.42 -33.31 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 112.767 0.654 . . . . 0.58999999999999997 112.767 -173.609 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -80.09 -5.03 55.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.926 0.393 . . . . 1.96 111.512 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.17 14.73 44.21 Favored Glycine 0 CA--C 1.507 -0.441 0 C-N-CA 121.276 -0.488 . . . . 0.32000000000000001 112.376 174.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.404 ' HB2' ' OG ' ' A' ' 18' ' ' SER . 17.3 mm100 -86.55 116.86 24.96 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.865 0.364 . . . . 2.21 110.753 -178.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.544 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.5 tt0 -84.47 117.52 23.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.371 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HG2' HG12 ' A' ' 16' ' ' VAL . 29.4 ptt85 -119.09 168.32 10.95 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.722 -0.473 . . . . 1.55 109.722 177.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.9 p -94.59 135.03 30.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.003 -0.544 . . . . 0.34999999999999998 110.372 -176.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.514 ' HB2' HG23 ' A' ' 14' ' ' VAL . 15.2 mt -103.08 118.39 36.7 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.605 0.717 . . . . 0.32000000000000001 110.321 178.447 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -114.0 176.88 4.85 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.493 -1.23 . . . . 1.6499999999999999 107.703 174.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 tp -67.69 134.53 51.24 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 119.042 -1.063 . . . . 0.23000000000000001 109.424 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.15 -12.22 66.95 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 119.676 -1.25 . . . . 0.23999999999999999 112.564 177.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.507 ' O ' HG12 ' A' ' 7' ' ' ILE . 10.7 m-20 -67.76 140.26 94.08 Favored Pre-proline 0 CA--C 1.514 -0.412 0 C-N-CA 120.219 -0.592 . . . . 1.9199999999999999 109.857 175.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.455 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 29.7 Cg_endo -86.1 144.48 8.29 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.003 2.468 . . . . 0.22 111.834 -179.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.0 mm -100.62 138.74 23.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.639 -0.504 . . . . 0.13 109.639 176.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -114.61 149.7 36.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.174 -0.466 . . . . 0.28999999999999998 109.836 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.522 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.8 t80 -68.6 109.58 3.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.096 -0.502 . . . . 0.17999999999999999 110.638 -175.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 123.8 -3.98 9.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.553 -0.832 . . . . 0.17000000000000001 113.673 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.533 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.0 mt-10 -82.3 150.49 27.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 117.851 0.825 . . . . 0.52000000000000002 110.981 -177.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.9 m -108.42 107.7 18.35 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.537 -0.756 . . . . 0.16 110.767 -177.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.603 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -79.04 137.05 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.3 0.571 . . . . 0.16 110.845 -175.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -123.46 99.25 6.23 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.043 -0.981 . . . . 0.27000000000000002 109.665 -177.413 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.5 p -101.01 153.46 19.52 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.119 0.485 . . . . 0.23000000000000001 110.158 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.917 0 CA-C-N 115.423 -0.808 . . . . 0.90000000000000002 111.65 178.412 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.494 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 36.8 m . . . . . 0 C--O 1.22 -0.465 0 N-CA-C 109.052 -0.722 . . . . 0.84999999999999998 109.052 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.9 t -145.71 132.21 14.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 C-N-CA 120.548 -0.461 . . . . 0.25 110.968 -176.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.552 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -106.69 105.96 16.26 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.103 0.478 . . . . 0.19 109.949 174.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.535 HD13 ' HE2' ' A' ' 66' ' ' MET . 60.7 mt -96.38 103.15 14.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.672 -0.694 . . . . 0.14999999999999999 110.082 177.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 106.04 10.19 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.229 -0.896 . . . . 0.14000000000000001 109.193 176.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.434 ' CE1' HG22 ' A' ' 56' ' ' VAL . 58.0 m-85 -71.43 146.75 48.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.591 0.71 . . . . 0.32000000000000001 110.916 -177.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -71.42 -12.41 15.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.572 -1.195 . . . . 0.25 111.512 -170.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.649 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 21.0 t70 -79.39 -21.04 46.23 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.289 -0.414 . . . . 0.75 110.736 178.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.75 -8.91 7.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.517 -0.849 . . . . 0.27000000000000002 112.717 -179.098 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.7 p -90.48 175.35 7.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.579 0.228 . . . . 0.35999999999999999 110.897 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -151.79 148.45 27.87 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.72 -0.474 . . . . 1.51 109.72 176.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.529 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.2 m -129.36 165.63 28.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 120.989 0.423 . . . . 1.3899999999999999 111.352 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.595 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.7 p -135.56 128.56 47.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-N 115.316 -0.856 . . . . 0.81000000000000005 110.426 177.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.494 ' O ' ' HA ' ' A' ' 45' ' ' SER . 18.5 mt -101.03 139.58 21.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.373 -0.83 . . . . 0.32000000000000001 109.988 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.52 -157.77 29.08 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.775 -0.726 . . . . 1.02 111.952 178.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.43 148.87 18.83 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.986 -0.625 . . . . 0.40000000000000002 111.664 -173.116 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.0 t70 56.87 27.37 12.88 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.96 0.886 . . . . 1.26 109.708 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.5 t -105.3 157.64 17.17 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.372 -0.831 . . . . 1.1899999999999999 110.579 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.603 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.0 mt -142.79 106.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.191 -0.67 . . . . 0.38 109.191 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.49 146.31 32.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.027 0.441 . . . . 1.0 111.339 -175.341 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -99.46 131.44 45.46 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.793 -0.64 . . . . 0.67000000000000004 110.354 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.535 ' HE2' HD13 ' A' ' 48' ' ' ILE . 51.0 mmm -68.18 89.15 0.31 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.454 -0.794 . . . . 0.88 110.315 -178.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.428 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 20.1 p -116.55 -166.99 1.21 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.653 -0.703 . . . . 0.28999999999999998 111.16 -175.35 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -63.89 -38.31 90.62 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 2.1299999999999999 110.647 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -62.75 -28.75 70.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.587 0.708 . . . . 2.5099999999999998 110.614 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.428 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.4 mm -81.97 -51.28 15.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 CA-C-N 114.904 -1.044 . . . . 0.25 110.939 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.759 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.316 -0.875 0 CA-C-N 115.553 -0.749 . . . . 0.31 109.845 -177.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 74.3 m-20 . . . . . 0 CA--C 1.513 -0.47 0 N-CA-C 110.153 -0.314 . . . . 2.0 110.153 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 109.62 6.79 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.374 0.607 . . . . 0.23999999999999999 110.019 179.117 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.798 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.6 pt -91.83 -13.66 8.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.017 -0.992 . . . . 0.14999999999999999 111.427 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.93 178.55 43.34 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.794 -0.717 . . . . 0.10000000000000001 111.415 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -144.73 150.38 37.17 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.8 0.333 . . . . 0.20000000000000001 110.425 -174.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.59 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.3 mm -77.12 124.19 35.08 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.026 -0.534 . . . . 0.14000000000000001 111.596 -175.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.3 p -116.1 -22.51 8.91 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.887 0.375 . . . . 0.20000000000000001 110.747 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.578 ' HB2' ' HB ' ' A' ' 47' ' ' THR . 6.4 tmtt? -134.38 144.34 48.15 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 109.364 -0.606 . . . . 2.3599999999999999 109.364 170.677 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.442 HD11 HG21 ' A' ' 14' ' ' VAL . 6.2 tt -156.38 141.68 17.48 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.089 -0.505 . . . . 0.20000000000000001 110.327 177.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -154.54 158.74 40.29 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.725 -0.671 . . . . 1.9399999999999999 110.75 -177.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.48 -140.56 35.48 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.806 -0.634 . . . . 0.27000000000000002 113.074 175.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.3 t -112.46 122.99 49.28 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.294 -0.632 . . . . 1.1599999999999999 109.294 -178.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.2 m -136.06 152.16 30.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.7 0.762 . . . . 0.20000000000000001 111.496 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.25 158.46 43.91 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 114.674 -1.148 . . . . 0.17000000000000001 108.881 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.676 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -136.51 135.44 49.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 119.94 -0.704 . . . . 0.16 110.946 173.512 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.434 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.0 mt-30 -103.22 99.87 9.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.973 -1.012 . . . . 0.51000000000000001 109.68 177.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.504 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.2 m -60.76 174.41 0.61 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.6 -0.273 . . . . 1.25 110.713 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 13.4 pt -59.42 -27.8 38.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 118.337 0.517 . . . . 0.58999999999999997 112.052 -174.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -77.46 -9.33 58.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.068 -0.515 . . . . 1.96 110.982 177.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.42 3.02 60.06 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 121.351 -0.452 . . . . 0.32000000000000001 112.342 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -75.06 122.02 22.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.704 0.288 . . . . 2.21 111.271 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.614 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.7 tt0 -92.8 123.18 35.89 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.919 -0.582 . . . . 1.0 110.193 177.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.676 ' HG2' HG12 ' A' ' 16' ' ' VAL . 19.4 ptt-85 -123.0 166.47 15.05 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.543 -0.54 . . . . 1.55 109.543 175.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.81 134.45 28.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 109.109 -0.7 . . . . 0.34999999999999998 109.109 177.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.516 HD22 ' CG ' ' A' ' 30' ' ' ASP . 5.3 mt -97.36 153.34 18.14 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.243 0.544 . . . . 0.32000000000000001 111.111 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.4 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 46.1 mttt -141.27 178.2 7.57 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.958 -1.019 . . . . 1.6499999999999999 108.395 -176.393 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -71.94 144.23 49.01 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 119.392 -0.923 . . . . 0.23000000000000001 109.203 177.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.53 -6.07 58.91 Favored Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 120.247 -0.978 . . . . 0.23999999999999999 112.338 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.59 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -70.66 142.84 89.07 Favored Pre-proline 0 C--N 1.332 -0.184 0 CA-C-O 121.388 0.613 . . . . 1.9199999999999999 110.157 179.414 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 24.3 Cg_endo -87.49 128.87 2.6 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.627 2.884 . . . . 0.22 113.485 -174.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.8 mm -93.62 137.05 23.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.011 -0.54 . . . . 0.13 109.745 177.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -115.06 151.39 34.35 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.052 -0.522 . . . . 0.28999999999999998 109.733 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.552 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -68.94 114.07 6.91 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.246 -0.433 . . . . 0.17999999999999999 110.494 -176.556 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.49 0.41 18.29 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.398 -0.906 . . . . 0.17000000000000001 113.54 177.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.504 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 30.2 mt-10 -88.53 146.51 25.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 118.071 0.936 . . . . 0.52000000000000002 110.882 -177.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.0 m -103.49 107.88 18.9 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.422 -0.808 . . . . 0.16 110.943 -176.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.474 HG22 HG23 ' A' ' 16' ' ' VAL . 3.9 t -84.0 130.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 CA-C-O 121.153 0.502 . . . . 0.16 110.869 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -115.57 109.57 17.98 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.245 -0.889 . . . . 0.27000000000000002 109.532 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.8 p -107.94 146.5 32.33 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.877 -0.416 . . . . 0.23000000000000001 109.877 178.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.44 -1.078 0 C-N-CA 120.934 -0.65 . . . . 0.90000000000000002 111.766 179.278 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 36.7 m . . . . . 0 C--O 1.222 -0.373 0 N-CA-C 109.434 -0.58 . . . . 0.84999999999999998 109.434 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.9 t -141.18 128.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-O 120.621 0.248 . . . . 0.25 110.945 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.578 ' HB ' ' HB2' ' A' ' 9' ' ' LYS . 92.8 m -101.27 107.93 19.43 Favored 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 109.559 -0.534 . . . . 0.19 109.559 173.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.475 HD13 ' HE2' ' A' ' 66' ' ' MET . 84.6 mt -95.69 101.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.556 -0.747 . . . . 0.14999999999999999 109.995 176.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.77 102.65 8.23 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.438 -0.801 . . . . 0.14000000000000001 109.329 177.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.563 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 55.5 m-85 -65.54 152.95 42.84 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.32000000000000001 111.22 -177.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -79.04 -3.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-N 114.664 -1.153 . . . . 0.25 110.917 -172.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.573 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 18.6 t70 -85.71 -21.45 28.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.605 -0.725 . . . . 0.75 110.44 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.55 -11.65 11.21 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.764 -0.731 . . . . 0.27000000000000002 112.122 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.2 p -88.07 157.53 18.84 Favored 'General case' 0 C--N 1.323 -0.555 0 O-C-N 122.879 -0.189 . . . . 0.35999999999999999 110.609 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -124.64 160.32 28.76 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.669 -0.493 . . . . 1.51 109.669 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.558 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.3 154.45 16.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.466 -0.334 . . . . 1.3899999999999999 110.108 -179.191 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.563 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -132.96 133.11 59.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.178 0.514 . . . . 0.81000000000000005 110.596 178.064 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 18.7 mt -101.57 143.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.901 -0.591 . . . . 0.32000000000000001 110.192 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.7 -164.91 39.78 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.842 -0.694 . . . . 1.02 111.998 177.049 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -115.52 153.0 17.84 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.251 -0.74 . . . . 0.40000000000000002 111.251 -174.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.3 t70 57.25 23.71 9.05 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.77 0.795 . . . . 1.26 109.665 -173.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -110.16 160.69 16.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.777 -0.647 . . . . 1.1899999999999999 111.369 -176.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.429 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -139.8 125.26 21.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.422 -0.808 . . . . 0.38 109.382 177.425 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.3 p -148.64 140.73 18.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.925 0.393 . . . . 1.0 110.96 -176.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.472 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.8 tt0 -95.5 132.57 40.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.456 -0.338 . . . . 0.67000000000000004 110.198 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.477 ' HE3' HG21 ' A' ' 70' ' ' ILE . 58.1 mmm -70.21 89.49 0.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.736 -0.666 . . . . 0.88 110.499 -178.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 36.0 p -117.06 -165.19 1.04 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.878 -0.601 . . . . 0.28999999999999998 111.138 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -64.42 -36.38 83.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.934 0.397 . . . . 2.1299999999999999 110.888 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -65.96 -22.35 66.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.625 0.726 . . . . 2.5099999999999998 110.313 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.477 HG21 ' HE3' ' A' ' 66' ' ' MET . 1.4 mm -87.06 -56.31 5.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 114.986 -1.007 . . . . 0.25 111.023 176.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.798 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.318 -0.792 0 CA-C-N 115.574 -0.739 . . . . 0.31 110.2 -173.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 . . . . . 0 C--O 1.235 0.302 0 N-CA-C 109.762 -0.458 . . . . 2.0 109.762 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.77 112.58 8.94 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.365 0.602 . . . . 0.23999999999999999 110.47 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.796 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 35.6 pt -95.94 -15.76 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 114.978 -1.01 . . . . 0.14999999999999999 111.937 -171.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.09 175.99 40.88 Favored Glycine 0 CA--C 1.499 -0.941 0 C-N-CA 120.615 -0.803 . . . . 0.10000000000000001 111.812 -177.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -145.07 147.44 32.57 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.042 0.449 . . . . 0.20000000000000001 110.661 -174.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.583 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.77 123.07 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.579 -0.737 . . . . 0.14000000000000001 110.964 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.2 p -112.41 -23.67 10.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.347 0.594 . . . . 0.20000000000000001 110.718 178.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.478 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.6 tptt -141.6 138.73 32.81 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 108.667 -0.864 . . . . 2.3599999999999999 108.667 175.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.46 HD11 HG21 ' A' ' 14' ' ' VAL . 5.7 tt -149.66 144.86 26.4 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.721 0.296 . . . . 0.20000000000000001 110.71 -178.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -152.65 153.33 33.1 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.015 -0.539 . . . . 1.9399999999999999 110.394 -177.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.16 -149.85 41.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.002 -0.618 . . . . 0.27000000000000002 113.164 174.078 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.2 t -108.0 123.84 49.26 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.31 -0.626 . . . . 1.1599999999999999 109.31 -177.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -136.37 152.28 29.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.855 0.836 . . . . 0.20000000000000001 112.296 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.03 158.88 44.68 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 114.422 -1.263 . . . . 0.17000000000000001 108.795 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.679 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.1 p -135.73 139.17 46.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 C-N-CA 120.042 -0.663 . . . . 0.16 110.895 173.097 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' GLN . 1.3 mt-30 -107.85 102.12 11.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.316 -0.856 . . . . 0.51000000000000001 110.077 177.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.518 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 11.6 m -63.91 172.26 2.38 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.462 -0.57 . . . . 1.25 109.462 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.0 pt -57.78 -30.0 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 119.031 0.832 . . . . 0.58999999999999997 112.521 -172.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.504 ' HB2' ' HG3' ' A' ' 22' ' ' GLN . 87.3 m-20 -63.94 -26.8 68.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.164 0.507 . . . . 1.96 110.826 175.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 106.33 13.3 23.16 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.505 -0.77 . . . . 0.32000000000000001 111.691 -174.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.504 ' HG3' ' HB2' ' A' ' 20' ' ' ASN . 21.5 mt-30 -77.1 116.72 17.99 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.947 -0.126 . . . . 2.21 110.885 -179.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.679 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.4 tt0 -93.76 117.66 30.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.876 0.369 . . . . 1.0 110.485 176.359 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.655 ' HG2' HG12 ' A' ' 16' ' ' VAL . 23.9 ptt-85 -120.11 166.95 12.72 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.209 -0.663 . . . . 1.55 109.209 175.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.1 p -91.2 131.71 37.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 109.47 -0.567 . . . . 0.34999999999999998 109.47 178.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' HG23 ' A' ' 14' ' ' VAL . 5.4 mt -94.25 156.49 16.51 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.852 -0.613 . . . . 0.32000000000000001 111.014 -178.124 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -143.54 177.9 8.15 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.321 -0.992 . . . . 1.6499999999999999 108.321 -172.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.61 142.18 46.55 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 118.973 -1.091 . . . . 0.23000000000000001 108.77 174.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.5 5.3 85.78 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.982 -1.104 . . . . 0.23999999999999999 112.173 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.583 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -80.47 139.09 51.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.671 0.748 . . . . 1.9199999999999999 110.739 178.942 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -77.03 130.6 11.38 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 123.685 2.924 . . . . 0.22 113.382 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 mm -97.42 136.04 29.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.344 -0.844 . . . . 0.13 109.018 174.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 -115.16 151.4 34.46 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 116.194 -0.457 . . . . 0.28999999999999998 110.101 -178.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.542 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -67.64 118.82 11.44 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.891 -0.595 . . . . 0.17999999999999999 110.531 -175.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.74 1.1 30.59 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.583 -0.818 . . . . 0.17000000000000001 113.203 177.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.524 ' O ' ' HG2' ' A' ' 66' ' ' MET . 34.4 mt-10 -88.62 146.15 25.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 117.9 0.85 . . . . 0.52000000000000002 110.644 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 11.3 m -104.34 106.85 17.51 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.249 -0.887 . . . . 0.16 110.738 -174.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.7 t -82.63 122.62 37.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 121.206 0.527 . . . . 0.16 110.883 -174.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.1 mp -105.76 109.27 21.18 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.135 -0.938 . . . . 0.27000000000000002 109.441 178.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.5 p -107.54 148.35 29.35 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.955 -0.387 . . . . 0.23000000000000001 109.955 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.912 0 C-N-CA 120.776 -0.726 . . . . 0.90000000000000002 111.984 177.391 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.617 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 3.1 m . . . . . 0 CA--C 1.511 -0.548 0 N-CA-C 109.55 -0.537 . . . . 0.84999999999999998 109.55 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.9 t -130.9 119.43 45.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 CA-C-N 116.048 -0.524 . . . . 0.25 111.278 -170.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.478 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.0 m -95.13 104.27 16.14 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.455 -0.793 . . . . 0.19 109.873 176.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.467 HD13 ' HE2' ' A' ' 66' ' ' MET . 60.2 mt -94.83 99.66 9.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 115.274 -0.875 . . . . 0.14999999999999999 109.697 177.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.21 110.11 16.38 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.413 -0.812 . . . . 0.14000000000000001 109.444 178.452 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.524 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 59.0 m-85 -73.14 151.86 41.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.635 0.731 . . . . 0.32000000000000001 111.128 -176.055 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.3 p -72.38 -5.89 6.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 114.548 -1.205 . . . . 0.25 110.671 -174.073 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -79.39 -21.37 45.76 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.079 -0.964 . . . . 0.75 110.938 176.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.11 -11.86 34.11 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.099 -0.8 . . . . 0.27000000000000002 111.099 -173.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.3 p -83.3 154.67 24.0 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.267 -0.466 . . . . 0.35999999999999999 109.959 175.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -126.88 156.79 40.85 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 120.777 -0.369 . . . . 1.51 110.454 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.524 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -139.44 152.0 23.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 115.905 -0.589 . . . . 1.3899999999999999 109.648 178.233 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -136.62 133.21 48.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-O 121.312 0.577 . . . . 0.81000000000000005 110.994 179.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.617 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -100.37 138.28 25.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.692 -0.685 . . . . 0.32000000000000001 109.46 178.341 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.08 -51.24 5.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.109 -0.567 . . . . 1.02 112.34 -179.114 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 133.16 172.49 13.0 Favored Glycine 0 CA--C 1.505 -0.568 0 CA-C-O 119.083 -0.843 . . . . 0.40000000000000002 111.521 176.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 38.3 47.07 0.97 Allowed 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 122.063 0.935 . . . . 1.26 110.559 -171.507 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.1 t -138.79 163.36 32.42 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 114.493 -1.231 . . . . 1.1899999999999999 109.785 -176.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 84.5 mt -140.26 113.97 5.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.491 -0.559 . . . . 0.38 109.491 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 p -138.66 142.38 34.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.93 0.395 . . . . 1.0 110.885 -175.098 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 45.0 tt0 -96.04 131.94 41.91 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.145 -0.48 . . . . 0.67000000000000004 110.406 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.546 ' CE ' HG21 ' A' ' 70' ' ' ILE . 59.9 mmm -71.07 88.97 0.8 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.643 -0.708 . . . . 0.88 110.72 -178.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 p -117.62 -162.42 0.87 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.245 -0.434 . . . . 0.28999999999999998 110.369 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -71.36 -28.51 64.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.051 0.453 . . . . 2.1299999999999999 110.26 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -64.49 -24.05 67.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.916 0.865 . . . . 2.5099999999999998 109.859 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.546 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.3 mm -91.67 -53.21 9.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 114.509 -1.223 . . . . 0.25 110.583 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.796 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 . . . . . 0 C--N 1.319 -0.749 0 CA-C-N 115.123 -0.944 . . . . 0.31 110.634 -174.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 20.3 m120 . . . . . 0 CA--C 1.515 -0.402 0 CA-C-O 120.891 0.377 . . . . 2.0 110.705 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.68 113.9 11.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.635 -0.711 . . . . 0.23999999999999999 109.845 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.752 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.1 pt -96.13 -15.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 115.351 -0.841 . . . . 0.14999999999999999 111.833 -171.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.21 175.88 42.24 Favored Glycine 0 CA--C 1.502 -0.774 0 N-CA-C 111.478 -0.649 . . . . 0.10000000000000001 111.478 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.62 148.67 36.18 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.096 0.474 . . . . 0.20000000000000001 110.949 -174.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.3 mm -75.89 123.09 31.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.689 -0.687 . . . . 0.14000000000000001 111.02 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.4 p -114.63 -26.35 7.92 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.364 0.602 . . . . 0.20000000000000001 110.395 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.528 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 83.6 tttt -136.21 145.82 46.12 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.584 -0.895 . . . . 2.3599999999999999 108.584 172.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.643 HD11 HG21 ' A' ' 14' ' ' VAL . 5.4 tt -158.42 141.18 14.57 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.972 0.415 . . . . 0.20000000000000001 110.513 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -152.12 146.45 25.51 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-N 115.705 -0.68 . . . . 1.9399999999999999 111.433 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 83.97 -152.34 28.38 Favored Glycine 0 N--CA 1.428 -1.884 0 CA-C-N 114.928 -1.033 . . . . 0.27000000000000002 113.115 168.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 39.8 m -95.01 118.64 32.17 Favored 'General case' 0 N--CA 1.445 -0.681 0 N-CA-C 109.747 -0.464 . . . . 1.1599999999999999 109.747 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.643 HG21 HD11 ' A' ' 10' ' ' LEU . 2.8 m -136.45 151.22 28.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 0.20000000000000001 111.678 -177.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -152.21 158.99 43.63 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 114.585 -1.189 . . . . 0.17000000000000001 108.841 179.214 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.677 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -136.67 133.57 48.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 C-N-CA 119.829 -0.749 . . . . 0.16 111.305 174.192 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.482 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.9 mt-30 -102.75 100.19 10.2 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.089 -0.96 . . . . 0.51000000000000001 109.794 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.414 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 26.5 p -62.65 179.2 0.36 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.484 0.179 . . . . 1.25 111.484 -176.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 11.8 pt -58.66 -27.89 35.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.78 0.324 . . . . 0.58999999999999997 111.661 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -75.42 -11.75 60.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.967 0.413 . . . . 1.96 110.617 178.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.46 21.26 48.95 Favored Glycine 0 CA--C 1.505 -0.563 0 N-CA-C 110.739 -0.945 . . . . 0.32000000000000001 110.739 -178.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -92.57 121.12 33.69 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.93 -0.635 . . . . 2.21 110.396 -178.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.607 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.9 tt0 -93.72 116.74 29.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.985 0.422 . . . . 1.0 110.931 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.677 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -118.98 169.36 9.96 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.948 -0.569 . . . . 1.55 109.82 176.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.37 143.14 11.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.82 -0.627 . . . . 0.34999999999999998 109.738 178.111 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.417 ' HB2' HG23 ' A' ' 14' ' ' VAL . 18.4 mt -107.85 127.23 53.54 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.154 -0.475 . . . . 0.32000000000000001 110.826 178.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -110.05 179.59 4.06 Favored 'General case' 0 C--N 1.319 -0.761 0 N-CA-C 108.709 -0.849 . . . . 1.6499999999999999 108.709 172.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.19 145.82 52.92 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.144 -0.622 . . . . 0.23000000000000001 109.695 174.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.63 2.2 87.72 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.137 -1.03 . . . . 0.23999999999999999 112.416 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 57.9 m-20 -78.95 142.77 60.63 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.044 0.45 . . . . 1.9199999999999999 110.701 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -77.34 138.71 17.95 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.038 2.492 . . . . 0.22 113.11 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.9 mm -103.83 135.23 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.687 0 CA-C-N 115.411 -0.813 . . . . 0.13 108.847 170.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.461 ' H ' ' CD ' ' A' ' 36' ' ' GLU . 62.2 m-85 -114.51 155.5 26.31 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 116.017 -0.538 . . . . 0.28999999999999998 109.947 -178.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -71.19 109.89 5.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.036 -0.529 . . . . 0.17999999999999999 110.243 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.12 0.22 10.6 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.455 -0.878 . . . . 0.17000000000000001 113.406 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.482 ' O ' ' HG2' ' A' ' 66' ' ' MET . 32.7 mt-10 -86.92 147.98 25.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 117.856 0.828 . . . . 0.52000000000000002 110.645 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.482 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 17.5 m -108.06 108.63 19.81 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.662 -0.699 . . . . 0.16 110.391 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.0 t -83.69 130.3 36.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.028 0.442 . . . . 0.16 110.618 -174.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.0 mp -117.46 108.02 15.02 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.357 -0.838 . . . . 0.27000000000000002 110.032 -178.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.0 p -101.02 152.97 19.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.235 -0.654 . . . . 0.23000000000000001 109.235 176.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.903 0 C-N-CA 120.622 -0.799 . . . . 0.90000000000000002 112.417 -177.989 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.4 m . . . . . 0 C--O 1.223 -0.303 0 CA-C-O 120.977 0.417 . . . . 0.84999999999999998 110.264 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.446 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.2 t -121.2 143.77 32.44 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 120.706 0.289 . . . . 0.25 110.758 -174.429 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.528 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -120.91 110.99 16.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.179 -0.464 . . . . 0.19 109.928 175.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.535 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 55.9 mt -99.68 104.6 16.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.785 -0.643 . . . . 0.14999999999999999 110.107 178.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.03 100.98 8.42 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.191 -0.913 . . . . 0.14000000000000001 109.424 177.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.485 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 68.4 m-85 -68.54 146.28 53.25 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-O 121.586 0.708 . . . . 0.32000000000000001 110.727 -178.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.4 p -70.99 1.62 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.567 -1.197 . . . . 0.25 110.991 -173.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.418 ' HB3' ' HE1' ' A' ' 71' ' ' TYR . 4.1 t70 -86.0 -20.84 28.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.32 -0.854 . . . . 0.75 110.432 175.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 111.97 -11.95 27.04 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 111.25 -0.74 . . . . 0.27000000000000002 111.25 -175.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.68 151.98 24.08 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.352 -0.424 . . . . 0.35999999999999999 110.478 176.179 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -133.0 138.94 47.0 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.08 -0.341 . . . . 1.51 110.08 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.535 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.7 m -118.32 164.47 14.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.115 0.483 . . . . 1.3899999999999999 111.47 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.446 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.0 p -133.64 135.4 55.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.402 -0.817 . . . . 0.81000000000000005 110.249 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 14.6 mt -109.15 133.7 53.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.977 -0.556 . . . . 0.32000000000000001 110.101 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.72 -169.78 36.7 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.147 -0.549 . . . . 1.02 111.811 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.87 149.98 17.05 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.934 -0.651 . . . . 0.40000000000000002 111.789 -173.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.3 t70 61.02 20.54 10.96 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 121.926 0.87 . . . . 1.26 109.523 -174.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.7 t -106.69 159.05 16.5 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.346 -0.843 . . . . 1.1899999999999999 110.686 -177.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.453 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.3 mt -140.3 124.55 18.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.8 -0.636 . . . . 0.38 109.922 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 13.1 p -147.09 143.76 20.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.814 0.34 . . . . 1.0 110.822 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.4 tt0 -99.27 133.92 42.88 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.968 0.413 . . . . 0.67000000000000004 110.587 -179.26 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.571 ' CE ' HG21 ' A' ' 70' ' ' ILE . 47.0 mmm -73.83 88.99 1.81 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.651 -0.704 . . . . 0.88 110.815 -177.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.3 p -119.02 -164.71 1.06 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.434 -0.348 . . . . 0.28999999999999998 110.088 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -67.69 -26.86 66.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.409 0.624 . . . . 2.1299999999999999 109.52 177.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -63.14 -25.7 68.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.131 -0.941 . . . . 2.5099999999999998 109.888 177.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.571 HG21 ' CE ' ' A' ' 66' ' ' MET . 0.9 OUTLIER -96.87 -55.31 6.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 114.743 -1.117 . . . . 0.25 110.595 177.794 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.752 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.3 t80 . . . . . 0 C--N 1.319 -0.757 0 CA-C-N 115.326 -0.852 . . . . 0.31 110.157 -174.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.7 m120 . . . . . 0 CA--C 1.514 -0.42 0 CA-C-O 120.905 0.383 . . . . 2.0 110.443 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.66 109.28 12.74 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 115.684 -0.689 . . . . 0.23999999999999999 109.328 175.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.8 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.1 pt -89.18 -12.05 10.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.32 -0.854 . . . . 0.14999999999999999 111.632 -171.363 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.35 174.03 40.38 Favored Glycine 0 CA--C 1.501 -0.837 0 C-N-CA 120.858 -0.687 . . . . 0.10000000000000001 111.55 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -144.91 149.7 35.75 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.013 0.435 . . . . 0.20000000000000001 110.327 -176.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.578 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.66 124.54 36.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-N 115.699 -0.682 . . . . 0.14000000000000001 110.871 -177.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 67.9 p -117.6 -16.83 10.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.378 0.609 . . . . 0.20000000000000001 110.875 178.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.442 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 27.4 tptp -146.73 138.59 24.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.335 -0.987 . . . . 2.3599999999999999 108.335 172.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.418 HD11 HG21 ' A' ' 14' ' ' VAL . 6.5 tt -150.37 148.03 28.3 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.807 -0.357 . . . . 0.20000000000000001 110.8 -178.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -157.48 154.49 28.78 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.923 -0.58 . . . . 1.9399999999999999 110.274 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.81 -157.4 48.85 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.11 -0.567 . . . . 0.27000000000000002 113.466 172.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 33.4 m -100.07 115.0 28.73 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.366 -0.417 . . . . 1.1599999999999999 110.056 -178.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.564 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.6 m -133.7 152.57 35.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.525 0.678 . . . . 0.20000000000000001 111.599 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.39 158.56 43.89 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 114.866 -1.061 . . . . 0.17000000000000001 109.045 -178.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.625 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.7 OUTLIER -134.59 139.49 47.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 C-N-CA 120.131 -0.628 . . . . 0.16 110.857 173.007 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.434 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.3 mt-30 -104.21 99.88 9.61 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.204 -0.907 . . . . 0.51000000000000001 109.251 175.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.495 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 68.6 p -63.75 -179.39 0.38 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.638 0.256 . . . . 1.25 110.935 -176.07 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -69.35 -3.33 2.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.944 0.402 . . . . 0.58999999999999997 111.514 178.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -94.19 -7.01 43.46 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.461 -0.57 . . . . 1.96 109.461 173.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.36 19.9 65.58 Favored Glycine 0 CA--C 1.503 -0.681 0 N-CA-C 110.881 -0.888 . . . . 0.32000000000000001 110.881 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -92.76 123.12 35.81 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.829 -0.686 . . . . 2.21 110.877 -177.153 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.608 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 19.8 tt0 -89.16 118.46 28.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.355 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.625 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -121.62 166.57 14.04 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.461 -0.57 . . . . 1.55 109.461 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.3 p -89.85 135.26 26.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 109.127 -0.694 . . . . 0.34999999999999998 109.127 177.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.564 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.3 mt -95.79 146.95 24.13 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.227 0.537 . . . . 0.32000000000000001 110.902 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.508 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 33.2 mttp -138.07 171.98 13.6 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.059 -0.973 . . . . 1.6499999999999999 108.544 -176.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.82 139.02 58.28 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 119.285 -0.966 . . . . 0.23000000000000001 109.254 177.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.35 89.89 Favored Glycine 0 N--CA 1.437 -1.265 0 C-N-CA 119.865 -1.16 . . . . 0.23999999999999999 112.478 178.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -76.94 140.4 66.78 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 121.54 0.686 . . . . 1.9199999999999999 110.48 178.581 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.14 129.3 7.73 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.601 2.868 . . . . 0.22 113.848 -176.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.2 mm -97.39 132.86 41.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 115.588 -0.733 . . . . 0.13 109.187 173.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -113.27 159.75 19.03 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.855 -0.612 . . . . 0.28999999999999998 109.786 -177.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.497 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.9 t80 -74.52 116.05 14.76 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.285 -0.416 . . . . 0.17999999999999999 110.16 -175.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.33 9.51 27.32 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.57 -0.824 . . . . 0.17000000000000001 113.265 177.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.495 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 38.7 mt-10 -90.61 139.92 30.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 118.088 0.944 . . . . 0.52000000000000002 110.343 177.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.3 m -98.28 106.25 18.51 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.207 -0.906 . . . . 0.16 110.727 -176.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.4 t -82.38 125.78 39.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.158 0.504 . . . . 0.16 110.771 -174.545 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -110.2 105.2 14.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.136 -0.938 . . . . 0.27000000000000002 109.701 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.468 HG21 HG21 ' A' ' 58' ' ' ILE . 62.7 p -109.79 143.66 39.32 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.987 -0.375 . . . . 0.23000000000000001 109.987 178.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.96 0 C-N-CA 120.485 -0.865 . . . . 0.90000000000000002 111.633 177.86 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.695 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 49.2 m . . . . . 0 CA--C 1.512 -0.492 0 N-CA-C 109.748 -0.464 . . . . 0.84999999999999998 109.748 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 6.1 t -142.92 119.99 6.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 CA-C-O 121.003 0.43 . . . . 0.25 111.286 -171.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 88.6 m -92.21 103.65 16.1 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.573 -0.739 . . . . 0.19 109.934 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.464 HD13 ' HE2' ' A' ' 66' ' ' MET . 68.2 mt -94.88 99.55 9.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 114.982 -1.008 . . . . 0.14999999999999999 109.51 177.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.16 107.54 13.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.395 -0.82 . . . . 0.14000000000000001 109.497 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.554 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 57.1 m-85 -70.7 145.67 50.39 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.47 0.652 . . . . 0.32000000000000001 110.947 -177.228 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.9 p -70.98 1.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.76 -1.109 . . . . 0.25 111.754 -172.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.744 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 13.8 t70 -99.42 -16.42 18.39 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.86 0.362 . . . . 0.75 110.815 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.85 -14.76 9.06 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.466 -0.873 . . . . 0.27000000000000002 112.374 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.7 p -84.38 154.61 22.74 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.372 -0.233 . . . . 0.35999999999999999 110.372 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -133.67 138.2 45.75 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 120.964 0.411 . . . . 1.51 110.345 -179.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.448 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 1.1 t -123.33 150.41 27.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.983 -0.553 . . . . 1.3899999999999999 110.286 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -135.54 129.91 49.61 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.419 0.628 . . . . 0.81000000000000005 110.731 178.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.695 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.3 mt -94.3 139.04 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.545 -0.752 . . . . 0.32000000000000001 109.599 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.85 -57.4 2.42 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 121.199 -0.524 . . . . 1.02 112.716 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 150.46 158.56 8.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.874 -0.679 . . . . 0.40000000000000002 111.857 178.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.6 t70 51.83 43.23 30.25 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.703 0.763 . . . . 1.26 110.521 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.5 t -129.28 158.08 40.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.757 -0.656 . . . . 1.1899999999999999 110.394 -176.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.56 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -140.28 106.88 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.536 -0.756 . . . . 0.38 109.148 177.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.33 140.41 44.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.897 0.38 . . . . 1.0 111.02 -174.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.464 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.8 tt0 -91.81 128.64 37.72 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.67000000000000004 109.729 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.477 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 55.8 mmm -66.28 89.45 0.13 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.149 -0.478 . . . . 0.88 110.313 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.425 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 59.4 p -110.81 -166.47 1.08 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.871 -0.604 . . . . 0.28999999999999998 111.724 -174.383 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.01 -33.41 74.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 2.1299999999999999 110.323 178.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -70.35 -25.66 63.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.731 0.777 . . . . 2.5099999999999998 109.975 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.425 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.3 mm -80.06 -53.51 12.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 114.596 -1.183 . . . . 0.25 111.079 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.8 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 . . . . . 0 C--N 1.316 -0.868 0 CA-C-N 115.355 -0.839 . . . . 0.31 110.274 -175.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 19.5 m120 . . . . . 0 CA--C 1.518 -0.267 0 N-CA-C 109.994 -0.372 . . . . 2.0 109.994 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.52 116.68 17.43 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 121.438 0.637 . . . . 0.23999999999999999 110.342 -178.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.787 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.1 pt -101.92 -14.62 8.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.095 -0.957 . . . . 0.14999999999999999 111.811 -171.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.81 179.22 41.27 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 120.796 -0.716 . . . . 0.10000000000000001 111.415 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.405 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 95.0 m-85 -143.79 152.51 41.32 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.939 0.4 . . . . 0.20000000000000001 110.569 -175.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.477 HG12 ' O ' ' A' ' 30' ' ' ASP . 34.2 mm -80.21 119.97 30.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.203 -0.453 . . . . 0.14000000000000001 110.945 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.2 p -113.12 -18.71 12.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.281 0.563 . . . . 0.20000000000000001 110.586 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.556 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.9 tttt -144.81 145.08 31.47 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.236 -1.024 . . . . 2.3599999999999999 108.236 172.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.608 HD11 HG21 ' A' ' 14' ' ' VAL . 7.0 tt -159.91 142.34 13.42 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.792 0.33 . . . . 0.20000000000000001 111.019 -177.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -150.67 153.25 35.26 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.779 -0.646 . . . . 1.9399999999999999 111.274 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.22 -155.14 50.18 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.982 -0.554 . . . . 0.27000000000000002 113.235 174.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 27.2 t -97.91 119.7 36.99 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.878 -0.415 . . . . 1.1599999999999999 109.878 -178.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.608 HG21 HD11 ' A' ' 10' ' ' LEU . 2.7 m -132.09 152.98 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.415 0.626 . . . . 0.20000000000000001 110.828 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.28 159.15 44.66 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.725 -1.125 . . . . 0.17000000000000001 108.174 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.708 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -134.97 130.44 52.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 C-N-CA 119.545 -0.862 . . . . 0.16 110.817 173.816 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.44 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.8 mt-30 -96.15 98.61 10.47 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.269 -0.878 . . . . 0.51000000000000001 109.255 175.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.506 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 15.9 m -63.79 176.49 0.91 Allowed 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.031 -0.532 . . . . 1.25 110.816 -176.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.6 pt -56.81 -28.03 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 112.687 0.625 . . . . 0.58999999999999997 112.687 -173.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -82.63 -1.1 50.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.788 0.328 . . . . 1.96 110.963 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 89.35 8.02 68.89 Favored Glycine 0 CA--C 1.506 -0.529 0 N-CA-C 111.047 -0.821 . . . . 0.32000000000000001 111.047 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 87.7 mm-40 -79.15 115.6 18.91 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.937 -0.631 . . . . 2.21 111.115 -177.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.592 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.6 tt0 -88.15 111.25 21.39 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.94 -0.573 . . . . 1.0 110.533 178.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.708 ' HG2' HG12 ' A' ' 16' ' ' VAL . 16.8 ptt85 -112.22 170.78 7.93 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.214 -0.662 . . . . 1.55 109.214 176.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.93 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 109.772 -0.455 . . . . 0.34999999999999998 109.772 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.445 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 21.2 mt -109.98 128.29 55.3 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.942 -0.572 . . . . 0.32000000000000001 110.593 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -116.03 -173.9 2.44 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 108.056 -1.09 . . . . 1.6499999999999999 108.056 171.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.83 143.5 52.87 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.734 -0.786 . . . . 0.23000000000000001 109.389 175.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.51 -2.75 84.69 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.295 -0.955 . . . . 0.23999999999999999 112.946 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.477 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.3 m-20 -73.0 143.7 84.31 Favored Pre-proline 0 CA--C 1.512 -0.488 0 N-CA-C 109.556 -0.535 . . . . 1.9199999999999999 109.556 174.392 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.405 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 25.4 Cg_endo -87.64 141.56 5.58 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.922 2.415 . . . . 0.22 112.41 -179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mm -100.93 139.16 22.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.662 -0.496 . . . . 0.13 109.662 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -115.33 150.0 36.98 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 116.019 -0.537 . . . . 0.28999999999999998 109.676 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.586 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -68.41 113.24 5.8 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.276 -0.42 . . . . 0.17999999999999999 110.322 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.68 -1.23 13.81 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.368 -0.92 . . . . 0.17000000000000001 113.463 178.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.518 ' HB3' HG22 ' A' ' 16' ' ' VAL . 36.9 mt-10 -85.48 148.6 25.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 117.789 0.795 . . . . 0.52000000000000002 110.951 -178.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 8.6 m -106.83 105.95 16.23 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.621 -0.718 . . . . 0.16 110.642 -176.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -81.86 126.39 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.351 0.596 . . . . 0.16 110.777 -174.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -114.76 100.76 8.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.83 -1.077 . . . . 0.27000000000000002 109.851 -177.203 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.6 p -99.02 152.88 19.34 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.284 -0.636 . . . . 0.23000000000000001 109.284 176.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.714 0 C-N-CA 120.34 -0.933 . . . . 0.90000000000000002 112.526 -179.425 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 8.7 m . . . . . 0 C--O 1.225 -0.191 0 N-CA-C 108.646 -0.872 . . . . 0.84999999999999998 108.646 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.5 t -148.4 134.05 11.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 O-C-N 122.012 -0.43 . . . . 0.25 110.958 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.556 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.2 m -109.84 108.16 18.38 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.76 -0.459 . . . . 0.19 109.76 173.182 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.619 HD13 ' HE2' ' A' ' 66' ' ' MET . 56.7 mt -99.14 104.22 15.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.593 -0.73 . . . . 0.14999999999999999 109.969 178.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.43 107.34 12.12 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.405 -0.816 . . . . 0.14000000000000001 109.133 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.44 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 63.0 m-85 -73.72 146.63 44.27 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.491 0.662 . . . . 0.32000000000000001 110.899 -177.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -77.36 0.89 2.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 114.821 -1.081 . . . . 0.25 111.398 -170.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.36 -21.75 27.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.223 0.535 . . . . 0.75 109.948 173.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.56 -12.69 7.41 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.77 -0.729 . . . . 0.27000000000000002 112.802 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.0 p -87.5 162.98 16.93 Favored 'General case' 0 C--N 1.327 -0.412 0 O-C-N 122.821 -0.223 . . . . 0.35999999999999999 111.074 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.2 147.46 50.73 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.762 -0.458 . . . . 1.51 109.762 176.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.539 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 11.9 m -128.2 161.2 37.05 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 CA-C-O 121.264 0.554 . . . . 1.3899999999999999 111.25 175.545 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.596 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 97.9 t -135.06 123.93 41.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.814 -1.084 . . . . 0.81000000000000005 110.159 178.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 45' ' ' SER . 24.0 mt -96.55 133.92 36.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.445 -0.798 . . . . 0.32000000000000001 110.191 -177.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -76.58 -163.91 17.67 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.047 -0.597 . . . . 1.02 112.346 177.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.07 149.86 17.85 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 111.208 -0.757 . . . . 0.40000000000000002 111.208 -174.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.5 t70 60.85 20.86 11.05 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 121.901 0.858 . . . . 1.26 109.744 -175.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.0 m -102.94 154.18 19.47 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.572 -0.74 . . . . 1.1899999999999999 110.967 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.56 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.4 mt -141.68 109.69 2.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.35 -0.841 . . . . 0.38 109.727 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.3 p -139.81 142.45 32.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.803 0.335 . . . . 1.0 110.827 -177.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.442 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 34.7 tt0 -91.16 132.87 35.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.929 0.395 . . . . 0.67000000000000004 110.488 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.619 ' HE2' HD13 ' A' ' 48' ' ' ILE . 63.4 mmm -67.13 89.88 0.19 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.448 -0.796 . . . . 0.88 110.808 -177.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.414 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.6 p -117.77 -162.99 0.9 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.488 -0.778 . . . . 0.28999999999999998 111.305 -175.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -66.92 -40.93 87.8 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.733 0.272 . . . . 2.1299999999999999 111.733 -175.538 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -64.57 -26.17 68.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.687 0.756 . . . . 2.5099999999999998 110.605 177.158 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.439 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.6 mm -76.36 -51.33 19.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.766 -1.106 . . . . 0.25 110.557 174.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.787 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.318 -0.769 0 CA-C-N 115.33 -0.85 . . . . 0.31 110.106 -177.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 . . . . . 0 CA--C 1.514 -0.421 0 CA-C-O 121.001 0.429 . . . . 2.0 110.778 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.95 109.61 13.39 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.622 -0.717 . . . . 0.23999999999999999 109.91 -178.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.774 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.4 pt -88.86 -14.9 9.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.179 -0.918 . . . . 0.14999999999999999 111.616 -171.117 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -166.98 177.15 41.79 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.886 -0.673 . . . . 0.10000000000000001 111.465 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -143.95 150.67 38.7 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.951 0.405 . . . . 0.20000000000000001 110.529 -175.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.613 HG12 ' O ' ' A' ' 30' ' ' ASP . 20.7 mm -78.75 122.2 33.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.981 -0.554 . . . . 0.14000000000000001 110.78 -178.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.7 p -114.75 -21.79 10.01 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.311 0.576 . . . . 0.20000000000000001 110.67 179.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.625 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 36.1 ttpt -141.1 145.71 36.15 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.417 -0.957 . . . . 2.3599999999999999 108.417 172.407 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.418 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -156.66 144.73 19.52 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 120.774 0.321 . . . . 0.20000000000000001 110.684 -177.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.484 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 6.3 t70 -151.75 148.32 27.74 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.881 -0.6 . . . . 1.9399999999999999 110.73 -178.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.96 -152.46 43.98 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.09 -0.576 . . . . 0.27000000000000002 113.503 173.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 9.0 t -103.63 120.07 40.16 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.927 -0.397 . . . . 1.1599999999999999 109.927 -177.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.599 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.9 m -135.83 153.2 32.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.20000000000000001 111.859 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.43 159.65 44.32 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.881 -1.054 . . . . 0.17000000000000001 109.457 -177.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.715 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -134.21 136.66 53.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 C-N-CA 120.152 -0.619 . . . . 0.16 110.984 173.188 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -103.28 103.52 13.55 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.155 -0.929 . . . . 0.51000000000000001 109.641 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.532 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 47.6 t -62.05 176.8 0.52 Allowed 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.572 -0.451 . . . . 1.25 110.392 -178.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.3 pt -60.36 -31.13 47.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-O 121.107 0.48 . . . . 0.58999999999999997 111.869 -173.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -74.35 -14.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.865 -0.607 . . . . 1.96 110.916 177.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.1 10.27 46.06 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.146 -0.55 . . . . 0.32000000000000001 112.522 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 -80.94 119.94 24.11 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.901 0.382 . . . . 2.21 111.214 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.567 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 18.5 tt0 -88.77 119.49 29.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.623 179.192 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.715 ' HG2' HG12 ' A' ' 16' ' ' VAL . 21.3 ptt-85 -119.1 166.1 13.34 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.43 -0.581 . . . . 1.55 109.43 174.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -86.56 137.58 20.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.942 -0.572 . . . . 0.34999999999999998 109.483 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.599 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.0 mt -102.08 151.88 21.64 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.196 0.522 . . . . 0.32000000000000001 111.167 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.432 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.5 mttt -139.57 175.97 9.12 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.105 -0.952 . . . . 1.6499999999999999 108.479 -175.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.95 140.92 49.4 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.566 -0.853 . . . . 0.23000000000000001 108.957 176.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.77 6.04 86.81 Favored Glycine 0 N--CA 1.435 -1.389 0 C-N-CA 119.877 -1.154 . . . . 0.23999999999999999 112.218 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.613 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.0 138.81 46.07 Favored Pre-proline 0 N--CA 1.454 -0.248 0 CA-C-O 121.75 0.786 . . . . 1.9199999999999999 110.35 178.19 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.92 130.29 11.27 Favored 'Trans proline' 0 C--N 1.325 -0.682 0 C-N-CA 123.719 2.946 . . . . 0.22 113.509 -178.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.446 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 26.3 mm -96.02 136.54 26.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 CA-C-N 115.349 -0.841 . . . . 0.13 109.266 173.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -117.87 151.35 37.56 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 109.565 -0.531 . . . . 0.28999999999999998 109.565 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.569 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.9 t80 -67.1 126.29 28.7 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.988 -0.551 . . . . 0.17999999999999999 110.188 -176.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.21 -12.8 33.88 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.462 -0.875 . . . . 0.17000000000000001 113.074 178.182 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.532 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.7 mt-10 -82.04 139.39 34.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.584 0.707 . . . . 0.52000000000000002 111.072 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.527 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 17.8 m -98.74 109.98 22.65 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.684 -1.144 . . . . 0.16 110.718 -177.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -82.19 132.9 30.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.48 -0.488 . . . . 0.16 110.618 -175.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -119.61 113.33 20.53 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.516 -0.766 . . . . 0.27000000000000002 110.298 -177.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 71.5 p -105.49 153.19 22.06 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.274 -0.639 . . . . 0.23000000000000001 109.274 173.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.815 0 C-N-CA 120.587 -0.816 . . . . 0.90000000000000002 111.076 177.756 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.484 ' HB2' ' HB3' ' A' ' 11' ' ' ASP . 25.4 m . . . . . 0 C--O 1.222 -0.354 0 N-CA-C 109.182 -0.673 . . . . 0.84999999999999998 109.182 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.619 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.4 t -148.32 145.02 18.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 O-C-N 122.242 -0.286 . . . . 0.25 110.334 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.625 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 97.9 m -115.98 106.81 14.2 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.158 0.504 . . . . 0.19 109.87 172.268 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.0 103.0 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.291 -0.868 . . . . 0.14999999999999999 109.807 178.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.74 103.67 8.85 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.463 -0.79 . . . . 0.14000000000000001 109.287 177.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.565 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 50.5 m-85 -68.73 147.09 52.32 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.618 0.723 . . . . 0.32000000000000001 110.907 -178.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.2 p -74.46 1.66 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.518 -1.219 . . . . 0.25 111.459 -172.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.474 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 22.0 t70 -97.26 -0.93 45.81 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.307 0.575 . . . . 0.75 109.752 177.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.61 -10.94 49.96 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.859 -0.686 . . . . 0.27000000000000002 112.847 177.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.3 p -87.79 164.08 16.13 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.534 -0.173 . . . . 0.35999999999999999 110.534 177.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -135.94 153.32 51.46 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.819 -0.438 . . . . 1.51 109.819 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.565 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.7 OUTLIER -135.41 147.66 28.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.968 0.413 . . . . 1.3899999999999999 110.542 -179.102 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.619 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 89.5 t -125.84 130.22 72.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.638 -0.71 . . . . 0.81000000000000005 110.176 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.1 mt -102.86 144.69 13.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.984 -0.553 . . . . 0.32000000000000001 110.614 -176.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -88.93 -161.53 37.57 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.926 -0.579 . . . . 1.02 112.11 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -113.63 147.96 18.65 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.431 -0.668 . . . . 0.40000000000000002 111.431 -174.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 29.7 t70 53.46 28.84 8.06 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.981 0.896 . . . . 1.26 109.888 -173.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.8 m -110.49 157.13 19.95 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.085 -0.961 . . . . 1.1899999999999999 110.809 -179.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.414 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.8 mt -140.96 123.76 15.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.456 -0.793 . . . . 0.38 109.731 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.6 p -149.55 145.02 17.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 1.0 110.525 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.527 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 44.0 tt0 -98.17 134.69 40.88 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.28 -0.418 . . . . 0.67000000000000004 111.076 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.554 ' SD ' HG21 ' A' ' 70' ' ' ILE . 21.8 mmt -64.32 89.24 0.06 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.704 -0.68 . . . . 0.88 110.725 175.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 16.5 p -121.59 -168.22 1.65 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.654 -0.703 . . . . 0.28999999999999998 110.312 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -68.07 -25.25 65.25 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.272 0.558 . . . . 2.1299999999999999 109.787 177.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 25.8 mm-40 -65.97 -21.73 66.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.41 -0.814 . . . . 2.5099999999999998 110.098 177.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.554 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.5 mm -103.02 -53.86 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 CA-C-N 114.721 -1.127 . . . . 0.25 110.883 -179.565 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.774 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 4.0 t80 . . . . . 0 C--N 1.318 -0.77 0 CA-C-N 115.261 -0.881 . . . . 0.31 110.226 -176.684 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . 0.414 ' O ' ' HA ' ' A' ' 33' ' ' PHE . 19.8 t-20 . . . . . 0 N--CA 1.465 0.31 0 CA-C-O 121.307 0.575 . . . . 2.0 110.434 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.39 116.29 21.15 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.4 0.619 . . . . 0.23999999999999999 110.654 -174.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.79 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.0 pt -105.55 -14.4 8.97 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.855 -1.066 . . . . 0.14999999999999999 111.765 -173.048 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.53 177.77 41.81 Favored Glycine 0 CA--C 1.5 -0.894 0 N-CA-C 111.046 -0.822 . . . . 0.10000000000000001 111.046 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -144.12 151.18 39.23 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.979 0.419 . . . . 0.20000000000000001 111.034 -175.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.468 HD13 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -78.62 120.85 30.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.715 -0.675 . . . . 0.14000000000000001 110.717 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.0 p -113.25 -23.35 9.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.259 0.552 . . . . 0.20000000000000001 110.205 179.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.62 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 37.8 ttpt -140.63 144.93 36.02 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.524 -0.762 . . . . 2.3599999999999999 109.069 172.343 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.443 HD11 HG21 ' A' ' 14' ' ' VAL . 6.3 tt -155.8 144.62 20.45 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 110.292 -0.262 . . . . 0.20000000000000001 110.292 -178.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -153.17 152.36 31.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.16 -0.473 . . . . 1.9399999999999999 111.136 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.25 -144.11 29.21 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.975 -0.557 . . . . 0.27000000000000002 112.74 175.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t -113.61 123.31 49.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.428 -0.582 . . . . 1.1599999999999999 109.428 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.491 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -138.16 152.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.20000000000000001 111.62 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.84 159.39 44.21 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.798 -1.092 . . . . 0.17000000000000001 108.175 177.454 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.541 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -132.33 133.18 60.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 C-N-CA 120.11 -0.636 . . . . 0.16 110.46 175.475 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.462 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.0 mt-30 -96.04 98.56 10.46 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.461 -0.79 . . . . 0.51000000000000001 109.327 178.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.53 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 25.0 m -63.62 173.43 1.69 Allowed 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.865 -0.607 . . . . 1.25 110.035 -177.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 9.1 pt -64.55 -3.31 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 N-CA-C 114.238 1.199 . . . . 0.58999999999999997 114.238 -168.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -106.03 6.98 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.344 0.592 . . . . 1.96 109.823 174.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.62 6.56 80.17 Favored Glycine 0 CA--C 1.504 -0.606 0 N-CA-C 110.75 -0.94 . . . . 0.32000000000000001 110.75 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.6 ' HA ' HE21 ' A' ' 22' ' ' GLN . 0.0 OUTLIER -78.4 117.44 19.62 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.833 -0.684 . . . . 2.21 111.403 -175.619 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -80.63 126.39 31.2 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.232 0.539 . . . . 1.0 110.582 178.76 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.41 144.59 51.49 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.452 -0.794 . . . . 1.55 109.239 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.3 p -78.2 142.76 13.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.963 0.411 . . . . 0.34999999999999998 110.242 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.491 ' HB2' HG23 ' A' ' 14' ' ' VAL . 25.5 mt -108.07 128.82 55.02 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.168 -0.469 . . . . 0.32000000000000001 110.615 178.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.2 mttm -111.13 -178.0 3.35 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.298 -1.001 . . . . 1.6499999999999999 108.298 172.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.2 144.49 53.72 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 119.618 -0.833 . . . . 0.23000000000000001 109.193 173.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.47 2.8 89.83 Favored Glycine 0 N--CA 1.439 -1.139 0 C-N-CA 120.249 -0.977 . . . . 0.23999999999999999 112.551 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.428 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -70.53 145.27 92.53 Favored Pre-proline 0 CA--C 1.51 -0.571 0 CA-C-O 121.218 0.533 . . . . 1.9199999999999999 109.923 174.418 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -90.04 135.75 2.36 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 123.251 2.634 . . . . 0.22 111.851 178.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -97.99 135.29 33.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.539 -0.541 . . . . 0.13 109.539 177.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.414 ' HA ' ' O ' ' A' ' 2' ' ' ASN . 80.2 m-85 -112.19 144.37 41.69 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.63 -0.714 . . . . 0.28999999999999998 109.894 -177.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.631 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.5 t80 -66.09 109.22 2.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.24 -0.437 . . . . 0.17999999999999999 109.987 -177.056 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.75 -4.19 8.03 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.308 -0.949 . . . . 0.17000000000000001 113.754 178.275 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.541 ' HB3' HG22 ' A' ' 16' ' ' VAL . 26.2 mt-10 -86.72 151.23 23.57 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 118.223 1.012 . . . . 0.52000000000000002 110.831 -177.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.462 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 25.6 m -111.15 107.49 16.86 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.467 -0.788 . . . . 0.16 110.687 -176.547 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.662 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.9 t -78.67 129.77 37.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 120.896 0.379 . . . . 0.16 111.28 -173.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -113.23 98.41 7.1 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.527 -0.761 . . . . 0.27000000000000002 109.913 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.404 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 82.5 p -96.4 152.99 18.08 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.584 -0.525 . . . . 0.23000000000000001 109.584 177.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.994 0 N-CA-C 111.517 -0.633 . . . . 0.90000000000000002 111.517 178.779 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.562 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 69.6 m . . . . . 0 C--O 1.222 -0.346 0 N-CA-C 109.172 -0.677 . . . . 0.84999999999999998 109.172 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.612 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 19.4 t -145.85 137.49 19.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 120.602 0.239 . . . . 0.25 110.531 -177.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.62 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 87.2 m -111.36 106.74 15.77 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.042 -0.527 . . . . 0.19 109.992 174.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.557 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.3 mt -97.87 103.16 14.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.654 -0.703 . . . . 0.14999999999999999 110.009 177.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.44 105.48 9.73 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.303 -0.862 . . . . 0.14000000000000001 109.25 177.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.489 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.5 m-85 -72.92 145.76 46.58 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.563 0.697 . . . . 0.32000000000000001 110.584 -178.623 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.0 p -74.07 -8.5 11.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 114.677 -1.147 . . . . 0.25 111.655 -169.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.45 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 15.2 t70 -81.62 -21.06 38.51 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.221 -0.445 . . . . 0.75 110.504 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.37 -13.52 6.25 Favored Glycine 0 CA--C 1.519 0.321 0 C-N-CA 120.567 -0.825 . . . . 0.27000000000000002 113.045 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.8 p -87.76 162.45 17.03 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 122.727 -0.278 . . . . 0.35999999999999999 111.344 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -135.41 148.0 49.18 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.96 -0.756 . . . . 1.51 108.96 177.097 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.557 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.6 m -129.7 166.54 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.574 0 CA-C-O 121.213 0.53 . . . . 1.3899999999999999 111.96 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.612 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.9 p -133.12 135.89 56.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 114.908 -1.042 . . . . 0.81000000000000005 110.15 176.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.562 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.3 mt -108.23 134.54 49.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.861 -0.609 . . . . 0.32000000000000001 109.656 178.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.65 -159.49 21.18 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.206 -0.521 . . . . 1.02 112.336 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.7 146.66 18.32 Favored Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.901 -0.666 . . . . 0.40000000000000002 111.775 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.404 ' HA ' ' O ' ' A' ' 40' ' ' THR . 29.2 t70 56.77 26.39 11.39 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 121.702 0.763 . . . . 1.26 109.909 -174.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 t -103.91 156.97 17.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.536 -0.756 . . . . 1.1899999999999999 110.495 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.662 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.7 mt -142.47 104.49 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.504 -0.771 . . . . 0.38 109.16 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.1 m -131.93 150.13 33.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.006 0.431 . . . . 1.0 111.736 -175.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -102.84 128.09 49.75 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.626 -0.715 . . . . 0.67000000000000004 110.609 -177.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.525 ' HE2' HD13 ' A' ' 48' ' ' ILE . 51.3 mmm -67.72 89.58 0.26 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.522 -0.763 . . . . 0.88 110.666 -177.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.5 p -121.37 -167.45 1.51 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.006 -0.543 . . . . 0.28999999999999998 111.118 -177.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -65.59 -29.6 70.22 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.735 0.303 . . . . 2.1299999999999999 110.846 -178.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.49 -17.3 62.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.6 0.714 . . . . 2.5099999999999998 110.354 177.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.512 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.1 mm -96.04 -50.43 11.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 115.127 -0.942 . . . . 0.25 110.562 177.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.79 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.317 -0.842 0 CA-C-N 115.363 -0.835 . . . . 0.31 109.658 -177.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 . . . . . 0 C--O 1.235 0.326 0 CA-C-O 120.848 0.356 . . . . 2.0 110.224 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.14 113.18 14.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.774 -0.648 . . . . 0.23999999999999999 110.282 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.783 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.3 pt -92.01 -16.77 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.085 -0.961 . . . . 0.14999999999999999 111.646 -172.192 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.42 177.25 40.82 Favored Glycine 0 CA--C 1.501 -0.816 0 C-N-CA 120.787 -0.72 . . . . 0.10000000000000001 111.535 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -144.59 152.08 39.98 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 120.788 0.328 . . . . 0.20000000000000001 110.291 -174.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.572 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.1 mm -80.09 123.29 36.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.272 -0.422 . . . . 0.14000000000000001 111.146 -178.245 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.5 p -112.79 -23.64 10.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.117 0.484 . . . . 0.20000000000000001 110.461 178.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.512 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 34.9 ttpt -141.88 145.51 34.69 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.706 -0.85 . . . . 2.3599999999999999 108.706 173.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.581 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -158.63 144.84 17.0 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.595 0.236 . . . . 0.20000000000000001 110.436 -176.076 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -154.2 152.44 30.36 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.017 -0.538 . . . . 1.9399999999999999 110.735 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.46 -156.03 46.11 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.988 -0.551 . . . . 0.27000000000000002 113.245 174.124 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 25.4 t -99.17 120.49 39.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.293 -0.632 . . . . 1.1599999999999999 109.293 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.581 HG21 HD11 ' A' ' 10' ' ' LEU . 4.6 m -137.75 152.33 26.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.659 0.743 . . . . 0.20000000000000001 111.729 -175.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.08 158.92 44.67 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 114.582 -1.19 . . . . 0.17000000000000001 108.863 -178.399 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.696 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.6 OUTLIER -136.4 132.37 48.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 C-N-CA 119.99 -0.684 . . . . 0.16 110.982 172.221 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.441 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.7 mt-30 -96.67 99.01 10.64 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.092 -0.958 . . . . 0.51000000000000001 109.284 174.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.474 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.6 m -66.32 179.6 0.95 Allowed 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.971 -0.292 . . . . 1.25 110.811 -176.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.2 pt -60.24 -26.76 37.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 O-C-N 121.886 -0.509 . . . . 0.58999999999999997 112.218 -175.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 -79.69 -8.79 59.45 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.998 0.428 . . . . 1.96 110.62 178.056 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.8 5.81 62.58 Favored Glycine 0 CA--C 1.506 -0.478 0 N-CA-C 111.234 -0.746 . . . . 0.32000000000000001 111.234 178.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -74.44 117.97 16.86 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.305 -0.447 . . . . 2.21 110.819 -179.383 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.696 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.5 tt0 -95.09 110.43 22.36 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.168 0.508 . . . . 1.0 110.224 177.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.63 ' HG2' HG12 ' A' ' 16' ' ' VAL . 17.1 ptt-85 -111.61 167.92 9.96 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.952 -0.567 . . . . 1.55 109.906 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.0 p -86.61 129.47 38.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.821 -0.627 . . . . 0.34999999999999998 109.317 176.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.555 HD22 ' OD1' ' A' ' 30' ' ' ASP . 2.8 mt -91.07 143.54 26.6 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 121.526 0.679 . . . . 0.32000000000000001 110.999 -178.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.488 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.8 mttp -131.21 171.59 13.13 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.658 -1.156 . . . . 1.6499999999999999 109.232 -172.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.86 134.74 46.27 Favored 'General case' 0 CA--C 1.507 -0.701 0 C-N-CA 119.171 -1.011 . . . . 0.23000000000000001 108.743 174.294 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.93 0.58 89.75 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 119.603 -1.284 . . . . 0.23999999999999999 111.656 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.572 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.08 139.73 79.75 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-O 121.69 0.757 . . . . 1.9199999999999999 110.203 177.06 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 37.2 Cg_endo -87.64 123.49 1.81 Allowed 'Trans proline' 0 C--N 1.323 -0.771 0 C-N-CA 123.923 3.082 . . . . 0.22 113.623 -174.376 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 34.4 mm -91.04 134.24 30.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.966 -0.561 . . . . 0.13 110.114 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -111.32 155.11 23.55 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.786 -0.643 . . . . 0.28999999999999998 109.693 179.1 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.54 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -69.42 116.6 10.03 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.813 0.34 . . . . 0.17999999999999999 110.543 -175.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.18 7.11 23.45 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.388 -0.91 . . . . 0.17000000000000001 113.478 178.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.544 ' O ' ' HG2' ' A' ' 66' ' ' MET . 48.2 mt-10 -89.21 145.11 25.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 117.699 0.75 . . . . 0.52000000000000002 110.489 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.7 m -106.06 107.28 18.19 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.807 -0.633 . . . . 0.16 110.781 -176.287 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -82.18 131.06 34.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.225 0.536 . . . . 0.16 110.719 -175.215 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -118.31 108.51 15.18 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.047 -0.979 . . . . 0.27000000000000002 109.703 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.4 p -106.06 155.32 19.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.048 0.451 . . . . 0.23000000000000001 109.955 177.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.763 0 N-CA-C 111.369 -0.693 . . . . 0.90000000000000002 111.369 177.531 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.433 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 67.0 m . . . . . 0 C--O 1.224 -0.258 0 N-CA-C 109.395 -0.595 . . . . 0.84999999999999998 109.395 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -148.39 133.29 10.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 C-N-CA 120.997 -0.281 . . . . 0.25 110.764 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.512 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.1 m -106.36 106.61 17.21 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.052 -0.522 . . . . 0.19 109.62 173.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.553 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 58.8 mt -97.7 107.61 20.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.756 -0.657 . . . . 0.14999999999999999 110.18 178.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.26 106.63 14.31 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.331 -0.85 . . . . 0.14000000000000001 109.323 177.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.547 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 67.8 m-85 -73.59 144.64 45.92 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.484 0.659 . . . . 0.32000000000000001 110.753 -178.48 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.7 p -73.53 -6.28 7.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 114.879 -1.055 . . . . 0.25 111.799 -169.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.56 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 11.5 t70 -84.95 -20.55 30.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.594 -0.276 . . . . 0.75 110.607 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.51 -17.32 5.57 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.479 -0.867 . . . . 0.27000000000000002 112.919 -179.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.6 p -86.59 156.84 19.88 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 122.795 -0.238 . . . . 0.35999999999999999 111.108 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -130.38 150.73 51.48 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.442 -0.577 . . . . 1.51 109.442 177.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.553 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.9 m -130.4 169.4 21.33 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.211 0.529 . . . . 1.3899999999999999 111.768 177.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.554 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.6 p -140.31 132.37 32.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.13 -0.941 . . . . 0.81000000000000005 110.327 176.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 45' ' ' SER . 23.5 mt -102.71 143.46 15.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.99 -0.55 . . . . 0.32000000000000001 110.15 -179.599 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.23 -161.54 36.63 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.858 -0.687 . . . . 1.02 112.23 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.91 146.42 17.99 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.959 -0.639 . . . . 0.40000000000000002 111.57 -175.052 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.5 t70 60.39 21.65 11.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.945 0.878 . . . . 1.26 109.655 -173.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 t -102.93 155.61 18.24 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.369 -0.832 . . . . 1.1899999999999999 110.847 -175.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.539 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.4 mt -140.28 122.88 16.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.248 -0.887 . . . . 0.38 109.351 179.004 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.18 141.93 17.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.702 0.287 . . . . 1.0 110.86 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.5 tt0 -94.38 130.78 40.58 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.928 0.394 . . . . 0.67000000000000004 110.175 178.603 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.544 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 53.6 mmm -65.8 89.93 0.12 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.425 -0.807 . . . . 0.88 110.495 -178.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.401 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.5 p -116.54 -166.39 1.15 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.391 -0.822 . . . . 0.28999999999999998 111.216 -175.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -63.8 -42.42 97.71 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.802 0.334 . . . . 2.1299999999999999 111.471 -177.32 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 56.4 mm-40 -62.89 -23.93 67.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.295 0.569 . . . . 2.5099999999999998 111.009 177.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.414 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.3 mm -82.72 -50.38 15.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.212 -0.904 . . . . 0.25 111.144 177.034 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.783 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 . . . . . 0 C--N 1.319 -0.761 0 CA-C-N 115.671 -0.695 . . . . 0.31 109.962 -177.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.8 m120 . . . . . 0 CA--C 1.515 -0.395 0 N-CA-C 110.115 -0.328 . . . . 2.0 110.115 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 119.35 17.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.906 -0.588 . . . . 0.23999999999999999 110.018 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.753 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.0 pt -101.11 -15.85 7.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-N 115.422 -0.808 . . . . 0.14999999999999999 111.592 -171.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.83 176.26 42.51 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 120.999 -0.62 . . . . 0.10000000000000001 111.595 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.417 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 93.9 m-85 -144.89 151.1 38.18 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.74 0.305 . . . . 0.20000000000000001 110.432 -175.154 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.471 HG12 ' O ' ' A' ' 30' ' ' ASP . 31.4 mm -79.18 122.2 33.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.375 -0.375 . . . . 0.14000000000000001 111.012 -178.363 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.6 p -114.35 -24.4 8.91 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.302 0.573 . . . . 0.20000000000000001 110.661 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.554 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.5 tttm -139.76 146.85 40.03 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 108.605 -0.887 . . . . 2.3599999999999999 108.605 172.037 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -160.24 140.63 11.69 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.128 -0.487 . . . . 0.20000000000000001 110.525 -176.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -146.44 152.46 39.08 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.155 -0.929 . . . . 1.9399999999999999 110.577 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.55 -160.7 53.82 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.883 -0.599 . . . . 0.27000000000000002 113.172 174.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 19.3 m -98.46 121.9 40.99 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.953 -0.388 . . . . 1.1599999999999999 109.953 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.56 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.8 m -139.18 153.57 24.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.669 0.747 . . . . 0.20000000000000001 111.819 -176.29 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.84 159.15 43.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.721 -1.127 . . . . 0.17000000000000001 109.082 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.561 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.3 p -131.21 133.77 62.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.097 -0.641 . . . . 0.16 110.608 172.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.486 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 8.5 mt-30 -97.73 97.88 9.38 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.284 -0.871 . . . . 0.51000000000000001 109.552 177.557 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.468 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 51.7 m -64.52 175.93 1.25 Allowed 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.471 -0.331 . . . . 1.25 110.547 -177.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 pt -58.75 -27.21 34.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 112.814 0.672 . . . . 0.58999999999999997 112.814 -175.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -80.49 -10.8 59.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 1.96 110.7 177.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.46 3.24 61.39 Favored Glycine 0 N--CA 1.452 -0.283 0 N-CA-C 111.71 -0.556 . . . . 0.32000000000000001 111.71 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.2 mm-40 -65.45 120.15 12.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.784 -0.208 . . . . 2.21 110.523 176.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.561 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.8 tt0 -95.77 108.33 20.64 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.716 -0.476 . . . . 1.0 109.716 -179.444 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.41 ' HG2' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -105.34 143.3 33.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.13 -0.486 . . . . 1.55 109.784 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.4 p -74.26 131.24 35.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.846 -0.798 . . . . 0.34999999999999998 108.846 171.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' HG23 ' A' ' 14' ' ' VAL . 26.3 mt -93.45 127.44 39.09 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.191 -0.603 . . . . 0.32000000000000001 110.502 -179.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -110.62 179.25 4.12 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 107.604 -1.258 . . . . 1.6499999999999999 107.604 171.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -68.12 143.39 55.45 Favored 'General case' 0 C--N 1.315 -0.915 0 C-N-CA 119.316 -0.954 . . . . 0.23000000000000001 109.417 175.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.07 -10.24 69.35 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.204 -0.998 . . . . 0.23999999999999999 113.057 176.242 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.471 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.8 m-20 -66.49 142.5 97.71 Favored Pre-proline 0 CA--C 1.515 -0.391 0 CA-C-O 121.108 0.48 . . . . 1.9199999999999999 109.788 175.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.417 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 35.7 Cg_endo -89.06 142.4 4.54 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 123.115 2.543 . . . . 0.22 112.713 -178.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.487 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.8 mm -102.57 136.8 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 115.779 -0.646 . . . . 0.13 109.591 175.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.442 ' H ' ' CD ' ' A' ' 36' ' ' GLU . 80.9 m-85 -113.84 153.65 28.79 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.839 -0.619 . . . . 0.28999999999999998 109.561 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.553 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -69.87 111.55 5.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.378 -0.374 . . . . 0.17999999999999999 110.231 -176.268 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.28 -5.6 8.78 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.601 -0.809 . . . . 0.17000000000000001 113.048 178.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.468 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 28.6 mt-10 -83.39 136.96 34.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.695 0.759 . . . . 0.52000000000000002 111.122 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -96.32 106.97 19.26 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.614 -1.175 . . . . 0.16 110.34 -178.168 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 6.0 t -81.37 133.2 29.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.114 0.483 . . . . 0.16 111.089 -173.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.1 mp -114.92 126.12 54.42 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.956 -1.02 . . . . 0.27000000000000002 109.636 178.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.3 p -119.8 152.39 37.34 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.613 -0.514 . . . . 0.23000000000000001 109.613 172.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.818 0 C-N-CA 120.992 -0.623 . . . . 0.90000000000000002 112.211 179.33 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.545 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 23.2 m . . . . . 0 C--O 1.22 -0.469 0 N-CA-C 108.625 -0.88 . . . . 0.84999999999999998 108.625 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -141.81 138.36 31.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 C-N-CA 120.385 -0.526 . . . . 0.25 111.158 -175.057 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.554 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.1 m -108.89 105.9 15.65 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.781 -0.645 . . . . 0.19 109.648 173.625 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.529 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.2 mt -94.5 109.45 22.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.896 -0.593 . . . . 0.14999999999999999 110.045 177.09 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.73 99.26 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.236 -0.893 . . . . 0.14000000000000001 109.335 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.504 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 66.9 m-85 -67.21 144.67 55.85 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.411 0.624 . . . . 0.32000000000000001 110.336 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -70.18 2.01 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 114.558 -1.201 . . . . 0.25 110.846 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -84.89 -21.97 29.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.925 -1.034 . . . . 0.75 110.725 177.105 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 115.99 -17.37 15.17 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 111.162 -0.775 . . . . 0.27000000000000002 111.162 -175.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 p -87.07 150.75 23.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.516 -0.342 . . . . 0.35999999999999999 111.042 178.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -126.13 150.2 48.42 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.277 -0.638 . . . . 1.51 109.277 178.363 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.529 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -125.14 171.39 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.012 0.434 . . . . 1.3899999999999999 111.366 178.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.534 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.1 p -137.81 130.08 40.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.461 -0.791 . . . . 0.81000000000000005 110.318 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -105.08 136.87 37.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.881 -0.6 . . . . 0.32000000000000001 109.926 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.94 -163.59 27.89 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.979 -0.629 . . . . 1.02 112.328 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.5 150.5 18.29 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.946 -0.645 . . . . 0.40000000000000002 111.736 -173.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 34.7 t70 56.89 22.68 7.35 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.723 0.773 . . . . 1.26 110.264 -173.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.3 m -105.64 164.02 12.23 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.122 0.487 . . . . 1.1899999999999999 111.338 -177.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.488 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.1 mt -140.86 128.2 22.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.506 -0.77 . . . . 0.38 109.374 176.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.429 HG21 HD11 ' A' ' 70' ' ' ILE . 11.0 p -149.61 138.68 15.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.852 0.358 . . . . 1.0 110.973 -177.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.507 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.9 tt0 -97.13 131.28 44.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.843 0.354 . . . . 0.67000000000000004 111.138 -176.038 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.628 ' SD ' HG21 ' A' ' 70' ' ' ILE . 17.8 mmt -62.94 90.48 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.651 -0.704 . . . . 0.88 111.177 177.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.6 p -126.13 -169.1 1.95 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.502 -0.772 . . . . 0.28999999999999998 110.241 -178.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -69.46 -26.61 64.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 117.814 0.279 . . . . 2.1299999999999999 111.157 -176.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.06 -22.93 63.02 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.972 0.891 . . . . 2.5099999999999998 109.688 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.628 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.9 mm -90.32 -51.76 11.48 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 114.72 -1.127 . . . . 0.25 110.762 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.753 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 . . . . . 0 C--N 1.314 -0.937 0 CA-C-N 115.491 -0.777 . . . . 0.31 110.729 -176.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 . . . . . 0 CA--C 1.517 -0.299 0 CA-C-O 120.914 0.388 . . . . 2.0 110.385 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.31 109.67 12.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.768 -0.651 . . . . 0.23999999999999999 109.623 178.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.842 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.5 pt -92.34 -11.39 9.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.088 -0.96 . . . . 0.14999999999999999 112.046 -169.564 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.45 42.79 Favored Glycine 0 CA--C 1.5 -0.85 0 C-N-CA 120.593 -0.813 . . . . 0.10000000000000001 111.48 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -144.98 151.05 37.98 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.954 0.407 . . . . 0.20000000000000001 110.883 -174.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.517 HG12 ' O ' ' A' ' 30' ' ' ASP . 21.2 mm -78.44 121.71 31.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 115.783 -0.644 . . . . 0.14000000000000001 110.903 -178.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 72.7 p -113.63 -21.16 10.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.343 0.592 . . . . 0.20000000000000001 110.406 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.464 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 84.4 tttt -142.63 145.2 33.25 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.775 -0.824 . . . . 2.3599999999999999 108.775 173.455 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.446 HD11 HG21 ' A' ' 14' ' ' VAL . 6.0 tt -159.47 142.62 14.29 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 120.765 0.317 . . . . 0.20000000000000001 110.945 -177.077 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -148.82 165.24 32.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.67 -0.695 . . . . 1.9399999999999999 110.795 176.441 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 67.57 -149.67 50.87 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.991 -0.55 . . . . 0.27000000000000002 113.183 175.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 29.8 t -108.9 133.64 52.64 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.042 -0.725 . . . . 1.1599999999999999 109.042 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.474 HG23 ' HB2' ' A' ' 26' ' ' LEU . 5.2 m -142.8 153.3 17.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.786 0.803 . . . . 0.20000000000000001 111.582 -176.467 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.26 157.99 43.3 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.683 -1.144 . . . . 0.17000000000000001 108.67 177.567 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.572 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.1 p -131.94 134.95 59.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.354 -0.538 . . . . 0.16 110.316 174.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.479 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -104.65 99.9 9.56 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.376 -0.829 . . . . 0.51000000000000001 109.56 178.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.489 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 22.5 p -62.96 178.46 0.47 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.552 -0.295 . . . . 1.25 111.279 -175.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 2.9 pt -57.03 -33.61 42.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 112.597 0.591 . . . . 0.58999999999999997 112.597 -174.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.485 ' OD1' ' HG3' ' A' ' 22' ' ' GLN . 9.5 p30 -81.93 -12.07 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.894 -0.322 . . . . 1.96 110.762 179.298 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.42 7.58 36.98 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.768 -0.73 . . . . 0.32000000000000001 113.755 176.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.485 ' HG3' ' OD1' ' A' ' 20' ' ' ASN . 54.7 mt-30 -70.88 120.87 17.1 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.107 0.453 . . . . 2.21 111.127 179.203 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.527 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.6 tt0 -91.59 113.11 25.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.976 0.417 . . . . 1.0 109.969 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.92 138.22 51.39 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.793 -0.639 . . . . 1.55 109.796 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.61 134.96 29.11 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 109.113 -0.699 . . . . 0.34999999999999998 109.113 175.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.6 HD22 ' OD1' ' A' ' 30' ' ' ASP . 5.4 mt -99.45 150.41 22.21 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.62 0.724 . . . . 0.32000000000000001 111.442 -177.508 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.544 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 41.1 mttp -135.52 173.12 12.07 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.424 -1.262 . . . . 1.6499999999999999 109.152 -171.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.52 141.78 46.74 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 119.133 -1.027 . . . . 0.23000000000000001 109.347 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.61 0.96 85.92 Favored Glycine 0 N--CA 1.435 -1.395 0 C-N-CA 120.13 -1.034 . . . . 0.23999999999999999 111.824 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.6 ' OD1' HD22 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -78.36 142.45 62.88 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-O 121.553 0.692 . . . . 1.9199999999999999 111.1 -179.187 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.04 133.74 11.26 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.771 2.981 . . . . 0.22 113.836 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mm -99.98 136.8 29.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.005 -0.998 . . . . 0.13 109.092 172.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -116.57 154.62 30.14 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 120.976 0.417 . . . . 0.28999999999999998 109.945 -178.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.509 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.7 t80 -71.51 115.7 11.0 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.003 -0.544 . . . . 0.17999999999999999 110.581 -175.462 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.13 7.61 22.89 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.461 -0.876 . . . . 0.17000000000000001 113.345 177.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.572 ' HB3' HG22 ' A' ' 16' ' ' VAL . 28.4 mt-10 -94.77 147.75 23.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.763 0.781 . . . . 0.52000000000000002 110.673 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.479 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 10.1 m -104.09 108.39 19.73 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.094 -0.957 . . . . 0.16 110.661 -176.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.2 t -83.56 121.88 36.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.315 0.579 . . . . 0.16 110.934 -175.094 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -107.46 104.77 14.42 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.796 -1.093 . . . . 0.27000000000000002 109.679 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.3 p -99.93 156.47 17.12 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.651 -0.5 . . . . 0.23000000000000001 109.651 177.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.994 0 C-N-CA 120.767 -0.73 . . . . 0.90000000000000002 111.982 179.688 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m . . . . . 0 CA--C 1.512 -0.482 0 N-CA-C 109.334 -0.617 . . . . 0.84999999999999998 109.334 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.1 t -126.63 132.46 70.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.93 -0.577 . . . . 0.25 111.206 -169.248 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.464 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.0 m -109.02 108.24 18.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.031 -0.531 . . . . 0.19 110.288 178.359 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.457 HD13 ' HE2' ' A' ' 66' ' ' MET . 79.1 mt -97.75 102.69 13.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-N 115.216 -0.902 . . . . 0.14999999999999999 109.966 178.184 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.05 99.68 8.59 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.644 -0.707 . . . . 0.14000000000000001 109.371 178.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.572 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 48.8 m-85 -61.77 144.9 54.02 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.518 0.675 . . . . 0.32000000000000001 111.197 -178.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.13 -12.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.707 -1.133 . . . . 0.25 111.493 -170.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.428 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 28.6 t70 -74.55 -17.38 60.75 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.215 0.531 . . . . 0.75 110.529 176.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.78 -7.3 17.51 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.916 -0.659 . . . . 0.27000000000000002 111.896 -177.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.0 p -88.63 177.47 6.75 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.396 -0.224 . . . . 0.35999999999999999 110.396 176.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -151.58 157.38 42.13 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.259 -0.274 . . . . 1.51 110.259 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.513 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.53 150.78 17.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.35 -0.387 . . . . 1.3899999999999999 110.427 -177.689 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 9.1 p -126.57 133.16 69.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.318 0.58 . . . . 0.81000000000000005 110.668 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -102.53 147.6 8.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.739 -0.664 . . . . 0.32000000000000001 110.196 -177.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.9 -178.44 43.48 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.733 -0.746 . . . . 1.02 111.413 175.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -101.57 148.57 17.95 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 121.043 -0.598 . . . . 0.40000000000000002 111.656 -172.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t70 58.3 24.53 11.68 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 121.843 0.83 . . . . 1.26 110.179 -173.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.7 t -106.1 161.13 14.77 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.439 -0.8 . . . . 1.1899999999999999 110.445 -179.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.507 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 79.1 mt -139.88 118.47 11.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.859 -0.61 . . . . 0.38 109.629 179.063 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.5 p -140.45 141.4 32.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.508 -0.315 . . . . 1.0 110.829 -175.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.416 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 41.8 tt0 -97.99 126.84 43.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.905 0.383 . . . . 0.67000000000000004 110.332 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.457 ' HE2' HD13 ' A' ' 48' ' ' ILE . 50.5 mmm -67.06 89.54 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.66 -0.7 . . . . 0.88 110.658 -178.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.407 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 10.8 p -115.02 -165.98 1.07 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.819 -0.628 . . . . 0.28999999999999998 111.547 -175.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.83 -36.77 75.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.814 0.34 . . . . 2.1299999999999999 110.718 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -61.97 -32.83 73.31 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.626 0.726 . . . . 2.5099999999999998 110.095 175.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.407 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.1 mm -75.41 -53.09 16.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-N 114.476 -1.238 . . . . 0.25 111.029 178.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.842 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 . . . . . 0 C--N 1.317 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.31 109.993 -176.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 . . . . . 0 CA--C 1.514 -0.442 0 CA-C-O 120.908 0.385 . . . . 2.0 110.517 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.06 113.17 18.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.547 0.689 . . . . 0.23999999999999999 110.351 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.828 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.9 pt -97.54 -14.09 7.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-N 115.106 -0.952 . . . . 0.14999999999999999 111.709 -172.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.9 176.39 42.52 Favored Glycine 0 CA--C 1.502 -0.767 0 N-CA-C 111.01 -0.836 . . . . 0.10000000000000001 111.01 179.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -143.35 151.57 40.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.041 0.448 . . . . 0.20000000000000001 111.041 -175.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 35.2 mm -78.19 121.87 31.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.94 -0.573 . . . . 0.14000000000000001 110.689 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.8 p -115.45 -20.28 10.31 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 0.20000000000000001 110.546 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.1 tttt -143.83 143.3 31.26 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.47 -0.937 . . . . 2.3599999999999999 108.47 173.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.3 tt -160.27 140.28 11.39 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-O 121.074 0.464 . . . . 0.20000000000000001 111.107 -178.026 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -149.08 149.75 31.6 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.164 -0.925 . . . . 1.9399999999999999 110.479 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.46 -160.2 41.54 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.972 -0.632 . . . . 0.27000000000000002 113.035 175.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.0 m -101.32 119.25 38.47 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 120.667 0.27 . . . . 1.1599999999999999 110.312 -177.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -136.91 152.0 28.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.817 0.817 . . . . 0.20000000000000001 111.753 -176.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 159.34 42.7 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 114.706 -1.134 . . . . 0.17000000000000001 108.703 178.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.573 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -131.57 132.62 62.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 121.29 0.567 . . . . 0.16 110.424 174.938 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.519 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.9 mt-30 -98.91 99.23 10.27 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.445 -0.798 . . . . 0.51000000000000001 109.734 178.592 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.561 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 13.9 m -60.94 172.85 0.88 Allowed 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 110.039 -0.356 . . . . 1.25 110.039 -179.223 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -60.99 -14.7 10.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 112.248 0.462 . . . . 0.58999999999999997 112.248 -177.499 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -85.53 -9.32 57.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.178 0.514 . . . . 1.96 110.372 177.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 88.54 5.66 74.78 Favored Glycine 0 CA--C 1.508 -0.372 0 N-CA-C 110.877 -0.889 . . . . 0.32000000000000001 110.877 -175.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.401 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 92.7 mt-30 -70.21 118.52 13.13 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.792 -0.704 . . . . 2.21 110.664 178.272 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 6.5 tt0 -90.41 111.28 22.47 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.228 0.537 . . . . 1.0 109.629 177.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.4 ' NH2' ' HD2' ' A' ' 31' ' ' PRO . 0.0 OUTLIER -115.35 142.14 47.09 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.232 -0.894 . . . . 1.55 109.706 -177.311 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -75.65 143.19 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.835 0.35 . . . . 0.34999999999999998 110.144 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' HG23 ' A' ' 14' ' ' VAL . 24.9 mt -110.12 128.97 55.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.994 0.426 . . . . 0.32000000000000001 110.933 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 77.5 mttt -117.77 -179.72 3.82 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 108.246 -1.02 . . . . 1.6499999999999999 108.246 170.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.4 tp -65.39 148.58 51.47 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.573 -0.851 . . . . 0.23000000000000001 110.3 178.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.55 -7.24 58.59 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.531 -0.842 . . . . 0.23999999999999999 112.677 177.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.9 143.68 97.16 Favored Pre-proline 0 CA--C 1.512 -0.515 0 CA-C-O 121.187 0.518 . . . . 1.9199999999999999 110.105 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.4 ' HD2' ' NH2' ' A' ' 24' ' ' ARG . 24.6 Cg_endo -90.15 131.4 1.79 Allowed 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 123.262 2.641 . . . . 0.22 111.827 178.641 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.523 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.3 mm -94.08 134.48 31.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 109.747 -0.464 . . . . 0.13 109.747 176.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.98 150.25 30.84 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.558 -0.746 . . . . 0.28999999999999998 109.396 -179.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.556 ' HD2' HG21 ' A' ' 4' ' ' ILE . 3.0 t80 -67.3 116.8 8.48 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.17999999999999999 110.364 -174.524 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.17 -10.42 20.28 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.789 -0.72 . . . . 0.17000000000000001 113.234 176.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.573 ' HB3' HG22 ' A' ' 16' ' ' VAL . 28.7 mt-10 -76.02 140.4 41.94 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 117.877 0.839 . . . . 0.52000000000000002 110.685 179.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -101.43 109.04 20.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.809 -1.087 . . . . 0.16 110.84 -175.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.6 t -82.11 132.04 32.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.189 0.518 . . . . 0.16 110.934 -174.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -117.84 109.49 16.62 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 114.975 -1.011 . . . . 0.27000000000000002 110.017 -177.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -105.26 157.01 17.6 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.428 -0.509 . . . . 0.23000000000000001 109.789 175.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.886 0 C-N-CA 120.81 -0.71 . . . . 0.90000000000000002 111.872 178.973 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.53 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 7.3 m . . . . . 0 C--O 1.225 -0.231 0 N-CA-C 109.349 -0.611 . . . . 0.84999999999999998 109.349 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.517 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 7.5 t -134.72 147.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.901 -0.32 . . . . 0.25 111.107 -173.444 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.569 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -117.98 110.63 17.93 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.157 -0.474 . . . . 0.19 110.01 173.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.554 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 64.4 mt -98.66 109.35 23.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.805 -0.634 . . . . 0.14999999999999999 110.014 176.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.44 102.22 11.92 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.418 -0.81 . . . . 0.14000000000000001 109.171 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.46 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.7 m-85 -70.1 144.43 52.11 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.372 0.606 . . . . 0.32000000000000001 110.78 -178.738 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.75 1.9 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 114.651 -1.159 . . . . 0.25 111.725 -171.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -92.51 -11.97 33.18 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.98 -0.554 . . . . 0.75 109.962 175.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.79 -5.41 25.93 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.516 -0.849 . . . . 0.27000000000000002 112.726 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.6 p -93.95 159.79 15.01 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.819 -0.224 . . . . 0.35999999999999999 110.717 177.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.63 143.6 47.39 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.417 -0.586 . . . . 1.51 109.417 179.178 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.554 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.9 m -121.75 164.16 18.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.103 0.478 . . . . 1.3899999999999999 111.441 177.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -131.86 129.44 60.9 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 115.241 -0.89 . . . . 0.81000000000000005 109.875 177.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.53 ' O ' ' HA ' ' A' ' 45' ' ' SER . 17.1 mt -103.43 131.58 51.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 116.257 -0.428 . . . . 0.32000000000000001 109.993 -178.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.23 -163.92 23.56 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 121.151 -0.547 . . . . 1.02 112.259 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.93 145.25 16.5 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.772 -0.728 . . . . 0.40000000000000002 111.728 -173.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.5 t70 58.24 25.22 12.38 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 121.547 0.689 . . . . 1.26 110.217 -174.313 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.4 m -103.04 156.47 17.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.957 -0.565 . . . . 1.1899999999999999 110.935 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.499 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 89.7 mt -140.6 117.31 8.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.618 -0.719 . . . . 0.38 109.588 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.8 p -147.66 143.96 19.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 110.108 -0.33 . . . . 1.0 110.108 -177.16 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.594 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -103.99 139.21 39.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.545 0.688 . . . . 0.67000000000000004 111.079 -176.113 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.553 ' SD ' HG21 ' A' ' 70' ' ' ILE . 22.7 mmt -64.19 89.62 0.06 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.627 -1.17 . . . . 0.88 111.667 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.428 HG23 ' CG ' ' A' ' 65' ' ' GLU . 2.3 p -114.25 -172.15 2.05 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.622 -0.717 . . . . 0.28999999999999998 110.125 177.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -71.98 -24.45 61.58 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.748 0.309 . . . . 2.1299999999999999 110.657 -178.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -70.08 -23.54 63.08 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.472 0.653 . . . . 2.5099999999999998 110.229 175.384 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.553 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.4 mm -88.17 -56.52 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.119 -0.946 . . . . 0.25 109.728 175.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.828 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 . . . . . 0 C--N 1.319 -0.757 0 CA-C-N 114.543 -1.208 . . . . 0.31 109.786 -178.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 . . . . . 0 CA--C 1.511 -0.539 0 N-CA-C 110.165 -0.309 . . . . 2.0 110.165 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.11 108.09 8.78 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.798 -0.816 . . . . 0.23999999999999999 108.798 174.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.749 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.3 pt -92.96 -10.42 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.22 -0.9 . . . . 0.14999999999999999 111.419 -170.485 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.78 176.3 42.47 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.623 -0.799 . . . . 0.10000000000000001 111.469 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -144.49 150.07 36.98 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.04 0.448 . . . . 0.20000000000000001 110.446 -175.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.578 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.2 mm -78.04 123.68 35.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.775 -0.648 . . . . 0.14000000000000001 110.972 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 p -116.19 -23.41 8.45 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.127 0.489 . . . . 0.20000000000000001 110.856 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.575 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 25.8 tptp -139.99 136.18 33.49 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.959 -1.126 . . . . 2.3599999999999999 107.959 173.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.492 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -152.85 138.11 17.47 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.016 0.436 . . . . 0.20000000000000001 111.043 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.4 m-20 -147.95 157.24 43.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.158 -0.928 . . . . 1.9399999999999999 110.861 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.03 -158.79 46.7 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.842 -0.617 . . . . 0.27000000000000002 112.752 176.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.9 t -103.68 118.69 37.31 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.251 -0.648 . . . . 1.1599999999999999 109.251 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.601 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.7 m -135.65 153.17 32.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.687 0.756 . . . . 0.20000000000000001 111.681 -175.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.11 158.86 44.52 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.796 -1.093 . . . . 0.17000000000000001 108.687 -178.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.681 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -136.61 134.5 49.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 119.917 -0.713 . . . . 0.16 111.375 173.636 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.419 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.1 mt-30 -97.56 100.32 11.73 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 114.924 -1.034 . . . . 0.51000000000000001 108.98 174.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.505 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 58.1 p -63.01 179.06 0.41 Allowed 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.962 -0.295 . . . . 1.25 111.145 -175.139 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.8 pt -60.98 -21.17 23.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 0.58999999999999997 110.937 176.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -80.1 -9.91 59.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 1.96 110.14 176.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.93 12.45 71.35 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 110.973 -0.851 . . . . 0.32000000000000001 110.973 179.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -89.06 121.74 31.71 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.9 -0.65 . . . . 2.21 110.81 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.681 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 22.2 tt0 -89.65 118.13 29.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.903 -0.59 . . . . 1.0 110.46 178.75 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.61 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.1 ptt-85 -119.16 165.96 13.55 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.502 -0.555 . . . . 1.55 109.502 175.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.7 p -91.24 127.49 43.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.372 0.606 . . . . 0.34999999999999998 109.432 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.601 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.1 mt -90.49 151.17 21.49 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.5 0.667 . . . . 0.32000000000000001 111.351 -175.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.41 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 18.6 mttp -141.87 176.15 9.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.748 -1.114 . . . . 1.6499999999999999 108.324 -171.257 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -74.29 141.63 45.27 Favored 'General case' 0 C--N 1.313 -1.014 0 C-N-CA 119.303 -0.959 . . . . 0.23000000000000001 108.988 176.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.77 7.31 88.31 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 119.918 -1.134 . . . . 0.23999999999999999 111.917 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -85.03 140.37 37.09 Favored Pre-proline 0 CA--C 1.52 -0.184 0 CA-C-O 121.612 0.72 . . . . 1.9199999999999999 110.472 178.6 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -78.21 132.01 11.16 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.677 2.918 . . . . 0.22 113.426 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.413 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.4 mm -99.45 133.61 41.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 0.13 109.175 173.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -113.88 152.61 30.51 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.145 -0.479 . . . . 0.28999999999999998 110.238 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.7 t80 -68.48 111.77 4.9 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.963 -0.562 . . . . 0.17999999999999999 110.019 -177.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.67 6.25 19.62 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.34 -0.933 . . . . 0.17000000000000001 113.348 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.545 ' O ' ' HG2' ' A' ' 66' ' ' MET . 39.9 mt-10 -91.05 135.12 33.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 117.869 0.834 . . . . 0.52000000000000002 110.739 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.541 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 9.0 m -94.47 106.12 18.09 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.99 -1.005 . . . . 0.16 110.94 -176.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.544 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 4.3 t -82.47 129.58 37.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.137 0.494 . . . . 0.16 110.916 -175.209 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.6 mp -117.31 108.09 15.19 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.223 -0.899 . . . . 0.27000000000000002 109.694 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.7 p -105.13 153.5 21.43 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.9 -0.408 . . . . 0.23000000000000001 109.9 178.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.826 0 C-N-CA 121.115 -0.564 . . . . 0.90000000000000002 111.886 178.872 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 50.7 m . . . . . 0 CA--C 1.518 -0.273 0 N-CA-C 109.596 -0.52 . . . . 0.84999999999999998 109.596 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.0 t -143.36 129.77 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.677 0.275 . . . . 0.25 111.034 -175.124 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.575 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -99.26 105.77 17.82 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.533 -0.543 . . . . 0.19 109.533 172.267 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.556 HD13 ' HE2' ' A' ' 66' ' ' MET . 69.3 mt -95.89 107.43 19.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 CA-C-N 115.821 -0.627 . . . . 0.14999999999999999 109.997 176.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.74 104.96 13.38 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.322 -0.853 . . . . 0.14000000000000001 109.08 176.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.497 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 60.9 m-85 -69.96 152.7 44.15 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.601 0.715 . . . . 0.32000000000000001 110.746 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.5 p -72.61 -11.6 15.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.654 -1.157 . . . . 0.25 111.496 -170.198 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -81.17 -21.77 39.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.102 0.477 . . . . 0.75 110.598 176.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.43 -7.12 14.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.615 -0.802 . . . . 0.27000000000000002 112.182 -177.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.5 p -85.19 150.11 25.04 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 110.366 -0.235 . . . . 0.35999999999999999 110.366 176.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -127.53 147.4 50.32 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.664 -0.414 . . . . 1.51 109.932 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.541 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.8 m -129.75 171.32 17.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.117 0.484 . . . . 1.3899999999999999 111.596 178.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.523 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.8 p -137.61 134.88 46.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.169 -0.923 . . . . 0.81000000000000005 110.168 177.517 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.604 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.7 mt -107.43 136.09 43.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.4 -0.364 . . . . 0.32000000000000001 110.309 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.51 -169.88 43.05 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.083 -0.579 . . . . 1.02 112.37 178.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -110.34 152.8 17.28 Favored Glycine 0 CA--C 1.504 -0.642 0 N-CA-C 111.595 -0.602 . . . . 0.40000000000000002 111.595 -173.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.3 t70 56.65 21.73 6.1 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.963 0.887 . . . . 1.26 109.775 -172.495 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.0 m -106.18 158.97 16.45 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.721 -0.672 . . . . 1.1899999999999999 111.297 -176.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.544 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.6 mt -139.99 119.63 12.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.417 -0.811 . . . . 0.38 109.459 178.329 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.4 p -145.71 138.3 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 120.904 0.383 . . . . 1.0 110.654 -178.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.0 tt0 -92.01 130.55 37.73 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.222 -0.444 . . . . 0.67000000000000004 109.963 179.332 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.556 ' HE2' HD13 ' A' ' 48' ' ' ILE . 60.8 mmm -66.67 89.56 0.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.948 -0.569 . . . . 0.88 110.591 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 17.0 p -115.46 -165.34 1.02 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.819 -0.628 . . . . 0.28999999999999998 111.47 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -64.89 -39.31 93.33 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.182 -0.463 . . . . 2.1299999999999999 111.061 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -64.35 -28.86 69.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.843 0.83 . . . . 2.5099999999999998 110.075 178.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -77.48 -46.45 27.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.734 -1.121 . . . . 0.25 111.212 176.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.749 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 . . . . . 0 C--N 1.315 -0.892 0 CA-C-N 115.638 -0.71 . . . . 0.31 110.662 -174.323 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 . . . . . 0 C--O 1.236 0.371 0 CA-C-O 121.031 0.444 . . . . 2.0 110.597 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.67 109.36 13.99 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.648 -0.705 . . . . 0.23999999999999999 109.584 178.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.773 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 32.9 pt -92.97 -12.99 8.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 114.896 -1.047 . . . . 0.14999999999999999 111.841 -170.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.38 176.34 44.02 Favored Glycine 0 CA--C 1.501 -0.814 0 C-N-CA 120.61 -0.805 . . . . 0.10000000000000001 111.688 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.94 149.39 36.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.972 0.415 . . . . 0.20000000000000001 110.961 -174.332 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.44 HD12 ' CG1' ' A' ' 46' ' ' VAL . 37.6 mm -76.43 124.08 33.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.829 -0.623 . . . . 0.14000000000000001 111.782 -176.147 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.2 p -116.75 -20.68 9.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.034 0.445 . . . . 0.20000000000000001 111.403 179.099 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.606 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 23.3 tptm -140.21 136.24 33.2 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.104 -1.073 . . . . 2.3599999999999999 108.104 174.359 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.595 HD11 HG21 ' A' ' 14' ' ' VAL . 5.6 tt -155.71 139.66 16.32 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.395 -0.522 . . . . 0.20000000000000001 111.552 -179.42 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -144.76 155.77 43.71 Favored 'General case' 0 CA--C 1.496 -1.119 0 CA-C-N 115.655 -0.702 . . . . 1.9399999999999999 110.914 173.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.16 -162.56 38.72 Favored Glycine 0 N--CA 1.419 -2.462 0 CA-C-N 115.005 -0.998 . . . . 0.27000000000000002 112.866 164.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.4 m -92.15 116.24 28.77 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 109.841 -0.429 . . . . 1.1599999999999999 109.841 177.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.595 HG21 HD11 ' A' ' 10' ' ' LEU . 3.7 m -135.5 152.67 32.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.711 0.767 . . . . 0.20000000000000001 111.397 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.98 158.3 44.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.701 -1.136 . . . . 0.17000000000000001 108.79 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.691 HG12 ' HG2' ' A' ' 24' ' ' ARG . 1.0 OUTLIER -131.62 133.11 61.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 C-N-CA 119.971 -0.692 . . . . 0.16 111.244 173.933 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.493 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -97.7 99.1 10.44 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.004 -0.998 . . . . 0.51000000000000001 109.503 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.477 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 20.0 m -64.52 176.54 1.08 Allowed 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 116.344 -0.389 . . . . 1.25 110.584 -178.352 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -59.66 -26.91 36.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 O-C-N 122.005 -0.434 . . . . 0.58999999999999997 111.569 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.6 m-20 -71.82 -16.51 62.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.04 0.448 . . . . 1.96 110.678 176.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.52 4.87 65.55 Favored Glycine 0 N--CA 1.451 -0.318 0 N-CA-C 110.839 -0.905 . . . . 0.32000000000000001 110.839 -175.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 92.5 mt-30 -73.53 129.19 37.45 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.827 -0.686 . . . . 2.21 110.619 179.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.666 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 6.8 tt0 -106.37 109.18 21.03 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.411 -0.359 . . . . 1.0 110.601 -176.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.691 ' HG2' HG12 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -109.57 165.74 11.43 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.669 -0.493 . . . . 1.55 109.669 176.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -89.92 139.45 17.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 115.862 -0.608 . . . . 0.34999999999999998 109.425 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.505 ' HB2' HG23 ' A' ' 14' ' ' VAL . 22.6 mt -103.91 131.1 51.47 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.129 0.49 . . . . 0.32000000000000001 110.799 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.3 mttp -118.46 -177.12 3.22 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 107.939 -1.134 . . . . 1.6499999999999999 107.939 171.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 146.7 54.26 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 119.859 -0.736 . . . . 0.23000000000000001 109.519 175.054 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.92 1.58 87.55 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 120.13 -1.033 . . . . 0.23999999999999999 112.918 176.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.401 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.4 m-20 -78.78 144.75 65.04 Favored Pre-proline 0 CA--C 1.517 -0.317 0 CA-C-O 121.103 0.478 . . . . 1.9199999999999999 110.608 176.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -79.5 142.95 16.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.967 2.445 . . . . 0.22 112.743 178.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.454 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.3 mm -108.44 135.97 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-N 115.614 -0.721 . . . . 0.13 109.092 171.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -115.96 152.45 33.46 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 116.218 -0.446 . . . . 0.28999999999999998 110.066 -177.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.529 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.4 t80 -69.41 110.89 4.94 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.872 -0.604 . . . . 0.17999999999999999 110.469 -176.397 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.58 4.06 15.76 Favored Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.478 -0.868 . . . . 0.17000000000000001 113.351 178.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.49 ' O ' ' HG2' ' A' ' 66' ' ' MET . 35.7 mt-10 -93.22 144.97 24.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 117.819 0.809 . . . . 0.52000000000000002 110.832 -179.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.5 m -105.01 109.16 21.05 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.383 -0.826 . . . . 0.16 110.921 -174.652 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -83.46 128.36 38.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.349 0.595 . . . . 0.16 111.028 -175.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.5 mp -114.29 106.5 14.4 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.759 -1.109 . . . . 0.27000000000000002 109.716 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 58.4 p -105.07 154.08 20.63 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.881 0.372 . . . . 0.23000000000000001 110.086 178.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.94 0 N-CA-C 111.517 -0.633 . . . . 0.90000000000000002 111.517 178.202 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.4 t . . . . . 0 CA--C 1.501 -0.913 0 N-CA-C 109.08 -0.711 . . . . 0.84999999999999998 109.08 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.4 t -145.35 136.75 20.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.841 -0.618 . . . . 0.25 111.001 -168.408 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.606 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 91.4 m -111.09 112.62 24.55 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.222 0.534 . . . . 0.19 109.876 175.427 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.466 HD13 ' HE2' ' A' ' 66' ' ' MET . 77.1 mt -99.78 103.52 14.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.205 -0.907 . . . . 0.14999999999999999 110.098 178.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.59 101.53 7.47 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.259 -0.882 . . . . 0.14000000000000001 109.44 177.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.529 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 51.9 m-85 -65.8 143.66 57.34 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.689 0.757 . . . . 0.32000000000000001 110.988 -178.748 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -69.03 -12.36 15.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 114.285 -1.325 . . . . 0.25 111.427 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.485 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 23.3 t70 -74.48 -21.67 59.46 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.169 -0.469 . . . . 0.75 110.624 177.323 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.39 -17.22 8.46 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.815 -0.707 . . . . 0.27000000000000002 112.137 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 6.1 p -85.86 164.78 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 122.084 0.154 . . . . 0.35999999999999999 110.729 178.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -133.54 163.44 29.39 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.158 -0.312 . . . . 1.51 110.158 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.529 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -146.05 157.1 12.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.423 -0.353 . . . . 1.3899999999999999 110.568 -177.409 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.539 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.9 p -133.14 133.91 58.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.166 0.508 . . . . 0.81000000000000005 110.916 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 20.6 mt -104.04 137.7 31.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.871 -0.604 . . . . 0.32000000000000001 109.952 -179.533 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.07 174.53 52.67 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.387 -0.911 . . . . 1.02 111.475 176.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.67 151.29 19.83 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 111.283 -0.727 . . . . 0.40000000000000002 111.283 -173.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.37 26.14 12.13 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-O 121.858 0.837 . . . . 1.26 109.448 -173.425 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -111.55 162.58 14.98 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.425 -0.807 . . . . 1.1899999999999999 110.944 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.2 mt -140.37 124.87 18.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.778 -0.646 . . . . 0.38 109.533 178.197 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.0 p -150.11 142.32 17.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.841 0.353 . . . . 1.0 110.843 -178.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.534 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.3 tt0 -94.79 136.08 35.52 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.892 0.377 . . . . 0.67000000000000004 110.528 178.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.49 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 50.5 mmm -71.46 88.57 0.91 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.697 -0.683 . . . . 0.88 110.393 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -111.08 -163.67 0.86 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.057 -0.519 . . . . 0.28999999999999998 111.249 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -77.1 -28.24 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.876 -0.147 . . . . 2.1299999999999999 111.003 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -66.68 -29.47 69.48 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.95 0.881 . . . . 2.5099999999999998 109.684 173.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.479 HG21 ' HE3' ' A' ' 66' ' ' MET . 1.5 mm -77.35 -55.35 10.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.268 -1.333 . . . . 0.25 110.345 176.352 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.773 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 . . . . . 0 C--N 1.318 -0.792 0 CA-C-N 115.271 -0.877 . . . . 0.31 109.742 -178.007 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 12.8 m120 . . . . . 0 CA--C 1.512 -0.496 0 N-CA-C 109.223 -0.658 . . . . 2.0 109.223 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.52 109.42 12.68 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.503 0.668 . . . . 0.23999999999999999 109.906 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.786 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.5 pt -96.92 -13.2 8.17 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.83 -1.077 . . . . 0.14999999999999999 111.577 -171.593 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.8 174.07 43.4 Favored Glycine 0 CA--C 1.501 -0.818 0 N-CA-C 111.171 -0.772 . . . . 0.10000000000000001 111.171 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -142.98 148.69 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.96 0.41 . . . . 0.20000000000000001 111.247 -174.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.479 HD13 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -77.01 121.67 29.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.704 -0.68 . . . . 0.14000000000000001 111.157 -177.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 71.1 p -116.53 -21.51 9.15 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.067 0.461 . . . . 0.20000000000000001 111.017 179.284 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.589 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.8 tptt -141.74 136.95 31.28 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.536 -0.913 . . . . 2.3599999999999999 108.536 173.275 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.532 HD11 HG21 ' A' ' 14' ' ' VAL . 6.1 tt -152.97 142.83 22.12 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.883 0.373 . . . . 0.20000000000000001 111.156 -178.007 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -143.97 141.85 30.4 Favored 'General case' 0 CA--C 1.499 -0.998 0 CA-C-N 115.777 -0.647 . . . . 1.9399999999999999 111.767 177.315 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.21 -148.88 19.56 Favored Glycine 0 N--CA 1.422 -2.28 0 CA-C-N 114.695 -1.139 . . . . 0.27000000000000002 113.159 164.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.2 t -104.49 113.04 26.35 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.527 -0.546 . . . . 1.1599999999999999 109.527 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.537 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.3 m -133.18 152.89 36.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.562 0.696 . . . . 0.20000000000000001 111.411 -177.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.18 159.43 43.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.959 -1.019 . . . . 0.17000000000000001 108.477 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.544 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.1 p -131.92 129.35 60.65 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 C-N-CA 119.957 -0.697 . . . . 0.16 110.691 175.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.461 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 1.9 mt-30 -93.36 98.71 11.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.44 -0.8 . . . . 0.51000000000000001 108.972 177.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.51 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.1 m -65.23 179.13 0.77 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.962 -0.563 . . . . 1.25 110.495 -176.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 15.1 pt -69.21 -4.88 4.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.913 0.709 . . . . 0.58999999999999997 112.913 -172.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 57.0 m-80 -95.78 -5.35 42.13 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.176 0.513 . . . . 1.96 109.944 173.004 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.32 8.56 74.47 Favored Glycine 0 CA--C 1.507 -0.456 0 N-CA-C 110.709 -0.956 . . . . 0.32000000000000001 110.709 -177.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -78.65 120.89 23.97 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.958 -0.621 . . . . 2.21 110.589 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.455 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.5 tt0 -89.25 109.9 20.73 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.323 0.582 . . . . 1.0 110.224 -179.016 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.83 144.74 39.37 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.206 -0.907 . . . . 1.55 109.711 -176.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -73.28 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.783 0.325 . . . . 0.34999999999999998 110.268 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HB2' HG23 ' A' ' 14' ' ' VAL . 16.4 mt -110.83 124.07 51.32 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.047 0.451 . . . . 0.32000000000000001 110.552 177.161 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -115.67 178.73 4.2 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.511 -0.922 . . . . 1.6499999999999999 108.511 173.126 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -65.61 147.74 52.9 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 119.766 -0.774 . . . . 0.23000000000000001 109.909 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.52 -8.73 63.99 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.237 -0.982 . . . . 0.23999999999999999 112.57 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.403 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 0.4 OUTLIER -65.08 144.59 99.09 Favored Pre-proline 0 CA--C 1.515 -0.377 0 CA-C-O 121.425 0.631 . . . . 1.9199999999999999 111.021 179.559 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 38.1 Cg_endo -83.17 133.55 6.53 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 123.467 2.778 . . . . 0.22 112.393 175.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.41 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 29.0 mm -98.54 132.66 43.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 109.136 -0.69 . . . . 0.13 109.136 174.276 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -114.41 149.01 36.85 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 116.007 -0.542 . . . . 0.28999999999999998 110.163 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.598 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -67.71 109.01 3.14 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.801 -0.636 . . . . 0.17999999999999999 110.375 -174.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 121.49 -1.29 11.31 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.271 -0.966 . . . . 0.17000000000000001 113.589 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.544 ' HB3' HG22 ' A' ' 16' ' ' VAL . 34.7 mt-10 -88.67 146.93 24.79 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 117.929 0.865 . . . . 0.52000000000000002 110.367 -179.188 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.1 m -105.76 107.98 19.25 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.72 -0.673 . . . . 0.16 111.171 -175.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.1 t -81.4 133.62 28.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.154 0.502 . . . . 0.16 110.913 -175.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.9 mp -119.06 109.63 16.14 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.044 -0.98 . . . . 0.27000000000000002 109.789 -178.691 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.9 p -105.01 155.7 18.72 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.541 -0.54 . . . . 0.23000000000000001 109.541 176.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.899 0 C-N-CA 120.724 -0.75 . . . . 0.90000000000000002 111.97 178.443 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 31.1 m . . . . . 0 CA--C 1.516 -0.362 0 N-CA-C 109.838 -0.43 . . . . 0.84999999999999998 109.838 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.6 t -139.61 131.28 33.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 CA-C-N 116.559 -0.291 . . . . 0.25 111.433 -170.861 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.589 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 80.2 m -102.64 107.95 19.05 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.079 -0.51 . . . . 0.19 109.842 175.018 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.577 HD13 ' HE2' ' A' ' 66' ' ' MET . 68.5 mt -96.52 109.64 23.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 CA-C-N 115.717 -0.674 . . . . 0.14999999999999999 110.22 176.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.21 100.81 12.01 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.289 -0.869 . . . . 0.14000000000000001 109.788 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.459 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 67.3 m-85 -68.09 148.36 51.06 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.71 0.767 . . . . 0.32000000000000001 111.082 -177.798 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.8 p -73.45 -8.71 12.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-N 114.276 -1.329 . . . . 0.25 111.128 -171.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.449 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 32.1 t70 -80.15 -20.63 44.47 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.014 -0.539 . . . . 0.75 110.395 176.448 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.92 -10.58 11.1 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.749 -0.738 . . . . 0.27000000000000002 112.173 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.7 p -85.23 157.29 20.65 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.65 -0.13 . . . . 0.35999999999999999 110.65 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -133.81 140.99 47.26 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.507 -0.553 . . . . 1.51 109.507 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.548 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.6 m -121.47 172.65 8.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.192 0.52 . . . . 1.3899999999999999 111.584 178.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.483 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -140.01 133.15 35.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.254 -0.884 . . . . 0.81000000000000005 110.124 177.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.482 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.7 mt -103.54 133.25 47.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.003 -0.544 . . . . 0.32000000000000001 109.951 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.51 178.97 53.71 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.661 -0.78 . . . . 1.02 111.367 175.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.52 155.08 20.84 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.718 -0.553 . . . . 0.40000000000000002 111.718 -171.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 37.9 t70 59.1 17.13 5.29 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.929 0.871 . . . . 1.26 109.702 -176.568 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -102.58 156.42 17.63 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.524 -0.762 . . . . 1.1899999999999999 111.343 -176.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.497 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 90.9 mt -140.69 120.73 12.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.292 -0.867 . . . . 0.38 109.57 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.4 p -150.2 143.74 17.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.644 0.259 . . . . 1.0 110.872 -177.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.55 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 36.2 tt0 -90.72 136.11 33.28 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.982 0.42 . . . . 0.67000000000000004 110.42 177.782 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.577 ' HE2' HD13 ' A' ' 48' ' ' ILE . 61.3 mmm -69.13 89.05 0.43 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.332 -0.849 . . . . 0.88 110.283 179.054 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.1 p -112.73 -164.21 0.9 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.86 -0.609 . . . . 0.28999999999999998 110.669 -177.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -75.4 -25.17 57.38 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.787 0.327 . . . . 2.1299999999999999 110.874 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -66.2 -29.81 70.15 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 122.07 0.938 . . . . 2.5099999999999998 109.612 172.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.478 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.2 mm -82.46 -51.94 14.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 114.254 -1.339 . . . . 0.25 110.489 177.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.786 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.317 -0.833 0 CA-C-N 115.459 -0.791 . . . . 0.31 110.147 -176.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 . . . . . 0 C--O 1.238 0.486 0 CA-C-O 121.293 0.568 . . . . 2.0 110.767 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.23 110.05 17.74 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.061 -0.972 . . . . 0.23999999999999999 109.931 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.779 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.9 pt -87.55 -14.87 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.125 -0.943 . . . . 0.14999999999999999 111.688 -171.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.82 175.84 40.71 Favored Glycine 0 CA--C 1.502 -0.728 0 C-N-CA 120.671 -0.776 . . . . 0.10000000000000001 111.817 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -144.15 149.55 36.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.038 0.446 . . . . 0.20000000000000001 110.61 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.522 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.6 mm -76.61 126.11 36.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 115.731 -0.668 . . . . 0.14000000000000001 110.787 -178.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.6 p -117.13 -16.92 10.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.307 0.575 . . . . 0.20000000000000001 110.773 177.342 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.477 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.4 tttt -145.3 143.83 30.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.607 -0.886 . . . . 2.3599999999999999 108.607 174.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.529 HD11 HG21 ' A' ' 14' ' ' VAL . 4.8 tt -160.47 139.1 10.26 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.778 0.323 . . . . 0.20000000000000001 110.987 -175.558 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -144.07 145.32 32.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.956 -0.566 . . . . 1.9399999999999999 111.49 177.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.18 -146.25 27.64 Favored Glycine 0 N--CA 1.436 -1.348 0 CA-C-N 115.026 -0.988 . . . . 0.27000000000000002 114.063 167.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.9 m -102.03 115.66 31.03 Favored 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 122.832 0.453 . . . . 1.1599999999999999 110.445 -175.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.529 HG21 HD11 ' A' ' 10' ' ' LEU . 3.8 m -135.14 153.59 34.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.594 0.711 . . . . 0.20000000000000001 111.598 -175.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.12 158.32 44.03 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.781 -1.099 . . . . 0.17000000000000001 108.954 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.67 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -134.31 139.06 48.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 C-N-CA 120.015 -0.674 . . . . 0.16 110.727 171.901 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -107.11 100.03 9.53 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.149 -0.932 . . . . 0.51000000000000001 109.71 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.453 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 43.0 t -62.73 179.93 0.31 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.594 -0.275 . . . . 1.25 110.753 -178.253 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.4 pt -61.16 -30.64 48.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.143 0.497 . . . . 0.58999999999999997 111.567 -176.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 16.4 p30 -80.64 -6.71 58.74 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.907 -0.588 . . . . 1.96 111.0 177.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 94.37 1.28 64.52 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.121 -0.561 . . . . 0.32000000000000001 112.413 176.033 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -67.08 121.24 15.16 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.817 0.341 . . . . 2.21 111.424 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.618 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 14.6 tt0 -93.77 118.18 31.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.641 177.069 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.67 ' HG2' HG12 ' A' ' 16' ' ' VAL . 21.8 ptt-85 -120.24 168.01 11.69 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.167 -0.679 . . . . 1.55 109.167 174.518 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.7 p -93.98 136.81 24.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.996 -0.742 . . . . 0.34999999999999998 108.996 177.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.599 HD22 ' OD1' ' A' ' 30' ' ' ASP . 5.2 mt -97.13 153.58 17.88 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.014 -0.539 . . . . 0.32000000000000001 111.316 -176.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.3 mttm -138.44 -178.12 5.15 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.149 -0.932 . . . . 1.6499999999999999 108.585 -173.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.78 140.85 39.48 Favored 'General case' 0 C--N 1.314 -0.954 0 C-N-CA 119.494 -0.882 . . . . 0.23000000000000001 108.971 174.26 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.81 1.09 77.07 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 120.041 -1.076 . . . . 0.23999999999999999 111.887 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.599 ' OD1' HD22 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -73.83 137.14 76.65 Favored Pre-proline 0 CA--C 1.517 -0.312 0 CA-C-O 121.79 0.805 . . . . 1.9199999999999999 110.614 179.095 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -77.23 130.23 10.94 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.62 2.88 . . . . 0.22 113.405 -177.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.403 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.5 mm -99.53 135.93 32.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.075 -0.966 . . . . 0.13 109.313 174.217 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -116.15 154.71 29.54 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 116.004 -0.544 . . . . 0.28999999999999998 109.731 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.56 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -71.21 109.57 5.33 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.361 -0.382 . . . . 0.17999999999999999 110.657 -174.555 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.14 10.28 9.04 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.443 -0.884 . . . . 0.17000000000000001 113.422 178.072 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.481 ' O ' ' HG2' ' A' ' 66' ' ' MET . 40.6 mt-10 -96.01 145.08 25.74 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 117.868 0.834 . . . . 0.52000000000000002 110.687 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 31.7 m -105.27 108.2 19.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.412 -0.813 . . . . 0.16 110.806 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -82.71 133.72 28.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.128 0.489 . . . . 0.16 110.756 -175.567 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -122.2 110.15 15.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.175 -0.921 . . . . 0.27000000000000002 110.051 -177.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.9 p -107.48 158.06 17.5 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.425 -0.583 . . . . 0.23000000000000001 109.425 176.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 C-N-CA 120.378 -0.915 . . . . 0.90000000000000002 113.346 -177.497 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.515 -0.368 0 CA-C-O 121.059 0.457 . . . . 0.84999999999999998 109.937 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.0 t -126.09 142.35 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 CA-C-O 120.793 0.33 . . . . 0.25 111.093 -170.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.1 m -119.34 110.59 17.15 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.297 0.57 . . . . 0.19 110.341 177.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.442 HD13 ' HE2' ' A' ' 66' ' ' MET . 70.2 mt -98.88 102.5 13.49 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-N 115.163 -0.926 . . . . 0.14999999999999999 109.925 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.76 102.62 11.68 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.476 -0.784 . . . . 0.14000000000000001 109.259 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.549 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 58.6 m-85 -64.85 149.28 49.76 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.437 0.637 . . . . 0.32000000000000001 110.881 -177.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.28 -9.03 12.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 114.784 -1.098 . . . . 0.25 111.134 -172.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.423 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 19.5 t70 -78.39 -22.27 48.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.71 -0.677 . . . . 0.75 111.0 177.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.21 -11.85 16.94 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.27000000000000002 111.65 -174.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -85.1 161.08 19.82 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.127 -0.323 . . . . 0.35999999999999999 110.127 175.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -131.78 155.53 47.58 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.24 -0.281 . . . . 1.51 110.24 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.49 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.8 OUTLIER -137.5 151.27 26.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.433 -0.349 . . . . 1.3899999999999999 110.151 178.401 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.43 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.1 p -129.39 141.53 46.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.333 -0.394 . . . . 0.81000000000000005 110.139 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 mt -116.2 131.38 68.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.224 -0.444 . . . . 0.32000000000000001 110.209 -177.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.46 179.7 52.83 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.925 -0.655 . . . . 1.02 111.635 176.201 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.78 148.73 19.09 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 111.285 -0.726 . . . . 0.40000000000000002 111.285 -173.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.8 t70 59.22 23.42 11.76 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 121.914 0.864 . . . . 1.26 109.605 -173.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -104.47 159.99 15.29 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.728 -0.669 . . . . 1.1899999999999999 110.712 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.483 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 92.2 mt -140.07 125.83 21.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.123 -0.944 . . . . 0.38 108.809 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.407 HG21 HD11 ' A' ' 70' ' ' ILE . 13.8 p -147.67 141.74 19.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-O 120.886 0.374 . . . . 1.0 110.866 -177.226 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.414 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.3 tt0 -100.86 124.93 47.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.151 -0.477 . . . . 0.67000000000000004 110.25 -179.089 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 44.3 mmm -65.46 90.29 0.11 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.72 -0.673 . . . . 0.88 110.725 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.408 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.3 p -118.48 -165.48 1.12 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 0.28999999999999998 111.7 -176.532 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -65.9 -44.22 85.88 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.857 0.317 . . . . 2.1299999999999999 111.857 -174.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -62.94 -29.99 71.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.456 0.646 . . . . 2.5099999999999998 110.49 178.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.432 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.1 mm -71.99 -53.11 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.903 -1.044 . . . . 0.25 110.769 176.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.779 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 . . . . . 0 C--N 1.318 -0.778 0 CA-C-N 115.61 -0.723 . . . . 0.31 110.318 -176.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 7.8 p30 . . . . . 0 N--CA 1.447 -0.604 0 CA-C-O 121.017 0.437 . . . . 2.0 110.35 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.08 117.94 20.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.488 -0.778 . . . . 0.23999999999999999 110.228 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.823 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 26.6 pt -96.96 -13.47 8.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.454 -0.794 . . . . 0.14999999999999999 111.487 -172.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.6 179.21 42.21 Favored Glycine 0 CA--C 1.502 -0.752 0 C-N-CA 120.947 -0.644 . . . . 0.10000000000000001 111.635 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.402 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 98.0 m-85 -145.18 152.24 39.69 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.819 0.342 . . . . 0.20000000000000001 110.604 -175.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 30' ' ' ASP . 29.6 mm -81.55 120.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.032 -0.531 . . . . 0.14000000000000001 111.11 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 43.8 p -111.94 -27.25 8.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.276 0.56 . . . . 0.20000000000000001 110.307 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.491 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 85.8 tttt -136.43 147.37 47.21 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.464 -0.939 . . . . 2.3599999999999999 108.464 172.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.484 HD11 HG21 ' A' ' 14' ' ' VAL . 4.9 tt -158.74 141.06 14.07 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.852 0.358 . . . . 0.20000000000000001 110.8 -176.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.51 144.36 30.51 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 115.643 -0.708 . . . . 1.9399999999999999 112.128 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.81 -148.4 27.35 Favored Glycine 0 N--CA 1.425 -2.038 0 CA-C-N 114.561 -1.2 . . . . 0.27000000000000002 113.479 165.562 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 5.7 t -103.05 109.91 21.65 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.715 -0.476 . . . . 1.1599999999999999 109.715 -179.142 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.579 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.6 m -132.21 153.02 37.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.379 0.609 . . . . 0.20000000000000001 111.569 -175.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.13 159.71 44.22 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.219 -0.901 . . . . 0.17000000000000001 109.413 -179.56 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.532 HG22 ' HB3' ' A' ' 36' ' ' GLU . 0.5 OUTLIER -132.6 131.09 59.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.239 0.543 . . . . 0.16 110.213 176.017 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 mt-30 -103.35 99.6 9.45 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.708 -0.678 . . . . 0.51000000000000001 109.835 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.54 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.6 m -61.64 174.07 0.86 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.535 -0.302 . . . . 1.25 111.072 -176.28 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.7 pt -54.92 -32.51 26.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.301 0.482 . . . . 0.58999999999999997 112.301 -176.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -75.71 -12.11 60.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.384 -0.371 . . . . 1.96 111.421 178.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.12 6.08 59.17 Favored Glycine 0 CA--C 1.51 -0.261 0 N-CA-C 111.864 -0.494 . . . . 0.32000000000000001 111.864 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.0 mm-40 -74.35 124.96 27.47 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.639 0.257 . . . . 2.21 110.491 178.589 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 23.7 tt0 -91.69 110.13 21.46 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.425 0.631 . . . . 1.0 110.801 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.08 139.05 40.33 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.295 -0.866 . . . . 1.55 109.872 177.466 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.22 138.03 21.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.444 -0.576 . . . . 0.34999999999999998 109.444 176.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.579 ' HB2' HG23 ' A' ' 14' ' ' VAL . 28.8 mt -102.96 127.54 50.15 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.304 0.574 . . . . 0.32000000000000001 111.102 -178.117 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 74.0 mttt -116.55 179.43 4.01 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.514 -1.291 . . . . 1.6499999999999999 107.514 170.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -67.58 146.74 53.59 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 119.306 -0.958 . . . . 0.23000000000000001 109.95 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.52 0.04 86.35 Favored Glycine 0 N--CA 1.438 -1.178 0 C-N-CA 120.313 -0.946 . . . . 0.23999999999999999 112.721 177.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.49 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.8 OUTLIER -71.84 143.13 86.44 Favored Pre-proline 0 CA--C 1.513 -0.461 0 C-N-CA 120.36 -0.536 . . . . 1.9199999999999999 109.775 173.946 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.402 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 21.4 Cg_endo -89.78 137.47 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.143 2.562 . . . . 0.22 112.1 178.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.467 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.5 mm -98.52 139.65 20.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 116.132 -0.485 . . . . 0.13 109.914 176.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -117.13 155.38 29.43 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.893 -0.594 . . . . 0.28999999999999998 109.498 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.51 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.5 t80 -71.64 118.6 14.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.39 -0.368 . . . . 0.17999999999999999 110.541 -175.424 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.68 -0.36 24.63 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.502 -0.856 . . . . 0.17000000000000001 113.324 177.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.54 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 23.4 mt-10 -85.42 147.94 26.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 117.8 0.8 . . . . 0.52000000000000002 110.909 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.8 m -107.71 108.27 19.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.812 -1.086 . . . . 0.16 110.388 -176.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.619 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.2 t -82.08 136.97 21.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 C-N-CA 120.703 -0.399 . . . . 0.16 110.759 -174.328 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -125.66 107.03 10.17 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.437 -0.801 . . . . 0.27000000000000002 110.562 -175.742 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.467 HG22 HG12 ' A' ' 14' ' ' VAL . 81.5 p -105.74 163.3 12.81 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 108.981 -0.748 . . . . 0.23000000000000001 108.981 173.27 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.316 -0.562 0 C-N-CA 120.384 -0.912 . . . . 0.90000000000000002 112.538 -179.664 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.554 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 46.6 t . . . . . 0 CA--C 1.508 -0.666 0 N-CA-C 109.09 -0.707 . . . . 0.84999999999999998 109.09 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 17.8 t -152.21 136.2 8.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 110.121 -0.325 . . . . 0.25 110.121 -176.256 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.491 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.9 m -109.79 105.36 14.55 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.145 0.497 . . . . 0.19 109.768 173.194 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 78.4 mt -96.34 99.88 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 115.43 -0.805 . . . . 0.14999999999999999 109.739 177.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.91 102.38 8.22 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.215 -0.902 . . . . 0.14000000000000001 109.079 176.639 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.613 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 53.1 m-85 -66.28 151.35 47.23 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.617 0.722 . . . . 0.32000000000000001 111.081 -176.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -75.24 1.63 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 114.588 -1.187 . . . . 0.25 111.273 -172.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -94.16 -20.79 19.55 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.106 0.479 . . . . 0.75 110.5 178.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 123.36 -19.77 7.57 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.637 -0.792 . . . . 0.27000000000000002 111.892 -176.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -78.27 160.2 28.03 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 122.15 0.18 . . . . 0.35999999999999999 110.766 177.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -133.3 146.03 50.99 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.427 -0.582 . . . . 1.51 109.427 178.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.613 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -130.85 147.27 33.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.008 0.432 . . . . 1.3899999999999999 110.834 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.3 p -120.7 138.94 49.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.841 -0.618 . . . . 0.81000000000000005 110.123 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.554 ' O ' ' HA ' ' A' ' 45' ' ' SER . 34.6 mt -110.64 134.45 52.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.078 -0.51 . . . . 0.32000000000000001 110.096 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.76 -168.96 43.56 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.803 -0.713 . . . . 1.02 112.262 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -100.56 143.39 16.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.95 -0.643 . . . . 0.40000000000000002 111.562 -176.149 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.2 t70 60.44 21.53 11.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 121.612 0.72 . . . . 1.26 110.052 -174.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.2 t -97.54 154.27 17.63 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.725 -0.67 . . . . 1.1899999999999999 110.176 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.619 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.6 mt -141.78 106.21 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.486 -0.779 . . . . 0.38 108.937 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -133.56 149.18 30.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.122 0.487 . . . . 1.0 111.414 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.406 ' O ' HG13 ' A' ' 70' ' ' ILE . 43.3 tt0 -105.94 128.96 54.14 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.611 -0.722 . . . . 0.67000000000000004 110.543 -175.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.546 ' SD ' HG21 ' A' ' 70' ' ' ILE . 22.2 mmt -64.3 89.88 0.06 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.607 -0.724 . . . . 0.88 111.333 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 72.7 p -124.89 -165.14 1.35 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.85 -0.613 . . . . 0.28999999999999998 110.988 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -68.33 -26.04 65.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.31 0.576 . . . . 2.1299999999999999 110.226 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -74.19 -20.28 60.25 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.362 -0.836 . . . . 2.5099999999999998 110.361 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.546 HG21 ' SD ' ' A' ' 66' ' ' MET . 2.2 mm -98.49 -55.1 6.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-N 114.785 -1.098 . . . . 0.25 110.948 -179.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.823 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.317 -0.822 0 CA-C-N 115.044 -0.98 . . . . 0.31 109.921 -175.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.3 p-10 . . . . . 0 CA--C 1.516 -0.36 0 CA-C-O 120.861 0.363 . . . . 2.0 110.201 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.04 109.2 14.27 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.854 -0.612 . . . . 0.23999999999999999 109.78 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.694 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.4 pt -95.35 -11.85 8.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 115.058 -0.974 . . . . 0.14999999999999999 111.565 -171.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.91 175.58 43.32 Favored Glycine 0 CA--C 1.498 -1.027 0 N-CA-C 111.241 -0.743 . . . . 0.10000000000000001 111.241 178.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -144.1 151.18 39.26 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.952 0.406 . . . . 0.20000000000000001 110.581 -174.363 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.564 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.7 mm -78.3 124.43 36.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.96 -0.563 . . . . 0.14000000000000001 111.389 -177.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.0 p -115.1 -21.3 10.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.182 0.515 . . . . 0.20000000000000001 110.627 177.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.549 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 81.8 tttt -140.9 143.58 34.72 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.54 -0.911 . . . . 2.3599999999999999 108.54 172.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.632 HD11 HG21 ' A' ' 14' ' ' VAL . 7.6 tt -161.21 140.84 10.53 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.682 0.277 . . . . 0.20000000000000001 110.82 -177.264 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -156.0 158.5 37.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.49 -0.777 . . . . 1.9399999999999999 111.159 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.81 -163.66 52.64 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.811 -0.631 . . . . 0.27000000000000002 112.974 175.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.0 m -92.83 116.62 29.2 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 109.762 -0.459 . . . . 1.1599999999999999 109.762 -177.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.632 HG21 HD11 ' A' ' 10' ' ' LEU . 3.9 m -134.48 152.5 33.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.672 0.748 . . . . 0.20000000000000001 111.988 -175.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.04 159.05 44.78 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 114.567 -1.197 . . . . 0.17000000000000001 108.853 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.664 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -133.95 135.76 54.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.109 -0.637 . . . . 0.16 110.922 172.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.413 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.3 mt-30 -102.46 100.75 10.9 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.364 -0.835 . . . . 0.51000000000000001 109.911 177.412 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.527 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 37.7 m -62.86 176.64 0.66 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.5 -0.318 . . . . 1.25 110.861 -178.367 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -66.68 -5.55 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 N-CA-C 112.142 0.423 . . . . 0.58999999999999997 112.142 -178.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -92.25 -8.48 45.21 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.294 0.569 . . . . 1.96 109.682 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.5 6.46 80.63 Favored Glycine 0 CA--C 1.507 -0.465 0 CA-C-N 115.278 -0.874 . . . . 0.32000000000000001 111.093 -177.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.411 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 46.6 mm-40 -79.65 127.85 32.68 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.225 -0.488 . . . . 2.21 110.953 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLU . . . . . 0.655 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 25.4 tt0 -101.64 117.87 35.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.702 -0.681 . . . . 1.0 110.762 -178.149 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.664 ' HG2' HG12 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -116.62 168.78 9.88 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.619 -0.512 . . . . 1.55 109.619 176.156 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -87.77 140.84 15.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.329 -0.619 . . . . 0.34999999999999998 109.329 176.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.545 HD22 ' CG ' ' A' ' 30' ' ' ASP . 4.8 mt -101.44 152.3 20.91 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.478 -0.489 . . . . 0.32000000000000001 111.129 179.15 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.46 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 53.4 mttt -141.61 178.53 7.4 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.139 -0.937 . . . . 1.6499999999999999 108.638 -174.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.14 139.3 44.43 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.353 -0.939 . . . . 0.23000000000000001 109.108 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 2.42 86.82 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 120.051 -1.071 . . . . 0.23999999999999999 111.968 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.564 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -74.89 141.59 75.39 Favored Pre-proline 0 N--CA 1.454 -0.237 0 CA-C-O 121.55 0.69 . . . . 1.9199999999999999 109.981 177.574 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 28.2 Cg_endo -86.88 127.28 2.6 Favored 'Trans proline' 0 C--N 1.325 -0.709 0 C-N-CA 123.628 2.885 . . . . 0.22 113.353 -174.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 32.2 mm -93.11 134.28 31.48 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-N 116.183 -0.462 . . . . 0.13 109.815 176.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -111.89 151.29 29.32 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.697 -0.683 . . . . 0.28999999999999998 109.747 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -69.42 113.9 7.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.318 -0.401 . . . . 0.17999999999999999 110.796 -175.527 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.13 0.55 22.44 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.527 -0.844 . . . . 0.17000000000000001 113.408 177.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLU . . . . . 0.546 ' O ' ' HG2' ' A' ' 66' ' ' MET . 30.8 mt-10 -86.87 144.7 26.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 117.976 0.888 . . . . 0.52000000000000002 110.81 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.6 m -101.33 107.64 19.05 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.211 -0.904 . . . . 0.16 110.887 -177.11 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.575 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.6 t -82.24 130.51 35.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.137 0.494 . . . . 0.16 110.412 -176.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.1 mp -119.11 103.4 9.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.075 -0.966 . . . . 0.27000000000000002 109.958 -177.357 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 20.3 p -100.67 159.33 15.26 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.253 -0.647 . . . . 0.23000000000000001 109.253 175.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -0.991 0 C-N-CA 120.66 -0.781 . . . . 0.90000000000000002 112.133 178.223 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.57 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 18.9 m . . . . . 0 C--O 1.224 -0.268 0 N-CA-C 109.002 -0.74 . . . . 0.84999999999999998 109.002 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 11.0 t -140.18 146.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 O-C-N 122.171 -0.33 . . . . 0.25 110.761 -176.085 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.5 m -119.43 111.21 17.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.115 -0.493 . . . . 0.19 109.731 174.106 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.585 HD13 ' HE2' ' A' ' 66' ' ' MET . 62.4 mt -101.0 104.16 15.85 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 CA-C-N 115.705 -0.679 . . . . 0.14999999999999999 110.271 179.798 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 104.4 9.09 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.406 -0.816 . . . . 0.14000000000000001 108.995 176.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.469 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 53.4 m-85 -69.55 148.72 49.06 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.269 0.557 . . . . 0.32000000000000001 110.681 -177.592 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -70.69 -5.55 5.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 114.878 -1.055 . . . . 0.25 111.04 -171.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.423 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 30.4 t70 -81.57 -21.37 38.49 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.37 0.605 . . . . 0.75 110.42 174.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 117.13 -7.01 16.9 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.781 -0.723 . . . . 0.27000000000000002 112.275 -177.444 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 23.3 p -86.55 175.18 8.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.436 -0.209 . . . . 0.35999999999999999 110.436 177.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -149.53 150.49 32.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.706 0.289 . . . . 1.51 110.338 177.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.546 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.8 m -130.88 166.86 27.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.972 -0.558 . . . . 1.3899999999999999 111.006 179.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' VAL . . . . . 0.541 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.0 p -135.19 132.21 52.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 115.763 -0.653 . . . . 0.81000000000000005 110.819 179.241 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.57 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.3 mt -106.24 132.97 52.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.607 -0.724 . . . . 0.32000000000000001 109.838 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.14 -160.38 26.9 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.977 -0.63 . . . . 1.02 112.598 -178.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -104.07 141.7 15.32 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.595 -0.602 . . . . 0.40000000000000002 111.595 -176.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.408 ' HA ' ' O ' ' A' ' 40' ' ' THR . 32.9 t70 58.16 26.15 13.4 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 122.174 0.988 . . . . 1.26 109.313 -171.084 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -91.05 131.67 36.49 Favored 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.465 -1.243 . . . . 1.1899999999999999 110.967 -178.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ILE . . . . . 0.575 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.0 mt -129.08 106.12 13.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.092 -0.707 . . . . 0.38 109.092 178.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.28 144.47 31.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.096 -0.502 . . . . 1.0 110.555 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.6 tt0 -97.46 131.04 44.47 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.426 -0.352 . . . . 0.67000000000000004 110.303 -179.571 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.585 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.5 mmm -68.45 89.46 0.35 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.748 -0.66 . . . . 0.88 110.717 -178.307 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.416 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 44.9 p -112.13 -164.62 0.93 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.098 -0.501 . . . . 0.28999999999999998 111.456 -176.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -72.35 -25.52 61.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.941 0.4 . . . . 2.1299999999999999 110.852 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -71.05 -31.24 67.64 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 122.102 0.954 . . . . 2.5099999999999998 109.236 176.124 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.416 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.2 mm -78.77 -47.03 23.86 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 CA-C-N 113.844 -1.525 . . . . 0.25 110.832 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.694 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 . . . . . 0 C--N 1.318 -0.797 0 CA-C-N 115.281 -0.872 . . . . 0.31 110.061 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.693 0 N-CA-C 111.738 -0.545 . . . . 1.71 111.738 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 -100.93 144.98 29.22 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.805 -0.443 . . . . 2.0 109.805 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.78 114.55 15.67 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.334 0.588 . . . . 0.23999999999999999 110.342 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.79 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 23.1 pt -93.98 -14.39 8.17 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 115.197 -0.91 . . . . 0.14999999999999999 111.431 -172.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.47 42.79 Favored Glycine 0 CA--C 1.504 -0.64 0 C-N-CA 120.739 -0.743 . . . . 0.10000000000000001 111.84 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -143.54 151.09 39.82 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.989 0.423 . . . . 0.20000000000000001 110.822 -174.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.519 ' HB ' ' H ' ' A' ' 29' ' ' GLY . 23.8 mm -78.75 124.43 37.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.875 -0.602 . . . . 0.14000000000000001 111.528 -177.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.8 p -113.39 -26.17 8.47 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.323 0.582 . . . . 0.20000000000000001 110.771 177.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.565 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.9 tptt -137.89 139.62 39.94 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.786 -0.82 . . . . 2.3599999999999999 108.786 174.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.567 HD11 HG21 ' A' ' 14' ' ' VAL . 6.9 tt -152.74 144.91 23.87 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 120.776 0.322 . . . . 0.20000000000000001 110.164 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.474 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 0.2 OUTLIER -155.35 156.32 35.22 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.852 -0.613 . . . . 1.9399999999999999 110.662 179.124 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.12 -155.49 50.64 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.95 -0.568 . . . . 0.27000000000000002 112.809 176.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.3 t -99.43 126.0 45.25 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.186 -0.672 . . . . 1.1599999999999999 109.186 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.589 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -139.76 152.96 22.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.538 0.685 . . . . 0.20000000000000001 111.498 -176.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.51 158.78 44.06 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.625 -1.17 . . . . 0.17000000000000001 108.982 178.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.535 HG23 HG22 ' A' ' 38' ' ' VAL . 0.5 OUTLIER -132.68 131.83 59.75 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.235 0.54 . . . . 0.16 110.034 174.857 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -97.42 99.01 10.43 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 109.471 -0.566 . . . . 0.51000000000000001 109.471 178.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.567 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 39.9 m -62.2 171.59 1.76 Allowed 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.928 -0.578 . . . . 1.25 109.703 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.2 pt -65.98 -1.44 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 113.757 1.021 . . . . 0.58999999999999997 113.757 -170.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 49.6 m-80 -98.03 -2.16 40.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.303 0.573 . . . . 1.96 109.722 173.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.84 14.63 74.91 Favored Glycine 0 N--CA 1.447 -0.582 0 N-CA-C 110.61 -0.996 . . . . 0.32000000000000001 110.61 -176.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 mm100 -84.38 118.2 24.09 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.721 -0.74 . . . . 2.21 110.519 179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.417 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 4.9 tt0 -85.56 113.86 22.13 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.294 0.568 . . . . 1.0 110.483 -178.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -106.01 138.76 41.64 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 114.958 -1.019 . . . . 1.55 109.401 177.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -75.8 141.32 15.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 109.249 -0.648 . . . . 0.34999999999999998 109.249 177.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.589 ' HB2' HG23 ' A' ' 14' ' ' VAL . 5.1 mt -106.99 145.05 32.74 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 121.493 0.663 . . . . 0.32000000000000001 111.614 -178.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 35.7 mttp -137.51 169.22 18.15 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.461 -1.245 . . . . 1.6499999999999999 107.735 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -61.23 140.17 57.99 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 119.761 -0.776 . . . . 0.23000000000000001 109.798 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.519 ' H ' ' HB ' ' A' ' 7' ' ' ILE . . . 82.79 9.31 84.71 Favored Glycine 0 N--CA 1.437 -1.289 0 C-N-CA 120.052 -1.07 . . . . 0.23999999999999999 113.08 177.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.509 ' OD1' HG13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.76 147.98 56.54 Favored Pre-proline 0 C--O 1.236 0.355 0 CA-C-N 117.419 0.609 . . . . 1.9199999999999999 109.474 176.191 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -84.05 131.04 5.0 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.635 2.224 . . . . 0.22 113.219 178.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 mm -95.98 137.37 24.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.392 -0.822 . . . . 0.13 109.211 174.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -118.8 157.22 27.98 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-N 116.057 -0.52 . . . . 0.28999999999999998 109.699 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.526 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.8 t80 -73.85 116.02 13.97 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.078 -0.51 . . . . 0.17999999999999999 110.493 -174.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.19 -4.2 18.35 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.527 -0.844 . . . . 0.17000000000000001 113.736 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.567 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 24.6 mt-10 -84.93 149.06 25.9 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 117.971 0.886 . . . . 0.52000000000000002 110.993 -177.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.425 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 11.7 m -104.31 108.07 19.29 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.388 -0.823 . . . . 0.16 110.777 -178.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 16' ' ' VAL . 2.8 t -81.72 133.53 29.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 121.145 0.498 . . . . 0.16 110.613 -176.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -122.08 107.68 12.48 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.18 -0.918 . . . . 0.27000000000000002 109.964 -176.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.423 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 69.7 p -104.26 152.04 22.67 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 109.79 -0.448 . . . . 0.23000000000000001 109.79 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -130.29 135.14 8.16 Favored Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 120.928 -0.653 . . . . 0.90000000000000002 112.205 179.395 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 56.61 -108.35 1.18 Allowed Glycine 0 N--CA 1.451 -0.318 0 O-C-N 123.946 0.439 . . . . 1.79 113.491 177.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.5 m -90.48 28.95 1.36 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.934 0.397 . . . . 1.6399999999999999 111.198 -174.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.474 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -65.49 134.13 35.75 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 121.062 -0.59 . . . . 0.89000000000000001 112.365 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 6.0 m -152.62 121.81 6.68 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.968 -0.753 . . . . 0.84999999999999998 108.968 173.212 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 4.7 t -133.53 139.54 48.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.739 -0.384 . . . . 0.25 111.141 -173.671 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.588 ' HA ' ' O ' ' A' ' 56' ' ' VAL . 89.3 m -113.89 110.85 20.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.966 -0.561 . . . . 0.19 109.956 174.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.496 HD13 ' HE2' ' A' ' 66' ' ' MET . 69.3 mt -100.37 102.0 12.85 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.585 -0.734 . . . . 0.14999999999999999 110.24 178.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.6 107.79 11.53 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.431 -0.804 . . . . 0.14000000000000001 109.388 177.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.49 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 61.7 m-85 -70.86 149.7 46.52 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.633 0.73 . . . . 0.32000000000000001 111.287 -177.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -77.4 0.95 2.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 114.743 -1.117 . . . . 0.25 111.086 -172.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -90.51 -21.41 21.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.958 -0.564 . . . . 0.75 110.649 175.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.42 -18.11 5.8 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.639 -0.791 . . . . 0.27000000000000002 112.8 -178.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 3.2 p -84.81 171.64 12.1 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.644 0.222 . . . . 0.35999999999999999 111.119 178.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -130.26 -178.0 4.56 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.14 -0.689 . . . . 1.51 109.14 175.308 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.588 ' O ' ' HA ' ' A' ' 47' ' ' THR . 0.5 OUTLIER -160.24 151.32 5.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 1.3899999999999999 109.896 178.982 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.532 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.2 p -129.12 131.53 67.82 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.355 0.597 . . . . 0.81000000000000005 110.783 178.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.8 mt -107.28 137.18 39.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 115.668 -0.696 . . . . 0.32000000000000001 109.788 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.06 -164.28 29.53 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.932 -0.651 . . . . 1.02 112.578 -179.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.2 142.67 17.66 Favored Glycine 0 CA--C 1.504 -0.612 0 N-CA-C 111.547 -0.621 . . . . 0.40000000000000002 111.547 -174.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.423 ' HA ' ' O ' ' A' ' 40' ' ' THR . 37.7 t70 56.64 30.11 16.87 Favored 'General case' 0 CA--C 1.529 0.152 0 CA-C-O 122.151 0.977 . . . . 1.26 109.207 -172.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 m -112.28 163.27 14.57 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-N 114.656 -1.156 . . . . 1.1899999999999999 110.727 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . . . . . . . . . 83.4 mt -140.05 127.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.845 -0.616 . . . . 0.38 109.838 178.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.1 p -148.53 143.72 18.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 109.886 -0.413 . . . . 1.0 109.886 -177.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.425 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 29.8 tt0 -103.37 133.58 48.19 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.758 -0.377 . . . . 0.67000000000000004 110.323 -178.292 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.496 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.2 mmm -69.19 89.2 0.45 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.645 -0.707 . . . . 0.88 110.366 -177.797 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.412 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 19.2 p -115.95 -164.9 0.99 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.756 -0.656 . . . . 0.28999999999999998 111.39 -176.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -68.94 -41.15 78.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.524 -0.307 . . . . 2.1299999999999999 111.252 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -61.53 -30.08 70.41 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.636 0.731 . . . . 2.5099999999999998 110.306 177.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.412 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.3 mm -73.45 -52.52 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 114.497 -1.229 . . . . 0.25 110.806 176.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.79 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -104.88 79.72 1.55 Allowed 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.489 -0.778 . . . . 0.31 110.378 -176.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -77.89 106.48 9.76 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.427 -0.806 . . . . 1.46 109.791 176.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.9 p -81.29 131.92 35.31 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.136 -0.484 . . . . 0.68999999999999995 111.061 -178.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.72 -40.63 7.6 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.965 -0.636 . . . . 1.9099999999999999 112.336 -178.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 47.8 m-20 -81.63 -79.56 0.17 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.773 0.321 . . . . 5.5700000000000003 110.176 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.981 0 CA-C-O 118.909 -0.567 . . . . 6.8700000000000001 110.141 178.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.724 0 N-CA-C 111.926 -0.47 . . . . 1.71 111.926 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 69.16 147.83 0.06 Allowed 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.413 0.685 . . . . 2.0 111.613 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.26 109.91 12.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.827 -0.624 . . . . 0.23999999999999999 109.642 177.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.779 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.0 pt -92.77 -13.6 8.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 115.295 -0.866 . . . . 0.14999999999999999 112.074 -170.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.64 176.64 42.3 Favored Glycine 0 CA--C 1.501 -0.799 0 C-N-CA 120.69 -0.767 . . . . 0.10000000000000001 111.513 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -143.51 150.41 38.89 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.048 0.451 . . . . 0.20000000000000001 110.921 -174.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.542 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -78.22 123.38 34.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.683 -0.689 . . . . 0.14000000000000001 110.883 -177.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.7 p -115.44 -21.29 9.88 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.218 0.532 . . . . 0.20000000000000001 110.801 178.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.562 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 52.3 tptt -140.82 139.65 34.55 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.317 -0.994 . . . . 2.3599999999999999 108.317 172.29 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.602 HD11 HG21 ' A' ' 14' ' ' VAL . 5.8 tt -153.57 146.34 24.32 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 110.234 -0.284 . . . . 0.20000000000000001 110.234 -179.23 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.678 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 3.9 t70 -146.82 153.57 40.34 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.292 -0.413 . . . . 1.9399999999999999 110.654 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.61 -149.48 49.67 Favored Glycine 0 N--CA 1.45 -0.402 0 O-C-N 123.689 0.618 . . . . 0.27000000000000002 113.768 171.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.9 m -100.22 124.49 45.71 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.954 -0.387 . . . . 1.1599999999999999 109.954 -177.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.602 HG21 HD11 ' A' ' 10' ' ' LEU . 3.9 m -136.05 152.32 30.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.638 0.732 . . . . 0.20000000000000001 111.692 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.23 157.55 43.21 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.751 -1.113 . . . . 0.17000000000000001 108.647 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.682 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -135.81 134.94 51.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 C-N-CA 120.048 -0.661 . . . . 0.16 111.049 174.549 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.46 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.8 mt-30 -100.05 102.79 14.23 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.328 -0.851 . . . . 0.51000000000000001 109.599 177.426 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.568 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 61.4 p -61.46 178.87 0.26 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 111.473 0.175 . . . . 1.25 111.473 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.7 pt -59.42 -24.36 27.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.091 0.472 . . . . 0.58999999999999997 111.16 178.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -77.57 -16.64 58.51 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.829 -0.623 . . . . 1.96 110.402 177.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.33 7.31 62.17 Favored Glycine 0 CA--C 1.504 -0.6 0 N-CA-C 110.909 -0.877 . . . . 0.32000000000000001 110.909 -176.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 16.0 mm100 -77.74 116.02 17.95 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-N 115.159 -0.521 . . . . 2.21 110.69 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.542 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 13.4 tt0 -81.89 118.44 22.93 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.069 -0.514 . . . . 1.0 110.056 176.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HG2' HG12 ' A' ' 16' ' ' VAL . 36.0 ptt85 -120.33 169.62 10.11 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.838 -0.801 . . . . 1.55 108.838 174.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.411 ' O ' HD23 ' A' ' 26' ' ' LEU . 7.4 p -96.62 144.33 10.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 109.496 -0.557 . . . . 0.34999999999999998 109.496 -178.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.553 HD22 ' CG ' ' A' ' 30' ' ' ASP . 7.3 mt -112.68 160.73 17.62 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.124 0.487 . . . . 0.32000000000000001 110.987 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.621 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 0.2 OUTLIER -159.46 177.04 11.38 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.278 -0.874 . . . . 1.6499999999999999 109.027 -179.502 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 143.51 56.82 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 119.81 -0.756 . . . . 0.23000000000000001 109.99 -179.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.57 6.71 81.81 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.219 -0.991 . . . . 0.23999999999999999 112.41 178.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.621 ' HB3' ' O ' ' A' ' 27' ' ' LYS . 0.0 OUTLIER -85.37 142.27 37.65 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.399 0.618 . . . . 1.9199999999999999 110.793 178.325 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.36 134.79 11.54 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 123.58 2.853 . . . . 0.22 113.756 -179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.8 mm -100.49 136.9 29.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.35 -0.841 . . . . 0.13 109.238 172.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -116.29 153.12 32.51 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 116.224 -0.444 . . . . 0.28999999999999998 110.134 -178.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.559 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -71.37 114.5 9.5 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.058 -0.519 . . . . 0.17999999999999999 110.869 -174.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.95 0.56 24.16 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.497 -0.858 . . . . 0.17000000000000001 113.279 178.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.568 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 34.7 mt-10 -84.28 147.7 27.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.676 0.738 . . . . 0.52000000000000002 110.465 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.496 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 22.2 m -106.59 106.88 17.61 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.462 -0.79 . . . . 0.16 110.488 -177.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.555 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -81.85 125.96 39.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-O 121.205 0.526 . . . . 0.16 110.916 -174.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -113.16 106.39 14.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.028 -0.987 . . . . 0.27000000000000002 109.454 179.124 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.485 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 73.0 p -101.93 157.42 16.87 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 120.44 -0.504 . . . . 0.23000000000000001 109.997 178.183 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -139.74 140.09 10.47 Favored Glycine 0 N--CA 1.441 -1.022 0 CA-C-N 115.631 -0.713 . . . . 0.90000000000000002 111.644 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 62.07 -121.37 25.39 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 121.307 -0.473 . . . . 1.79 112.562 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 97.5 p -86.84 25.33 1.31 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.862 0.331 . . . . 1.6399999999999999 110.9 -178.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.678 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -58.74 94.63 0.05 OUTLIER Glycine 0 C--O 1.222 -0.656 0 CA-C-N 116.096 -0.502 . . . . 0.89000000000000001 112.772 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.5 m -120.26 112.35 18.94 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.231 -0.655 . . . . 0.84999999999999998 109.231 -175.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.8 t -126.5 130.43 71.79 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 C-N-CA 120.677 -0.409 . . . . 0.25 111.878 -169.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.562 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 97.2 m -106.79 108.85 20.57 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.781 -0.645 . . . . 0.19 109.751 175.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.549 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 62.3 mt -97.73 105.35 17.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-N 115.623 -0.717 . . . . 0.14999999999999999 110.117 177.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.81 105.42 11.08 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.413 -0.812 . . . . 0.14000000000000001 109.042 176.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.448 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 62.5 m-85 -71.18 146.79 48.88 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.508 0.67 . . . . 0.32000000000000001 110.867 -177.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.59 2.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-N 114.634 -1.166 . . . . 0.25 111.582 -171.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -94.66 -20.68 19.35 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.076 -0.511 . . . . 0.75 110.384 177.316 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.0 -17.65 7.12 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.66 -0.781 . . . . 0.27000000000000002 112.552 -178.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.7 p -82.99 155.7 23.83 Favored 'General case' 0 C--N 1.324 -0.503 0 O-C-N 122.903 -0.175 . . . . 0.35999999999999999 110.866 178.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -132.33 143.26 49.74 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 109.897 -0.408 . . . . 1.51 109.897 178.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.549 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 10.7 m -124.44 168.56 16.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.068 0.461 . . . . 1.3899999999999999 111.584 178.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.506 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.7 p -138.78 133.37 41.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-N 115.331 -0.849 . . . . 0.81000000000000005 110.25 177.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -106.34 136.15 42.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 115.99 -0.55 . . . . 0.32000000000000001 109.929 -179.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.49 178.71 53.74 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.551 -0.833 . . . . 1.02 111.606 177.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.0 151.08 19.93 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 111.584 -0.607 . . . . 0.40000000000000002 111.584 -172.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.485 ' HA ' ' O ' ' A' ' 40' ' ' THR . 34.5 t70 51.15 28.48 4.08 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 121.379 0.609 . . . . 1.26 110.509 -171.22 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.5 t -104.72 161.71 13.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.882 -0.599 . . . . 1.1899999999999999 110.761 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.555 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 81.3 mt -138.92 123.15 20.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.629 -0.714 . . . . 0.38 109.51 178.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -147.14 137.04 16.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.935 0.398 . . . . 1.0 110.855 -178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.496 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.7 tt0 -91.46 131.84 36.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.315 -0.402 . . . . 0.67000000000000004 110.41 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.539 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.2 mmm -71.68 89.18 1.0 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 0.88 110.6 -178.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.2 p -111.05 -166.77 1.11 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.092 -0.504 . . . . 0.28999999999999998 110.9 -178.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -72.9 -27.89 62.15 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.013 0.435 . . . . 2.1299999999999999 110.044 178.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -65.46 -30.09 70.84 Favored 'General case' 0 CA--C 1.521 -0.144 0 CA-C-O 121.882 0.849 . . . . 2.5099999999999998 109.789 174.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.438 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.0 OUTLIER -80.51 -54.02 11.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 114.457 -1.247 . . . . 0.25 110.732 176.777 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.779 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -98.0 79.76 2.65 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.407 -0.815 . . . . 0.31 109.772 -177.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -80.55 98.68 7.72 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.634 -0.712 . . . . 1.46 109.892 178.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 10.3 p -71.17 135.25 47.48 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.081 -0.509 . . . . 0.68999999999999995 111.261 -178.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 131.35 42.17 0.2 Allowed Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.525 -0.845 . . . . 1.9099999999999999 112.711 178.152 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -65.99 -37.44 85.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.222 0.534 . . . . 5.5700000000000003 110.036 175.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 14.8 m120 . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.569 -0.729 . . . . 6.8700000000000001 109.715 175.392 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.705 0 N-CA-C 111.811 -0.516 . . . . 1.71 111.811 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 69.35 152.68 0.1 Allowed 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 123.091 0.557 . . . . 2.0 110.937 179.198 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.53 109.85 16.37 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.485 0.66 . . . . 0.23999999999999999 109.817 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.759 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.3 pt -95.11 -12.32 8.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 114.945 -1.025 . . . . 0.14999999999999999 111.777 -171.215 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.49 179.26 41.09 Favored Glycine 0 CA--C 1.5 -0.853 0 C-N-CA 120.684 -0.769 . . . . 0.10000000000000001 111.698 178.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.455 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 92.3 m-85 -144.41 152.13 40.23 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.76 0.314 . . . . 0.20000000000000001 110.535 -176.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.507 HG12 ' O ' ' A' ' 30' ' ' ASP . 33.0 mm -79.77 122.48 35.07 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.441 -0.345 . . . . 0.14000000000000001 110.86 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.0 p -115.72 -21.59 9.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.207 0.527 . . . . 0.20000000000000001 110.966 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.552 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.8 tttt -141.87 144.94 34.09 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 108.219 -1.03 . . . . 2.3599999999999999 108.219 173.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.425 HD11 HG21 ' A' ' 14' ' ' VAL . 6.5 tt -158.95 146.54 17.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.877 0.37 . . . . 0.20000000000000001 111.029 -177.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.449 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 9.0 t70 -153.36 152.14 30.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.811 -0.631 . . . . 1.9399999999999999 110.854 179.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.15 -154.42 44.58 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.129 -0.558 . . . . 0.27000000000000002 113.112 173.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 49.4 m -103.34 120.78 41.43 Favored 'General case' 0 N--CA 1.443 -0.822 0 N-CA-C 109.804 -0.443 . . . . 1.1599999999999999 109.804 -176.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.514 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.0 m -138.35 152.1 25.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.769 0.795 . . . . 0.20000000000000001 111.596 -176.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.41 159.43 44.47 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 114.64 -1.164 . . . . 0.17000000000000001 108.463 178.039 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.682 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -132.95 136.45 55.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 119.86 -0.736 . . . . 0.16 110.94 174.377 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -101.05 102.51 13.5 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.295 -0.866 . . . . 0.51000000000000001 109.843 177.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.533 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 7.6 p -63.01 172.08 1.93 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.854 -0.338 . . . . 1.25 110.507 -178.436 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -54.42 -33.31 25.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 112.767 0.654 . . . . 0.58999999999999997 112.767 -173.609 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.8 p30 -80.09 -5.03 55.17 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.926 0.393 . . . . 1.96 111.512 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.17 14.73 44.21 Favored Glycine 0 CA--C 1.507 -0.441 0 C-N-CA 121.276 -0.488 . . . . 0.32000000000000001 112.376 174.445 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.404 ' HB2' ' OG ' ' A' ' 18' ' ' SER . 17.3 mm100 -86.55 116.86 24.96 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.865 0.364 . . . . 2.21 110.753 -178.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.544 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.5 tt0 -84.47 117.52 23.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.371 179.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HG2' HG12 ' A' ' 16' ' ' VAL . 29.4 ptt85 -119.09 168.32 10.95 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.722 -0.473 . . . . 1.55 109.722 177.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.9 p -94.59 135.03 30.01 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.003 -0.544 . . . . 0.34999999999999998 110.372 -176.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.514 ' HB2' HG23 ' A' ' 14' ' ' VAL . 15.2 mt -103.08 118.39 36.7 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.605 0.717 . . . . 0.32000000000000001 110.321 178.447 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 23.1 mtmm -114.0 176.88 4.85 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.493 -1.23 . . . . 1.6499999999999999 107.703 174.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.3 tp -67.69 134.53 51.24 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 119.042 -1.063 . . . . 0.23000000000000001 109.424 178.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.15 -12.22 66.95 Favored Glycine 0 N--CA 1.434 -1.481 0 C-N-CA 119.676 -1.25 . . . . 0.23999999999999999 112.564 177.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.507 ' O ' HG12 ' A' ' 7' ' ' ILE . 10.7 m-20 -67.76 140.26 94.08 Favored Pre-proline 0 CA--C 1.514 -0.412 0 C-N-CA 120.219 -0.592 . . . . 1.9199999999999999 109.857 175.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.455 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 29.7 Cg_endo -86.1 144.48 8.29 Favored 'Trans proline' 0 N--CA 1.453 -0.883 0 C-N-CA 123.003 2.468 . . . . 0.22 111.834 -179.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.0 mm -100.62 138.74 23.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.639 -0.504 . . . . 0.13 109.639 176.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -114.61 149.7 36.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.174 -0.466 . . . . 0.28999999999999998 109.836 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.522 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.8 t80 -68.6 109.58 3.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.096 -0.502 . . . . 0.17999999999999999 110.638 -175.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 123.8 -3.98 9.23 Favored Glycine 0 N--CA 1.447 -0.603 0 C-N-CA 120.553 -0.832 . . . . 0.17000000000000001 113.673 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.533 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.0 mt-10 -82.3 150.49 27.22 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 117.851 0.825 . . . . 0.52000000000000002 110.981 -177.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 13.9 m -108.42 107.7 18.35 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.537 -0.756 . . . . 0.16 110.767 -177.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.603 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -79.04 137.05 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.3 0.571 . . . . 0.16 110.845 -175.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -123.46 99.25 6.23 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.043 -0.981 . . . . 0.27000000000000002 109.665 -177.413 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.5 p -101.01 153.46 19.52 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 121.119 0.485 . . . . 0.23000000000000001 110.158 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -116.99 -153.0 9.72 Favored Glycine 0 N--CA 1.442 -0.917 0 CA-C-N 115.423 -0.808 . . . . 0.90000000000000002 111.65 178.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -61.38 131.23 47.37 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.962 -0.637 . . . . 1.79 112.26 -178.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 18.8 m 63.66 19.83 11.92 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 122.94 0.496 . . . . 1.6399999999999999 111.049 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.51 132.83 23.04 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.78 -0.724 . . . . 0.89000000000000001 111.647 177.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.494 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 36.8 m -152.66 134.69 14.85 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.052 -0.722 . . . . 0.84999999999999998 109.052 175.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.595 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.9 t -145.71 132.21 14.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.795 0 C-N-CA 120.548 -0.461 . . . . 0.25 110.968 -176.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.552 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -106.69 105.96 16.26 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.103 0.478 . . . . 0.19 109.949 174.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.535 HD13 ' HE2' ' A' ' 66' ' ' MET . 60.7 mt -96.38 103.15 14.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.672 -0.694 . . . . 0.14999999999999999 110.082 177.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 106.04 10.19 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.229 -0.896 . . . . 0.14000000000000001 109.193 176.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.434 ' CE1' HG22 ' A' ' 56' ' ' VAL . 58.0 m-85 -71.43 146.75 48.47 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.591 0.71 . . . . 0.32000000000000001 110.916 -177.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.5 p -71.42 -12.41 15.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.572 -1.195 . . . . 0.25 111.512 -170.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.649 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 21.0 t70 -79.39 -21.04 46.23 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.289 -0.414 . . . . 0.75 110.736 178.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.75 -8.91 7.25 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.517 -0.849 . . . . 0.27000000000000002 112.717 -179.098 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.7 p -90.48 175.35 7.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.579 0.228 . . . . 0.35999999999999999 110.897 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -151.79 148.45 27.87 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.72 -0.474 . . . . 1.51 109.72 176.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.529 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.2 m -129.36 165.63 28.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 120.989 0.423 . . . . 1.3899999999999999 111.352 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.595 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.7 p -135.56 128.56 47.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-N 115.316 -0.856 . . . . 0.81000000000000005 110.426 177.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.494 ' O ' ' HA ' ' A' ' 45' ' ' SER . 18.5 mt -101.03 139.58 21.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.373 -0.83 . . . . 0.32000000000000001 109.988 -178.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.52 -157.77 29.08 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.775 -0.726 . . . . 1.02 111.952 178.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -114.43 148.87 18.83 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.986 -0.625 . . . . 0.40000000000000002 111.664 -173.116 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.0 t70 56.87 27.37 12.88 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.96 0.886 . . . . 1.26 109.708 -174.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.5 t -105.3 157.64 17.17 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.372 -0.831 . . . . 1.1899999999999999 110.579 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.603 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.0 mt -142.79 106.2 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 109.191 -0.67 . . . . 0.38 109.191 -179.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -133.49 146.31 32.27 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-O 121.027 0.441 . . . . 1.0 111.339 -175.341 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -99.46 131.44 45.46 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.793 -0.64 . . . . 0.67000000000000004 110.354 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.535 ' HE2' HD13 ' A' ' 48' ' ' ILE . 51.0 mmm -68.18 89.15 0.31 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.454 -0.794 . . . . 0.88 110.315 -178.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.428 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 20.1 p -116.55 -166.99 1.21 Allowed 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.653 -0.703 . . . . 0.28999999999999998 111.16 -175.35 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -63.89 -38.31 90.62 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.051 0.453 . . . . 2.1299999999999999 110.647 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -62.75 -28.75 70.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.587 0.708 . . . . 2.5099999999999998 110.614 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.428 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.4 mm -81.97 -51.28 15.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.052 0 CA-C-N 114.904 -1.044 . . . . 0.25 110.939 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.759 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -102.7 83.63 2.29 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.553 -0.749 . . . . 0.31 109.845 -177.176 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.9 t-20 -71.96 97.94 1.96 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.477 -0.783 . . . . 1.46 109.89 175.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 11.1 p -80.61 127.94 33.04 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.987 -0.551 . . . . 0.68999999999999995 110.903 -178.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -143.18 72.4 0.37 Allowed Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 120.732 -0.747 . . . . 1.9099999999999999 111.956 -179.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -84.64 94.9 8.73 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.936 0.398 . . . . 5.5700000000000003 110.361 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 . . . . . 0 C--O 1.251 1.133 0 CA-C-O 118.315 -0.85 . . . . 6.8700000000000001 110.438 179.506 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.609 0 N-CA-C 112.069 -0.412 . . . . 1.71 112.069 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 74.3 m-20 -95.1 174.96 6.81 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 110.153 -0.314 . . . . 2.0 110.153 177.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 109.62 6.79 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 121.374 0.607 . . . . 0.23999999999999999 110.019 179.117 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.798 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.6 pt -91.83 -13.66 8.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.017 -0.992 . . . . 0.14999999999999999 111.427 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.93 178.55 43.34 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.794 -0.717 . . . . 0.10000000000000001 111.415 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -144.73 150.38 37.17 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.8 0.333 . . . . 0.20000000000000001 110.425 -174.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.59 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.3 mm -77.12 124.19 35.08 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.026 -0.534 . . . . 0.14000000000000001 111.596 -175.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.3 p -116.1 -22.51 8.91 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.887 0.375 . . . . 0.20000000000000001 110.747 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.578 ' HB2' ' HB ' ' A' ' 47' ' ' THR . 6.4 tmtt? -134.38 144.34 48.15 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 109.364 -0.606 . . . . 2.3599999999999999 109.364 170.677 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.442 HD11 HG21 ' A' ' 14' ' ' VAL . 6.2 tt -156.38 141.68 17.48 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.089 -0.505 . . . . 0.20000000000000001 110.327 177.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -154.54 158.74 40.29 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.725 -0.671 . . . . 1.9399999999999999 110.75 -177.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 68.48 -140.56 35.48 Favored Glycine 0 N--CA 1.446 -0.635 0 CA-C-N 115.806 -0.634 . . . . 0.27000000000000002 113.074 175.487 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.3 t -112.46 122.99 49.28 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.294 -0.632 . . . . 1.1599999999999999 109.294 -178.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.515 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.2 m -136.06 152.16 30.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.7 0.762 . . . . 0.20000000000000001 111.496 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.25 158.46 43.91 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 114.674 -1.148 . . . . 0.17000000000000001 108.881 179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.676 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -136.51 135.44 49.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 C-N-CA 119.94 -0.704 . . . . 0.16 110.946 173.512 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.434 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.0 mt-30 -103.22 99.87 9.75 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.973 -1.012 . . . . 0.51000000000000001 109.68 177.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.504 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.2 m -60.76 174.41 0.61 Allowed 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.6 -0.273 . . . . 1.25 110.713 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 13.4 pt -59.42 -27.8 38.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 118.337 0.517 . . . . 0.58999999999999997 112.052 -174.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 14.5 p30 -77.46 -9.33 58.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.068 -0.515 . . . . 1.96 110.982 177.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.42 3.02 60.06 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 121.351 -0.452 . . . . 0.32000000000000001 112.342 175.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -75.06 122.02 22.91 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.704 0.288 . . . . 2.21 111.271 -179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.614 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.7 tt0 -92.8 123.18 35.89 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.919 -0.582 . . . . 1.0 110.193 177.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.676 ' HG2' HG12 ' A' ' 16' ' ' VAL . 19.4 ptt-85 -123.0 166.47 15.05 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.543 -0.54 . . . . 1.55 109.543 175.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -89.81 134.45 28.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 N-CA-C 109.109 -0.7 . . . . 0.34999999999999998 109.109 177.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.516 HD22 ' CG ' ' A' ' 30' ' ' ASP . 5.3 mt -97.36 153.34 18.14 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.243 0.544 . . . . 0.32000000000000001 111.111 -178.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.4 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 46.1 mttt -141.27 178.2 7.57 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.958 -1.019 . . . . 1.6499999999999999 108.395 -176.393 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -71.94 144.23 49.01 Favored 'General case' 0 C--N 1.315 -0.908 0 C-N-CA 119.392 -0.923 . . . . 0.23000000000000001 109.203 177.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.53 -6.07 58.91 Favored Glycine 0 N--CA 1.44 -1.038 0 C-N-CA 120.247 -0.978 . . . . 0.23999999999999999 112.338 178.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.59 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -70.66 142.84 89.07 Favored Pre-proline 0 C--N 1.332 -0.184 0 CA-C-O 121.388 0.613 . . . . 1.9199999999999999 110.157 179.414 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 24.3 Cg_endo -87.49 128.87 2.6 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 123.627 2.884 . . . . 0.22 113.485 -174.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.8 mm -93.62 137.05 23.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.011 -0.54 . . . . 0.13 109.745 177.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -115.06 151.39 34.35 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 116.052 -0.522 . . . . 0.28999999999999998 109.733 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.552 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -68.94 114.07 6.91 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.246 -0.433 . . . . 0.17999999999999999 110.494 -176.556 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.49 0.41 18.29 Favored Glycine 0 N--CA 1.445 -0.756 0 C-N-CA 120.398 -0.906 . . . . 0.17000000000000001 113.54 177.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.504 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 30.2 mt-10 -88.53 146.51 25.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 118.071 0.936 . . . . 0.52000000000000002 110.882 -177.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.472 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.0 m -103.49 107.88 18.9 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.422 -0.808 . . . . 0.16 110.943 -176.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.474 HG22 HG23 ' A' ' 16' ' ' VAL . 3.9 t -84.0 130.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 CA-C-O 121.153 0.502 . . . . 0.16 110.869 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -115.57 109.57 17.98 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.245 -0.889 . . . . 0.27000000000000002 109.532 -179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 64.8 p -107.94 146.5 32.33 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.877 -0.416 . . . . 0.23000000000000001 109.877 178.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -125.69 147.57 16.66 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.934 -0.65 . . . . 0.90000000000000002 111.766 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.4 -112.55 3.07 Favored Glycine 0 N--CA 1.449 -0.462 0 O-C-N 123.922 0.424 . . . . 1.79 113.668 177.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.3 m -97.61 34.31 1.87 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.057 0.456 . . . . 1.6399999999999999 110.847 -175.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.24 133.9 52.56 Favored Glycine 0 N--CA 1.448 -0.511 0 CA-C-N 115.672 -0.694 . . . . 0.89000000000000001 112.276 177.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 36.7 m -152.8 124.61 7.87 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.434 -0.58 . . . . 0.84999999999999998 109.434 174.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.9 t -141.18 128.06 20.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-O 120.621 0.248 . . . . 0.25 110.945 -173.083 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.578 ' HB ' ' HB2' ' A' ' 9' ' ' LYS . 92.8 m -101.27 107.93 19.43 Favored 'General case' 0 C--N 1.316 -0.862 0 N-CA-C 109.559 -0.534 . . . . 0.19 109.559 173.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.475 HD13 ' HE2' ' A' ' 66' ' ' MET . 84.6 mt -95.69 101.54 12.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.556 -0.747 . . . . 0.14999999999999999 109.995 176.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.77 102.65 8.23 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.438 -0.801 . . . . 0.14000000000000001 109.329 177.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.563 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 55.5 m-85 -65.54 152.95 42.84 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.32000000000000001 111.22 -177.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -79.04 -3.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-N 114.664 -1.153 . . . . 0.25 110.917 -172.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.573 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 18.6 t70 -85.71 -21.45 28.29 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 115.605 -0.725 . . . . 0.75 110.44 177.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.55 -11.65 11.21 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.764 -0.731 . . . . 0.27000000000000002 112.122 -176.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.2 p -88.07 157.53 18.84 Favored 'General case' 0 C--N 1.323 -0.555 0 O-C-N 122.879 -0.189 . . . . 0.35999999999999999 110.609 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -124.64 160.32 28.76 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.669 -0.493 . . . . 1.51 109.669 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.558 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.3 154.45 16.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 116.466 -0.334 . . . . 1.3899999999999999 110.108 -179.191 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.563 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -132.96 133.11 59.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.178 0.514 . . . . 0.81000000000000005 110.596 178.064 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 18.7 mt -101.57 143.63 14.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.901 -0.591 . . . . 0.32000000000000001 110.192 -179.425 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -85.7 -164.91 39.78 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.842 -0.694 . . . . 1.02 111.998 177.049 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -115.52 153.0 17.84 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.251 -0.74 . . . . 0.40000000000000002 111.251 -174.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.3 t70 57.25 23.71 9.05 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 121.77 0.795 . . . . 1.26 109.665 -173.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -110.16 160.69 16.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.777 -0.647 . . . . 1.1899999999999999 111.369 -176.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.429 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -139.8 125.26 21.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.422 -0.808 . . . . 0.38 109.382 177.425 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.3 p -148.64 140.73 18.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.925 0.393 . . . . 1.0 110.96 -176.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.472 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.8 tt0 -95.5 132.57 40.46 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.456 -0.338 . . . . 0.67000000000000004 110.198 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.477 ' HE3' HG21 ' A' ' 70' ' ' ILE . 58.1 mmm -70.21 89.49 0.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.736 -0.666 . . . . 0.88 110.499 -178.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 36.0 p -117.06 -165.19 1.04 Allowed 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.878 -0.601 . . . . 0.28999999999999998 111.138 -177.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -64.42 -36.38 83.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.934 0.397 . . . . 2.1299999999999999 110.888 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -65.96 -22.35 66.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.625 0.726 . . . . 2.5099999999999998 110.313 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.477 HG21 ' HE3' ' A' ' 66' ' ' MET . 1.4 mm -87.06 -56.31 5.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 114.986 -1.007 . . . . 0.25 111.023 176.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.798 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -95.4 86.0 4.38 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.574 -0.739 . . . . 0.31 110.2 -173.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -64.99 102.6 0.63 Allowed 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.95 -1.023 . . . . 1.46 109.737 171.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.441 ' HB ' ' OD1' ' A' ' 75' ' ' ASP . 26.7 p -95.36 140.92 29.56 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.099 -0.5 . . . . 0.68999999999999995 111.291 -176.556 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.414 ' H ' ' CG ' ' A' ' 52' ' ' ASP . . . -101.04 -12.99 35.05 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.898 -0.668 . . . . 1.9099999999999999 111.481 178.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.441 ' OD1' ' HB ' ' A' ' 73' ' ' THR . 5.5 p-10 -76.82 -20.67 56.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.47 0.176 . . . . 5.5700000000000003 110.534 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 18.6 m120 . . . . . 0 C--O 1.247 0.936 0 CA-C-O 118.135 -0.936 . . . . 6.8700000000000001 110.867 -179.627 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.708 0 N-CA-C 112.037 -0.425 . . . . 1.71 112.037 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.58 158.53 15.39 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.762 -0.458 . . . . 2.0 109.762 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -72.77 112.58 8.94 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.365 0.602 . . . . 0.23999999999999999 110.47 -178.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.796 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 35.6 pt -95.94 -15.76 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 114.978 -1.01 . . . . 0.14999999999999999 111.937 -171.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.09 175.99 40.88 Favored Glycine 0 CA--C 1.499 -0.941 0 C-N-CA 120.615 -0.803 . . . . 0.10000000000000001 111.812 -177.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -145.07 147.44 32.57 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.042 0.449 . . . . 0.20000000000000001 110.661 -174.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.583 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.77 123.07 33.88 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 115.579 -0.737 . . . . 0.14000000000000001 110.964 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.2 p -112.41 -23.67 10.19 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 121.347 0.594 . . . . 0.20000000000000001 110.718 178.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.478 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.6 tptt -141.6 138.73 32.81 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 108.667 -0.864 . . . . 2.3599999999999999 108.667 175.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.46 HD11 HG21 ' A' ' 14' ' ' VAL . 5.7 tt -149.66 144.86 26.4 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 120.721 0.296 . . . . 0.20000000000000001 110.71 -178.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.467 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 14.1 t70 -152.65 153.33 33.1 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.015 -0.539 . . . . 1.9399999999999999 110.394 -177.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.16 -149.85 41.46 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 121.002 -0.618 . . . . 0.27000000000000002 113.164 174.078 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.2 t -108.0 123.84 49.26 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 109.31 -0.626 . . . . 1.1599999999999999 109.31 -177.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 26' ' ' LEU . 4.3 m -136.37 152.28 29.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.855 0.836 . . . . 0.20000000000000001 112.296 -175.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.03 158.88 44.68 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 114.422 -1.263 . . . . 0.17000000000000001 108.795 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.679 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.1 p -135.73 139.17 46.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 C-N-CA 120.042 -0.663 . . . . 0.16 110.895 173.097 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' GLN . 1.3 mt-30 -107.85 102.12 11.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.316 -0.856 . . . . 0.51000000000000001 110.077 177.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.518 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 11.6 m -63.91 172.26 2.38 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.462 -0.57 . . . . 1.25 109.462 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 22.0 pt -57.78 -30.0 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 119.031 0.832 . . . . 0.58999999999999997 112.521 -172.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.504 ' HB2' ' HG3' ' A' ' 22' ' ' GLN . 87.3 m-20 -63.94 -26.8 68.75 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.164 0.507 . . . . 1.96 110.826 175.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 106.33 13.3 23.16 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.505 -0.77 . . . . 0.32000000000000001 111.691 -174.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.504 ' HG3' ' HB2' ' A' ' 20' ' ' ASN . 21.5 mt-30 -77.1 116.72 17.99 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.947 -0.126 . . . . 2.21 110.885 -179.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.679 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 24.4 tt0 -93.76 117.66 30.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.876 0.369 . . . . 1.0 110.485 176.359 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.655 ' HG2' HG12 ' A' ' 16' ' ' VAL . 23.9 ptt-85 -120.11 166.95 12.72 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.209 -0.663 . . . . 1.55 109.209 175.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.1 p -91.2 131.71 37.63 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.885 0 N-CA-C 109.47 -0.567 . . . . 0.34999999999999998 109.47 178.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' HG23 ' A' ' 14' ' ' VAL . 5.4 mt -94.25 156.49 16.51 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.852 -0.613 . . . . 0.32000000000000001 111.014 -178.124 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 14.4 mttp -143.54 177.9 8.15 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 108.321 -0.992 . . . . 1.6499999999999999 108.321 -172.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.61 142.18 46.55 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 118.973 -1.091 . . . . 0.23000000000000001 108.77 174.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.5 5.3 85.78 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 119.982 -1.104 . . . . 0.23999999999999999 112.173 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.583 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -80.47 139.09 51.4 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.671 0.748 . . . . 1.9199999999999999 110.739 178.942 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -77.03 130.6 11.38 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 123.685 2.924 . . . . 0.22 113.382 -179.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 mm -97.42 136.04 29.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.344 -0.844 . . . . 0.13 109.018 174.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 -115.16 151.4 34.46 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 116.194 -0.457 . . . . 0.28999999999999998 110.101 -178.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.542 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -67.64 118.82 11.44 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.891 -0.595 . . . . 0.17999999999999999 110.531 -175.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.74 1.1 30.59 Favored Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 120.583 -0.818 . . . . 0.17000000000000001 113.203 177.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.524 ' O ' ' HG2' ' A' ' 66' ' ' MET . 34.4 mt-10 -88.62 146.15 25.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 117.9 0.85 . . . . 0.52000000000000002 110.644 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 11.3 m -104.34 106.85 17.51 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.249 -0.887 . . . . 0.16 110.738 -174.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.7 t -82.63 122.62 37.46 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-O 121.206 0.527 . . . . 0.16 110.883 -174.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.1 mp -105.76 109.27 21.18 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.135 -0.938 . . . . 0.27000000000000002 109.441 178.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.5 p -107.54 148.35 29.35 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.955 -0.387 . . . . 0.23000000000000001 109.955 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.32 138.47 9.54 Favored Glycine 0 N--CA 1.442 -0.912 0 C-N-CA 120.776 -0.726 . . . . 0.90000000000000002 111.984 177.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.95 71.18 0.77 Allowed Glycine 0 N--CA 1.447 -0.571 0 O-C-N 123.959 0.447 . . . . 1.79 113.092 178.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 65.0 m 53.89 39.33 30.31 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.817 0.342 . . . . 1.6399999999999999 111.734 179.005 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.513 ' N ' ' HA3' ' A' ' 60' ' ' GLY . . . -60.09 96.83 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.411 0 N-CA-C 111.395 -0.682 . . . . 0.89000000000000001 111.395 172.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.617 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 3.1 m -101.77 109.6 21.4 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.55 -0.537 . . . . 0.84999999999999998 109.55 -171.13 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.9 t -130.9 119.43 45.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 CA-C-N 116.048 -0.524 . . . . 0.25 111.278 -170.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.478 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.0 m -95.13 104.27 16.14 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.455 -0.793 . . . . 0.19 109.873 176.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.467 HD13 ' HE2' ' A' ' 66' ' ' MET . 60.2 mt -94.83 99.66 9.78 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-N 115.274 -0.875 . . . . 0.14999999999999999 109.697 177.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.21 110.11 16.38 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.413 -0.812 . . . . 0.14000000000000001 109.444 178.452 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.524 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 59.0 m-85 -73.14 151.86 41.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.635 0.731 . . . . 0.32000000000000001 111.128 -176.055 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.3 p -72.38 -5.89 6.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 114.548 -1.205 . . . . 0.25 110.671 -174.073 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -79.39 -21.37 45.76 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.079 -0.964 . . . . 0.75 110.938 176.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.11 -11.86 34.11 Favored Glycine 0 N--CA 1.446 -0.656 0 N-CA-C 111.099 -0.8 . . . . 0.27000000000000002 111.099 -173.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.3 p -83.3 154.67 24.0 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.267 -0.466 . . . . 0.35999999999999999 109.959 175.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -126.88 156.79 40.85 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 120.777 -0.369 . . . . 1.51 110.454 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.524 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -139.44 152.0 23.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-N 115.905 -0.589 . . . . 1.3899999999999999 109.648 178.233 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -136.62 133.21 48.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-O 121.312 0.577 . . . . 0.81000000000000005 110.994 179.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.617 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -100.37 138.28 25.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.692 -0.685 . . . . 0.32000000000000001 109.46 178.341 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.08 -51.24 5.87 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 121.109 -0.567 . . . . 1.02 112.34 -179.114 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.513 ' HA3' ' N ' ' A' ' 44' ' ' GLY . . . 133.16 172.49 13.0 Favored Glycine 0 CA--C 1.505 -0.568 0 CA-C-O 119.083 -0.843 . . . . 0.40000000000000002 111.521 176.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 38.3 47.07 0.97 Allowed 'General case' 0 N--CA 1.471 0.604 0 CA-C-O 122.063 0.935 . . . . 1.26 110.559 -171.507 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.1 t -138.79 163.36 32.42 Favored 'General case' 0 N--CA 1.448 -0.57 0 CA-C-N 114.493 -1.231 . . . . 1.1899999999999999 109.785 -176.287 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.472 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 84.5 mt -140.26 113.97 5.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 N-CA-C 109.491 -0.559 . . . . 0.38 109.491 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.5 p -138.66 142.38 34.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.93 0.395 . . . . 1.0 110.885 -175.098 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 45.0 tt0 -96.04 131.94 41.91 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.145 -0.48 . . . . 0.67000000000000004 110.406 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.546 ' CE ' HG21 ' A' ' 70' ' ' ILE . 59.9 mmm -71.07 88.97 0.8 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.643 -0.708 . . . . 0.88 110.72 -178.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 p -117.62 -162.42 0.87 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.245 -0.434 . . . . 0.28999999999999998 110.369 -179.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -71.36 -28.51 64.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.051 0.453 . . . . 2.1299999999999999 110.26 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 -64.49 -24.05 67.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.916 0.865 . . . . 2.5099999999999998 109.859 176.011 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.546 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.3 mm -91.67 -53.21 9.09 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 114.509 -1.223 . . . . 0.25 110.583 175.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.796 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 -111.41 72.77 0.79 Allowed 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.123 -0.944 . . . . 0.31 110.634 -174.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -87.96 103.25 15.51 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.852 -0.795 . . . . 1.46 108.852 171.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.0 p -60.79 138.11 58.14 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.753 -0.658 . . . . 0.68999999999999995 112.265 -173.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -101.83 -19.43 15.29 Favored Glycine 0 N--CA 1.445 -0.733 0 CA-C-N 115.698 -0.683 . . . . 1.9099999999999999 111.944 179.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -110.94 80.05 1.26 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.087 0.47 . . . . 5.5700000000000003 110.46 179.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.414 ' N ' HD22 ' A' ' 76' ' ' ASN . 0.9 OUTLIER . . . . . 0 C--O 1.248 1.0 0 CA-C-O 118.849 -0.595 . . . . 6.8700000000000001 109.724 176.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.601 0 N-CA-C 111.76 -0.536 . . . . 1.71 111.76 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -94.91 155.51 16.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.891 0.377 . . . . 2.0 110.705 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.68 113.9 11.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.635 -0.711 . . . . 0.23999999999999999 109.845 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.752 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.1 pt -96.13 -15.27 7.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 115.351 -0.841 . . . . 0.14999999999999999 111.833 -171.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.21 175.88 42.24 Favored Glycine 0 CA--C 1.502 -0.774 0 N-CA-C 111.478 -0.649 . . . . 0.10000000000000001 111.478 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.62 148.67 36.18 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.096 0.474 . . . . 0.20000000000000001 110.949 -174.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 37.3 mm -75.89 123.09 31.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.689 -0.687 . . . . 0.14000000000000001 111.02 -178.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 55.4 p -114.63 -26.35 7.92 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.364 0.602 . . . . 0.20000000000000001 110.395 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.528 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 83.6 tttt -136.21 145.82 46.12 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.584 -0.895 . . . . 2.3599999999999999 108.584 172.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.643 HD11 HG21 ' A' ' 14' ' ' VAL . 5.4 tt -158.42 141.18 14.57 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.972 0.415 . . . . 0.20000000000000001 110.513 -177.448 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -152.12 146.45 25.51 Favored 'General case' 0 CA--C 1.502 -0.898 0 CA-C-N 115.705 -0.68 . . . . 1.9399999999999999 111.433 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.598 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 83.97 -152.34 28.38 Favored Glycine 0 N--CA 1.428 -1.884 0 CA-C-N 114.928 -1.033 . . . . 0.27000000000000002 113.115 168.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 39.8 m -95.01 118.64 32.17 Favored 'General case' 0 N--CA 1.445 -0.681 0 N-CA-C 109.747 -0.464 . . . . 1.1599999999999999 109.747 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.643 HG21 HD11 ' A' ' 10' ' ' LEU . 2.8 m -136.45 151.22 28.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.766 0.793 . . . . 0.20000000000000001 111.678 -177.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -152.21 158.99 43.63 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 114.585 -1.189 . . . . 0.17000000000000001 108.841 179.214 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.677 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -136.67 133.57 48.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 C-N-CA 119.829 -0.749 . . . . 0.16 111.305 174.192 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.482 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.9 mt-30 -102.75 100.19 10.2 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.089 -0.96 . . . . 0.51000000000000001 109.794 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.414 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 26.5 p -62.65 179.2 0.36 Allowed 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.484 0.179 . . . . 1.25 111.484 -176.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 11.8 pt -58.66 -27.89 35.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.78 0.324 . . . . 0.58999999999999997 111.661 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -75.42 -11.75 60.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.967 0.413 . . . . 1.96 110.617 178.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.46 21.26 48.95 Favored Glycine 0 CA--C 1.505 -0.563 0 N-CA-C 110.739 -0.945 . . . . 0.32000000000000001 110.739 -178.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -92.57 121.12 33.69 Favored 'General case' 0 N--CA 1.446 -0.646 0 CA-C-N 114.93 -0.635 . . . . 2.21 110.396 -178.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.607 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.9 tt0 -93.72 116.74 29.25 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.985 0.422 . . . . 1.0 110.931 -179.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.677 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -118.98 169.36 9.96 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.948 -0.569 . . . . 1.55 109.82 176.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.37 143.14 11.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.82 -0.627 . . . . 0.34999999999999998 109.738 178.111 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.417 ' HB2' HG23 ' A' ' 14' ' ' VAL . 18.4 mt -107.85 127.23 53.54 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.154 -0.475 . . . . 0.32000000000000001 110.826 178.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 48.4 mttp -110.05 179.59 4.06 Favored 'General case' 0 C--N 1.319 -0.761 0 N-CA-C 108.709 -0.849 . . . . 1.6499999999999999 108.709 172.039 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.19 145.82 52.92 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.144 -0.622 . . . . 0.23000000000000001 109.695 174.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.63 2.2 87.72 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.137 -1.03 . . . . 0.23999999999999999 112.416 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 57.9 m-20 -78.95 142.77 60.63 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.044 0.45 . . . . 1.9199999999999999 110.701 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -77.34 138.71 17.95 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 123.038 2.492 . . . . 0.22 113.11 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.9 mm -103.83 135.23 42.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.687 0 CA-C-N 115.411 -0.813 . . . . 0.13 108.847 170.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.461 ' H ' ' CD ' ' A' ' 36' ' ' GLU . 62.2 m-85 -114.51 155.5 26.31 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 116.017 -0.538 . . . . 0.28999999999999998 109.947 -178.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -71.19 109.89 5.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.036 -0.529 . . . . 0.17999999999999999 110.243 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.12 0.22 10.6 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.455 -0.878 . . . . 0.17000000000000001 113.406 178.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.482 ' O ' ' HG2' ' A' ' 66' ' ' MET . 32.7 mt-10 -86.92 147.98 25.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 117.856 0.828 . . . . 0.52000000000000002 110.645 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.482 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 17.5 m -108.06 108.63 19.81 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 115.662 -0.699 . . . . 0.16 110.391 -177.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.0 t -83.69 130.3 36.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.028 0.442 . . . . 0.16 110.618 -174.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.0 mp -117.46 108.02 15.02 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.357 -0.838 . . . . 0.27000000000000002 110.032 -178.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.0 p -101.02 152.97 19.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.235 -0.654 . . . . 0.23000000000000001 109.235 176.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -130.64 128.72 5.61 Favored Glycine 0 N--CA 1.442 -0.903 0 C-N-CA 120.622 -0.799 . . . . 0.90000000000000002 112.417 -177.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 54.8 -108.84 1.03 Allowed Glycine 0 N--CA 1.449 -0.444 0 O-C-N 124.172 0.572 . . . . 1.79 112.431 -179.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.598 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 18.2 m -92.46 66.96 4.69 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.88 0.372 . . . . 1.6399999999999999 110.852 -178.462 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -101.4 132.37 10.93 Favored Glycine 0 CA--C 1.523 0.55 0 CA-C-N 115.804 -0.635 . . . . 0.89000000000000001 111.726 176.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.4 m -142.57 110.04 5.72 Favored 'General case' 0 C--O 1.223 -0.303 0 CA-C-N 118.04 0.92 . . . . 0.84999999999999998 110.264 175.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.446 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.2 t -121.2 143.77 32.44 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 CA-C-O 120.706 0.289 . . . . 0.25 110.758 -174.429 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.528 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.9 m -120.91 110.99 16.97 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.179 -0.464 . . . . 0.19 109.928 175.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.535 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 55.9 mt -99.68 104.6 16.29 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.851 0 CA-C-N 115.785 -0.643 . . . . 0.14999999999999999 110.107 178.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.03 100.98 8.42 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.191 -0.913 . . . . 0.14000000000000001 109.424 177.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.485 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 68.4 m-85 -68.54 146.28 53.25 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-O 121.586 0.708 . . . . 0.32000000000000001 110.727 -178.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.4 p -70.99 1.62 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.567 -1.197 . . . . 0.25 110.991 -173.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.418 ' HB3' ' HE1' ' A' ' 71' ' ' TYR . 4.1 t70 -86.0 -20.84 28.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.32 -0.854 . . . . 0.75 110.432 175.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 111.97 -11.95 27.04 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 111.25 -0.74 . . . . 0.27000000000000002 111.25 -175.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.68 151.98 24.08 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.352 -0.424 . . . . 0.35999999999999999 110.478 176.179 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -133.0 138.94 47.0 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.08 -0.341 . . . . 1.51 110.08 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.535 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.7 m -118.32 164.47 14.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.115 0.483 . . . . 1.3899999999999999 111.47 179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.446 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.0 p -133.64 135.4 55.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 CA-C-N 115.402 -0.817 . . . . 0.81000000000000005 110.249 177.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 14.6 mt -109.15 133.7 53.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.977 -0.556 . . . . 0.32000000000000001 110.101 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.72 -169.78 36.7 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 121.147 -0.549 . . . . 1.02 111.811 176.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.87 149.98 17.05 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 120.934 -0.651 . . . . 0.40000000000000002 111.789 -173.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.3 t70 61.02 20.54 10.96 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 121.926 0.87 . . . . 1.26 109.523 -174.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.7 t -106.69 159.05 16.5 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.346 -0.843 . . . . 1.1899999999999999 110.686 -177.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.453 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.3 mt -140.3 124.55 18.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.8 -0.636 . . . . 0.38 109.922 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 13.1 p -147.09 143.76 20.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.814 0.34 . . . . 1.0 110.822 -178.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 37.4 tt0 -99.27 133.92 42.88 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.968 0.413 . . . . 0.67000000000000004 110.587 -179.26 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.571 ' CE ' HG21 ' A' ' 70' ' ' ILE . 47.0 mmm -73.83 88.99 1.81 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.651 -0.704 . . . . 0.88 110.815 -177.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 53.3 p -119.02 -164.71 1.06 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.434 -0.348 . . . . 0.28999999999999998 110.088 179.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -67.69 -26.86 66.39 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.409 0.624 . . . . 2.1299999999999999 109.52 177.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -63.14 -25.7 68.48 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.131 -0.941 . . . . 2.5099999999999998 109.888 177.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.571 HG21 ' CE ' ' A' ' 66' ' ' MET . 0.9 OUTLIER -96.87 -55.31 6.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 114.743 -1.117 . . . . 0.25 110.595 177.794 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.752 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.3 t80 -96.76 82.66 3.32 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.326 -0.852 . . . . 0.31 110.157 -174.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 49.2 t30 -85.92 98.68 10.93 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.162 -0.926 . . . . 1.46 110.102 175.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 24.7 p -68.75 124.37 23.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.68999999999999995 110.758 -179.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -103.23 -42.08 2.11 Favored Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.585 -0.816 . . . . 1.9099999999999999 112.064 -177.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -134.99 -1.06 2.71 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.749 0.309 . . . . 5.5700000000000003 111.033 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.508 -0.758 . . . . 6.8700000000000001 110.752 177.188 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.71 0 N-CA-C 112.165 -0.374 . . . . 1.71 112.165 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -97.72 144.74 27.04 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-O 120.905 0.383 . . . . 2.0 110.443 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.66 109.28 12.74 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 115.684 -0.689 . . . . 0.23999999999999999 109.328 175.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.8 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.1 pt -89.18 -12.05 10.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-N 115.32 -0.854 . . . . 0.14999999999999999 111.632 -171.363 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.35 174.03 40.38 Favored Glycine 0 CA--C 1.501 -0.837 0 C-N-CA 120.858 -0.687 . . . . 0.10000000000000001 111.55 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -144.91 149.7 35.75 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.013 0.435 . . . . 0.20000000000000001 110.327 -176.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.578 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.0 mm -77.66 124.54 36.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 CA-C-N 115.699 -0.682 . . . . 0.14000000000000001 110.871 -177.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 67.9 p -117.6 -16.83 10.08 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.378 0.609 . . . . 0.20000000000000001 110.875 178.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.442 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 27.4 tptp -146.73 138.59 24.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.335 -0.987 . . . . 2.3599999999999999 108.335 172.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.418 HD11 HG21 ' A' ' 14' ' ' VAL . 6.5 tt -150.37 148.03 28.3 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.807 -0.357 . . . . 0.20000000000000001 110.8 -178.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -157.48 154.49 28.78 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.923 -0.58 . . . . 1.9399999999999999 110.274 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.81 -157.4 48.85 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.11 -0.567 . . . . 0.27000000000000002 113.466 172.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 33.4 m -100.07 115.0 28.73 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.366 -0.417 . . . . 1.1599999999999999 110.056 -178.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.564 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.6 m -133.7 152.57 35.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.525 0.678 . . . . 0.20000000000000001 111.599 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.39 158.56 43.89 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 114.866 -1.061 . . . . 0.17000000000000001 109.045 -178.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.625 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.7 OUTLIER -134.59 139.49 47.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 C-N-CA 120.131 -0.628 . . . . 0.16 110.857 173.007 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.434 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.3 mt-30 -104.21 99.88 9.61 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.204 -0.907 . . . . 0.51000000000000001 109.251 175.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.495 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 68.6 p -63.75 -179.39 0.38 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.638 0.256 . . . . 1.25 110.935 -176.07 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -69.35 -3.33 2.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 120.944 0.402 . . . . 0.58999999999999997 111.514 178.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -94.19 -7.01 43.46 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.461 -0.57 . . . . 1.96 109.461 173.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 81.36 19.9 65.58 Favored Glycine 0 CA--C 1.503 -0.681 0 N-CA-C 110.881 -0.888 . . . . 0.32000000000000001 110.881 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -92.76 123.12 35.81 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.829 -0.686 . . . . 2.21 110.877 -177.153 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.608 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 19.8 tt0 -89.16 118.46 28.88 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.355 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.625 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.4 ptt-85 -121.62 166.57 14.04 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.461 -0.57 . . . . 1.55 109.461 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 11.3 p -89.85 135.26 26.69 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 N-CA-C 109.127 -0.694 . . . . 0.34999999999999998 109.127 177.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.564 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.3 mt -95.79 146.95 24.13 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.227 0.537 . . . . 0.32000000000000001 110.902 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.508 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 33.2 mttp -138.07 171.98 13.6 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.059 -0.973 . . . . 1.6499999999999999 108.544 -176.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -65.82 139.02 58.28 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 119.285 -0.966 . . . . 0.23000000000000001 109.254 177.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.35 89.89 Favored Glycine 0 N--CA 1.437 -1.265 0 C-N-CA 119.865 -1.16 . . . . 0.23999999999999999 112.478 178.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -76.94 140.4 66.78 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 121.54 0.686 . . . . 1.9199999999999999 110.48 178.581 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -80.14 129.3 7.73 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.601 2.868 . . . . 0.22 113.848 -176.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.2 mm -97.39 132.86 41.09 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-N 115.588 -0.733 . . . . 0.13 109.187 173.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -113.27 159.75 19.03 Favored 'General case' 0 C--N 1.309 -1.177 0 CA-C-N 115.855 -0.612 . . . . 0.28999999999999998 109.786 -177.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.497 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.9 t80 -74.52 116.05 14.76 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.285 -0.416 . . . . 0.17999999999999999 110.16 -175.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.33 9.51 27.32 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.57 -0.824 . . . . 0.17000000000000001 113.265 177.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.495 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 38.7 mt-10 -90.61 139.92 30.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 118.088 0.944 . . . . 0.52000000000000002 110.343 177.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.3 m -98.28 106.25 18.51 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.207 -0.906 . . . . 0.16 110.727 -176.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.4 t -82.38 125.78 39.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.158 0.504 . . . . 0.16 110.771 -174.545 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -110.2 105.2 14.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.136 -0.938 . . . . 0.27000000000000002 109.701 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.468 HG21 HG21 ' A' ' 58' ' ' ILE . 62.7 p -109.79 143.66 39.32 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.987 -0.375 . . . . 0.23000000000000001 109.987 178.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -121.37 151.89 16.91 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 120.485 -0.865 . . . . 0.90000000000000002 111.633 177.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.66 -113.25 2.96 Favored Glycine 0 N--CA 1.453 -0.227 0 C-N-CA 121.467 -0.396 . . . . 1.79 113.006 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.6 m -103.5 35.61 2.54 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.771 0.32 . . . . 1.6399999999999999 110.621 -178.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.16 93.99 0.09 OUTLIER Glycine 0 CA--C 1.52 0.374 0 CA-C-N 115.91 -0.586 . . . . 0.89000000000000001 112.543 177.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.695 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 49.2 m -109.54 124.68 51.52 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.748 -0.464 . . . . 0.84999999999999998 109.748 -174.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 6.1 t -142.92 119.99 6.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 CA-C-O 121.003 0.43 . . . . 0.25 111.286 -171.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 88.6 m -92.21 103.65 16.1 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.573 -0.739 . . . . 0.19 109.934 175.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.464 HD13 ' HE2' ' A' ' 66' ' ' MET . 68.2 mt -94.88 99.55 9.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 114.982 -1.008 . . . . 0.14999999999999999 109.51 177.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -80.16 107.54 13.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.395 -0.82 . . . . 0.14000000000000001 109.497 178.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.554 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 57.1 m-85 -70.7 145.67 50.39 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.47 0.652 . . . . 0.32000000000000001 110.947 -177.228 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.9 p -70.98 1.51 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 114.76 -1.109 . . . . 0.25 111.754 -172.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.744 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 13.8 t70 -99.42 -16.42 18.39 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 120.86 0.362 . . . . 0.75 110.815 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.85 -14.76 9.06 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.466 -0.873 . . . . 0.27000000000000002 112.374 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.7 p -84.38 154.61 22.74 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 110.372 -0.233 . . . . 0.35999999999999999 110.372 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -133.67 138.2 45.75 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-O 120.964 0.411 . . . . 1.51 110.345 -179.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.448 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 1.1 t -123.33 150.41 27.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.983 -0.553 . . . . 1.3899999999999999 110.286 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -135.54 129.91 49.61 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.419 0.628 . . . . 0.81000000000000005 110.731 178.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.695 ' O ' ' HA ' ' A' ' 45' ' ' SER . 14.3 mt -94.3 139.04 19.19 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.545 -0.752 . . . . 0.32000000000000001 109.599 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.85 -57.4 2.42 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 121.199 -0.524 . . . . 1.02 112.716 -177.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 150.46 158.56 8.3 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.874 -0.679 . . . . 0.40000000000000002 111.857 178.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.6 t70 51.83 43.23 30.25 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.703 0.763 . . . . 1.26 110.521 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.5 t -129.28 158.08 40.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.757 -0.656 . . . . 1.1899999999999999 110.394 -176.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.56 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 88.0 mt -140.28 106.88 2.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.536 -0.756 . . . . 0.38 109.148 177.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.4 p -135.33 140.41 44.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.897 0.38 . . . . 1.0 111.02 -174.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.464 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.8 tt0 -91.81 128.64 37.72 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.729 -0.471 . . . . 0.67000000000000004 109.729 178.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.477 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 55.8 mmm -66.28 89.45 0.13 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.149 -0.478 . . . . 0.88 110.313 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.425 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 59.4 p -110.81 -166.47 1.08 Allowed 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.871 -0.604 . . . . 0.28999999999999998 111.724 -174.383 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -68.01 -33.41 74.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.874 -0.603 . . . . 2.1299999999999999 110.323 178.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -70.35 -25.66 63.38 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.731 0.777 . . . . 2.5099999999999998 109.975 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.425 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.3 mm -80.06 -53.51 12.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 114.596 -1.183 . . . . 0.25 111.079 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.8 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 -102.99 82.52 2.1 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.355 -0.839 . . . . 0.31 110.274 -175.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -73.54 113.1 10.26 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.602 -0.726 . . . . 1.46 109.842 174.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.9 p -93.7 140.52 29.54 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 116.097 -0.501 . . . . 0.68999999999999995 110.966 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 78.39 32.2 43.55 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.853 -0.689 . . . . 1.9099999999999999 112.514 178.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -79.07 -44.77 21.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.491 0.186 . . . . 5.5700000000000003 111.046 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.451 ' N ' HD22 ' A' ' 76' ' ' ASN . 0.9 OUTLIER . . . . . 0 C--O 1.246 0.918 0 CA-C-O 117.99 -1.005 . . . . 6.8700000000000001 110.627 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.593 0 N-CA-C 112.062 -0.415 . . . . 1.71 112.062 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -102.55 160.51 14.5 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.994 -0.372 . . . . 2.0 109.994 179.312 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.52 116.68 17.43 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-O 121.438 0.637 . . . . 0.23999999999999999 110.342 -178.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.787 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.1 pt -101.92 -14.62 8.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.095 -0.957 . . . . 0.14999999999999999 111.811 -171.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.81 179.22 41.27 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 120.796 -0.716 . . . . 0.10000000000000001 111.415 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.405 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 95.0 m-85 -143.79 152.51 41.32 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.939 0.4 . . . . 0.20000000000000001 110.569 -175.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.477 HG12 ' O ' ' A' ' 30' ' ' ASP . 34.2 mm -80.21 119.97 30.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.203 -0.453 . . . . 0.14000000000000001 110.945 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.2 p -113.12 -18.71 12.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 121.281 0.563 . . . . 0.20000000000000001 110.586 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.556 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 78.9 tttt -144.81 145.08 31.47 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.236 -1.024 . . . . 2.3599999999999999 108.236 172.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.608 HD11 HG21 ' A' ' 14' ' ' VAL . 7.0 tt -159.91 142.34 13.42 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.792 0.33 . . . . 0.20000000000000001 111.019 -177.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -150.67 153.25 35.26 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.779 -0.646 . . . . 1.9399999999999999 111.274 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.22 -155.14 50.18 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.982 -0.554 . . . . 0.27000000000000002 113.235 174.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 27.2 t -97.91 119.7 36.99 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.878 -0.415 . . . . 1.1599999999999999 109.878 -178.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.608 HG21 HD11 ' A' ' 10' ' ' LEU . 2.7 m -132.09 152.98 37.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.415 0.626 . . . . 0.20000000000000001 110.828 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.28 159.15 44.66 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.725 -1.125 . . . . 0.17000000000000001 108.174 178.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.708 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.5 OUTLIER -134.97 130.44 52.08 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 C-N-CA 119.545 -0.862 . . . . 0.16 110.817 173.816 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.44 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.8 mt-30 -96.15 98.61 10.47 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.269 -0.878 . . . . 0.51000000000000001 109.255 175.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.506 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 15.9 m -63.79 176.49 0.91 Allowed 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.031 -0.532 . . . . 1.25 110.816 -176.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.6 pt -56.81 -28.03 27.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 112.687 0.625 . . . . 0.58999999999999997 112.687 -173.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -82.63 -1.1 50.0 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.788 0.328 . . . . 1.96 110.963 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 89.35 8.02 68.89 Favored Glycine 0 CA--C 1.506 -0.529 0 N-CA-C 111.047 -0.821 . . . . 0.32000000000000001 111.047 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 87.7 mm-40 -79.15 115.6 18.91 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.937 -0.631 . . . . 2.21 111.115 -177.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.592 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 16.6 tt0 -88.15 111.25 21.39 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.94 -0.573 . . . . 1.0 110.533 178.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.708 ' HG2' HG12 ' A' ' 16' ' ' VAL . 16.8 ptt85 -112.22 170.78 7.93 Favored 'General case' 0 C--N 1.323 -0.556 0 N-CA-C 109.214 -0.662 . . . . 1.55 109.214 176.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.3 p -98.93 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 109.772 -0.455 . . . . 0.34999999999999998 109.772 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.445 ' HB2' ' CG2' ' A' ' 14' ' ' VAL . 21.2 mt -109.98 128.29 55.3 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.942 -0.572 . . . . 0.32000000000000001 110.593 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -116.03 -173.9 2.44 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 108.056 -1.09 . . . . 1.6499999999999999 108.056 171.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -69.83 143.5 52.87 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.734 -0.786 . . . . 0.23000000000000001 109.389 175.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.51 -2.75 84.69 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.295 -0.955 . . . . 0.23999999999999999 112.946 177.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.477 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.3 m-20 -73.0 143.7 84.31 Favored Pre-proline 0 CA--C 1.512 -0.488 0 N-CA-C 109.556 -0.535 . . . . 1.9199999999999999 109.556 174.392 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.405 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 25.4 Cg_endo -87.64 141.56 5.58 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.922 2.415 . . . . 0.22 112.41 -179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mm -100.93 139.16 22.91 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 109.662 -0.496 . . . . 0.13 109.662 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -115.33 150.0 36.98 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 116.019 -0.537 . . . . 0.28999999999999998 109.676 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.586 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -68.41 113.24 5.8 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.276 -0.42 . . . . 0.17999999999999999 110.322 -177.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 119.68 -1.23 13.81 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.368 -0.92 . . . . 0.17000000000000001 113.463 178.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.518 ' HB3' HG22 ' A' ' 16' ' ' VAL . 36.9 mt-10 -85.48 148.6 25.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 117.789 0.795 . . . . 0.52000000000000002 110.951 -178.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 8.6 m -106.83 105.95 16.23 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.621 -0.718 . . . . 0.16 110.642 -176.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -81.86 126.39 39.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.351 0.596 . . . . 0.16 110.777 -174.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -114.76 100.76 8.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 114.83 -1.077 . . . . 0.27000000000000002 109.851 -177.203 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.6 p -99.02 152.88 19.34 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.284 -0.636 . . . . 0.23000000000000001 109.284 176.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -126.22 136.88 9.8 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.34 -0.933 . . . . 0.90000000000000002 112.526 -179.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 52.6 -103.24 0.11 Allowed Glycine 0 C--N 1.33 0.248 0 O-C-N 123.844 0.379 . . . . 1.79 113.69 177.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 18.3 m -96.15 26.38 4.27 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.719 0.295 . . . . 1.6399999999999999 111.644 -175.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.21 144.68 47.0 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 121.123 -0.56 . . . . 0.89000000000000001 112.74 177.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.402 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 8.7 m -151.12 139.61 20.52 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.646 -0.872 . . . . 0.84999999999999998 108.646 175.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.5 t -148.4 134.05 11.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 O-C-N 122.012 -0.43 . . . . 0.25 110.958 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.556 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.2 m -109.84 108.16 18.38 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.76 -0.459 . . . . 0.19 109.76 173.182 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.619 HD13 ' HE2' ' A' ' 66' ' ' MET . 56.7 mt -99.14 104.22 15.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 115.593 -0.73 . . . . 0.14999999999999999 109.969 178.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -79.43 107.34 12.12 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.405 -0.816 . . . . 0.14000000000000001 109.133 176.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.44 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 63.0 m-85 -73.72 146.63 44.27 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.491 0.662 . . . . 0.32000000000000001 110.899 -177.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.1 p -77.36 0.89 2.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 114.821 -1.081 . . . . 0.25 111.398 -170.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -86.36 -21.75 27.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 121.223 0.535 . . . . 0.75 109.948 173.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 125.56 -12.69 7.41 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.77 -0.729 . . . . 0.27000000000000002 112.802 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.0 p -87.5 162.98 16.93 Favored 'General case' 0 C--N 1.327 -0.412 0 O-C-N 122.821 -0.223 . . . . 0.35999999999999999 111.074 179.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.2 147.46 50.73 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.762 -0.458 . . . . 1.51 109.762 176.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.539 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 11.9 m -128.2 161.2 37.05 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 CA-C-O 121.264 0.554 . . . . 1.3899999999999999 111.25 175.545 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.596 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 97.9 t -135.06 123.93 41.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 114.814 -1.084 . . . . 0.81000000000000005 110.159 178.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 45' ' ' SER . 24.0 mt -96.55 133.92 36.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.445 -0.798 . . . . 0.32000000000000001 110.191 -177.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -76.58 -163.91 17.67 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.047 -0.597 . . . . 1.02 112.346 177.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.07 149.86 17.85 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 111.208 -0.757 . . . . 0.40000000000000002 111.208 -174.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.5 t70 60.85 20.86 11.05 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 121.901 0.858 . . . . 1.26 109.744 -175.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.0 m -102.94 154.18 19.47 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.572 -0.74 . . . . 1.1899999999999999 110.967 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.56 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.4 mt -141.68 109.69 2.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-N 115.35 -0.841 . . . . 0.38 109.727 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.3 p -139.81 142.45 32.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 120.803 0.335 . . . . 1.0 110.827 -177.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.442 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 34.7 tt0 -91.16 132.87 35.81 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.929 0.395 . . . . 0.67000000000000004 110.488 178.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.619 ' HE2' HD13 ' A' ' 48' ' ' ILE . 63.4 mmm -67.13 89.88 0.19 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.448 -0.796 . . . . 0.88 110.808 -177.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.414 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.6 p -117.77 -162.99 0.9 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.488 -0.778 . . . . 0.28999999999999998 111.305 -175.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -66.92 -40.93 87.8 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.733 0.272 . . . . 2.1299999999999999 111.733 -175.538 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -64.57 -26.17 68.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.687 0.756 . . . . 2.5099999999999998 110.605 177.158 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.439 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.6 mm -76.36 -51.33 19.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.766 -1.106 . . . . 0.25 110.557 174.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.787 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -108.42 76.78 1.05 Allowed 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.33 -0.85 . . . . 0.31 110.106 -177.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -73.65 107.23 5.79 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.605 -0.725 . . . . 1.46 109.167 175.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 5.6 p -80.16 127.08 31.91 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.002 -0.545 . . . . 0.68999999999999995 110.919 -176.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -92.45 -60.9 1.2 Allowed Glycine 0 N--CA 1.445 -0.754 0 CA-C-N 115.894 -0.593 . . . . 1.9099999999999999 113.36 -173.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -139.43 -37.2 0.5 Allowed 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.498 0.555 . . . . 5.5700000000000003 112.498 -175.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 . . . . . 0 C--O 1.25 1.117 0 CA-C-O 118.337 -0.84 . . . . 6.8700000000000001 110.946 -176.066 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.58 0 N-CA-C 112.106 -0.398 . . . . 1.71 112.106 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -102.31 141.08 35.71 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.001 0.429 . . . . 2.0 110.778 178.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.95 109.61 13.39 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.622 -0.717 . . . . 0.23999999999999999 109.91 -178.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.774 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.4 pt -88.86 -14.9 9.2 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.179 -0.918 . . . . 0.14999999999999999 111.616 -171.117 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -166.98 177.15 41.79 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.886 -0.673 . . . . 0.10000000000000001 111.465 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -143.95 150.67 38.7 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 120.951 0.405 . . . . 0.20000000000000001 110.529 -175.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.613 HG12 ' O ' ' A' ' 30' ' ' ASP . 20.7 mm -78.75 122.2 33.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.981 -0.554 . . . . 0.14000000000000001 110.78 -178.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.7 p -114.75 -21.79 10.01 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.311 0.576 . . . . 0.20000000000000001 110.67 179.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.625 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 36.1 ttpt -141.1 145.71 36.15 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 108.417 -0.957 . . . . 2.3599999999999999 108.417 172.407 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.418 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -156.66 144.73 19.52 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 120.774 0.321 . . . . 0.20000000000000001 110.684 -177.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.484 ' HB3' ' HB2' ' A' ' 45' ' ' SER . 6.3 t70 -151.75 148.32 27.74 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.881 -0.6 . . . . 1.9399999999999999 110.73 -178.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.517 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 74.96 -152.46 43.98 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 121.09 -0.576 . . . . 0.27000000000000002 113.503 173.388 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 9.0 t -103.63 120.07 40.16 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.927 -0.397 . . . . 1.1599999999999999 109.927 -177.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.599 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.9 m -135.83 153.2 32.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 0.20000000000000001 111.859 -175.148 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.43 159.65 44.32 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.881 -1.054 . . . . 0.17000000000000001 109.457 -177.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.715 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.8 OUTLIER -134.21 136.66 53.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 C-N-CA 120.152 -0.619 . . . . 0.16 110.984 173.188 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.3 mt-30 -103.28 103.52 13.55 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.155 -0.929 . . . . 0.51000000000000001 109.641 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.532 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 47.6 t -62.05 176.8 0.52 Allowed 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.572 -0.451 . . . . 1.25 110.392 -178.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.3 pt -60.36 -31.13 47.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-O 121.107 0.48 . . . . 0.58999999999999997 111.869 -173.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -74.35 -14.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.865 -0.607 . . . . 1.96 110.916 177.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.1 10.27 46.06 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 121.146 -0.55 . . . . 0.32000000000000001 112.522 177.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 -80.94 119.94 24.11 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.901 0.382 . . . . 2.21 111.214 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.567 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 18.5 tt0 -88.77 119.49 29.31 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.559 -0.746 . . . . 1.0 110.623 179.192 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.715 ' HG2' HG12 ' A' ' 16' ' ' VAL . 21.3 ptt-85 -119.1 166.1 13.34 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.43 -0.581 . . . . 1.55 109.43 174.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -86.56 137.58 20.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-N 115.942 -0.572 . . . . 0.34999999999999998 109.483 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.599 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.0 mt -102.08 151.88 21.64 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.196 0.522 . . . . 0.32000000000000001 111.167 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.432 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.5 mttt -139.57 175.97 9.12 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.105 -0.952 . . . . 1.6499999999999999 108.479 -175.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.95 140.92 49.4 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.566 -0.853 . . . . 0.23000000000000001 108.957 176.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.77 6.04 86.81 Favored Glycine 0 N--CA 1.435 -1.389 0 C-N-CA 119.877 -1.154 . . . . 0.23999999999999999 112.218 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.613 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -82.0 138.81 46.07 Favored Pre-proline 0 N--CA 1.454 -0.248 0 CA-C-O 121.75 0.786 . . . . 1.9199999999999999 110.35 178.19 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -76.92 130.29 11.27 Favored 'Trans proline' 0 C--N 1.325 -0.682 0 C-N-CA 123.719 2.946 . . . . 0.22 113.509 -178.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.446 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 26.3 mm -96.02 136.54 26.6 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 CA-C-N 115.349 -0.841 . . . . 0.13 109.266 173.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -117.87 151.35 37.56 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 109.565 -0.531 . . . . 0.28999999999999998 109.565 -179.118 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.569 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.9 t80 -67.1 126.29 28.7 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.988 -0.551 . . . . 0.17999999999999999 110.188 -176.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.21 -12.8 33.88 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.462 -0.875 . . . . 0.17000000000000001 113.074 178.182 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.532 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 36.7 mt-10 -82.04 139.39 34.51 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.584 0.707 . . . . 0.52000000000000002 111.072 -177.316 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.527 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 17.8 m -98.74 109.98 22.65 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 114.684 -1.144 . . . . 0.16 110.718 -177.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.8 t -82.19 132.9 30.35 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.48 -0.488 . . . . 0.16 110.618 -175.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -119.61 113.33 20.53 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.516 -0.766 . . . . 0.27000000000000002 110.298 -177.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 71.5 p -105.49 153.19 22.06 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.274 -0.639 . . . . 0.23000000000000001 109.274 173.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -113.61 -171.13 17.58 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 120.587 -0.816 . . . . 0.90000000000000002 111.076 177.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 43' ' ' SER . . . -51.71 117.15 5.55 Favored Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 110.694 -0.962 . . . . 1.79 110.694 175.557 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.517 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 32.6 t 69.96 80.74 0.17 Allowed 'General case' 0 C--N 1.327 -0.379 0 O-C-N 124.229 0.606 . . . . 1.6399999999999999 109.768 -169.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -142.39 139.38 9.12 Favored Glycine 0 N--CA 1.448 -0.55 0 N-CA-C 110.879 -0.888 . . . . 0.89000000000000001 110.879 174.09 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.484 ' HB2' ' HB3' ' A' ' 11' ' ' ASP . 25.4 m -156.01 142.61 18.65 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.182 -0.673 . . . . 0.84999999999999998 109.182 174.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.619 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.4 t -148.32 145.02 18.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 O-C-N 122.242 -0.286 . . . . 0.25 110.334 -179.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.625 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 97.9 m -115.98 106.81 14.2 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.158 0.504 . . . . 0.19 109.87 172.268 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.0 103.0 14.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.291 -0.868 . . . . 0.14999999999999999 109.807 178.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.74 103.67 8.85 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 115.463 -0.79 . . . . 0.14000000000000001 109.287 177.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.565 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 50.5 m-85 -68.73 147.09 52.32 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.618 0.723 . . . . 0.32000000000000001 110.907 -178.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.2 p -74.46 1.66 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.518 -1.219 . . . . 0.25 111.459 -172.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.474 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 22.0 t70 -97.26 -0.93 45.81 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.307 0.575 . . . . 0.75 109.752 177.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.61 -10.94 49.96 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.859 -0.686 . . . . 0.27000000000000002 112.847 177.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 10.3 p -87.79 164.08 16.13 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 110.534 -0.173 . . . . 0.35999999999999999 110.534 177.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -135.94 153.32 51.46 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.819 -0.438 . . . . 1.51 109.819 179.794 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.565 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.7 OUTLIER -135.41 147.66 28.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.968 0.413 . . . . 1.3899999999999999 110.542 -179.102 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.619 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 89.5 t -125.84 130.22 72.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 CA-C-N 115.638 -0.71 . . . . 0.81000000000000005 110.176 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.1 mt -102.86 144.69 13.35 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.984 -0.553 . . . . 0.32000000000000001 110.614 -176.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -88.93 -161.53 37.57 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.926 -0.579 . . . . 1.02 112.11 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -113.63 147.96 18.65 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.431 -0.668 . . . . 0.40000000000000002 111.431 -174.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 29.7 t70 53.46 28.84 8.06 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-O 121.981 0.896 . . . . 1.26 109.888 -173.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.8 m -110.49 157.13 19.95 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.085 -0.961 . . . . 1.1899999999999999 110.809 -179.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.414 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 83.8 mt -140.96 123.76 15.66 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.456 -0.793 . . . . 0.38 109.731 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.6 p -149.55 145.02 17.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.996 0.427 . . . . 1.0 110.525 -178.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.527 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 44.0 tt0 -98.17 134.69 40.88 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.28 -0.418 . . . . 0.67000000000000004 111.076 -177.396 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.554 ' SD ' HG21 ' A' ' 70' ' ' ILE . 21.8 mmt -64.32 89.24 0.06 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.704 -0.68 . . . . 0.88 110.725 175.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 16.5 p -121.59 -168.22 1.65 Allowed 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.654 -0.703 . . . . 0.28999999999999998 110.312 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -68.07 -25.25 65.25 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.272 0.558 . . . . 2.1299999999999999 109.787 177.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 25.8 mm-40 -65.97 -21.73 66.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.41 -0.814 . . . . 2.5099999999999998 110.098 177.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.554 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.5 mm -103.02 -53.86 7.04 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.805 0 CA-C-N 114.721 -1.127 . . . . 0.25 110.883 -179.565 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.774 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 4.0 t80 -113.27 73.86 0.84 Allowed 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.261 -0.881 . . . . 0.31 110.226 -176.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -79.64 98.24 6.85 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.755 -0.657 . . . . 1.46 109.814 175.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 32.5 p -68.62 142.36 55.14 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.902 -0.59 . . . . 0.68999999999999995 111.383 -176.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 143.55 15.83 0.26 Allowed Glycine 0 N--CA 1.449 -0.452 0 C-N-CA 120.339 -0.934 . . . . 1.9099999999999999 113.246 178.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -95.09 -52.51 4.18 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.891 -0.411 . . . . 5.5700000000000003 109.891 177.097 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 . . . . . 0 C--O 1.249 1.027 0 O-C-N 123.848 0.717 . . . . 6.8700000000000001 111.048 179.162 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.922 0 N-CA-C 111.96 -0.456 . . . . 1.71 111.96 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.414 ' O ' ' HA ' ' A' ' 33' ' ' PHE . 19.8 t-20 67.22 162.73 0.18 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.59 0.756 . . . . 2.0 110.434 -179.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.39 116.29 21.15 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.4 0.619 . . . . 0.23999999999999999 110.654 -174.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.79 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.0 pt -105.55 -14.4 8.97 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 114.855 -1.066 . . . . 0.14999999999999999 111.765 -173.048 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.53 177.77 41.81 Favored Glycine 0 CA--C 1.5 -0.894 0 N-CA-C 111.046 -0.822 . . . . 0.10000000000000001 111.046 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -144.12 151.18 39.23 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 120.979 0.419 . . . . 0.20000000000000001 111.034 -175.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.468 HD13 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -78.62 120.85 30.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.715 -0.675 . . . . 0.14000000000000001 110.717 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 73.0 p -113.25 -23.35 9.98 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.259 0.552 . . . . 0.20000000000000001 110.205 179.046 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.62 ' HE2' ' OG1' ' A' ' 47' ' ' THR . 37.8 ttpt -140.63 144.93 36.02 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.524 -0.762 . . . . 2.3599999999999999 109.069 172.343 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.443 HD11 HG21 ' A' ' 14' ' ' VAL . 6.3 tt -155.8 144.62 20.45 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 110.292 -0.262 . . . . 0.20000000000000001 110.292 -178.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -153.17 152.36 31.16 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 116.16 -0.473 . . . . 1.9399999999999999 111.136 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.25 -144.11 29.21 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.975 -0.557 . . . . 0.27000000000000002 112.74 175.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t -113.61 123.31 49.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.428 -0.582 . . . . 1.1599999999999999 109.428 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.491 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -138.16 152.94 26.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.20000000000000001 111.62 -176.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.84 159.39 44.21 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.798 -1.092 . . . . 0.17000000000000001 108.175 177.454 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.541 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -132.33 133.18 60.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 C-N-CA 120.11 -0.636 . . . . 0.16 110.46 175.475 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.462 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 3.0 mt-30 -96.04 98.56 10.46 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.461 -0.79 . . . . 0.51000000000000001 109.327 178.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.53 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 25.0 m -63.62 173.43 1.69 Allowed 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.865 -0.607 . . . . 1.25 110.035 -177.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 9.1 pt -64.55 -3.31 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 N-CA-C 114.238 1.199 . . . . 0.58999999999999997 114.238 -168.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -106.03 6.98 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.344 0.592 . . . . 1.96 109.823 174.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.62 6.56 80.17 Favored Glycine 0 CA--C 1.504 -0.606 0 N-CA-C 110.75 -0.94 . . . . 0.32000000000000001 110.75 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.6 ' HA ' HE21 ' A' ' 22' ' ' GLN . 0.0 OUTLIER -78.4 117.44 19.62 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.833 -0.684 . . . . 2.21 111.403 -175.619 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -80.63 126.39 31.2 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.232 0.539 . . . . 1.0 110.582 178.76 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.41 144.59 51.49 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.452 -0.794 . . . . 1.55 109.239 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 8.3 p -78.2 142.76 13.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 120.963 0.411 . . . . 0.34999999999999998 110.242 179.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.491 ' HB2' HG23 ' A' ' 14' ' ' VAL . 25.5 mt -108.07 128.82 55.02 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.168 -0.469 . . . . 0.32000000000000001 110.615 178.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.2 mttm -111.13 -178.0 3.35 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.298 -1.001 . . . . 1.6499999999999999 108.298 172.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -69.2 144.49 53.72 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 119.618 -0.833 . . . . 0.23000000000000001 109.193 173.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.47 2.8 89.83 Favored Glycine 0 N--CA 1.439 -1.139 0 C-N-CA 120.249 -0.977 . . . . 0.23999999999999999 112.551 178.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.428 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -70.53 145.27 92.53 Favored Pre-proline 0 CA--C 1.51 -0.571 0 CA-C-O 121.218 0.533 . . . . 1.9199999999999999 109.923 174.418 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 21.7 Cg_endo -90.04 135.75 2.36 Favored 'Trans proline' 0 N--CA 1.451 -1.025 0 C-N-CA 123.251 2.634 . . . . 0.22 111.851 178.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 27.1 mm -97.99 135.29 33.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 N-CA-C 109.539 -0.541 . . . . 0.13 109.539 177.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.414 ' HA ' ' O ' ' A' ' 2' ' ' ASN . 80.2 m-85 -112.19 144.37 41.69 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.63 -0.714 . . . . 0.28999999999999998 109.894 -177.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.631 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.5 t80 -66.09 109.22 2.51 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.24 -0.437 . . . . 0.17999999999999999 109.987 -177.056 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 125.75 -4.19 8.03 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.308 -0.949 . . . . 0.17000000000000001 113.754 178.275 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.541 ' HB3' HG22 ' A' ' 16' ' ' VAL . 26.2 mt-10 -86.72 151.23 23.57 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 118.223 1.012 . . . . 0.52000000000000002 110.831 -177.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.462 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 25.6 m -111.15 107.49 16.86 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.467 -0.788 . . . . 0.16 110.687 -176.547 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.662 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.9 t -78.67 129.77 37.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 120.896 0.379 . . . . 0.16 111.28 -173.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -113.23 98.41 7.1 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.527 -0.761 . . . . 0.27000000000000002 109.913 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.404 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 82.5 p -96.4 152.99 18.08 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 109.584 -0.525 . . . . 0.23000000000000001 109.584 177.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -116.79 -155.82 10.43 Favored Glycine 0 N--CA 1.441 -0.994 0 N-CA-C 111.517 -0.633 . . . . 0.90000000000000002 111.517 178.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -56.76 128.7 47.58 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.898 -0.668 . . . . 1.79 112.333 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 15.4 m 68.69 19.83 8.4 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 123.119 0.568 . . . . 1.6399999999999999 111.621 178.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.35 134.33 22.71 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.885 -0.674 . . . . 0.89000000000000001 112.596 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.562 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 69.6 m -152.82 136.73 16.27 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.172 -0.677 . . . . 0.84999999999999998 109.172 172.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.612 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 19.4 t -145.85 137.49 19.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 120.602 0.239 . . . . 0.25 110.531 -177.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.62 ' OG1' ' HE2' ' A' ' 9' ' ' LYS . 87.2 m -111.36 106.74 15.77 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.042 -0.527 . . . . 0.19 109.992 174.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.557 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.3 mt -97.87 103.16 14.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.654 -0.703 . . . . 0.14999999999999999 110.009 177.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.44 105.48 9.73 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.303 -0.862 . . . . 0.14000000000000001 109.25 177.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.489 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.5 m-85 -72.92 145.76 46.58 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.563 0.697 . . . . 0.32000000000000001 110.584 -178.623 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.0 p -74.07 -8.5 11.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 114.677 -1.147 . . . . 0.25 111.655 -169.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.45 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 15.2 t70 -81.62 -21.06 38.51 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.221 -0.445 . . . . 0.75 110.504 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.37 -13.52 6.25 Favored Glycine 0 CA--C 1.519 0.321 0 C-N-CA 120.567 -0.825 . . . . 0.27000000000000002 113.045 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.8 p -87.76 162.45 17.03 Favored 'General case' 0 C--N 1.324 -0.52 0 O-C-N 122.727 -0.278 . . . . 0.35999999999999999 111.344 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -135.41 148.0 49.18 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 108.96 -0.756 . . . . 1.51 108.96 177.097 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.557 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 8.6 m -129.7 166.54 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.574 0 CA-C-O 121.213 0.53 . . . . 1.3899999999999999 111.96 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.612 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.9 p -133.12 135.89 56.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-N 114.908 -1.042 . . . . 0.81000000000000005 110.15 176.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.562 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.3 mt -108.23 134.54 49.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.861 -0.609 . . . . 0.32000000000000001 109.656 178.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.65 -159.49 21.18 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 121.206 -0.521 . . . . 1.02 112.336 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.7 146.66 18.32 Favored Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.901 -0.666 . . . . 0.40000000000000002 111.775 -173.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.404 ' HA ' ' O ' ' A' ' 40' ' ' THR . 29.2 t70 56.77 26.39 11.39 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 121.702 0.763 . . . . 1.26 109.909 -174.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 t -103.91 156.97 17.41 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.536 -0.756 . . . . 1.1899999999999999 110.495 -178.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.662 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.7 mt -142.47 104.49 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 115.504 -0.771 . . . . 0.38 109.16 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 1.1 m -131.93 150.13 33.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.006 0.431 . . . . 1.0 111.736 -175.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -102.84 128.09 49.75 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.626 -0.715 . . . . 0.67000000000000004 110.609 -177.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.525 ' HE2' HD13 ' A' ' 48' ' ' ILE . 51.3 mmm -67.72 89.58 0.26 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.522 -0.763 . . . . 0.88 110.666 -177.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.5 p -121.37 -167.45 1.51 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.006 -0.543 . . . . 0.28999999999999998 111.118 -177.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -65.59 -29.6 70.22 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.735 0.303 . . . . 2.1299999999999999 110.846 -178.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -70.49 -17.3 62.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.6 0.714 . . . . 2.5099999999999998 110.354 177.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.512 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.1 mm -96.04 -50.43 11.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 CA-C-N 115.127 -0.942 . . . . 0.25 110.562 177.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.79 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -98.55 87.25 3.77 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.363 -0.835 . . . . 0.31 109.658 -177.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -69.52 88.26 0.49 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.732 -1.122 . . . . 1.46 110.659 176.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 16.5 p -83.96 118.04 23.76 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.077 -0.511 . . . . 0.68999999999999995 110.226 176.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.433 ' C ' ' H ' ' A' ' 76' ' ' ASN . . . -164.1 36.79 0.3 Allowed Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.037 -1.077 . . . . 1.9099999999999999 112.838 -178.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 29.6 t70 73.72 -32.81 0.24 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 123.464 0.706 . . . . 5.5700000000000003 111.74 177.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.433 ' H ' ' C ' ' A' ' 74' ' ' GLY . 10.3 t-20 . . . . . 0 C--O 1.248 0.987 0 O-C-N 123.819 0.699 . . . . 6.8700000000000001 110.414 177.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.657 0 N-CA-C 112.054 -0.419 . . . . 1.71 112.054 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 -122.5 154.37 37.94 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 120.848 0.356 . . . . 2.0 110.224 -179.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.14 113.18 14.59 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.774 -0.648 . . . . 0.23999999999999999 110.282 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.783 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.3 pt -92.01 -16.77 7.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-N 115.085 -0.961 . . . . 0.14999999999999999 111.646 -172.192 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -165.42 177.25 40.82 Favored Glycine 0 CA--C 1.501 -0.816 0 C-N-CA 120.787 -0.72 . . . . 0.10000000000000001 111.535 179.294 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -144.59 152.08 39.98 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 120.788 0.328 . . . . 0.20000000000000001 110.291 -174.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.572 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.1 mm -80.09 123.29 36.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 116.272 -0.422 . . . . 0.14000000000000001 111.146 -178.245 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.5 p -112.79 -23.64 10.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.117 0.484 . . . . 0.20000000000000001 110.461 178.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.512 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 34.9 ttpt -141.88 145.51 34.69 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.706 -0.85 . . . . 2.3599999999999999 108.706 173.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.581 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -158.63 144.84 17.0 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.595 0.236 . . . . 0.20000000000000001 110.436 -176.076 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -154.2 152.44 30.36 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.017 -0.538 . . . . 1.9399999999999999 110.735 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.46 -156.03 46.11 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.988 -0.551 . . . . 0.27000000000000002 113.245 174.124 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 25.4 t -99.17 120.49 39.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.293 -0.632 . . . . 1.1599999999999999 109.293 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.581 HG21 HD11 ' A' ' 10' ' ' LEU . 4.6 m -137.75 152.33 26.64 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.659 0.743 . . . . 0.20000000000000001 111.729 -175.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.08 158.92 44.67 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 114.582 -1.19 . . . . 0.17000000000000001 108.863 -178.399 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.696 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.6 OUTLIER -136.4 132.37 48.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 C-N-CA 119.99 -0.684 . . . . 0.16 110.982 172.221 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.441 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.7 mt-30 -96.67 99.01 10.64 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.092 -0.958 . . . . 0.51000000000000001 109.284 174.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.474 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 50.6 m -66.32 179.6 0.95 Allowed 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 120.971 -0.292 . . . . 1.25 110.811 -176.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.2 pt -60.24 -26.76 37.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 O-C-N 121.886 -0.509 . . . . 0.58999999999999997 112.218 -175.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 -79.69 -8.79 59.45 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.998 0.428 . . . . 1.96 110.62 178.056 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 93.8 5.81 62.58 Favored Glycine 0 CA--C 1.506 -0.478 0 N-CA-C 111.234 -0.746 . . . . 0.32000000000000001 111.234 178.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.4 mm100 -74.44 117.97 16.86 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.305 -0.447 . . . . 2.21 110.819 -179.383 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.696 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 27.5 tt0 -95.09 110.43 22.36 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.168 0.508 . . . . 1.0 110.224 177.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.63 ' HG2' HG12 ' A' ' 16' ' ' VAL . 17.1 ptt-85 -111.61 167.92 9.96 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.952 -0.567 . . . . 1.55 109.906 179.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.0 p -86.61 129.47 38.31 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 115.821 -0.627 . . . . 0.34999999999999998 109.317 176.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.555 HD22 ' OD1' ' A' ' 30' ' ' ASP . 2.8 mt -91.07 143.54 26.6 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 121.526 0.679 . . . . 0.32000000000000001 110.999 -178.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.488 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 39.8 mttp -131.21 171.59 13.13 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.658 -1.156 . . . . 1.6499999999999999 109.232 -172.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.86 134.74 46.27 Favored 'General case' 0 CA--C 1.507 -0.701 0 C-N-CA 119.171 -1.011 . . . . 0.23000000000000001 108.743 174.294 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.93 0.58 89.75 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 119.603 -1.284 . . . . 0.23999999999999999 111.656 -179.707 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.572 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -73.08 139.73 79.75 Favored Pre-proline 0 N--CA 1.451 -0.404 0 CA-C-O 121.69 0.757 . . . . 1.9199999999999999 110.203 177.06 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 37.2 Cg_endo -87.64 123.49 1.81 Allowed 'Trans proline' 0 C--N 1.323 -0.771 0 C-N-CA 123.923 3.082 . . . . 0.22 113.623 -174.376 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 34.4 mm -91.04 134.24 30.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.966 -0.561 . . . . 0.13 110.114 178.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -111.32 155.11 23.55 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 115.786 -0.643 . . . . 0.28999999999999998 109.693 179.1 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.54 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.0 t80 -69.42 116.6 10.03 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.813 0.34 . . . . 0.17999999999999999 110.543 -175.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.18 7.11 23.45 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.388 -0.91 . . . . 0.17000000000000001 113.478 178.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.544 ' O ' ' HG2' ' A' ' 66' ' ' MET . 48.2 mt-10 -89.21 145.11 25.62 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 117.699 0.75 . . . . 0.52000000000000002 110.489 179.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 25.7 m -106.06 107.28 18.19 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.807 -0.633 . . . . 0.16 110.781 -176.287 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.5 t -82.18 131.06 34.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 CA-C-O 121.225 0.536 . . . . 0.16 110.719 -175.215 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.9 mp -118.31 108.51 15.18 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.047 -0.979 . . . . 0.27000000000000002 109.703 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 80.4 p -106.06 155.32 19.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.048 0.451 . . . . 0.23000000000000001 109.955 177.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -117.46 -156.07 10.33 Favored Glycine 0 N--CA 1.445 -0.763 0 N-CA-C 111.369 -0.693 . . . . 0.90000000000000002 111.369 177.531 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -58.1 132.02 52.34 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.8 -0.714 . . . . 1.79 112.034 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 14.8 m 67.43 19.39 10.05 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-O 121.096 0.474 . . . . 1.6399999999999999 111.266 179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -78.83 136.15 17.06 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.951 -0.642 . . . . 0.89000000000000001 112.362 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.433 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 67.0 m -156.9 141.13 16.48 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.395 -0.595 . . . . 0.84999999999999998 109.395 174.507 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -148.39 133.29 10.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 C-N-CA 120.997 -0.281 . . . . 0.25 110.764 -178.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.512 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.1 m -106.36 106.61 17.21 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.052 -0.522 . . . . 0.19 109.62 173.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.553 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 58.8 mt -97.7 107.61 20.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.756 -0.657 . . . . 0.14999999999999999 110.18 178.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.26 106.63 14.31 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 115.331 -0.85 . . . . 0.14000000000000001 109.323 177.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.547 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 67.8 m-85 -73.59 144.64 45.92 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.484 0.659 . . . . 0.32000000000000001 110.753 -178.48 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.7 p -73.53 -6.28 7.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 CA-C-N 114.879 -1.055 . . . . 0.25 111.799 -169.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.56 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 11.5 t70 -84.95 -20.55 30.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.594 -0.276 . . . . 0.75 110.607 177.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.51 -17.32 5.57 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.479 -0.867 . . . . 0.27000000000000002 112.919 -179.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.6 p -86.59 156.84 19.88 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 122.795 -0.238 . . . . 0.35999999999999999 111.108 179.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -130.38 150.73 51.48 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.442 -0.577 . . . . 1.51 109.442 177.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.553 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.9 m -130.4 169.4 21.33 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 CA-C-O 121.211 0.529 . . . . 1.3899999999999999 111.768 177.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.554 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.6 p -140.31 132.37 32.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.13 -0.941 . . . . 0.81000000000000005 110.327 176.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 45' ' ' SER . 23.5 mt -102.71 143.46 15.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.99 -0.55 . . . . 0.32000000000000001 110.15 -179.599 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -87.23 -161.54 36.63 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.858 -0.687 . . . . 1.02 112.23 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -111.91 146.42 17.99 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 120.959 -0.639 . . . . 0.40000000000000002 111.57 -175.052 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.5 t70 60.39 21.65 11.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 121.945 0.878 . . . . 1.26 109.655 -173.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.4 t -102.93 155.61 18.24 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.369 -0.832 . . . . 1.1899999999999999 110.847 -175.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.539 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.4 mt -140.28 122.88 16.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.248 -0.887 . . . . 0.38 109.351 179.004 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 11.0 p -149.18 141.93 17.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.702 0.287 . . . . 1.0 110.86 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.5 tt0 -94.38 130.78 40.58 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.928 0.394 . . . . 0.67000000000000004 110.175 178.603 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.544 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 53.6 mmm -65.8 89.93 0.12 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.425 -0.807 . . . . 0.88 110.495 -178.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.401 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.5 p -116.54 -166.39 1.15 Allowed 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.391 -0.822 . . . . 0.28999999999999998 111.216 -175.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -63.8 -42.42 97.71 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.802 0.334 . . . . 2.1299999999999999 111.471 -177.32 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 56.4 mm-40 -62.89 -23.93 67.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.295 0.569 . . . . 2.5099999999999998 111.009 177.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.414 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.3 mm -82.72 -50.38 15.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.212 -0.904 . . . . 0.25 111.144 177.034 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.783 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.1 t80 -103.51 81.31 1.9 Allowed 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.671 -0.695 . . . . 0.31 109.962 -177.36 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -79.26 110.18 14.3 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.698 -0.683 . . . . 1.46 109.889 177.09 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 21.8 p -90.49 154.79 19.37 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.944 -0.571 . . . . 0.68999999999999995 110.944 -178.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 142.01 18.15 0.31 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 120.595 -0.812 . . . . 1.9099999999999999 113.161 177.524 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -111.02 133.54 53.33 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 117.033 0.416 . . . . 5.5700000000000003 110.187 176.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.2 t-20 . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.44 -0.79 . . . . 6.8700000000000001 110.614 -178.508 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 112.29 -0.324 . . . . 1.71 112.29 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 17.8 m120 -119.69 147.78 44.16 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 110.115 -0.328 . . . . 2.0 110.115 178.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.13 119.35 17.24 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.906 -0.588 . . . . 0.23999999999999999 110.018 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.753 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.0 pt -101.11 -15.85 7.45 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 CA-C-N 115.422 -0.808 . . . . 0.14999999999999999 111.592 -171.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.83 176.26 42.51 Favored Glycine 0 N--CA 1.444 -0.815 0 C-N-CA 120.999 -0.62 . . . . 0.10000000000000001 111.595 -179.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.417 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 93.9 m-85 -144.89 151.1 38.18 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.74 0.305 . . . . 0.20000000000000001 110.432 -175.154 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.471 HG12 ' O ' ' A' ' 30' ' ' ASP . 31.4 mm -79.18 122.2 33.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.375 -0.375 . . . . 0.14000000000000001 111.012 -178.363 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 57.6 p -114.35 -24.4 8.91 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.302 0.573 . . . . 0.20000000000000001 110.661 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.554 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 55.5 tttm -139.76 146.85 40.03 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 108.605 -0.887 . . . . 2.3599999999999999 108.605 172.037 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.4 tt -160.24 140.63 11.69 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.128 -0.487 . . . . 0.20000000000000001 110.525 -176.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -146.44 152.46 39.08 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.155 -0.929 . . . . 1.9399999999999999 110.577 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.55 -160.7 53.82 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.883 -0.599 . . . . 0.27000000000000002 113.172 174.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 19.3 m -98.46 121.9 40.99 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 109.953 -0.388 . . . . 1.1599999999999999 109.953 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.56 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.8 m -139.18 153.57 24.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.669 0.747 . . . . 0.20000000000000001 111.819 -176.29 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.84 159.15 43.62 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.721 -1.127 . . . . 0.17000000000000001 109.082 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.561 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 1.3 p -131.21 133.77 62.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.097 -0.641 . . . . 0.16 110.608 172.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.486 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 8.5 mt-30 -97.73 97.88 9.38 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.284 -0.871 . . . . 0.51000000000000001 109.552 177.557 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.468 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 51.7 m -64.52 175.93 1.25 Allowed 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.471 -0.331 . . . . 1.25 110.547 -177.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 pt -58.75 -27.21 34.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 112.814 0.672 . . . . 0.58999999999999997 112.814 -175.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 56.0 m-80 -80.49 -10.8 59.73 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.85 0.357 . . . . 1.96 110.7 177.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 95.46 3.24 61.39 Favored Glycine 0 N--CA 1.452 -0.283 0 N-CA-C 111.71 -0.556 . . . . 0.32000000000000001 111.71 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.2 mm-40 -65.45 120.15 12.32 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.784 -0.208 . . . . 2.21 110.523 176.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.561 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.8 tt0 -95.77 108.33 20.64 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.716 -0.476 . . . . 1.0 109.716 -179.444 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.41 ' HG2' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -105.34 143.3 33.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.13 -0.486 . . . . 1.55 109.784 -179.788 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.4 p -74.26 131.24 35.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.846 -0.798 . . . . 0.34999999999999998 108.846 171.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' HG23 ' A' ' 14' ' ' VAL . 26.3 mt -93.45 127.44 39.09 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.191 -0.603 . . . . 0.32000000000000001 110.502 -179.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 45.5 mttp -110.62 179.25 4.12 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 107.604 -1.258 . . . . 1.6499999999999999 107.604 171.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.2 tp -68.12 143.39 55.45 Favored 'General case' 0 C--N 1.315 -0.915 0 C-N-CA 119.316 -0.954 . . . . 0.23000000000000001 109.417 175.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 87.07 -10.24 69.35 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.204 -0.998 . . . . 0.23999999999999999 113.057 176.242 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.471 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.8 m-20 -66.49 142.5 97.71 Favored Pre-proline 0 CA--C 1.515 -0.391 0 CA-C-O 121.108 0.48 . . . . 1.9199999999999999 109.788 175.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.417 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 35.7 Cg_endo -89.06 142.4 4.54 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 123.115 2.543 . . . . 0.22 112.713 -178.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.487 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.8 mm -102.57 136.8 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 CA-C-N 115.779 -0.646 . . . . 0.13 109.591 175.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.442 ' H ' ' CD ' ' A' ' 36' ' ' GLU . 80.9 m-85 -113.84 153.65 28.79 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.839 -0.619 . . . . 0.28999999999999998 109.561 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.553 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -69.87 111.55 5.68 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.378 -0.374 . . . . 0.17999999999999999 110.231 -176.268 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 124.28 -5.6 8.78 Favored Glycine 0 N--CA 1.445 -0.708 0 C-N-CA 120.601 -0.809 . . . . 0.17000000000000001 113.048 178.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.468 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 28.6 mt-10 -83.39 136.96 34.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.695 0.759 . . . . 0.52000000000000002 111.122 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.507 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -96.32 106.97 19.26 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 114.614 -1.175 . . . . 0.16 110.34 -178.168 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 6.0 t -81.37 133.2 29.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.114 0.483 . . . . 0.16 111.089 -173.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.1 mp -114.92 126.12 54.42 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.956 -1.02 . . . . 0.27000000000000002 109.636 178.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.3 p -119.8 152.39 37.34 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.613 -0.514 . . . . 0.23000000000000001 109.613 172.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -131.38 138.99 10.57 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 120.992 -0.623 . . . . 0.90000000000000002 112.211 179.33 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 56.47 -113.86 4.6 Favored Glycine 0 N--CA 1.451 -0.345 0 O-C-N 123.822 0.366 . . . . 1.79 113.204 178.256 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.9 p -89.16 24.15 2.23 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.985 0.421 . . . . 1.6399999999999999 111.34 -177.522 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -58.14 136.03 51.29 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.992 -0.549 . . . . 0.89000000000000001 112.418 177.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.545 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 23.2 m -154.12 136.24 14.76 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.625 -0.88 . . . . 0.84999999999999998 108.625 174.053 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 10.6 t -141.81 138.36 31.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 C-N-CA 120.385 -0.526 . . . . 0.25 111.158 -175.057 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.554 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.1 m -108.89 105.9 15.65 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.781 -0.645 . . . . 0.19 109.648 173.625 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.529 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 61.2 mt -94.5 109.45 22.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.896 -0.593 . . . . 0.14999999999999999 110.045 177.09 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.73 99.26 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 115.236 -0.893 . . . . 0.14000000000000001 109.335 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.504 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 66.9 m-85 -67.21 144.67 55.85 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.411 0.624 . . . . 0.32000000000000001 110.336 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -70.18 2.01 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 114.558 -1.201 . . . . 0.25 110.846 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -84.89 -21.97 29.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 114.925 -1.034 . . . . 0.75 110.725 177.105 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 115.99 -17.37 15.17 Favored Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 111.162 -0.775 . . . . 0.27000000000000002 111.162 -175.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.1 p -87.07 150.75 23.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.516 -0.342 . . . . 0.35999999999999999 111.042 178.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -126.13 150.2 48.42 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.277 -0.638 . . . . 1.51 109.277 178.363 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.529 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -125.14 171.39 14.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.012 0.434 . . . . 1.3899999999999999 111.366 178.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.534 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.1 p -137.81 130.08 40.62 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 115.461 -0.791 . . . . 0.81000000000000005 110.318 178.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.0 mt -105.08 136.87 37.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.881 -0.6 . . . . 0.32000000000000001 109.926 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.94 -163.59 27.89 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.979 -0.629 . . . . 1.02 112.328 179.153 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -112.5 150.5 18.29 Favored Glycine 0 N--CA 1.446 -0.695 0 C-N-CA 120.946 -0.645 . . . . 0.40000000000000002 111.736 -173.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 34.7 t70 56.89 22.68 7.35 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 121.723 0.773 . . . . 1.26 110.264 -173.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.3 m -105.64 164.02 12.23 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.122 0.487 . . . . 1.1899999999999999 111.338 -177.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.488 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.1 mt -140.86 128.2 22.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.506 -0.77 . . . . 0.38 109.374 176.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.429 HG21 HD11 ' A' ' 70' ' ' ILE . 11.0 p -149.61 138.68 15.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.852 0.358 . . . . 1.0 110.973 -177.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.507 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.9 tt0 -97.13 131.28 44.05 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.843 0.354 . . . . 0.67000000000000004 111.138 -176.038 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.628 ' SD ' HG21 ' A' ' 70' ' ' ILE . 17.8 mmt -62.94 90.48 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.651 -0.704 . . . . 0.88 111.177 177.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 6.6 p -126.13 -169.1 1.95 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.502 -0.772 . . . . 0.28999999999999998 110.241 -178.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -69.46 -26.61 64.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 117.814 0.279 . . . . 2.1299999999999999 111.157 -176.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -70.06 -22.93 63.02 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.972 0.891 . . . . 2.5099999999999998 109.688 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.628 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.9 mm -90.32 -51.76 11.48 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 114.72 -1.127 . . . . 0.25 110.762 176.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.753 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 -113.18 77.14 1.02 Allowed 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.491 -0.777 . . . . 0.31 110.729 -176.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 47.2 t-20 -80.52 107.82 13.64 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.852 -0.613 . . . . 1.46 109.413 171.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 26.1 p -76.21 133.81 40.05 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.463 -0.335 . . . . 0.68999999999999995 110.987 -178.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -141.35 14.19 2.75 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.923 -0.656 . . . . 1.9099999999999999 112.228 -177.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -67.48 -21.31 65.52 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 122.261 0.225 . . . . 5.5700000000000003 110.78 178.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.111 -0.947 . . . . 6.8700000000000001 110.86 178.165 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.858 0 N-CA-C 112.252 -0.339 . . . . 1.71 112.252 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 -95.84 160.47 14.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.914 0.388 . . . . 2.0 110.385 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.31 109.67 12.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.768 -0.651 . . . . 0.23999999999999999 109.623 178.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.842 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 29.5 pt -92.34 -11.39 9.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.088 -0.96 . . . . 0.14999999999999999 112.046 -169.564 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.05 177.45 42.79 Favored Glycine 0 CA--C 1.5 -0.85 0 C-N-CA 120.593 -0.813 . . . . 0.10000000000000001 111.48 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -144.98 151.05 37.98 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 120.954 0.407 . . . . 0.20000000000000001 110.883 -174.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.517 HG12 ' O ' ' A' ' 30' ' ' ASP . 21.2 mm -78.44 121.71 31.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 115.783 -0.644 . . . . 0.14000000000000001 110.903 -178.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 72.7 p -113.63 -21.16 10.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.343 0.592 . . . . 0.20000000000000001 110.406 178.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.464 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 84.4 tttt -142.63 145.2 33.25 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.775 -0.824 . . . . 2.3599999999999999 108.775 173.455 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.446 HD11 HG21 ' A' ' 14' ' ' VAL . 6.0 tt -159.47 142.62 14.29 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 120.765 0.317 . . . . 0.20000000000000001 110.945 -177.077 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.541 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 2.3 m-20 -148.82 165.24 32.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.67 -0.695 . . . . 1.9399999999999999 110.795 176.441 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 67.57 -149.67 50.87 Favored Glycine 0 N--CA 1.449 -0.466 0 CA-C-N 115.991 -0.55 . . . . 0.27000000000000002 113.183 175.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 29.8 t -108.9 133.64 52.64 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.042 -0.725 . . . . 1.1599999999999999 109.042 -179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.474 HG23 ' HB2' ' A' ' 26' ' ' LEU . 5.2 m -142.8 153.3 17.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.786 0.803 . . . . 0.20000000000000001 111.582 -176.467 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.26 157.99 43.3 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.683 -1.144 . . . . 0.17000000000000001 108.67 177.567 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.572 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.1 p -131.94 134.95 59.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 120.354 -0.538 . . . . 0.16 110.316 174.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.479 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -104.65 99.9 9.56 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.376 -0.829 . . . . 0.51000000000000001 109.56 178.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.489 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 22.5 p -62.96 178.46 0.47 Allowed 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.552 -0.295 . . . . 1.25 111.279 -175.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 2.9 pt -57.03 -33.61 42.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 112.597 0.591 . . . . 0.58999999999999997 112.597 -174.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.485 ' OD1' ' HG3' ' A' ' 22' ' ' GLN . 9.5 p30 -81.93 -12.07 58.57 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.894 -0.322 . . . . 1.96 110.762 179.298 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 105.42 7.58 36.98 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.768 -0.73 . . . . 0.32000000000000001 113.755 176.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.485 ' HG3' ' OD1' ' A' ' 20' ' ' ASN . 54.7 mt-30 -70.88 120.87 17.1 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 117.107 0.453 . . . . 2.21 111.127 179.203 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.527 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.6 tt0 -91.59 113.11 25.29 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.976 0.417 . . . . 1.0 109.969 178.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.92 138.22 51.39 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.793 -0.639 . . . . 1.55 109.796 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -70.61 134.96 29.11 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.422 0 N-CA-C 109.113 -0.699 . . . . 0.34999999999999998 109.113 175.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.6 HD22 ' OD1' ' A' ' 30' ' ' ASP . 5.4 mt -99.45 150.41 22.21 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.62 0.724 . . . . 0.32000000000000001 111.442 -177.508 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.544 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 41.1 mttp -135.52 173.12 12.07 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-N 114.424 -1.262 . . . . 1.6499999999999999 109.152 -171.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.52 141.78 46.74 Favored 'General case' 0 C--N 1.319 -0.724 0 C-N-CA 119.133 -1.027 . . . . 0.23000000000000001 109.347 177.257 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.61 0.96 85.92 Favored Glycine 0 N--CA 1.435 -1.395 0 C-N-CA 120.13 -1.034 . . . . 0.23999999999999999 111.824 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.6 ' OD1' HD22 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -78.36 142.45 62.88 Favored Pre-proline 0 C--O 1.234 0.256 0 CA-C-O 121.553 0.692 . . . . 1.9199999999999999 111.1 -179.187 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.04 133.74 11.26 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 123.771 2.981 . . . . 0.22 113.836 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mm -99.98 136.8 29.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.005 -0.998 . . . . 0.13 109.092 172.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -116.57 154.62 30.14 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 120.976 0.417 . . . . 0.28999999999999998 109.945 -178.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.509 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.7 t80 -71.51 115.7 11.0 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.003 -0.544 . . . . 0.17999999999999999 110.581 -175.462 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.13 7.61 22.89 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.461 -0.876 . . . . 0.17000000000000001 113.345 177.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.572 ' HB3' HG22 ' A' ' 16' ' ' VAL . 28.4 mt-10 -94.77 147.75 23.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 117.763 0.781 . . . . 0.52000000000000002 110.673 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.479 ' HB ' ' HB2' ' A' ' 17' ' ' GLN . 10.1 m -104.09 108.39 19.73 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.094 -0.957 . . . . 0.16 110.661 -176.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.507 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.2 t -83.56 121.88 36.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.315 0.579 . . . . 0.16 110.934 -175.094 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.3 mp -107.46 104.77 14.42 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.796 -1.093 . . . . 0.27000000000000002 109.679 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.461 ' HB ' ' HA3' ' A' ' 44' ' ' GLY . 69.3 p -99.93 156.47 17.12 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.651 -0.5 . . . . 0.23000000000000001 109.651 177.24 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -149.42 121.37 1.28 Allowed Glycine 0 N--CA 1.441 -0.994 0 C-N-CA 120.767 -0.73 . . . . 0.90000000000000002 111.982 179.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 59.51 89.73 0.02 OUTLIER Glycine 0 N--CA 1.448 -0.549 0 O-C-N 123.799 0.353 . . . . 1.79 113.576 177.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 22.7 t 62.08 32.78 17.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.077 0.465 . . . . 1.6399999999999999 111.004 175.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.541 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -77.17 83.81 1.07 Allowed Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.857 -0.687 . . . . 0.89000000000000001 111.797 177.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.1 m -102.33 109.92 21.72 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.334 -0.617 . . . . 0.84999999999999998 109.334 -174.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.1 t -126.63 132.46 70.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 CA-C-N 115.93 -0.577 . . . . 0.25 111.206 -169.248 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.464 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 96.0 m -109.02 108.24 18.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.031 -0.531 . . . . 0.19 110.288 178.359 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.457 HD13 ' HE2' ' A' ' 66' ' ' MET . 79.1 mt -97.75 102.69 13.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-N 115.216 -0.902 . . . . 0.14999999999999999 109.966 178.184 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -81.05 99.68 8.59 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.644 -0.707 . . . . 0.14000000000000001 109.371 178.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.572 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 48.8 m-85 -61.77 144.9 54.02 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.518 0.675 . . . . 0.32000000000000001 111.197 -178.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -72.13 -12.86 16.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.707 -1.133 . . . . 0.25 111.493 -170.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.428 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 28.6 t70 -74.55 -17.38 60.75 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.215 0.531 . . . . 0.75 110.529 176.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.78 -7.3 17.51 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.916 -0.659 . . . . 0.27000000000000002 111.896 -177.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.0 p -88.63 177.47 6.75 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.396 -0.224 . . . . 0.35999999999999999 110.396 176.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -151.58 157.38 42.13 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.259 -0.274 . . . . 1.51 110.259 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.513 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -143.53 150.78 17.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 116.35 -0.387 . . . . 1.3899999999999999 110.427 -177.689 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 9.1 p -126.57 133.16 69.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 121.318 0.58 . . . . 0.81000000000000005 110.668 179.458 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.5 mt -102.53 147.6 8.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.739 -0.664 . . . . 0.32000000000000001 110.196 -177.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -90.9 -178.44 43.48 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 120.733 -0.746 . . . . 1.02 111.413 175.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -101.57 148.57 17.95 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 121.043 -0.598 . . . . 0.40000000000000002 111.656 -172.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 31.0 t70 58.3 24.53 11.68 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-O 121.843 0.83 . . . . 1.26 110.179 -173.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.7 t -106.1 161.13 14.77 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.439 -0.8 . . . . 1.1899999999999999 110.445 -179.46 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.507 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 79.1 mt -139.88 118.47 11.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.859 -0.61 . . . . 0.38 109.629 179.063 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 12.5 p -140.45 141.4 32.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.508 -0.315 . . . . 1.0 110.829 -175.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.416 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 41.8 tt0 -97.99 126.84 43.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.905 0.383 . . . . 0.67000000000000004 110.332 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.457 ' HE2' HD13 ' A' ' 48' ' ' ILE . 50.5 mmm -67.06 89.54 0.18 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.66 -0.7 . . . . 0.88 110.658 -178.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.407 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 10.8 p -115.02 -165.98 1.07 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.819 -0.628 . . . . 0.28999999999999998 111.547 -175.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.83 -36.77 75.87 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.814 0.34 . . . . 2.1299999999999999 110.718 -177.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -61.97 -32.83 73.31 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.626 0.726 . . . . 2.5099999999999998 110.095 175.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.407 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.1 mm -75.41 -53.09 16.82 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 CA-C-N 114.476 -1.238 . . . . 0.25 111.029 178.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.842 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.5 t80 -103.34 81.3 1.92 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.65 -0.704 . . . . 0.31 109.993 -176.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -77.42 106.39 9.15 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.543 -0.753 . . . . 1.46 109.512 175.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 39.2 p -92.6 144.55 25.22 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.082 -0.508 . . . . 0.68999999999999995 111.561 -174.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -85.6 -17.17 62.48 Favored Glycine 0 N--CA 1.448 -0.52 0 N-CA-C 111.144 -0.782 . . . . 1.9099999999999999 111.144 172.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -83.79 -29.7 27.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.991 0.424 . . . . 5.5700000000000003 110.04 175.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 t30 . . . . . 0 C--O 1.248 1.022 0 CA-C-O 117.957 -1.02 . . . . 6.8700000000000001 110.689 179.316 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.657 0 N-CA-C 112.027 -0.429 . . . . 1.71 112.027 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 -99.18 146.76 25.82 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.908 0.385 . . . . 2.0 110.517 -178.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.06 113.17 18.04 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-O 121.547 0.689 . . . . 0.23999999999999999 110.351 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.828 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 36.9 pt -97.54 -14.09 7.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-N 115.106 -0.952 . . . . 0.14999999999999999 111.709 -172.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.9 176.39 42.52 Favored Glycine 0 CA--C 1.502 -0.767 0 N-CA-C 111.01 -0.836 . . . . 0.10000000000000001 111.01 179.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -143.35 151.57 40.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.041 0.448 . . . . 0.20000000000000001 111.041 -175.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 35.2 mm -78.19 121.87 31.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.94 -0.573 . . . . 0.14000000000000001 110.689 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.8 p -115.45 -20.28 10.31 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 0.20000000000000001 110.546 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.569 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.1 tttt -143.83 143.3 31.26 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.47 -0.937 . . . . 2.3599999999999999 108.47 173.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.3 tt -160.27 140.28 11.39 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-O 121.074 0.464 . . . . 0.20000000000000001 111.107 -178.026 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -149.08 149.75 31.6 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.164 -0.925 . . . . 1.9399999999999999 110.479 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.46 -160.2 41.54 Favored Glycine 0 N--CA 1.448 -0.524 0 C-N-CA 120.972 -0.632 . . . . 0.27000000000000002 113.035 175.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 16.0 m -101.32 119.25 38.47 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 120.667 0.27 . . . . 1.1599999999999999 110.312 -177.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.535 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.8 m -136.91 152.0 28.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.817 0.817 . . . . 0.20000000000000001 111.753 -176.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 159.34 42.7 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 114.706 -1.134 . . . . 0.17000000000000001 108.703 178.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.573 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.0 OUTLIER -131.57 132.62 62.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 121.29 0.567 . . . . 0.16 110.424 174.938 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.519 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.9 mt-30 -98.91 99.23 10.27 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.445 -0.798 . . . . 0.51000000000000001 109.734 178.592 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.561 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 13.9 m -60.94 172.85 0.88 Allowed 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 110.039 -0.356 . . . . 1.25 110.039 -179.223 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.9 pt -60.99 -14.7 10.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 112.248 0.462 . . . . 0.58999999999999997 112.248 -177.499 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -85.53 -9.32 57.56 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.178 0.514 . . . . 1.96 110.372 177.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 88.54 5.66 74.78 Favored Glycine 0 CA--C 1.508 -0.372 0 N-CA-C 110.877 -0.889 . . . . 0.32000000000000001 110.877 -175.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.401 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 92.7 mt-30 -70.21 118.52 13.13 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.792 -0.704 . . . . 2.21 110.664 178.272 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 6.5 tt0 -90.41 111.28 22.47 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.228 0.537 . . . . 1.0 109.629 177.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.4 ' NH2' ' HD2' ' A' ' 31' ' ' PRO . 0.0 OUTLIER -115.35 142.14 47.09 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.232 -0.894 . . . . 1.55 109.706 -177.311 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -75.65 143.19 13.5 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 120.835 0.35 . . . . 0.34999999999999998 110.144 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' HG23 ' A' ' 14' ' ' VAL . 24.9 mt -110.12 128.97 55.76 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.994 0.426 . . . . 0.32000000000000001 110.933 179.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 77.5 mttt -117.77 -179.72 3.82 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 108.246 -1.02 . . . . 1.6499999999999999 108.246 170.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.4 tp -65.39 148.58 51.47 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 119.573 -0.851 . . . . 0.23000000000000001 110.3 178.586 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.55 -7.24 58.59 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 120.531 -0.842 . . . . 0.23999999999999999 112.677 177.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.9 143.68 97.16 Favored Pre-proline 0 CA--C 1.512 -0.515 0 CA-C-O 121.187 0.518 . . . . 1.9199999999999999 110.105 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.4 ' HD2' ' NH2' ' A' ' 24' ' ' ARG . 24.6 Cg_endo -90.15 131.4 1.79 Allowed 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 123.262 2.641 . . . . 0.22 111.827 178.641 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.523 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.3 mm -94.08 134.48 31.53 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 109.747 -0.464 . . . . 0.13 109.747 176.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -111.98 150.25 30.84 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-N 115.558 -0.746 . . . . 0.28999999999999998 109.396 -179.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.556 ' HD2' HG21 ' A' ' 4' ' ' ILE . 3.0 t80 -67.3 116.8 8.48 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.189 -0.46 . . . . 0.17999999999999999 110.364 -174.524 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.17 -10.42 20.28 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.789 -0.72 . . . . 0.17000000000000001 113.234 176.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.573 ' HB3' HG22 ' A' ' 16' ' ' VAL . 28.7 mt-10 -76.02 140.4 41.94 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 117.877 0.839 . . . . 0.52000000000000002 110.685 179.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 28.0 m -101.43 109.04 20.8 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.809 -1.087 . . . . 0.16 110.84 -175.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.6 t -82.11 132.04 32.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.189 0.518 . . . . 0.16 110.934 -174.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.2 mp -117.84 109.49 16.62 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 114.975 -1.011 . . . . 0.27000000000000002 110.017 -177.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 68.3 p -105.26 157.01 17.6 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.428 -0.509 . . . . 0.23000000000000001 109.789 175.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -136.0 137.16 8.92 Favored Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 120.81 -0.71 . . . . 0.90000000000000002 111.872 178.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 53.73 -112.22 2.34 Favored Glycine 0 N--CA 1.449 -0.494 0 O-C-N 123.931 0.43 . . . . 1.79 113.207 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 33.4 m -87.6 28.11 1.03 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.91 0.386 . . . . 1.6399999999999999 111.491 -176.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.27 130.38 35.07 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.949 -0.644 . . . . 0.89000000000000001 111.874 176.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.53 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 7.3 m -150.68 126.24 10.2 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.349 -0.611 . . . . 0.84999999999999998 109.349 174.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.517 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 7.5 t -134.72 147.02 29.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 C-N-CA 120.901 -0.32 . . . . 0.25 111.107 -173.444 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.569 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -117.98 110.63 17.93 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.157 -0.474 . . . . 0.19 110.01 173.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.554 ' HB ' ' CG2' ' A' ' 56' ' ' VAL . 64.4 mt -98.66 109.35 23.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.805 -0.634 . . . . 0.14999999999999999 110.014 176.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -83.44 102.22 11.92 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.418 -0.81 . . . . 0.14000000000000001 109.171 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.46 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 65.7 m-85 -70.1 144.43 52.11 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.372 0.606 . . . . 0.32000000000000001 110.78 -178.738 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.75 1.9 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 114.651 -1.159 . . . . 0.25 111.725 -171.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -92.51 -11.97 33.18 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.98 -0.554 . . . . 0.75 109.962 175.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.79 -5.41 25.93 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.516 -0.849 . . . . 0.27000000000000002 112.726 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.6 p -93.95 159.79 15.01 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 122.819 -0.224 . . . . 0.35999999999999999 110.717 177.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -134.63 143.6 47.39 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.417 -0.586 . . . . 1.51 109.417 179.178 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.554 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.9 m -121.75 164.16 18.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.103 0.478 . . . . 1.3899999999999999 111.441 177.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 14.8 p -131.86 129.44 60.9 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.938 0 CA-C-N 115.241 -0.89 . . . . 0.81000000000000005 109.875 177.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.53 ' O ' ' HA ' ' A' ' 45' ' ' SER . 17.1 mt -103.43 131.58 51.62 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 CA-C-N 116.257 -0.428 . . . . 0.32000000000000001 109.993 -178.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -78.23 -163.92 23.56 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 121.151 -0.547 . . . . 1.02 112.259 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -108.93 145.25 16.5 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.772 -0.728 . . . . 0.40000000000000002 111.728 -173.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 28.5 t70 58.24 25.22 12.38 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-O 121.547 0.689 . . . . 1.26 110.217 -174.313 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.4 m -103.04 156.47 17.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.957 -0.565 . . . . 1.1899999999999999 110.935 -179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.499 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 89.7 mt -140.6 117.31 8.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.618 -0.719 . . . . 0.38 109.588 178.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.8 p -147.66 143.96 19.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 110.108 -0.33 . . . . 1.0 110.108 -177.16 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.594 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 0.3 OUTLIER -103.99 139.21 39.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.545 0.688 . . . . 0.67000000000000004 111.079 -176.113 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.553 ' SD ' HG21 ' A' ' 70' ' ' ILE . 22.7 mmt -64.19 89.62 0.06 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.627 -1.17 . . . . 0.88 111.667 -179.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.428 HG23 ' CG ' ' A' ' 65' ' ' GLU . 2.3 p -114.25 -172.15 2.05 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.622 -0.717 . . . . 0.28999999999999998 110.125 177.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.7 p-10 -71.98 -24.45 61.58 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.748 0.309 . . . . 2.1299999999999999 110.657 -178.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 29.7 mm-40 -70.08 -23.54 63.08 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.472 0.653 . . . . 2.5099999999999998 110.229 175.384 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.553 HG21 ' SD ' ' A' ' 66' ' ' MET . 1.4 mm -88.17 -56.52 5.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.835 0 CA-C-N 115.119 -0.946 . . . . 0.25 109.728 175.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.828 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.7 t80 -100.46 80.02 2.18 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.543 -1.208 . . . . 0.31 109.786 -178.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 10.7 t30 -80.05 105.92 11.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.641 -0.709 . . . . 1.46 109.694 176.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 24.3 p -80.04 126.3 30.88 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.997 -0.547 . . . . 0.68999999999999995 111.512 -176.16 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -79.68 -37.65 22.59 Favored Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 110.688 -0.965 . . . . 1.9099999999999999 110.688 174.042 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -95.37 104.82 16.73 Favored 'General case' 0 C--N 1.324 -0.507 0 N-CA-C 109.273 -0.64 . . . . 5.5700000000000003 109.273 173.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.7 m-80 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.568 -0.729 . . . . 6.8700000000000001 110.699 -176.774 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.643 0 N-CA-C 112.037 -0.425 . . . . 1.71 112.037 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -112.25 149.03 32.9 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 110.165 -0.309 . . . . 2.0 110.165 178.217 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.11 108.09 8.78 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.798 -0.816 . . . . 0.23999999999999999 108.798 174.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.749 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 31.3 pt -92.96 -10.42 9.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.22 -0.9 . . . . 0.14999999999999999 111.419 -170.485 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -167.78 176.3 42.47 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.623 -0.799 . . . . 0.10000000000000001 111.469 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -144.49 150.07 36.98 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.04 0.448 . . . . 0.20000000000000001 110.446 -175.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.578 HG12 ' O ' ' A' ' 30' ' ' ASP . 22.2 mm -78.04 123.68 35.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 115.775 -0.648 . . . . 0.14000000000000001 110.972 -177.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 p -116.19 -23.41 8.45 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.127 0.489 . . . . 0.20000000000000001 110.856 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.575 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 25.8 tptp -139.99 136.18 33.49 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 107.959 -1.126 . . . . 2.3599999999999999 107.959 173.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.492 HD11 HG21 ' A' ' 14' ' ' VAL . 6.4 tt -152.85 138.11 17.47 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.016 0.436 . . . . 0.20000000000000001 111.043 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 23.4 m-20 -147.95 157.24 43.42 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.158 -0.928 . . . . 1.9399999999999999 110.861 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.03 -158.79 46.7 Favored Glycine 0 N--CA 1.448 -0.509 0 CA-C-N 115.842 -0.617 . . . . 0.27000000000000002 112.752 176.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.9 t -103.68 118.69 37.31 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.251 -0.648 . . . . 1.1599999999999999 109.251 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.601 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.7 m -135.65 153.17 32.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.687 0.756 . . . . 0.20000000000000001 111.681 -175.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.11 158.86 44.52 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 114.796 -1.093 . . . . 0.17000000000000001 108.687 -178.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.681 ' O ' ' HA ' ' A' ' 23' ' ' GLU . 0.8 OUTLIER -136.61 134.5 49.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 119.917 -0.713 . . . . 0.16 111.375 173.636 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.419 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.1 mt-30 -97.56 100.32 11.73 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 114.924 -1.034 . . . . 0.51000000000000001 108.98 174.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.505 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 58.1 p -63.01 179.06 0.41 Allowed 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.962 -0.295 . . . . 1.25 111.145 -175.139 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.8 pt -60.98 -21.17 23.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.943 0.401 . . . . 0.58999999999999997 110.937 176.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -80.1 -9.91 59.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.14 -0.482 . . . . 1.96 110.14 176.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.93 12.45 71.35 Favored Glycine 0 CA--C 1.504 -0.652 0 N-CA-C 110.973 -0.851 . . . . 0.32000000000000001 110.973 179.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.4 mt-30 -89.06 121.74 31.71 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.9 -0.65 . . . . 2.21 110.81 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.681 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 22.2 tt0 -89.65 118.13 29.04 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.903 -0.59 . . . . 1.0 110.46 178.75 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.61 ' HG2' HG12 ' A' ' 16' ' ' VAL . 22.1 ptt-85 -119.16 165.96 13.55 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.502 -0.555 . . . . 1.55 109.502 175.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.7 p -91.24 127.49 43.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.372 0.606 . . . . 0.34999999999999998 109.432 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.601 ' HB2' HG23 ' A' ' 14' ' ' VAL . 4.1 mt -90.49 151.17 21.49 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.5 0.667 . . . . 0.32000000000000001 111.351 -175.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.41 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 18.6 mttp -141.87 176.15 9.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.748 -1.114 . . . . 1.6499999999999999 108.324 -171.257 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -74.29 141.63 45.27 Favored 'General case' 0 C--N 1.313 -1.014 0 C-N-CA 119.303 -0.959 . . . . 0.23000000000000001 108.988 176.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.77 7.31 88.31 Favored Glycine 0 N--CA 1.437 -1.249 0 C-N-CA 119.918 -1.134 . . . . 0.23999999999999999 111.917 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.578 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -85.03 140.37 37.09 Favored Pre-proline 0 CA--C 1.52 -0.184 0 CA-C-O 121.612 0.72 . . . . 1.9199999999999999 110.472 178.6 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -78.21 132.01 11.16 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.677 2.918 . . . . 0.22 113.426 -178.454 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.413 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.4 mm -99.45 133.61 41.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 0.13 109.175 173.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -113.88 152.61 30.51 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 116.145 -0.479 . . . . 0.28999999999999998 110.238 -178.133 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.7 t80 -68.48 111.77 4.9 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.963 -0.562 . . . . 0.17999999999999999 110.019 -177.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.67 6.25 19.62 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 120.34 -0.933 . . . . 0.17000000000000001 113.348 178.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.545 ' O ' ' HG2' ' A' ' 66' ' ' MET . 39.9 mt-10 -91.05 135.12 33.96 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 117.869 0.834 . . . . 0.52000000000000002 110.739 179.585 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.541 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 9.0 m -94.47 106.12 18.09 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.99 -1.005 . . . . 0.16 110.94 -176.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.544 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 4.3 t -82.47 129.58 37.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.137 0.494 . . . . 0.16 110.916 -175.209 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.6 mp -117.31 108.09 15.19 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.223 -0.899 . . . . 0.27000000000000002 109.694 -178.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 82.7 p -105.13 153.5 21.43 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.9 -0.408 . . . . 0.23000000000000001 109.9 178.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -128.66 142.3 13.4 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 121.115 -0.564 . . . . 0.90000000000000002 111.886 178.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 55.27 -115.49 5.79 Favored Glycine 0 N--CA 1.451 -0.337 0 O-C-N 123.756 0.327 . . . . 1.79 113.129 178.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 17.1 t -95.04 45.31 1.1 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.332 0.587 . . . . 1.6399999999999999 110.388 -178.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.46 135.92 27.62 Favored Glycine 0 N--CA 1.448 -0.558 0 CA-C-N 115.702 -0.681 . . . . 0.89000000000000001 111.487 175.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 50.7 m -152.79 134.98 14.93 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 117.286 0.543 . . . . 0.84999999999999998 109.596 173.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 14.0 t -143.36 129.77 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-O 120.677 0.275 . . . . 0.25 111.034 -175.124 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.575 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 98.9 m -99.26 105.77 17.82 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.533 -0.543 . . . . 0.19 109.533 172.267 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.556 HD13 ' HE2' ' A' ' 66' ' ' MET . 69.3 mt -95.89 107.43 19.66 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 CA-C-N 115.821 -0.627 . . . . 0.14999999999999999 109.997 176.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.74 104.96 13.38 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.322 -0.853 . . . . 0.14000000000000001 109.08 176.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.497 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 60.9 m-85 -69.96 152.7 44.15 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.601 0.715 . . . . 0.32000000000000001 110.746 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.5 p -72.61 -11.6 15.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-N 114.654 -1.157 . . . . 0.25 111.496 -170.198 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -81.17 -21.77 39.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.102 0.477 . . . . 0.75 110.598 176.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 118.43 -7.12 14.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.615 -0.802 . . . . 0.27000000000000002 112.182 -177.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.5 p -85.19 150.11 25.04 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 110.366 -0.235 . . . . 0.35999999999999999 110.366 176.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -127.53 147.4 50.32 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 120.664 -0.414 . . . . 1.51 109.932 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.541 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 6.8 m -129.75 171.32 17.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-O 121.117 0.484 . . . . 1.3899999999999999 111.596 178.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.523 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.8 p -137.61 134.88 46.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.169 -0.923 . . . . 0.81000000000000005 110.168 177.517 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.604 ' O ' ' HA ' ' A' ' 45' ' ' SER . 20.7 mt -107.43 136.09 43.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.4 -0.364 . . . . 0.32000000000000001 110.309 179.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -81.51 -169.88 43.05 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 121.083 -0.579 . . . . 1.02 112.37 178.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -110.34 152.8 17.28 Favored Glycine 0 CA--C 1.504 -0.642 0 N-CA-C 111.595 -0.602 . . . . 0.40000000000000002 111.595 -173.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.3 t70 56.65 21.73 6.1 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 121.963 0.887 . . . . 1.26 109.775 -172.495 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.0 m -106.18 158.97 16.45 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.721 -0.672 . . . . 1.1899999999999999 111.297 -176.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.544 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 86.6 mt -139.99 119.63 12.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.417 -0.811 . . . . 0.38 109.459 178.329 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.4 p -145.71 138.3 20.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 120.904 0.383 . . . . 1.0 110.654 -178.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 39.0 tt0 -92.01 130.55 37.73 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.222 -0.444 . . . . 0.67000000000000004 109.963 179.332 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.556 ' HE2' HD13 ' A' ' 48' ' ' ILE . 60.8 mmm -66.67 89.56 0.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.948 -0.569 . . . . 0.88 110.591 -179.252 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 17.0 p -115.46 -165.34 1.02 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.819 -0.628 . . . . 0.28999999999999998 111.47 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -64.89 -39.31 93.33 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.182 -0.463 . . . . 2.1299999999999999 111.061 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -64.35 -28.86 69.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.843 0.83 . . . . 2.5099999999999998 110.075 178.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -77.48 -46.45 27.79 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.734 -1.121 . . . . 0.25 111.212 176.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.749 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 -110.48 79.48 1.21 Allowed 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.638 -0.71 . . . . 0.31 110.662 -174.323 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -81.61 106.94 13.96 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.789 -0.641 . . . . 1.46 109.748 174.394 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.1 p -82.2 137.86 34.81 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.424 -0.353 . . . . 0.68999999999999995 111.471 -177.213 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 109.07 97.67 2.5 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.785 -0.721 . . . . 1.9099999999999999 113.232 176.039 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -83.3 168.03 17.06 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.968 0.413 . . . . 5.5700000000000003 110.365 173.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.3 t30 . . . . . 0 C--O 1.251 1.145 0 CA-C-O 118.662 -0.685 . . . . 6.8700000000000001 109.997 178.216 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.796 0 N-CA-C 112.028 -0.429 . . . . 1.71 112.028 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.0 p-10 -88.31 162.27 16.68 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.031 0.444 . . . . 2.0 110.597 -179.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.67 109.36 13.99 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.648 -0.705 . . . . 0.23999999999999999 109.584 178.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.773 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 32.9 pt -92.97 -12.99 8.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 114.896 -1.047 . . . . 0.14999999999999999 111.841 -170.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -170.38 176.34 44.02 Favored Glycine 0 CA--C 1.501 -0.814 0 C-N-CA 120.61 -0.805 . . . . 0.10000000000000001 111.688 179.546 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -143.94 149.39 36.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.972 0.415 . . . . 0.20000000000000001 110.961 -174.332 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.44 HD12 ' CG1' ' A' ' 46' ' ' VAL . 37.6 mm -76.43 124.08 33.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.829 -0.623 . . . . 0.14000000000000001 111.782 -176.147 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.2 p -116.75 -20.68 9.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.034 0.445 . . . . 0.20000000000000001 111.403 179.099 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.606 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 23.3 tptm -140.21 136.24 33.2 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 108.104 -1.073 . . . . 2.3599999999999999 108.104 174.359 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.595 HD11 HG21 ' A' ' 14' ' ' VAL . 5.6 tt -155.71 139.66 16.32 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 120.395 -0.522 . . . . 0.20000000000000001 111.552 -179.42 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.574 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 25.9 t70 -144.76 155.77 43.71 Favored 'General case' 0 CA--C 1.496 -1.119 0 CA-C-N 115.655 -0.702 . . . . 1.9399999999999999 110.914 173.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 84.16 -162.56 38.72 Favored Glycine 0 N--CA 1.419 -2.462 0 CA-C-N 115.005 -0.998 . . . . 0.27000000000000002 112.866 164.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.4 m -92.15 116.24 28.77 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 109.841 -0.429 . . . . 1.1599999999999999 109.841 177.721 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.595 HG21 HD11 ' A' ' 10' ' ' LEU . 3.7 m -135.5 152.67 32.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.711 0.767 . . . . 0.20000000000000001 111.397 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -149.98 158.3 44.02 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 114.701 -1.136 . . . . 0.17000000000000001 108.79 -178.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.691 HG12 ' HG2' ' A' ' 24' ' ' ARG . 1.0 OUTLIER -131.62 133.11 61.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 C-N-CA 119.971 -0.692 . . . . 0.16 111.244 173.933 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.493 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 5.6 mt-30 -97.7 99.1 10.44 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.004 -0.998 . . . . 0.51000000000000001 109.503 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.477 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 20.0 m -64.52 176.54 1.08 Allowed 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 116.344 -0.389 . . . . 1.25 110.584 -178.352 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 pt -59.66 -26.91 36.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 O-C-N 122.005 -0.434 . . . . 0.58999999999999997 111.569 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 55.6 m-20 -71.82 -16.51 62.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.04 0.448 . . . . 1.96 110.678 176.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 92.52 4.87 65.55 Favored Glycine 0 N--CA 1.451 -0.318 0 N-CA-C 110.839 -0.905 . . . . 0.32000000000000001 110.839 -175.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 92.5 mt-30 -73.53 129.19 37.45 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.827 -0.686 . . . . 2.21 110.619 179.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.666 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 6.8 tt0 -106.37 109.18 21.03 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.411 -0.359 . . . . 1.0 110.601 -176.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.691 ' HG2' HG12 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -109.57 165.74 11.43 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.669 -0.493 . . . . 1.55 109.669 176.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.4 p -89.92 139.45 17.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 115.862 -0.608 . . . . 0.34999999999999998 109.425 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.505 ' HB2' HG23 ' A' ' 14' ' ' VAL . 22.6 mt -103.91 131.1 51.47 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.129 0.49 . . . . 0.32000000000000001 110.799 179.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 41.3 mttp -118.46 -177.12 3.22 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 107.939 -1.134 . . . . 1.6499999999999999 107.939 171.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -66.43 146.7 54.26 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 119.859 -0.736 . . . . 0.23000000000000001 109.519 175.054 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.92 1.58 87.55 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 120.13 -1.033 . . . . 0.23999999999999999 112.918 176.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.401 ' O ' HG12 ' A' ' 7' ' ' ILE . 2.4 m-20 -78.78 144.75 65.04 Favored Pre-proline 0 CA--C 1.517 -0.317 0 CA-C-O 121.103 0.478 . . . . 1.9199999999999999 110.608 176.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo -79.5 142.95 16.77 Favored 'Trans proline' 0 N--CA 1.453 -0.909 0 C-N-CA 122.967 2.445 . . . . 0.22 112.743 178.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.454 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 31.3 mm -108.44 135.97 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-N 115.614 -0.721 . . . . 0.13 109.092 171.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 58.7 m-85 -115.96 152.45 33.46 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 116.218 -0.446 . . . . 0.28999999999999998 110.066 -177.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.529 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.4 t80 -69.41 110.89 4.94 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.872 -0.604 . . . . 0.17999999999999999 110.469 -176.397 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.58 4.06 15.76 Favored Glycine 0 N--CA 1.445 -0.734 0 C-N-CA 120.478 -0.868 . . . . 0.17000000000000001 113.351 178.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.49 ' O ' ' HG2' ' A' ' 66' ' ' MET . 35.7 mt-10 -93.22 144.97 24.79 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 117.819 0.809 . . . . 0.52000000000000002 110.832 -179.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.5 m -105.01 109.16 21.05 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.383 -0.826 . . . . 0.16 110.921 -174.652 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -83.46 128.36 38.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.349 0.595 . . . . 0.16 111.028 -175.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.5 mp -114.29 106.5 14.4 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 114.759 -1.109 . . . . 0.27000000000000002 109.716 -178.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 58.4 p -105.07 154.08 20.63 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 120.881 0.372 . . . . 0.23000000000000001 110.086 178.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -129.97 139.51 11.01 Favored Glycine 0 N--CA 1.442 -0.94 0 N-CA-C 111.517 -0.633 . . . . 0.90000000000000002 111.517 178.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 58.32 -104.25 0.45 Allowed Glycine 0 N--CA 1.45 -0.418 0 O-C-N 123.782 0.342 . . . . 1.79 113.402 179.272 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 19.5 m -103.9 20.03 18.9 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.696 0.284 . . . . 1.6399999999999999 110.932 -177.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.574 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -59.76 96.34 0.08 OUTLIER Glycine 0 C--O 1.224 -0.471 0 CA-C-N 115.955 -0.566 . . . . 0.89000000000000001 112.97 178.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 40.4 t -119.45 138.45 53.12 Favored 'General case' 0 CA--C 1.501 -0.913 0 N-CA-C 109.08 -0.711 . . . . 0.84999999999999998 109.08 -178.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.4 t -145.35 136.75 20.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.284 0 CA-C-N 115.841 -0.618 . . . . 0.25 111.001 -168.408 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.606 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 91.4 m -111.09 112.62 24.55 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.222 0.534 . . . . 0.19 109.876 175.427 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.466 HD13 ' HE2' ' A' ' 66' ' ' MET . 77.1 mt -99.78 103.52 14.87 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.205 -0.907 . . . . 0.14999999999999999 110.098 178.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.59 101.53 7.47 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.259 -0.882 . . . . 0.14000000000000001 109.44 177.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.529 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 51.9 m-85 -65.8 143.66 57.34 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.689 0.757 . . . . 0.32000000000000001 110.988 -178.748 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -69.03 -12.36 15.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 114.285 -1.325 . . . . 0.25 111.427 -171.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.485 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 23.3 t70 -74.48 -21.67 59.46 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.169 -0.469 . . . . 0.75 110.624 177.323 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.39 -17.22 8.46 Favored Glycine 0 N--CA 1.448 -0.533 0 C-N-CA 120.815 -0.707 . . . . 0.27000000000000002 112.137 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 6.1 p -85.86 164.78 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 122.084 0.154 . . . . 0.35999999999999999 110.729 178.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -133.54 163.44 29.39 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 110.158 -0.312 . . . . 1.51 110.158 -179.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.529 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.5 OUTLIER -146.05 157.1 12.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.423 -0.353 . . . . 1.3899999999999999 110.568 -177.409 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.539 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.9 p -133.14 133.91 58.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.166 0.508 . . . . 0.81000000000000005 110.916 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 20.6 mt -104.04 137.7 31.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.871 -0.604 . . . . 0.32000000000000001 109.952 -179.533 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -83.07 174.53 52.67 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.387 -0.911 . . . . 1.02 111.475 176.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.67 151.29 19.83 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 111.283 -0.727 . . . . 0.40000000000000002 111.283 -173.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.37 26.14 12.13 Favored 'General case' 0 CA--C 1.535 0.404 0 CA-C-O 121.858 0.837 . . . . 1.26 109.448 -173.425 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 t -111.55 162.58 14.98 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 115.425 -0.807 . . . . 1.1899999999999999 110.944 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 85.2 mt -140.37 124.87 18.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.778 -0.646 . . . . 0.38 109.533 178.197 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.0 p -150.11 142.32 17.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-O 120.841 0.353 . . . . 1.0 110.843 -178.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.534 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.3 tt0 -94.79 136.08 35.52 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.892 0.377 . . . . 0.67000000000000004 110.528 178.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.49 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 50.5 mmm -71.46 88.57 0.91 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.697 -0.683 . . . . 0.88 110.393 179.179 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -111.08 -163.67 0.86 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.057 -0.519 . . . . 0.28999999999999998 111.249 -177.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -77.1 -28.24 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.876 -0.147 . . . . 2.1299999999999999 111.003 -178.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 67.9 mm-40 -66.68 -29.47 69.48 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.95 0.881 . . . . 2.5099999999999998 109.684 173.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.479 HG21 ' HE3' ' A' ' 66' ' ' MET . 1.5 mm -77.35 -55.35 10.79 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.268 -1.333 . . . . 0.25 110.345 176.352 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.773 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.8 t80 -109.4 76.41 1.0 Allowed 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.271 -0.877 . . . . 0.31 109.742 -178.007 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -81.34 96.35 7.29 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.747 -0.66 . . . . 1.46 109.835 177.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 33.4 p -72.05 131.81 43.38 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.339 -0.392 . . . . 0.68999999999999995 110.806 -179.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 88.52 27.8 23.8 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.634 -0.793 . . . . 1.9099999999999999 111.883 179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -82.8 79.61 9.13 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.346 0.593 . . . . 5.5700000000000003 109.976 179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.339 -0.839 . . . . 6.8700000000000001 110.195 179.869 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.743 0 N-CA-C 112.344 -0.302 . . . . 1.71 112.344 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -120.22 141.83 49.57 Favored 'General case' 0 CA--C 1.512 -0.496 0 N-CA-C 109.223 -0.658 . . . . 2.0 109.223 177.127 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.52 109.42 12.68 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.503 0.668 . . . . 0.23999999999999999 109.906 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.786 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 33.5 pt -96.92 -13.2 8.17 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.83 -1.077 . . . . 0.14999999999999999 111.577 -171.593 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.8 174.07 43.4 Favored Glycine 0 CA--C 1.501 -0.818 0 N-CA-C 111.171 -0.772 . . . . 0.10000000000000001 111.171 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -142.98 148.69 37.24 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.96 0.41 . . . . 0.20000000000000001 111.247 -174.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.479 HD13 HG12 ' A' ' 48' ' ' ILE . 35.8 mm -77.01 121.67 29.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.704 -0.68 . . . . 0.14000000000000001 111.157 -177.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 71.1 p -116.53 -21.51 9.15 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.067 0.461 . . . . 0.20000000000000001 111.017 179.284 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.589 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 50.8 tptt -141.74 136.95 31.28 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.536 -0.913 . . . . 2.3599999999999999 108.536 173.275 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.532 HD11 HG21 ' A' ' 14' ' ' VAL . 6.1 tt -152.97 142.83 22.12 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 120.883 0.373 . . . . 0.20000000000000001 111.156 -178.007 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -143.97 141.85 30.4 Favored 'General case' 0 CA--C 1.499 -0.998 0 CA-C-N 115.777 -0.647 . . . . 1.9399999999999999 111.767 177.315 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.21 -148.88 19.56 Favored Glycine 0 N--CA 1.422 -2.28 0 CA-C-N 114.695 -1.139 . . . . 0.27000000000000002 113.159 164.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 4.2 t -104.49 113.04 26.35 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.527 -0.546 . . . . 1.1599999999999999 109.527 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.537 HG23 ' HB2' ' A' ' 26' ' ' LEU . 3.3 m -133.18 152.89 36.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.562 0.696 . . . . 0.20000000000000001 111.411 -177.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.18 159.43 43.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.959 -1.019 . . . . 0.17000000000000001 108.477 179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.544 HG22 ' HB3' ' A' ' 36' ' ' GLU . 1.1 p -131.92 129.35 60.65 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 C-N-CA 119.957 -0.697 . . . . 0.16 110.691 175.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.461 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 1.9 mt-30 -93.36 98.71 11.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.44 -0.8 . . . . 0.51000000000000001 108.972 177.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.51 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.1 m -65.23 179.13 0.77 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 115.962 -0.563 . . . . 1.25 110.495 -176.814 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 15.1 pt -69.21 -4.88 4.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.913 0.709 . . . . 0.58999999999999997 112.913 -172.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 57.0 m-80 -95.78 -5.35 42.13 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.176 0.513 . . . . 1.96 109.944 173.004 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.32 8.56 74.47 Favored Glycine 0 CA--C 1.507 -0.456 0 N-CA-C 110.709 -0.956 . . . . 0.32000000000000001 110.709 -177.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -78.65 120.89 23.97 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 114.958 -0.621 . . . . 2.21 110.589 -179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.455 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 8.5 tt0 -89.25 109.9 20.73 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.323 0.582 . . . . 1.0 110.224 -179.016 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.83 144.74 39.37 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.206 -0.907 . . . . 1.55 109.711 -176.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.9 p -73.28 141.96 15.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.783 0.325 . . . . 0.34999999999999998 110.268 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HB2' HG23 ' A' ' 14' ' ' VAL . 16.4 mt -110.83 124.07 51.32 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.047 0.451 . . . . 0.32000000000000001 110.552 177.161 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 36.3 mtmt -115.67 178.73 4.2 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.511 -0.922 . . . . 1.6499999999999999 108.511 173.126 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.5 tp -65.61 147.74 52.9 Favored 'General case' 0 C--N 1.318 -0.769 0 C-N-CA 119.766 -0.774 . . . . 0.23000000000000001 109.909 179.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.52 -8.73 63.99 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.237 -0.982 . . . . 0.23999999999999999 112.57 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.403 ' HA ' ' HD3' ' A' ' 31' ' ' PRO . 0.4 OUTLIER -65.08 144.59 99.09 Favored Pre-proline 0 CA--C 1.515 -0.377 0 CA-C-O 121.425 0.631 . . . . 1.9199999999999999 111.021 179.559 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 38.1 Cg_endo -83.17 133.55 6.53 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 123.467 2.778 . . . . 0.22 112.393 175.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.41 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 29.0 mm -98.54 132.66 43.25 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 109.136 -0.69 . . . . 0.13 109.136 174.276 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -114.41 149.01 36.85 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 116.007 -0.542 . . . . 0.28999999999999998 110.163 -177.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.598 ' HD2' HG21 ' A' ' 4' ' ' ILE . 1.6 t80 -67.71 109.01 3.14 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.801 -0.636 . . . . 0.17999999999999999 110.375 -174.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 121.49 -1.29 11.31 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.271 -0.966 . . . . 0.17000000000000001 113.589 178.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.544 ' HB3' HG22 ' A' ' 16' ' ' VAL . 34.7 mt-10 -88.67 146.93 24.79 Favored 'General case' 0 C--O 1.224 -0.254 0 CA-C-N 117.929 0.865 . . . . 0.52000000000000002 110.367 -179.188 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 24.1 m -105.76 107.98 19.25 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.72 -0.673 . . . . 0.16 111.171 -175.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.1 t -81.4 133.62 28.87 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.154 0.502 . . . . 0.16 110.913 -175.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 2.9 mp -119.06 109.63 16.14 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.044 -0.98 . . . . 0.27000000000000002 109.789 -178.691 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 81.9 p -105.01 155.7 18.72 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 109.541 -0.54 . . . . 0.23000000000000001 109.541 176.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -124.14 137.92 11.01 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.724 -0.75 . . . . 0.90000000000000002 111.97 178.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 60.09 -100.43 0.21 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 121.677 -0.297 . . . . 1.79 113.266 178.661 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 20.2 m -111.17 17.26 20.49 Favored 'General case' 0 C--N 1.326 -0.434 0 O-C-N 122.792 -0.24 . . . . 1.6399999999999999 111.053 -179.355 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -47.83 110.74 0.68 Allowed Glycine 0 C--O 1.221 -0.68 0 O-C-N 123.505 0.503 . . . . 0.89000000000000001 112.856 178.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.482 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 31.1 m -125.17 130.61 52.49 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.838 -0.43 . . . . 0.84999999999999998 109.838 -174.493 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 5.6 t -139.61 131.28 33.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 CA-C-N 116.559 -0.291 . . . . 0.25 111.433 -170.861 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.589 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 80.2 m -102.64 107.95 19.05 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.079 -0.51 . . . . 0.19 109.842 175.018 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.577 HD13 ' HE2' ' A' ' 66' ' ' MET . 68.5 mt -96.52 109.64 23.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.858 0 CA-C-N 115.717 -0.674 . . . . 0.14999999999999999 110.22 176.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.21 100.81 12.01 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.289 -0.869 . . . . 0.14000000000000001 109.788 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.459 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 67.3 m-85 -68.09 148.36 51.06 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.71 0.767 . . . . 0.32000000000000001 111.082 -177.798 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 4.8 p -73.45 -8.71 12.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-N 114.276 -1.329 . . . . 0.25 111.128 -171.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.449 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 32.1 t70 -80.15 -20.63 44.47 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.014 -0.539 . . . . 0.75 110.395 176.448 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 119.92 -10.58 11.1 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.749 -0.738 . . . . 0.27000000000000002 112.173 -177.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 2.7 p -85.23 157.29 20.65 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.65 -0.13 . . . . 0.35999999999999999 110.65 177.949 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -133.81 140.99 47.26 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.507 -0.553 . . . . 1.51 109.507 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.548 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 9.6 m -121.47 172.65 8.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.192 0.52 . . . . 1.3899999999999999 111.584 178.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.483 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 12.7 p -140.01 133.15 35.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-N 115.254 -0.884 . . . . 0.81000000000000005 110.124 177.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.482 ' O ' ' HA ' ' A' ' 45' ' ' SER . 22.7 mt -103.54 133.25 47.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.003 -0.544 . . . . 0.32000000000000001 109.951 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -80.51 178.97 53.71 Favored Glycine 0 N--CA 1.446 -0.687 0 C-N-CA 120.661 -0.78 . . . . 1.02 111.367 175.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -96.52 155.08 20.84 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 111.718 -0.553 . . . . 0.40000000000000002 111.718 -171.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 37.9 t70 59.1 17.13 5.29 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.929 0.871 . . . . 1.26 109.702 -176.568 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.1 m -102.58 156.42 17.63 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-N 115.524 -0.762 . . . . 1.1899999999999999 111.343 -176.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.497 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 90.9 mt -140.69 120.73 12.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.292 -0.867 . . . . 0.38 109.57 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.4 p -150.2 143.74 17.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.644 0.259 . . . . 1.0 110.872 -177.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.55 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 36.2 tt0 -90.72 136.11 33.28 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.982 0.42 . . . . 0.67000000000000004 110.42 177.782 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.577 ' HE2' HD13 ' A' ' 48' ' ' ILE . 61.3 mmm -69.13 89.05 0.43 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.332 -0.849 . . . . 0.88 110.283 179.054 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 44.1 p -112.73 -164.21 0.9 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.86 -0.609 . . . . 0.28999999999999998 110.669 -177.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.3 p-10 -75.4 -25.17 57.38 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 120.787 0.327 . . . . 2.1299999999999999 110.874 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 68.5 mm-40 -66.2 -29.81 70.15 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 122.07 0.938 . . . . 2.5099999999999998 109.612 172.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.478 HG21 ' CE ' ' A' ' 66' ' ' MET . 1.2 mm -82.46 -51.94 14.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 114.254 -1.339 . . . . 0.25 110.489 177.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.786 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -103.42 82.86 2.09 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.459 -0.791 . . . . 0.31 110.147 -176.773 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 7.2 t30 -75.27 100.18 4.28 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.484 -0.78 . . . . 1.46 109.669 175.056 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 5.8 p -82.62 121.59 27.02 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.832 -0.622 . . . . 0.68999999999999995 111.632 -176.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -172.96 -68.44 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 111.241 -0.743 . . . . 1.9099999999999999 111.241 178.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -176.77 -37.61 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.531 -0.544 . . . . 5.5700000000000003 109.531 175.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.0 t30 . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.548 -0.739 . . . . 6.8700000000000001 109.562 177.953 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.773 0 N-CA-C 112.258 -0.337 . . . . 1.71 112.258 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 -93.43 155.01 17.61 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.293 0.568 . . . . 2.0 110.767 178.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.23 110.05 17.74 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.061 -0.972 . . . . 0.23999999999999999 109.931 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.779 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 30.9 pt -87.55 -14.87 9.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.125 -0.943 . . . . 0.14999999999999999 111.688 -171.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -164.82 175.84 40.71 Favored Glycine 0 CA--C 1.502 -0.728 0 C-N-CA 120.671 -0.776 . . . . 0.10000000000000001 111.817 179.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -144.15 149.55 36.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.038 0.446 . . . . 0.20000000000000001 110.61 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.522 HG12 ' O ' ' A' ' 30' ' ' ASP . 23.6 mm -76.61 126.11 36.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 115.731 -0.668 . . . . 0.14000000000000001 110.787 -178.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 56.6 p -117.13 -16.92 10.39 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.307 0.575 . . . . 0.20000000000000001 110.773 177.342 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.477 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 80.4 tttt -145.3 143.83 30.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.607 -0.886 . . . . 2.3599999999999999 108.607 174.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.529 HD11 HG21 ' A' ' 14' ' ' VAL . 4.8 tt -160.47 139.1 10.26 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 120.778 0.323 . . . . 0.20000000000000001 110.987 -175.558 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.539 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 0.0 OUTLIER -144.07 145.32 32.09 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.956 -0.566 . . . . 1.9399999999999999 111.49 177.487 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.733 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 80.18 -146.25 27.64 Favored Glycine 0 N--CA 1.436 -1.348 0 CA-C-N 115.026 -0.988 . . . . 0.27000000000000002 114.063 167.037 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 17.9 m -102.03 115.66 31.03 Favored 'General case' 0 N--CA 1.447 -0.618 0 C-N-CA 122.832 0.453 . . . . 1.1599999999999999 110.445 -175.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.529 HG21 HD11 ' A' ' 10' ' ' LEU . 3.8 m -135.14 153.59 34.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.594 0.711 . . . . 0.20000000000000001 111.598 -175.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.12 158.32 44.03 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.781 -1.099 . . . . 0.17000000000000001 108.954 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.67 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -134.31 139.06 48.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 C-N-CA 120.015 -0.674 . . . . 0.16 110.727 171.901 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 mt-30 -107.11 100.03 9.53 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.149 -0.932 . . . . 0.51000000000000001 109.71 178.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.453 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 43.0 t -62.73 179.93 0.31 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.594 -0.275 . . . . 1.25 110.753 -178.253 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.4 pt -61.16 -30.64 48.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.143 0.497 . . . . 0.58999999999999997 111.567 -176.683 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 16.4 p30 -80.64 -6.71 58.74 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.907 -0.588 . . . . 1.96 111.0 177.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 94.37 1.28 64.52 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 121.121 -0.561 . . . . 0.32000000000000001 112.413 176.033 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -67.08 121.24 15.16 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.817 0.341 . . . . 2.21 111.424 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.618 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 14.6 tt0 -93.77 118.18 31.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.641 177.069 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.67 ' HG2' HG12 ' A' ' 16' ' ' VAL . 21.8 ptt-85 -120.24 168.01 11.69 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.167 -0.679 . . . . 1.55 109.167 174.518 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.7 p -93.98 136.81 24.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 108.996 -0.742 . . . . 0.34999999999999998 108.996 177.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.599 HD22 ' OD1' ' A' ' 30' ' ' ASP . 5.2 mt -97.13 153.58 17.88 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.014 -0.539 . . . . 0.32000000000000001 111.316 -176.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 28.3 mttm -138.44 -178.12 5.15 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.149 -0.932 . . . . 1.6499999999999999 108.585 -173.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.78 140.85 39.48 Favored 'General case' 0 C--N 1.314 -0.954 0 C-N-CA 119.494 -0.882 . . . . 0.23000000000000001 108.971 174.26 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.81 1.09 77.07 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 120.041 -1.076 . . . . 0.23999999999999999 111.887 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.599 ' OD1' HD22 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -73.83 137.14 76.65 Favored Pre-proline 0 CA--C 1.517 -0.312 0 CA-C-O 121.79 0.805 . . . . 1.9199999999999999 110.614 179.095 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -77.23 130.23 10.94 Favored 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.62 2.88 . . . . 0.22 113.405 -177.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.403 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 30.5 mm -99.53 135.93 32.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.075 -0.966 . . . . 0.13 109.313 174.217 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -116.15 154.71 29.54 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 116.004 -0.544 . . . . 0.28999999999999998 109.731 -177.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.56 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -71.21 109.57 5.33 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.361 -0.382 . . . . 0.17999999999999999 110.657 -174.555 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.14 10.28 9.04 Favored Glycine 0 N--CA 1.445 -0.729 0 C-N-CA 120.443 -0.884 . . . . 0.17000000000000001 113.422 178.072 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.481 ' O ' ' HG2' ' A' ' 66' ' ' MET . 40.6 mt-10 -96.01 145.08 25.74 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 117.868 0.834 . . . . 0.52000000000000002 110.687 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 31.7 m -105.27 108.2 19.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.412 -0.813 . . . . 0.16 110.806 -176.041 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.483 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.3 t -82.71 133.72 28.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-O 121.128 0.489 . . . . 0.16 110.756 -175.567 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.7 mp -122.2 110.15 15.36 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.175 -0.921 . . . . 0.27000000000000002 110.051 -177.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.424 ' HB ' ' HA3' ' A' ' 44' ' ' GLY . 68.9 p -107.48 158.06 17.5 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.425 -0.583 . . . . 0.23000000000000001 109.425 176.272 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -135.56 108.12 0.67 Allowed Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.378 -0.915 . . . . 0.90000000000000002 113.346 -177.497 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.606 ' H ' ' HB2' ' A' ' 61' ' ' ASP . . . 62.92 -87.55 0.05 OUTLIER Glycine 0 C--N 1.332 0.339 0 CA-C-O 121.196 0.331 . . . . 1.79 112.367 179.739 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.733 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 15.7 m -93.41 93.14 7.98 Favored 'General case' 0 N--CA 1.436 -1.148 0 N-CA-C 107.826 -1.175 . . . . 1.6399999999999999 107.826 174.251 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.539 ' HA2' ' O ' ' A' ' 11' ' ' ASP . . . -153.2 91.7 0.13 Allowed Glycine 0 C--N 1.309 -0.97 0 CA-C-N 115.328 -0.851 . . . . 0.89000000000000001 112.189 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -117.99 114.13 22.71 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.281 0.541 . . . . 0.84999999999999998 109.937 -175.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 3.0 t -126.09 142.35 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 CA-C-O 120.793 0.33 . . . . 0.25 111.093 -170.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 89.1 m -119.34 110.59 17.15 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 121.297 0.57 . . . . 0.19 110.341 177.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.442 HD13 ' HE2' ' A' ' 66' ' ' MET . 70.2 mt -98.88 102.5 13.49 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-N 115.163 -0.926 . . . . 0.14999999999999999 109.925 178.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -82.76 102.62 11.68 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.476 -0.784 . . . . 0.14000000000000001 109.259 177.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.549 ' HB3' ' CE1' ' A' ' 71' ' ' TYR . 58.6 m-85 -64.85 149.28 49.76 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.437 0.637 . . . . 0.32000000000000001 110.881 -177.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 6.4 p -71.28 -9.03 12.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-N 114.784 -1.098 . . . . 0.25 111.134 -172.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.423 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 19.5 t70 -78.39 -22.27 48.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.71 -0.677 . . . . 0.75 111.0 177.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 116.21 -11.85 16.94 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.27000000000000002 111.65 -174.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -85.1 161.08 19.82 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.127 -0.323 . . . . 0.35999999999999999 110.127 175.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -131.78 155.53 47.58 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 110.24 -0.281 . . . . 1.51 110.24 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.49 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.8 OUTLIER -137.5 151.27 26.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.433 -0.349 . . . . 1.3899999999999999 110.151 178.401 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.43 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.1 p -129.39 141.53 46.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.333 -0.394 . . . . 0.81000000000000005 110.139 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 mt -116.2 131.38 68.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.224 -0.444 . . . . 0.32000000000000001 110.209 -177.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -79.46 179.7 52.83 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.925 -0.655 . . . . 1.02 111.635 176.201 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -95.78 148.73 19.09 Favored Glycine 0 N--CA 1.444 -0.778 0 N-CA-C 111.285 -0.726 . . . . 0.40000000000000002 111.285 -173.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.606 ' HB2' ' H ' ' A' ' 42' ' ' GLY . 31.8 t70 59.22 23.42 11.76 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-O 121.914 0.864 . . . . 1.26 109.605 -173.024 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 14.6 m -104.47 159.99 15.29 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.728 -0.669 . . . . 1.1899999999999999 110.712 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.483 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 92.2 mt -140.07 125.83 21.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-N 115.123 -0.944 . . . . 0.38 108.809 178.808 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.407 HG21 HD11 ' A' ' 70' ' ' ILE . 13.8 p -147.67 141.74 19.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-O 120.886 0.374 . . . . 1.0 110.866 -177.226 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.414 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 43.3 tt0 -100.86 124.93 47.27 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.151 -0.477 . . . . 0.67000000000000004 110.25 -179.089 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 36' ' ' GLU . 44.3 mmm -65.46 90.29 0.11 Allowed 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.72 -0.673 . . . . 0.88 110.725 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.408 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 1.3 p -118.48 -165.48 1.12 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 0.28999999999999998 111.7 -176.532 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -65.9 -44.22 85.88 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 111.857 0.317 . . . . 2.1299999999999999 111.857 -174.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 35.2 mm-40 -62.94 -29.99 71.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.456 0.646 . . . . 2.5099999999999998 110.49 178.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.432 HG21 ' HA ' ' A' ' 66' ' ' MET . 1.1 mm -71.99 -53.11 21.15 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.903 -1.044 . . . . 0.25 110.769 176.484 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.779 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.4 t80 -103.76 80.27 1.75 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.61 -0.723 . . . . 0.31 110.318 -176.495 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -79.87 105.0 10.83 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.549 -0.751 . . . . 1.46 109.482 175.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 29.3 p -79.09 125.5 29.49 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.079 -0.51 . . . . 0.68999999999999995 111.428 -177.078 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -97.84 -1.18 58.7 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 120.999 -0.62 . . . . 1.9099999999999999 111.73 176.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 36.8 t70 -70.22 121.27 17.27 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.735 0.303 . . . . 5.5700000000000003 110.433 176.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 . . . . . 0 C--O 1.247 0.959 0 CA-C-O 118.216 -0.897 . . . . 6.8700000000000001 109.942 178.812 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.701 0 N-CA-C 111.777 -0.529 . . . . 1.71 111.777 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -135.09 159.88 40.11 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.017 0.437 . . . . 2.0 110.35 179.426 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.08 117.94 20.59 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.488 -0.778 . . . . 0.23999999999999999 110.228 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.823 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 26.6 pt -96.96 -13.47 8.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.454 -0.794 . . . . 0.14999999999999999 111.487 -172.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -169.6 179.21 42.21 Favored Glycine 0 CA--C 1.502 -0.752 0 C-N-CA 120.947 -0.644 . . . . 0.10000000000000001 111.635 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.402 ' CE1' ' HB3' ' A' ' 31' ' ' PRO . 98.0 m-85 -145.18 152.24 39.69 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 120.819 0.342 . . . . 0.20000000000000001 110.604 -175.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.49 HG12 ' O ' ' A' ' 30' ' ' ASP . 29.6 mm -81.55 120.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.032 -0.531 . . . . 0.14000000000000001 111.11 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 43.8 p -111.94 -27.25 8.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.276 0.56 . . . . 0.20000000000000001 110.307 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.491 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 85.8 tttt -136.43 147.37 47.21 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.464 -0.939 . . . . 2.3599999999999999 108.464 172.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.484 HD11 HG21 ' A' ' 14' ' ' VAL . 4.9 tt -158.74 141.06 14.07 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.852 0.358 . . . . 0.20000000000000001 110.8 -176.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -145.51 144.36 30.51 Favored 'General case' 0 CA--C 1.503 -0.851 0 CA-C-N 115.643 -0.708 . . . . 1.9399999999999999 112.128 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.678 ' HA3' ' O ' ' A' ' 43' ' ' SER . . . 81.81 -148.4 27.35 Favored Glycine 0 N--CA 1.425 -2.038 0 CA-C-N 114.561 -1.2 . . . . 0.27000000000000002 113.479 165.562 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 5.7 t -103.05 109.91 21.65 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.715 -0.476 . . . . 1.1599999999999999 109.715 -179.142 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.579 HG23 ' HB2' ' A' ' 26' ' ' LEU . 2.6 m -132.21 153.02 37.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.379 0.609 . . . . 0.20000000000000001 111.569 -175.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.13 159.71 44.22 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.219 -0.901 . . . . 0.17000000000000001 109.413 -179.56 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.532 HG22 ' HB3' ' A' ' 36' ' ' GLU . 0.5 OUTLIER -132.6 131.09 59.95 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.239 0.543 . . . . 0.16 110.213 176.017 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.8 mt-30 -103.35 99.6 9.45 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.708 -0.678 . . . . 0.51000000000000001 109.835 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.54 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 19.6 m -61.64 174.07 0.86 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.535 -0.302 . . . . 1.25 111.072 -176.28 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.7 pt -54.92 -32.51 26.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 112.301 0.482 . . . . 0.58999999999999997 112.301 -176.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -75.71 -12.11 60.13 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.384 -0.371 . . . . 1.96 111.421 178.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.12 6.08 59.17 Favored Glycine 0 CA--C 1.51 -0.261 0 N-CA-C 111.864 -0.494 . . . . 0.32000000000000001 111.864 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 78.0 mm-40 -74.35 124.96 27.47 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 120.639 0.257 . . . . 2.21 110.491 178.589 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.423 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 23.7 tt0 -91.69 110.13 21.46 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.425 0.631 . . . . 1.0 110.801 -179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.08 139.05 40.33 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.295 -0.866 . . . . 1.55 109.872 177.466 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 12.3 p -78.22 138.03 21.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.444 -0.576 . . . . 0.34999999999999998 109.444 176.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.579 ' HB2' HG23 ' A' ' 14' ' ' VAL . 28.8 mt -102.96 127.54 50.15 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.304 0.574 . . . . 0.32000000000000001 111.102 -178.117 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 74.0 mttt -116.55 179.43 4.01 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 107.514 -1.291 . . . . 1.6499999999999999 107.514 170.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -67.58 146.74 53.59 Favored 'General case' 0 C--N 1.315 -0.9 0 C-N-CA 119.306 -0.958 . . . . 0.23000000000000001 109.95 179.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.52 0.04 86.35 Favored Glycine 0 N--CA 1.438 -1.178 0 C-N-CA 120.313 -0.946 . . . . 0.23999999999999999 112.721 177.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.49 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.8 OUTLIER -71.84 143.13 86.44 Favored Pre-proline 0 CA--C 1.513 -0.461 0 C-N-CA 120.36 -0.536 . . . . 1.9199999999999999 109.775 173.946 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.402 ' HB3' ' CE1' ' A' ' 6' ' ' PHE . 21.4 Cg_endo -89.78 137.47 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 123.143 2.562 . . . . 0.22 112.1 178.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.467 ' CG2' ' HG3' ' A' ' 66' ' ' MET . 28.5 mm -98.52 139.65 20.04 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-N 116.132 -0.485 . . . . 0.13 109.914 176.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -117.13 155.38 29.43 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.893 -0.594 . . . . 0.28999999999999998 109.498 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.51 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.5 t80 -71.64 118.6 14.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.39 -0.368 . . . . 0.17999999999999999 110.541 -175.424 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 113.68 -0.36 24.63 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.502 -0.856 . . . . 0.17000000000000001 113.324 177.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.54 ' HG2' ' HA ' ' A' ' 18' ' ' SER . 23.4 mt-10 -85.42 147.94 26.24 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 117.8 0.8 . . . . 0.52000000000000002 110.909 179.586 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 9.8 m -107.71 108.27 19.43 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.812 -1.086 . . . . 0.16 110.388 -176.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.619 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 2.2 t -82.08 136.97 21.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 C-N-CA 120.703 -0.399 . . . . 0.16 110.759 -174.328 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -125.66 107.03 10.17 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.437 -0.801 . . . . 0.27000000000000002 110.562 -175.742 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.467 HG22 HG12 ' A' ' 14' ' ' VAL . 81.5 p -105.74 163.3 12.81 Favored 'General case' 0 C--N 1.317 -0.822 0 N-CA-C 108.981 -0.748 . . . . 0.23000000000000001 108.981 173.27 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -141.69 120.7 1.7 Allowed Glycine 0 C--N 1.316 -0.562 0 C-N-CA 120.384 -0.912 . . . . 0.90000000000000002 112.538 -179.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.526 ' H ' ' HB2' ' A' ' 61' ' ' ASP . . . 54.24 -94.36 0.02 OUTLIER Glycine 0 C--N 1.334 0.436 0 O-C-N 124.021 0.483 . . . . 1.79 112.551 -178.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.678 ' O ' ' HA3' ' A' ' 12' ' ' GLY . 8.5 m -89.23 87.76 7.27 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.677 -0.86 . . . . 1.6399999999999999 108.677 177.161 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -141.26 137.66 8.27 Favored Glycine 0 N--CA 1.443 -0.867 0 CA-C-N 115.023 -0.99 . . . . 0.89000000000000001 111.54 176.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.554 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 46.6 t -153.54 151.36 29.7 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 109.09 -0.707 . . . . 0.84999999999999998 109.09 169.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 17.8 t -152.21 136.2 8.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 110.121 -0.325 . . . . 0.25 110.121 -176.256 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.491 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.9 m -109.79 105.36 14.55 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.145 0.497 . . . . 0.19 109.768 173.194 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 78.4 mt -96.34 99.88 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 115.43 -0.805 . . . . 0.14999999999999999 109.739 177.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.91 102.38 8.22 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.215 -0.902 . . . . 0.14000000000000001 109.079 176.639 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.613 ' CE1' ' HB ' ' A' ' 56' ' ' VAL . 53.1 m-85 -66.28 151.35 47.23 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.617 0.722 . . . . 0.32000000000000001 111.081 -176.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.2 p -75.24 1.63 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 114.588 -1.187 . . . . 0.25 111.273 -172.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -94.16 -20.79 19.55 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.106 0.479 . . . . 0.75 110.5 178.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 123.36 -19.77 7.57 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.637 -0.792 . . . . 0.27000000000000002 111.892 -176.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.8 p -78.27 160.2 28.03 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 122.15 0.18 . . . . 0.35999999999999999 110.766 177.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -133.3 146.03 50.99 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.427 -0.582 . . . . 1.51 109.427 178.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.613 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -130.85 147.27 33.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.008 0.432 . . . . 1.3899999999999999 110.834 179.699 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 11.3 p -120.7 138.94 49.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 115.841 -0.618 . . . . 0.81000000000000005 110.123 179.055 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.554 ' O ' ' HA ' ' A' ' 45' ' ' SER . 34.6 mt -110.64 134.45 52.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 116.078 -0.51 . . . . 0.32000000000000001 110.096 -179.421 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.76 -168.96 43.56 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.803 -0.713 . . . . 1.02 112.262 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -100.56 143.39 16.26 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.95 -0.643 . . . . 0.40000000000000002 111.562 -176.149 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.526 ' HB2' ' H ' ' A' ' 42' ' ' GLY . 28.2 t70 60.44 21.53 11.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 121.612 0.72 . . . . 1.26 110.052 -174.051 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.2 t -97.54 154.27 17.63 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.725 -0.67 . . . . 1.1899999999999999 110.176 -179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.619 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 87.6 mt -141.78 106.21 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.486 -0.779 . . . . 0.38 108.937 -177.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -133.56 149.18 30.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 121.122 0.487 . . . . 1.0 111.414 -174.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.406 ' O ' HG13 ' A' ' 70' ' ' ILE . 43.3 tt0 -105.94 128.96 54.14 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.611 -0.722 . . . . 0.67000000000000004 110.543 -175.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.546 ' SD ' HG21 ' A' ' 70' ' ' ILE . 22.2 mmt -64.3 89.88 0.06 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.607 -0.724 . . . . 0.88 111.333 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 72.7 p -124.89 -165.14 1.35 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.85 -0.613 . . . . 0.28999999999999998 110.988 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -68.33 -26.04 65.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.31 0.576 . . . . 2.1299999999999999 110.226 178.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -74.19 -20.28 60.25 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.362 -0.836 . . . . 2.5099999999999998 110.361 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.546 HG21 ' SD ' ' A' ' 66' ' ' MET . 2.2 mm -98.49 -55.1 6.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-N 114.785 -1.098 . . . . 0.25 110.948 -179.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.823 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -95.47 85.81 4.31 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.044 -0.98 . . . . 0.31 109.921 -175.676 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 35.7 t30 -73.74 115.23 12.91 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.241 -0.89 . . . . 1.46 109.944 173.039 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 2.1 p -95.01 115.16 27.07 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.186 -0.461 . . . . 0.68999999999999995 110.299 176.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . 146.51 43.93 0.04 OUTLIER Glycine 0 N--CA 1.441 -0.999 0 C-N-CA 120.654 -0.784 . . . . 1.9099999999999999 112.322 -178.209 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -82.08 55.91 2.97 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.609 0.719 . . . . 5.5700000000000003 109.86 177.094 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 . . . . . 0 C--O 1.247 0.948 0 CA-C-N 115.327 -0.851 . . . . 6.8700000000000001 109.74 -178.115 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.762 0 N-CA-C 112.316 -0.313 . . . . 1.71 112.316 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 27.3 p-10 -90.58 164.61 14.14 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.861 0.363 . . . . 2.0 110.201 178.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.04 109.2 14.27 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.854 -0.612 . . . . 0.23999999999999999 109.78 178.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.694 ' HB ' ' CE2' ' A' ' 71' ' ' TYR . 37.4 pt -95.35 -11.85 8.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 CA-C-N 115.058 -0.974 . . . . 0.14999999999999999 111.565 -171.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -168.91 175.58 43.32 Favored Glycine 0 CA--C 1.498 -1.027 0 N-CA-C 111.241 -0.743 . . . . 0.10000000000000001 111.241 178.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -144.1 151.18 39.26 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.952 0.406 . . . . 0.20000000000000001 110.581 -174.363 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.564 HG12 ' O ' ' A' ' 30' ' ' ASP . 27.7 mm -78.3 124.43 36.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.96 -0.563 . . . . 0.14000000000000001 111.389 -177.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 47.0 p -115.1 -21.3 10.06 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.182 0.515 . . . . 0.20000000000000001 110.627 177.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.549 ' HB3' ' HB ' ' A' ' 47' ' ' THR . 81.8 tttt -140.9 143.58 34.72 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 108.54 -0.911 . . . . 2.3599999999999999 108.54 172.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.632 HD11 HG21 ' A' ' 14' ' ' VAL . 7.6 tt -161.21 140.84 10.53 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.682 0.277 . . . . 0.20000000000000001 110.82 -177.264 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -156.0 158.5 37.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.49 -0.777 . . . . 1.9399999999999999 111.159 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.403 ' HA3' ' HA2' ' A' ' 44' ' ' GLY . . . 76.81 -163.66 52.64 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.811 -0.631 . . . . 0.27000000000000002 112.974 175.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 11.0 m -92.83 116.62 29.2 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 109.762 -0.459 . . . . 1.1599999999999999 109.762 -177.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.632 HG21 HD11 ' A' ' 10' ' ' LEU . 3.9 m -134.48 152.5 33.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.672 0.748 . . . . 0.20000000000000001 111.988 -175.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.04 159.05 44.78 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 114.567 -1.197 . . . . 0.17000000000000001 108.853 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.664 HG12 ' HG2' ' A' ' 24' ' ' ARG . 0.9 OUTLIER -133.95 135.76 54.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 C-N-CA 120.109 -0.637 . . . . 0.16 110.922 172.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.413 ' HB2' ' HB ' ' A' ' 37' ' ' THR . 2.3 mt-30 -102.46 100.75 10.9 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.364 -0.835 . . . . 0.51000000000000001 109.911 177.412 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.527 ' HA ' ' HG2' ' A' ' 36' ' ' GLU . 37.7 m -62.86 176.64 0.66 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.5 -0.318 . . . . 1.25 110.861 -178.367 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.7 pt -66.68 -5.55 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 N-CA-C 112.142 0.423 . . . . 0.58999999999999997 112.142 -178.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -92.25 -8.48 45.21 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.294 0.569 . . . . 1.96 109.682 174.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.5 6.46 80.63 Favored Glycine 0 CA--C 1.507 -0.465 0 CA-C-N 115.278 -0.874 . . . . 0.32000000000000001 111.093 -177.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.411 ' O ' ' HA ' ' A' ' 17' ' ' GLN . 46.6 mm-40 -79.65 127.85 32.68 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.225 -0.488 . . . . 2.21 110.953 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLU . . . . . 0.655 ' HA ' ' O ' ' A' ' 16' ' ' VAL . 25.4 tt0 -101.64 117.87 35.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.702 -0.681 . . . . 1.0 110.762 -178.149 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.664 ' HG2' HG12 ' A' ' 16' ' ' VAL . 25.7 ptt-85 -116.62 168.78 9.88 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.619 -0.512 . . . . 1.55 109.619 176.156 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.9 p -87.77 140.84 15.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 N-CA-C 109.329 -0.619 . . . . 0.34999999999999998 109.329 176.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.545 HD22 ' CG ' ' A' ' 30' ' ' ASP . 4.8 mt -101.44 152.3 20.91 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.478 -0.489 . . . . 0.32000000000000001 111.129 179.15 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.46 ' O ' ' HB3' ' A' ' 30' ' ' ASP . 53.4 mttt -141.61 178.53 7.4 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.139 -0.937 . . . . 1.6499999999999999 108.638 -174.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.14 139.3 44.43 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.353 -0.939 . . . . 0.23000000000000001 109.108 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 2.42 86.82 Favored Glycine 0 N--CA 1.435 -1.415 0 C-N-CA 120.051 -1.071 . . . . 0.23999999999999999 111.968 -179.595 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.564 ' O ' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -74.89 141.59 75.39 Favored Pre-proline 0 N--CA 1.454 -0.237 0 CA-C-O 121.55 0.69 . . . . 1.9199999999999999 109.981 177.574 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 30' ' ' ASP . 28.2 Cg_endo -86.88 127.28 2.6 Favored 'Trans proline' 0 C--N 1.325 -0.709 0 C-N-CA 123.628 2.885 . . . . 0.22 113.353 -174.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 32.2 mm -93.11 134.28 31.48 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-N 116.183 -0.462 . . . . 0.13 109.815 176.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 76.9 m-85 -111.89 151.29 29.32 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 115.697 -0.683 . . . . 0.28999999999999998 109.747 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.596 ' HD2' HG21 ' A' ' 4' ' ' ILE . 2.2 t80 -69.42 113.9 7.16 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.318 -0.401 . . . . 0.17999999999999999 110.796 -175.527 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.13 0.55 22.44 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.527 -0.844 . . . . 0.17000000000000001 113.408 177.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . 0.546 ' O ' ' HG2' ' A' ' 66' ' ' MET . 30.8 mt-10 -86.87 144.7 26.88 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 117.976 0.888 . . . . 0.52000000000000002 110.81 -178.266 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.458 ' HA ' ' HA ' ' A' ' 65' ' ' GLU . 23.6 m -101.33 107.64 19.05 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.211 -0.904 . . . . 0.16 110.887 -177.11 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.575 ' O ' ' HA ' ' A' ' 63' ' ' ILE . 3.6 t -82.24 130.51 35.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 121.137 0.494 . . . . 0.16 110.412 -176.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 1.1 mp -119.11 103.4 9.51 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.075 -0.966 . . . . 0.27000000000000002 109.958 -177.357 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 61' ' ' ASP . 20.3 p -100.67 159.33 15.26 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.253 -0.647 . . . . 0.23000000000000001 109.253 175.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -138.78 138.07 9.15 Favored Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.66 -0.781 . . . . 0.90000000000000002 112.133 178.223 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 54.33 -104.77 0.26 Allowed Glycine 0 N--CA 1.451 -0.339 0 O-C-N 124.097 0.528 . . . . 1.79 113.777 177.648 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 10.1 t -87.18 27.61 1.03 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.187 0.518 . . . . 1.6399999999999999 110.82 -174.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.406 ' HA3' ' HB ' ' A' ' 40' ' ' THR . . . -71.96 135.46 22.98 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 121.128 -0.558 . . . . 0.89000000000000001 112.723 -179.295 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.57 ' HA ' ' O ' ' A' ' 58' ' ' ILE . 18.9 m -156.27 133.07 10.35 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 109.002 -0.74 . . . . 0.84999999999999998 109.002 172.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 57' ' ' VAL . 11.0 t -140.18 146.21 25.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 O-C-N 122.171 -0.33 . . . . 0.25 110.761 -176.085 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 9' ' ' LYS . 95.5 m -119.43 111.21 17.85 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.115 -0.493 . . . . 0.19 109.731 174.106 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.585 HD13 ' HE2' ' A' ' 66' ' ' MET . 62.4 mt -101.0 104.16 15.85 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.929 0 CA-C-N 115.705 -0.679 . . . . 0.14999999999999999 110.271 179.798 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -78.51 104.4 9.09 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.406 -0.816 . . . . 0.14000000000000001 108.995 176.42 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.469 ' HE1' ' CG1' ' A' ' 56' ' ' VAL . 53.4 m-85 -69.55 148.72 49.06 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.269 0.557 . . . . 0.32000000000000001 110.681 -177.592 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 5.8 p -70.69 -5.55 5.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 114.878 -1.055 . . . . 0.25 111.04 -171.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.423 ' HB2' ' OH ' ' A' ' 71' ' ' TYR . 30.4 t70 -81.57 -21.37 38.49 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.37 0.605 . . . . 0.75 110.42 174.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 117.13 -7.01 16.9 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.781 -0.723 . . . . 0.27000000000000002 112.275 -177.444 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 23.3 p -86.55 175.18 8.47 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 110.436 -0.209 . . . . 0.35999999999999999 110.436 177.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -149.53 150.49 32.37 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.706 0.289 . . . . 1.51 110.338 177.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.546 ' CG2' ' HB ' ' A' ' 48' ' ' ILE . 5.8 m -130.88 166.86 27.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.972 -0.558 . . . . 1.3899999999999999 111.006 179.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' VAL . . . . . 0.541 ' HA ' ' O ' ' A' ' 46' ' ' VAL . 13.0 p -135.19 132.21 52.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 115.763 -0.653 . . . . 0.81000000000000005 110.819 179.241 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.57 ' O ' ' HA ' ' A' ' 45' ' ' SER . 16.3 mt -106.24 132.97 52.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.607 -0.724 . . . . 0.32000000000000001 109.838 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . -82.14 -160.38 26.9 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.977 -0.63 . . . . 1.02 112.598 -178.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -104.07 141.7 15.32 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 111.595 -0.602 . . . . 0.40000000000000002 111.595 -176.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.408 ' HA ' ' O ' ' A' ' 40' ' ' THR . 32.9 t70 58.16 26.15 13.4 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 122.174 0.988 . . . . 1.26 109.313 -171.084 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -91.05 131.67 36.49 Favored 'General case' 0 N--CA 1.435 -1.221 0 CA-C-N 114.465 -1.243 . . . . 1.1899999999999999 110.967 -178.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.575 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 91.0 mt -129.08 106.12 13.67 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 N-CA-C 109.092 -0.707 . . . . 0.38 109.092 178.003 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 p -137.28 144.47 31.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.096 -0.502 . . . . 1.0 110.555 -174.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 37' ' ' THR . 35.6 tt0 -97.46 131.04 44.47 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.426 -0.352 . . . . 0.67000000000000004 110.303 -179.571 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.585 ' HE2' HD13 ' A' ' 48' ' ' ILE . 53.5 mmm -68.45 89.46 0.35 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.748 -0.66 . . . . 0.88 110.717 -178.307 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.416 ' H ' ' HB ' ' A' ' 70' ' ' ILE . 44.9 p -112.13 -164.62 0.93 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.098 -0.501 . . . . 0.28999999999999998 111.456 -176.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -72.35 -25.52 61.57 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.941 0.4 . . . . 2.1299999999999999 110.852 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -71.05 -31.24 67.64 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-O 122.102 0.954 . . . . 2.5099999999999998 109.236 176.124 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.416 ' HB ' ' H ' ' A' ' 67' ' ' THR . 1.2 mm -78.77 -47.03 23.86 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 CA-C-N 113.844 -1.525 . . . . 0.25 110.832 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.694 ' CE2' ' HB ' ' A' ' 4' ' ' ILE . 1.2 t80 -110.45 78.38 1.12 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.281 -0.872 . . . . 0.31 110.061 -178.135 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -88.18 101.81 14.19 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.817 -0.629 . . . . 1.46 109.465 174.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 32.3 p -65.6 134.7 53.86 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.992 -0.549 . . . . 0.68999999999999995 111.542 -176.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . . . . . . . . . . . -114.63 -38.81 1.04 Allowed Glycine 0 N--CA 1.443 -0.854 0 N-CA-C 111.476 -0.649 . . . . 1.9099999999999999 111.476 178.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -79.67 -42.82 23.95 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.584 0.23 . . . . 5.5700000000000003 110.682 -178.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.422 HD22 ' HA ' ' A' ' 76' ' ' ASN . 9.2 m120 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.563 -0.732 . . . . 6.8700000000000001 110.443 175.301 . . . . . . . . 1 1 . 1 stop_ save_